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Ultra-Rush Speciﬁc Immune Therapy with Depigmented and
Polymerized Allergen Extracts is Effective and Safe in Patients
With Severe SAR Highly Sensitized against Pollen Allergens
Michaela Gruber, and Ulrich Amon, MD. PsoriSol Clinic for Dermatology
& Allergy, Hersbrcuk, Germany.
Background: Procedures for speciﬁc immune therapy (SIT) vary widely. We
were interested whether a pre-seasonal ultra-rush treatment with depigmented
and polymerized allergen extracts is effective and safe in patients with severe
SAR.
Methods: 31 pts (21 f, 10 m, mean age 39.7 years, range: 17–69 years) with
severe SAR and partial asthma attacks (31.3%) during pollen season (mean
total IgE level 152 kU/L, range: 5–5113 kU/L; mean Phadia CAP class 3.7
and 3.5 against birch pollen and Bet v1, resp.; mean Phadia CAP class 3.7
and 3.3 against grass pollen and Phl p1,5, resp.) were treated with an ultra-
rush schedule receiving the maximum dose of 0.2 plus 0.3 mL of a allergen
extract (DepiQuick, Novartis, Germany) on day one, followed by further
injecting the maximum dose of 0.5 mL at weekly intervals for 5 weeks.
Patients were interviewed by a questionnaire 2 months after the pollen season.
Results: 75.8% of patients reported a good or very good effect of SIT with
respect to their symptoms during the pollen season after having received only
one cycle of ultra-rush SIT; 18.4 did not notice any effect after the ﬁrst cycle;
one patient reported an increase of symptoms. 56.5% of patients did use less
anti-allergic medication in comparison with their mean need before SIT; in
18.8% the need of medication was comparable to the year before. In 77.8% of
all cases ultra-rush SIT was well tolerated subjectively. Local swelling at the
injection site was reported in 25.9% (immediate) and 42.4% (delayed); 4
patients felt a mild discomfort after injection with pruritus, fatigue, or
dizziness, respectively. The systemic symptoms disappeared spontaneously
without medication.
Conclusions: Even for patients with clinically severe SAR and high speciﬁc
sensitization against birch or grass pollen the pre-seasonal ultra-rush SIT
regimen with depigmented, polymerized allergen extracts showed a good
efﬁcacy and tolerability.
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Dose Optimizing Study of a Depigmented Polymerized Allergen
Extract of Birch Pollen by Means of Conjunctival
Provocation Test
Angelika Sager, MD,1 and Margitta Worm2. 1Medical Department, LETI
Pharma GmbH, Witten, Germany; 2Dermatology, Charite University Clinic,
Berlin, Germany.
Background: Clinical efﬁcacy of a depigmented polymerized birch pollen
extract has been shown in 2 large phase III studies with 1000 DPP/mL. To
date dose-response studies are required to show optimal efﬁcacy at a deﬁned
allergen dose. The conjunctival provocation test (CPT) is a possible outcome
parameter and from the regulatory authorities accepted test procedure.
Methods: 301 (PP) patients with conﬁrmed rhinitis and/or rhinoconjunctivitis
were treated in a double-blind study with 4 doses of 100 DPP/mL, 1000 DPP/
mL, 5000 DPP/mL and 10.000 DPP/mL allergen extract over 22 weeks in
Germany, Poland, and Lithuania. A 1-day build-up phase applying 0.1 mL
and 2 times 0.2 mL allergen extract was followed by a maintenance period
applying 0.5 mL in 3 to 4 weeks intervals. Before treatment a CPT was
performed with semi-logarithmically increasing doses up to 10,000 SQ-U/mL
of native birch extract, after treatment the CPT was repeated with doses up to
100,000 SQ-U/mL. The main parameter was the percentage of patients with
an increase of allergen extract to provoke a positive CPT after SIT. Secondary
parameters were speciﬁc IgE, IgG1 and IgG4 as well as safety. The main
parameter was investigated using a hierarchic test procedure comparing the
highest dose against the lowest, if statistically signiﬁcant testing the next
lower dose against the lowest until the difference was no longer signiﬁcant.
Results: An increase in allergen amount to provoke a positive CPT after SIT
was reached in 37.5% of the 100 DPP/mL, 50.7% of the 1000 DPP/mL,
54.9% of the 5000 DPP/mL and 55.8% of the 10,000 DPP/mL group. Results
compared to the lowest dose were statistically signiﬁcant for the 5000 DPP/
mL (P ¼ 0.0236) and 10,000 DPP/mL group (P ¼ 0.0159). Speciﬁc IgEs
remained stable in all groups whereas speciﬁc IgG1 and IgG4 showed dose-
dependent increases. Grade 1 systemic reactions occurred in 18% (100 DPP/
mL), 14.8% (1000 DPP/mL), 17.4% (5000 DPP/mL) and 25.3% (10,000
DPP/mL) of patients.
Conclusions: We determined increased allergen amounts to obtain a positive
CPT after SIT from 1000 to 10,000 DPP/mL depigmented polymerized birch
pollen extract. The 5000 DPP/mL dose extract suggest a good beneﬁt/risk
ratio with the potential for further development.
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Double-blind Study of the Use of Transfer Factor (TF) Combined
With Sublingual Immunotherapy in Management of Patients
With Allergic Rhinitis in Mexican Population
María Isabel Rojo Gutiérrez,1 Misael Gonzalez-Ibarra, QFB,2 Teresa Sandoval,
QFB,3and Jaime Mellado-Abrego, MD1. 1Allergy; 2Allergy and Immunology;
3Investigation, Juarez Hospital, Mexico City, Mexico.
Background: Allergic diseases affect 20% of world population and allergic
rhinitis (AR) is the most common, alone or associated with asthma. Antigen-
speciﬁc immunotherapy has been world-desensitizing type studied showing that
it is capable of modifying the natural history of the disease through changes in
the immune response increasing the role of clones of lymphocytes T helper type
I (LTh1) and inhibiting the activity of type 2 (LTh2). Dialyzable leukocyte
extract or transfer factor (TF) has shown the same stimulatory effect.
Objective: Evaluate the synergistic effect of TF associated with SLIT in
patients with RA.
Material and Methods: We studied 94 patients with RA. We included
randomized into 2 groups (47 each one) both received antigen-speciﬁc
sublingual immunotherapy (SLITAE) and also in group 1 was given oral TF
Unit at one 200 mg monthly for 3 months, and group 2 placebo. We used
a control group only to compared the normal results. All patients underwent
complete blood count (BHC), immunoglobulins, quantiﬁcation of cell-type
lymphocyte CD3, CD4, CD8, interleukin (IL2, IL4, IL5, IL10, TNF and
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IFN). The nasal symptoms were evaluated monthly for 3 months, with test
score symptoms questionary 4 (TSSQ4) and auto-evaluation by scale Linker.
Results:We studied 94 AR patients (50% women and 50% men, range age
between 5 and 40 years). Indoor antigens (mites, house dust and
cockroach) were the main cause of allergy. Allergic patients had more
eosinophiles and IgE than the healthy controls (P , 0.05). The number of
CD81 lymphocytes was slightly reduced in group 2 after treatment (P ,
0.05), whereas the amount of IL-4 and IFN ƒnwere increased in both
groups (P , 0.005) and the amount of IL-10 was signiﬁcantly increased
in group 1 (P , 0.01) after treatment. Clinical evaluation was with initial
TSSQ4 of 11.6 before handling and 5.1 (44%) after, with signiﬁcant im-
provement (P , 0.0001) and Likert score was reduced 69% than the star
the treatment.
Conclusions: The TF along with SLITAE in the treatment of patients with
RA did not alter the clinical improvement induced by SLITAE alone for 3
months of treatment, but the combination increased production of IL 10 and
production of IFNg.
4
The Risk of Severe Treatment Related Adverse Events is
Signiﬁcantly Lower in Children Compared to Adults When
Treated With Standardized Timothy Grass Allergy
Immunotherapy Tablets: Post Hoc Analysis of 7 Clinical Trials
Jens Strodl Andersen,1 Peter Astrup Fejerskov,1 and Hendrik Nolte2. 1ALK-
Abello, Hørsholm, Denmark; 2Merck Research Laboratories, Kenilworth, NJ.
Background: Allergy immunotherapy tablets (AIT) provides a safer and
more convenient alternative to subcutaneous speciﬁc immunotherapy
treatment. However, severe adverse events occur infrequently. These
events are rare and therefore pooled safety data from 1 phase II/III and 6
phase III clinical trials (5 in adults, 2 in children (5–17 years)) with grass
AIT (Grazax, Phleum pratense 75,000 SQ-T/2800 BAU, ALK, Denmark)
were analysed.
Method: All trials were randomised, double-blind, placebo-controlled
multi-centre trials. Subjects suffered from grass pollen induced allergic
rhinoconjunctivitis with or without asthma, had positive skin prick test and
speciﬁc IgE to Phleum pratense. Subjects received once-daily sublingual
treatment with grass AIT or placebo for approximately 24 weeks. The 5
adult trials comprised 2095 treated subjects (AIT ¼ 1060, placebo ¼ 1035)
and the 2 children trials comprised 597 treated subjects (AIT ¼ 301, pla-
cebo ¼ 296). Adverse events were assessed by the investigator as treat-
ment-related (possible or probable) or unlikely related and for seriousness.
Application site-related events were deﬁned as adverse events in relation to
the oral cavity.
Results: In the adult trials, 71% of AIT-treated subjects reported treatment-
related adverse events compared to 24% for placebo. In the children trials the
corresponding numbers were 63% for AIT and 27% for placebo. Of the AIT-
treated subjects 2 children (0.7%) and 32 adults (3.0%) experienced severe
treatment-related events. The odds for severe events was 4.7 times lower in
children compared to adults (odds-ratio with 95% CI, 0.22 [0.025-0.85], P ¼
0.019). Both AIT-treated children (0.7%) and 18 (1.7%) of the AIT-treated
adults experienced severe treatment-related events that were application site-
related. The odds for having severe related application site adverse events was
2.6 times lower in children compared to adults (odds-ratio with 95% CI, 0.39
[0.04-1.63], P ¼ 0.27, not statistically signiﬁcant). No serious treatment-re-
lated adverse events were reported.
Conclusion: This pooled analysis of over 2000 subjects in 7 clinical
trials shows that the risk of experiencing severe treatment-related adverse
events was signiﬁcantly lower in children compared to adults when treated
with of Timothy grass allergy immunotherapy tablets. This analysis
provides evidence that Timothy grass AIT is an important and safe
immunotherapy treatment option in children with grass pollen induced
rhinoconjunctivitis.
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Posttreatment, Long-Term Clinical Efﬁcacy of a 300 IR
Sublingual Tablet of 5-Grass Pollen Allergen Extract in Adults
With Grass Pollen Induced Allergic Rhinoconjunctivitis
Alain Didier,1 Friedrich Horak,2 Margitta Worm,3 Hans-Jorgen Malling,4
Armelle Montagut,5 Patricia Rodriguez,5 Robert K. Zeldin,5
and Michèle Lheritier-Barrand6. 1Respiratory Diseases Department, Ran-
gueil-Larrey Hospital, Toulouse, France; 2Allergy Centre Vienna West,
Dptm. - Institute for Allergy Research, Vienna, Austria; 3Allergy-Centre-
Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany; 4National
University Hospital, Copenhagen, Denmark; 5Stallergenes SA, Antony,
France; 6Stallergenes, Antony Cedex, France.
Background: A 5-year study of adults with grass-pollen related rhinocon-
junctivitis has demonstrated the sustained efﬁcacy of discontinuous treatment
with a 300 IR sublingual tablet of 5-grass pollen allergen extract, initiated 4 or
2 months before each pollen season and continued for its duration for 3
consecutive years. Here we report on the persistence of efﬁcacy during the
ﬁrst of 2 post-treatment pollen seasons.
Methods: 633 adults were randomized to either placebo or one of 2 active
groups receiving pre- and co-seasonal treatment for 3 pollen seasons starting
each year either 4 months [4M] or 2 months [2M] prior to the pollen season.
Patients were followed during the subsequent, treatment-free, grass pollen
season. The primary endpoint for the Year 4 assessment of the post-treatment
long-term efﬁcacy was the Average Adjusted Symptom Score (AAdSS,
adjusting the Rhinoconjunctivitis Total Symptom Score for rescue medication
usage) during the fourth pollen period. Secondary efﬁcacy criteria included
the Average Rescue Medication Score (ARMS) and the overall Rhinocon-
junctivitis Quality of Life Questionnaire (RQLQ) score.
Results: Statistically signiﬁcant differences compared to Placebo in the
mean AAdSS during the Year 4 pollen period were observed for both 300
IR (4M) and 300 IR (2M). The treatment effect for 300 IR (4M) was
estimated as the difference in LS Means of 21.14 (95% CI, [22.03 to
20.26], P ¼ 0.0114), corresponding to a relative LS Mean difference from
Placebo of222.9%, whilst the treatment effect for 300 IR (2M) is estimated
as the difference in LS Means of 21.43 (95% CI, [22.32 to 20.53]), P ¼
0.0019), corresponding to a relative LS Mean difference from Placebo of
228.5%. The primary results were conﬁrmed over the worst pollen period.
Compared to placebo, the active treatment groups (4M and 2M) also
showed a statistically signiﬁcant LS Mean difference in ARMS (224.6%;
P ¼ 0.00184 and 227.9%; P ¼ 0.0082) and in overall RQLQ score
(232.8%; P ¼ 0.0001 and 237.6%; P , 0.0001). No unexpected risk
was identiﬁed in this study.
Conclusions: The post-treatment, long-term efﬁcacy of 300 IR sublingual
tablets of grass pollen allergen extract was demonstrated during the ﬁrst of 2
post-treatment pollen seasons. This persistent improvement was clinically
meaningful to patients.
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Escherichia coli Heat-Labile Enterotoxin (LTS61K) Modulates
Dendritic Cell Function and Attenuates Airway Inﬂammation in
Mouse Model of Allergic Asthma
Jiu-yao Wang, MD, PhD,1 Yu-Shen Hsu Hsu, PhD,2 and I-Ping Lin, MSc3.
1College of Medicne, National Cheng Kung University HospiTak, Tainan,
Taiwan; 2Development Center for Biotechnology, Taipei, Taiwan; 3College
of Medicine, National Cheng Kung University, Tainan, Taiwan.
Background: Escherichia coli heat-labile enterotoxin (LT) with different
mutant forms has been used as adjuvant for vaccines due to its ability to
enhance immune response to speciﬁc antigen in vivo. We hypothesis that
LTS61K or LTS61K mixed with dust mite allergen, Der p, (LTS61K/Der p)
can modulate dendritic cells (DCs) s’ functions thus alleviate allergen-in-
duced airway inﬂammation.
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Methods: Two protocols (ie, preventive and therapeutic protocol) were
designed to evaluate the effects of LTS61K in Der p sensitized and
challenged mouse model of asthma.
Results: Both intranasal inoculations with LTS61K or LTS61K/Der p
decreased allergen-induced airway inﬂammation and alleviated systemic
TH2-type immune response. In addition, bronchoalveolar lavage (BAL) ﬂuids
and sera from LTS61K/Der p treated mice have higher concentrations of Der
p-speciﬁc IgA than those of other groups. In the in vitro study, bone marrow-
derived dendritic cells (BMDCs) and DC cell line, DC2.4 cells stimulated
with LTS61K/Der p both secreted pro-inﬂammation cytokines IL-6 and TNF-
a. In contrast, after LTS61K treatment, only BMDCs decreased production of
IL-6 and TNF-a as well as decreased maturation. Furthermore, we found that
pre-treatment BMDC with LTS61K inhibited Der p-induced NF-kB trans-
location which might explain the delayed maturation and decreased produc-
tions of IL-6 and TNF-a in LTS61K pre-treated BMDCs. Intratracheally
adoptive transferred with LTS61K- or LTS61K/Der p-primed DC2.4 cells
or BMDCS into Der p-sensitized mice decreased inﬂammatory cells inﬁltra-
tion and TH2-type chemokines in BAL ﬂuids and alleviated airway
inﬂammation.
Conclusions: Our results show that LTS61K may inﬂuence DCs maturation
and its cytokine production. On the other hands, LTS61K/Der p may induce
more Der p-speciﬁc IgA production to decrease allergic TH2 cytokine
responses and alleviate airway inﬂammation in murine model of asthma.
These ﬁnding suggested that LTS61K may have clinical application as an
immune-modulator effect on the diseases of allergy and asthma.
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Comparison of Efﬁcacy and Safety of a Dipigmented Polymerized
Allergen Extract of Grass andBirchwith Placebo in PatientsWith
Type-1 Allergic Rhinoconjunctivitis
Angelika Sager, MD,1 Tilo Biedermann,2 and Oliver Pfaar, MD3. 1Medical
Department, LETI Pharma GmbH, Witten, Germany; 2Department of Der-
matology, University of Tuebingen, Tuebingen, Germany; 3Center for Rhi-
nology and Allergology, Department of Otorhinolaryngology, University
Hospital Mannheim, Wiesbaden, Germany.
Background: The safety and efﬁcacy of speciﬁc immunotherapy (SIT) with
depigmented and polymerized allergen extracts of pollen is well documented in
several clinical trials. We investigated efﬁcacy and safety of an extract
containing 2 taxonomically non-related pollen species (birch and grasses) in
a subcutaneous immunotherapy over 2 pollen seasons in co-sensitized allergic
patients with rhinitis and/or rhinoconjunctivitis with or without allergic asthma.
Methods: 269 (ITT) patients with conﬁrmed rhinitis and/or rhinoconjuncti-
vitis were treated during 2009 and 2010 in Germany, Romania, Poland,
Lithuania, and Bulgaria. For each patient a 1-day build-up phase applying 0.2
mL and 0.3 mL of 1000 DPP/mL allergen extract was applied. During the
remaining 18-month period maintenance 500 DPP were administered in 4 to 6
weeks intervals. Patients were randomised to the treatment groups on a 2:1
basis (175 verum: 94 placebo). The main parameter in this study was the
combined symptom and medication score during the birch and grass pollen
season 2010 over 7 weeks. Secondary parameters were symptom score,
medication score, IgE, IgG4 as well as quality of life.
Results: During the 2010 season a statistically signiﬁcant difference (P ¼
0.0385) was observed between treatment groups: in patients treated with the
allergen extract the median time weighted AUC of the combined symptom
and medication score was 5.70, in patients treated with placebo 7.07. This
effect was predominantly due to the reduction of symptom score by 21% over
placebo. The intake of recue medication was very low during both seasons
leading only to a 10% reduction (ns). Birch and phleum speciﬁc IgE did not
change during the course of the study in both groups whereas respective IgG4
levels increased only in the verum group and remained nearly unchanged in
the placebo group (P , 0.0001). Total QoL score was improved in verum
patients (P ¼ 0.0254). 5.4% of the patients in the verum group and 4.0% of
the patients in the placebo group developed mild systemic reactions.
Conclusions: The results show that speciﬁc immunotherapy with a depig-
mented polymerized extract of 2 taxonomically non-related pollen (birch and
grass) was effective and safe demonstrated by clinical and immunological
parameter.
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Allergenic Composition of Polymerized Allergen Extracts of
Betula verrucosa, Dermatophagoides Pteronyssinus and
Phleum Pratense
Enrique Fernandez-Caldas, PhD,1,2 Barbara Cases, PhD,1 Jose Ignacio
Tudela, BS,1 Eva Abel Fernandez, BS,1 Miguel Casanovas, MD, PhD,1
and Jose Luis Subiza, MD, PhD1. 1Research & Development, Inmunotek
SL, Madrid, Spain; 2Division of Allergy and Immunology, University of South
Florida College of Medicine, Tampa.
Background: Allergoids have been successfully used in the treatment of
respiratory allergic diseases. They are modiﬁed allergen extracts that allow
the administration of high allergen doses, due to their reduced IgE binding
capacity.They maintain allergen-speciﬁc T-cell recognition. Since they are
native allergen extracts that have been polymerized with glutaraldehyde,
identiﬁcation of the allergenic molecules requires more complicated methods.
The aim of the study was to determine the qualitative composition of different
polymerized extracts and investigate the presence of deﬁned allergenic
molecules using Mass spectrometry.
Methods: Proteomic analysis was carried out at the Proteomics Facility of the
Hospital Nacional de Parapléjicos (Toledo, Spain). After reduction and alkyl-
ation, proteins were digested with trypsin and the resulting peptides were
cleaned using C18 SpinTips Sample Prep Kit; peptides were separated on
an Ultimate nano-LC system using a Monolithic C18 column in combination
with a precolumn for salt removal. Fractionation of the peptides was per-
formed with a Probot microfraction collector and MS and MS/MS analysis of
ofﬂine spotted peptide samples were performed using the Applied Biosystems
4800 plus MALDI TOF/TOF Analyzer mass spectrometer. ProteinPilot Soft-
ware V 2.0.1 and the Paragon algorithm were used for the identiﬁcation of the
proteins. Each MS/MS spectrum was searched against the SwissProt 2010_10
database, Uniprot-Viridiplantae database and Uniprot_Betula database.
Results: Analysis of the peptides revealed the presence of native allergens in
the polymerized extracts: Der p 1, Der p 2, Der p 3, Der p 8 and Der p 11 in
D. pteronyssinus; Bet v 2, Bet v 6, Bet v 7 and several Bet v 1 isoforms in B.
verrucosa and Phl p 1, Phl p 3, Phl p 5, Phl p 11 and Phl p 12 in P. pratense
allergoids. In all cases, potential allergenic proteins were also identiﬁed, in-
cluding ubiquitin, actin, Eenolase, fructose-bisphosphate aldolase, luminal-
binding protein (Heat shock protein 70), calmodulin, among others.
Conclusions: The characterization of the allergenic composition of allergoids
is possible using MS/MS analysis. The analysis conﬁrms the presence of
native allergens in the allergoids. Mayor allergens are preserved during
polymerization.
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AProteomic Style Approach toCharacterize aGrassMix Product
Reveals Potential Immunotherapeutic Beneﬁt
Murray Skinner, PhD, Alan Bullimore, Nicola Swanc, MS, and
Wemimo Alawode, PhD. R & D, Allergy Therapeutics, Worthing, United
Kingdom.
Background: Grass allergy immunotherapies often consist of a mix of
different grass extracts each containing several proteins of different
physiochemical properties; however the subtle contributions of each protein
are difﬁcult to elucidate. This study aimed to identify and characterise the
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group 1 and 5 allergens in a 13 grass extract and to standardise the extraction
method.
Methods: The grass pollens were extracted in isolation and pooled and also
in combination and analysed using a variety of techniques including enzyme-
linked immunosorbent assay (ELISA), liquid chromatography-mass spec-
trometry (LC-MS) and sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE).
Results: Gold-staining and IgE immunoblotting revealed a high degree of
homology of protein bands between the 13 species and the presence of
a densely stained doublet at 25 to 35 kD along with protein bands at
approximately 12.5, 17 and 50 kD. The doublet from each grass species
demonstrated a high level of group 1 and 5 interspecies homology. However,
there were a number of bands unique to speciﬁc grasses consistent with
evolutionary change and indicative that a grass mix immunotherapeutic could
be considered broad spectrum.
Conclusions: SDS-PAGE and IgE immunoblotting showed all 13 grasses
share a high degree of homology particularly in terms of group 1 and 5
allergens. IgE and IgG ELISA potencies were shown to be independent of
extraction method.
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Seasonal Versus Symptom-based Evaluation of a Depigmented
Grass-Birch Allergoid
Oliver Pfaar, MD,1 Tilo Biedermann,2 and Angelika Sager, MD3. 1Center
for Rhinology and Allergology, Department of Otorhinolaryngology, Univer-
sity Hospital Mannheim, Wiesbaden, Germany; 2Department of Dermatol-
ogy, University Hospital, Tübingen, Germany; 3Medical Department, LETI
Pharma GmbH, Witten, Germany.
Background: The safety and efﬁcacy of speciﬁc immunotherapy (SIT) with
depigmented and polymerized allergen extracts of pollen is well documented
in several clinical trials. The results of such clinical studies are highly
dependent on the quantity and quality of pollen exposure and their measure-
ments. To identify a pollen-independent efﬁcacy assessment we compared the
combined symptom and medication score (SMS) measured during the pollen
season with the SMS deﬁned by a minimum symptom score of the placebo
group in a subcutaneous immunotherapy with a depigmented Grass-Birch
allergoid over 2 years.
Methods: 269 (ITT) patients with conﬁrmed rhinitis and/or rhinoconjuncti-
vitis were treated during 2009 and 2010 in Germany, Romania, Poland,
Lithuania, and Bulgaria. Patients were randomised to the treatment groups on
a 2:1 basis (175 verum: 94 placebo). The main parameter in this study was the
combined symptom and medication score during the birch and grass pollen
season 20101. In addition the SMS of the actively treated patients was ana-
lyzed following the placebo treated patients eliciting a considerable symptom
burden .2.
Results: The clinical results following the seasonal approach are given in the
other abstract of our group1. Taking all days with mean symptom score.2 in
the placebo group as calculation basis, the combined SMS values were con-
siderably lower for actively treated patients than for placebo treated patients.
For both seasons, the differences between the treatment groups were highly
statistically signiﬁcant (median; 2009: 5.06 vs 7.97, 2010: 4.26 vs 6.43; ITT
set) with P-values of 0.0038 and 0.003.
Conclusions: The results show that the efﬁcacy assessment of speciﬁc
immunotherapy might be better discriminated in relation to the actual
symptoms of the placebo group rather than following the days of pollen
exposure.
REFERENCE
1. Abstract # 3093: Biedermann T, Pfaar O, Sager A. "Comparison of efﬁcacy
and safety of a depigmented polymerized allergen extract of grass and birch
with placebo in patients with type-I allergic rhinoconjunctivitis.".
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Efﬁcacy and Tolerability of HDM Injective ImmunotherapyWith
Monomeric Allergoid
Enrico Compalati, MD,1 Isabella Atzeni, MD,2 Sergio Cabras, MD,3
Paolo Fancello, MD,2 Giulio Gaspardini, MD,4 Rocco Longo, MD,5
Vincenzo Patella, MD,6,7 and Giorgio Tore, MD8. 1Allergy & Respiratory
Diseases Clinic, University of Genoa, Genova, Italy; 2Servizio di Allergolo-
gia, Ospedale "San Gavino Monreale", ASL 6, Sanluri (CR), Italy; 3Casa di
Cura "Madonna del Rimedio", Oristano, Italy; 4Divisione ORL, Ospedale,
Cagliari, Italy; 5Servizio Territoriale di Allergologia, Azienda Sanitaria Pro-
vinciale, Vibo Valenzia, Italy; 6Division of Clinical Immunology and Allergy,
General Hospital, ASL SALERNO, Agropoli (SA), Italy; 7U.O. di Allergolo-
gia e Immunologia Clinica, Ospedale Generale, Agropoli (SA), Italy; 8Divi-
sione ORL, Ospedale "Santissima Trinità", Cagliari, Italy.
Background: Subcutaneous immunotherapy (SCIT) is an effective treatment of
respiratory allergy and carbamylated monomeric allergoids (monoids), by virtue
of their reduced IgE-binding activity, resulted clinically safe by sublingual
administration. Purpose of this study was to investigate the efﬁcacy and
tolerability of immunotherapy with house dust mites (HDM) monoid admin-
istered by injective route in patients with allergic rhinoconjunctivitis (AR).
Methods: A preparation of 0.70 mL of 10 BU/mL containing modiﬁed
extract with 50% Dermatophagoides pteronyssinus and 50% Dermatopha-
goides farinae (amount of major allergen: 4 mg of group 1 per milliliter) was
delivered monthly for 12 months, following a 5-week build-up induction
phase (0.10–0.20–0.30–0.50–0.70 mL), to 58 patients (60% males, mean
age 25.16 12.7) suffering from AR due to mites for at least 2 years, whereas
60 patients with similar baseline characteristics were observed as controls. All
patients were allowed to assume traditional drug therapy for their condition.
At the end of the study changes from baseline in symptoms scores, in number
of days with drug assumption, in severity of AR (according to ARIA classi-
ﬁcation) were compared between the 2 groups; moreover an overall assess-
ment of clinical efﬁcacy and tolerability was based on patients’ and
physicians’ judgements (unsatisfactory, mild, good, optimal).
Results: In respect to baseline both groups showed, after 1 year, an
improvement in symptoms score (P , 0.001) with a signiﬁcant difference
in favour of SCIT group (P , 0.05). Days of drug intake were signiﬁcantly
lower in patients receiving SCIT (P , 0.05). The number of patients with
severe AR decreased in the ﬁrst group while no variation was observed in
controls. The subjective clinical overall assessment was optimal in 31 cases
and good in 24 according to physicians’ and patients’ judgements; similarly
38 patients judged tolerability as optimal and 18 as good, whereas according
to physicians it was optimal in 37 patients and good in 19; in only 1 patient
the treatment was considered unsatisfactory.
Conclusions: In this prospective controlled study, SCIT with HDM carbamy-
lated allergoid was associated with a signiﬁcant clinical beneﬁt observed
through objective and subjective outcomes; the traditional safety of monomeric
allergoids was conﬁrmed by the subjective judgements of tolerability.
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ComprehensiveDetection of Allergens inGrass PollenExtracts by
Mass Spectrometry
Steffen Augustin, PhD,1 Liane Mitulski,2 Oliver Cromwell, PhD,3
Gerald Reese, PhD,4 and Andreas Nandy, PhD5. 1Allergopharma Joachim
Ganzer KG, Laboratory Molecular Biology, Reinbek, Germany; 2Allergo-
pharma Joachim Ganzer KG, Reinbek, Germany; 3Research and Develop-
ment; 4Allergen Research; 5Molecular Biology Research, Allergopharma
Joachim Ganzer KG, Reinbek, Germany.
Background: More than 40% of type 1-allergic individuals suffer from
hypersensitivity to grass pollen. Patients are treated traditionally with speciﬁc
Abstracts WAO Journal  February 2012
S4  2012 World Allergy Organization
immunotherapy using pollen extracts derived from one or several different
Pooideae species. While for several species the most important allergens
(group 1 and group 5) have been identiﬁed, other allergens have either not
been identiﬁed or sequence data are still missing. We have used mass spec-
trometry (MS) together with genetic and immunological methods to identify
allergens in various grass pollen extracts.
Methods: Pollen extracts of 6 different grass species (Phleum pratense,
Holcus lanatus, Lolium perenne, Dactylus glomerata, Festuca pratensis,
Poa pratensis) and a mixture thereof were analyzed. For identiﬁcation of
allergens by MS, extracts were subjected to enzymatic digestion. Result-
ing peptides were separated by liquid chromatography and analyzed by
tandem mass spectrometry. Protein identiﬁcation was performed by
searching both the NCBIPlant release and an individually designed data-
base. The presence of individual allergens was conﬁrmed with allergen-
speciﬁc monoclonal antibodies. Unknown sequences were determined fol-
lowing cDNA synthesis from pollen RNA and allergen sequence ampliﬁ-
cation by PCR.
Results: Fes p 1 and Fes p 5 were identiﬁed by the PCR approach. MS
analysis of pollen extracts from the 6 individual species resulted in detection
of all known allergens including the newly identiﬁed Fes p 1 and Fes p 5.
Based on the homology of allergens from different grass species, previously
unknown sequences of representatives of groups 2, 3, 4, 7, 11, 12 and 13
were detected by MS in investigated extracts with high sequence coverage.
Group 6 allergens could not be identiﬁed in some of the analyzed extracts.
These ﬁndings are supported by immunological analyses and thus demon-
strate the speciﬁcity of the applied method. Members of all allergen groups
were identiﬁed in an extract mix prepared from pollen of all 6 grass species
studied.
Conclusions: The most important grass allergens (group 1 and group 5) were
detected in all extracts. In addition all other known allergens of the assayed
species and homologues thereof could also be identiﬁed, thus demonstrating
the quality of the tested extracts.
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Gene Expression Pattern of Arabidopsis EXPB1, a Nonallergenic
Homologue of Grass Group 1 Pollen Allergens
Prem Bhalla, PhD, Ruby Tiwari, PhD, and Mohan Singh, PhD. Agriculture
and Food Systems, The University of Melbourne, Parkville, Australia.
Background: Grass pollen allergy is one of the most common allergies
worldwide. Group I allergens constitute the major allergenic component of
grass pollen with more than 85% of grass pollen allergic patients showing IgE
reactivity. These are highly immunologically cross-reactive glycoproteins
speciﬁcally expressed in pollen of all grasses. Alignments of the amino-acid
sequences of grass group I allergens derived from diverse grass species reveal
up to 95% homology. It is therefore likely that these molecules share a similar
biological function.
Methods: RT-PCR analysis, In situ hybridisation, Promoter-GFP construct
design, plant transformation and analysis of transgenic plants.
Results: Sequence comparison has identiﬁed a homologue (b-expansin
clone At2g20750 or EXPB1) in Arabidopsis of the Cyn d 1 gene. The
EXPB1 protein is 42% similar to the Cyn d 1 protein. This gene represents
a member of a small multigene family in Arabidopsis. RT-PCR analysis
showed expression only in ﬂoral not vegetative tissues. In situ hybridisation
using 150 bp region of the 39 UTR of the Arabidopsis gene as probe showed
speciﬁc expression in mature Arabidopsis pollen. We further cloned the
promoter region for the Arabidopsis EXPB1 and prepared and GFP fusion
constructs. These constructs were then introduced in to Arabidopsis plants
by ﬂoral dip method. GFP-promoter fusions showed high level of expres-
sion in tri-cellular pollen.
Conclusions: Our study provides evidence that EXPB1, a non-allergenic
homologue of grass group 1 pollen allergens, gene is expressed in mature
pollen.
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Comprehensive Expression of Recombinant House Dust Mite
Allergens for Component-Resolved Diagnosis
Yoshiharu Watakabe,1 Seiji Kawamoto,1 Hikaru Nakahara,1 Takaaki Hiragun,2
Tsunehiro Aki,1 Yoshiko Asaoku,3 Takaharu Hayashi,4 Shoji Mihara,2
Michihiro Hide,2 and Kazuhisa Ono1. 1Department of Molecular Biotechnology,
Graduate School of Advanced Science of Matter, and; 2Division of Molecular
Medical Science, Department of Dermatology, Graduate School of Biomedical
Sciences, Hiroshima University, Hiroshima, Japan; 3Nagasaki Hospital, Hir-
oshima, Japan; 4Takanobashi Central Hospital, Hiroshima, Japan.
Background: Allergen-speciﬁc immunotherapy (SIT) is the only promising
treatment of allergy. However, current SIT has limitations such as a need for
long-term medication and a risk of systemic anaphylaxis. Those issues are
raised mainly because current SIT procedure is carried out using crude
allergen extract, which may also induce a harmful neo-sensitization. Use of
deﬁned recombinant allergens would be a preferable alternative for the next
generation SIT vaccine as well as for the development of component-resolved
diagnosis (CRD), which enables to prescribe a patient-tailored vaccine.
Objective of this study is to construct a production system of recombinant
house dust mite (Dermatophagoides farinae) allergens, and to test their
usefulness for molecular diagnosis.
Methods: Thus far, the WHO/IUIS allergen nomenclature subcommittee has
approved 24 Dermatophagoides allergens. Among them, we sought to
express 20 groups of D. farinae allergens (Der f 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 13, 14, 15, 16, 17, 18, 20, 21, and 22) using the Escherichia coli cold
shock expression system. We also tried to express additional new antigens
[Mag133 (a highly-conserved UK114/YER057c/YjgF family member),
DFA22 (a new group 2 family member), and DFA67 (peroxiredoxin)] that
we originally identiﬁed as major allergens with high IgE-binding frequencies.
IgE-binding ability of those recombinant allergens was assessed by western
blot analysis. We also tested whether these allergens were applicable for the
development of CRD.
Results: We conﬁrmed successful expression of above D. farinae allergen
molecules as soluble recombinant proteins. Western blot analysis revealed
that these recombinant allergens retained IgE-binding capacity. We also
found that house dust mite-allergic patients showed differential IgE-binding
signatures against them, suggesting that our recombinant allergens are useful
to determine sensitized allergen molecules in individual patients.
Conclusions: Here we carried out the comprehensive expression of
recombinant D. farinae major allergens. The recombinant allergen repertoire
offers an essential platform for the future molecular diagnostics of dust mite
allergy.
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A Bioinformatic Approach to Allergen Nomenclature Applied to
Allergens From the Non-Biting Midge Chironomus
thummi thummi
Heimo Breiteneder, PhD,1 Peter Rozynekc, MSc,2 Monika Raulf-
Heimsoth, PhD,2 Richard Goodman, PhD,3 and Christian Radauer, PhD1.
1Department of Pathophysiology and Allergy Research, Medical University
of Vienna, Vienna, Austria; 2Institute of Prevention and Occupational Med-
icine of the German Social Accident Insurance, Ruhr-University Bochum,
Bochum, Germany; 3Food Allergy Research & Resource Program, Univer-
sity of Nebraska - Lincoln, Lincoln, NE.
Background: Representatives of the family Chironomidae (non-biting
midges; order Diptera) are found worldwide. Freeze-dried chironomid larvae,
predominantly of the species Chironomus thummi thummi are frequently used
as ﬁsh food and are an allergen source for ﬁsh keepers and persons employed
in the manufacture of ﬁsh food. At present, 9 allergens of C. thummi thummi
have been assigned an ofﬁcial designation by the WHO/IUIS allergen no-
menclature sub-committee: Chi t 1 to 9. All of them are hemoglobins with
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molecular weights of 16 kDa. IgE binding and cross-reactivity was clearly
demonstrated for all these proteins. However, the assignment of 9 distinct
allergen numbers to members of the same protein family is quite unusual.
Methods: Currently, the IUIS allergen database contains 12 allergen and
isoallergen sequences from C. thummi thummi. The Uniprot database has
demerged entry P02225, listed in the database for Chi t 7, into 7 entries, 5
from C. thummi thummi and 2 from C. thummi piger that are identical to 2 of
the sequences from C. thummi thummi. Consequently, the 16 unique amino
acid sequences of the mature C. thummi allergens were aligned using Clus-
talX2, a neighbor-joining tree was generated from the alignment and a percent
sequence identity matrix was built to evaluate appropriate nomenclature.
Results: Pairwise sequence alignments showed that sequences belonging to
allergens Chi t 5, 6, 7 and 8 possess sequence identities to Chi t 3 of between 51
and 63%. Chi t 1, 2, 4, and 9 diverge to a greater extent from Chi t 3 (,50%
identical) and from each other. Phylogenetic tree analysis suggests the clustering
of Chi t 3, 6, 7, and 8, while Chi t 1, 2, 4, 5, and 9 form separate clades.
Conclusions: Based on these analyses, the IUIS Allergen Nomenclature Sub-
Committee renames Chi t 5, 6, 7 and 8 isoallergens of Chi t 3, even though
their sequence identities to Chi t 3 are below the 67% threshold previously
deﬁned for isoallergens. The remaining hemoglobins, previously designated
Chi t 1, 2, 4 and 9 will retain their previous names.
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Pollen Allergens Differ From Nonallergenic Pollen Proteins by
Their Lower Extent of Evolutionary Conservation
Christian Radauer, PhD, Eva Guhslc, MSc, Merima Bublin, PhD, and Heimo
Breiteneder,PhD. Department of Pathophysiology and Allergy Research, Medical
University of Vienna, Vienna, Austria.
Background: Pollen contains hundreds of different proteins. However, only
a small fraction of them have been identiﬁed to be allergenic. We aimed to
test the hypothesis that most pollen proteins are non-allergenic due to their
high extent of sequence conservation among non-related species.
Methods: Data on the composition of pollen proteomes of birch (Betula
pendula), pellitory (Parientaria judaica) and timothy grass (Phleum pra-
tense) were obtained from the literature. Sequences were downloaded from
UniProt and manually classiﬁed into allergens and non-allergens. Complete
proteome sequences of 3 dicotyledonous species (Arabidopsis thaliana, Pop-
ulus trichocarpa and Vitis vinifera), 2 monocotyledons (Oryza sativa subsp.
japonica and Zea mays) and one moss (Physcomitrella patents) were down-
loaded from ENSEMBL Plants. Sequences of pollen proteins were compared
to these proteomes by using BLAST and the hits yielding the highest se-
quence identity recorded taking into account only sequence alignments at
least 40 residues in length. The distributions of maximum sequence identities
of allergens and non-allergens from each species were compared using the
Mann-Whitney test.
Results: Allergens from birch and pellitory pollen were signiﬁcantly (P ,
0.001) less similar to proteins from monocots than non-allergenic pollen pro-
teins. Median sequence identities to the nearest rice and maize homologues
were 49 and 52% for birch allergens, 86 and 85% for birch non-allergens, 37
and 37% for pellitory allergens, and 87 and 89% for pellitory non-allergens.
Similarly, timothy grass pollen allergens were signiﬁcantly (P , 0.0001) less
similar to dicot proteins than non-allergenic pollen proteins. Median sequence
identities to the nearest homologues were 43 to 44% for allergens and 81 to
83% for non-allergens. A comparison of all 3 pollen proteomes to sequences
from the moss P. patens yielded similarly signiﬁcant differences.
Conclusions: Pollen allergens belong to evolutionary less conserved protein
families than non-allergenic pollen proteins. The continual exposure of the
human immune system to nearly identical and hence highly cross-reactive
conserved proteins from multiple pollen and plant food species most likely leads
to the induction of immunological tolerance rather than allergic sensitization.
This study was supported by grants P-22559-B11 (to CR) and SFB-F01802
(to HB) from the Austrian Science Fund.
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Sensitization to Betula verrucosa and RBET V1 in Spain
Barbara Cases, PhD,1 Ramon Orjales, MD,2 Guro Gafvelin, PhD,3 Francisco
Carballada,MD, PhD,2 Manuel Boquete, MD, PhD,2 Jose Ignacio Tudela,BS,1
and Enrique Fernandez-Caldas, PhD,1,4. 1Research & Development, Inmunotek
SL, Madrid, Spain; 2Servicio de Alergia, Hospital Xeral-Calde, Lugo, Spain;
3Karolinska Institut, Stockholm, Sweden; 4Division of Allergy and Immunology,
University of South Florida College of Medicine, Tampa, FL.
Background: Sensitization to Betula verrucosa pollen is common in North
Central Europe. In Spain, it is also common in patients from Galicia, a region
located in the Northwest of Spain. Birch trees are abundant in this region and
several birch species have been described. The main objectives were to de-
termine the differences in the IgE reactivity to B. verrucosa and rBet v 1
between patients from Sweden and Spain, as well as the contribution of the
major allergen Bet v 1 to the overall reactivity of B. verrucosa. Allergenicity
was also compared using a serum pool derived from sera of North American
(USA) patients.
Methods: IgE reactivity to B. verrucosa and rBet v 1 was measured in sera
from 44 Spanish and 21 Swedish patients. rBet v 1 was produced as N-
terminal His-tagged fusion protein and puriﬁed as originally described. All
of them were sensitized to the pollen of this tree species and suffered from
allergic rhinitis during the pollination period. rBet v 1 contribution was de-
termined by inhibition ELISA using 3 pools of sera: from Spanish, North
American and Swedish patients. IgE binding pattern was evaluated by West-
ern blots using the same pools of sera. Speciﬁc IgE binding was expressed in
arbitrary units.
Results: Speciﬁc IgE to B. verrucosa was detected in 50 from the 65 sera
analyzed (mean ¼ 3.77 6 3.71 Units). Speciﬁc IgE levels to rBet v 1 were
3.136 3.32 Units. Immunoblot assays conﬁrmed speciﬁc IgE binding to rBet
v 1, and also to other allergens present in the extract. The Spanish pool
presented reactivity to more allergens than the Swedish pool. ELISA Inhibi-
tion assays, performed with a native extract and rBet v 1, revealed a signiﬁcant
contribution (.80% inhibition) of rBet v 1 to the allergenicity of the extract,
with no differences according to the origin of the sera.
Conclusions: Bet v 1 has a great importance in birch allergy in Galicia and
Sweden. Nevertheless, there are differences in the IgE recognition pattern
according to the rest of birch allergens. Mayor allergen from birch, Bet v 1,
signiﬁcantly contributes to the allergenicity of B. verrucosa in Galicia.
ALLERGEN STRUCTURE 2
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Proteomic and Immunological Characterization of
Ragweed Allergens
Steffen Augustin, PhD,1 Marion Stock,2 Oliver Cromwell, PhD,3
Andreas Nandy, PhD,4 and Gerald Reese, PhD5. 1Allergopharma Joachim
Ganzer KG, Laboratory Molecular Biology, Reinbek, Germany; 2Allergo-
pharma Joachim Ganzer KG, Reinbek, Germany; 3Research and Develop-
ment; 4Molecular Biology Research; 5Allergen Research, Allergopharma
Joachim Ganzer KG, Reinbek, Germany.
Background: The prevalence of sensitization to ragweed has risen in North
America and across Europe. Although the pectate lyase Amb a 1, the major
allergen of ragweed, was identiﬁed as long ago as the 1960s, little is known
about the allergenicity of the 5 Amb a 1 isoallergens and other allergens
present in ragweed pollen. Ragweed extracts and puriﬁed Amb a 1
isoallergens have now been characterized for their allergenic potential to
determine whether a single Amb a 1 isoallergen, several isoallergens or
a combination with other allergens should be included in a recombinant SIT
vaccine.
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Methods: Extracts from North American short ragweed (Ambrosia artemi-
siifolia) pollen were investigated by mass spectrometry (MS), 2D-PAGE and
immunoblotting. Furthermore, Amb a 1 isoallergens were puriﬁed and IgE
reactivity determined by immunoblotting and IgE inhibition.
Results: 2D-PAGE and MS of ragweed extract proved the presence of all 5
known Amb a 1 isoallergens, of which Amb a 1.01 represents the dominant
form. Additionally all other ragweed allergens known by sequence (Amb a 3,
Amb a 4, Amb a 5, Amb a 6, Amb a 8, Amb a 9, Amb a 10) were identiﬁed.
The highest IgE reactivity by immunoblotting was observed for Amb a 1.01
followed by Amb a 1.03; other Amb a 1 isoallergens as well as other detected
ragweed allergens showed only weak IgE reactivity. All isoallergens with the
exception of Amb a 1.04, which is only of low abundance in ragweed extract,
were puriﬁed. Similar to the immunoblot analysis with crude extract, the
puriﬁed isoallergens Amb a 1.02 and Amb a 1.05 showed weak IgE binding,
whereas Amb a 1.01 and Amb a 1.03 had high IgE reactivity. First IgE
inhibition experiments suggest that Amb a 1.01 contains all relevant IgE
epitopes.
Conclusions: Amb a 1.01 is the most abundant Amb a 1 isoallergen, and
presumably the most important ragweed allergen. However, a larger panel of
ragweed-allergic subjects has to be analyzed with regard to IgE and T cell
reactivities, to be able to choose a candidate for a recombinant vaccine for
speciﬁc immunotherapy of ragweed allergy.
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Proteomic Analysis of Major and Minor Allergens From Isolated
Pollen Cytoplasmic Granules
Oussama Abou Chakra, PhD,1,2 Jean-Pierre Sutra, PhD,1 Emmanuelle Demey
Thomas, MSc,3 Joëlle Vinh, PhD,3 Pascal Poncet, PhD,1,4 Ghislaine Lacroix,
PhD,5 and Hélène Sénéchal, PhD,1,6. 1LSABM - Allergy and Environment,
ESPCI ParisTech, Paris, France; 2R & D, FAREVACARE, Savigny le Temple,
France; 3SMBP - CNRS USR 3149, ESPCI ParisTech, Paris, France; 4Infec-
tion and Epidemiology, Institut Pasteur, Paris, France; 5DRC - TOXI, INERIS,
Verneuil-en-Halatte, France; 6CSS 5, INSERM, Paris, France.
Background: Grass pollen is one of the most important vectors of
aeroallergens. Under atmospheric conditions, pollen grains can release pollen
cytoplasmic granules (PCGs). The allergens associated with these intrinsic
sub-fractions induce, in laboratory animals as well as in asthmatic patients
allergic and inﬂammatory responses. The aims of this study were to
characterize and identify the intrinsic allergens of PCGs, to compare them
with those of pollen grains.
Methods: PCGs were isolated from Phleum pratense pollen by osmotic
shock. The water-soluble proteins were extracted from pollen grains and
their PCGs. Nine out of 26 grass sensitized patient sera were selected on
the basis of previous ELISA and immunoblotting results showing IgE
speciﬁc binding to numerous grass pollen allergens. IgE-binding pro-
teins were analyzed by 1- and 2D-immunobloting using grass pollen-
sensitized patient sera. Once located, allergens were characterized by
mass spectrometry.
Results: 2D gels of pollen and PCGs extract revealed about 100 and 40
proteins respectively, with a large spectrum of Mr (10–.94 kDa) and pI
(,4.5–10.0). More proteins as well as more allergens in pollen than in
PCGs were detected by immunoblotting. Several of the allergens listed in
the IUIS nomenclature - Phl p 1, 4, 5, 6, 11 and 12 - were found in pollen
and PCGs extracts while Phl p 11 was found only in PCGs and Phl p 2 as
well as Phl p 13 only in pollen extract. Some other allergens, not listed in
the IUIS nomenclature, were also characterized in both pollen and PCGs
extracts.
Conclusions: Since the major grass pollen allergens were found in PCGs
and because of their small size, these sub-micronic particles should be
considered as very potent sensitizing and challenging respirable vectors of
allergens. We demonstrate here that PCGs are at least as much dangerous as
pollen grains.
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Cross-Reactivity Between Olive Pollen and 3 Species of Grasses in
Madrid, Spain
Enrique Fernandez-Caldas, PhD,1 M. Dolores Ibañez, MD,2 Barbara
Cases, PhD,1 Eva Abel Fernandez, BS,1 Jose Ignacio Tudela, BS,1
Silvia Sanchez-Garcia, MD,2 Pablo Rodriguez del Rio, MD,2 and Miguel
Casanovas, MD, PhD1. 1Research & Development, Inmunotek SL, Madrid,
Spain; 2Allergy Section, Hospital Infantil Universitario Niño Jesús, Madrid,
Spain.
Background: The most common allergenic pollens in patients with pollinosis
in Central Spain are grasses and olive pollen, with a prevalence of positive
skin prick test results of 94 and 61%, respectively. Shared proteins have been
described in olive and grasses, such as proﬁlins, polcalcin and trypsin
inhibitors, but there are few in vitro studies analyzing the potential cross
reactivity between both species. The aim of the present study was to analyze
the protein composition of both allergen extracts, and the allergenic cross-
reactivity between O. europaea and different grass pollen species.
Methods: Seventy-two (72) patients (mean age 10.4 years) were included in
the study. All of them suffered rhinoconjuntivitis and/or asthma and were
sensitized to olive and/or grass pollen. Speciﬁc IgE of the individual patients
against O. europaea, and to the grass species: Dactylis glomerata, Phleum
pratense and Trisetum paniceum were determined by ELISA. Inhibition
assays were performed to verify allergenic crossreactivity between grass spe-
cies and olive. Mass spectrometry analysis was performed to characterize the
extracts and establish if there are common proteins in both, grass and olive
pollens, that could act as cross reactive proteins.
Results: Three different sensitization patterns were observed: 1) sensitization
to olive and grass pollen, 2) sensitization to olive and not to grasses and 3)
sensitization to grasses and not to olive. Different pools of sera were mixed
according to this classiﬁcation and used for the different assays. Correlation
coefﬁcients found for the 3 grass species were signiﬁcant (P , 0.0001;
Spearman), but not for olive pollen (P ¼ 0.14; Spearman). Proteomic analysis
revealed the presence of more than 40 common proteins in grasses and olive
pollens, but inhibition assays demonstrated no allergenic cross-reactivity be-
tween both families.
Conclusions: There is no in vitro crossreactivity between O. europaea and
Grass pollen extracts, in spite of the allergens and the large number of
common proteins shared by these pollens. We can conclude that sensitization
to olive and grasses is species speciﬁc.
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Molecular Properties and Immunological Reactivity of
Arabidopsis EXPB1, a Nonallergenic Homologue of Grass Group
1 Allergens
Mohan Singh, PhD, Ruby Tiwari, PhD, and Prem Bhalla, PhD. Agriculture
and Food Systems, The University of Melbourne, Parkville, Australia.
Background: Grass group 1 allergens are glyco-proteins of about 30kDa that
are highly soluble and profusely released by grass pollen upon hydration.
They bind to IgE antibodies that initiate the allergic response causing hay
fever, seasonal asthma, and related immune responses in humans. Bermuda
grass (Cynodon dactylon; subfamily Chloridoideae) is an important source of
seasonal aeroallergens in warm tropical and sub-tropical areas worldwide.
Improved approaches to diagnosis and therapy of allergic diseases require
a thorough understanding of the structure and epitopes on the allergen mol-
ecule that are crucial for the antigen-antibody interaction. In order to under-
stand structural basis of IgE reactivity of group 1 allergen Cyn d1, we have
pursued a comparative genomic approach to search for hypoallergenic or non-
allergenic homologues.
Methods: Gene cloning, Protein expression in bacteria, protein structure
modeling, IgE reactivity analysis through Immunoblotting.
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Results: EXPB1, an Arabidopsis protein (belonging to the beta expansin
multi gene family), showed signiﬁcant sequence and structural similarity to
Cyn d 1. This protein was expressed in E. coli and the recombinant protein
did not react with serum IgE from grass pollen allergic patients, suggesting
that EXPB1 represented a non-allergenic homologue of grass group 1 aller-
gens. It is proposed that differences in the amino acid sequence are respon-
sible for the difference in the allergenicity proﬁle of the Arabidopsis and grass
pollen proteins.
Conclusions: Our study provides valuable data for further investigations of
the molecular basis of allergenicity and cross-reactivity of grass group 1
allergens.
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Protein-Protein Interactions Determine IgE Reactivity to
Polygalacturonase From Cupressus sempervirens Pollen
Youcef Shahali,1 Jean-Pierre Sutra, PhD,1 Sylvie Chollet-Martin,2
Iman Haddad,3 Joëlle Vinh, PhD,3 Adriano Mari, MD,4 Denis Charpin,5
Hélène Sénéchal, PhD,1,6 and Pascal Poncet, PhD,1,7. 1UMR 7195 LSABM,
ESPCI-ParisTech, Paris, France; 2Unity of Immunology Autoimmunity and
Hypersensibility, Bichat Hospital, Paris, France; 3USR 3149 SMBP, ESPCI-
ParisTech, Paris, France; 4CMA, Rome, Italy; 5Hopital Nord de Marseille,
Marseille, France; 6CSS 5, INSERM, Paris, France; 7Infection and Epide-
miology, Institut Pasteur, Paris, France.
Background: In a recent proteomic study, we identiﬁed in Italian cypress
(Cupressus sempervirens, Cups) pollen grains, 2 proteins at 43 and 60
kDa, homologous to already known Cupressaceae polygalacturonase
(PG) proteins. The 60-kDa PG is suspected to be a multi-protein complex
including the 43-kDa PG and one or more proteins with lectin-like
properties
Objective: In the present study, cypress pollen PGs were further character-
ized and the molecular basis of their allergenicity including the presence of
speciﬁc IgE directed against cross-reactive carbohydrate determinants
(CCDs) were investigated.
Methods: Cups pollen PBS extracts were characterized using 2- and dou-
ble one-dimensional electrophoresis followed by IgE immunoblotting. The
IgE reactivity to carbohydrate- versus peptide-speciﬁc determinants was
investigated using both bromelain inhibition and Con A-binding assays.
Pollen proteins were also prefractionated in their native forms using
size exclusion chromatography. The presence of multi-protein complexes
were investigated by using 2-D blue native (BN)-PAGE/SDS-PAGE
electrophoresis.
Results: Upon bromelain inhibition assay, we revealed that 70% of tested
patients displayed CCD-speciﬁc IgE to the 43-kDa PG while its isoenzyme
of 60 kDa appeared to be exclusively recognized for its peptide-speciﬁc
determinants. The speciﬁc binding of the Con A lectin to the 43-kDa PG,
and not to the 60-kDa isoenzyme, demonstrated the presence of exposed
mannose-containing oligosaccharides only on the 43-kDa protein. This fact
reﬂects fundamental differences between speciﬁc IgE-binding epitopes
involved in the recognition of the 43-kDa and 60-kDa proteins making
these 2 cypress pollen PGs immunologically distinguishable. The present
results suggest that in the 60-kDa protein complex, the CCDs of the 43-
kDa PG are not exposed due to the binding of a lectin-like protein
exhibiting peptidic IgE reactive epitopes recognized by 25% of tested
patients.
Conclusion: The current study demonstrates that the sensitization to the Cups
pollen PG is mainly due to CCD bromelain-type epitopes and directly asso-
ciated with an increased prevalence of IgE reactivity to cypress pollen
extracts due to CCD interference. However, the Cups pollen PG and its
carbohydrate-speciﬁc determinants seem to play a key role in the dynamics
of protein-protein interaction in cypress pollen and may confer to protein
complexes a higher allergenicity.
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Grafting of BETV1Epitopes onto itsHomologueAPIG1Reveals
Patient-Speciﬁc IgE Recognition Proﬁles
Barbara Gepp,1 Nina Balazs,1 Wolfgang Hemmer,2 Christian Radauer, PhD,1
and Heimo Breiteneder, PhD1. 1Department of Pathophysiology and Allergy
Research, Medical University of Vienna, Vienna, Austria; 2Floridsdorfer Aller-
giezentrum, Vienna, Austria.
Background: Up to 70% of birch pollen-allergic individuals show adverse
reactions to certain plant foods. This cross-reactivity is caused by sensitisation
to the major birch pollen allergen Bet v 1 and binding of Bet v 1-speciﬁc IgE
antibodies to homologous plant food allergens. We aimed to assess the
importance of selected conformational epitopes for IgE binding to Bet v 1.
Methods: Chimeras of Bet v 1.0101 and its homologue Api g 1.0101 were
constructed. In each of the 4 chimeras, roughly one fourth of the surface residues
of Api g 1.0101 were replaced by corresponding residues of Bet v 1.0101. The
proteins were expressed in Escherichia coli and puriﬁed by chromatographic
methods. Secondary structures were checked by CD-spectroscopy. IgE ELISA
with Bet v 1.0101, Api g 1.0101 and the chimeras were performed with sera of 63
Bet v 1-sensitized birch pollen allergic patients. For inhibition ELISAs, chimeras
were coated and inhibition was performed with the chimeras or Api g 1.0101.
Results: IgE binding to Api g 1.0101, Api-Bet-1, -2, -3 and -4 was observed for
22, 81, 79, 70 and 38% of the sera, respectively. To assess the relevance of the
grafted regions for IgE binding to Bet v 1, the amounts of IgE binding to the
chimeras were compared with those to Api g 1.0101. Most of the sera recognised
either 3 chimeras (39%) or all 4 chimeras (21%) better than Api g 1.0101. Only
a minority of the sera showed increased binding to a single chimera. Inhibition
ELISAs conﬁrmed the presence of IgE speciﬁc for the grafted regions.
Conclusions: Our study indicates that the epitope recognition proﬁle of Bet v
1-speciﬁc IgE is highly patient speciﬁc. Due to the different IgE binding
patterns to Bet v 1, determined by binding of IgE to different chimeras, the
existence of a single major IgE epitope on Bet v 1 can be excluded.
Moreover, the Bet v 1-speciﬁc IgE repertoire is polyclonal and the IgE
epitopes are distributed over the whole surface of Bet v 1.
This study was supported by grants P22559-B11 (CR) and SFB-F01802 (HB)
from the Austrian Science Fund.
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Common and Rare Variation in the T Helper 2 Gene Pathway
Predicts Allergic Asthma Phenotypes
Rebecca Slager, PhD, MS,1 Wendy Moore, MD,2 Huashi Li, MS,2
William Busse, MD,3 Mario Castro, MD, MPH,4 Serpil Erzurum, MD,5
Anne Fitzpatrick, PhD,6 Sally Wenzel, MD,7 Deborah Meyers, PhD,1
and Eugene R. Bleecker, MD1. 1Center for Genomics and Personalized
Medicine Research, Wake Forest University Health Sciences, Winston-Salem,
NC; 2Center for Genomics and Personalized Medicine Research, Wake For-
est University School of Medicine, Winston Salem, NC; 3Medicine, University
of Wisconsin School of Medicine and Public Health, Madison, WI; 4Division
of Pulmonary and Critical Care Medicine, Washington University School of
Medicine, St. Louis, MO; 5Department of Pathobiology, Lerner Research
Institute, Cleveland, OH; 6Department of Pediatrics, Emory University,
Atlanta, GA; 7Medicine, University of Pittsburgh, Pittsburgh, PA.
Background: The T helper 2 (Th2) inﬂammatory pathway, including the
Th2-activating cytokine interleukin 33 and its receptor interleukin 1 receptor-
like 1 have been strongly implicated in asthma susceptibility (Moffatt MF, et
al NEJM 2010). However, the role of Th2 pathway genetic variation in
asthma progression and severity is not well understood. Our research group
recently developed a clustering algorithm based on comprehensive phenotype
information to assign subjects with asthma in the Severe Asthma Research
Program (SARP) to 5 primary clusters; 3 of which represent increasing severe
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allergic asthma (Moore WC, et al AJRCCM, 2010). We hypothesized that
common and potentially deleterious rare variation in this pathway would be
associated with severe asthma based on SARP cluster designation.
Methods: To evaluate common variants (minor allele frequency or MAF
.5%), 419 SARP non-Hispanic white participants with a cluster assignment
were genotyped for 182 single nucleotide polymorphisms (SNPs) in Th2 path-
way genes using whole-genome SNP data. Individual SNPs and a cumulative
model of signiﬁcant SNPs were evaluated using contingency tables with a chi-
square test for trend and ordinal regression models adjusted for age, sex, and
principal components. Rare (MAF ,5%) amino acid changes and splice site
alterations in this pathway were tested for association with asthma severity
outcomes in 20 SARP subjects with whole exome sequence data.
Results: Individual Th2 pathway variants were associated with overall SARP
cluster assignment, and allergic clusters of increasing severity (1, 2, and 4),
including GATA3 polymorphism rs1244186 (P ¼ 0.005). In an 18-SNP
additive model, an increasing number of Th2 pathway risk genotypes were
highly associated with severe allergic asthma (P ¼ 3.9 · 1026). For example,
in cluster 4, the percentage of subjects with at least 9 risk genotypes was 83%
compared to 35% in cluster 1. Additionally, there was evidence that subjects
with rare variants in this pathway were more likely to report allergy symp-
toms (P ¼ 0.006), especially in the fall (P ¼ 0.003), compared to subjects
with no rare variants.
Conclusions: Common Th2 pathway variants predict an increased likelihood
of severe allergic asthma and rare variants were associated with increased
seasonal allergy symptoms.
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Role of Myeloid Derived Suppressor Cells in Asthma
Allison Nelson,1 Jim Parkerson, DO,2 Richard F. Lockey, MD,2 Subhra
Mohapatra, PhD,3 Shyam Mohapatra, PhD,4 and Srinivas Nagaraj, PhD1.
1Nanomedicine Research Center and Divisions of Translational Medicine
and Allergy and Immunology, Department of Internal Medicine, University
of South Florida, Tampa, FL; 2Division of Allergy & Immunology, University
of South Florida and James A. Haley Veterans’ Hospital, Tampa, FL;
3Nanomedicine Research Center and Divison of Translational Medicine,
Departments of Molecular Medicine and Internal Medicine, University of
South Florida and James V Haley Veterans’ Hospital, Tampa, FL; 4Nano-
medicine Research Center and Divisions of Translational Medicine, Allergy
and Immunology, Departments of Internal Medicine and Molecular Medi-
cine, University of South Florida and James V Haley Veterans’ Hospital,
Tampa, FL.
Background: We know that a heterogeneous group of myeloid cells termed
myeloid derived suppressor cells (MDSC) accumulate in almost all
pathological conditions, which elicit an inﬂammatory signal. The exact role
played by these cells in asthma is not known. In this study we investigated the
function and role of these cells in asthma.
Methods: Accumulation of MDSC and other subsets of myeloid cells were
analyzed from peripheral blood mononuclear cells from patients with non-
severe asthma (FEV1) .60) and severe asthma (FEV1 ,60) by multicolor-
ﬂowcytometry and compared to healthy controls. Allergic mouse models
were used to determine the role of microRNA-142 (miR-142) in regulation
and expansion of MDSC.
Results: There is a signiﬁcant increase in the proportion of MDSC in severe
versus non-severe asthmatics and controls, corresponding to a decrease in
myeloid dendritic cells. Allergic mice had signiﬁcant increased levels of
MDSC expansion which were associated with increased levels of IL-6 and
downregulation of miR-142. miR-142 overexpression induced MDSC
differentiation.
Conclusions: An accumulation of MDSC is associated with severe asthma in
humans and mice. In an allergic mouse model, IL-6 levels increase. miR-142
may play an important role in regulation and differentiation of MDSC,
leading to altered immunity.
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MIR-150 Suppresses Lung Inﬂammation in a Mouse Model of
Experimental Asthma
Jia-Wang Wang, PhD,1 Kunyu Li, BS,1 Gary Hellermann, PhD,1 Richard F.
Lockey, MD,2 Subhra Mohapatra, PhD,3 and Shyam Mohapatra, PhD4.
1Internal Medicine, University of South Florida, Tampa, FL; 2Division of
Allergy & Immunology, University of South Florida and James A. Haley
Veterans’ Hospital, Tampa, FL; 3Nanomedicine Research Center and Divi-
son of Translational Medicine, Departments of Molecular Medicine and
Internal Medicine, University of South Florida and James V Haley Veterans’
Hospital, Tampa, FL; 4USF Nanomedicine Research Center, University of
South Florida College of Medicine & VA Hospital, Tampa, FL.
Background: Asthma is a complex disorder of the immune system caused by
a combination of genetic predisposition with environmental exposures. The
environmental factors play a predominant role in the etiology of asthma. It is
hypothesized that epigenetic changes in miRNAs play a critical role in
pathogenesis of asthma as an interface between genetic makeup and
environmental exposures. (Wang, Jia-wang; Li, Kunyu; Hellermann, Gary;
Lockey, Richard F.; Mohapatra, Subhra; and Mohapatra, Shyam. Regulating
the Regulators: microRNA and Asthma.World Allergy Organization Journal.
June 2011, Volume 4, Issue 6).
Methods: In the present study, we used miRNA array proﬁling in a mouse
model of ovalbumin-induced asthma to identify differentially regulated
miRNAs and characterized miR-150 in terms of cellular and humoral
involvement and analysis of lung inﬂammation markers.
Results: We found that miR-150 was downregulated in CD4 T lymphocytes
during asthmatic inﬂammation and Th1 and Th2 induction. Over-expression of
miR-150 delivered by chitosan nanoparticles inhibited lung inﬂammation and
decreased Th1 and Th2 cytokine levels. miR-150 suppressed Akt3, Cbl1 and
Elk1 oncogenes, which are involved in inﬂammation and cytokine production.
Transgenic mice overexpressing miR-150 are resistant to asthma induction,
demonstrated by reduced AHR and cytokine inﬂammation production.
Conclusions: These results suggest that deregulation of miRNAs may be
involved in the pathogenesis of asthma and miR-150 may suppress in-
ﬂammation in asthma by inhibiting cytokine production by downregulating
critical genes such as Akt, Elk1 and Cbl1. miR-150 may be an attractive
candidate for asthma gene therapy.
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Serine Protease Inhibitor Attenuates Ova Induced Inﬂammation
in Mouse Model of Allergic Airway Disease
Sanjay Sawc, MSc, Sagar Kalec, MSc, Bhanu Pratap Singh, PhD, and
Naveen Arora, PhD. Allergy and Immunology, Institute of Genomics and
Integrative Biology, Delhi, India.
Background: Serine proteases promote inﬂammation and tissue remodeling
by activating proteinase-activated receptors, urokinase, metalloproteinases
and angiotensin. In the present study, AEBSF (4-(2-Aminoethyl) benzene-
sulfonyl ﬂuoride) a serine protease inhibitor, was evaluated for prophylactic
and therapeutic treatment in mouse model of airway allergy.
Methods: BALB/c mice were sensitized by i.p route on 0 and 14 day and
challenged with OVA (25, 26 and 27 day) by i.n. route. Mice were treated i.n. with
AEBSF, 1 hour before/after challenge and sacriﬁced on day 29 to collect BALF,
blood and lungs. OVA speciﬁc immunoglobulins were measured in serum.
Proteolytic activity, total cell/eosinophil count, eosinophil peroxidase activity
(EPO), IL-4, IL-5, IL-10, cysteinyl leukotrienes and 8-isoprostane (oxidative stress
marker) were determined in BALF. Haematoxylin and eosin stained lung sections
were examined for cellular inﬁltration and airway inﬂammation.
Results: Mice exposed to OVA and treated with PBS showed signiﬁcantly
high levels of IgE, IgG1 and IgG2a as compared to sham mice. Both
prophylactic and symptomatic AEBSF treatment reduced serum IgE and
IgG1 signiﬁcantly (P# 0.05) than control, however there was little increment
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in IgG2a level. AEBSF could effectively reduce the proteolytic activity in
BALF. IL-4 and IL-5 decreased signiﬁcantly (P # 0.05) after AEBSF treat-
ment while a signiﬁcant (P # 0.05) increase was observed in IL-10 in BALF.
Airway inﬂammation reduced signiﬁcantly as revealed by lung histopathol-
ogy, EPO activity and cysteinyl leukotrienes in BALF after treatment.
AEBSF also suppressed oxidative stress in terms of 8-isoprostane in BALF.
Among the treatment doses, 10 and 50 mg of AEBSF were most effective in
reducing majority of the inﬂammatory parameters.
Conclusions: Prophylactic and therapeutic treatment of AEBSF attenuates
the airway inﬂammation in mouse model of airway allergy and have potential
for the treatment of inﬂammatory allergic diseases.
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Potential Role of Scavenger Receptors in Human Mast Cell
Cytokine Response to Oxidized ldl
Rita Faigerc, MSc,1 Jani Lappalainenc, MSc,2 Wolfgang J. Schneider, PhD,3
Petri Kovanen, MD, PhD,2 and Francesca Levi-Schaffer, PhD4. 1Department
of Pharmacology, The Hebrew University of Jerusalem, Jerusalem, Israel;
2Wihuri Research Institute, Helsinki, Finland; 3Department of Molecular
Genetics, University of Vienna, Vienna, Austria; 4Department of Pharmacol-
ogy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine,
The Hebrew University of Jerusalem, Jerusalem, Israel.
Background: Human atherosclerotic lesions contain mast cells and oxidatively
modiﬁed low-density lipoprotein particles (oxLDL). Scavenger receptors are cell
surface receptors that bind and internalize oxLDL, and they play an important
role in macrophage foam cell development, a key event in the initiation and
development of atherosclerotic lesions. The purpose of the study was to analyze
expression of the most common scavenger receptors in mast cells, and determine
whether oxLDL particles can induce them to secrete pro-inﬂammatory cytokines
that are potentially capable of inducing and amplifying atherogenic processes.
Methods: Mast cells were differentiated from human cord blood-derived
CD341 progenitor cells in vitro (CBMC), and their expression of scavenger
receptors was analyzed by conventional RT-PCR, ﬂow cytometry and West-
ern blot techniques. Fluorescently-labeled oxLDL was used to investigate
LDL internalization by mast cells. Secretion of pro-inﬂammatory cytokines
into the incubation medium and degranulation of the mast cells in response to
oxLDL were assayed by ELISA and a colorimetric-enzymatic test for beta-
hexosaminidase, respectively.
Results: CBMC expressed mRNA and protein for LOX-1, SR-AI and CD68,
but not for CD36, and the expression of LOX-1 and SR-AI was upregulated by
incubation of the cells with oxLDL. CBMC internalized oxLDL more efﬁciently
than native LDL, while simultaneous neutralization of CD68, SR-AI and LOX-1
with monoclonal antibodies resulted in reduced oxLDL uptake. Moreover, in
response to oxLDL, CBMC showed increased release of b-hexosaminidase, and
a dose-dependent secretion of the pro-inﬂammatory cytokines IL-8 and MCP-1.
Conclusion: Our results reveal that cultured human mast cells express
scavenger receptors that are upregulated by oxLDL. In atherosclerotic lesions,
oxLDL may activate MC to secrete pro-inﬂammatory cytokines, and so they




Allergic Rhinitis to Ragweed Pollen
Ioana Corina Bocsan,1 Ioana Adriana Bujor, MD,2 Cristina Barbinta, MD,3
and Diana Deleanu, MD, PhD2. 1Clinical Pharmacology; 2Immunology-
Allergology, University of Medicine and Pharmacy, Cluj- Napoca, Romania;
3Allergology, Almedo Clinic, Cluj Napoca, Romania.
Background: The prevalence of pollen allergy is estimated around 40% in
general population. Ragweed (ambrosia artemisiifolia) pollen represents
a major source of allergen but was rare in Romania. The aim is to evaluate
the symptoms and associated factors in patients with allergic rhinitis to
ragweed pollen in the northwest region of Romania.
Methods: 74 patients (pts) (mean age 27.97 6 13.85 years) with allergic
rhinitis to ragweed pollen were included in the study. The patients were
clinically evaluated regarding the severity of the symptoms on a scale from
0 to 3 and their duration. A total score over 6 indicates a moderate/severe
form of rhinitis. We evaluated the association with other allergic manifesta-
tions (asthma and urticaria). All the patients had skin prick tests to inhalant
allergens. The obtained data were statistically analyzed using Anova, Chi-
square and Fischer tests, with a signiﬁcance of P , 0.05.
Results: 50.94% of the pts were female. 58.1% of them presented mild
allergic rhinitis, while 41.9% moderate severe forms. 27% of the pts were
monosensitised to ragweed pollen and 73% of the pts were polisensitised. The
patients monosensitised to ragweed had moderate/severe forms of rhinitis (14
vs 86%, P¼ 0.004) compared with polisensitised group. The symptoms score
was higher in pts with monosensitisation compared with polisensitisation pts
(7.05 vs 5.28, P ¼ 0.02). In monosensitized group the ocular szmptoms were
more frequently present (65 vs 18%, P ¼ 0.02) and were more severe (0.65 vs
0.33, P ¼ 0.01). The number of pts with association of allergic rhinitis and
asthma was higher in the polisensitised group compared to the monosensi-
tised one (44.4 vs 11.11%, P ¼ 0.029). The interval between the onset of the
symptoms and diagnosis of rhinitis is higher in polisensitised pts and signif-
icantly increased in pts with asthma. There is no correlation between envi-
ronment (rural–urban), age, sex, family and personal allergic history and the
type of sensitisation and severity of the symptoms.
Conclusions: Ragweed produces intense allergogen pollen and determines
severe forms of allergic rhinitis and also the presence of ocular symptoms.
Polisensitisation increases the risk of associated asthma and also increases the
interval betweeen the onset of the symptoms and diagnosis.
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Ragweed Allergy –What Role Does It Play in Bavaria?
Mareike McIntyre,1,2 Teresa Jaeger,1,2 Johannes Huss-Marp,1,2 Michael Hauser,3
Fatima Ferreira,3 Markus Ollert,1 Johannes Ring,1 Carsten Schmidt-Weber,2
Heidrun Behrendt,2 and Ulf Darsow,1,2. 1Department of Dermatology and
Allergy Biederstein, Technische Universitaet Muenchen, Munich, Germany;
2Center of Allergy and Environment (ZAUM), Helmholtz Center Munich/
Technische Universitaet Muenchen, Munich, Germany; 3Department of
Molecular Biology, University of Salzburg, Salzburg, Austria.
Background: Ragweed (Ambrosia artemisiifolia), is increasingly spreading
in Southern Germany and Central Europe. Little is yet known about the
sensitization and allergy rates in Bavaria.
Methods: In 2008 to 2010 patients from a Bavarian university allergy unit
were enrolled into the study. The patient’s history was recorded by a stand-
ardised questionnaire concerning allergies. Sensitization rates were measured
by skin prick test (SPT) for seasonal aeroallergens including ragweed.
Patients sensitized to ragweed were further characterized by measuring
speciﬁc serum immunoglobulin E (IgE) for ragweed speciﬁc allergens
(by ImmunoCAP and ELISA). To determine the clinical relevance challenge
tests (nasal/conjunctival) with ragweed were performed.
Results: 1022 patients were enrolled in the study (665 female, 357 male). 289
patients were sensitized to ragweed (SPT positive). In ragweed sensitized
patients the sensitization rate to mugwort was 61.8% whilst in patients not
sensitized to ragweed it was 7.4%. The sensitization to birch was 78.1% resp.
36.4%. In 120 ragweed sensitized patients challenge tests with ragweed extract
were performed (nasal n ¼ 110; conjunctival n ¼ 60) with positive results in 29
(26%) resp. 12 (20%) patients. In 232 ragweed sensitized patients speciﬁc IgE
to nArt v 1 was observed signiﬁcantly more frequently than to nAmb a 1.
Conclusions: The results of this 3-year study show that in a Bavarian allergy
unit sensitization to ragweed is frequent. Often ragweed-sensitized patients
have sensitivities to multiple seasonal aeroallergens. There is a coexistence of
ragweed and mugwort speciﬁc allergens. One fourth of the challenged
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patients that are sensitized to ragweed show clinical allergy symptoms. With
sufﬁcient ambient allergen exposure, a prolonged allergy season can be
expected for this at-risk population.
Supported by grant #34a-G8158.2-2007/3-6 by the Bavarian State Ministry of
the Environment and Public Health.
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Nasal Nitric Oxide and Nasal Polyposis as Determinants of
Asthma Control
Enrico Hefﬂer, MD, Stefano Pizzimenti, MD, Carolina Quaccia, MD,
Iuliana Badiu, MD, and Giovanni Rolla, MD. Biomedical Sciences and
Human Oncology, Allergy and Clinical Immunology - University of Torino -
AO Mauriziano "Umberto I", Torino, Italy.
Background: The relationship between asthma control, its comorbidities and
noninvasive markers of airway inﬂammation has been investigated with
controversial results. The aim of this study was to analyze the relationship
between level of asthma control (evaluated by ACT and ACQ question-
naires), its main comorbidities (rhinitis, chronic rhinosinusitis - CRS,
obesity), exhaled nitric oxide (FENO) and nasal nitric oxide (nNO).
Methods: Forty-one consecutive asthmatic patients (mean age: 50 years, range:
21–80; 21 females; 2 smokers) were enrolled into the study. All patients were
investigated to assess diagnosis of rhinitis, CRS (with or without nasal polyps) and
obesity (by measuring the BMI). All patients underwent skin prick tests for a panel
of common inhalant allergens, spirometry, FENO and nNO, and completed ACT
and ACQ questionnaires. An univariate analysis was performed to identify deter-
minants of asthma control (deﬁned by means of ACT and ACQ values).
Results: Twenty-seven (65.9%) patients had ACQ values indicating asthma
control (ACQ #1), while, according to ACT, only 14.6% of patients were
completely controlled (ACT ¼ 25), 48.8% partially controlled (20$ ACT
,25) and 36.6% uncontrolled (ACT ,20). ACT and ACQ values were
negatively correlated with nNO levels (R2 ¼ 20.175 and R2 ¼ 0.013 re-
spectively). The univariate analysis showed that the the only signiﬁcant
determinants of lack of asthma control were nNO and the diagnosis of
CRS with nasal polyps (P ¼ 0.020 and 0.018 respectively).
Conclusions: Nasal nitric oxide was the only biomarker, amongst those
evaluated, which was correlated to asthma control. This ﬁnding suggests that
nNO may reﬂect particular aspects of airway inﬂammation which may be
more strictly correlated with asthma, underlying the importance of CRS with
nasal polyps in loosing asthma control.
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Peak Nasal Inspiratory Flow Levels in Children With Allergic
Rhinitis and Their Health Related Quality of Life (HRQL)
Major K. Nagaraju . Pediatric allergy and immunology, Kanchi Kamakoti
CHILDS Trust Hospital, Chennai, India.
Background: Allergic rhinitis impairs the quality of life children. There is
paucity of data with regards to clinical proﬁle and health related quality of life
(HRQL) of children with Allergic rhinitis in India and hence we studied the
clinical proﬁle and measured Peak nasal inspiratory ﬂow (PNIF) of children
with allergic rhinitis in an urban population, and assessed their Quality of life.
Methods: Children with moderate to severe persistent Allergic rhinitis,
diagnosed as per Allergic Rhinitis and Impact on Asthma (ARIA) guidelines,
in the age group of 6 to 18 years were included in this study. The quality of
life questionnaire, pediatric and adolescent by Juniper et al was used. PNIF
was measured by using ‘In- Check’ peak nasal inspiratory ﬂow meter.
Results: Of the 100 children studied, 70 (70%) were in the age group of 6 to
11years and 30/100 (30%) were between 12 and 18 years of age. An equal
distribution of sex was observed in 6 to 11 year age group, and in the 12 to 18
year age group there was a male preponderance (1.9:1). Majority (87%) of
children in our study had Moderate Allergic rhinitis and 13% had severe
Allergic rhinitis. Bronchial asthma, a commonly reported entity in Allergic
rhinitis was seen in 19% of the cases. 66% of children in our study had PNIF
values of the ﬁfth to 50th percentile where as 24% were in the third to ﬁfth
percentile and 10% had their PNIF values less than third percentile. PNIF
showed a linear correlation with severity of allergic rhinitis. HRQL
assessment showed that children in the 6 to 11 year group had derangement
in the activity and physical symptoms domain while children in the12 to 18
year group had predominately involvement of emotional and practical
problem domains. Quality of life score worsened with decrease in PNIF.
Conclusions: PNIF is very useful tool to quantify the nasal obstruction in
Allergic Rhinitis. PNIF is easy to administer, reproducible and correlates well
with the severity of the disease. HRQL assessment helps us to do psycho
educational training to adhere compliance.
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Exhaled Nitric Oxide and Airway Function in Seasonal
Allergic Rhinitis
Masanobu Shinogami, MD, PhD,1 Ryoji Kagoya, MD,1 Wakako
Nakanishi, MD,2 and Hiroyoshi Yoshinami, MD, PhD3. 1Otolaryngology,
Tokyo Metropolitan Police Hospital, Tokyo, Japan; 2University of Tokyo,
Tokyo, Japan; 3Otorhhinolaryngology, Saitama Medical University, Saitama,
Japan.
Background: Seasonal allergic rhinitis could predispose to the development
of chronic bronchial inﬂammation. However, association between seasonal
allergic rhinitis and airway function, especially exhaled nitric oxide [FENO],
are not fully understood.
Objectives: The aim of this study was to evaluate the relationship among
FENO and airway function and nasal symptoms in patients with seasonal
allergic rhinitis without asthma.
Methods: We included 37 subjects [9 males and 28 females] in this study.
Total serum IgE were investigated and speciﬁc IgE for 4 pollen allergens and 5
perennial antigens were determined by RAST. Sensitization to a speciﬁc
allergen was deﬁned as over RAST score 2. We compared 4 groups. Group A:
7 nonatopic subjects [no nasal symptoms and RIST, RAST negative, 1 males
and 6 females, mean age: 33.2 24–52 years]. Group B: 10 atopic subjects with
a sensitization to Japanese ceder without medication [6 males and 4 females,
mean age: 44 20–58 years]. Group C: 10 atopic subjects with a sensitization to
Japanese ceder who took oral anti-histamine medicine during pollen season [2
males and 8 females, mean age: 34.9 24–52 years]. Group D: 10 atopic subjects
with a sensitization to Japanese ceder who receive intranasal corticosteroid
treatment during pollen season [2 males and 8 females, mean age: 40.2 26–
56 years]. Score of nasal symptoms, FENO, spirometry, total eosinophils, nasal
eosinophils, were investigated before, during, and after pollen season.
Results: Regardless of having treatment or not, in comparison with the
subjects without the allergy, FENO showed a statistically signiﬁcant increase
in all patients with a sensitization to Japanese after pollen season. In group D,
v 50/v 25 was the tendency to adversely affect after the pollen season, and
correlation between FeNO rate of the change and v 50/v25 rate of the change
admitted. As for the other indexes, a statistically change were not showed in
the comparison of each group.
Conclusions: These results suggest that FENO is a primarily marker of
bronchial inﬂammation in patients with seasonal allergic rhinitis during
pollen season and intranasal corticosteroid treatment may be effective for
improvements in lower airway outcome.
ANAPHYLAXIS
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Immunologic Evaluation of the Patients With
Ranitidine Anaphylaxis
Hyun-Jung Jin, MD,1 Jeong-Eun Kim,2 Young-Hee Nam, MD,1 Hwang
Eui-Kyung, MD,1 Yoon-Seok Chang, MD, PhD,3 Seung Ihm Lee, PhD,1
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Seung-Hyun Kim,1 and Hae-Sim Park, MD, PhD1. 1Department of Allergy
and Clinical Immunology, Ajou University School of Medicine, Suwon-si,
South Korea; 2Department of Internal Medicine, Samsung Changwon Hos-
pital, Sungkyunkwan University School of Medicine, Changwon, South Ko-
rea; 3Department of Internal Medicine, Seoul National University Bundang
Hospital, Seongnam, South Korea.
Background: There have been a few reports of hypersensitivity reactions to
Ranitidine and cross-reactivities between H2-receptor antagonists. The
pathogenic mechanisms of H2 receptor antagonist induced hypersensitivity
reactions are not understood. The purpose of this study was to observe the
clinical characteristics of the patients with Ranitidine anaphylaxis and
investigate the pathogenic mechanisms with detection of serum speciﬁc IgE
antibody to Ranitidine-HSA conjugate.
Methods: Ten patients with anaphylaxis to Ranitidine were enrolled from
Ajou University Hospital and Seoul National University Bundang Hospital.
Skin prick test (SPT) using Ranitidine extract were performed in 7 patients.
Serum speciﬁc IgE and G1 antibodies were detected by ELISA using
Ranitidine-HSA conjugate. The study subjects were divided into 2 groups
according to the presence of serum speciﬁc IgE antibody to Ranitidine-HSA
conjugate: 3 subjects had high serum speciﬁc IgE (Group I) and 7 subjects
showed negative results (Group II), when positive cut off value was
determined from mean 1 3 SD of absorbance values of healthy controls.
Results: Six (60%) were female and 9 (90%) were atopics. 6 (86%) patients
had positive responses to ranitidine on SPT, however, high serum speciﬁc IgE
to Ranitidine-HSA conjugate was detected in only 3 patients (30%), while
serum speciﬁc IgG1 was detectable in one patient (10%). There were no
signiﬁcant differences in clinical characteristics including age, sex, atopy and
serum total IgE level between group I and II.
Conclusions:We conﬁrmed the presence of serum speciﬁc IgE to Ranitidine-
HSA conjugate by ELISA, suggesting that IgE mediated response is a major
pathogenic mechanism of Ranitidine induced anaphylaxis. Further studies
will be needed to investigate other immunologic and non-immunologic
mechanisms and cross-reactivity among other H2 receptor antagonists.
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Body Mass Index (BMI) and Immediate (“STAT”) Dose of
Epinephrine im (EPI IM) Needed to Treat Subcutaneous Allergen
Immunotherapy (SCIT) Systemic Reactions (SRS)
Michel Alkhalil, MD,1 Dona Shearer, RN,2 Stacey Hattaway,2 Roger
Fox, MD,1 Mark Glaum, MD,1 Dennis Ledford, MD,1 and Richard F.
Lockey, MD1. 1Division of Allergy & Immunology, University of South
Florida and James A. Haley Veterans’ Hospital, Tampa, FL; 2University of
South Florida and James A. Haley Veterans’ Hospital, Tampa, FL.
Background: The purposes of this study are to document the number of SRs
to SCIT, the relationship between BMI versus the severity of SRs [World
Allergy Organization (WAO) Grade 1 to 5 reactions], and the possible
relationship between BMI and the total amount of epi IM needed to treat the
SRs.
Methods: This is a retrospective study of SRs to optimal dose SCIT with any
combination of approximately 20 allergens (pollens, animal emanations,
molds, and Hymenoptera) in 840 subjects representing 13,812 encounters
over 12 months (June 2010–May 2011). Nurses administered stat epi IM
(1:1000 v/v), 0.2 mg, immediately into the arm or thigh for any systemic
signs or symptoms (SS) of a SR, including, but not limited to, itchy eyes,
nose, pharynx, palms; rhinorrhea, nasal congestion, sneezing; and generalized
erythema, pruritus, or urticaria. Repeat doses of epi IM were administered as
necessary.
Results: 32 subjects (3.8%) each had one SR: 21 (66%) Grade 1, 10 (31%)
Grade 2, 1 (3%) Grade 3, and Grades 4 or 5. BMIs were missing in 3 subjects.
Fifteen of 29 were in the normal weight range (BMI 18.5–24.9), 9 Grade 1
(mean epi IM, 0.27 mg) and 6 Grade 2 (mean epi IM, 0.3 mg). Mean epi IM
was 0.28 mg. Eight of 29 subjects were overweight (BMI 25–29.9), 7 Grade 1
(mean epi IM, 0.23 mg), and 1 Grade 3 (mean epi IM, 0.3 mg). Mean epi IM
was 0.24 mg. Six of 29 were obese (BMI .30), 4 Grade 1 (mean epi IM, 0.3
mg) and 2 Grade 2 (mean epi IM, 0.2 mg). Mean epi IM was 0.27 mg.
Conclusions: SRs occurred in 3.8% of SCIT subjects. No signiﬁcant
association was found between BMI and the WAO Grade severity (P ¼
0.13 by Fisher’s exact test) and BMI and total epi IM dose given (P ¼
0.82 by Kruskal-Wallis test). BMI should not inﬂuence risk assessment of
SCIT or IM epi administered for SR.
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Muscle Relaxant Induced Allergic Reactions
Gyu-Young Hur,1 Eui-kyung Hwang,2 Jae-Young Moon,1 Young-Min Ye,2
Jae-Jeong Shim, MD, PhD,1 Hae-Sim Park, MD, PhD,2 and Kyung-Ho
Kang1. 1Internal Medicine, Korea University College of Medicine, Seoul,
South Korea; 2Department of Allergy and Clinical Immunology, Ajou Uni-
versity School of Medicine, Suwon-si, South Korea.
Background: Both eperisone and aﬂoqualone act by relaxing both
skeletal muscles and vascular smooth muscles to improve circulation
and suppress pain reﬂex. These drugs are usually prescribed combined
with non-steroid anti-inﬂammatory drugs (NSAIDs) as pain killers.
Although there have been no report on serious adverse reactions to
muscle relaxant, this is the ﬁrst report of 3 anaphylactic reactions caused
by eperisone and aﬂoqualone.
Methods: All 3 patients had previous histories of anaphylaxis after oral
intake of multiple pain killers including muscle relaxant and NSAID for
chronic muscle pain. Open label oral challenge tests were performed with
each drug to ﬁnd out which drugs caused systemic reactions.
Results: All experienced the same reactions within an hour after oral intake
of eperisone or aﬂoqualone. The severity of these reactions ranged from
laryngeal edema to hypotension. To conﬁrm the systemic reaction caused by
eperisone or aﬂoqualone, skin prick testing and intradermal skin tests with
eperisone or aﬂoqualone extract were performed in vivo, and the basophil
activity tests were performed with stimulation with these drugs in vitro. In
one patient with laryngeal edema, intradermal test with aﬂoqualone results
showed positive result and CD63 level increased after the stimulation with
aﬂoqualone dose-dependently.
Conclusions: We report 3 allergic reactions caused by oral muscle relaxants
that might be mediated by non-IgE-mediated responses. As muscle relaxant,
eperisone and aﬂoqualone, commonly prescribed drugs for chronic muscle
pain, can induce severe allergic reactions therefore we should prescribe them
carefully.
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Features of 51 Patients With Perioperative Anaphylaxis History
Laila Sabino Garro, MD, Adriana Teixeira Rodrigues,MD, Marisa Rosimeire
Ribeiro, MD, Marcelo Vivolo Aun, MD, Antonio Abilio Motta, MD, PhD,
Jorge Kalil,MD, PhD, and Pedro Giavina-Bianchi,MD, PhD. Clinical Immunology
and Allergy, University of Sao Paulo, Sao Paulo, Brazil.
Background: To evaluate the prevalence and the etiology of perioperative
anaphylaxis (APEO) referred to an outpatient clinic specialized in adverse
drug reactions.
Methods: We evaluated 806 patients throw the questionnaire “European
Network for Drug Allergy” (ENDA) in the period from October 2006 to June
2011. Patients with a history of APEO were selected. The diagnostic criteria
for anaphylaxis were based on the World Allergy Organization. Etiological
investigation was made with skin tests for latex, neuromuscular blockers
(NMBs), antibiotics, hypnotics, opioids and local anesthetics. Provocation
tests for antibiotics, NSAIDs, local anesthetics and latex were also done.
Speciﬁc IgE was tested for antibiotics (Penicillin G and V, Ampicillin and
amoxicillin) and latex.
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Results: We identiﬁed 51 (6%) patients with a history of APEO. Among
them, 16 patients (31%) had hypersensitivity reactions with positive
cutaneous test, 14 patients (27%) abandoned the investigation and 8 patients
(16%) completed the investigation with all tests negative. Currently 12
patients (23%) are being investigated and one of them (2%) performed tests to
drugs to use in the next sirgury. The main cause of APEO was latex allergy
(22%), followed by NMB hypersensitivity (6%). Three patients had positive
tests for 2 different agents.
Conclusions: Latex allergy is the main cause of APEO in this study. The
importance of testing all the possible agents involved was demonstrated by
the occurrence of 3 cases with positive test for 2 agents.
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Drug Induced Anaphylaxis in a University Hospital in Sao
Paulo, Brazil
Marcelo Vivolo Aun,MD,1 Adriana Teixeira Rodrigues,MD,1 Marisa Rosimeire
Ribeiro, MD,1 Laila Sabino Garro, MD,1 Ana Príscia Castro-Coelho, MD,1
Luciana Kase Tanno, MD,1 Luis Felipe Chiaverini Ensina, MD,2,3 Jorge Kalil,
MD, PhD,1 Antonio Abilio Motta,MD, PhD,1 and Pedro Giavina-Bianchi, MD,
PhD1. 1Clinical Immunology and Allergy, University of Sao Paulo, Sao Paulo,
Brazil; 2Rheumatology, Federal University of Sao Paulo, Sao Paulo, Brazil;
3Rheumatology, Allergy and Immunology, University of Santo Amaro, Sao Paulo,
Brazil.
Background: Adverse drug reactions (ADRs) are common in clinical
practice, most of them presented only with mucocutaneous symptoms. Drug
induced anaphylaxis is rare, but it is responsible for most deaths due to
ADRs. The aim of this study was to evaluate drug induced anaphylaxis
treated in an Allergy Outpatient Clinic of a University Hospital.
Methods: Retrospective analysis of medical records from patients who seek
assistance because of ADR. We looked for clinical criteria for diagnosing
anaphylaxis, as recommended in WAO Guidelines. Criteria were classiﬁed in
numbers 1 to 3:1) Acute onset of an illness (minutes to several hours) with
involvement of the skin-mucosal tissue and respiratory and/or cardiovascular
compromise; 2) Two or more of the following that occur rapidly after
exposure to a likely allergen: involvement of skin-mucosal tissue, respiratory,
cardiovascular and/or gastrointestinal compromise; 3) Reduced blood pres-
sure after exposure to known allergen for that patient. We analyzed patients
gender and age, drugs involved in reactions and administration of epinephrin.
Results: We studied 806 patients with history of ADR, of whom 123 (15.3%)
presented clinical criteria of anaphylaxis (mean age 39.0 year old, female 101).
The ﬁrst clinical criteria was found in 60.2% and the second one in 38.2%.
Epinephrin was injected in only 42 patients (34.1%). Non-steroidal anti-
inﬂammatory drugs (NSAIDs) were most commonly suspected culprit drugs
involved in anaphylactic reactions, with 59 patients (47.9%), followed by 40
patients with perioperative anaphylaxis (32.5%), 6 cases due to local anesthetics
(4.9%) and 4 to antibiotics (3.2%). Between perioperative anaphylaxis, latex
was involved in 10 reactions and neuromuscular blocking agents in 3.
Conclusions: We found a high prevalence of anaphylaxis, probably because
patients with severe ADRs tend to be followed in university hospitals.
Nevertheless, anaphylaxis is underdiagnosed in emergency departments, as
we observed less than 35% of patients with drug induced anaphylaxis were
treated with epinephrin. NSAIDs are still the most common drugs involved in
ADRs in Brazil, including severe reactions, as anaphylaxis. In our country,
latex still is an important agent incriminated in perioperative anaphylaxis, but
anaphylaxis due to antibiotics are less common than in other countries.
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Analysis of Anaphylactic Reactions to Biological Agents Reported
to the Italian Pharmacovigilance Database
Ugo Moretti, MD,1 Laura Sottosanti,2 Simona Potenza,2 Elisa Boccola,3
and Giovanna Zanoni, MD3. 1Clinical Pharmacology Unit, University of
Verona, Verona, Italy; 2Italian Medicine Agency, Pharmacovigilance Ofﬁce,
Rome, Italy; 3Immunology Unit, University Hospital, Verona, Italy.
Background: Spontaneous reporting of adverse drug reactions (ADR) to
biological agents used for cancer and immuno-mediated disease treatment is
important for furthering knowledge regarding the safety of these new drugs.
An analysis was carried out in Italy on reports of anaphylaxis caused by
biological agents.
Methods: Data were extracted from the national Spontaneous Reporting
Database. Since biological drugs refer to different ATC (Anatomical
Therapeutic Classiﬁcation) codes, in this study they have been extracted by
the presence of "mab" and/or "cept" sufﬁxes. Cases were deﬁned as follow-
ing: A) reports with the string “anaph” in the description of the event or in the
WHO-ART (Adverse Reactions Terminology) coded preferred terms; B)
reports with adverse reactions referring to at least 2 of selected System Organ
Classes (skin, respiratory, cardiovascular and gastrointestinal disorders) with
an onset within 24 hours after administration. All selected cases were
reviewed and the case deﬁnition from the "Second Symposium on the Def-
inition and Management of Anaphylaxis" was applied to evaluate the reports
(JACI 2005;115(3):584–591).
Results: The Italian database up to March 2011 contains 3820 reports related
to biologicals. According to selection criteria, a total of 334 reports were
extracted: 65 for group A and 269 for group B. By application of the
anaphylaxis case deﬁnition, 2 cases belonging to group A and 139 to group B
were excluded after individual review. Out of 193 reports meeting the case
deﬁnition, 8 (4.1%) were reported in children and adolescents up to 18 years
of age. The most reported responsible drugs were inﬂiximab with 83 (43%)
cases, followed by cetuximab (41–21%) and rituximab (28–14%); other 11
different biologicals were associated with the remaining 32 cases (22%), with
up to 8 reports each.
Conclusions: Spontaneous reporting is an important source to provide further
knowledge on the reactogenicity of biological agents. Three-fourths of Italian
reports of anaphylaxis concern 3 chimaeric antibodies containing a murine
component. In our study, the best identiﬁcation of cases of anaphylactic
reactions came out of the combination of selected reported terms, application
of case deﬁnition and expert review of individual reports.
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Contribution of IL-33 and Nuocyte to Experimental
Allergic Dermatitis
Yasutomo Imai, MD, PhD,1 Koubun Yasuda, PhD,2 Tomohiro
Yoshimoto, MD, PhD,3 Kenji Nakanishi, MD, PhD,2 and Kiyofumi
Yamanishi, MD, PhD1. 1Department of Dermatology; 2Department of Immu-
nology and Medical Zoology; 3Laboratory of Allergic Diseases, Institute for
Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
Background: IL-33 is a member of the IL-1 family cytokines and the ligand
of ST2 (IL-33R alpha chain). IL-33 stimulates Th2 cells, basophils, mast
cells, and nuocyte, a recently discovered new lymphocyte, to produce various
cytokines. We have previously shown that the serum level of IL-33 is
signiﬁcantly elevated in patients with Japanese cedar pollinosis1 and IL-33
has the potential to induce Th2 cytokine-mediated allergic conjunctivitis2. As
these results suggest that IL-33 may also have some relations to allergic
dermatitis, we now examined the pathological role of IL-33 in dermatitis.
First, we investigated an immediate reaction of skin by challenging BALB/c
mice with DNFB repeatedly. We also tested the involvement of natural helper
cells (nuocyte) in dermatitis of NC/Nga mice.
Methods: (1) Wild-type BALB/c mice or ST2 KO mice were sensitized and
repeatedly challenged with DNFB on the left ear at 1 week intervals. When
they are challenged 4 or 5 times, the ear shows biphasic (bimodal) responses
which consist of an immediate phase and a delayed-type reaction. (2) When
NC/Nga mice are raised in conventional (non-SPF) circumstances, skin
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lesions that are clinically similar to human atopic dermatitis spontaneously
appears on the skin. We separated lymphocytes from the inﬂamed skin of NC/
Nga mice using collagenase I (Sigma-Aldrich) and counted the numbers of
nuocytes (ST21/Sca-11/lineage marker-negative) by FACS.
Results: (1) The reactions were hapten speciﬁc. Wild-type BALB/c mice
showed both immediate and delayed-type reactions, whereas ST2 KO mice
did not show any immediate reaction. (2) When IL-33 was administered
subcutaneously, NC/Nga mice showed increase of serum IgE level. The
number of nuocytes in inﬂamed skin of NC/Nga mice signiﬁcantly increased
compared to non-inﬂamed skin. The nuocytes showed very weak expression
of ST2 in non-inﬂamed skin, whereas the expression of ST2 in inﬂamed skin
was very signiﬁcant.
Conclusions: These results suggest that IL-33 may have an important role in the
mechanism of immediate contact hypersensitivity, and nuocytes may contribute
to the development of atopic dermatitis-like skin lesion in NC/Nga mice.
REFERENCES
1. Clin Exp Allergy. 2008;38:1875.
2. Int Immunol. 2010;22:479.
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S100A8/A9, a DampMolecule Activated by IL-17 andHouse Dust
Mite is Upregulated in Atopic Dermatitis
Shan Jin, MS, Chang Ook Park, MD, Ji Yeon Noh, PhD, Yun Sun Lee,
Byung Gi Bae, MD, Seongmin Noh, MD, and Kwang Hoon Lee, MD,
PhD. Department of Dermatology and Cutaneous Biology Research Institute,
Yonsei University College of Medicine, Seoul, South Korea.
Background: S100A8/A9 (Calgranulin A/B, Calprotectin), a heterodimer of
2 calcium-binding proteins originally found in the cytoplasm of neutrophils
and membrane of monocytes. It has emerged as an important pro-in-
ﬂammatory mediator, so called “damage-associated molecular pattern
(DAMP)” molecule in acute and chronic inﬂammation. Our previous proteo-
mics data showed that S100A8/A9 was signiﬁcantly downregulated after
immunotherapy with house dust mite in patients with atopic dermatitis (AD).
Methods: The purpose of this study was to evaluate S100A8/A9 expression
in serum and lesional skin of AD patients, and then to assess S100A8/A9
expression in HaCaT cells and primary human keratinocytes, which were
cultured with Th2, Th17 cytokines and house dust mite (HDM) extracts.
Results: Compared with healthy controls, serum S100A8/A9 levels were
higher in AD patients and correlated with eczema area and severity index
(EASI) scores (P , 0.01, r2 ¼ 0.2037). S100A8/A9 was strongly expressed
in the upper epidermis of AD tissues by immunoﬂuorescence. IL-17A
strongly induced S100A8/A9, and enhanced S100A8/A9 expression in
HaCaT cells and human keratinocytes which were cultured with Th2 cyto-
kines. S100A8/A9 mRNA and protein levels were also increased in HaCaT
cells and human keratinocytes which were stimulated with Dermatopha-
goides farinae by time dependent manner. IL-17A also strongly enhanced
S100A8/A9 expression in HaCaT cells which were cultured with D. farinae,
but Th2 cytokines did not.
Conclusions: These results suggest that elevated S100A8/A9 levels of AD
patients may reﬂect the importance of DAMP-associated inﬂammation, which
could be triggered by Th17 cytokines and HDM allergens in AD.
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Polyprenol Could Prevent Loss of Filaggrin in Epithelial Cells in
Atopic Dermatitis
Ivans S. Kuznecovs, MD,1 Inese Joksta, MD,1 Sergejs Kuznecovs, MD,2
and Galina Kuznecovac,MSc3. 1Allergy and Immunology, Preventive Medicine
Institute, Riga, Latvia; 2Preventive Medicine Institute, Riga, Latvia; 3Epidemi-
ology, Preventive Medicine Institute, Riga, Latvia.
Background: In epithelial cells loss of ﬁlaggrin correlates with atopic
dermatitis (AD) presence and activity. Dysregulation of DPAGT1 (Dolichyl-
phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotrans-
ferase 1 (GlcNAc-1-P transferase) causes disturbances in ﬁlaggrin expression.
The resent results are in favour of the idea that N-glycosylation in
keratinocytes cells is limited by Dolichyl Phosphate Cycle (DPC) intermedi-
ates. The aim of the present study is to investigate the effect of Polyprenol
(PP), which provides a dolichol phosphate (DolP) substitute on regulation of
ﬁlaggrin expression.
Methods: Filaggrin expression was measured in skin biopsies from 42
persons with AD and 36 with normal skin and cultured keratinocytes; PP
concentration in the culture medium made up 1022 to 1026. Immunohisto-
chemical and Western blotting methods were used to detect the changes in the
expression levels of ﬁlaggrin and DPAGT1. IL-4 and IL-13 was determined
using ELISA. Intermediates of DPC fractions were analysed by HPLC
method.
Results: Overexpression of DPAGT1 was 5-fold higher in AD skin biopsies
than in normal skin biopsies. AD cells differ from normal one in ﬁlaggrin
content lost by 3 to 4 times. IL-4 and IL-13 cause overexpression and
abberant N-glycosylation of ﬁlaggrin in DPC. The study showed over-
expression of DPAGT1 and 6-fold DPC intermediates decrease in keratino-
cytes in presence of IL-13 and 2-fold in presence of IL-4 cells. Treatment of
keratinocytes with PP resulted in downregulation of DPAGT1. It is
established that PP in the concentration 1022 M could overcome DPAGT1
overexpression which leads to regulation of ﬁlaggrin N-glycosylation.
Conclusions: IL-13 could cause DPAGT overexpression and dysregulation
of N-glycosylation in keratinocytes which leads to AD fenotype affecting the
stability of tight assembly and adherence junctions in skin. The ﬁndings
indicate that DPAGT1 overexpression in keratinocytes treated with IL-4 and
IL-13 can be overcomed by PP, which provides a DolP substitute for
DPAGT1 normal expression, N-glycosylation and ﬁlaggrin loss prevention
without neutralization of interleukins. Polyprenol could be a promising agent
for atopic dermatis prevention and control.
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Role of Sweating on Impaired Skin Barrier Functions in
Atopic Dermatitis
Aya Takahashi, MD, PhD, Akihiro Kimura Student, Saki Matsui, MD,
Akiko Kijima, MD, Shun Kitaba, MD, Hiroyuki Murota, MD, PhD,
and Ichiro Katayama, MD, PhD. Osaka University School of Medicine,
Suita-shi, Japan.
Background: Atopic dermatitis (AD) is known to have skin barrier
dysfunction and impaired sweating. To assess the relationship between sweating
and skin barrier function, we measured 2 parameters reﬂecting skin barrier
function; transepidermal water loss (TEWL), and water holding capacity of
stratum corneum. Sweating function was evaluated by quantitative sudomotor
axon reﬂex test (QSART) system in AD patients and non-atopic controls.
Methods: Thirty-nine AD patients (21 males and 18 females, mean 6 SD age
37.8 6 10.9 years) and 37 normal controls (17 males and 20 females, mean 6
SDage 34.9 6 10.1 years) were enrolled in this study. For measurement of
TEWL and water holding capacity of stratum corneum on axilla, cubital fossa,
scapular, and elbow. By using the QSART in which the axon reﬂex is stimu-
lated by acetylcholine iontophoresis we measured the axon reﬂex (AXR) sweat-
ing volume for 5 minutes on cubital fossa. The measurements were performed
at room temperature (21–228C) and at relative humidity of 54%.
Results: The AD patients showed higher TEWL and lower water holding
capacity value compared with normal controls on all 4 points. And the AD
patients showed lower volumes of AXR sweating than normal controls on
cubital fossa. We could not ﬁnd out correlation between TEWL and AXR
sweating volume. The same result was observed between water holding
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capasity and AXR sweating volume. To our knowledge, elevated TEWL and
decreased water holding capacity are believed to skin barrier dysfunction. It
was surprising that we found positive correlation between TEWL and water
holding capacity in AD.
Conclusions: The results of TEWL and water holding capacity suggest that
the barrier function of stratum corneum is impaired in AD patients. On the
one hand, further studies should be required to explain the unexpected
correlation between TEWL and water holding capacity. Both TEWL and
water holding capasity didn’t correlate with AXR sweating volume. This
appeared that the 2 factors are not under the inﬂuence of the AXR sweating
at the same site.
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The Risk of Atopic Dermatitis in Children Exposed to Pets
During Pregnancy
Neetu Vasu, MD,1 Ganesa Wegienka, PhD,2 Suzanne Havstad, MA,2
Christine Cole Johnson,3 and Edward Zoratti, MD4. 1Allergy Immunology,
Henry Ford Health System, Birmingham, MI; 2Public Health Sciences, Henry
Ford Hospital & Health System, Detroit, MI; 3Public Health Sciences, Henry
Ford Health System, Detroit, MI; 4Allergy and Immunology, Henry Ford
Hospital & Health System, Detroit, MI.
Background: Although the mechanism is uncertain, some studies have
linked prenatal and early-life pet exposure to a decreased risk of atopic
dermatitis (AD).
Methods: 675 participants in a southeast Michigan population-based birth
cohort were evaluated at age 2 to 4 years. Based on medical history and
examination, a study physician was asked to determine whether there was
evidence of current AD or a past history consistent with AD. Information
regarding the presence of indoor dogs or cats was prospectively collected
from the participants’ mothers during pregnancy.
Results: Of 675 maternal-child pairs, 255 (37.7%) mothers reported living with
a pet during pregnancy and 150 children (22%) were diagnosed with either
current or prior atopic dermatitis by age 2 to 4 years. Compared to mothers not
exposed to indoor pets during pregnancy, the risk of AD was lower among
offspring of 255 mothers that lived with an indoor pet prenatally [OR ¼ 0.6,
95% CI, (0.4-0.9), P ¼ 0.01]. The lower risk was seen primarily among 137
mothers reporting indoor dogs only [OR¼ 0.5, (0.3, 0.8), P ¼ 0.009] or 43 that
had lived with both indoor cat(s) and dog(s) [OR ¼ 0.4 (0.1, 1.0), P ¼ 0.05].
There did not appear to be a similar effect among 75 mothers with cat only
prenatal exposure [OR ¼ 0.9 (0.5, 1.6), P ¼ 0.79]. When analyses were re-
stricted to the presence or absence of dog exposure (not considering cat co-
exposure), offspring were also less likely to have had current or prior AD [OR
0.5(0.3, 0.8), P ¼ 0.002]. Results of analyses further restricted to dog exposure
and “current AD” (AD present at the 2–4 year evaluation) were similar [OR 0.5
(0.3, 0.9), P ¼ 0.013]. These results were not substantially different in logistic
regression models adjusting for the child’s total IgE level or the presence of
atopy as assessed by positive allergen-speciﬁc IgE tests or positive skin prick
tests to a panel of common allergens.
Conclusions: Prenatal dog exposure is associated with a lower risk of AD in
young children. The mechanism(s) responsible for this relationship require
further study.
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Economic Analyses of Partially Hydrolyzed Infant Formulas in
Prevention of Atopic Dermatitis: Results From 5
European Countries
Patrick Detzel, PhD,1 Joerg Spieldenner, MD,1 Vincent Navarro, DPharm,2
Jade Berbari, BSC,3 and Michael Iskedjian, DPharm3. 1Health Economics,
Nestlé Nutrition Institute, Vevey, Switzerland; 2PharmIdeas Europe SAS, Lyon,
France; 3PharmIdeas Research and Consulting Inc., Ottawa, ON, Canada.
Background: Economic analyses (EAs) were performed in 5 European
countries to determine costs, outcomes and cost-effectiveness of a partially
hydrolysed 100% whey-based infant formula (PHF-W) in the prevention of
atopic dermatitis (AD) in ‘at risk’ children when compared to standard cow’s
milk formula (SF) or extensively hydrolyzed formula (EHF).
Methods: The EAs were performed in France, Germany, Spain, Denmark and
Switzerland, using decision-analytic models describing AD treatment pathways,
as well as resource utilisation and costs associated with the treatment of AD in
healthy yet ‘at risk’ newborns who could not be exclusively breastfed. A time
horizon of 12 months including 6 months of formula consumption was applied,
with country-speciﬁc resource use and costs. In 4 settings, SF was the main
comparator. The outcomes of the EAs were the number of avoided cases and
the incremental cost per avoided case (ICER) of AD when comparing subjects
who used PHF-W versus SF. An ICER represents the additional cost for obtain-
ing each additional clinical outcome gained; in this instance each avoided case.
Given a lack of signiﬁcant differences in efﬁcacy between PHF-W and EHF,
a cost-minimization approach was used in all settings to compare them. A
negative ICER represents savings. Three perspectives were applied: the Minis-
try of Health (MOH), the family and society.
Results: In the base case analyses selecting PHF-W over SF yielded numbers
of avoided cases of AD ranging from 1653 (Switzerland) to 13,356 cases
(France) for respective “at risk” birth cohorts of 22,933 and 185,298 infants.
The analyses of PHF-W versus SF generated ICERs ranging from €801 to
€1343 (MOH), from 2€1796 to 2€454 (family) and from 2€995 to €719
(society). The costs of formula and time loss were the main cost drivers.
When comparing PHF-W to EHF in prevention, PHF-W demonstrated sav-
ings ranging from €4 to €120 million for society, or €1.3 to €64 million for
the MOH perspective. The robustness of the models and the direction of the
results were conﬁrmed by one-way and probabilistic sensitivity analyses.
Conclusions: In 5 European countries, PHF-W appears to offer a better
prevention than SF at a reasonable cost, and at a lower cost than EHF.
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Prevalence and Associated Risk Factors for Atopic Dermatitis
Symptoms in Mexican Children
Eunice Sandoval-Ramírez, MD,1 Blanca del Rio, MD,1 Jaime Mariano del
Río-Chivardí, MD,1 Dino Pietropaolo-Cienfuegos, MD,1 Miguel Angel
Rosas-Vargas, MD,1 Lourdes Avila, MD,1 Sandra González-Díaz, MD,
PhD,2 Roberto García-Almaraz, MD,3 Juan Valente Merida Palacios, MD,4
Sergio de Jesus Romero Tapia, MD,5 Francisco Javier Linares Zapien, MD,6
and Alberto Escalante Dominguez, MD7. 1Pediatric Allergy and Clinical
Immunology, Hospital Infantil de Mexico “Federico Gomez”, Mexico City,
Mexico; 2Hospital Universitario, Medical School, Universidad Autónoma
de Nuevo León, Monterrey, Mexico; 3COMPEDIA, Tamaulipas, Mexico;
4Mexicali Health Care, Mexicali, Mexico; 5Hospital Angeles Villahermosa,
Villahermosa, Mexico; 6COMPEDIA, Toluca, Mexico; 7Hospital General de
Rosarito, Tijuana, Mexico.
Background: Describe AD prevalence and identify associated risk factors in
Mexican children.
Methods: Multi-centric, cross-sectional ambiental survey. We applied the
standardized Spanish-version ISAAC questionnaire to children’s tutors aged
6 to 7 years in 8 Mexican cities. Sampling units randomly selected from local
schools with advisable sample size of 3000 questionnaires per centre. Ques-
tions to evaluate actual AD: Has your child had itchy rash at any time in the
past 12-months? Has this itchy rash at any time affected any of the following
places: the folds of the elbows, behind the knees, in front of the ankles, under
the buttocks or around the neck, ears or eyes? A risk analysis was made
through multivariate logistical regression, central tendency and dispersion
measures were obtained with respective 95% conﬁdence intervals.
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Results: A total of 25,809 questionnaires were applied at 274 schools. For
current AD symptoms 18,095 questionnaires were analyzed and for severe
current AD symptoms 19,173. Current AD symptoms mean global prevalence
was 6.1% (95% CI, 5.7-6.4%). Mean prevalence and 95% CI per center:
Monterrey 4.2% (3.5-4.9%), Mexicalli 6.3% (5.3-4.9%), Ciudad Victoria
2.3% (1.8-2.9%), Tijuana 4.9%(4.1-5.7%); North DF 8.5% (7.6-9.4%),
Southeasat DF 9.4% (8.0-10.7%), Toluca 5.4% (4.6-6.2%); Veracruz 5.3%
(4.3-6.2%); Villahermosa 8.6% (7.3-9.8%). Severe current AD symptoms
mean global prevalence was 0.7% (95% CI, 0.6-0.9). Mean prevalence and
95% CI per center: Monterrey 0.6% (0.3-0.9%), Mexicalli 0.8% (0.5-1.2%),
Ciudad Victoria 0.3% (0.1-0.6%), Tijuana 0.9% (0.5-1.2%); North DF 1.1%
(0.7-1.5%), DF Southeast 1% (0.5-1.4%), Toluca 0.3% (0.1-0.5%); Veracruz
0.7% (0.4-1.1%); Villahermosa 1.2% (0.8-1.7%). Identiﬁed risk factors for
current AD symptoms: presence of allergic rhinitis symptoms OR 1.94 (95%
CI, 1.53-2.14; P # 0.005); conjunctivitis symptoms OR 1.81 (95% CI, 1.53-
2.14; P # 0.005); accumulated asthma symptoms OR 1.51 (95% CI, 1.3-
1.76; P # 0.03). Identiﬁed risk factors for severe current AD symptoms:
presence of conjunctivitis symptoms OR 2.20 (95% CI, 1.42-3.4; P #
0.005); accumulated asthma symptoms OR 2.16 (95% CI, 1.38-3.39; P #
0.005); use of acetaminophen in the ﬁrst year of life OR 1.80 (95% CI, 1.21-
2.69; P # 0.005).
Conclusions: Current AD symptoms prevalence was higher at north DF,
followed by Toluca and southeast DF; current severe AD symptoms were
higher at Villahermosa, followed by north DF and Tijuana. The presence
of rhinoconjuntivitis and accumulated asthma symptoms doubles the risk
for current AD and current severe symptoms in Mexican children and
Acetaminophen use in the ﬁrst year of life was associated with severe
current AD symptoms.
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Involvement of Human Histamine N-Methyltransferase Gene
Polymorphisms in Susceptibility to Atopic Dermatitis in
Korean Children
Hee Seon Lee, MD,1 Kyu-Earn Kim, MD, PhD,2 and Yong Ju Lee, MD3.
1Department of Pediatrics and Institute of Allergy, and; 2Department of
Pediatrics, Yonsei University College of Medicine, Seoul, South Korea;
3Pediatrics, Kangnam Sacred Heart Hospital, Hallym University, Seoul,
South Korea.
Background: Histamine N-methyltransferase (HNMT) catalyzes one of 2
major metabolic pathways for histamine. Histamine is one of the mediators
for pruritus of atopic dermatitis. The aim of this study was to evaluate the role
of HNMT polymorphisms in children with atopic dermatitis.
Methods: We genotyped 763 children for allelic determinants at 4 poly-
morphic sites, which were2465T.C, 2413C.T, 314C.T and 939A.G in
the HNMT gene, and the functional effect of the 939A.G polymorphism was
analyzed. The genotyping was screened using the TaqMan ﬂuorogenic 5’
nuclease assay (ABI, Foster City, CA, USA).
Results: Among these 763 children, 520 had eczema and 542 had atopy.
Distributions of the genotype and allele frequencies of HNMT 314C.T
polymorphism were signiﬁcantly associated with non-atopic eczema (P ¼
0.004) and those of HNMT 939A.G polymorphism were signiﬁcantly
associated with eczema in atopy groups (P ¼ 0.048). However, those of
HNMT 654T.C and 413C.T polymorphisms were not. In addition, sub-
jects with the homozygous AA or heterozygous AG of the 939A.G poly-
morphism showed signiﬁcantly higher IgE levels than those with the
homozygous GG genotype (P ¼ 0.009). In U937 cells, the variant geno-
type reporter construct showed signiﬁcantly higher mRNA stability (P ,
0.001) and HNMT enzyme activity (P , 0.001) than the common
genotype.
Conclusions: Polymorphisms in the HNMT gene appear to confer suscep-
tibility to atopic dermatitis in Korean children.
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Circadian Regulation of Scratching Behavior in NC/TND Mice,
a Mouse Model for Human Atopic Dermatitis
Keitaro Ohmori, DVM, PhD, Akane Tanaka, DVM, PhD, Akira
Matsuda, DVM, PhD, and Hiroshi Matsuda, DVM, PhD. Tokyo University
of Agriculture and Technology, Fuchu, Tokyo, Japan.
Background: Scratching behavior is a pivotal clinical sign and a therapeutic
target of atopic dermatitis; however, due to the lack of an appropriate animal
model, circadian regulation of this behavior remains unclear.
Methods: NC/Tnd mice, a mouse model for human atopic dermatitis, have
been shown to exhibit severe scratching behavior together with the de-
velopment of spontaneous atopic dermatitis when they are raised under air-
uncontrolled environment. In this study, scratching behavior of the mice was
measured by a SCLABA-Real system, a newly developed equipment that
provides us with the real-time, long-term, quick and accurate quantiﬁcation of
murine scratching behavior by analyzing images with the high-speed camera
and the invisible near-infrared light.
Results: Analysis by a SCLABA-Real system demonstrated that the
frequency and duration of scratching behavior signiﬁcantly correlated with
the exacerbation of dermatitis in the mice, indicating that this system was able
to measure scratching behavior without putting stress upon the mice. Twenty-
four hours analysis revealed that the frequency and duration of scratching
behavior increased in from the afternoon to the midnight and decreased in the
morning. In addition to scratching behavior, transepidermal water loss
(TEWL) also changed during a day in the mice. TEWL increased in the
midnight and decreased in the morning.
Conclusions: These results indicate that scratching behavior and skin barrier
function in atopic dermatitis exhibited circadian rhythm. In addition, NC/Tnd
mice are considered to be an appropriate mouse model to investigate circadian
rhythm of scratching behavior associated with atopic dermatitis.
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Metallic SoapAggravates SkinConditions inPatientsWithAtopic
Dermatitis and aMouseModel forHumanAtopic Dermatitis, NC/
TND Mice
Akane Tanaka, DVM, PhD,1 Akira Matsuda, DVM, PhD,1 Yuka
Makita, MS,2 Masaki Takai, PhD,2 Keitaro Ohmori, DVM, PhD,1
and Hiroshi Matsuda, DVM, PhD1. 1Tokyo University of Agriculture and
Technology, Fuchu, Tokyo, Japan; 2Miura CO., Ltd., Matsuyama, Ehime,
Japan.
Background: Hardness in water is consisted with mineral salts, including
calcium (Ca11) and magnesium (Mg11). The mineral salts react with soap to
form an insoluble precipitate known as metallic soap (soap scum). Since
metallic soap remains tightly on the skin and is hard to rinse off, it may
become one of irritants that exacerbate dermatitis. In this study, we used
cation-exchange resin to prepare ultra-pure soft water (UPSW) excluding
both Ca11 and Mg11, and investigated effect of UPSW rinsing on skin
conditions in subjects with atopic dermatitis. Furthermore, antigenic activity
of metallic soap was investigated by in vivo experiments.
Methods: Stratum corneum was collected from arms of healthy volunteers
who rinsed soap in tap water or UPSW, and the quantity of remained soap
scum was determined with a gas chromatography. After 4 weeks of bathing in
UPSW, the water content of the stratum corneum and transepidermal water
loss (TEWL) of volunteers with mild atopic dermatitis were measured. With
atopic NC/Tnd mice, a model for atopic dermatitis, we attempted to conﬁrm
results obtained from atopic volunteers. Plasma total IgE was measured by an
ELISA after immunization of mice with metallic soap.
Results: On skins rinsed in UPSW, soap was disappeared immediately and
remained metallic soap was signiﬁcantly reduced when compared to that on
skins rinsed in tap water. In skins of atopic volunteers who used UPSW for
bath, the water content in stratum corneum was increased and TEWL was
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decreased. Skin dryness and itch scores were reduced in most volunteers.
After washed with soap and rinsed in UPSW for 2 weeks, severe dermatitis of
NC/Tnd mice were reduced as well as TEWL. On the other hand, dermatitis
in NC/Tnd mice rinsed in tap water became worse. Plasma total IgE was
increased in mice that were immunized with metallic soap.
Conclusions: UPSW protected skins from residue of metallic soap. Metallic
soap has antigenic activity and increased plasma IgE levels. Clinical
symptoms and the skin barrier function were improved by the use of soap
with UPSW. UPSW is beneﬁcial for the skin of patients with atopic
dermatitis.
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The Allergic March Resolved at Allergen Component Level
Giovanni Melioli, MD,1 Laura Marcomini, BS,1 Alessia Agazzi, BS,1
Gyada Bazurro, BS,1 Lucilla Rossi,1 Mariangela Tosca, MD,2 Paola
Minale,3 Renato Rossi,4 Giovanni Passalacqua, MD,5 and Giorgio Walter
Canonica, PhD5. 1Laborario Centrale di Analisi, Istituto Giannina Gaslini,
Genoa, Italy; 2UO Pediatria ad Indirizzo Penumologico ed Allergologico,
Istituto Giannina Gaslini, Genoa, Italy; 3Allergologia, AOU San Martino,
Genoa, Italy; 4Rete di Allergologia Regione Piemonte, Azienda Sanitaria
Cuneo 1, Cuneo, Italy; 5Allergy & Respiratory Diseases, Universita Degli
Studi Di Genova, Genoa, Italy.
Background: The allergic march is well known at the level of pattern of
sensitisation, but there is no information of its evolution in term of
sensitzation to single allergenic molecules. We investigated the evolution
of the IgE repertoire by means of a microarray allergen assay.
Methods: Serum samples from allergic patients of a wide age range were
analyzed by a micorarray chip, which allow to identify in a single assay the
presence of speciﬁc IgE towards 103 allergenic molecules. Total IgE were
also evaluated as an internal control. Patients were stratiﬁed in 6 groups
according to their age (0–2; 3–5; 6–9; 10–13; 14–17 and .17 years).
Results: Samples from 609 patients were analysed. The behaviour of total
IgE according to age strictly paralleled that of the sum of speciﬁc IgE. Food-
related components were the more frequently recognized in the ﬁrst ages,
whereas speciﬁc IgE to plant allergens appeared later. Nonetheless, mite-
speciﬁc IgE were the most represented in all age classes. Speciﬁc IgE against
cross-reacting allergens were virtually absent in the ﬁrst years and tended to
appear after the age of 6.
Conclusions: The molecular pattern of allergen recognition according to age
well reﬂects the clinical characteristics of the allergic march.
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Prevalence ofWheezing andRisk Factors Associated toWheezing
in Infants in the First Year of Life, Cuibá, MT, Brazil
Lillian Sanchez Lacerda Moraes, MD,1 Olga Akiko Takano, PhD,2
and Dirceu Solé, PhD1. 1Department of Pediatrics, Federal University of
São Paulo, São Paulo, Brazil; 2Department of Pediatrics, Federal University
of Mato Grosso, Cuiabá, Brazil.
Background: The purpose of this study was to evaluate the prevalence of
wheezing and risk factors related to wheezing in infants (12–15 month-old) in
the city of Cuiabá, Mato Grosso State, Brazil.
Methods: Cross-sectional study by applying a standardized written ques-
tionnaire from “Estudio Internacional de sibilancia en lactentes” (EISL)
phase III. Parents and/or guardians of infants were interviewed at a primary
health care clinic or at home from August 2009 to November 2010. Signed
written informe consent was obtained from parents and/or guardians of all
subjects. Factors associated to wheezing were studied using bivariate and
multivariate analysis (SPSS v.18.0) and expressed as odds ratio (OR) and
conﬁdence interval 95% (95% CI).
Results: One thousand sixty parents were interviewed (N ¼ 1060), 27.7%
(N ¼ 294) infants had at least one wheezing episode in their ﬁrst year of
life, with onset at 5.8 6 3.0 months (mean 6 standard deviation), and
45.9% (N ¼ 135) had had 3 or more episodes (recurrent wheezing). The
use of inhaled b2-agonists, oral corticosteroids or leukotriene receptor
antagonist, nocturnal symptoms, respiratory distress, hospitalization and
medical diagnose of asthma were signiﬁcantly more frequent in the group
with recurrent wheezing (P , 0.05). Independent risk factors associated
with wheezing in the ﬁrst year of life were: history of previous pneumonia
(OR ¼ 10.80; 95% CI, 4.52-25.77); to have more than 6 upper respiratory
infections (URI) (OR ¼ 2.95; 95% CI, 2.11-4.14); asthma in sibling (OR ¼
2.13; 95% CI, 1.18-3.87); asthma in father (OR ¼ 1.98; 95% CI, 1.22-
3.23); asthma in mother (OR ¼ 1.62; 95% CI, 1.07-2.43); exposure
to paracetamol in the ﬁrst year of life for URI (OR ¼ 2.13; 95% CI,
1.54-2.95); exposure to moderate air pollution from trafﬁc (OR ¼ 1.59;
95% CI, 1.08-2.33); and a ﬁrst URI before of third month of age (OR ¼
1.50; 95% CI, 1.04-2.17).
Conclusions: The prevalence of wheezing episodes among one year-old
infants living in Cuiabá was high and early in life. Risk factors for wheezing
are similar to risk factors for asthma. Exposure to paracetamol was associated
with wheezing but more researches are required to clarify this potential
association.
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Risk Factors Associated to Wheezing in Mexican Children. A
Multicentric Isaac-based Survey Study
Armando Partida-Gaytan, MD,1 Blanca del Rio, MD,1 Dino Pietropaolo-
Cienfuegos, MD,1 Jaime Mariano del Río-Chivardí, MD,1 Lourdes
Avila, MD,1 Juan Valente Merida Palacios, MD,2 Sergio de Jesus Romero
Tapia, MD,3 Francisco Javier Linares Zapien, MD,4 Alberto Escalante
Dominguez, MD,5 Sandra González-Díaz, MD, PhD,6 Roberto García-
Almaraz, MD,7 and Sergio Carvajal Abdala, MD8. 1Pediatric Allergy and
Clinical Immunology, Hospital Infantil de Mexico Federico Gomez, Mexico
City, Mexico; 2Mexicali Health Care, Mexicali, Mexico; 3Hospital Angeles
Villahermosa, Villahermosa, Mexico; 4COMPEDIA, Toluca, Mexico; 5Hos-
pital General de Rosarito, Tijuana, Mexico; 6Hospital Universitario, Medical
School, Universidad Autónoma de Nuevo León, Monterrey, Mexico; 7COM-
PEDIA, Tamaulipas, Mexico; 8COMPEDIA, Veracruz, Mexico.
Background: Asthma affects around 300 million people around the world,
and is expected to increase 100 million more in the next 15 years. Multiple
risk factors had been associated with its prevalence, though little is known
about the regional variations of these risk factors.
Objective: Identify the main risk factors associated to the presence of
wheezing in the last 12 months in Mexican children aged 6 to 7 years old.
Methods: Multicentric, cross-sectional survey. The standardized Spanish-
version ISAAC questionnaire was applied to tutors of children aged 6 to 7
years old in 8 cities of the Mexican Republic. Sample was randomly selected
through public and private schools of each city, and a sample of 3000 children
per center was advisable. Risk analysis was made through multivariate
logistical regression, central tendency and dispersion measures were obtained
with respective 95% conﬁdence intervals.
Results: Nine centers of 8 cities participated, data of 24,504 question-
naires were analyzed with an answer rate of 90.7%. Grouping the 9
participating centers, a prevalence of 8.4% (95% CI, 8.1-8.8%) for
wheezing in the last 12 months was found, with the next distribution:
Monterrey 8.6% (95% CI, 7.6-9.6%), Mexicali 9.6% (95% CI, 8.4-
10.7%), Ciudad Victoria 8.6% (95% CI, 7.5-9.7%), Villahermosa 10.2%
(95% CI, 9.1-11.4%), Northern Distrito Federal 7.3% (95% CI, 6.5-8.2%),
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Southeast Distrito Federal 9.9% (95% CI, 8.5-11.3%), Toluca 5.9% (95%
CI, 5.1-6.7%), Tijuana 8.2% (95% CI, 7.2-9.2%), Veracruz 9.7% (95%
CI, 8.4-10.9%).Identiﬁed risk factors for the presence of wheezing in the
last 12 months were: nasal symptoms accompanied with ocular symptoms
(itching and tearing) in the last 12 months, OR 2.31 (95% CI, 2.01-2.66; P
# 0.0001). Nasal symptoms (blocked nose, runny nose, and/or itching) in
the last 12 months, OR 2.2 (95% CI, 1.66-2.92; P # 0.0001). Hay fever
diagnosis by medical staff OR 2.02 (95% CI, 1.72-2.37; P # 0.0001).
Atopic dermatitis symptoms (classic morphology and distribution) in the
last 12 months, OR 1.65 (95% CI, 1.39-1.96; P # 0.0001). Use of anti-
biotics in the ﬁrst 12 months of life, OR 1.68 (95% CI, 1.48-1.90; P #
0.0001). Use of acetaminophen in the last 12 months, OR 1.49 (95% CI,
1.35-1.65; P # 0.0001).
Conclusions: The presence of allergic rhinoconjuntivitis symptoms in the last
12 months doubles the risk for the presence of wheezing in Mexican children.
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Association Between Eosinophil Apoptosis in Induced Sputum
and Asthma Severity in Children
Alla Nakonechna, MD, PhD,1 Yuriy Antipkin,2 Tatiana Umanets, MD,
PhD,2 Vladimir Lapshyn,2 and Tamara Zadorozhnaja, MD2. 1Allergy, Royal
Liverpool and Broadgreen University Hospitals NHS Trust, Neston, United
Kingdom; 2Institute of Paediatrics, Obstetrics and Gynaecology, Kiev,
Ukraine.
Background: There is increasing evidence that the disorder of eosinophil
apoptosis contributes to the mechanism of prominent airway inﬂammation in
asthma. However the relationship between dysregulation of eosinophil
apoptosis and severity of childhood asthma is still unclear.
Objective: Investigate the relationship between eosinophil apoptosis in
induced sputum and severity of asthma in children.
Methods: Eighty-six children aged 6 to 12 years with asthma and 32 age-
matched healthy controls were observed. Diagnosis of asthma was made
using a clinical questionnaire, physical examination and skin prick tests
(SPTs). Lung function, and induced sputum analysis were measured in all
patients. Total and antigen speciﬁc IgE levels were assessesed by ELISA.
Eosonophils apoptosis was determined by staining nuclei with propidium
iodide, and analyzed with a FACScan. Expression Apo-1/Fas antigen (CD95)
in sputum eosinophils was assessed by immunohistochemical staining
techniques.
Results: Diagnosis of asthma was conﬁrmed by positive SPT and
increased total and speciﬁc IgE levels. Asthma severity (assessed by
FEV1, peak expiratory ﬂow (PEF) variability and daily symptom scores)
complied with mild and moderate asthma. The percentage sputum
eosinophils was expressively increased (threshold of ,3%) in all asth-
matic children (compared to control group) and directly correlated with
peripheral blood eosinophilia, skin sensitization, increased level of total
and speciﬁc IgE and clinical symptoms of asthma and all of these markers
were more signiﬁcant in children with moderate asthma (P , 0.05).
Asthma children showed decreased eosinophils apoptosis (“apoptotic ra-
tio”-AR) in induced sputum as compared to controls (P , 0.001), which
directly correlated with predicted value of FEV1, PEF variability and in-
versely with symptoms score (P ¼ 0.005), and was signiﬁcantly lower in
patients with moderate asthma than those in patients with mild (P ¼
0.001). More of that, these parameters also correlated with decreased
expression of Apo-1/Fas antigen (CD95), especially in moderate asthmatic
children (P , 0.05).
Conclusions: Our investigation: 1. Conﬁrms that reduced eosinophil
apoptosis in induced sputum associated with increased clinical severity of
asthma in children. 2. Provides additional evidence that eosinophil apoptosis
may be important in the resolution of eosinophilic airway inﬂammation in
asthma, because of their prolonged survival that maintains inﬂammation.
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Antibiotics but not Paracetamol Reduce the Risk for Recurrent
Wheezing in Infants
Herberto Jose Chong Neto, MD, PhD, Nelson Rosario, MD, PhD,
Flávia Carnieli Silva, Lylia Fátima Melniski Bojarski, Emanuel Antonio
Grasselli, Cristine Secco Rosario, Bernardo Augusto Rosario, and
Fernando Henrique Chong. Allergy and Immunology, Federal University of
Paraná, Curitiba, Brazil.
Background: Paracetamol (PCM) and antibiotic (ATB) use have been
associated with risk for wheezing and asthma in children. The aim of this
study was to verify the association of recurrent wheezing ($3 episodes) in
infancy and use of ATB or PCM in the ﬁrst year of life.
Methods: Cross-sectional study using a standardized and validated ques-
tionnaire (EISL: Estudio Internacional sobre Sibilancias en Lactantes) with
questions: Has your baby had wheezing or whistling in the chest area or
bronchitis in the ﬁrst 12 months of life? Has your baby had 3 or more
wheezing episodes in the ﬁrst year of life? How often has your baby used
antibiotics in the ﬁrst year of life? How often has your baby used paracetamol
in the ﬁrst year of life? Parents of infants, ages 12 to 15 months that attended
to Health Centers for routine immunization were interviewed between
September 2009 to September 2010 (EISL Phase III). Risk was demonstrated
using Odds ratio and 95% CI.
Results: One thousand and 3 parents participated in the survey and 19.8% of
infants had recurrent wheezing starting at 6.1 6 3 months. The use of PCM
was not related to the presence of recurrent wheezing [No PCM (OR ¼ 0.91;
95% CI, 0.38-2.19; P ¼ 0.83), PCM 1–3 times (OR ¼ 1.21; 95% CI, 0.77-
1.91; P ¼ 0.4), PCM 4–6 times (OR ¼ 1.21; 95% CI, 0.77-1.9; P ¼ 0.41) and
PCM $7 times (OR ¼ 0.76; 95% CI, 0.51-1.13; P ¼ 0.17)], while more
frequent use of ATB reduced the risk of recurrent wheezing in the ﬁrst year of
life [No ATB (OR ¼ 2.18; 95% CI, 1.35-3.51; P ¼ 0.001), ATB 1–3 times
(OR ¼ 1.39; 95% CI, 0.93-2.07; P ¼ 0.1), ATB 4–6 times (OR ¼ 0.37; 95%
CI, 0.22-0.62; P ¼ 0.001) and PCM$7 times (OR ¼ 0.22; 95% CI, 0.07-
0.66; P ¼ 0.001)].
Conclusions: The frequent use of ATB reduced the risk of recurrent
wheezing in the ﬁrst year of life unlike PCM that was not associated with
recurrent wheezing in this study population.
CONJUNCTIVITIS
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Ocular Signs and Symptoms Elicited by a Naturalistic Allergen
Challenge in anEnvironmental ExposureChamberModel Versus
a Direct Allergen Instillation Model
Michael S. Blaiss, MD. University of Tennessee Health Science Center`,
Memphis, TN.
Background: Direct-instillation ocular models are well established for
eliciting allergic responses in research and clinical testing. This study
compared direct ocular instillation of allergen to a more naturalistic airborne
allergen exposure.
Methods: Thirteen subjects with histories of ragweed allergy and positive
skin prick responses attended screening, dose-ﬁnding, dose‑conﬁrmation, and
analysis study visits. For conjunctival allergen provocation testing (CAPT), 1
drop of ragweed allergen was administered to each eye, at the lowest possible
subject-speciﬁc concentration between 1.6 and 100 protein nitrogen units per
25 ml drop. For environmental exposure chamber (EEC) testing, subjects
were exposed to continual airborne ragweed pollen at 3500 6 500 par-
ticles/m3. Symptoms of itching and tearing were self-assessed on diary cards
by subjects. Signs of hyperemia, swelling, and mucous discharge were
assessed by clinicians. Assessment time points started at 30 minutes before
exposure and continued through 180 minutes after exposure.
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Results: At baseline, there were minimal signs and symptoms. Maximum
mean hyperemia with CAPT was 2.3 6 0.6 units (between moderate and
severe) and with EEC was 1.9 6 0.5 units (approximately moderate); these
maxima occurred after 30 minutes with CAPT (rapid spike) and after 180
minutes with EEC (gradual increase). Mean swelling was ,1 unit out of 4
units at all times (CAPT and EEC), and mucous discharge was observed in
only 1 subject during the study (with CAPT). Maximum mean itching with
both CAPT and EEC was 2.8 6 1.0 units (approximately severe), but this
maximum occurred after 20 minutes with CAPT (rapid spike) and after 180
minutes with EEC (gradual increase). Maximum mean tearing with CAPT
was 1.2 6 0.7 units (approximately mild) and with EEC was 1.6 6 0.6 units
(between mild and moderate); these maxima occurred after 15 minutes with
EEC (rapid spike) and after 120 minutes with EEC (gradual increase).
Conclusions: The time courses of allergic signs and symptoms differed
between CAPT and EEC models; however, both models evoked similar
maximum response levels. This demonstrates that the EEC model is a useful
challenge model for mimicking natural airborne ocular allergen exposure.
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Increased Frequency of CD41 CD251 FOXP3- in Allergic
Conjunctivitis Patients
Jorge Galicia-Carreón, MD, MSc,1 Miguel E. Alonso-Sánchez, MD,1
Atzin Robles-Contreras, MSc,1 Enrique Hong, MD, PhD,2 Raul Chávez, MD,
PhD,3 and Maria C Jiménez-Martínez, MD, PhD,1,3. 1Research Unit and
Department of Immunology, Institute of Ophthalmology, México D.F., Mexico;
2Farmacobiología, Cinvestav, México D.F., Mexico; 3Department of Biochem-
istry, Faculty of Medicine, UNAM, México D.F., Mexico.
Background: Allergic conjunctivitis (AC) is one of the most common eye
disorders in clinical practice. It has been shown that AC is a disorder
mediated by Th2 lymphocytes producing IL-4 and IL-5, where the eye
damage is caused by a type I hypersensitivity. It has been suggested in asthma
and rhinitis that T regulatory cells (Tregs) CD41 CD251 FOXP31 have been
involved in control allergic status, favoring an optimal microenvironment
with immunosuppressive cytokines (IL-10, TGF-b). However is unknown
if Tregs have a role in human allergic conjunctivitis, thus it was the aim of
this study.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from
blood samples of healthy donors (HD) and AC-patients, and then PBMC were
labeled with mAbs against CD4, CD25 and FOXP3. Labeled cells were
analyzed by ﬂow cytometry. Statistical analysis was performed with Graph-
Pad v.5.
Results: AC-patients showed 55-times more CD41 CD251 cells than HD (P
¼ 0.02). Most of CD41 CD251 were FOXP3- (90 6 5.4), when we com-
pared MFI of FOXP3 in CD41 CD251 cells, we observed a decreased ex-
pression in AC-patients than HD (28.5 vs 85.36, P ¼ 0.02).
Conclusions: Despite we observed higher frequency of CD41 CD251 in AC-
patients, these cells were FOXP32, more interesting, the few cells FOXP31
showed a diminished MFI. These data suggest that allergic conjunctivitis
status could be related with a regulatory dysfunction, as has been suggested
in asthma and rhinitis.
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Increased Frequency of CD41 CCR41 CCR91 Cells in Patients
With Allergic Conjunctivitis
Miguel E. Alonso-Sánchez, MD,1 Jorge Galicia-Carreón, MD, MSc,1 Julio
Ayala-Balboa, MD,1 Atzin Robles-Contreras, MSc,1 Enrique Hong, MD,
PhD,2 Raul Chávez, MD, PhD,3 and Maria C. Jiménez-Martínez, MD,
PhD,1,3. 1Research Unit and Department of Immunology, Institute of Oph-
thalmology, México D.F., Mexico; 2Farmacobiologia, Cinvestav, Mexico D.
F., Mexico; 3Department of Biochemistry, Faculty of Medicine, UNAM, Méx-
ico D.F., Mexico.
Background: Allergic conjunctivitis is one of the most common diseases
affecting the ocular surface, it has been suggested that T CD41 cells regulate
immune response in allergic diseases such as asthma and rhinitis, in a pre-
dominant Th2 response. In animal models, it has been observed a selective
migration of CD41 T cells to conjunctiva directed by chemokines; however
molecules involved in CD41 T cell migration in humans is unknown, thus it
was the aim of this study.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from
blood samples of healthy donors (HD) and AC-patients. PBMC were labeled
with mAbs against CD4, CCR4, CCR5, and CRR9, and then labeled cells
were analyzed by ﬂow cytometry. T test was used to perform statistical
analysis, P , 0.05 were considered statistically signiﬁcant.
Results: We observed increased frequency of CCR41 and CCR91 on
PBMC cells; interestingly, expression of CCR41 was 1.46 times increased
on CD41 T cells of AC-patients compared to CD41 T cells of HD (P ¼
0.01). Similarly, we observed higher frequency of CCR9 expression on
CD41 cells of AC-patients than on CD41 T cells of HD (P ¼ 0.01). On
the other hand, CCR5 expression was diminished on PBMC from AC-
patients than in HD (P ¼ 0.0002).
Conclusions: Increased frequency of CD41 CCR41 CCR91 was observed
in AC patients with diminished frequency of CCR5 expression on PBMC.
CCR4 and CCR9 have been involved in inﬂammatory process such arthritis
and asthma, both could be related to inﬂammatory reaction at conjunctiva.
CCR5 expression is mainly on Th1 cells, diminished frequency on PBMC in
allergic conjunctivitis patients could be related with imbalance of immune
response favoring a Th2 chronic inﬂammation.
58
Long-term IFN-g Treatment Alters Allergic Inﬂammation-
Associated Gene Expression in Conjunctival Fibroblasts
Naoko Okada, PhD,1,2 Keisuke Oboki, PhD,1 Kazumi Fukagawa, MD,
PhD,2 Hiroshi Fujishima, MD, PhD,3 Tetsuya Kawakita, MD, PhD,2
Kazuo Tsubota, MD, PhD,2 Hirohisa Saito, MD, PhD,1 and Kenji
Matsumoto, MD, PhD1. 1Department of Allergy and Immunology, National
Research Institute for Child Health & Development, Tokyo, Japan; 2Depart-
ment of Ophthalmology, Keio University, Tokyo, Japan; 3Department of
Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan.
Background: Interferon-g (IFN-g) is a T helper type 1 (Th1) cytokine which
has antiviral, anti-proliferative, and immunomodulatory properties. Despite
the presence of IFN-g in the conjunctiva or tear ﬂuid of patients with severe
allergic conjunctivitis, the role of IFN-g in allergic conjunctivitis is contro-
versial and enigmatic. In this study, we assess the effect of long-term treat-
ment of IFN-g on human conjuctival ﬁbroblasts.
Methods: Primary cultured ﬁbroblasts derived from human conjunctiva
specimens were established. Cultured ﬁbroblasts were incubated with or
without IFN-g (10 ng/mL) for up to 14 days. After IFN-g treatment, cells were
washed out and were re-stimulated with combinations of IL-4 (10 ng/mL) and
TNFa (10 ng/mL) for 6 hours. Then, total mRNAs were isolated and mRNA
expression levels were measured using a microarray and real time-PCR.
Results: In IFN-g treated ﬁbroblasts in short-term (6 hours), we conﬁrmed the
increased expression levels of well-known interferon induced genes, such as
MHC class II, IRF1 and CXCL10. Increased expression of CCL11 stimulated
by IL-4 1 TNFa was suppressed by short-term IFN-g treatment as described
previously. In long-term (14 days) IFN-g treated cells, the expression of CCL11
and several proinﬂammatory chemokines, which were associated with Th2 cell
and eosinophil migration, was slightly but signiﬁcantly increased without any
other stimulations. Interestingly, IL-41 TNFa stimulation greatly enhanced the
expression levels of these chemokines, suggesting that long-term IFN-g treat-
ment alters the competency of gene expression potential on these gene loci in
contrast to the situation for short term treatment. Time-course analysis of IFN-g
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treatment revealed that the treatment of IFN-g up to 24 hours suppressed the IL-
4 1 TNFa-induced CCL11 expression, whereas the CCL11 expression was
enhanced 3 days after the treatment.
Conclusions: These results uncovered previously unsuspected contribution
of IFN-g to the ﬁbroblasts in allergic inﬂammatory milieu in terms of the
change in production of certain chemokines. In other words, the antagonistic
function of IFN-g to Th2 cells at the early phase may represent only a small
part. The intracellular signaling and IFN-g-dependent secondary events are
needed to be explored to explain the long-term effect or the late phase phe-
nomenon after IFN-g administration.
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Hyperosmolar Conjunctival Provocation Test (HCPT) in the
Evaluation of Ocular Symptoms
Elizabeth Maria Mercer Mourão, MD, MSc, and Nelson Rosario, MD, PhD.
Allergy and Immunology, Federal University of Paraná, Curitiba, Brazil.
Background: Non-allergic environmental factors may cause ocular symp-
toms in atopic and non atopic subjects, which are known as nonspeciﬁc
conjunctival hyperreactivity (CHR). This study aims to investigate the
presence of CHR to the HCPT in subjects with ocular symptoms.
Methods: 63 adults with ocular symptoms (itching, red eyes or tearing) were
selected and tested for allergy to house dust mites and grass pollen by skin
prick tests (ALK Abelló) and serum speciﬁc IgE (Immunocap-Phadia). They
were considered atopic if these tests were positive to at least one allergen and
non atopic if tests were negative. HCPT with 10-fold serial diluted glucose
solutions was performed in all subjects until it produced conjunctival redness.
Digital images were analyzed by 2 investigators (MD and technician) regis-
tering redness of the challenged eyes in red and the total area of contra-lateral
eyes in blue using the ﬁne brush tool (software GIMP 2.6.5). The number of
red dots of the affected eye (%) was compared to the number of blue dots of
the control eye.
Results: TPCH was positive in 33/38 atopic subjects (87%) and in 4/25 non
atopic (16%). Most reactions occurred at the 40% glucose solution.
Sensitivity was 87% and speciﬁcity 84% (P , 0.0001). There was a signiﬁ-
cant correlation (96.5%, Pearson, P , 0.0001) between the number of red
dots reported by investigators in 23 digitalized images.
Conclusions: TPCH identiﬁes CHR in both atopic and non atopic subjects.
Atopic subjects exhibit CHR more frequently than non-atopic subjects.
Digital images may be useful for grading ocular hyperemia in TPCH.
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Tear IFN-G is Increased After Sublingual Immunotherapy in
Allergic Conjunctivitis Patients and Correlates With
Clinical Improvement
Gustavo Aguilar-Velazquez, MD, PhD,1 Concepcion Santacruz, MD,2
Pedro M. Hernandez, MD,1 Raul Chavez, MD, PhD,3 Julio Ayala-
Balboa, MD,4 Sergio Estrada-Parra, PhD,5 Mayra Perez-Tapia, PhD,6
and Maria C Jiménez-Martínez, MD, PhD3. 1Research Unit, Department of
Immunology, and; 2Department of Cornea, Institute of Ophthalmology
"Conde de Valenciana", Mexico, Mexico; 3Department of Biochemistry, Fac-
ulty of Medicine, UNAM, Mexico, Mexico; 4Research Unit and Department of
Immunology, Institute of Ophthalmology, México D.F., Mexico; 5Molecular
Immunology Lab-I, National School of Biological Sciences, IPN, Mexico,
Mexico; 6Unidad de Desarrollo e Investigacion de Biologicos, National
School of Biological Sciences, IPN, Mexico, Mexico.
Background: Despite success of sublingual immunotherapy (SLIT) in the
treatment of allergy diseases, more research is needed related to ocular allergy.
Thus, the aim of this work was to analyze the ocular microenvironment
provided by tear cytokines in allergic conjunctivitis (AC) patients treated with
SLIT and to correlate tear and serum cytokines with ocular ﬁndings.
Methods: 19 AC-patients were included in this study. AC diagnosis was
based on a clinical history and full ophthalmologic examination according
to the diagnosis standards of the American Academy of Ophthalmology.
Routine immunological studies were performed to corroborate allergic
status Negative coproparasitoscopic results were documented. This study
was approved by Scientiﬁc and Ethics Committees if Institute of
Ophthalmology “Conde de la Valenciana,” Mexico City an all subjects
gave their informed consent to obtain samples. Tear and serum samples
were collected to determine cytokines IL2, IL-4, IL-5, IFN-g, TNF-a,
IL-10 by cytometric bead arrays (CBA), following manufacturer’s
instructions.
Results: After 6 months of treatment with SLIT we observed signi-
ﬁcant higher IFN-g concentration, without signiﬁcant changes in
IL2, IL4, IL5, TNFa or IL10. We observed signiﬁcant clinical
improvement since 3 months of treatment and it was maintained until
the end of 6 months. Clinical improvement correlated with IFN-g
concentration.






Hypoxia-Inducible Factor 1 (HIF-1)Transcription is a “Signalling
Driver” for Allergic Inﬂammation, Host Innate Immune Defence
and Leukaemia Progression
Vadim Sumbayev, PhD, Inna Yasinska, PhD, and Bernhard Gibbs, PhD.
Medway School of Pharmacy, University of Kent, Chatham Maritime, United
Kingdom.
Background: Hypoxia-inducible factor 1 is a transcription complex that plays
a pivotal role in cellular adaptation to low oxygen availability, which occurs
during allergic responses, host immune defence and leukaemia progression.
We investigated the role of HIF-1 in cellular adaptation to stress associated
with different types of pathological reactions of immune cells. We studied IgE-
dependent responses of human mast cells and basophils, Toll-like receptor
(TLR)-mediated innate immune reactions of human myeloid cells and stem
cell factor (SCF)-mediated responses of hematopoietic cells of myeloid
lineage.
Methods: LAD2 human mast cells1, primary human basophils, and THP-1
human myeloid cells were used for investigations of FceRI, TLR ligand and
SCF-induced responses. Quantitative real-time PCR, Western blot analysis,
ELISA, ﬂuorometry, luminometry and ﬂuorescence microscopy were
employed to run the assays.
Results: We observed that HIF-1 activation is differentially regulated in
the cases of pro-allergic, TLR-dependent and SCF-induced cellular
responses. While PI3K/mTOR and MAP kinase pathways were the major
contributors to HIF-1 activation during allergic/SCF-dependent responses,
TLR-mediated processes occurred mostly via redox-dependent mecha-
nisms. Experiments with HIF-1a (the inducible subunit regulating HIF-1
transactivation) knockdown cells demonstrated that HIF-1 plays a crucial
role in the expression of the primary angiogenic cytokine VEGF and con-
trols intracellular energy metabolism by regulating glycolytic metabolic
activity.
Conclusions: The HIF-1 transcription complex supports not only the survival
of immune cells (mast cells, basophils, myeloid cells) in pathological
environments but also determines their abilities to generate pro-allergic,
pro-inﬂammatory as well as pro-angiogenic cytokines over sustained periods.
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Keratinocytic Thymic Stromal Lymphopoietin Plays an
Important Role in Epicutaneous Sensitization and the
Atopic March
Juan Manuel Leyva Castillo, MSc, Pierre Hener, Hua Jiang, PhD,
Daniel Metzger, PhD, Pierre Chambon, PhD, and Mei Li, PhD. Functional
Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et
Cellulaire, CNRS UMR-7104/INSERM U964/UdS, Illkirch CEDEX, France.
Background: Atopic dermatitis (AD or eczema) often precedes the develop-
ment of asthma and allergic rhinitis in atopic subjects, a phenomenon known
as atopic march. An important role of epicutaneous (e.c.) sensitization has been
recognized in the atopic march; however, the factors involved in e.c. sensiti-
zation remain poorly understood. Our previous studies using mouse models
have shown that induced overexpression of Thymic Stromal Lymphopoietin
(TSLP) in keratinocytes not only triggers an AD [Li, M. et al. Proc Natl Acad
Sci U S A. 2006;103:11736–11741] but also aggravates experimental asthma
induced by systemic sensitization and airway challenge of ovalbumin (OVA)
[Zhang Z, et al. Proc Natl Acad Sci U S A. 2009;106:1536–1541], suggesting
that TSLP represents an important factor linking AD to asthma. However,
whether keratinocytic TSLP is essentially required for developing e.c. sensiti-
zation and triggering the atopic march remained to be determined.
Methods: We develop a mouse model in which e.c. sensitization of OVA
through tape-stripped skin is followed by intranasal challenge to induce an
allergic asthma. TSLPep2/2mice (in which TSLP is selectively ablated in
epidermal keratinocytes at adult stage) or TSLPover mice (in which keratino-
cytic TSLP overexpression is induced by topical application of MC903,
a low-calcemic vitamin D analog) are subjected to this mouse model.
Results: Upon OVA e.c. treatment, TSLPep2/2 mice develop a defective
allergen sensitization evidenced by decreased production of OVA-speciﬁc
IgE and IgG1 and a reduction of the secretion of Th2 and Th17 (but not
Th1) cytokines by in vitro OVA stimulated splenocytes. TSLPep2/2 mice also
exhibit a decreased OVA-induced skin inﬂammation. Finally, upon intranasal
challenge, TSLPep2/2 mice develop a less severe airway allergic inﬂammation
and a reduced airway hyperresponsiveness. In contrast, overproduction of ker-
atinocytic TSLP boosts the e.c. sensitization and triggers an aggravated asthma.
Conclusions: Our results demonstrate an important role of keratinocytic
TSLP in developing epicutaneous sensitization, generating allergic skin
inﬂammation and triggering the atopic march. Thus, blocking the expression
or activity of keratinocytic TSLP could be helpful to limit epicutaneous
sensitization and prevent the atopic march.
This study is supported by CNRS, INSERM, ARI and ANR projects (07-
PHYSIO-002–01 and JCJC-1106-01).
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Pivotal Role of Intestinal Interleukin-17-Producing Gammadeltat
Cells in the Food Allergy
Ryusuke Nakagawa, PhD. Immunology, University of Yamanashi, Faculty of
Medicine, Chuoh, Japan.
Background: Food allergy is a serious health problem, which affect 5% of
children in westernized countries and evoke life-threatening hypersensitivity,
termed anaphylaxis shock. Type 2 helper T cell (Th2) response and
immunoglobulin E (IgE) has been implicated in the progression of food
allergy, but the roles of speciﬁc lymphocyte subpopulations and cytokines
remain to be clariﬁed.
Methods: The mucosal adjuvant, cholera toxin (CT) and ovalbumin (OVA)
were co-administered orally into mice, while OVA alone could induce oral
tolerance. To evaluate the contribution of various cytokines, we used
interleukin-17 (IL-17) or IL-23 knockout (KO) and wild type (WT) mice as
control.
Results: Here we demonstrate that gamma delta T cells in the intestinal
mucosa, as well as the cytokines interleukin-23 (IL-23) and IL-17, have
pivotal roles to suppress the induction of serum OVA speciﬁc immunoglo-
bulins and anaphylaxis in the food allergy model. The expression of IL-23,
which was derived mostly from mucosal macrophages, and IL-17 levels were
elevated after CT and OVA sensitization, and this induction of IL-17 was
dependent on IL-23.
Conclusions: These data, together with analysis of mice genetically disrupted
for IL-17 and IL-23, suggest that IL-23 suppress the food allergy, whereas IL-
17 has an important role in the anaphylaxis shock. Moreover, depletion of
gamma delta T cells exacerbates the food allergy. We propose that T
lymphocytes, including gamma delta T cells, could be a therapeutic target for
mitigating the allergic response that evokes the anaphylaxis shock.
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Effect of Formoterol on Eosinophil Trans-Basement Migration
Induced by Interleukin-8-Stimulated Neutrophils
Akiko Kawashima, MD, Fuyumi Nishihara, MD, Takehito Kobayashi, MD,
PhD, Kazuyuki Nakagome, MD, PhD, and Makoto Nagata, MD, PhD.
Allergy Center, Department of Respiratory Medicine, Saitama Medical
University, Moroyama-Machi, Japan.
Background: Neutrophils are often increased in the airways of either chronic
severe disease or acute exacerbation of asthma. Neutrophils migrated in
response to interleukin-8 (IL-8) may lead eosinophils to accumulate in the
airways of asthma and possibly aggravate this disease. In this study, we
investigated whether formoterol modify the trans-basement membrane
migration (TBM) of eosinophils stimulated with neutrophils and IL-8.
Methods: Neutrophils and eosinophils were isolated from peripheral blood
obtained from healthy donors. The TBM of eosinophils was examined using
a modiﬁed Boyden’s chamber technique. Neutrophils were preincubated with
or without formoterol (0.1 mM) at 378C for 30 minutes. Eosinophils were
added to the upper compartment of a chamber with a Matrigel-coated trans-
well insert. Medium that contained preincubated neutrophils and IL-8 was
added to the lower compartment of the chamber. After 90 minute incubation,
migrated eosinophils in the lower chamber were calculated using eosinophil
peroxidase assays.
Results: A combination of neutrophils and IL-8 signiﬁcantly induced TBM
of eosinophils. Formoterol by itself did not modify the TBM of eosinophils.
However, formoterol signiﬁcantly attenuated TBM of eosinophils stimulated
with neutrophils and IL-8.
Conclusions: These results suggest that formoterol may act as a therapeutic
agent on enhanced eosinophilic inﬂammation in acute exacerbation or
persistent severe disease of asthma. This effect of formoterol likely involves
inhibition of activation of neutrophils.
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Characteristics of Liver Injury in Drug-induced Systemic
Hypersensitivity Reactions
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PhD,2 and Hee-Bom Moon,MD, PhD2. 1Department of Internal Medicine, Inje
University Heaundae Paik Hospital, Busan, South Korea; 2Department of
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Background: Liver is the second most commonly involved organ in drug-
induced systemic hypersensitivity reactions (DiSH). Although liver function
is very important indicator in the course of DiSH, there have been few studies
about the characteristics of the liver injury. In present study, we investigated
clinical characteristics of DiSH associated with liver injury (liver-DiSH)
Methods: We retrospectively reviewed medical records of 38 hospitalized
patients who developed liver-DiSH (AST or ALT $80 IU/L) from January
2008 to February 2011 in a tertiary referral hospital. We analyzed culprit
drugs, the type and degree of liver injury, and the effect of systemic cortico-
steroids. Fisher’s exact test and Chi-square test and Mann-Whitney test were
used for statistical analysis.
Results: Thirty-eight patients of liver-DiSH were enrolled, whose clinical
phenotypes were Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/
TEN) (n ¼ 9, 24%), drug reaction with eosinophilia and systemic symptoms
(DRESS) (n ¼ 23, 60%), maculopapular rash (MP rash) (n ¼ 5, 13%) and acute
generalized exanthematous pustulosis (AGEP) (n ¼ 1, 3%). Antibiotics (n ¼ 16/
38, 41%) was the most common cause of liver-DiSH. Culprit agents of liver-
DiSH were allopurinol (n ¼ 3/9, 33%) in SJS/TEN and antibiotics (n ¼ 13/23,
57%) in DRESS. Mortality tended to be higher in SJS/TEN than in DRESS (22%
(2/9) vs 17% (4/23), P ¼ 0.846). Degree of liver injury was statistically more
severe in DRESS than in SJS/TEN (mean peak AST [423 IU/L vs 144 IU/L, P¼
0.062], mean peak ALT [428 IU/L vs 156 IU/L, P ¼ 0.013], mean peak ALP
(alkaline phosphatase) [252 IU/L vs 85 IU/L, P ¼ 0.002], mean total bilirubin
[7.7 mg/dL vs 1.3 mg/dL, P ¼ 0.064], and time required for AST/ALT to drop
below 80 IU/L [15.8 days vs 4.1 days, P ¼ 0.049]). Seventy-six percents (29/38)
of patients were treated with systemic corticosteroid. The use of corticosteroid did
not signiﬁcantly affect both recovery of liver injury and mortality.
Conclusions: Our results suggest that liver-DiSH has distinguished clinical
characteristics according to the disease phenotypes. Further studies are
needed to evaluate the role of systemic corticosteroid in liver injury in DiSH.
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DrugReactionwithEosinophilia andSystemic Symptoms (Dress):
What We Still Have to Learn?
Luciana Kase Tanno, MD,1,2 Michel Dracoulakis, MD,3 Luis Felipe Chiaverini
Ensina, MD,4,5 Pedro Giavina-Bianchi, MD, PhD,1 Jorge Kalil, MD, PhD,1
Wilson T. Aun, MD,2 João Ferreira Mello, PhD,2 and Antonio Abilio Motta,
MD,PhD1. 1Clinical Immunology and Allergy, University of Sao Paulo, Sao
Paulo, Brazil; 2Allergy and Immunology, Hospital do Servidor Público Estad-
ual de São Paulo, São Paulo, Brazil; 3Allergy, Hospital Servidor Público
Estadual de São Paulo, São Paulo, Brazil; 4Rheumatology, Federal University
of Sao Paulo, Sao Paulo, Brazil; 5Rheumatology, Allergy and Immunology,
University of Santo Amaro, Sao Paulo, Brazil.
Background: Cases of drug induced hypersensitivity syndrome are reported
under various names and case deﬁnition for this reaction pattern is regularly
poorly applied. Our aim was to analyze series of cases of Drug Reaction with
Eosinophilic Hypersensitivity Syndrome (DRESS) and their clinical and
demographic data.
Methods: A prospective study was developed in Allergy Clinics of 2
Services in São Paulo, Brazil, from November 2008 to June 2011. The
patients were studied based on history of DRESS based on standardized
scoring systems and using an adapted ENDA (European Network of Drug
Allergy) questionnaire. Clinical and demographic data were analysed.
Results: Twenty-nine cases were validated as probable or deﬁnitive DRESS,
20 females (69%) and the mean age was 43.6. The reactions generally started
with fever and exanthema. All cases had exanthema, mucosal involvement was
found in 4 patients (13%). Fever .388C was present in 89% and lymphade-
nopathy in 55%. Involvement of a single internal organ (69%) or variable
combination of 2 or more internal organs (17%) was common, predominantly
related to liver (79%), kidney (17%) and lung (6.8%). Eighty percent of patients
with renal involvement required dialysis. Eosinophilia was documented in
89% and atypical lymphocytes in 31%. Sixty-nine percent were related with
antiepileptics, 10% with sulfonamides and 6.8% with allopurinol, 6.8% with
b-lactams antibiotics and 6.8% with non-steroidal anti-inﬂammatory drugs. The
mean interval between the intake of the suspected drug and the reaction was
27.6. In all patients the duration of the reaction was protracted (.15 days).
Forty-eight patients reported the intake of more than 2 drugs at the same time of
the reaction, but in all cases there was 01 drug suspected. No fatalities occurred.
Conclusions: This series conﬁrmed the clinical variability of DRESS,
highlighting skin, fever, lymphadenopathy, internal organs involvement and
eosinophilia. There was severe internal organ involvement, but no fatalities
occurred. Clinical characters and time of onset of the reactions differs from
others non-immediate hypersensitivity reactions, it supports that DRESS is an
original phenotype. Prospective long-term multicentric epidemiological
studies may be important for better understanding of this syndrome.
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Inﬂuence of Transglutaminase and the Reducing Agent
Glutathione in the Gastric Digestion and Immunogenicity of
Beta-Lactoglobulin
Milena Morandi Vuolo, MD,1 Mariana Battaglin Villas-Boas,1 Flavia Maria
Netto, PhD,1 and Ricardo de Lima Zollner, PhD2. 1Food and Nutrition,
University of Campinas (UNICAMP), Campinas, Brazil; 2Department of
Clinical Immunology and Allergy, Faculty of Medical Sciences, UNICAMP,
Campinas, Brazil.
Background: Among the milk whey proteins, b-lactoglobulin (b-Lg) is the
main allergen. In native state, b-Lg is resistant to pepsin, which is considered
an indicator of its allergenic potential. Protein antigenicity can be reduced by
treatment with transglutaminase (TG), an enzyme which catalyses inter or
intra crosslink between Lys and Gln residues. Reducing agents have been
used to increase the access of TG to the Lys and Gln residues. This study
aimed at investigating the antigenicity and digestibility by pepsin of b-Lg
modiﬁed by TG in the presence of the reducing agent glutathione (GSH).
Methods and Results: The polymerization of b-Lg (Davisco, MN, USA) by
microbial TG (WM, Ajinomoto Ltda, Brazil) was studied using a central-com-
posite experimental design with 2 independent variables, GSH concentration
[GSH] (0–0.2 mmol L21) and enzyme:substrate ratio (E/S) (0–44.1 U g21). The
dependent variable was the response of speciﬁc IgE obtained from the serum of
BALB/c mice sensitized with native b-Lg (IgE anti-b-Lg) against the modiﬁed
protein. Polymerization was carried out at 508C/180 minutes and stopped by
heating at 808C/5 min. Digestion was simulated using pepsin (E/S 1:20 w/w,
pH 2, 378C, 1 hour), and SDS-PAGE and the ELISA assay used to characterize
and evaluate the antigenicity of the samples, respectively. The linear and qua-
dratic factors of [GSH] and E/S, and their interaction, showed no signiﬁcant
effect on the response of lgE. No treatment resulted in a decrease in the re-
sponse of IgE anti-b-Lg, but a signiﬁcant (P , 0.05) increase was observed in
the response of IgE against treatments 1, 7 and center point. Intact b-Lg was
observed in the electrophoretic proﬁle of the digested samples, indicating re-
sistance to pepsin. After digestion, the samples not presented difference with
respect to the digested native b-Lg sample (213.06 6 9.59 ng mL21).
Conclusion: Polymerization of the b-Lg with TG in the presence of the GSH
did not alter its digestibility by pepsin or decrease the antigenicity. Under
some of the conditions studied the antigenicity of the b-Lg increased, in-
dicating that the treatment could have created or exposed epitopes.
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Immediate and No Immediate Reactions Induced by Iodinated
Contrast Medium Nonionic Among Hospitalized Patients:
Incidence and Severity
Martín Bedolla-Barajas, MD. Servicio de Alergia e Inmunología Clínica,
Hospital Civil de Guadalajara, Guadalajara, Mexico.
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Background: Contrast media (CM) are among the most widely used
medications in the world. Our objective was to estimate the severity and
incidence of adverse reactions to MC, ﬁrst administered in hospitalized patients.
Methods: We prospectively studied 99 patients requiring computed tomog-
raphy (CT) enhanced with MC. Immediate adverse reactions were identiﬁed
by direct questioning and/or physical examination after administration of
iodinated CM nonionic low osmolarity. Additionally, blood pressure, heart
rate, oxygen saturation, serum creatinine and total count of eosinophils were
measured before and after the procedure.
Results: Mean age of patients was 50.4 6 20.2 years, women were 52. The
occurrence of immediate adverse reactions and no immediate observed were
26.3 and 10.1% respectively. Eighteen (69.2%) of the immediate reactions
were mild, 6 (23.1%) moderate and 2 (7.7%) severe (both developed symp-
tomatic arrhythmias). The most common manifestations were warmth, nausea
and itching, nephrotoxicity was observed in 5.1% of patients and eosinophilia
in 3.1%. No skin reactions documented. Median serum creatinine before and
after the procedure not observed signiﬁcant difference (P ¼ 0.130), instead
the total number of eosinophils did show difference (P , 0.001).
Conclusions: Our results demonstrate a high incidence of adverse reactions
compared with previously published reports worldwide. Although most adverse
reactions are mild, those of severe intensity, with increased mortality and
morbidity, increased costs and hospital length of stay continue to occur despite
the increased use of contrast media of low osmolarity. More prospective studies
that share the same methodology are needed to determine the actual frequency.
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Severe Cutaneus Drug Reactions: Description of a Serie Cases
Fátima Fernandes, MD, Aline Camporez, MD, Luciana Kase Tanno, MD,
Simone Valadão Curi, Paula Perini, MD, Maria Elisa Andrade, MD,
Wilson T. Aun,MD, and João Ferreira Mello, PhD. Allergy and Immunology,
Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil.
Objective: To describe the cases of severe cutaneus drug reactions reported
in patients admitted to a hospital in São Paulo, assisted by the Service of
Allergy and Immunology.
Methods: A case serie study based on record’s analysis of patients who were
hospitalized from January 2002 to June 2011 evaluated by the allergist.
Results:We evaluated 25 cases of severe drug reactions, among which 13 (52%)
were Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), 7 (29.4%)
Stevens-Johnson syndrome (SJS), 4 (16) Toxic Epidermal Necrolysis (TEN) and
1 (4%) Acute Generalized Exanthematous Pustulosis (PEGA). The patients’ ages
ranged from 5 to 77 years (median ¼ 37), 13 (52%) were male. The drug classes
more closely related were antibiotics 18 (45%), non-steroidal anti-inﬂammatory
12 (30%) and anticonvulsants 9 (25%). The mean length of hospital stay was 15
days. Systemic involvement occurred in 15 (60%) patients, of whom 15 (100%)
liver involvement, 5 (33%) kidney, 2 (13%) pancreatic and 1 (6%) thyroid. There
was mucosal involvement in 12 (80%) cases. Three patients (12%) had septice-
mia, which led to mortality. All of them had TEN with extensive cutaneus
involvement. Other patients presented sequelae in the skin (4–16%) and in the
eyes (5–20%). Other complications observed were: cholestatic syndrome, immu-
nodeﬁciency and autoimunidade, each of them in one patient.
Conclusion: In this serie of cases, DRESS was the most frequent disease and
antibiotics were the drugs most commonly implicated. The average hospital
stay was prolonged. Liver involvement was the main systemic commitment.
TEN was responsible for the major mortality rate.
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Frequency of Sensitization for Food and Aero-Allergens in
Patients Received in a Venezuelan Laboratory During 2010 to
2011 Period
Daniela Figueroa, Lic,1 Rosy Barroso, Dra,2 Natacha Camacho, Lic,1
Cristina Najm, Lic,1 Jhonarly Guzmán, Lic,1 Angel Perdomo, Lic,1
Nirsen García, Lic,1 and Noel A. Silva, Esp1. 1Corpodiagnosticas Laboratory,
Caracas, Venezuela; 2Clínica Lepoldo Aguerrevere, Caracas, Venezuela.
Background: Type I Allergy had been deﬁned as an adverse immunologic
reaction mediated by IgE that occurs after a repeated exposure to speciﬁc
protein. The prevalence of the allergies has increased considerably in the past
20 years, thus increasing the need of study the response to several allergens.
The objective was evaluate the frequency of foods and respiratory allergens
sensitization in patients referred to Corpodiagnostica Laboratory (Caracas,
Venezuela, ISO 9001:2008 certiﬁed laboratory) in the period that correspond
from January 2010 and to July 2011.
Methods: There were a total of 2.445 patients with a request of speciﬁc IgE
against some foods and aero-allergens. The sample was divided in groups
according the age and sex. We measured the speciﬁc IgE to each patient by the
in vitro RIDA Allergy-screen immunoblot method (r-biopharm, Germany).
Results: The frequency of sensitization to aeroallergens were 41, 48% in
2010 (the most frequent were dust mites in the fallowing order: Dermato-
phagoides pteronissinus, D. farinae and Blomia tropicalis), and 51, 20% in
2011, being the frequent: D. farinae, B. tropicalis and D. pteronissinus. In the
case of food allergens the frequency of sensitization were 25, 99% in 2010
and 36, 47% in 2011.
Conclusions: In Venezuela the most frequent aero-allergens during the whole
period were the dust mites, unlike other countries with established weather
seasons, by another hand for food allergens the most frequent were milk and
cheese. In most patients, the speciﬁc concentration of IgE type antibodies against
the aero-allergens and food proteins were low, however, we observed that for
some allergens such as dust mites and seafood the concentration achieved were
higher. The food allergies could predisposes to a further respiratory complica-
tion, therefore it is important the diagnosis of this kind of reactions.
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Glutathione Exposed Sequential Epitopes of Ovomucoid Are
Relevant for Persistent Egg-Allergic Patients
Franziska Roth-Walter, PhD,1 Philipp Starkl,1 Torsten Zuberbier, MD,2
Richard Brunner, MD,1 Isabella Pali-Schöll, PhD, MSc,1 Janis Kinkel,1
Ferdinand Felix,1 Erika Jensen-Jarolim, MD,1 and Tamar Kinaciyan, MD3.
1Department of Pathophysiology and Allergy Research, Medical University
of Vienna, Vienna, Austria; 2Clinic for Dermatology, Venereology and Aller-
gology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3DIAID, De-
partment of Dermatology, Medical University of Vienna, Vienna, Austria.
Background: The egg allergen ovomucoid (Gal d 1) is conformationally
stabilized by 9 disulﬁde bonds. However, patients with persistent egg-allergy
have more IgE against sequential than conformational epitopes of ovomucoid.
We investigated whether natural or added food compounds may cause
reduction of disulﬁde bonds and linearization of ovomucoid.
Methods: Reduced ovomucoid in raw eggwhite was detected using
a ﬂuorescence-labeled alkylation probe. The common anti-oxidants glutathi-
one and cystein were used for in vitro linearization and effects were
monitored by CD-spectrometry. Egg-allergic patients were tested serologi-
cally (n ¼ 19) and by skin prick test (n ¼ 9) for IgE against native and
linearized ovomucoid and optionally its cooked state.
Results: Linearized ovomucoid could be detected in native eggwhite. Glutathi-
one and cystein treatments, but not cooking linearized ovomucoid, as conﬁrmed
by CD-spectrometry. In Western Blot involving cooking more patients had IgE
against reduced than native ovomucoid. In ELISA, most IgE was found against
raw and native ovomucoid. Cooking of native ovomucoid signiﬁcantly de-
creased, whereas cooking of previously linearized ovomucoid enhanced IgE-
binding. In skin prick test 5/9 patients reacted with linearized ovomucoid.
Conclusions: Linearized ovomucoid is present in natural eggwhite. Glutathi-
one which is occurring naturally but is also frequently used as structure
improving additive in processed food is partly responsible. Additional cooking
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of linearized ovomucoid increases IgE-reactivity in patients with persistent egg-
allergy in vitro and in skin prick tests. Our data provide evidence that reduction
is a novel principle which contributes to the allergenicity of food. This may be
relevant for new allergies to modern processed food.
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The Choice of Hypoallergens for Fish and Peach to Develop Food
Allergy Speciﬁc Immunotherapy (TheFAST Project)
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Michael Clausen, MD, PhD,8 Carsten Bindslev-Jensen, MD, PhD,9
Angela Neubauer, PhD,10 Stef Koppelman, PhD,11 Clare Mills, PhD,12
Juan A. Asturias, PhD,13 and Ronald van Ree14. 1Experimental Immunology,
Academic Medical Center, Amsterdam, Netherlands; 2Region Hovestaden,
Kopenhagen, Denmark; 3Hospital Clinico San Carlos, Madrid, Spain; 4Im-
munology, Rheumatology & Allergy, Faculty of Medicine, Medical University
of Lodz, Lodz, Poland; 5National Kapodistrian University of Athens, Athens,
Greece; 6Instituto Dermopatico dell’Immacolata, Rome, Italy; 7Medical Uni-
versity of Vienna, Vienna, Austria; 8Landspitali University Hospital Reykja-
vik, Reykjavik, Iceland; 9Odense University Hospital, Odense, Denmark;
10Biomay AG, Vienna, Austria; 11HAL Allergy BV, Leiden, Netherlands;
12Institute of Food Research, Norwich, United Kingdom; 13BIAL Aristegui,
Bilbao, Spain; 14Academisch Medisch Centrum, Amsterdam, Netherlands.
Background: Classical allergen-speciﬁc immunotherapy (SIT), using sub-
cutaneous injections with food extracts, may be effective but dangerous due
to anaphylactic side-effects. The FAST project (Food Allergy Speciﬁc
Immunotherapy) aims at the development of safe and effective treatment of
food allergies, targeting persistent and severe allergy to ﬁsh (cod) and fruit
(peach). Both are caused by a single major allergen, parvalbumin (Cyp c 1)
and lipid transfer protein (Pru p 3), respectively. FAST will apply hypo-
allergenic recombinant major allergens for SIT.
Methods: Two approaches were evaluated for achieving hypo-allergenicity,
i.e. site-directed mutagenesis and chemical modiﬁcation. Wildtype (wt)
natural and recombinant allergens and the hypo-allergens were extensively
puriﬁed and characterized physico-chemically. Their stability was tested and
allergenicity was compared by CAP-inhibition and histamine release experi-
ments while immunogenicity was tested in T-cell proliferation experiments
and rabbit and mice immunizations.
Results: For Cyp c 1, the mutant without calcium-binding site showed up to
a 1000 times reduced allergenicity, while secondary fold and immunogenicity
(tested in human PBMC stimulations and by immunization of laboratory
animals) were retained. Chemically modiﬁed Cyp c 1 demonstrated a reduced
capacity to stimulate T-cells and showed less immunogenicity in rabbits. The
calcium-binding mutant has been produced under GMP conditions.For Pru p
3, 5 potential hypoallergens were compared. The allergenicity was reduced to
a similar extent (w1000-fold) for both variants in which disulﬁde bridges
were disrupted, i.e. either by mutagenesis or by reduction/alkylation. The
modiﬁcation resulted in loss of alpha-helical secondary structure. However,
unexpectedly, the immunogenicity was also signiﬁcantly lowered/absent.
Conclusions: For the Cyp c 1 calcium-binding mutant we are preparing to
enter Phase I clinical trials. For Pru p 3, we need to evaluate new molecules to
generate a hypoallergenic mutant that retains immunogenicity.
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IFN-ã Induces Milk Allergen-Speciﬁc IL-10-Producing
Regulatory B Cells in Non-IGE Mediated Milk Allergy
Jae Ho Lee, Sr, MD, PhD. Department of Pediatrics, School of Medicine,
Chungnam National University, Taejeon, South Korea.
Background: Tolerance induction is one of the most important concerns in the
treatment of allergies and autoimmune diseases. L-10-producing regulatory B
cells (Br1s) seem to have a role in immune tolerance to food allergens. Oral
immunotherapy using IFN-gamma has been successful for food allergy
treatmen. We were to investigate the effects of IFN-gamma on allergen-speciﬁc
Br1 responses in milk allergy patients and milk-tolerant subjects to evaluate the
mmunomodulatory effects of IFN-gamma on Br1 cell responses.
Methods: The 6 milk allergy patients and 8 milk-tolerant subjects were
selected by DBPCFC and clinical characteristics. The PBMCs were
stimulated in vitro with casein only, IFN-gamma with casein, or without
any stimulant. And the CD19(1) CD5(1) B cells were gated and the expres-
sion of IL-10 and Annexin V binding were subsequently analysed.
Results: In milk allergy group, the Br1 fraction decreased from 24.4 to 15.0%
(P¼ 0.002) after casein stimulation and it was recovered to 22.6% in the presence
of IFN-gamma (P ¼ 0.006). In milk-tolerant group, the Br1 fraction increased
from 9.4 to 17.1% after casein stimulation (P ¼ 0.014) and to 15.7% after IFN-
gamma were added (P ¼ 0.066). The proportion of apoptotic Br1s among CD5
(1) B cells decreased from 16.5 to 8.1% with casein (P ¼ 0.003) and to 11.8%
with IFN-gamma and casein (P ¼ 0.141) in milk allergy group, while in milk-
tolerant group, the proportion of apoptotic Br1 increased from 8.2 to 15.0% after
casein stimulation (P ¼ 0.014), but was unchanged by casein with IFN-gamma.
Conclusions: Allergen-speciﬁc Br1 responses and the apoptotic Br1 fraction
were induced by IFN-gamma in milk allergy patients, but were not changed
in milk-tolerant subjects. Finally IFN-gamma induced allergen-speciﬁc Br1
responses and immune tolerance to speciﬁc allergens in milk allergy patients.
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Analysis of IGE, IGERastValue andPrickTest inWheat orHen’s
Egg-Allergy Infants Treated with Slow Speciﬁc Oral Tolerance
Induction Therapy
Takeshi Noma, MD, PhD,1 Norifumi Ogawa, MD, PhD,2 Akihiro Oshiba,
MD, PhD,3 and Kentaro Mikami, MD2. 1Department of Pediatrics, Kitasato
University School of Medicine, Sagamihara, Japan; 2Department of Pediat-
rics, Chiba Aiyukai Memorial Hospital, Nagareyama, Japan; 3Department of
Pediatrics, Tokyo Kousei-nenkin Hospital, Tokyo, Japan.
Background: Food allergy primarily causes anaphylaxis in children. Food
such as egg, cow milk, wheat and peanut are common allergen in Japan.
Methods: In this study total IgE, IgE RAST value and prick test are evaluated
to monitor the efﬁcacy outcome in wheat or hen’s egg-allergy infants treated
with slow speciﬁc oral tolerance induction (sSOTI) therapy.
Results: The 3 infants suffered from IgE-mediated food allergy (wheat: 2 years
8 or 10 months old boy [threshold dose 25 g] and girl [0.7 g], hen’s egg: 4 years
9 months old girl [1.8 g]), diagnosed, by food challenge, as allergy to wheat and
egg. Then, the patients were treated with sSOTI either with hard-boiled egg or
wheat noodle at home daily starting with 0.1 g, respectively, increased to a dose
of 60 g egg or 100 g wheat, every one to 2 weeks in double dose of the weight,
until tolerance was taken on. The daily maintenance dose was 10 g for each
food. Four weeks later conﬁrmed was evolution of tolerance by re-challenge.
The safety and efﬁcacy of the sSOTI therapy were conﬁrmed in these infants.
Total IgE levels were increased after SOTI therapy whereas IgE RAST value to
causative antigen such as egg and wheat, contrastingly reduced. IgE RAST
value to some other food as cow’s milk, reduced coincidently by bystander
inhibition. IgE RAST value to a food, negative in prick test, was increased
again, whereas that to a food, positive in the test, was carried on.
Conclusions: The results indicates that sSOTI therapy induced causative
antigen-speciﬁc IgE-mediated tolerance in children with wheat or egg allergy,
and the set of total IgE increased, reduced IgE RAST value and positive prick
test was of service to evaluate evolution of tolerance in slow SOTI therapy.
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Efﬁcacy of Slow Oral Immunotherapy for Cow’s Milk Allergy
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Tomohiro Utsunomiya, MD,1 Katsuhito Iikura, MD,1 Sakura Satou, MD,2
Chizuko Sugizaki,2 Morimitsu Tomikawa, MD,1 Akinori Shukuya, MD,
PhD,1 Takanori Imai, MD, PhD,1 and Motohiro Ebisawa, MD, PhD2. 1De-
partment of Pediatrics, and; 2Clinical Research Center for Allergy and Rheu-
matology, Sagamihara National Hospital, Sagamihara, Japan.
Background: Efﬁcacy and safety of slow oral immunotherapy (SOIT) is not
yet clear, especially regarding tolerance acquisition.
Methods: We recruited 32 cow’s milk (CM) allergy conﬁrmed by oral food
challenge (OFC). Twenty-ﬁve subjects were enrolled as SOIT group, and
remaining 7 were as control. The inclusion criteria were as follows; (1)
CM allergy without anaphylaxis conﬁrmed by OFC just before the trial,
and (2) children .4 years. In SOIT group, they were asked to take small
amount of CM at home after the OFC. The initial dose was about 1/4 of the
threshold eliciting positive objective symptoms, and it was built up to 200 mL
CM depends on the symptoms (build up phase). After reaching 200 mL, they
were asked to take 200 mL CM daily until the asymptomatic duration lasting
for more than 3m (maintenance phase). The subjects, who completed main-
tenance phase, underwent OFC to conﬁrm the tolerance acquisition after the
cessation of CM ingestion for 2w (conﬁrm-OFC). In control group, they had
eliminated CM completely and underwent the conﬁrm-OFC after 9.86 2.9 m
(mean 6 SD). We investigated the endpoints (adverse reactions, medical
treatments, results of conﬁrm-OFC, and laboratory ﬁndings), prospectively.
Results: In SOIT group (n ¼ 25) and control group (n ¼ 7), the average age
was 6.6y and 4.7y, respectively. The average threshold was 52 mL and 17
mL, and the CM speciﬁc IgE was 17.6 Ua/mL/9.9 Ua/mL, respectively. The
average period of build up and maintenance phases in SOIT group was 80d (n
¼ 25) and 98d (n ¼ 15), respectively. The frequency of adverse reactions in
all of build up (1973d) and maintenance phases (2924d) were 13.5% (mild
symptoms)/2.3% (moderate symptoms) and 1.7% (mild)/0.3% (moderate),
respectively. No patient had administered adrenaline during SOIT. Fifteen
subjects in SOIT and 7 in control underwent the conﬁrm-OFC. In SOIT, 8
subjects (53.3%) passed the conﬁrm-OFC, whereas 2 (28.6%) passed in
control. There was no statistically signiﬁcant difference regarding tolerance
acquisition between these 2 groups (P ¼ 0.277).
Conclusions: This study suggests that SOIT for about 1/2 year induces
desensitization effectively for CM allergy without severe adverse reactions.
Further and longer study would be required to prove accelerated tolerance
acquisition by SOIT.
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Factors Associated with Development of Food Allergy in
Liver-Transplanted Children
Tetsuo Shoda, MD,1 Ichiro Nomura, MD, PhD,1 Yukihiro Ohya, MD, PhD,1
Seisuke Sakamoto, MD, PhD,2 and Mureo Kasahara, MD, PhD2. 1Division
of Allergy, and; 2Department of Transplant Surgery, National Center for
Child Health and Development, Tokyo, Japan.
Background: The development of food allergy (FA) after transplantation has
been described mainly about liver transplantation in children (Pediatr Allergy
Immunol. 2009; 20: 741–747). It has been becoming important issue in this
population. Although tacrolimus immunosuppressive therapy has been con-
sidered a signiﬁcant risk factor (J Allergy Clin Immunol. 2011; 127: 1296–
1298), other risk factors are not identiﬁed yet. This study was undertaken to
evaluate the risk factors other than tacrolimus immunosuppressive therapy.
Methods: This study was a retrospective analysis of pediatric liver transplant
recipients in our hospital. We reviewed the medical records of all patients
who underwent liver transplantation during study period. Data collected
including preceding-hepatic diseases, the number of previous surgeries, age at
liver transplantation and etc.
Results: Between November 2005 and May 2010, 106 children received liver
transplantation. The most common indication for liver transplantation was
biliary atresia (BA; 47 patiens, 44.3%). The other conditions were: congenital
metabolic diseases in 27 patients, fulminant hepatic failure in 19, liver
cirrhosis in 6, congenital absence of portal vein in 3, congenital hepatic
ﬁbrosis in 2 and hepatic tumor in 2 patients. After transplantation, all the
patients received immunosuppressive therapy based on tacrolimus regimen.
Fifteen patients (10 female and 5 male) developed new-onset FA (14.2%).
The average age at transplantation was 10 months and FA has been developed
within 2 years (median 11 months, IQR, 4.5–19.0). Eleven patients with BA
(23.4%) and 4 patients with the other conditions (6.8%) developed new-onset
FA (P ¼ 0.023). Among the patients who developed FA, the number of
previous surgeries was signiﬁcantly higher in patients with BA (P ¼ 0.008).
Conclusions: New-onset food allergy after liver transplantation is now
becoming a signiﬁcant problem. We observed a trend toward an excess of FA
in patients with BA compared to patients with other indications for liver
transplantation. Patients with BA received surgical operations in several times
before liver transplantation. Frequent operations might add some stimulation
to generate new-onset FA and should be considered as a susceptible subgroup
that requires speciﬁc attention.
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Recurrent Wheezing in Infancy: Epidemiological Changes
Between EISL Phase i and iii
Herberto Jose Chong Neto,MD, PhD, Nelson Rosario,MD, PhD, Flávia Carnieli
Silva,Lylia Fátima Melniski Bojarski,Emanuel Antonio Grasselli, Cristine Secco
Rosario,Bernardo Augusto Rosario,and Fernando Henrique Chong. Allergy and
Immunology, Federal University of Paraná, Curitiba, Brazil.
Background: Prevalence of allergic diseases has increased in the last years.
Data on recurrent wheezing ($3 episodes) in infancy is scarce. The aim of
this study was to verify changing in prevalence of recurrent wheezing infants
in the south of Brazil.
Methods: Cross-sectional study using a standardized and validated
questionnaire (EISL: Estudio Internacional sobre Sibilancias en Lac-
tantes) with questions: Has your baby had wheezing or whistling in the
chest area or bronchitis in the ﬁrst 12 months of life? Has your baby had 3
or more wheezing episodes in the ﬁrst year of life? Parents of infants, ages
12 to 15 months that attended to Health Centers for routine immunization
were interviewed between August 2005 to December 2006 (EISL Phase I)
and September 2009 to September 2010 (EISL Phase III). Categorical
variables are shown as proportion and differences veriﬁed by chi-square
test, and continuous variables were expressed as mean 6 SD and analyzed
by Student t test.
Results: Three thousand three parents of infants answered questionnaire in the
EISL Phase I, and 45.4% had had at least one wheezing episode; 50.7% were
male, and 22.6% had recurrent wheezing episode starting at 5.5 6 3.1 months.
Five years later, in the EISL Phase III, 1003 parents participated in the survey:
40.6% had at least one wheezing episode (P ¼ 0.46), 51.1% were male, and
19.8% had recurrent wheezing (P ¼ 0.1) starting at 6.16 3 months (P ¼ 0.06).
Conclusions: Recurrent wheezing in infancy is highly prevalent and starts
early in life. In our population, recurrent wheezing rates did not modify in the
time period of study.
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Asthma Admission Rates in Germany: An Analysis of the
Nationwide DRG-Statistic of the Year 2009
Maria Weyermann, Silke Knorr, and Saskia E. Drösler. Faculty of Health
Care, Niederrhein University of Applied Sciences, Krefeld, Germany.
Background: Within the OECD Health Care Quality Indicators (HCQI)
Project up to 21 countries participated in calculations of 6 indicators on care for
chronic conditions. Those so-called Health Promotion, Prevention and Primary
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Care Indicators originally had been introduced by the US Agency for
Healthcare Research and Quality and rely on the principal diagnoses of an
adult hospitalization stored in a hospital administrative database. 2007 age-sex
standardized asthma admission rates varied considerably across the countries
and ranged from 17 (Italy) to 120 (United States) admissions per 100,000
population (OECD mean: 51). It was concluded that asthma outpatient
treatment was not optimal in countries reporting higher rates. Germany
provided the third lowest asthma admission rate of 21 (Health at a Glance
2009 OECD Indicators. http://www.oecd.org/health/healthataglance). As data
collections from various countries can differ in, e.g. coding responsibility,
incentives for coding, and implementation of coding guidelines, international
variations cannot exclusively be explained by differences in health system
performance. This study aimed to calculate asthma admission rates separately
for all 16 Federal States of Germany, assuming national comparisons are not
biased by these factors.
Methods: Using the 2009 nationwide Diagnosis Related Groups statistic we
calculated age-sex standardized asthma admission rates according to the
OECD HCQI Data Collection Guidelines.
Results: Among all adult hospitalizations (15 years or older) we found
14,399 admissions with a principal diagnosis code of asthma. Related to the
corresponding population of 70,779,623, the crude rate is 20.34 admissions
per 100,000. Age and sex standardized rate is 20.20 (95% Conﬁdence-
Interval, 19.86-20.54). Among the 16 Federal States of Germany age-
standardized rates ranges from 7.62 in Berlin (95% CI, 6.17-9.08) to 20.26 in
North Rhine-Westphalia (95% CI, 19.13-21.39) among men and from 16.15
in Berlin (95% CI, 14.07-18.23) to 36.70 in Bremen (95% CI, 29.89-43.98)
among women, respectively.
Conclusions: Prevention Quality Indicators calculated on national hospital
administrative databases might be a useful tool to identify national variations
of asthma admission rates reﬂecting areas with differences in outpatient care.
Reasons for the differences found, e.g., a varying regional density of primary
care providers or regional differences on asthma prevalence are in focus of
further investigations.
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Prevalence and Classiﬁcation of Asthma in Freshmen Students of
a Guatemalan University and its Relationship With
Aeroallegens Sensitization
Juan Pablo Maselli, MD, Joel Mazariegos, Rosario Allara, Jaime Coti, Karla
Cortave, Moises Garcia, and Luisa Sun. 1Career of Medicine, Universidad
Rafael Landivar, Guatemala, Guatemala.
Background: Establish the prevalence and classiﬁcation of asthma in young
adults and determine the sensitization to common aeroallergens.
Methods: ISAAC modiﬁed questionnaire for asthma in ﬁrst year students
between the ages of 18 to 22 years old, who attend the morning hours at the
Universidad Rafael Landivar of Guatemala. Between the months of July
throw October of 2009 on the campus of Guatemala City. We selected the
students who meet the criteria for asthma and request and informed consent
for the participation. In 70 students who accepted. We performed: Peak ﬂow
with a hand held apparatus and used the GINA questionnaire parameters for
classiﬁcation. We performed prick test with a panel of 8 aeroallergens and its
positive and as negative controls to determine sensitization.
Results: Prevalence of asthma was the 23% according to the ISAAC
modiﬁed questionnaire. Of this group of 287 students, 70 accepted to
participate in the study. According to GINA guideliness: 56% classify as mild
intermittent, 5% mild persistent, 33% as moderate persistent and 6% as severe
persistent. In accordance to control: 54% appear to be controlled, 42% partly
controlled and 4% uncontrolled. In the prick test the results of positive
sensitization were: Canis familiaris 35%, Felis domesticus 37%, D. ptero-
nyssinus 76%, D. Farinae 77%, Cynodon dactylon 19%, Zea mays 26%,
Eucalyptus globulus 17% and Casuarina equisetifola 16%.
Conclusions: Almost one quarter of population were classiﬁed as asthmatics
using the ISSAC modiﬁed questionnaire. Dahl report, a prevalence of asthma
in various countries of Europe between 16 and 37% in people 16 to 29 years
old.1 Most of the students who participate, classiﬁed in the category of mild
intermittent asthma, but one third of the students belong to the moderate
persistent category.We found that a large percentage of the students were
sensitized to aeroallergens, most of them, to both of species of dust mites.
Heinzerling, refer sensitization of 25 to 67% for mites in various countries of
Europe.2
REFERENCES
1. Dahl R, et al. Allergy living and learning. Respir Med. 2004.
2. Heinzerling LM, et al. GA2LEN skin test study I. Allergy. 2009;64:1498.
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Asthma Mortality in Brazil (1998–2006)
Carolina Souza-Machado, MSc, RN,1,2 Adelmir Souza-Machado, MD, PhD,2,3
Ana Carla Carvalho Coelho, MSc, RN,1,2 Magali Teresópolis Reis Amaral,
MSc,4 and Alvaro Cruz, MD5. 1School of Nursing; 2ProAR - Centro de
Excelência em Asma, and; 3Institute of Science Biomorphology Health
Department, Federal University of Bahia, Salvador, Brazil; 4State University
of Feira de Santana, Salvador, Brazil; 5Medicine, Faculdade de Medicina,
ProAR - Núcleo de Excelência em Asma da Universidade Federal da Bahia,
Salvador, Brazil.
Background: Some countries have virtually abolished asthma deaths, thus
demonstrating asthma mortality is largely preventable.
Objectives: To evaluate the speciﬁc mortality due to asthma in Brazil (1998–
2006) and its correlation with access to health services and social indicators.
Methods: Data were obtained from the National Mortality Database from
The Ministry of Health of Brazil. Mortality rates for each state and region
were evaluated for the period 1998 to 2006 using linear regression models
with gamma distribution and log link function. The correlation between
human development index (HDI), the Gini index, GDP per capita and number
of hospital beds and mortality rates were performed using the Spearman test.
Results: We recorded 23,758 deaths from asthma from 1998 to 2006. The
annual mortality rate per 100,000 inhabitants was 1.68, 1.38, and 1.67, in
1998, 2002 and 2006, respectively (1998–2006 average: 1.51). Comparing
only the extremes, 1998 and 2006, mortality rates declined in most econom-
ically developed regions of the country: Midwest (226.11), South
(223.58%), Southeast (28.83%), and show up rising in the poorest regions
in the North (15.34%) and Northeast (131.33%). GDP per capita was
inversely correlated with asthma mortality rate (rho ¼ 20.378, P ¼ 0.048).
In men and women, the asthma mortality rates were respectively, 1.98 and
1.37 in 1998 and 2.01 and 1.30 in 2006. Analysis by age groups, found the
coefﬁcients increased with age after adulthood. Individuals over the age of
75 years had the highest rates and greater tendency to increase in the period.
Conclusions: There was an overall stabilization of asthma mortality in Brazil
during the study period. However, a trend toward increasing mortality rates
was observed in socio-economically disadvantaged regions, where access to
health care and medication is still a problem.
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Atopy and Bronchial Hyper-Responsiveness but not Allergic
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Perth, Australia; 4Division of Allergy, University of Cape Town, Cape Town,
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Background: The relationship between sensitisation to helminths and atopy,
bronchial-hyperresponsiveness and allergic diseases may differ depending on
many factors, including the genes of the population studied. We sought to
examine this relationship in an African cohort.
Methods: Urban Xhosa children were tested for ascaris IgE levels, bronchial
hyper-responsiveness (BHR) by methacholine challenge, atopic sensitisation
(skin tests to aeroallergens) and allergic disease (asthma, eczema and rhinitis)
assessed by questionnaire.
Results: Ascaris sensitisation was strongly associated with BHR but not
with asthma, eczema or rhinitis. There was a dose-response relationship
between increasing class of ascaris IgE and increased BHR (Prevalence
ratio (PR) 1.75; CI 1.09-2.82). Higher levels of ascaris IgE were seen in
those with BHR. Ascaris IgE was associated with atopic sensitisation to
aeroallergens. There was a dose-response relationship between increasing
class of ascaris IgE and sensitisation to one or more allergen (PR 1.65; CI,
1.27-2.13), sensitisation to house dust mites (HDM) (PR 1.79; CI, 1.29-
2.46) and grass (PR 2.66; CI, 1.24-5.71) and number of positive skin prick
tests (PR 1.78; CI, 1.27-2.49). Presence of any sensitisation to ascaris was
associated with more than doubling the prevalence of HDM sensitisation
(41.5 vs 18.5%) and almost quadrupling the prevalence of grass sensitisa-
tion (10.8 vs 2.8%).
Conclusions: Ascaris sensitisation was strongly associated with BHR and
with atopy, but not with allergic diseases. Possible explanations might be that
the type of ascaris infection that causes high levels of ascaris IgE in this
genetic population may also favour the development of atopy or that atopics
in Africa have upregulation of their defence system against parasitic infection.
These hypotheses are not mutually exclusive.
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Association of Matrix Metalloproteinase-7 and -12 Genes
polymorphisms With Asthma: A Case-Control Study of MMP-7
and -12 in a Japanese Population
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Background: Genetic variants inﬂuencing lung function or immune system
may be involved in the development of asthma and/or its symptoms. Matrix
metalloproteinases (MMPs) contribute to both normal and pathological tissue
remodeling and also act as regulatory molecules by processing cytokines or
adhesion molecules. In animal models, growing evidences suggest that
MMPs play important roles in asthma phenotypes. Some MMP genes (e.g.
MMP-9 andMMP-12) have recently been shown to be associated with asthma
in Caucasian populations. We investigated whether single nucleotide
polymorphisms (SNPs) in MMP-7 and MMP-12 could affect the susceptibil-
ity to and clinical phenotypes of asthma in the Japanese population.
Methods: We conducted a case-control study between SNPs in MMP-7 and
MMP-12 genes and asthma-related phenotypes using childhood and adult
Japanese populations (653 childhood asthma patients and 423 controls, and
428 adult asthma patients and 646 controls, respectively). To investigate the
effects of amino acid substitutions by SNPs on MMPs’ enzymatic activity,
MMP activity assays were performed using commercially available kits based
on ﬂuorescence resonance energy transfer (FRET) peptide. We also evaluated
the effect of 3’UTR SNP in MMP-7 on its mRNA stability and the effect of
SNP in MMP-12 on its antimicrobial activity.
Results: We found that, in the Japanese population, SNPs of MMP-7
(rs10502001, G/A, Arg77His; rs14983, C/T, 3’UTR) (P ¼ 0.006; odds ratio
(OR), 1.46; 95% conﬁdential interval (CI), 1.126-1.903) and MMP-12
(rs652438, A/G, Asn357Ser) (P ¼ 0.015; OR, 1.60; 95% CI, 1.002-
2.556) showed signiﬁcant association with adult and childhood asthma,
respectively. We also found that the SNP (rs652438) in MMP-12 was
associated with severity in adult asthma (P ¼ 0.010). Using supernatant
from cultured HEK293 cells stably transfected with the pcDNA3.1
(1)-MMP-7 or MMP-12 as MMP proteins, we evaluated activation kinet-
ics, rate of proteolytic cleavage of FRET peptide, Michaelis constant, and
substrate speciﬁcity of the enzyme. In this system, we couldn’t detect the
functional effects of amino acid substitutions by SNPs on the enzymatic
activity.
Conclusions: Our association study suggested that genetic variants of MMP7




Hereditary Angioedema and Normal C1-Inhibitor (HAE TYPE
III): A Novel Mutation in the Coagulation Factor 12 Gene
Konrad Bork, MD,1 Karin Wulff, PhD,2 Peter Meinke,2 Nicola Wagner,
MD,3 Jochen Hardt, PhD,4 and Guenther Witzke, PhD5. 1Department of
Dermatology, University Hospital Mainz, Mainz, Germany; 2Institute of Hu-
man Genetics, University Greifswald, Greifswald, Germany; 3Department of
Dermatology, District Hospital Darmstadt, Darmstadt, Germany; 4Depart-
ment of Medical Psychology and Medical Sociology, and; 5Department of
Dermatology, University Mainz, Mainz, Germany.
Background: Hereditary angioedema with normal C1-inhibitor and muta-
tions in the coagulation factor 12 gene is a recently described disease entity
that occurs predominantly in women. Up to date, 2 different missense
mutations of codon p.Thr328* in the coagulation factor 12 gene have been
reported, co-segregating with clinical signs. Aim of the study was to assess
the clinical symptoms, mutations in the factor 12 gene, and plasma parame-
ters of this disease in a family with hereditary angioedema with normal C1-
inhibitor.
Methods: Six members of one family were studied, including 2 women with
recurrent angioedema. Mutation analysis of the factor XII gene was
performed.
Results: By sequencing the factor 12 gene, a hitherto unknown mutation, the
deletion of 72 base pairs (c.971_1018124del72*), was identiﬁed in a family
of Turkish origin, in 2 women with recurrent skin swellings and abdominal
pain attacks, and in their symptom-free father. The novel mutation
c.971_1018124del72* caused a loss of 48 base pairs of exon 9 (coding
amino acids 324* to 340*) in addition to 24 base pairs of intron 9, including
the authentic donor splice site of exon 9. All carriers of this mutation had
normal plasma concentrations and activity of C1-inhibitor, C4, factor XII
clotting activity, and activated partial thromboplastin times.
Conclusions: The novel deletion mutation in the factor 12 gene was located
in the same F12 gene region as the missense mutations p.Thr328Lys* and
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p.Thr328Arg* reported previously, suggesting the importance of the exon
9 to intron 9 DNA region for the development of hereditary angioedema with
normal C1-inhibitor.
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Immuno-Safety of Recombinant Human C1 Inhibitor in Patients
With Hereditary Angioedema: An Integrated Analysis
Erik Hack, MD, PhD,1 Anurag Relan, MD,2 Leonard Kaufman, PhD,3
and Rienk Pijpstra, MD2. 1Department of Immunology, Dermatology/Aller-
gology & Reumatology, University Medical Center, Utrecht, Utrecht, Nether-
lands; 2Pharming Technologies BV, Leiden, Netherlands; 3Veeda Clinical
Research, Brussels, Belgium.
Background: Recombinant C1 inhibitor (rhC1INH) is a novel therapeutic
option for the treatment of acute angioedema attacks in patients with
hereditary angioedema (HAE). The amino acid sequence of rhC1INH is
identical to that of endogenous C1INH. However, any recombinant protein
may elicit antibodies against the protein and/or host related impurities (HRI).
Clinical consequences of these antibodies can theoretically range from no
clinical symptoms to allergic reactions and reduced C1INH activity due to
neutralizing antibodies.
Objective: To analyze the immuno-safety of rhC1INH in symptomatic
patients with HAE.
Methods: Plasma samples were collected pre-treatment and 22 and 90 days
post-treatment of an acute angioedema attack. Plasma samples were tested for
the presence of antibodies against plasma-derived C1INH and rhC1INH using
6 different, validated enzyme-linked immunosorbent assays (ELISAs), to
detect IgM, IgG and IgA antibodies against plasma-derived C1INH or
rhC1INH. Antibodies against HRI in plasma samples were measured in an
ELISA testing for all antibody classes. Plasma samples from normal healthy
controls and HAE patients, never exposed to rhC1INH, were used to estimate
cut off levels of the assays. Plasma samples with antibody levels above the
cut-off level in the screening assays were tested in conﬁrmatory displacement
assay in case of anti-HRI antibodies and in an assay for neutralizing
antibodies in case of antibodies against C1INH.
Results: Data from 155 symptomatic HAE patients having received a total
of 424 administrations of rhC1INH were analyzed. The frequency of anti-
C1INH antibody levels above the assay cut-off was low and similar in
pre- and post-exposure samples (1.7 and 1.8%, respectively). Results above
the assay cut-off were sporadic and transient. Occurrence of anti-C1INH
antibodies did not correlate with repeated treatment or time since last
treatment. No neutralizing antibodies were detected. A total of 5/155 (3%)
rhC1INH-treated patients had conﬁrmed anti-HRI antibodies; these included
1 patient with presence of anti-HRI antibodies prior to exposure to rhC1INH.
The presence of anti-C1INH and anti-HRI antibodies was not associated with
clinical symptoms. The presence of anti-C1INH antibodies did not affect
clinical efﬁcacy.
Conclusions: rhC1INH used for the treatment of acute HAE attacks has a low
potential to induce antibodies and has a reassuring immuno-safety proﬁle.
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Clinical Efﬁcacy of Recombinant Human C1 Inhibitor in Patients
with Acute Hereditary Angioedema Attacks
Avner Reshef, MD,1 Marc Riedl,2 Dumitru Moldovan, MD, PhD,3
Richard F. Lockey, MD,4 Vincenzo Montinaro,5 Daniel Suez,6
Anurag Relan, MD,7 Marco Cicardi, MD,8 and Bruce Zuraw9. 1Allergy
and Immunology, Sheba Medical Center, Angioedema Center, Tel Aviv, Is-
rael; 2Clinical Immunology and Allergy, UCLA - David Geffen School of
Medicine, Los Angeles, CA; 3University of Medicine and Pharmacy, Mures
County Hospital, Tirgu Mures, Romania; 4Division of Allergy &
Immunology, University of South Florida and Veterans’ Hospital, Tampa,
FL; 5Azienda Ospedaliera Policlinico Consorziale di Bari, Bari, Italy;
6Allergy, Asthma & Immunology Clinic, P.A., Irving, TX; 7Pharming Tech-
nologies BV, Leiden, Netherlands; 8Scienze Cliniche “Luigi Sacco”, Univer-
sità di Milano, Ospedale L.Sacco, Milano, Italy; 9Medicine, University of
California, San Diego, La Jolla, CA.
Background: Recombinant human C1 Inhibitor (rhC1INH) has been
approved in Europe for the treatment of acute hereditary angioedema attacks.
The efﬁcacy of rhC1INH was demonstrated in 2 randomized-controlled trials.
Open-label extension studies, where patients could be treated for subsequent
HAE attacks, demonstrated continued efﬁcacy for repeated rhC1INH
treatments.
Objective: To review the integrated efﬁcacy data of rhC1INH for treatment
of acute HAE attacks.
Methods: Efﬁcacy was assessed using patient-reported HAE-speciﬁc visual
analog scales. The primary endpoint was time to onset of relief of symptoms
(VAS decrease $20 mm), and the secondary efﬁcacy endpoint was time to
minimal symptoms (VAS,20 mm at all locations). Other endpoints included
clinical response (relief achieved within 4 hours) and relapse (recurrence of
symptoms within 24 hours following initial improvement). Subgroup analy-
ses by attack location were also performed.
Results: The dataset included 141 HAE patients treated for 403 attacks.
Median times to the onset of symptom relief for attacks treated with 100 U/
kg, 50 U/kg and 2100 U rhC1INH were 66, 60, and 61 minutes, respectively,
compared to 495 minutes in the placebo-treated group. Median times for time
to minimal symptoms were 266, 240 and 241 minutes for the 100 U/kg, 50 U/
kg, and 2100 U rhC1INH-treated attacks respectively compared to 1210
minutes for the placebo-treated attacks. High clinical response rates were
observed for the rhC1INH-treated groups (93, 96 and 88% for the 100 U/kg,
50U/kg, and 2100 U respectively) compared to the placebo group (41%).
None of the rhC1INH-treated attacks relapsed. Subgroup analysis by attack
location showed that abdominal attacks had the fastest median time to onset
of symptom relief (50, 36 and 60 minutes for 100 U/kg, 50 U/kg and 2100 U
doses respectively), followed by oro-facial-pharyngeal-laryngeal attacks
(70, 65 and 120 minutes), and peripheral attacks (75, 84 and 121 minutes).
No drug-related serious adverse events or hypersensitivity reactions were
observed.
Conclusions: RhC1INH has demonstrated efﬁcacy for the treatment of
repeated HAE attacks for all doses tested (100 U/kg, 50 U/kg and 2100 U).
Controlled studies did not show additional beneﬁt with doses greater than
50 U/kg. RhC1INH was generally safe and well tolerated.
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The Efﬁcacy and Safety of Human Plasma-derived C1-Inhibitor
Concentrate Administered for the Treatment of Attacks in
Pediatric Patients with Hereditary Angioedema Due to
C1-Inhibitor Deﬁciency
Henriette Farkas, MD, PhD, DSc,1 Dorottya Csuka, PhD,1 Zsuzsanna Zotter,1
Erika Szabó, MD,1 Zsuzsanna Kelemen, MD,1 Lilian Varga, PhD,1
János Fejes, MD,2 and George Harmat, MD2. 13rd Department of Internal
Medicine, Semmelweis University, Budapest, Hungary; 2“Heim Pál” Child-
ren’s Hospital, Budapest, Hungary.
Background: Hereditary angioedema due to C1-inhibitor deﬁciency (HAE-
C1-INH) is a life-threatening, rare disease characterized by recurrent
edematous attacks. In 50% of cases, the initial onset of symptoms occurs
between 5 and 11 years of age. There are limited data on the emergency
treatment of acute episodes in pediatric patients. Our aim was to analyze the
efﬁcacy and safety of human plasma-derived C1-INH concentrate in our
pediatric patient population with HAE-C1-INH.
Methods: 50 pediatric patients (23 boys, 27 girls; 45 HAE type I, 5 HAE type
II patients) were enrolled. The follow-up period began at the time of diagnosis
and ended when the patient turned 18 years old. The indications for the use of
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C1-INH concentrate were upper airway oedema of any severity; moderate-to-
severe abdominal edema; edema of face, neck, or lips and severe edema of the
extremities and trunk. Clinical and laboratory data were entered into the
Hungarian HAE Registry.
Results: 152 attacks out of 1392 experienced by 42 patients were treated with
C1-INH concentrate (28% of attacks at home and 72% at the clinic). The
distribution of C1-INH-treated attacks by location was as follows: 38%
subcutaneous, 32% abdominal, 30% upper airway. In all locations, the
clinical symptoms were consistently relieved by 500 IU C1-INH concentrate.
An additional 500 IU dose of C1-INH concentrate was required in 4 cases
only. The symptoms improved within 15 to 60 minutes of drug administra-
tion. Time to complete resolution was 24 to 48 hours in subcutaneous edema,
12 to 24 hours in abdominal attacks, and less than 12 hours when the edema
involved the upper airways. No progression or recurrence of the attack was
observed. Repeated administration did not reduce therapeutic efﬁcacy of the
drug. Adverse events did not occur. Transmission of viral infections (HIV,
HBV, HBC, Parvo virus B19) was not detected. Comparing the ﬁrst and last
year of follow-up, anti-C1-INH antibodies (IgA, IgG, IgM types) did not
show any relationship with the administration of C1-INH concentrate.
Conclusions: Our prospective study demonstrated that the administration
of C1-INH concentrate is highly effective and safe for the treatment of
edematous attacks – regardless their location – in pediatric patients with
HAE-C1-INH.
87
Treatment of Idiopathic Nonhistaminergic Angiodema
with Icatibant
Ramon Lleonart, MD,1 Blanca Andres, MD,1 Javier Jacob, MD,2
Lourdes Pasto, MD,3 and Mercè Corominas, MD1. 1Allergy Unit; 2Emer-
gency Department, and; 3Pharmacy Service, Hospital Universitari de Bell-
vitge, L’Hospitalet de Llobregat, Spain.
Background: Patients with Idiopathic nonhistaminergic angioedema appear
to have similar clinical features and pathogenesis as those with hereditary
angioedema. Icatibant, a selective bradykinin b2 receptor antagonist, licensed
for use in acute attacks of hereditary angioedema could be also effective in
treating other forms of angioedema. We report a patient with idiopathic
angioedema who was successfully treated with icatibant.
Methods: A 77-year-old man with a history of arterial hypertension currently
treated with hydrochlorothiazide and type II diabetes under insulin treatment.
He had suffered from recurrent angioedema attacks located on his tongue
without urticaria during the last 7 years. Serum levels of C1-INH, C4 and C1q
and C1-INH activity were normal. In spite of cessation of treatment with
ACE inhibitors and RAAS-blockers (he had been treated with enalapril and
losartan previously) he continued with the angioedema attacks. As no cause
of angioedema could be identiﬁed and the angioedema did not response to
antihistamines, the patient was diagnosed of idiopathic nonhistaminergic
angioedema. In one of the episodes he was admitted at the emergency room
with a swollen tongue. The edema gradually progressed in spite of the
treatment with antihistamines, corticosteroids and epinephrine. Tracheotomy
was considered due to the severity of the angioedema that began to cause
airway compromise. After consulting the Allergy Unit, treatment with
icatibant was administered.
Results: Approximately 30 minutes after the subcutaneous administration of
icatibant 30 mg the symptoms improved and the angioedema resolved
completely within 6 hours. The only adverse effect following the icatibant
administration was pain localized in the injection site. After 5 months the
patient suffered a similar attack that was also successfully treated with
icatibant sc.
Conclusions: Icatibant administered subcutaneously provided an effective
and well-tolerated treatment option for acute angioedema attacks in a patient
with idiopathic nonhistaminergic angioedema. This form of angioedema
could have a pathogenic mechanism similar to the bradikinin mediated
angioedema. We suggest the use of icatibant in the treatment of severe attacks




Clinical Features and Diagnostic Value of Speciﬁc IGE to
Component Allergen in Bee Venom Allergy in Korea
Yoo Seob Shin, MD, PhD,1 Jing Nan Liu, 1 Gyu-Young Hur,2 Eui-
kyung Hwang,1 Young-Hee Nam, MD,1 Hyun-Jung Jin, MD,1 Young-
Min Ye,1 Dong-Ho Nahm,1 and Hae-Sim Park, MD, PhD1. 1Department
of Allergy and Clinical Immunology, Ajou University School of Medicine,
Suwon-si, South Korea; 2Internal Medicine, Korea University College of
Medicine, Seoul, South Korea.
Background: Although history taking is primary method in the diagnosis
of bee venom allergy, serum speciﬁc IgE detection is critical to identify
causative bee and assess the effect of immunotherapy. Component-resolved
diagnosis (CRD) in allergy has been used for its high sensitivity and
speciﬁcity in many allergy diseases caused by food, cat, birch, and grass
pollens. The purposes of this study are to evaluate diagnostic value of serum
speciﬁc IgE to 3 bee venom component allergens and observe the changes of
allergen speciﬁc IgE during bee venom immunotherapy.
Methods: Fifty-six bee venom anaphylaxis patients receiving bee venom
immunotherapy were recruited from Ajou University Hospital. Clinical
manifestations and serum speciﬁc IgE levels to bee venoms and component
allergen (rApi m1 of Apidae, rVes v5 and rPol d5 of Vespidae) measured by
using ImmunoCAP (Phadia, Sweden) were analyzed retrospectively.
Results: Thirty-ﬁve (62.5%) patients were male and 33 (73.3%) were atopics.
Their mean age was 44.9 6 13.8 years ranged from 11 to 73 years. Local
reactions were found in 13 (23.2%) patients, while systemic reactions, in 43
(76.8%) patients. The most frequent manifestation was anaphylaxis which were
severe (37.5%) and moderate (39.3%) manifestations followed by urticaria and
angioedema. Yellow Jacket (80.8%) was the most prevalent bee followed by
yellow hornet, white faced hornet, honey bee and paper wasp at the time of
diagnosis with concurrent sensitization in both Apidae and Vespidae at 70.9%
patients. The positive predictive value (PPV) of serum speciﬁc IgE levels to
rVes v5 and rPol d5 were 85.7 and 87.5%, and they signiﬁcantly correlated with
conventional serum speciﬁc IgE level (r ¼ 0.762 and r ¼ 0.757, respectively),
however, PPV of rApi m1 was only 34.8% at the time of initial diagnosis. After
3 years of bee venom immunotherapy, all kinds of bee venom speciﬁc IgE
levels tended to decline compared to those collected before allergen immuno-
therapy, especially in component speciﬁc IgE to Vespidae.
Conclusions: Yellow jacket sting and male gender may be risk factors for bee
venom allergy in Korea. Component allergen speciﬁc IgE to Vespidae, not
Apidae had a diagnostic and monitoring value comparable to conventional
speciﬁc IgE in bee venom allergy.
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Is Basophil Speciﬁc Response to Hymenoptera Venom Related to
T Regulatory Cells?
Petr Kucera, MD,1 Katarina Hulikova,2 Milada Cvackova, MD,1
Daniela Planska,3 and Kamila Riegerova3. 1Department of Allergy Immunol-
ogy, 3rd Medical Faculty Charles University, University Hospital KV,
Prague, Czech Republic; 2Department of Allergy Immunology, 3rd Medical
Facultym, CHU, Prague, Czech Republic; 3Department of Allergy Immunol-
ogy, 3rd Medical Faculty, Charles University, Prague, Czech Republic.
Background: The exact mechanism of systemic hypersensitivity to venom is
not exactly understood. It is suggested T cells with regulatory potential can
downregulate other T cell subsets and effector cells, ex. mast cell or
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basophils. We focused on relationship of speciﬁc basophil reactivity in
relationship to proportion of regulatory T cells.
Methods: Forty-ﬁve patients with history of systemic symptoms of allergy to
Hymenoptera venom were included. Basophil reactivity before the treatment
and after one year of allergen immunotherapy (AIT) was measured by CD63
expression, CD203c marker used for basophil identiﬁcation. Cells were
stimulated by aqueous solution of allergen in concentration range 0.01 to 1
mg/mL. T regulatory cells were identiﬁed as CD4 positive, CD25 bright and
CD127 negative at the same interval of treatment. Monoclonal antibodies
conjugated with ﬂuorochromes were used, measured by FACSCalibur. Paired
t test and correlation analysis used for statistical evaluation.
Results: Median Treg proportion before therapy was 2.160, after IT 1.960,
basophil speciﬁc response (proportion of CD63 positive cells) at the same interval
were 3.65 and 4.11 at 0.01 mg/mL, 13.1 and 16.1 for 0.1 mg/mL and 33.85 and
40.8 for 1 mg/mL. All differences were not statistically signiﬁcant. Differences of
basophil activation were not signiﬁcantly related to proportion of T regulatory cells.
Conclusions: In our group of patients with HV allergy, treated by AIT, we
did not found any relationship between basophil speciﬁc activation during
allergen immunotherapy and proportion of T regulatory cells.
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Improving the Diagnosis of Hymenoptera Venom Allergy:
Component Resolved Diagnosis
Liliana Cifuentes, MD,1 Lukas Balzer, MD,1 Blank Simon, PhD,2
Henning Seismann, PhD,2 Ulf Darsow,3 Edzard Spillner, PhD,2
Johannes Ring,3 and Markus Ollert3. 1Clinical Research Division of Molec-
ular and Clinical Allergotoxicology, Department of Dermatology and Al-
lergy, Technical University Munich, Munich, Germany; 2Institute of
Biochemistry and Molecular Biology, Department of Chemistry, University
of Hamburg, Hamburg, Germany; 3Department of Dermatology and Allergy
Biederstein, Technische Universitaet Muenchen, Munich, Germany.
Background: Up to 3% of the general population suffers from potentially life-
threatening systemic reactions after honeybee and wasp stings. Unfortunately,
there are still individuals who have a convincing history of an anaphylactic event,
but lack the necessary diagnostic, making difﬁcult the decision for immunother-
apy. Our aims were to evaluate the feasibility of using recombinant allergens in
the Basophil activation test (BAT) for the diagnosis of Hymenoptera allergy and
to develop a high-throughput diagnostic device combining the advantages of
basophil activation tests with a panel of recombinant allergens: rVes v 1, rVes v
2, rVes v 3, rVes v 5, rApi m 1, rApi m 2, rApi m 3 and rApi m 5.
Methods: Basophil activation test (BAT) and measurement of speciﬁc IgE
was performed on 47 wasp venom, 14 Honeybee venom allergic patients and
17 healthy controls. Speciﬁcity and sensitivity of BAT performed with
recombinant His-tag puriﬁed wasp venom allergens Ves v 1, Ves v 2, Ves v 3
and Ves v 5, recombinant honeybee venom allergens Api m 1, Api m 2, Api
m 3 and Api m 5 and commercial extracts have been compared. Each patient
had a history of grade I or II anaphylaxis after an insect sting. All patient sera
were collected before initiation of SIT.
Results: BAT performed with the panel of recombinant allergens markedly
increased the speciﬁcity and the sensitivity in the detection of wasp venom
allergic subjects.
Conclusions: Basophil activation test provides a valuable new in vitro
method for the detection of allergy to wasp venom and may supplement
routine tests for allergy diagnosis in problematic cases. Recombinant
allergens might help to dissect relevant allergens for basophil degranulation.
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Efﬁcacy of Venom Immunotherapy Given Every 3 or 4Months. A
Direct Prospective Comparison With the Conventional Regimen
Livio Simioni,1 Alberto Vianello,1 Patrizia Bonadonna,2 Guido Marcer,3
Maurizio Severino,4 Mauro Pagani,5 Luca Morlin,3 Mariangiola Crivellaro,3
and Giovanni Passalacqua, MD6. 1Allergy and Clinical Immunology, Int.
Med. Dpt., S. Maria del Prato - Feltre Hospital, Feltre, Italy; 2Allergy Unit,
Verona General Hospital, Verona, Italy; 3Occupational and Environmental
Medicine, University of Padua, Padova, Italy; 4Allergy Clinic, Nuovo Ospe-
dale San Giovanni di Dio - Firenze, Firenze, Italy; 5Allergy and Oncology
Unit, Asola Hospital, Asola, Italy; 6Allergy & Respiratory Diseases, Univer-
sita Degli Studi Di Genova, Genoa, Italy.
Background: The standard venom immunotherapy involves the administra-
tion of the maintenance dose every 4 to 6 weeks. This regimen may have
compliance problem especially in the long term, thus extended intervals have
been proposed. We prospectively compared the efﬁcacy of 3- or 4-month
extended maintenance dose and the conventional regimen.
Methods: Patients receiving immunotherapy of a single venom were offered
the delayed maintenance dose, and were then followed-up for ﬁeld re-stings.
Only the re-stings by the insect for which the patients received immunotherapy
were considered. A matched group of patients receiving the conventional
maintenance were used for comparison, by univariate and multivariate analysis.
Results: Fifty-two patients (44 male, 8 female, mean age 52 years) were
certainly re-stung on 113 occasions by the insect for which they were
receiving immunotherapy. 90 re-stings occurred during the 3- month
maintenance and 23 during the 4-month maintenance. The control group,
on conventional protocol with one single venom, included 103 patients (79
male, 24 female, mean age 41 years) certainly re-stung on 160 occasions by
the speciﬁc insect. The rate of re-sting without reaction was 97% in the
delayed maintenance and 82% in the conventional group with a signiﬁcant
difference in favour of the former (P ¼ 0.01). None of the variables consid-
ered resulted predictive for systemic reactions by logistic regression analysis
Conclusions: The delayed maintenance dose approach is al least as effective
and safe as the conventional one. The 4-month maintenance seems to be the
best option in term of convenience and economic save.
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Serum CTLA-4 AND IL-10 in Hymenoptera Venom
Immunotherapy: Equivalence of Different Induction Regimens
Anna Maria Riccio, 1 Daniele Saverino,2 Anthi Rogkakou,1 Marcello
Bagnasco,2 Patrizia Bonadonna,3 Giorgio Walter Canonica, PhD,1 Erminia
Ridolo,4 Maurizio Severino,5 Giampaola Pesce,2 and Giovanni Passalacqua,
MD1. 1Allergy and Respiratory Diseases, Universita Degli Studi Di Genova,
Genoa, Italy; 2Medical and Radiomethabolic Therapy, Università di Genova,
Genoa, Italy; 3Allergy Service, Verona General Hospital, Verona, Italy;
4Department of Clinical Sciences, University of Parma, Parma, Italy;
5Allergy Clinic, Nuovo Ospedale San Giovanni di Dio - Firenze, Firenze,
Italy.
Background: Cytotoxic T lymphocyte associated gene-4 (CTLA-4) is
involved in the activation pathways of T lymphocytes. It has been shown
that the circulating form of CTLA-4 is elevated in patients with hymenoptera
allergy and can be downregulated by immunotherapy. We assessed the effects
on CTLA4 of venom immunotherapy given by different induction protocols
(classic, rush or ultra rush).
Methods: Sera from patients with hymenoptera allergy were collected at baseline
and at the end of the induction phase. In the classical regimen, the induction lasted
6 weeks, in the rush protocol it lasted 3 days, and in the ultra-rush maintenance
was achieved in 24 hours. Soluble IL-10 was assayed in the same samples for
comparison. CTLA-4 and IL10 were measured by commercial immuoassays.
Results: Seventy-six patients (52 male, mean age 35 years) were studied. Of
them, 30 underwent the classic induction, 22 the rush and 24 the ultra rush.
Soluble CTLA-4 was detectable in all patients at baseline, and signiﬁcantly
decreased at the end of the induction in all groups, thus irrespective of its
duration. Of note, a signiﬁcant decrease of sCTLA-4 could be seen already at
24 hours. In parallel, the same behaviour was observed with IL-10 that
signiﬁcantly increased at the end of the induction.
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Conclusions: Soluble CTLA-4 is a useful immunological marker of the effect
of immunotherapy for hymenoptera allergy. From an immunologic point of
view, there is no difference among the various protocol of induction.
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Puriﬁcation of the Allergenic Protein Hyaluronidase From the
Venom of SocialWasp Polybia Paulista (Hymenoptera: Vespidae)
Débora Laís Justo Jacomini, MD,1 Franco Dani Campos Pereira, 1
José Roberto Aparecido dos Santos Pinto, MD,2 Lucilene Delazari dos
Santos, PhD,2 Anally Ribeiro da Silva Menegasso,2 Mário Sérgio Palma,
PhD,2 Ricardo de Lima Zollner, PhD,3 and Márcia Regina Brochetto-
Braga, PhD1. 1Department of Biology, Univ Estadual Paulista, Rio Claro,
Brazil; 2Center of the Study of Social Insects/Department of Biology, Univ
Estadual Paulista, Rio Claro, Brazil; 3Department of Clinical Imunology and
Allergy, Faculty of Medical Sciences, UNICAMP, Campinas, Brazil.
Background: Between 9.3 and 28.5% of world population are estimated to
be allergic to the protein components of Hymenoptera venom and among
them, the hyaluronidase (HYAL) is one of the most important, although the
nature of its IgE binding epitopes is unknown.
Methods: Enzyme was puriﬁed from P. paulista venom by cation exchange
chromatography in AKTA-FPLC system with a Hiprep CM FF column.
Fractions with HYAL activity were pooled, lyophilized, dialyzed against
distilled water in presence of protease inhibitor (PMSF) and subjected to
SDS-PAGE 15%. The only protein bands visualized were submitted to tryptic
digestion and to MALDI-ToF/ToF mass spectrometry. Digested peptides pro-
duced were compared with partial/complete protein sequences from Data
Bank including with the HYAL (Q9U6V9) of Polistes annularis venom used
as model. Western blotting was performed with Pp-HYAL-speciﬁc antibody
to test the identity of pure protein.
Results: All analysis performed identiﬁed the pure protein as an HYAL present
in P.paulista venom, which also had its cDNA sequence (GI:302201582) cloned
and determined in previous studies, being its high similarity with the Polistes
annularis enzyme already conﬁrmed. The mature allergenic protein has 338
amino acids and a molecular weight of 39 KDa. The same allergen is known
in other insects, venoms and immunological cross reactivity may sometimes be
observed among closely related species. Here, the immunoblotting assay
revealed that the Pp-HYAL-speciﬁc antibody used recognized the correspon-
dent protein in the puriﬁed fraction and in the crude venom of P. paulista, but
not in the Apis mellifera and Solenopsis invicta venoms.
Conclusions: The methodology used was able to purify the allergen, which is
a key step in the characterization of its binding epitopes. Such knowledge
has direct implications in accuracy of diagnostic procedures and strategies
for speciﬁc immunotherapy of allergic patients to the venom of this insect.
Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).
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High Immunogenicity of the Allergen PHL P 5 Expressed in
Transgenic Mice as a Membrane-anchored Protein
Andreas Farkas,1 Ulrike Baranyi, PhD,1 Rudolf Valenta, MD,2 and Thomas
Wekerle, MD1. 1Department of Surgery, Division of Transplantation, and;
2Department of Pathophysiology, Division of Immunopathology, Center of Path-
ophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna,
Austria.
Background: Induction of long-term tolerance towards Phl p 5 was
previously achieved by transplantation of hematopoetic stem cells (HSCs)
genetically modiﬁed to express membrane-bound Phl p 5 allergen. To
facilitate the further development of tolerogenic cell therapies for allergy,
a transgenic mouse expressing Phl p 5 ubiquitously as membrane-anchored
protein, was generated. Here we investigated the immunogenicity of the
membrane-anchored version of Phl p 5.
Methods: The Phl p 5-transgenic mouse (Balb/c background) was generated
by pronuclear injection integrating Phl p 5 fused to a leader peptide and
a transmembrane domain under control of a CMV-promotor with a GFP-
reporter. Splenocytes (2.5 · 106 per mouse), cell extracts containing mainly
membrane proteins and recombinant (r) Phl p 5 [5 mg1/2 Al(OH)3 per
mouse] were injected subcutaneously into naïve Balb/c mice (n ¼ 8 per
group). The amount of Phl p 5 of splenocytes and cell extracts was semi-
quantitatively determined via western blotting. Furthermore skin of Phl p 5-
transgenic mice was grafted onto naïve Balb/c (n ¼ 13 in 2 independent
experiments), a rejection model in allo-transplantation since skin is highly
immunogenic and therefore readily rejected. Phl p 5-speciﬁc antibody re-
sponse was determined in sera by ELISAs. For T-cell responses spleno-
cyte-proliferation was assessed in vitro after stimulation with rPhl p 5.
Results: Surprisingly, a prompt rejection (within 8-10 days) was elicited,
accompanied by a strong Phl p 5 speciﬁc antibody response including Phl p 5-
speciﬁc IgE in wildtype Balb/c after skin rejection of Phl p 5-transgenic mice.
Additionally to the skin grafted group, mice receiving splenocytes or rPhl p 5
plus adjuvant showed a comparable response in matters of Phl p 5-speciﬁc
IgE- and IgG1-levels through the whole follow-up (week 1, 2, 3, 5, 7, 9, 11)
suggesting an unusually strong immune response to cell or tissue-bound Phl p
5. Furthermore Phl p 5-speciﬁc IgG2a/2b/3, IgA and IgM were induced.
Besides in vitro splenocyte-proliferation assays showed Phl p 5 speciﬁc T-cell
responses in all groups of mice that showed strong humoral responses.
Conclusions: The high immunogenicity of tissue-bound Phl p 5 may
represent a new mode of rendering antigens highly immunogenic.
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Speciﬁc Recognition of the Major Birch Pollen Allergen BET V 1
Programs Dendritic Cells to Induce Either th2 or
Tolerogenic Responses
Ursula Smole, Nina Balazs, Christian Radauer, PhD, Yury Sobanov,
Merima Bublin, PhD, Sonja Gaier, Karin Hoffmann-Sommergruber,
Erika Jensen-Jarolim, MD, Diana Mechtcheriakova, and Heimo Breiteneder,
PhD. Department of Pathophysiology and Allergy Research, Medical
University of Vienna, Vienna, Austria.
Background: Only a limited number of proteins have the potential to induce
Th2-polarized immune responses and speciﬁc IgE in genetically predisposed
individuals. However, why the contact with an allergen results either in
allergic sensitization or tolerance induction has remained unclear so far. Here,
we focused on the in depth study of uptake, induction of signal transduction
pathways, and gene regulation in monocyte-derived dendritic cells (MoDCs)
of allergic and normal individuals in response to the major birch pollen (BP)
allergen Bet v 1.0101 and its structural homolog from celery, Api g 1.0101.
Methods: Live cell ﬂuorescence microscopy was used to analyze uptake
kinetics, competitive binding, and internalization pathways of labeled
allergens by iMoDCs. To delineate allergen-mediated gene activation,
iMoDCs were incubated with the allergens, a control stimulus, or left
untreated followed by real-time PCR-based gene expression proﬁling.
Surface-bound IgE was detected by immunoﬂuorescence microscopy and
IgE-mediated gene activation by real-time PCR.
Results: Comparable kinetics of Bet v 1.0101 and Api g 1.0101 uptake were
observed for both allergic and healthy donors. In competititve binding assays,
however, Bet v 1.0101 outcompeted Api g 1.0101 for surface recognition in
both donor groups. Pharmacological inhibition evidenced that Bet v 1.0101
internalization occurred in a receptor-mediated manner showing character-
istics of lipid raft-dependent endocytosis. MoDCs of both donor groups were
IgE positive and showed marked upregulation in NF-kB dependent genes
after Fce receptor activation by anti-IgE. Bet v 1.0101-stimulation, in con-
trast, exclusively triggered transcription of the Th2 cytokines IL-4 and IL-13
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S31
but not NF-kB related genes in MoDCs of BP allergic donors. Healthy donors
were either unresponsive or showed elevated mRNA levels of the Th1-pro-
moting chemokines CXCL10 and CXCL11.
Conclusions: This study supported by grant SFB-F1802 of the Austrian
Science Fund shows for the ﬁrst time that the allergen uptake is speciﬁc and
similar in DCs from allergic and healthy individuals. More important, the
ensuing signal cascade that is triggered by the allergen differs between DCs
of the 2 donor groups and results in a Th2-polarized immune response in
allergic individuals as compared to ignorance/tolerance in normal donor cells.
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Recombinant SCFV Antibodies for IGE Epitope Mapping and
Detection of Parvalbumins
Merima Bublin, PhD,1 Maria Kostadinova, MSc,1 Daniela Ackerbauer,1
Christof Ebner, MD, PhD,2 Radauer Christian, PhD,1 and Heimo
Breiteneder, PhD1. 1Department of Pathophysiology and Allergy Research,
Medical University of Vienna, Vienna, Austria; 2Allergy Clinic Reumann-
platz, Vienna, Austria.
Background: Parvalbumin, the major ﬁsh allergen, is responsible for IgE
cross-reactivity among different ﬁsh species. We aimed to generate
recombinant single chain antibody fragments (scFv) binding to epitopes
responsible for IgE cross-reactivity among parvalbumins.
Methods: The parvalbumin-speciﬁc scFvs were selected from the human
synthetic scFv phage library ETH-2 by alternating the parvalbumin from cod
(Gad m 1), carp (Cyp c 1) and trout (Onc m 1) during 3 rounds of sequential
biopanning. Based on their reactivity to parvalbumins by ELISA, 2 clones
were expressed in Escherichia coli. The ability of the 2 scFv antibodies to
inhibit the binding of parvalbumin-speciﬁc IgE from ﬁsh allergic patients’
sera was showed by ELISA competition experiments and the rat basophilic
leukemia mediator release assay.
Results: Based on ability to bind different parvalbumins and sequence
analysis, phage clones scFv-gco9 and scFv-goo8 were selected for production
of soluble scFv antibodies. We obtained 1 mg of scFv-gco9 and 1.3 mg of
scFv-goo8 per litre of bacterial culture. The scFv-gco9 was able to detect all 3
parvalbumins at a concentration of 10 ng/mL. The scFv-goo8 bound to cod
parvalbumin, but not to carp and trout parvalbumin. The detection limit for 1
mg/mL of the scFv-gco9 was 0.01 mg/mL of the Gad m 1 and 0.2 mg/mL of
Onc m 1 or Cyp c 1. We found that scFv-gco9 dose-dependently blocked the
binding of IgE to immobilized Gad m 1, Cyp c 1 and Onc m 1. At a concen-
tration of 5 mg/mL of scFv-gco9 binding of IgE to the 3 parvalbumins was
inhibited by approximately 40%, and at a concentration of 20 mg/mL the IgE
binding was inhibited to w70%. In the case of the scFv-goo8, inhibition of
IgE binding to Gad m 1 was about 15%. The inhibition of degranulation of
basophils was 55% in the presence of 2 mg/mL scFv-gco9.
Conclusions: This work, supported by grant SFB-F01802, revealed that the
scFv antibodies can be used for the standardization of protein extracts used
for allergy diagnosis and for IgE epitope mapping. Epitope characterization
enables the engineering of parvalbumin molecules with reduced IgE binding
for allergen-speciﬁc immunotherapy.
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Grass Pollen Allergen-induced Surface Expression of CD203C,
CD63 andCD107AonCRTH21Basophils: Novel Biomarkers for
Monitoring Efﬁcacy of Allergen-speciﬁc Immunotherapy
Mohamed Shamji, PhD,1 Janice A. Layhadi, BSc,1 Delica K. M. Cheung,
MSc,1 Shireen Q. Khan,1 Deborah Phippard, PhD,2 and Stephen Durham,
MD1. 1Allergy and Clinical Immunology, Imperial College London, London,
United Kingdom; 2Immune Tolerance Network, Washington, WA.
Background: Grass pollen immunotherapy is associated with reduction in
symptoms, the need for rescue medication and improvement of quality of life
in patients with severe seasonal pollinosis. Although, the suppression of the
early allergic response following in vivo cutaneous allergen challenge is
associated with inhibition of basophil histamine release, the effects of
immunotherapy on basophil reactivity is yet to be fully determined. We
hypothesized that basophil reactivity as measured by increased expression of
surface activation markers CD203c, CD63 and CD107a on CRTH21 baso-
phils is increased in grass pollen allergic individuals following in vitro aller-
gen stimulation. We further hypothesized that this hypereactivity is reduced
in immunotherapy-treated patients.
Methods: Heparinized blood obtained from grass pollen allergics (n ¼ 7),
immunotherapy treated patients (n ¼ 6) and non-atopic controls (n ¼ 9) was
incubated with 0, 0.1, 1, 10 and 100 ng/mL of P. Pratense extract at 378C for
15 minutes. Cells were stained with anti-CD3, CRTh2, CD123, CD303,
CD203c, CD63 and CD107a. Additionally, whole blood basophil histamine
release was measured pre/post immunotherapy by ELISA (n ¼ 6).
Results: A dose-dependent increase in the proportion of CD203c1, CD631
and CD107a1 CRTH21 basophils was observed following in vitro grass
pollen stimulation in allergics but not in non-atopic controls. At 100 ng/mL of
P. Pratense extract, CD203c1, CD631 and CD107a1CRTH21 basophils
were signiﬁcantly elevated in allergics compare to non-topics (P , 0.001,
P , 0.001 and P , 0.009). This increase in CD203c1, CD631CRTH21
basophils in allergic individuals signiﬁcantly correlated with timothy-speciﬁc
IgE (r ¼ 0.84, P , 0.0001; r ¼ 0.85, P , 0.0001). Interestingly, 10- to 100-
fold more allergen was required for CRTH21 basophils to express CD203c,
CD63 and CD107a in immunotherapy-treated patients compare to grass pol-
len allergics. At suboptimal allergen-concentration (10 ng/mL), CD203c1,
CD631 and CD107a1CRTH21 basophils were signiﬁcantly reduced in
immunotherapy treated subjects compare to allergics (P , 0.001, P ,
0.001 and P , 0.002). Basophil histamine release measured after treatment
was signiﬁcantly reduced compared to pre-treatment levels (P , 0.03).
Conclusions: Basophil reactivity and histamine release is signiﬁcantly
reduced following grass pollen immunotherapy. The use of surface activation
markers CD203c, CD63 and CD107a on basophils for monitoring clinical
efﬁcacy requires further investigations.
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Speciﬁc IGE and IGG Binding to Allergoids of Phleum pratense
Barbara Cases, PhD,1 Enrique Fernandez-Caldas, PhD,1,2 Jose Ignacio Tudela,
BS,1 Eva Abel Fernandez,BS,1 Silvia Sanchez-Garcia,MD,3 M. Dolores Ibañez,
MD,3 Carmelo Escudero,MD,3 and Miguel Casanovas,MD, PhD1. 1Research &
Development, Inmunotek SL, Madrid, Spain; 2Division of Allergy and Immunol-
ogy, University of South Florida College of Medicine, Tampa, FL; 3Allergy
Section, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Background: Allergoids were ﬁrst used in the decades of the 60s and 70s of
the last century as an effective treatment of allergic respiratory diseases.
Allergoids can be modiﬁed with formaldehyde or glutaraldehyde. Modiﬁed
allergens, or allergoids, decrease the risk of adverse reactions while admini-
stering higher allergen doses. The objective of this study was to analyse
speciﬁc IgE and IgG binding to glutaraldehyde modiﬁed and non-modiﬁed
allergen extracts of Phleum pratense.
Methods: The sera of 69 patients sensitized to P. pratense were tested. All
these patients had signs and symptoms of rhinoconjunctivitis with, or without,
asthma in May and June of 2011. All these patients had positive skin prick
tests to a standardized extract of P. pratense, and other grass species. Most
patients were also sensitized to olive pollen. Speciﬁc IgE and IgG binding
were analysed by direct ELISA against P. pratense native (non-modiﬁed)
and allergoid extracts. Relative potencies were evaluated through ELISA
inhibition assays, and the protein composition of non-modiﬁed and allergoid
samples was determined by Mass Spectrometry (MS/MS).
Results: Mean Speciﬁc IgE levels against the native extract was 16.68 6
11.65 Units (U) and against the allergoid: 7.26 6 8.24 U (P , 0.0001;
Mann-Whitney). On the other hand, mean speciﬁc IgG binding against the
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non-modiﬁed extract was 90.34 6 75.57 U versus 76.19 6 70.31 U against
the allergoid (P ¼ 0.16; Mann-Whitney). Linear regression coefﬁcients
obtained between immunoglobulin reactivity against both extracts were:
r2 ¼ 0.51 for speciﬁc IgE and r2 ¼ 0.83 for speciﬁc IgG. An important
decrease in the allergenic activity, measured by inhibition ELISA, was clearly
observed. The MS/MS assay revealed the presence of the mayor allergen, and
some isoforms, in non-modiﬁed and allergoid extracts.
Conclusions: Results obtained demonstrate that the glutaraldehyde polymer-
ization process induces an important decrease in speciﬁc IgE binding to
allergoids of P. pratense while there are no signiﬁcant differences in speciﬁc
IgG binding. The allergenic composition of the P. pratense allergoid was
equivalent to the non-modiﬁed pollen extract.
IMMUNODEFICIENCY
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Anxiety and Depression in Patients With Variable Common
Immunodeﬁciency in the Service of Allergy and Clinical
Immunology - Centro Médico Nacional Siglo XXI
Nelva Guillén, MD,1 Nora Hilda Segura Mendez, MD,2 Janett Silva Perea,
MD,3 and Martín Felipe Vazquez Estupiñan, MD3. 1Allergy and Immunol-
ogy, Speciality Hospital - Centro Médico Nacional Siglo XXI, México Distrito
Federal, Mexico; 2Specialty Hospital Centro Medico Nacional Siglo XXI,
Allergy and Clinical Immunology, Mexico City, Mexico; 3Psychiatry, Spe-
cialty Hospital - Centro Medico Nacional Siglo XXI, Mexico City, Mexico.
Background: Depression and anxiety disorder are topics of interest, not only
to psychiatrists. It comes in a 10 to 20% of cases, with the highest ﬁgures in
people with chronic diseases. It has been shown that depressed patients have
more mortality (not only attributable to suicide) than the general population.
Depressive disorders in the community reach a lifetime prevalence of 15%.
The average age of onset is situated close to 30 years, being similar in both
sexes. The Variable Common Immunodeﬁciency (ICV) is a disorder
characterized by low levels of immunoglobulins (Ig), these patients have an
increased susceptibility to infection. The exact cause of low levels of serum Ig
is not known and autoimmune diseases is complicated by up to 20%. It has
a prevalence estimated at 1 in 25,000, is the most common primary
immunodeﬁciencies, however, the diagnosis is not made until the third and
fourth decade of life.
Objective: To evaluate the presence of anxiety disorders and depression in
patients with ICV.
Methods: A cohort study, observational, cross-ﬁfteen patients (11 female and
4 male) with ICV, aged between 17 and 71, diagnosed with ICV. Are
individually applied assessment instruments and the preparation of tables and
graphs. The data were expressed in absolute ﬁgures and percentages.
Results: 1) 13.3% had very severe, 6.6% had severe, 13.3% moderate and
66.6% mild depression. 2) 33.3% moderate-severe anxiety and 66.6% mild.
Conclusions: In this study, most patients are between the second and third
decade of life, the moderate-severe anxiety was found in 5 patients and mild
in 10 patients, a mild depression 10, a moderate 2, a severe 1 and 2 very
severe. This allows to evaluate the ability of the patient with ICV to accept
their illness and see the level of infection on the psychological, and offer
a multidisciplinary therapy with counseling and/or psychiatric treatment for
patients with moderate-severe anxiety and moderate depression to very severe
and thus improve their quality of life. These patients have associated
autoimmune disorders and family problems.
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ComputedTomographyFindingsConsistentWithRhinosinusitis,
Clinical Correlation andQuality of Life in PatientsWithCommon
Variable Immunodeﬁciency. Original Article
Elizabeth Mendieta,1 and Leonel Gerardo Del Rivero, MD2. 1Allergy &
Clinical Immunology, Specialty Hospital Medical Center XXI Century, Mex-
ico City, Mexico; 2Allergy and Immunology, MD, Mexico City, Mexico.
Background: Common Variable Immunodeﬁciency (CVID) is a clinical
syndrome characterized by a reduction and/or absence of IgG, IgM and IgA
to respiratory tract infections and/or gastrointestinal can be associated with
lymphoproliferative and autoimmune processes. The infections found in
paranasal sinuses are an important cause of morbidity and generate de-
terioration in the quality of life in this patient population. Multidetector
Computed Tomography (MDCT) of the sinuses is the Gold standard for
diagnosis of rhinosinusitis. The Rhinosinusitis disability index (RSDI)
developed by Benninger and Senior, evaluates the quality of life in patients
with nasal disease, including rhinosinusitis.
Methods: Fourteen patients were included with a deﬁnitive diagnosis of
CVID according to the diagnostic criteria of the European Society for
Immunodeﬁciencies in each of the patients were evaluated: (1) The diagnostic
criteria according to the European Consensus on Rhinosinusitis and nasal
polyposis (EPOS 2007) (2) MDCT of Sinuses. (3) Each patient answered the
questionnaire of RSDI. Correlation was calculated using Spearman Ro (rs).
Results: Ten patients were female (71.4%) and 4 were male (28.5%). The
average age was 34 years. In 8 patients (57%) received the diagnosis of
rhinosinusitis. The maxillary sinus was affected in 5 patients ﬁnd us (45%),
followed by ethmoid sinus (36%), frontal sinus and sphenoid was affected in
9% of patients. The correlation between clinical symptoms and MDCT study
was consistent with rhinosinusitis rs ¼ 0.84. The correlation between the
clinical diagnosis, CT and rhinosinusitis disability index was rs ¼ 0.71. In
5 of the 14 patients studied showed no clinical symptoms of rinosinuistis, but
in MDCT of the sinuses if they showed data compatible with the disease.
Three of these patients showed bilateral location (69%) and in one patient the
ﬁndings were found in 3 sinuses frontal, ethmoid and maxillary.
Conclusions: The sinus infection is a major cause of morbidity in patients
with CVID. As in the initial study, should include a CT scan of paranasal
sinuses for proper assessment and timely diagnosis.
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Case Report: Recurrent Mucocutaneous Candidiasis and
Recurrent Diarrhea by Gram Negative Bacteria
Juan Aldave Becerra, MD. Allergy and Immunology, Edgardo Rebagliati
Martins National Hospital, Lima, Peru.
Background: Primary Immunodeﬁciencies (PID) are inherited disorders of
immune system function that predispose affected individuals to increased rate
and severity of infection, immune dysregulation with autoimmune disease,
and malignancy.1 In Peru there is a sub diagnosis and report of these diseases.
Methods: I present a case of a 7 month girl with recurrent mucocutaneous
candidiasis and recurrent diarrhea by gram negative bacteria. Patient’s current
illness start at 3 days of age with macular anular lesions in skin and thrush,
with poor response to topical antifungals and oral Itraconazole. Resolved with
IV Amphotericin and then Posaconazole. Recurrence few days after treatment
withdrawal. Culture of the lesions: Candida albicans. At 1 month of age she
Sex Age Groups
Female Male ,20 20–30 31–40 41–50 51–60 61–70
11 4 2 4 5 1 3 1
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starts with recurrent diarrhea. Stool culture: Escherichia coli, Klebsiella pneu-
moniae. Intermittent fever coincident with the worsening of diarrhea or thrush
lesions. Sepsis in one opportunity. Poor weight gain. We requested some
procedures.
Results: IgM (1) to CMV, positive viral load by PCR, asymptomatic, received
ganciclovir. Chest CT: thymus with normal size. HIV: negative. Normal: WBC,
glucose, creatinine, IgG, IgA, IgM, abdominal US, echocardiography. Flux
cytometry (at 3 months of age): WBC ¼ 13,040; Total lymphocytes ¼ 4564;
T CD4 ¼ 1734; T CD8 ¼ 1121; B cells ¼ 913; NK cells ¼ 574. GENETIC
ANALYSIS: Gain-of-function human STAT1 mutation. Diagnosis: Chronic
mucocutaneous candidiasis associated with STAT1 mutation.
Conclusions: Susceptibility to Candida sp has been described in combined
immunodeﬁciency, phagocyte defects, or other immune defects resulting
from mutations in AIRE, CARD9, dectin1, dectin2, NLRP3, STAT3 or
MyD88.2 As described in this case, the gain-of-function STAT1 mutation can
also result in susceptibility to candida. There is a huge work to do in the ﬁeld
of PI in Peru. There has been until now a subdiagnosis and subreport of PI,
but we have recently started working hard in purpose of giving affected
patients a speciﬁc diagnosis and appropriate treatment.
REFERENCES
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Bronchiectasis: Localization and Characteristics, Identiﬁed by
Using a High Resolution CT Scan in Adults With Common
Variable Immunodeﬁciency
Laura Mendoza, MD,1 Nora Hilda Segura Mendez, MD,2 Francisco Flores,
MD,3 Freya Helena Campos Romero, MD,1 and Nelva Guillén, MD1. 1Al-
lergy and Clinical Immunology, Specialty Hospital Centro Médico Nacional
Siglo XXI, México Distrito Federal, Mexico; 2Allergy & Clinical Immunol-
ogy, Specialty Hospital Centro Medico Nacional Siglo XXI, Mexico, Mexico;
3Imagenología y Radiología, Centro Medico Nacional La Raza Servicio de
Radiología e Imagenología, México Distrito Federal, Mexico.
Background: The common variable Immunodeﬁciency (CVID) is the second
cause of primary immunodeﬁciency. The bronchiectasis are the most frequent
structural pulmonary alterations in CVID, which have been principally
described in pediatric population, ﬁnding the presence of the same ones in
50% of the cases, nevertheless exists inssuﬁcient information about the
location and characteristics as type and distribution of the bronchiectasis; in
adult population, less information exists still on this matter. High resolution
CT scan is valuable for detection of bronchiectasis and may alter treatment of
these patients.
Objective: The purpose of this study was to determine the presence of
bronchiectasis, their characteristics and most frequent location using a high
resolution CT scan in adults with diagnosis of CVID.
Methods: This was a cohort study whit 15 adult subjects whit the diagnosis
of CVID, who underwent a chest high-resolution computed tomography scan,
previous signature of a letter of informed consent and with the approval of the
committee of ethics and investigation (F-2011-3601-21).
Results: We studied all the subjects (n ¼ 15) whit CVID, ﬁnding the pres-
ence of bronquiectasias in 73% of the subjects with CVID, 82% was a women
and 8% males. The most frequent location was in the left lung in 46% of
the cases and 45 bilateral %, with only 9% of location in right lung. These
were more frequent in the lower lobe in 42, 17% in top lobe and l6% diffuse,
the rest of them were brought like diffuse, bibasal or parahiliar. In one patient
we found the presence of a left apical cavitation and only one was brought
by presence of pulmonary diffuse ﬁbrosis.
Conclusions: There was realized a search of bronchiectasis and their
characteristics in subjects with CVID disorders, the incidence of bronchiec-
tasis is higher in our poblation (82%) than in the rest (50% described in other
pubiclations). The most affected lung was the left in the lower lobe. The most
frequent type of bronchiectasis was the cystic form.
IMMUNOMODULATORS
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Modulation of Human Basophilic Responses by a Fibroleukin-
Allergen Fusion Protein
Maaike Dooper, PhD,1 Heidi Myrset,1 Eliann Egaas, PhD,1 Keith Thompson,
PhD,2 and Bjarne Bogen2. 1Norwegian Veterinary Institute, Oslo, Norway;
2University of Oslo and Oslo University Hospital, Oslo, Norway.
Background: Fibroleukin or ﬁbrinogen-like protein-2 is a immunomodula-
tory protein that was described to bind to Fcgamma-receptor-IIb and III. In
the present study the effects of a fusion protein consisting of ﬁbroleukin and
the major allergen of shrimp, tropomyosin, on human basophilic responses
were investigated in vitro.
Methods: The fusion molecule was generated by molecular cloning and
expressed in E. coli. Receptor binding studies were performed by immuno-
blot, ELISA, and ﬂow cytometry. Activation of basophils was studied by
basophil activation test (BAT) with blood from shrimp allergic individuals.
Results: Tropomyosin and the C-terminal part of ﬁbroleukin were fused by
a short ﬂexible linker consisting of the amino acids RADAAP. The fusion
protein bound to the human Fcgamma-receptor-IIb in immunoblot and
ELISA and binding of the fusion protein to human B-cells was shown by
ﬂow-cytometry. Shortening of the allergen into a peptide covering one-ﬁfth of
whole tropomyosin increased the binding to B-cells. Futhermore, a decrease
in the activation of basophils to shrimp tropomyosin was observed in
presence of the fusion protein.
Conclusions: Here we describe a novel fusion protein based on ﬁbroleukin
and shrimp tropomyosin that may have tolerizing effects on basophils and
B-cells in shrimp allergic individuals.
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Immunogenicity and Safety Aspects of Adeno-Associated Virus–
Like Particles (AAVLPS) as Carriers for B-Cell Vaccines
Erika Jensen-Jarolim, MD,1,2 Krisztina Szalai, MDsci,1,3 Kathrin Thell,
MSc,1,3 Josef Singer, MD,1,3 Mirko Ritter, PhD,4 Beatrix Pfanzagl, PhD,1
Anna Willensdorfer,1,3 Caroline Stremnitzer, MSc,1 and Uwe Michaelis,
PhD4. 1Medical University Vienna, Inst. of Pathophysiology and Allergy
Research, Vienna, Austria; 2Messerli Institute Vienna, Veterinary University
Vienna, Vienna, Austria; 3Biomedical Int. R 1 D, Vienna, Austria; 4Medi-
Gene AG, Martinsried, Germany.
Background: Adeno-associated viruses (AAV) are non-human pathogenic
and replication defective ssDNA viruses. The surface of AAV consists of 60
capsomers, which can be exploited for high density display of recombinant
peptides. AAV-like particles (AAVLP) can be generated via assembly of the
recombinant capsid protein VP3. The aim of this study was to evaluate the
uptake mechanism, immunogenicity and safety aspects of an AAVLP-displayed
B-cell epitope, taking ovalbumin (OVA) as a model antigen/allergen.
Methods: An OVA derived linear B-cell epitope and for control purposes
OVA-non related peptide TP18 (cholesterol-ester transfer protein 18) were
inserted into capsid protein VP3 of AAVLPs.
Results: Life cell microscopy indicated that AAVLP internalized into HeLa
epithelial cells and remained in intracellular vesicles up to 18 hours. When we
immunized BALB/c subcutaneously, sera of AAVLP-OVA immunized mice
showed similar titres of OVA-speciﬁc IgG1 compared to mice immunized
with OVA protein. However, in OVA immunized mice high OVA-speciﬁc
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IgE levels could be recorded, whereas immunizations with OVA-AAVLP
rendered background IgE levels only. In accordance, sera of OVA mice which
permitted mast cell degranulation upon OVA trigger in a speciﬁc b-hexosamin-
idase release assay, whereas sera of OVA-AAVLP mice did not contain
anaphylactogenic antibodies. In an in vivo anaphylaxis experiment, upon
intravenous OVA challenge OVA-immunized mice presented signiﬁcant drop
of body temperature, whereas AAVLP-OVA mice remained unaffected.
Conclusions: Our study demonstrates the immunogenicity, safety and
efﬁcacy of AAVLP as display system of B-cell epitopes for vaccination.
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M-Cell Targeting by Neuraminidase Functionalized
Microparticles for Future Application in Oral Immunotherapy
Susanne C. Diesner,1 Cornelia Schultz,2 Xueyan Wang,3 Gerda Ratzinger,3
Philipp Starkl,2 Vera Assmann,2 Kristina Kreiner,2 Franziska Roth-Walter,
PhD,2 Isabella Pali-Schöll, PhD, MSc,2 Erika Jensen-Jarolim, MD,2
Franz Gabor,3 and Eva Untersmayr2. 1Department of Pathophysiology and
Allergy Research and Department of Pedriatics and Adolescent Medicine,
Medical University of Vienna, Vienna, Austria; 2Department of Pathophysi-
ology and Allergy Research, Medical University of Vienna, Vienna, Austria;
3University of Vienna, Department of Pharmaceutical Technology and Bio-
pharmaceutics, Vienna, Austria.
Background: Recently, we demonstrated in an experimental mouse study
that mucosal M-cell targeting with Aleuria aurantia lectin (AAL) coated Poly
(D,L-lactide-co-glycolide) (PLGA) microspheres represents a promising oral
treatment approach in IgE mediated allergy. Due to its structural similarities
with AAL we aimed to assess Neuraminidase (NA) from Vibrio cholerae as
a novel M-cell speciﬁc targeters and compared its properties to AAL and
wheat germ agglutinin (WGA) representing 2 plant lectins, which target either
M-cells or epithelial cells, respectively.
Methods: The resistance against gastric digestion of NA, AAL and WGA was
analyzed in simulated gastric ﬂuid (SGF) experiments. Intestinal epithelial
binding was determined using the colon carcinoma cell line Caco2, which
represents a well established model for the human intestinal epithelium. Binding
speciﬁcity was evaluated by inhibition experiments by incubating Caco2 cells
with Biotin-labeled NA, AAL or WGA, after preincubation with a-L fucose,
monoganglioside (GM1) or N,N9,N99-triacetyl-chitotriose (TCT). The stimula-
tory effects of the targeting substances on the intestinal microenvironment were
investigated by cytokine read-out experiments in real-time PCR. Further, the
transeptihelial uptake of NA-, AAL- or WGA-functionalized ﬂuospheres was
evaluated in a human M-cell co-culture model.
Results: All 3 targeters were stable up to 180 minutes in SGF, indicating their
suitability for oral application. The binding partners were a-L fucose for AAL
and TCT for WGA, whereas NA interacts with intestinal epithelial cells via
a-L fucose and additionally GM1. NA skewed the cytokine production by
inducing a 2-fold increase of the Th1 cytokine IFNg after 60 minutes,
whereas AAL decreased the overall cytokine expression. In a human M-cell
co-culture model, a higher transepithelial transport rate of ﬂuospheres coated
with NA and AAL was observed as compared to WGA and plain particles.
Conclusions: NA speciﬁcally targets M-cells via a-L fucose and additionally
GM1 and, thus, increases the transepithelial transport of NA coated particles.
Due to the immunomodulatory capacity on intestinal epithelial cells, NA
functionalized microspheres may represent a promising M-cell speciﬁc




Wendy Ramírez González, MSc,1 Alexis Labrada, PhD,2 Virgilio Bourg,
MSc,3 Bárbara González, PhD,4 Damarys Torralba,1 Arelis Más Quintero,MSc,1
Oliver Pérez,PhD,5 and Miriam Lastre,PhD5. 1Allergens Laboratory; 2Allergens,
and; 3Department of Biological Tests, National Center of Bioproducts, Havana,
Cuba; 4CENPALAB, Havana, Cuba; 5Finlay Institute, Havana City, Cuba.
Background: In recent years one important trend of Allergen-speciﬁc
immunotherapy is to investigate new adjuvants with immunomodulatory
properties. The outer membrane vesicle or proteoliposome (PL) from
Neisseria meningitidis serogroup B has been reported as a potent adjuvant
inducing a Th1-skewed response. The aim of this work was to assess the
immunogenicity of a novel anti-allergic vaccine candidate based on puriﬁed
allergens from Dermatophagoides siboney mite and PL as adjuvant, both
components adsorbed onto Aluminum hydroxide.
Methods: In a preventative experimental setting BALB/c mice were admini-
stered with 3 doses containing 5 mg of Der s 1 allergen at one week intervals
by subcutaneous route. Further, mice were subjected to allergen challenge by
aerosol inhalation. In another experiment, mice were administered ﬁrst with 2
doses of PL1 Alum and later with the whole vaccines formulation, including
the allergen. The allergen-speciﬁc antibody response was assessed deter-
mining serum levels of IgE, IgG1, and IgG2a by ELISA. The local allergic
inﬂammatory response was evaluated by measuring cytokine levels (IL-4,
IL-5, IFNg and IL-10) in broncho-alveolar lavage (BAL) by ELISA.
Results: The formulation consistently induced IgG2a, as well as IgG1
antibodies with a potential anti-IgE blocking effect. The induction of IgG2a
was clearly PL dependent while IgG1 was dependent mostly of Alum. Prior
administration of the proteoliposome with alum without allergen showed to
enhance this allergen-speciﬁc immunogenic effect. The vaccine prevented the
development of systemic (IgE) and local allergic response in mice subjected
to allergen exposure by inhalant route. Vaccinated mice showed lower levels
of serum IgE, Th2 cytokines (IL-4, IL-5) in BAL and lower eosinophil
counting in blood as compared to controls. Histological examination of lungs
showed also a diminished allergic inﬂammatory response in vaccinated mice
in contrast with mice which were administered with the conventional
formulation of Alum-adsorbed allergen.
Conclusions: The antiallergic protective effect was proven in a preventative
setting, showing to decrease the inﬂammatory response in the lungs of mice
exposed to allergen aerosol, as well as, a Th2-antagonistic immune response
with few injections.
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Immunomodulatory Effects of Manumycin-type Antibiotics on
Human Macrophages
Ilja Striz, MD, PhD,1 Eva Brabcova, MSc,1 Katerina Petrickova, PhD,2
Libor Kolesar, MSc,1 Eliska Thorburn, MSc,1 Marcela Jaresova, MSc,1
Alena Sekerkova, MSc,1 and Miroslav Petricek, PhD2. 1Institute for Clinical
and Experimental Medicine, Prague, Czech Republic; 2Institute of Microbi-
ology, Academy of Sciences of Czech Republic, Prague, Czech Republic.
Background: Polyketide-derived antibiotics including macrolides are known
to exert potent anti-inﬂammatory and immunomodulatory effects beyond
their purely antibacterial action. The mechanisms of their biological activities
are still being investigated but the effect on signalling pathways of
transcription factors which regulate a number of pro-inﬂammatory and/or
pro-ﬁbrotic genes might be preferentially involved. The aim of our study was
to assess the effect of manumycin and structurally related compounds
asukamycin and collabomycin on a release of proinﬂammatory cytokines
IL-1beta and IL-18 from THP-1 monocyte/macrophage cell line. Further-
more, the level of mRNA expression of multiple genes associated with
immune regulation has been studied.
Methods: The THP-1 cells were cultured in RPMI1640 with 5% fetal calf
serum and then stimulated with TNF alpha (20 ng/mL) under serum
free conditions in the presence or absence of manumycin and asukamycin
(both at 0.3 mg/mL). The concentrations of cytokines in culture supernatants
were measured by ELISA (IL-18, MBL) or Luminex (IL-1 beta, R&D).
Quantitative RT-PCR (SABiosciences) was used for the evaluation of 84
different gene expressions in TNF alpha and manumycin stimulated cultures.
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Results: IL-1 beta was not detectable in culture supernatants of unstimulated
THP-1 cells but appeared in response to TNF alpha (4.96 1 0.59 pg/mL).
Both manumycin (0.34 1 0.48 pg/mL) and asukamycin (1.06 1 0.81)
inhibited IL-1 beta release induced by TNF alpha. IL-18 was found to be
constitutively produced (14.68 1 7.83 pg/mL) and the release was doubled
by TNF alpha (30.98 1 2.21 pg/mL) and inhibited to basal values by both
manumycin (18.04 1 10.21 pg/mL) and asukamycin (12.96 1 2.32 pg/mL).
Manumycin inhibited mRNA expression of several genes associated with
proinﬂammatory responses including IL-1 beta, IL-6, and TLR8. Among
the genes upregulated in response to manumycin, HMOX1, gene for heme
oxigenase 1, showed the highest mRNA induction.
Conclusions: We assume from our study that manumycin and asukamycin
represent potent inhibitors of IL-1 beta and IL-18 release from human
macrophages. Some of the potentially proinﬂammatory genes are regulated
on the level of transcription.
Supported by MSMT grant 2B06154.
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The Relationship of Pets, Vitamin D and IGE Concentrations to
Upper Respiratory Infections in the First Year of Life
Dennis Ownby, MD,1 Edward Peterson, PhD,2 Ganesa Wegienka, PhD,2
Susan Lynch, PhD,3 Homer Boushey, MD,4 Nicholas Lukacs, PhD,5
Edward Zoratti, MD,6 Suzanne Havstad, MA,2 Kevin Bobbitt, PhD,2
Kimberley Woodcroft, PhD,2 and Christine Cole Johnson7. 1Pediatrics, Sec-
tion of Allergy, Immunology, Rheumatology, Georgia Health Sciences Uni-
versity, Augusta, GA; 2Public Health Sciences, Henry Ford Hospital &
Health System, Detroit, MI; 3University of California San Francisco, San
Francisco, CA; 4Medicine, University of California, San Francisco, San
Francisco, CA; 5Pathology, University of Michigan, Ann Arbor, MI; 6Allergy
and Immunology, Henry Ford Hospital & Health System, Detroit, MI; 7Pub-
lic Health Sciences, Henry Ford Health System, Detroit, MI.
Background: The childhood origins of asthma are highly complex but viral
respiratory infections during the ﬁrst year of life may be associated with
wheezing and later asthma risk. Recent studies have shown that both
exposure to household pets and higher serum vitamin D concentrations
may reduce wheezing illness in children.
Methods: To investigate potential relationships between household pet exposure,
cord blood (CB) vitamin D and IgE concentrations and the number of upper
respiratory infections (URIs) in the ﬁrst year of life, we analyzed information
from a geographically-based, prospective, non-high-risk, birth cohort. Household
pets were assessed during pregnancy and medical records were abstracted for
doctor visits of URIs. Because of large differences in vitamin D concentrations
between Blacks and Whites racial stratiﬁcation was done for some analyses.
Results: The cohort consisted of 1055 children of whom 62.4% were Black
and 49.4% were female. When all children were considered, a one natural log
unit increase in CB vitamin D concentration was associated with a greater risk
of a URI visit (RR ¼ 1.27, 95% CI, 1.01-1.59, P ¼ 0.037) which remained
after adjusting for the season of birth (RR ¼ 1.28, P ¼ 0.033). Individually
adjusting for the number of children in the family, CB IgE, child gender,
family or maternal smoking and race did not substantially change the asso-
ciation of vitamin D to URIs (all RR’s were 1.25-1.27), although the risks
only remained statistically signiﬁcant with CB IgE (P ¼ 0.035) and gender
(P ¼ 0.043). When models stratiﬁed by race including pets, dogs only, or cats
only, and CB IgE were ﬁtted with the other variables, the relationship
between CB vitamin D disappeared for whites but did not change in magni-
tude for blacks (RR ¼ 1.31; 95% CI, 0.89-1.92; P ¼ 0.165). Among Whites
the only variable associated with URIs was a relationship with female gender
(RR ¼ 0.62, 95% CI, 0.41-0.94; P ¼ 0.025) with being in daycare approach-
ing signiﬁcance (RR ¼ 1.72, 95% CI, 0.94-3.14; P ¼ 0.08).
Conclusions: In a large, prospective, non-high-risk birth cohort higher, CB
vitamin D concentration, after adjusting for other potential confounding
variables, was not associated with a decreased risk of physician diagnosed
URIs in the ﬁrst year of life.
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Prevalence of Cockroach and Mouse Sensitization Among
Children Hospitalized for Wheezing and Asthma
Terri Moncrief, MD,1 Andrew Beck, MD,2 Emily Greenberg, BA,2
Heather Strong, BA,2 Jeffrey Simmons, MD, MS,2 and Robert Kahn, MD,
MPH2. 1Allergy/Immunology, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2General and Community Pediatrics, Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH.
Background: The prevalence and demographic correlates of cockroach (CR)
and mouse sensitization among children hospitalized for wheezing and
asthma are not known. Objectives: (1) To describe the prevalence of CR and
mouse sensitization in a population-based sample; (2) To examine factors
potentially associated with allergic sensitization including sociodemographic
factors and asthma history.
Methods: We examined baseline data of the ﬁrst 416 children enrolled in
a prospective study cohort between August 2010 and February 2011. Eligible
children were aged 1 to 16 years, were admitted for bronchodilator-
responsive wheezing or acute asthma to a single children’s hospital that
captures .90% of all asthma admissions in the county. Allergic sensitization
was determined using speciﬁc Ig-E to CR and mouse. Caregivers were sur-
veyed regarding sociodemographic characteristics and asthma history. Asso-
ciations were assessed using chi-square statistics.
Results: The sample is 65% African-American, 76% publically insured. 78%
report household income less than $60,000. 81% have a previous physician-
diagnosis of asthma. 26% of children are sensitized to CR, 16% to mouse, and
34% are sensitized to either CR or mouse. 8% are sensitized to both. Patients
younger than 4 years are less likely to be sensitized to CR (10 vs 34%, P ,
0.0001) and mouse (8 vs 20%, P ¼ 0.002) than older patients. Patients with
a previous physician-diagnosis of asthma are more likely to be sensitized to
CR (29 vs 13%, P ¼ 0.007) and mouse (13 vs 9%, P ¼ 0.06) than patients
without a previous diagnosis. Compared to children in families with annual
income .$90,000, those in families earning less than $15,000 were more
likely to be CR sensitized (33 vs 18%, P ¼ 0.01). The opposite trend exists
for mouse sensitization: 13% of low income children are sensitized compared
to 25% of high income children (P ¼ 0.02).
Conclusions: In a population based sample, one-third of children admitted
for bronchodilator-responsive wheezing or asthma are sensitized to either CR
or mouse. Sensitization is associated with older age, a previous physician-
diagnosis of asthma, and household income. Assessment of allergic
sensitization during an inpatient admission may be an opportunity to target
interventions for children at highest risk of allergy-related asthma morbidity.
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Is Pet Ownership Associated with Higher Vitamin D?
Christine Cole Johnson,1 Edward Peterson, PhD,1 Ganesa Wegienka, PhD,1
Suzanne Havstad, MA,1 Kimberley Woodcroft, PhD,1 Kevin Bobbitt, PhD,1
Susan Lynch, PhD,2 Homer Boushey, MD,2 Nicholas Lukacs, PhD,3
Edward Zoratti, MD,4 and Dennis Ownby, MD5. 1Public Health Sciences,
Henry Ford Hospital & Health System, Detroit, MI; 2Medicine, University of
California, San Francisco, San Francisco, CA; 3Pathology, University of
Michigan, Ann Arbor, MI; 4Allergy and Immunology, Henry Ford Hospital
& Health System, Detroit, MI; 5Pediatrics, Section of Allergy, Immunology,
Rheumatology, Georgia Health Sciences University, Augusta, GA.
Background: Pet keeping has been linked with decreased risk of allergic
sensitization, which has been associated with the Hygiene Hypothesis; and
more recently, by ourselves and others, to particular home microbiome
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patterns. Another factor possibly associated with pet ownership is increased
Vitamin D among family members as pet keeping may be correlated with
lifestyles involving increased outdoor exposure, such as dog walking.
Prenatal vitamin D inadequacy has been hypothesized as a risk factor for
pediatric atopy and asthma.
Methods: To investigate potential relationships between household pet
exposure and cord blood vitamin D concentrations, we analyzed information
from a large, geographically-based, general risk birth cohort. Household pets
were assessed during pregnancy and serum level of 25 (OH)D (25-
hydroxyvitamin D) in cord blood was used as the measure of vitamin D
and a marker of maternal level. Because of notable differences in vitamin D
concentrations between African Americans and Whites, analyses were
stratiﬁed by race.
Results: A total of 1055 newborns were included in the study: 62.4% were
African Americans and 49.4% were female. For Whites, but not African
Americans, having no pet compared to 1 or .1 pet during pregnancy was
associated with lower cord blood vitamin D concentrations (37.7, 45.2, 47.0
nmol/L, respectively, P ¼ 0.001). Considering type of pet, the relationship for
no pet compared to 1 or .1 dog (37.7, 46.1, 49.9 nmol/L, respectively, P ¼
0.001) was similar to that for no pet versus 1 or .1 cat (37.7, 43.0, 46.5
nmol/L, respectively, P ¼ 0.065).
Conclusions: In a large ethnically diverse cohort of newborns, the presence
of a pet in the home during the prenatal time period was associated with
higher cord blood vitamin D, but only among Whites. This racial difference
may reﬂect an impact on pet owner behavior resulting in increased outdoor
exposure that is limited to lighter skinned individuals. However, as the effect
doesn’t vary by cats versus dogs, differences by race in factors correlated with
pet ownership or variations in pet keeping styles may be more important.
Vitamin D should be considered in studies of pets and atopic conditions.
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Taxonomic Identiﬁcation of the House Dust Mites Associated to
Allergic Patients in 6 Locations From Mexico
Naomi Cuervo, MD,1 Barbara Fernandez, MD,2 Jesus Rodriguez, MD,3
Celio Murillo,3 Tila M. Perez, PhD,4 and Daniel Juarez3. 1Zoology of Inver-
tebrates, Institute of Ecology and Systematic, Habana, Cuba; 2National Cen-
ter of Bioproducts, Bejucal, Cuba; 3Rocel Laboratories, Puebla, Mexico;
4Institute of Biology, UNAM, D.F., Mexico.
Background: Taxonomic research on house dust mites carried out by
acarologists doesn’t exist in Mexico since 1991. However, the allergologists
should know the sources of allergens present in their country. A survey of
dust samples from 6 locations was made in Mexico to determine the diversity
of indoor acarofauna.
Methods: All the samples of dust (1 g each) were collected with vacuum
cleaners from mattresses of allergic patients from 10 georeferenced houses in
each of 6 localities (3 coastal and 3 continental) from Mexico during February
2010 and May 2011. The mites were isolated by the sedimentation ﬂotation
method Spieskma-Boezeman 1967. All the identiﬁed material was deposited
in a Basic Collection from Rocel Laboratories in Puebla and in the National
Collection of Acarology from the Institute of Biology, UNAM, Mexico.
Results: Eleven mite species were found of which the most important were
house dust mites, specially: Dermatophagoides pteronyssinus (Trouessart,
1897) and Dermatophagoides farinae Hughes, 1961. Both species were
reported for the ﬁrst time for the 6 localities under study. Dermatophagoides
siboney Dusbabek, Cuervo and Cruz, 1982 is a vicariant species of D. farinae
and was registered for the ﬁrst time for Mexico in Ciudad del Carmen,
Campeche, but we consider this result should be corroborated in future stud-
ies. Blomia tropicalis (Bronswijk, Cook and Oshima, 1973) was also regis-
tered for the ﬁrst time for Mexico in 3 of the 6 Mexican localities and it has
a tropical distribution. This last species has been used in Mexico for skin tests
and this result favours its use for diagnosis and inmunotherapy.
Conclusions: This survey revealed the existence of house dust mites in
Mexico. It seems there are differences between the geographical distribution
of the species because of the local conditions of temperature and humidity of
each urban ecosystem. This knowledge may be useful in the ﬁeld of allergy
medicine.
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Comparison of the Use Ciclesonide Versus Fluticasone for the
Treatment of Asthma in Children
Said Arablin Oropeza, MD,1 Jose Huerta Lopez,2 and Horacio Del Olmo Tellez,
MD3. 1Allergy and Clinical Immunology, Instituto Nacional de Pediatría, Mexico
City, Mexico; 2Instituto Nacional De Pediatria, Mexico City, Mexico; 3Allergy,
Private Practice, Mexico City, Mexico.
Background: The mainteinance treatment in patients with asthma is based in
the use of inhaled corticosteroids as ciclesonide and ﬂuticasone. The objective
of this stutdy is to compare the utility between ciclesonide versus ﬂuticasone
for treatment of asthma in children.
Methods: A search was done in journals databases of PubMed, EMBASE,
LILACS and Cochrane, from 1996 to 2009. We searched for studies
comparing treatment with ciclesonide versus ﬂuticasone in the treatment of
children younger than 18 years diagnosed with persistent moderate and severe
asthma. The outcomes measured were: FEV 1, peak expiratory ﬂow
improvement, absence of nocturnal symptoms, decrease the number of crisis
compared to baseline and need to use beta 2 agonist rescue crisis.
Results: When making comparisons between ciclesonide and ﬂuticasone in
terms of effectiveness in reducing nocturnal symptoms use of beta 2 agonists,
peak expiratory ﬂow improvement and prevention of asthma attacks, the
studies reported equal effectiveness for both corticosteroids. Studies provide
equally effective in improving FEV1. In terms of local effects, it refers in
2 studies presented the same presentation with both steroids, but there are 2
others less concerned with ciclesonide local effects, but both without
presenting conclusive results. With respect to adrenal suppression, there are
2 articles that refer to is less with the use of ciclesonide with ﬂuticasone, one
adult on the other hand more equal terms the presence of adrenal suppression
with both steroids. However, in all studies to make the overall analysis refers
without signiﬁcant changes. Ciclesonide showed the advantage of not
inhibiting cortisol secretion. There were studies that compared quality of life
by the result of health-related quality of life (PAQLQ) symptom-free days,
days without the use of beta 2 agonists and days without nocturnal
awakenings, all refers to both corticosteroids as equivalent. By comparing
ciclesonide versus placebo, by applying PAQLQ only one study refers
improved quality of life with the steroid.
Conclusions: Ciclesonide is equally effective as ﬂuticasone in the treatment
of children with persistent moderate and severe asthma. Besides, bio-
availability of ciclesonide allows administration once a day, with less adrenal
supression.
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Type I and III Interferon Are Attenuated in a Human In Vitro
Model of Alternatively Activated Macrophages
Ashraf EL Fiky, MD, PhD. Laboratory of Immunobiochemistry, US Food
and Drug Administration, Rockville, MD.
Background: The alternatively activated macrophages (AAM) are induced
by IL-4 and IL-13 and are distinct from the IFN-gamma mediated pathway of
classically activated macrophages (CAM). The AAM are implicated in a wide
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range of physiologic and pathological processes including clearance of
helminthic infections, and allergy. They are closely associated with recruiting
and amplifying T helper 2 (Th2) lymphocyte response in contrast to Th1-
asscoiated CAMs. Wide donor-to-donor variability of human primary
monocytes and their limited life span in vitro is a current impediment to
investigating human AAM biology and their contribution to enhancing Th2-
mediated pathologic inﬂammation found in asthmatic lungs.
Methods: Using the human promonocytic cell line, THP1, we have
successfully established a THP1-derived and committed CAM and AAM
populations demonstrating typical macrophage-oriented morphological
characteristics.
Results: Quantitative PCR and ELISA demonstrated that THP1-AAM cell
model express classic pathogen neutralizing dectin receptors such as
scavenger type mannose receptor (MRC1) and Th2-associated signature
chemokines including CCL13, 17, 18 and 22, and are tolerant to TLR4
challenge by LPS treatment in contrast to THP1-CAM which expressed an
LPS enhanced expression of pro-inﬂammatory mediators such as TNF-a,
CXCL10 and -11. Furthermore, THP1-AAM cell model expressed 50- to
100-fold lower expression IFN-alpha 4, IFN-beta, and IFN-lambda1 com-
pared to THP1-CAM. Quantitative PCR array revealed that a select group of
interferon regulatory factors (IRFs), antiviral genes such as Mx1, and
interferon stimulated genes such as ISG15 are down-regulated only in
THP-1 AAM cell model upon differentiation or LPS treatment emphasizing
its classic infection tolerant phenotype. In addition, IRF4 was found to be up-
regulated only in the THP1-AAM model which may point towards its critical
role in orchestrating the macrophage lineage commitment towards an
alternatively activated phenotype as well as governing its unique cytokine
and chemokines expression proﬁle.
Conclusions: Compared to the donor variability of primary human mono-
cytes, establishing THP1-AAM and CAM cell models will enable a more
rapid and efﬁcient investigation of a spectrum of molecular mechanisms
governing innate, classic, and alternative phenotypes in macrophage pop-
ulations and their role in pathologic processes, in particular allergic
inﬂammation of the upper airways.
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AHighly Sensitive and Speciﬁc UniversalMirna ProﬁlingMethod
Jia-Wang Wang, PhD,1 Kunyu Li, BS,1 Richard F. Lockey, MD,2
Subhra Mohapatra, PhD,3 and Shyam Mohapatra, PhD4. 1Internal Medicine,
University of South Florida, Tampa, FL; 2Division of Allergy & Immunology,
University of South Florida and James A. Haley Veterans’ Hospital, Tampa,
FL; 3Nanomedicine Research Center and Division of Translational Medicine,
Departments of Molecular Medicine and Internal Medicine, University of
South Florida and James V Haley Veterans’ Hospital, Tampa, FL; 4USF
Nanomedicine Research Center, University of South Florida College of Med-
icine & VA Hospital, Tampa, FL.
Background: miRNAs can be used as robust biomarkers for diagnosis,
staging, prognosis and the response to therapy in various diseases. Although
a wide spectrum of miRNA detection techniques have been developed, none
can accurately and sensitively perform genome-wide high-throughput
miRNA proﬁling (Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH,
Nguyen JT, Barbisin M, Xu NL, et al 2005. Real-time quantiﬁcation of
microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e179). This prob-
lem stems from that miRNAs are only w22 bases, and multiple species of
nucleic acids that contain the mature miRNA sequences are present in the
total RNA samples that are usually used for miRNA detection.
Methods: A novel RT-qPCR miRNA assay (UQmiR, universally quantitat-
ing miRNA) was developed to overcome the difﬁculty. This assay requires
only one RT reaction and one universal set of multiple hydrolysis probes to
detect all miRNAs, using one universal RT primer, a common reverse primer,
and individual miRNA-speciﬁc forward primers. A computer program
(MSPPD, miRNA-speciﬁc primer and probe designer) was developed for
the assay.
Results: The UQmiR has the advantages, but not the disadvantages, of the 2
mostly used miRNA assays. It has the speciﬁcity of hydrolysis probe assay
and the universal detection of SYBR Green assay. This assay is more
sensitive and speciﬁc than the commercially available hydrolysis probe assay
and SYBR Green assay. Using this method, we have successfully detected 91
out of 96 miRNAs in 0.8 mL of plasma for each miRNA.
Conclusions: This approach affords a highly speciﬁc, sensitive, economical
and convenient system to proﬁle the expression of all known miRNAs.
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Caspase-4 Plays a Role in the Activation of the Cryopyrin/
NLRP3 Inﬂammasome
Ruan Cox, Jr,1 Salman Aljubran, MD,2 Richard F. Lockey, MD,3
and Narasaiah Kolliputi, PhD,1,4. 1Internal Medicine, and; 2Allergy and Im-
munology, University of South Florida, Tampa, FL; 3Division of Allergy &
Immunology, University of South Florida and James A. Haley Veterans’
Hospital, Tampa, FL; 4Division of Allergy and Immunology.
Background: The inﬂammasome is a multi-protein complex which regulates
the activation of caspase-1. This activation results in the cleavage and
secretion of the IL-1b super family cytokines, IL-1b, IL-18, and IL-33. NLR
family-pyrin domain containing- 3 (NLRP3) is a nucleotide binding domain-
leucine rich repeat (NLR) family protein responsible for sensitization and
oligomerization of the NLRP3 inﬂammasome complex. Although various
damage and pathogen associated patterns have been implicated as stimuli,
the exact mechanism of activation has yet to be elucidated. Capase-5, an
inﬂammatory caspase with similar homology to caspase-1, is a key molecule
activation of the NLRP1 inﬂammasome. Caspase-4, an evolutionary duplicate
in humans to murine caspase 12 along with caspase 5, is important in IL-1b
processing; its involvement with the NLRP3 inﬂammasome is unknown. We
therefore investigated whether caspase-4 plays a role in the activation of the
NLRP3 inﬂammasome.
Methods: Inﬂammasomes in THP-1 macrophages were activated using
Nigericin (10 mg/mL), a bacterial pore causing toxin and NLRP3 inﬂamma-
some activator, in the presence or absence of various concentrations (0.1 mM,
1 mM, and 10 mM) of caspase-4 inhibitor, Z-YVAD-FMK. We analyzed the
inﬂammasome activation, caspase-1 cleavage, and IL-1b release by western
blot and ELISA analysis.
Results: Our results indicate that inhibition of caspase-4 leads to a dose
dependant decrease in IL-1b secretion. In addition, our results show that
caspase-4 contributes to IL-1b and caspase-1 cleavage, both of which are
hall marks of inﬂammasome activation.
Conclusions: These ﬁndings suggest that caspase-4 is important to the
activation of the NLRP3 inﬂammasome. In modulating the inﬂammasome,
caspase-4 appears to be a druggable target for treatment of chronic
inﬂammatory pulmonary conditions such as allergy and asthma.
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Genome-Wide Association Studies of Asthma Indicate Opposite
Immunopathogenesis Direction From Autoimmune Diseases
Xingnan Li, PhD, MS,1 Elizabeth Ampleford, PhD,1 Timothy Howard,
PhD,1 Dara Torgerson, PhD,2 Huashi Li, MS,1 Wendy Moore, MD,1
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search Institute, Cleveland, OH; 6Department of Pediatrics, Emory Univer-
sity School of Medicine, Atlanta, GA; 7Department of Pediatrics, University
of Virginia Health Systems, Charlottesville, VA; 8Brigham & Women’s Hos-
pital, Harvard University, Boston, MA; 9Departments of Medicine and Public
Health Sciences, University of Wisconsin Hospitals and Clinics, Madison,
WI; 10Medicine, University of Pittsburgh, Pittsburgh, PA.
Background: Genome-wide association studies (GWAS) of asthma and
asthma-related traits, including our previous TENOR study1, have consis-
tently identiﬁed ORMDL3-GSDMB, IL33, IL1RL1-IL18R1, RAD50-IL13,
TSLP-WDR36, and HLA-DR/DQ regions.2
Methods: In this study, GWAS of asthma was performed in non-Hispanic
white population from STAMPEED study (813 cases and 1564 controls). Our
GWAS results were compared with the published GWAS of asthma and
autoimmune diseases (AD).
Results: Multiple SNPs in TNFAIP3 interacting protein 1 (TNIP1) on chromo-
some 5q32-q33.1 were associated with asthma in STAMPEED: rs1422673 (P¼
3.44 · 1027) and rs10036748 (P ¼ 1.41 · 1026). rs1422673 was weakly
associated with asthma in the published GABRIEL study (P ¼ 0.018 for
meta-analysis)2 but not in the TENOR study (P ¼ 0.18 but same trend).1 TNIP1
may interact with TNFAIP3 and inhibit TNFa-induced NFkB inﬂammation
pathway. Joint analyses were performed on 6 SNPs in GSDMB (rs2872507),
IL33 (rs3939286), IL1RL1 (rs13431828), IL13 (rs20541), TSLP (rs1837253),
and HLA-DRA (rs2395185) in STAMPEED and TENOR populations, but only
limited variance can be explained (percentage of deviance¼ 1.5–1.9%; the area
under the receiver operating characteristic curve (AUC) ¼ 0.58–0.59). Minor
allele T of rs20541 in IL13 is the risk allele for asthma but the protective allele
for psoriasis. Minor allele A of rs2872507 in GSDMB is the protective allele for
asthma but the risk allele for rheumatoid arthritis, Crohn’s disease and ulcerative
colitis. T allele of rs10036748 in TNIP1 is the minor protective allele for asthma,
but the minor or major risk allele for systemic lupus erythematosus in non-
Hispanic white or Chinese population, respectively.
Conclusions: Our study provides genetic evidence that asthma and AD have
opposite immunopathogenesis directions.
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Allergy is an Epithelial Barrier Disease
Risto Renkonen, MD. Transplantation Laboratory & Infection Biology Re-
search Program, University of Helsinki & Helsinki University Central Hos-
pital, Helsinki, Finland.
Background: The purpose of this study is to explore the role of epithelium in
acute allergic diseases.
Methods: Birch pollen allergic patients and healthy control subjects were
recruited. In vivo nasal pollen challenges were performed and nasal epithelial
specimens were collected. A systems biology approach using a wealth of
methods, including several microscopy techniques (light, confocal, immuno
transmission electron [TEM]), transcriptomics (chips and massive parallel
sequencing), mass spectrometry, immunohistology, in silico analyses were
used.
Results: Already 1 minute after the birch pollen perturbation Bet v 1 was
found both on cell surfaces as well as within villae, in cytoplasm, in
intracellular vesicles, and also in nuclei of epithelial cells in allergic patients,
but not in the healthy individuals. Anti-Bet v 1 stainings in conjunctival
biopsies supported a very rapid trafﬁc through the epithelium in allergic
patients, but not in healthy subjects. A striking speciﬁcity is observed when
birch pollen allergic subjects were also challenged with timothy grass pollen
and no entry of this pollen allergen Phl p 1 into epithelial cells was detected.
While the speciﬁc transport mechanism for birch pollen remains unsolved the
ﬁrst hints of the role of caveolae in this have been obtained. In the double
immunoTEM analyses caveolin 2, but not caveolin 1 or 3, was present on the
conjunctival epithelial surface in the same clusters as Bet v 1. Transcriptomics
indicated that the health epithelium displayed a strong immune response
against pollen allergens while this response was absent in the epithelium of
allergic patients.
Conclusions: Active transport of allergens through the epithelium might be
incorporated to the pathogenesis of allergy. It is possible that the healthy
epithelium displays a strong immune response against pollen allergens and thus
escapes from becoming allergic. If allergy turns out to be, at least in part, a result
of epithelial hyposensitivity, it could have major consequences in the strategies
of prevention and treatment of these diseases. Towards this end, a national
allergy program has been launched in Finland, which changes the basic idea of
trying to avoid allergens to the concept of natural exposure and tolerance.
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EGCG Downregulates Mucin Gene Expression Through the
Mapk Signaling Pathway in Asthma
Yong-Dae Kim, Sang Baik Ye, Chang Hoon Bae, and Si-Youn Song.
Yeungnam University College of Medicine, Daegu, South Korea.
Background: Mucus plays an important role in protecting human airway
from external environments. Highly glycosylated mucin proteins are the
major components of mucus, responsible for its viscoelastic properties.
Excessive mucus is major manifestation of inﬂammatory respiratory diseases.
Epigallocatechin-3-gallate (EGCG) is major component of green tea extract
and known to provide numerous functions, such as anti-oxidant effect, anti-
tumor effect, anti-diabetic effect and anti-inﬂammatory effect. But precise
mechanisms are still unclear.
Methods: Using NCI-H292 human airway epithelial cells, we measured
phorbol 12-myrisate 13-acetate (PMA)-induced MUC5B mRNA expression
with the treatment of indicated doses of EGCG. We also measured PMA-
induced MUC5B protein secretion with the treatment of indicated doses of
EGCG using ELISA technique in NCI-H292 cells. To test the brief signaling
pathways, we performed activation study of mitogen-activated protein kinase
(MAPK) pathways, which is well-known to signaling the PMA-induced
mucin gene over-expression, using Western blot technique in NCI-H292
cells. And then we performed in vivo study using ovalbumin-induced
asthmatic mice model and control mice group. In ovalbumin-sensitized
asthmatic mice model, EGCG was treated with indicated dose. And then
ovalbumin was challenged and we sacriﬁced the mice. Tissue samples from
the mice were stained with PAS (periodic acid-Schiff) for mucin distribution
in bronchioles of each group. Immunocytochemical stain was performed
using MUC5B speciﬁc antibody. MUC5B mRNA and protein level was
measured using extracted lung tissues.
Results: PMA-induced MUC5B mRNA and protein level was signiﬁcantly
decreased after treatment of EGCG at all doses in NCI-H292 cells. PMA-
induced phosphorylation of p38 MAPK was signiﬁcantly decreased after
treatment of EGCG at all doses in NCI-H292 cells. Results from in vivo
studies showed that decreased bronchiolar mucin distribution in the group of
pretreated with EGCG in asthmatic mice. MUC5B mRNA and protein levels
were signiﬁcantly decreased in the group of pretreated with EGCG in
asthmatic mice.
Conclusions: PMA-induced MUC5B mRNA and protein over-expression
in both NCI-H292 cells and extracted tissues from asthmatic mice were
signiﬁcantly decreased with the treatment of EGCG. We demonstrated that
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EGCG downregulates mucin gene expression through the MAPK signaling
pathway in asthma.
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Enhancer of Zeste Homolog 2: A Pivotal Role in Pulmonary
Artery Smooth Muscle Cell Proliferation
Salman Aljubran, MD,1 Ruan Cox,2 Prasanna Tamarapu Parthasarathy, 3
Richard F. Lockey, MD,4 and Narasaiah Kolliputi, PhD,2,5. 1Allergy and
Immunology, University of South Florida, Tampa, FL; 2Internal Medicine,
University of South Florida, Tampa, FL; 3University of South Florida,
Tampa, FL; 4Division of Allergy & Immunology, University of South Florida
and James A. Haley Veterans’ Hospital, Tampa, FL; 5Division of Allergy and
Immunology.
Background: Pulmonary arterial hypertension (PAH) is a progressive and
a devastating disease characterized by excessive proliferation of pulmonary
artery smooth muscle cells (PASMCs). The pathogenesis of PAH is not fully
understood and treatment options are limited. Studies suggest that PAH and
cancers share apoptosis resistant state featuring excessive cell proliferation.
Proliferation of cancer cells is mediated by increased expression of Enhancer
of Zeste Homolog 2 (EZH2), a mammalian histone methyltransferase that
contributes to the epigenetic silencing of target genes. However, the role of
EZH2 in PAH has not been studied. In this study, we hypothesized that EZH2
could play a role in PASMCs proliferation.
Methods: In the present study the effects of EZH2 overexpression on human
PASMCs proliferation were tested. PASMCs were transfected with wild type
EZH2 cDNA or GFP using the Lonza 4D nucleofector system. After transfection,
cells were incubated for 48 hours at 378C. PASMCs proliferation and cell cycle
analysis were performed by ﬂow cytometry; PASMCs apoptosis was determined
using annexin V staining, and cell migration was tested by the wound healing
assay. Expression levels of EZH2 were conﬁrmed by real time PCR.
Results: The overexpression of EZH2 in PASMCs enhances proliferation,
migration, and decreases the rate of apoptosis when compared to GFP trans-
fected cells. There was a 3.5-fold increase in proliferation and a 1.5-fold increase
in the percentage of cells in the G2/M phase in the EZH2 transfected cells while
there was a signiﬁcant decrease in the rate of apoptosis in the PASMCs.
Conclusions: These ﬁndings suggest that EZH2 plays a role in the migration
and proliferation of PASMCs .It also suggest that EZH2 could play a role in
PAH development and serve as a potential target for new therapies for PAH.
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The Features of Airway Remodeling Are More Severe in
Female Mice
Masahide Takeda, MD, PhD, Wataru Ito,MD, PhD, Shigeharu Ueki,MD, PhD,
Hiroyuki Hirasawa,PhD, Miyoshi Fujita, PhD, Yasunori Konno,Mami Chihara,
MD, Masamichi Itoga,MD, Yuki Moritoki, MD, PhD, Yoshiki Kobayashi,MD,
PhD, Hiroyuki Kayaba,MD, PhD, and Junichi Chihara,MD, PhD. Department
of Infection, Allergy, Clinical Immunology and Laboratory Medicine, Akita
University Graduate School of Medicine, Akita, Japan.
Background: Epidemiological studies have already shown that females are
dominant in terms of the sex ratio of adult asthma prevalence and severe
asthma. It has also been reported that female mice are more susceptible to the
development of allergic airway inﬂammation and airway hyperresponsiveness
(AHR) than males. However, there have been few reports of studies on sex
difference in the pathogenesis of severe asthma, especially airway remodeling
in an animal model. In this study, we investigated sex difference in formation
of airway remodeling using a long-term antigen challenged asthma model.
Methods: Following ovalbumin (OVA)/alum intraperitoneal injection, male
or female mice (BALB/c) were challenged with aerosolized 1% OVA on 3
days/week for 5 weeks, and we investigated the sex difference in AHR,
airway inﬂammation, as well as airway remodeling.
Results: In OVA-sensitized and -challenged (OVA/OVA) female mice, AHR,
the number of eosinophils and lymphocytes, as well as Th2 cytokines and
growth factors in BAL ﬂuid were increased compared with OVA/OVA male
mice. On the other hand, there is no signiﬁcant difference in the level of eotaxin
in BAL ﬂuid. The histological features of airway remodeling, including goblet
cell hyperplasia, subepithelial ﬁbrosis and myoﬁbroblast hypertrophy, were also
increased in OVA/OVA female mice. Moreover, serum total and OVA-speciﬁc
IgE were signiﬁcantly elevated in OVA/OVA female mice.
Conclusions: These results indicate that female mice are dominant in terms
of forming airway remodeling as compared with male mice. The involvement
of sex difference for sensitization and growth factor release in lung tissue
based on inﬂammatory cell inﬁltration is indicated for the mechanism of sex
difference of airway remodeling.
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Ovalbumin-induced Bronchial Asthma is Compromised in
Apoptosis Signal-Regulating Kinase-Deﬁcient Mice
Junichiro Mizuguchi, MD, PhD,1 Masae Furuhata,1 Hidenori Ichijo, PhD,2
and Eiko Takada, PhD1. 1Immunology, Tokyo Medical University, Tokyo,
Japan; 2Laboratory of Cell Signaling, University of Tokyo, Tokyo, Japan.
Background: Apoptosis signal-regulating kinase 1 (ASK1), a member of
mitogen –activated protein (MAP) kinase kinase kinases (MAP3Ks) protein
family, plays a crucial role in the induction of apoptosis and inﬂammation in
some cell types. Allergic asthma is a chronic inﬂammatory airway disease
characterized by airway hyperresponsiveness (AHR), inﬂammatory cell in-
ﬁltration, and airway remodeling. In the present study, we examined whether
ASK1 is involved in the induction of bronchial asthma using a mouse model
of airway inﬂammation.
Methods: ASK1-deﬁcient (ASK12/2) and wild-type (WT) control mice
were sensitized with ovalbumin (OVA) in saline intraperitoneally on consec-
utive 7 days. Eighteen days later, mice received intranasal administration of
OVA aerosol and were assayed for AHR, cytokine production, cell prolifer-
ation, antibody (Ab) production, and lung tissue histopathology at 24 hours
after the last serial OVA administration. Levels of Ab and cytokines were
determined by enzyme-linked immunosorbent assay (ELISA).
Results: Control WT mice showed inﬂammatory inﬁltrates in airways in
response to OVA to a greater extent than ASK12/2 mice. The number of
cells, especially eosinophils accumulating in airways, was reduced in
ASK12/2 mice relative to control mice. OVA-induced AHR is also com-
promised in ASK12/2 mice. Anti-OVA IgE Ab production in ASK12/2
mice was substantially reduced, although levels of other isotypes were com-
parable to those in control mice. Levels of some Th2 cytokines (IL-5 and IL-
13) and pro-inﬂammatory cytokine TNF-a in BAL ﬂuid from ASK12/2
mice were substantially diminished relative to control, although a comparable
level of a typical Th2 cytokine IL-4 and anti-inﬂammatory cytokine IL-10
was produced. Although the BAL ﬂuid TNF-a levels from ASK12/2 mice
were severely diminished, lymph node cells from ASK12/2 mice produced
comparable levels of TNF-a to WT in vitro. Intranasal administration of
recombinant TNF-a caused a comparable increase in AHR between
ASK12/2 and WT mice, whereas the TNF-a -induced accumulation of in-
ﬂammatory cells was severely reduced in ASK12/2 mice.
Conclusions: ASK1 appears to be involved in the induction of OVA-induced
bronchial asthma, probably through cytokine production such as TNF-a and IL-
13. Moreover, TNF-a sensitivity in response to OVA is also regulated by ASK1.
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Role of the CC2Chemokine Receptor CCR9 in the Regulation of
Inﬂammatory Process During Allergic Airway Inﬂammation
Cynthia López-Pacheco, MD,1 Gisela Du Pont,1 Marc-André Wurbel, PhD,2
Teresa Fortoul, PhD,3 Gloria Soldevila, PhD,1 and Eduardo García-Zepeda,
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Background: Airway eosinophilia and Th2 lymphocytes-recruitment to the
lung are one of the main pathological features of asthma. It is clear now that
the axis chemokine/chemokine receptors have a role in controlling leukocyte
recruitment and development of the inﬂammatory process observed in
asthma. Although it has been reported that CCR9 receptor is expressed in
asthmatic patients, it is not known whether CCR9 may have a regulatory role
of the development of this disease. Our aim was to analyze the expression of
CCR9 in a murine model of allergic airway inﬂammation (WT) and compared
to CCR9 deﬁcient (KO) mice.
Methods: Four groups of 6 to 8 weeks female CCR9-deﬁcient mice were
sensitized by intraperitoneal injections of 10 micrograms of ovalbumin
(OVA) in alum (ALOH3) diluted in PBS, on days 1 and 8 of the established
sensitization protocol. Aerosolised OVA was administered (1% in PBS) on
days 15, 20 and 34. 24 hours after last OVA exposure, mice were sacriﬁced
and bronchoalveolar lavage (BAL) ﬂuid and cells were obtained. Total and
differential cell numbers were obtained and characterized cell subpopulations
by FACS analysis. Cytokine/chemokine levels were quantiﬁed by ELISA and
qRT-PCR respectively.
Results: Total cell numbers in BAL were no signiﬁcantly different between
WT and KO mice. Interestingly, reduction in the numbers of eosinophils was
observed in CCR9 KO mice compared to WT mice. Histological analysis of
lung tissue demonstrated a reduction in the granulocytic population
(eosinophils) in CCR9 KO mice. Analysis of cell subpopulations by FACS
demonstrated that CD41 lymphocytes were signiﬁcantly reduced but CD81
and CD191 lymphocytes numbers were not different between WT and
CCR9-deﬁcient mice. A population of CCR91 Gr11 was altered in KO
mice and it correlated with cytological analysis. Furthermore, histological
analysis demonstrated alteration in mucus production in allergic airway in
CCR9 deﬁcient mice, accompanied with a no-signiﬁcant reduction of OVA-
speciﬁc anti-IgE antibodies in serum at the time of analysis.
Conclusions: Altogether, these results suggest that CCR9 may be involved in
recruitment of granulocytic cell subpopulation into the allergic airways and
have an impact in the regulation of the chronic inﬂammatory process.
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Serum IL6 and Soluble IL6RAreCorrelatedWithLung Function
in Non-Hispanic Whites with Asthma
Gregory Hawkins, PhD,1 Mac Robinson, PhD,2 Wendy Moore, MD,1
Annette Hastie, PhD,2 Rodolfo Pascual, MD,2 Stephen P. Peters, MD,
PhD,3 Deborah Meyers, PhD,2 and Eugene R. Bleecker, MD2. 1Center for
Genomics and Personalized Medicine Research, Wake Forest University
School of Medicine, Winston Salem, NC; 2Center for Genomics and Person-
alized Medicine Research, Wake Forest School of Medicine, Winston Salem,
NC; 3Center for Genomics and Personalized Medicine Research, Wake For-
est University Health Sciences, Winston-Salem, NC.
Background: Interleukin 6 (IL6) belongs to a family of cytokines with both
pro- and anti-inﬂammatory properties. The functional relationship between
IL6 signaling and airway disease has not be well characterized; however, IL6
expression is increased during lung inﬂammation and injury. In this study,
serum IL6 and soluble IL6R levels were assessed in non-Hispanic whites with
asthma from the Severe Asthma Research Program. Correlations between
serum IL6 and IL6R levels, lung function, phenotypic asthma clusters, and
asthma severity were evaluated.
Methods: Serum IL6 and soluble IL6R was measured in 149 subjects with
mild to severe asthma. Serum sIL6R levels were measured using the sIL-6R
DuoSet (R&D Systems, Minneapolis, MN) ELISA kit and reported as ng/ml.
Serum IL6 measurements were determined using the IL-6 ELISA kit (R&D
Systems, Minneapolis, MN) and reported as pg/ml. Serum IL6 and sIL6R
measurements were transformed to normalize distribution. The continuous
variables analyzed included: % predicted FEV1 [ppFEV1], % predicted
FVC [ppFVC], and FEV1/FVC. Serum samples were collected at Wake
Forest. Phenotypic asthma clusters were derived as previously described
(Am J Respir Crit Care Med. 2010;181:315–323).
Results: Elevated serum IL6 was associated with lower ppFEV1 (P ¼ 0.02)
and lower ppFVC (P ¼ 0.003), while elevated serum soluble IL6R was
associated with lower ppFEV1 (P ¼ 0.02) and lower ppFVC (P ¼ 0.008).
Increasing trends in serum IL6 were observed in atopic asthma Clusters 2 and
4 and the later onset ﬁxed airways obstruction Cluster 5. The highest IL6
serum levels were observed in Cluster 3 characterized has having late onset
asthma and elevated BMI. Serum IL6 levels were elevated in subjects with
severe asthma (log IL6 ¼ 0.33; N ¼ 25) compared to subjects with mild/
moderate asthma (log IL6 ¼ 0.16; N ¼ 69).
Conclusions: Serum IL6 and sIL6R levels are elevated in non-Hispanic white
asthma subjects with lower lung function. Serum IL6 and sIL6R are
potentially important biomarkers that may distinguish between non-severe
and severe asthma and between atopic asthma Clusters.
MECHANISMS OF ASTHMA AND ALLERGIC
INFLAMMATION
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Heterogeneity of Allergen Epitope-speciﬁc CD41 T Cells
Responses: Steps Toward Optimal Composition for
Peptide-based Immunotherapy
Erik Wambre, PhD,1 Jonathan Delong, BS,1 Eddie James, PhD,1 Nadia Torres-
Chinn,1 David Robinson, MD,2 and William Kwok, PhD1. 1Immunology,
Benaroya Research Institute at Virginia Mason, Seattle, WA; 2Asthma,
Allergy and Clinical Immunology, Virginia Mason Medical Center,
Seattle, WA.
Background: Peptide-based allergen immunotherapy is a promising alterna-
tive to conventional allergy vaccine. However, the optimal composition of
such vaccines, in terms of the choice of the appropriate peptides, has
remained unclear. Knowledge of the epitope-speciﬁc T cell responses to
allergens can give important information on the pathogenesis and regulation
of allergic inﬂammation. In this study we sought to identify candidate
allergen-epitopes that can be used to improve peptide-based allergen
immunotherapy.
Methods: Tetramer Guided Epitope Mapping was ﬁrst used to identify
CD41 T cell epitopes for group 1 and group 5 timothy grass pollen allergens.
MHC class II tetramer technology was then used in an ex vivo approach to
assess the grass pollen-speciﬁc CD41 T cell responses in allergic and non-
allergic individuals. The frequency, surface marker phenotype and cytokine
proﬁle of these cells were directly analysed by ﬂow cytometry.
Results: CD41 T cell responses to Timothy grass allergens are directed to
a broad range of epitopes characterized by deﬁned immunodominance hier-
archy patterns. We observed heterogeneity of phenotype within the allergen-
speciﬁc CD41 T cells that depends on the epitope for which the cells are
speciﬁc. T cell epitopes associated with production of IL-10 or IFN-g are
recognized at low frequencies in both allergic and healthy individuals. In
contrast, allergy-associated epitopes are only recognized in allergic individ-
uals by high frequency, terminally differentiated allergen-speciﬁc CD41 T
cells, which are susceptible to deletion by repeated stimulation with high
doses of antigen. Allergen-speciﬁc immunotherapy caused signiﬁcant
changes in the epitopes hierarchy of the grass pollen allergen-speciﬁc mem-
ory CD4 T cell pool.
Conclusions: The ability to evaluate epitope-speciﬁc T cell responses to
allergens can give important information on the pathogenesis and regulation
of allergic inﬂammation and could be of great use in designing peptide-based
allergy vaccination strategies. Some epitopes may play a prominent role in
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driving a protective response, while others may directly impair the pathogenic
response.
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The Association betweenMast Cells andRemodelling of the Small
Airways in Chronic Asthma
Kenneth Snibson, PhD, and Joanne Van der Velden,. Veterinary Science,
University of Melbourne, Parkville, Australia.
Background: Repeated airway challenges with House Dust Mite (HDM)
allergen results in marked remodelling and mast cell hyperplasia in the
small airways of allergic sheep. We now examine mast cell activation and
its association with small airway function and remodelling in these sheep
using a novel segmental allergen challenge approach.
Methods: Eight allergic sheep received weekly intra-lung challenges of
HDM to the left caudal lung for 24 weeks. Eight separate sheep were used as
controls. Baseline lung function was assessed in the left caudal segments of
all sheep throughout the challenge regime using a wedged-bronchoscope
technique. Airway tissue was collected from challenged segments from all
sheep, 7 days following the ﬁnal intra-lung challenge. The airway tissues
were immunohistochemically labelled for chymase-mast cells and eosino-
phils. Collagen and airway smooth muscle content were assessed on
Masson’s Trichrome stained sections.
Results: Resting lung function in the left caudal segment is elevated in 4 out
of 8 sheep at the end of the repeated allergen challenge regime. Chymase mast
cell density was signiﬁcantly increased in the small bronchial walls of the
HDM-challenged group compared to the control group (526 8 vs 86 4; P,
0.01). There were signiﬁcant increases in bronchial collagen deposition in
HDM-exposed segments compared to control segments (0.17 6 0.02 vs 0.11
6 0.02 mm2/BM, P , 0.05). A correlation analysis of individual sheep data
showed that there was a trend for a direct association between the increases in
bronchial collagen deposition and the density of chymase-labelled mast cells
(rs ¼ 0.71, P ¼ 0.088). Eosinophil density in the small bronchial walls of
HDM-challenged segments was also signiﬁcantly increased compared to con-
trols (65 6 19 vs 11 6 3 cells/mm2, P , 0.001), but not associated with
collagen content. The bronchial smooth muscle content was not different
between HDM-challenged and unexposed control segments.
Conclusions: The results show that repeated exposure to allergen results in
signiﬁcant increases in density of chymase-labelled mast cells, together with
increased levels of collagen content in the small airways. The segmental
challenge protocol allows for a novel approach to characterise the progressive
remodelling events occurring in the small airways in chronic asthma.
126
Creation of a Humanized Model for Respiratory Allergy Using
a Human Mugwort-speciﬁcT-Cell Receptor and HLA-DR1
Alina Neunkirchner, MSc,1,2 Lukas Mager, MD,2 Victoria Reichl, PhD,1,2
Klaus Schmetterer, MD,2 Daniela Haiderer, MSc,2 Edward Rosloniec, PhD,3
Ronald Naumann, MSc,4 Beatrice Jahn-Schmid, PhD,5 Barbara Bohle,
PhD,1,5 and Winfried F. Pickl, MD,1,2. 1Christian Doppler Laboratory for
Immunomodulation, Vienna, Austria; 2Institute of Immunology, Medical Uni-
versity of Vienna, Vienna, Austria; 3Veterans Affairs Medical Center, Mem-
phis, TN; 4Max Planck Institute for Molecular Cell Biology and Genetics,
Dresden, Germany; 5Department of Pathophysiology and Allergy Research,
Medical University of Vienna, Vienna, Austria.
Background: Currently, T cell receptor (TCR) transgenic (tg) mice with
a murine TCR speciﬁc for chicken ovalbumin in the context of a murine
restriction element (I-Ad) are frequently used in allergy research to investigate
T helper cell differentiation and allergy treatment in vivo.
Methods: We here aimed to generate double tg mice expressing a human
TCR speciﬁc for the immuno-dominant epitope of the major mugwort
(Artemisia vulgaris) pollen allergen Art v 1 in the context of the human
restriction element HLA-DR1 to provide a valid model for studying allergy
development and treatment in vivo. To obtain high expression levels the
allergen-speciﬁc human TCR variable sequences were chimerized with mu-
rine TCR constant sequences. Resulting transgenes were cloned into the
pTcass vector system and thus put under the transcriptional control of the
natural TCR alpha and beta promotor/enhancer elements. Allergen-speciﬁc
TCR tg founder mice were cross-bread with HLA-DR11 B10.M-DR1dlAb1-Ea
mice.
Results: Immunophenotyping of double tg TCR/HLA-DR1 mice revealed
clear-cut expression of the Art v 1-speciﬁc TRBV18 chain on peripheral
blood CD31 T lymphocytes and HLA-DR1 expression on CD141 monocytes
and B2201 B lymphocytes. In vitro, splenocytes from TCR/HLA-DR1 dou-
ble tg mice but not of HLA-DR1 single tg mice or wt mice speciﬁcally
proliferated upon incubation with the human-relevant immuno-dominant
Art v 125 to 36 peptide or whole Art v 1 protein. No proliferation was observed
upon incubation with control peptides or proteins. Allergen-speciﬁc cellular
proliferation is accompanied by the production of a balanced cytokine milieu
including IFN-gamma, IL-2, IL-4, IL-6, IL-13 and IL-17 (.50 pg/mL per 2 ·
105 splenocytes). No cytokine secretion was evident upon incubation of
splenocytes with a control peptide or medium alone. Importantly, double tg
mice are proﬁcient to mount both IgG2a and IgG1, IgE responses when i.p.
immunized with antigen plus alum.
Conclusions: A fully humanized allergy model, in which all components of
the allergen-speciﬁc synapse are well-deﬁned enables to analyze the relevant
T-cell dependent (and independent) pathways by which allergic diseases can
be inﬂuenced in vivo and will provide important insights into the
pathophysiology of allergic diseases and their possible cure in the future.
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Eosinophils Enhance Airway Smooth Muscle Cell Proliferation
Via the Release of Cysteinyl Leukotrines
Rabih Halwani, MSc, Ph.D,1 Saleh Al-Muhsen, MD, FRCPC, FAAP,2
Ahmed Bahammam, MD,1 Hamdan Al-Jahdali, MD, FRCPC, FCCP,3
and Qutayba Hamid, MD, PhD4. 1Prince Naif Center for Immunological
Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia;
2Prince Naif Center for Immunology Research, Department of Pediatrics,
College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3King
Saud University for Health Sciences, Riyadh, Saudi Arabia; 4McGill Univer-
sity, Meakins-Christie Laboratories, Montreal, QC, Canada.
Background: Asthma is a chronic inﬂammatory disorder of the lung airways
that is associated with airway remodeling and hyperresponsiveness. Its is well
documented that the smooth muscle mass in asthmatic airways is increased
due to hypertrophy and hyperplasia of the ASM cells. Moreover, eosinophils
have been proposed in different studies to play a major role in airway
remodeling. Here, we hypothesized that eosinophils modulate the airways
through enhancing ASM cell proliferation. The aim of this study is to
examine the effect of eosinophils on ASM cell proliferation using eosinophils
isolated from asthmatic and normal control subjects.
Methods: Eosinophils were isolated from peripheral blood of 6 mild
asthmatics and 6 normal control subjects. ASM cells were incubated with
eosinophils or eosinophil membranes and ASM proliferation was estimated
using thymidine incorporation. The mRNA expression of extracellular matrix
(ECM) in ASM cells was measured using quantitative real-time PCR. The
effect of eosinophil-derived proliferative cytokines on ASM cells was
determined using neutralizing antibodies. The role of eosinophil derived
Cysteinyl Leukotrienes in enhancing ASM was also investigated.
Results: Co-culture with eosinophils signiﬁcantly increased ASM cell
proliferation. However, there was no signiﬁcant difference in ASM pro-
liferation following incubation with eosinophils from asthmatic versus normal
control subjects. Co-culture with eosinophil membranes had no effect on
ASM proliferation. Moreover, there was no signiﬁcant change in the mRNA
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expression of ECM proteins in ASM cells following co-culture with
eosinophils when compared with medium alone. Interestingly, blocking the
activity of cysteinyl Leukotries using antagonists inhibited eosinophil-derived
ASM proliferation.
Conclusions: Eosinophils enhances the proliferation of ASM cells. This role
of eosinophil does not seem to depend on ASM derived ECM proteins nor on
Eosinophil derived TGF-b or TNF-a. Eosinophil seems to induce ASM pro-
liferation via the secretion of Cysteinyl Leukotrienes.
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Colour Change in the Human Histamine Wheal; a Sign of
Desensitized Histamine Vasoconstrictory Receptors
Lars Malm, MD, PhD. Clinical Science, Lund University, Lund, Sweden.
Background: The aim was to ﬁnd the cause and consequences of a colour
change in histamine wheals found after ordinary histamine skin prick tests
(SPTs) (10 mg/mL). A rapid change to a darker red colour from the 18th and
to the 20th minute has been demonstrated by using a digital image-processing
technique called LYYN and ImageJ to yield numerical values.1
Methods: Repeated histamine SPTs in the middle of the site for earlier
performed histamine SPTs in humans. Calculations of the sizes of photo-
graphed wheals. Histamine solutions perfused in isolated rabbit ears.
Results: Histamine SPT performed 90 minutes or 6 hours apart from initial
histamine SPTs evoked a ring of wheal peripherally around the site of the
initial wheal or no wheal at all. The initial wheals had at those times
disappeared. Histamine perfusion in isolated rabbit ears indicated ﬁrst
vasoconstriction and after a mean of 17 minutes vasodilatation in post-
capillary vessels despite continued histamine perfusion.
Conclusions: The results indicate that total desensitization of histamine-1
receptors in the wheal is the cause of the colour change in human histamine
SPTs and that such desensitization lasts long time. If histamine released at
allergen provocations also evokes such a long-lasting desensitization and
post-capillary vasodilatation it opens new aspects on vascular events in
allergic reactions.
REFERENCE
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Involvement of the Hypoxia-Inducible Factor-1 Transcription
Complex in the Inﬂammatory Responses of Human Mast Cells
and Basophils
Inna Yasinska, PhD, Vadim Sumbayev, PhD, and Bernhard Gibbs, PhD.
Medway School of Pharmacy, University of Kent, Chatham Maritime, United
Kingdom.
Background: We recently found that hypoxia-inducible factor 1 (HIF-1)
plays a crucial role in the pro-allergic functions of human basophils by
transcriptional control of energy metabolism via glycolysis as well as directly
triggering the expression of the angiogenic cytokine vascular endothelial
growth factor (VEGF). Here, we investigated whether there is an overarching
principle of HIF-1 involvement in controlling the synthesis of angiogenic and
inﬂammatory cytokines from various human effector cells stimulated by IgE-
dependent or innate immune triggers.
Methods: LAD2 human mast cells,1 primary human basophils, and THP-1
human myeloid cells were used for investigations of FceRI and Toll-like
receptor (TLR) ligand-induced responses. Quantitative real-time PCR, West-
ern blot analysis, ELISA, ﬂuorometry, luminometry and ﬂuorescence micros-
copy were used to run the assays.
Results: In contrast to basophils, LAD2 mast cells expressed high
background levels of HIF-1a, which was largely independent of the effects
of stem cell factor (SCF).2 Both mast cells and basophils expressed TLR2 and
4, albeit weakly compared to THP-1 cells. Cytokine production in mast cells
following TLR ligand stimulation was markedly reduced by HIF-1a knock-
down in LAD2 mast cells. In contrast, although HIF-1 is involved in IgE-
mediated IL-4 secretion from basophils, it was not clearly induced by the
TLR2 ligand PGN.
Conclusions: HIF-1a accumulation is fundamentally important for sustaining
human allergic effector cell survival and function. This transcription complex
facilitates the generation of both pro-angiogenic and inﬂammatory cytokines
in mast cells but has a differential role in basophil stimulation comparing
IgE-dependent triggering with innate immune stimuli.
REFERENCES
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PATHO-BIOLOGY OF NASAL POLYPS
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Mutiplex Analyses of Cytokine and Chemokine Release From the
Cultured Fibroblast of Nasal Polyp: the Effect of IL-17A
Katsuhisa Ikeda, MD. Otorhinolaryngology, Juntendo University Faculty of
Medicine, Tokyo, Japan.
Background: Nasal polyps of chronic rhinosinusitis (CRS) are characterized
by epithelial damage, basement membrane thickness and subepithelial
ﬁbrosis. The ﬁbroblast, one of the main cell types making up nasal polyps,
is thought to be a target cell of various cytokines. The role of IL-17A in
immunoresponse in the nasal poly ﬁbroblast has not yet elucidated.
Methods: Subcultured ﬁbroblasts were established from human polyp biopsy
tissues in addition to normal mucosal membranes of sphenoid sinuses
(controls).
Results: The IL-17A receptor was expressed at similar levels in all 3 groups.
Simultaneous quantiﬁcation of 27 kinds of cytokines and chemokines in
culture supernatants was performed with a human multiplex cytokine assay
system. In the eosinophilic group, basal secretion levels of IL-6 were
signiﬁcantly higher than those in the control and non-Eo groups. Basal
secretion of MCP-1 in both the non-eosinophilic and eosinophilic groups was
also higher than that of the control group. Both IL-9 and G-CSF secretion
were remarkably enhanced by IL-17A stimulation in all 3 groups. The
receptor-mediated response by IL-17A signiﬁcantly upregulated IL-6 release
alone in the non-eosinophilic and eosinophilic groups as compared with the
control group. Only the basic FGF secretion was decreased by stimulation of
IL-17A in all groups.
Conclusions: Our results demonstrate for the ﬁrst time a potentially enhanced
secretion of IL-6 and MCP-1 from nasal polyp ﬁbroblasts, and a remarkable
upregulation of IL-9 and G-CSF from nasal ﬁbroblasts by IL-17A stimula-
tion, which might contribute to nasal polyp formation and airway remodeling.
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Expression ofChemokineReceptorsCCR1,CCR3,CCR4,CCR5,
CCR8 and CXCR3 in Human Nasal Polyps (NP); Comparison
With NP From Allergic Patients With Aspirin Intolerance
Petra Fundova, MD,1 David Funda, MD, PhD,2 Daniel Kovar, MD,1
and Helena Tlaskalova-Hogenova, MD, DSc2. 1ENT Department, Central
Military Hospital, Prague, Prague 6, Czech Republic; 2Immunology & Gno-
tobiology, Institute of Microbiology, Prague 4, Czech Republic.
Background: Inﬂammatory processes play an important role in development
of nasal polyps (NP), but the etiology and to a great degree also the
pathogenesis of NP is not known. Several cytokines and chemokines such as
eotaxin, IL-3, IL-5, IL-6, IL-8, RANTES may inﬂuence development of NP
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by regulation of migration, activation and survival of the chronic inﬂamma-
tory cellular inﬁltrate.
Methods: In this study we investigated expression of selected chemokine
receptors in human NP and non-affected human nasal mucosa and carried out
a comparison with NP from allergic patients with aspirin intolerance. Biopsies
of NP were obtained from 20 patients and 4 patients with NP and aspirin
intolerance. Mucosal biopsy specimens of the inferior turbinate were obtained
from 12 NP patients and 4 healthy controls. Using indirect imunohistochem-
istry, frozen tissue sections were stained for CCR1, CCR3, CCR4, CCR5,
CCR8 and CXCR3.
Results: Numbers of inﬁltrating cells expressing CCR3, CCR8 and to a lesser
extend also CCR1 were signiﬁcantly higher in biopsies of NP compared to
healthy nasal mucosa. Only a slight increase in CCR5 expressing cells was
detected in NP compared to nasal mucosa. No differences in expression of
CCR4 and CXCR3 were found in NP compared to nasal mucosa. There were
no signiﬁcant differences between NP of patients with or without aspirin
intolerance.
Conclusions:We documented an increased expression of selected chemokine
receptors within the cellular inﬁltrate of NP that may play an important part in
the inﬂammatory pathogenesis of NP.
Supported by grant NS10054 from the IGA MZ, Czech Republic.
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Characterization of 2 Epithelial Cell Air-Liquid Interface (ALI)
Culture Models for Human Healthy Nasal Mucosa and
Nasal Polyps
Fco de Borja Callejas,1,2 Asunción Martínez-Antón, PhD,1,2 Jordi Roca-
Ferrer, PhD,1,2 Julio Cortijo, MD, PhD,2 César Picado, MD, PhD,1,2,3
and Joaquim Mullol, MD, PhD,2,4,5,6. 1Clinical and Experimental Respira-
tory Immunoallergy, IDIBAPS, Hospital Clínic, Barcelona, Spain; 2CIBER of
Respiratory Diseases (CIBERES), Palma de Mallorca, Spain; 3Allergy Unit,
Pneumology and Allergy Department, Hospital Clínic, Barcelona, Spain;
4Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barce-
lona, Spain; 5Rhinology Unit & Smell Clinic, ENT Department, Hospital
Clínic, Barcelona, Spain; 6Rhinology Unit & Smell Clinic, ENT Department,
Hospital Clínic i Universitari, Barcelona, Spain.
Background: Primary human airway epithelial cells, when submerged in
culture, undergo a dedifferentiation with loss of many features of the in vivo
airway epithelium. However, when cultured in an air-liquid interface (ALI),
cells develop a well-differentiated, polarized, and pseudostratiﬁed epithelium.
The aim of the current study was to characterize the mucociliary differen-
tiation of human nasal mucosa and polyp epithelial cells cultured using an
ALI system.
Methods: Nasal mucosa (NM, n ¼ 3) and nasal polyps (NP, n ¼ 3) were
obtained from patients undergoing nasal corrective surgery and endoscopic
sinus surgery, respectively. Epithelial cells were obtained from the explant
method, and differentiated in ALI culture during 28 days. Cultures were
studied at different time points (0, 7, 14, 21, and 28 days): tissue ultrastructure
by scanning electron microscopy (SEM) and transmission electron micros-
copy (TEM); mucous (MUC5AC, MUC5B) and serous (lactoferrin) cell se-
cretion by ELISA; and cytokeratin 18 (epithelial marker), b-tubulin IV (cilia
marker), MUC5AC (goblet cell marker), and p63 (basal cell marker) expres-
sion by immunocytochemistry.
Results: In both NM and NP ALI cultures and at days 14 and 28,
a pseudostratiﬁed epithelium with ciliated, mucus-secreting and basal cells
was observed, and expression of cytokeratin 18, b-tubulin IV, MUC5AC and
p63 was detected. In NP cultures, both MUC5AC (day 14: 2.2 6 0.1-folds;
day 28: 3.6-fold 6 0.7-fold) and MUC5B (day 14: 3.2-fold 6 0.6-fold; day
28: 3.1-fold 6 1-fold) increased over time compared to day 0 (P , 0.05). In
NM cultures, only MUC5B (day 14: 3.9-fold 6 0.9-fold; day 28: 3.4-fold 6
0.4-fold; P , 0.05) but not MUC5AC increased over time compared to day
0 (P , 0.05). Secretion of lactoferrin was present but showed no changes
over time in either NM or NP ALI cultures.
Conclusions: Epithelial cell ALI cultures provide a well-differentiated human
nasal mucosa and polyp tissues that may be used as an in vitro model to study
mucin regulation, inﬂammatory mechanisms of upper airways, and their
regulation by antiinﬂammatory drugs.
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Corticosteroid Rreatment Reduces Tissue Eosinophilia and the
Expression of Matrix Metalloproteinases (MMP-1, MMP-2,
MMP-7, MMP-9) and Their Tissue Inhibitor (TIMP-1) in
Nasal Polyps
Fco de Borja Callejas,1,2 Asunción Martínez-Antón, PhD,1,2 Jordi Roca-
Ferrer, PhD,1,2 Isam Alobid, MD, PhD,3 César Picado, MD, PhD,1,2,4
and Joaquim Mullol, MD, PhD,2,3,5,6. 1Clinical and Experimental Respira-
tory Immunoallergy, IDIBAPS, Hospital Clínic, Barcelona, Spain; 2CIBER of
Respiratory Diseases (CIBERES), Palma de Mallorca, Spain; 3Rhinology
Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain;
4Allergy Unit, Pneumology and Allergy Department, Hospital Clínic, Barce-
lona, Spain; 5Clinical and Experimental Respiratory Immunoallergy, IDI-
BAPS, Barcelona, Spain; 6Rhinology Unit & Smell Clinic, ENT
Department, Hospital Clínic i Universitari, Barcelona, Spain.
Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors
(TIMPs) may play an important role in both inﬂammation and remodeling of
nasal polyposis. The aim of the current study was to compare the expression
levels of MMPs and TIMP-1 between nasal mucosa and polyps, and to evaluate
the effect of corticosteroid treatment in their expression in nasal polyps.
Methods: Nasal mucosa (NM, n ¼ 12) were obtained from patients under-
going nasal corrective surgery while nasal polyp biopsies (NP, n ¼ 33) were
obtained from patients before (week 0) and after 2 (week 2) and 12 (week 12)
weeks of corticoisteroid treatment (oral prednisone for 2 weeks and intranasal
budesonide for 12 weeks). Matrix metalloproteases (MMP-1, MMP-2, MMP-
7, MMP-9) and tissue inhibitor of metalloproteinases type 1 (TIMP-1) ex-
pression was evaluated by immunohistochemistry in tissue structural cells
(epithelium, glands, vessels) and eosinophils.
Results: MMP and TIMP-1 expression were found in the epithelium, glands,
vessels (in both NM and NP), and in eosinophils (only in NP). Expression of
MMP-7 in epithelium (34% of tissues) and MMP-9 (19%) in glands was
lower (P , 0.05) in NP than in NM (78 and 67%, respectively). Cortico-
isteroid treatment reduced tissue eosinophilia (Eos/5 ﬁelds) at week 2 (8.0 6
2.9, P ¼ 0.001) and week 12 (10.0 6 2.3, P , 0.003) compared to week
0 (25.5 6 8.4); and also decreased the expression of MMPs and TIMP-1 in
eosinophils at week 2 and week 12 compared to week 0 (P , 0.05). In the
epithelium, corticosteroids increased MMP-7 and TIMP-1 at week 2 and
week 12, while decreased MMP-9 at week 12 (P , 0.05). In vessels, cortico-
steroids increased MMP-9 at week 2 and decreased MMP-1 at week 12 (P ,
0.05). No effects were found in the glands.
Conclusions: Treatment of nasal polyposis with corticosteroids reduces both
tissue eosinophilia and MMP expression in eosinophils while modifying the
expression of remodeling markers in nasal polyp structural cells.
134
Expression and Localization of CYSLT2 Receptor in Human
Nasal Mucosa
Shirasaki Hideaki, MD, PhD,1 Etsuko Kanaizumi, MD, PhD,1 Manabu Fujita,
PhD,2 and Tetsuo Himi, MD, PhD1. 1Otolaryngology, Sapporo Medical
University, Sapporo, Japan; 2Minase Research Institute, Ono Pharmaceuti-
cal, Osaka, Japan.
Background: We have previously reported the localization of CysLT1
receptor by using immunohistochemistry and in situ hybridization (Shirasaki
H et al. Clin Exp Allergy. 2002;32:1007–1012).
Methods: To clarify the expression of CysLT2 receptor in human nasal
mucosa, we investigated CysLT2 receptor mRNA expression and its protein
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localization in human nasal mucosa, by polymerase chain reaction (PCR) and
immunohistochemistry.Human turbinates were obtained after turbinectomy
from 6 patients with nasal obstruction refractory to medical therapy. Total
RNA was isolated from human nasal mucosa, and CysLT2 receptor mRNA
was detected in these tissues by using reverse transcriptase-PCR analysis. To
identify the cells expressing CysLT2 receptor protein, double immunostain-
ing was performed using anti-CysLT2 receptor antibody and anti-CD31
(endothelial cell) antibody.
Results: Reverse transcriptase-PCR analysis of total nasal RNA demonstrated
the expression of CysLT2 receptor mRNA. The immunohistochemical studies
revealed that anti-CysLT2 receptor antibody mainly labeled blood vessels.
Conclusions: The results suggest a primary role for CysLT2 receptor as the
vascular responses in upper respiratory tract.
PRIMARY IMMUNODEFICIENCY
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Mycobacterial Infections in cChildren With Chronic
Granulomatous Disease
Saul Lugo-Reyes,MD,1 Lizbeth Blancas Galicia,MD,1 and Jacinta Bustamante,
MD, PhD2. 1National Institute of Pediatrics, Immunodeﬁciencies Re-
search Unit, Mexico City, Mexico; 2Laboratory of Human Genetics of
Infectious Diseases, Faculté de Médecine Necker-Enfants Malades,
Paris, France.
Background: Chronic granulomatous disease (CGD) is a rare primary
immunodeﬁciency caused by inborn errors of the phagocyte NADPH oxidase
activity. Affected patients display severe, recurrent and multiple infections
from the ﬁrst year of life onwards, in particular caused by various pyogenic
bacteria and fungi. Mycobacterial infections have more rarely been reported
in these patients.
Methods: We examined the clinical features of mycobacterial disease in 59
CGD patients from 52 kindreds in 16 countries of 4 continents. Tuberculosis
or BCG adverse reactions were identiﬁed by culture, staining, biopsy,
polymerase chain reaction (PCR), and/or by a combination of clinical criteria
with response to treatment. CGD was conﬁrmed by NBT, DHR, cytochrome
C reduction assay, or a combination of these. Genetic diagnosis was achieved
by means of immunoblotting, ﬂow cytometry, PCR and automated gene
sequencing.
Results: We found that mycobacterial infections are fairly common in
patients with CGD living in certain regions of the world. Twenty-four patients
(45%) had tuberculosis, 43 (80%) presented with adverse effects shortly after
Bacille Calmette-Guérin (BCG) vaccination; 12 of the patients (21%) had
both tuberculosis infection and BCG adverse reactions. Most patients (93%)
had also pyogenic and fungal infections; 7% of them, however, presented
solely with mycobacterial disease. Most cases were one-time self-limited
localized infections, but recurrence (13 patients, 20%), disseminated disease
(18 patients, 30%) and even death (5 patients, 8%) were observed. A recurrent
ﬁnding was early age of presentation for BCG reaction, with a median of 3
months of age; BCG disease was the ﬁrst manifestation of immunodeﬁciency
in 60% of these patients.
Conclusions: Our study offers compelling evidence for an important
susceptibility to mycobacterial diseases in patients with CGD, more easily
noticed in countries where tuberculosis is endemic and BCG vaccine
mandatory. BCG adverse reactions should raise the suspicion of CGD.
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Increased Pro-Inﬂammatory Cytokine Production After
Lipopolysaccharide Stimulation in Patients with X-
linked Agammaglobulinemia
Maria Edith Gonzalez Serrano, MD, MSc,1 Gabriela López Herrera,
PhD,1 Laura Berrón-Ruiz, PhD,1 Iris Citlali Estrada García, PhD,2
Dolores Mogica Martínez, MD,3 Sara Espinosa, MD, PhD,1 Yamazaki-
Nakashimada Marco Antonio, MD,4 Alejandro González Garay, MD,
MSc,4 Alexander Vargas Hernández, PhD,5 Leopoldo Santos Argumedo,
PhD,6 Sergio Antonio Estrada Parra, PhD,2 and Francisco Javier Espinosa
Rosales, MD, MSc4. 1Immunodeﬁciency Research Unit, National Institute of
Pediatrics, México City, Mexico; 2National School of Biological Sciences,
México City, Mexico; 3Medical Center “La Raza”, Mexican Social Security
Institute, México City, Mexico; 4National Institute of Pediatrics, México City,
Mexico; 5Center for Research and Advanced Studies, México City, Mexico;
6Department of Molecular Biomedicine, Center for Research and Advanced
Studies, México City, Mexico.
Background: X-linked agammaglobulinemia (XLA) is characterized by
impaired B-cell differentiation caused by mutations in Bruton’s tyrosine ki-
nase (Btk) gen. Btk is expressed in myeloid cells and recent evidence support
that it participates in Toll like receptor signaling, but results regarding its rol
in XLA patients are contradictories.
Objective: To evaluate lipopolysaccharide (LPS)-induced pro-inﬂammatory
cytokine response in peripheral blood mononuclear cells (PBMC) from XLA
patients.
Methods: Thirteen patients with XLA were included in the study. PBMC
LPS-induced TNF-a, IL-1b, IL-6, and IL-10 production was determined by
ELISA and compared with that obtained from matched healthy controls.
Cytokine production was correlated with the severity of the mutation, affected
domain and clinical characteristics.
Results: In response to LPS, PBMC from XLA patients produced signiﬁ-
cantly higher amounts of pro-inﬂammatory cytokines and IL-10 compared
with controls and this production is not inﬂuenced by the neither severity of
mutation or the affected domain. PBMC from patients with a history of more
hospital admissions before diagnosis and patients with lower expression of
Btk in monocytes produced higher levels of TNF-a and IL-1b, respectively.
PBMC from patients with lower IgA levels showed a higher production of
TNF-a and IL-1b. Less severe (punctual) mutations in Btk gene were asso-
ciated with higher IgG levels at diagnosis.
Conclusions: Our results demonstrated a predominantly inﬂammatory
response in XLA patients after LPS stimuli and suggest a TLR signaling
dysregulation in absence of Btk. This response may be inﬂuenced by
environmental factors.
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Hypogammaglobulinemia in a Boy: Consider Also X-linked
Lymphoproliferative Disease
Luisa Gamez, MD,1 Marco Antonio Yamazaki, MD,2 Sara Espinosa, MD,
PhD,3 Saul Lugo-Reyes, MD,4 and Victor Hernandez, MD5. 1Allergy and
Immunolgy Clinic, National Institute of Pediatrics, Mexico Distrito Federal,
Mexico; 2National Institute of Pediatrics, Mexico D.F., Mexico; 3Immunode-
ﬁciency Research Unit, and; 4Allergy & Clinical Immunology, National In-
stitute of Pediatrics, Mexico City, Mexico; 5National Institute of Pediatrics,
Mexico City, Mexico.
Background: X-linked lymphoproliferative disease (XLP) is a primary
immunodeﬁciency presenting with a variety of clinical manifestations, the
most common being dysgammaglobulinemia and B-cell lymphoma. The ﬁrst
gene causing XLP, when defective, was termed SH2D1A or SAP for signaling
lymphocyte activation molecule (SLAM)-associated protein. The absence of
SH2D1A leads to an overwhelming and uncontrolled TH1- shifted cytotoxic
immune response, which might, at least in part, explain the severe clinical
picture. A second gene, XIAP (X-linked inhibitor of apoptosis), was later
identiﬁed.
Methods: An 8 year old Mexican boy was admitted in June 2008 for
bronchopneumonia, with no previous history of recurrent or severe infections.
He had a family history of a brother deceased at 7 years from fulminate
hepatitis, who was diagnosed with agammaglobulinemia. A laboratory
evaluation for primary immunodeﬁciency was made, including serum
immunoglobulins: IgG 30 mg/dL, IgA ,5 mg/dL IgM 8.6 mg/dL; and ﬂow
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citometry for lymphocyte subpopulations: CD31 2590 mm3 (56%) CD41
1004 mm3 (42%), CD81 1267 mm3(53%) CD16/56 171mm3 (41%) CD191
1493 mm3 (35%). The patient was started on monthly intravenous gamma-
globulin (IVIG) therapy. He was admitted in December 2008 with fever and
severe abdominal pain; an exploratory laparotomy revealed a rectal-sigmoid
tumor. The biopsy reported an atypical Burkitt lymphoma (Immunopheno-
type “B”: Bcl 21, CD101) with surgical margins negative for malignancy.
Bone marrow aspirate and biopsy were negative for malignancy. In February
2009, management with chemotherapy was started with the diagnosis of
Burkitt’s lymphoma stage III. Patient received 6 courses of chemotherapy
with complete response to induction; for consolidation, 4 doses of rituximab
were given. PCR ampliﬁcation and direct automated sequencing by the
Sanger method was performed in both genes known to be responsible for
XLP in chromosome X.
Results: A hemizygous splice-site deletion in SAP was found, in intron 2:
c.187_201110del25, which deletes exon 2 splice donor site, and is predicted
to result in the skipping of exon 2, and thus in a truncated, nonfunctional
protein. XIAP was also sequenced and no mutation was found.
Conclusions: Final diagnosis: XLP.The patient is currently in the program
for hematopoietic stem-cell transplantation.
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Transmission Pattern andCarriers Identiﬁcation inMale Patients
with Chronic Granulomatous Disease
Blancas-Galicia Lizbeth, MD, MSc,1 Laura Berrón-Ruiz, PhD,2 Morin-
Contreras Andrea,1 Yamazaki-Nakashimada Marco Antonio, MD,3
and Francisco Espinosa-Rosales, MD2. 1Unidad de Investigación en Inmu-
nodeﬁciencias, Instituto Nacional de Peditría, Mexico City, Mexico; 2Unidad
de Investigación Para Inmunodeﬁciencias, Instituto Nacional de Pedriatría,
Distrito Federal, Mexico; 3Inmunologia, Instituto Nacional de Peditría, Mex-
ico City, Mexico.
Background: To identify the pattern of transmission in male CGD patients
and the CGD X-linked carriers among their female relatives.
Methods: Through the 123 Dihydrorodamine assay in blood samples of the
female relatives of CGD patients we identiﬁed a positive bimodal pattern in
each woman. A positive bimodal pattern reveled 2 points, ﬁrst, that the
pattern of transmission in the patients was X-linked, second, that the woman
was a carrier.
Results: We analyzed 59 female relatives of 18 male CGD patients. Among
14 CGD males we found 28 women whit a positive bimodal pattern; in 4 male
CGD patients we did not ﬁnd any relative with a positive bimodal pattern.
Conclusions: 123 DHR assay is an accessible and quickly technique to
determinate the pattern of transmission and the carriers in X-CGD. However
a negative ﬁnding of a bimodal pattern in the female relatives suggests an
autosomal recessive pattern but it does not rule out an X-CDD because of
a novo mutation or non-random (skewed) X-chromosome inactivation.
Deﬁnitive diagnosis is based on candidate gene sequencing.
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Genetic Association Study of the IgE Immunodeﬁciency in
Mexican Population
Jose Augusto Malpica Cruz, MD,1 Javier Gomez Vera, MD,2 Ramírez Del
Pozo María Elena, MD,2 Jesus Lopez Tiro, MD,3 Silvia Jimenez Morales,4
and Lorena Orozco5. 1Alergia e Inmunologia, Hospital Regional, Ciudad de
México, Mexico; 2Alergia e Inmunologia, Hospital Regional "Lic, Adolfo
López Mateos" ISSSTE, Ciudad de México, Mexico; 3Alergia e Inmunología,
Hospital Regional "Lic. Adolfo López Mateos", Ciudad de México, Mexico;
4Genetica, Instituto Nacional de Medicina Genómica de Mexico, Ciudad de
México, Mexico; 5Immunogenomics and Metabolic Diseases Laboratory, In-
stituto Nacional de Medicina Genomica, Mexico.
Background: Primary immunodeﬁciencies (PID) are genetic diseases in
which one or multiple components of the immune system, including cells (i.e.
B cells, T cells, natural killer cells, phagocytes, complement components) or
molecules (cytokines, chemokines, etc) are affected, leading to a low capacity
to eliminate microorganisms and a high susceptibility to infection diseases.
Most of the PID are multifactorial entities were the environmental and
multiple genetic factor are involved. The single nucleotide polymorphisms
(SNPs) analysis in case and control groups has been increasing the knowledge
of the etiopathogenesis of several diseases and the opportunity to identify
molecular markers useful in the clinical diagnosis.
Methods: We performed a case control study including 19 pediatric patients
with IgE deﬁciency (5 U/mL), and 180 healthy controls. 25 SNPs distributed
in the IL-13, IL-10, IL-5, IL4, FCER1B, INF g, GM-CSF, STAT 3, GATA 3
and TIK-2 were analyzed. Genotyping was performed using sondas TaqMan.
Hardy-Weinberg Equilibrium (HWE) and statistical signiﬁcance were evalu-
ated using FINETTI and STATCAL software.
Results: All genotypes, both in cases and controls were in HWE. We
documented statistically signiﬁcant differences in the distribution of the SNPs
located in IL-4 rs4986964, P ¼ 0.018, OR ¼ 14.74, IL-4R, rs18005010, P ¼
0.018, OR ¼ 2.22, FCER-1B, rs556917, P ¼ 0.00001, OR ¼ 16.9, GM-CSF,
STAT-3 and GATA-3 genes: GMFCS-130 (P ¼ 4986964, OR ¼ 0.22), STAT-
3 rs2293152 (P ¼ 5.06 · 1029, OR ¼ 6.18), GATA-3 rs2229360 (P ¼ 0.005,
OR ¼ 13.52). The highest difference was found in the T allele of rs556917,
which was more frequent in cases than controls (42.1 and 1.5%, respectively,
P¼ 0.00001 OR¼ 16.907, 95% CI, 5.02-54.93). Interestingly, the C allele of
4986964 (IL-4) increased signiﬁcantly in homozygote genotype (C: OR ¼
14.74, 95% CI, 2.38-91.234, P ¼ 0.018 to CC OR ¼ 29.4, 95% CI, 1.154-
749.32, P ¼ 0.002).
Conclusions: Our results suggest that SNPs located in the genes involved in
the IgE production are risk genetic factor to IgE immunodeﬁciency.
Increasing of the sample size is currently to get solid conclusions.
RESPIRATORY INFECTIONS
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Inhibition of AKT Kinase Activity Decreases Replication of
Human Respiratory Syncytial Virus
Kim Tran,1,2 Sandra Fuentes,3,4 Biao He,3,4 and Michael Teng, PhD,1,2. 1In-
ternal Medicine, University of South Florida, Tampa, FL; 2Biochemistry and
Molecular Biology, Pennsylvania State University, University Park, PA;
3Infectious Diseases, University of Georgia, Athens, GA; 4Veterinary and
Biomedical Sciences, Pennsylvania State University, University Park, PA.
Background: Human Respiratory Syncytial Virus (RSV) is a leading cause
of pediatric pulmonary disease and severe RSV infection predisposes to
wheezing later in life. RSV infection has also been shown to be an environ-
mental trigger for asthma. We are investigating whether targeting host factors
important for RSV infection is a viable antiviral strategy. Lowering viral
burden through these therapies will result in decreased severity of infection
and may also prevent the occurrence of pathologic sequelae.
Methods: Inhibition of AKT by chemical inhibitors, siRNA, or dominant-
negative mutants, was tested for activity against RSV replication in cultured
cells. We examined the effect of viral protein expression on Akt activation
and downstream signal transduction by Western blot and promoter assay. In
addition, we examined the effect of Akt on speciﬁc viral processes (entry,
macromolecular synthesis, and assembly) and proteins both in vitro and in
RSV-infected cells, using kinase assays, Western blotting, and qRT-PCR.
Results: We found that AKT inhibition decreases RSV protein expression
and viral titers. Expression of RSV NS2 protein activates AKT, leading to
NFkB-dependent transcription, and inhibition of AKT blocks this effect.
Activated AKT also phosphorylates RSV P protein at a speciﬁc site.
Interestingly, AKT inhibitors that target the pleckstrin homology (PH)
domain of AKT showed decreased efﬁcacy against RSV compared to those
that target AKT kinase activity.
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Conclusions: Inhibition of AKT can effectively decrease RSV replication in
culture, likely by decreasing P phosphorylation and thus viral protein
transcription and expression. Activation of AKT during RSV infection likely
involves the NS2 protein and does not depend on the PH domain of AKT.
AKT inhibitors have been found to be safe and efﬁcacious in clinical trials for
a number of different cancers; thus, AKT inhibition may be a potential
therapeutic treatment for severe RSV infection.
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Abnormal Immune Response Against Respiratory Pathogens in
Olympic Athletes
Marcin Kurowski, MD, PhD,1 Janusz Jurczyk, MD,2 Marzanna Jarzebska,
MSc,1 Sylwia Moskwa, MSc,1 Joanna S. Makowska, MD, PhD,1
Hubert Krysztoﬁak, MD, PhD,2 and Marek L. Kowalski, MD, PhD1. 1De-
partment of Immunology, Rheumatology and Allergy, Medical University of
Lodz, Lodz, Poland; 2National Centre for Sports Medicine (COMS), Warsaw,
Poland.
Background: Viruses and bacteria are important contributors to asthma
exacerbations. Exercise at competitive level is believed to increase suscep-
tibility to respiratory infections. The study aimed at investigation of the anti-
infectious immune response in athletes in the context of exercise intensity,
atopy and allergic diseases.
Methods: Questionnaire data were obtained from 219 Polish athletes (median
age 26 years) preparing for Beijing Olympic Games during the multicenter
study within the GA2LEN project (WP 2.8.2). Allergy Questionnaire for
Athletes (AQUA) (Bonini et al 2009) was used to obtain data about symp-
toms and exercise pattern. Athletes were evaluated by allergist. Control group
consisted of 77 healthy never-smokers (median age 29 years) not performing
sport at competitive level. Serum IgG against parainﬂuenza virus 1,2 and 3
(PIV), respiratory syncytial virus (RSV), adenovirus and Mycoplasma pneu-
moniae were determined by ELISA.
Results: Percentage of athletes with positive serological testing was lower
than percentage of HC in case of PIV (P , 0.0003), RSV (P ¼ 0.01) and M.
pneumoniae (P ¼ 0.01). Analysis of IgG only in subjects with positive testing
showed lower anti-PIV IgG levels in non-atopic athletes compared to HC (P
, 0.001) and atopic athletes (P , 0.01) (median 66.0 vs 104.8 and 88.1 U/
mL). In contrast, higher adenovirus IgG titres were found in atopic and non-
atopic athletes as compared to HC (52.3 and 48.5 vs 36.6 EIU, P , 0.001).
Positive anti-PIV serology test was most frequent in athletes with allergic
rhinitis compared to asthmatic and healthy athletes (78.3 vs 50.0 and 46.8%;
P ¼ 0.002). For PIV and M. pneumoniae the difference was also seen when
atopic and non-atopic athletes were compared separately with HC. Positive
RSV serology was more frequent in atopic versus non-atopic athletes (76.3 vs
60.8%, P ¼ 0.03) and in HC versus non-atopic athletes (84.4 vs 60.8%, P ¼
0.001) but no signiﬁcant difference between atopic athletes and HC was seen.
Positive RSV serology was associated with atopy (OR 2.89; 95% CI, 1.34-
6.23; P ¼ 0.007). No differences were observed with regard to exercise
pattern (endurance vs non-endurance).
Conclusions: Competitive sport at Olympic level may be associated with
altered immune response against respiratory pathogens. For some agents this
response may be affected by the atopic status.
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The ImmuneResponse Against Respiratory Pathogens in Patients
with Chronic Rhinosinusitis/Nasal Polyps and Asthma with or
without Sensitivity to Aspirin
Agnieszka Olszewska-Ziaber, MD, PhD, Marzanna Jarzebska,
and Marek L. Kowalski, MD, PhD. Department of Immunology, Rheuma-
tology and Allergy, Medical University of Lodz, Łódz, Poland.
Background: Viral and bacterial infections can modulate the ongoing
inﬂammation in both upper and lower airways of patients with chronic
rhinosinusitis with nasal polyps (CRS/NP) and asthma. It was not clear if the
protective immune response to pathogens may differ depending on the
disease severity.Object: To compare serum IgG immune response against
respiratory pathogens in patients with chronic airway disease (CRS/NP and
asthma) with and without sensitivity to aspirin, and to refer the sensitization
to severity of chronic rhinosinusitis.
Methods: We recruited 73 patients with CRS/NP and asthma with (43
patients) and without (30 patients) hypersensitivity to aspirin. The extent of
mucosal hypertrophy in paranasal sinuses was assessed by CT scans and the
sense of smell was valuated with “snifﬁng smell” test. Serum IgG immuno-
globulin levels against respiratory pathogens: Respiratory Syncytial Virus
(RSV), Adenowirus (ADV), Parainﬂuenza virus (PIV) and Mycoplasma
pneumoniae were determined by ELISA.
Results: Patients with ASA-hypersensitivity had history of signiﬁcantly more
nasal polypectomies (P ¼ 0.002), lower smell test score (P ¼ 0.03) and
higher mean paranasal CT score (P ¼ 0.03) as compared to ASA-tolerant
patients, reﬂecting higher severity of the upper airway disease. The percent-
age of positive serological testing to respiratory pathogens was very high in
the whole group of patients with CRS/NP and asthma (RSV, 95.8%; ADV,
95.9%; PIV, 84.9% and Mycoplasma pneumonieae, 100% patients) without
any difference between ASA-sensitive and ASA-tolerant subjects. Patients
with ASA-sensitivity had signiﬁcantly lower concentrations of PIV- speciﬁc
IgG (mean 188.67 6 34.46 U/mL versus 207.56 6 30.036 U/mL; P , 0.04)
as compared to ASA-tolerant subjects. There was a signiﬁcant trend (P ,
0.048) for lower PIV–speciﬁc IgG concentrations with increased number of
polypectomies. No correlation of IgG immunoglobulin concentrations for
other pathogens with the number of polypectomies, paranasal sinuses CT
score or presences of smell were observed.
Conclusions: Patients with CRS/NP and asthma had high frequency of IgG
immunoglobulin against common respiratory pathogens. Serum IgG immune
response to paramyxoviruses may be related to the recurrence of nasal polyps
and the presence of aspirin sensitivity.
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Immunologic and Clinical Characteristics of Pediatric Population
with Human Inﬂuenza Virus H1N1 Infection in Federal Hospital
of Mexico
Jaime Mellado-Abrego, MD,1 Dianitzel Gastaldi, MD,2 Beatriz Mariscal-
Martinez, MD,3 M. A. Isabel Rojo-Gutierrez, MD,1 Mario-Alberto Bermejo,
MD,1 and Teresa Sandoval-Hernandez, CHEM1. 1Allergy and Immunology;
2Pediatric, and; 3Internal Medicine, Juarez Hospital Mexico City, Mexico.
Mexico 2009 faced the H1N1VI inﬂuenza pandemic, a complex immunologic
and clinical host response, whose defense mechanisms have yet to be
identiﬁed. Lack of information on clinical an immunological features in
pediatric population with H1N1VI, delay detection of patients at risk of
contracting it. This study aims to identify speciﬁc immunologic and/or
clinical features of pediatric patients with H1N1VI in a federal Hospital in
Mexico City.
Methods: Single-center, observational, non-experimental, prospective trail
from September to October 2009, for pediatric patients arriving to Emergency
room of Juarez Hospital, with suspicion of H1N1VI, needing to be younger
than 17 years, and agree and sign the consent form by tutor. Samples obtained
were peripheral blood, and pharyngeal exudate. From blood LS, Cytokine
levels, and routine measurements (CBC, BCH) were investigated; the
pharyngeal sample underwent PCR study to viral genetic material. Comple-
mentary studies such as arterial blood gases or Torax radiography were
realized as needed.
Results: 32 patients participated. PCR results conﬁrmed 18 cases (56%),
1 patient resulted positive for SII. The average age was 9 years old; 12 (67%)
were female, and 6 (33%) were male. The mean amount of days from
symptom onset to receiving medical attention was 2.5 days. Main symptoms
and signs were fever, malaise, cough, rhinorrhea, and headache. Associated
risk factors included malnutrition and tobacco exposure. It was demonstrated
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an elevation of IL-8, followed by IL-6, IL-12 and IL-10. Blood analysis
proved no signiﬁcant ﬁndings, though cases of neutrophilia and leukopenia
were detected.
Conclusions: Limited resources, restricted participation from all the possible
H1N1VI patients, thus biasing results due to small sample size; however, the
obtained data is consistent with existing reports, nevertheless the information
is not enough to establish standardized recommendations. Further collabora-
tion among centers, is needed to identify features that can prompt H1N1VI
early identiﬁcation and prevention in pediatric population.
SII = Stational Inﬂuenza infection; LS = lymphocyte subpoulations; CBC =
Complete blood count, BCH (blood chemistry) = Includes levels of
glucose, urea, creatinine, ALT, AST, CPK CPK-MB, amylase and lipase.
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Evaluation of Various Forms of Sinusitis Using Bone Spect
Sergul Ulus, MD,1 Fuat Tosun, MD,1 Abdullah Durmaz,MD,1 Mustafa Gerek,
MD,1 and Serdar Ulus,MD2. 1Otorhinolaryngology, Gulhane Military Medical
Academy, Ankara, Turkey; 2Public Health, Gulhane Military Medical Academy,
Ankara, Turkey.
Background: Computed tomography (CT), a standard diagnostic technique
used to evaluate the extent of the sinus disease, fails to show bone
involvement in patients with sinusitis. Bone scintigraphy is the gold standard
procedure for detecting the bone involvement. Osteitis may be one of the
reasons for discrepancies between extent of the disease as evaluated by CT
and symptom scores. The aim of the study was to determine whether or not
nuclear scintigraphy is useful in the diagnosis and management of acute,
complicated acute and chronic sinusitis.
Methods: Forty patients with sinusitis were involved (9 acute, 4 complicated
acute, 27 chronic sinusitis). 20 of the chronic sinusitis patients were with
nasal polyps. All patients were evaluated with CT and SPECT (Single-photon
emission tomography). 99Technetium-methylenediphosphate (99Tc-MDP) was
administered for scintigraphic examination of the skull. Abnormal patterns of
increased radionuclide uptake were identiﬁed and subjectively described. The
mucosal involvement of sinusitis graded on Lund-Mackay Scale (LMS) was
compared to degree of bone involvement evaluated by SPECT.
Results: While, SPECT uptakes were negative (mean uptake index is less than
about 2.5) in acute sinusitis, it’s highly positive (mean uptake index is more than
about 4) in complicated acute sinusitis. In group of chronic sinusitis, a positive
correlation between the SPECT uptakes and LMS grade was found (P , 0.05).
Conclusions: In our view, the bone involvement as evaluated by SPECT
correlates with the stage of chronic sinusitis. Poorer subjective response was
observed in patients with positive SPECT. The clinical value of scintigraphy,
is limited to special indications.
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Rhinitis: Where is the Bioﬁlm?
Matteo Gelardi,1 Nicola Quaranta,1 Maria Luisa Fiorella,1 and Giovanni
Passalacqua,MD2. 1Unit of Rhinology and Nasal Cytology, Clinical Otorhyno-
laringology, University of Bari, Bari, Italy; 2Allergy & Respiratory Diseases,
Universita Degli Studi Di Genova, Genoa, Italy.
Background: Several ultramicroscopic studies have conﬁrmed the presence of
bioﬁlms in ENT diseases, such as chronic rhinosinusitis, nasal polyposis or
adenoid hypertrophy. Recently, it has been reported that light microscopy nasal
cytology can identify bioﬁlms, which appear as cyan-stained “Infectious Spots.”
Methods: Subjects suffering from a wide spectrum of nasal disorders, after
a detailed clinical history and ENT examination, underwent nasal ﬁbroendo-
scopy, skin prick test, rhinomanometry and nasal cytology.
Results: 1410 subjects were studied. The infectious spot was present in 107
of them (7.6%) patients; this percentage reached 55.4% in 193 patients who
had clear cytologic signs of infectious rhinitis. Bioﬁlms were largely more
frequent in patients with adenoid hypertrophy (57.4%), followed by nasal
polyposis (24%), chronic rhinosinusitis (9.5%) and non-allergic “cellular”
rhinitis (7.6%). Nasal cytology was normal in the remaining patients, with
no infectous spot detectable. Statistical analysis showed that nasal resistances
were signiﬁcantly higher in presence of bioﬁlms in patients affected by ad-
enoid hypertrophy (P ¼ 0.003), nasal polyposis (P , 0.001), chronic rhino-
sinusitis (P ¼ 0.018) and septal deviation (P ¼ 0.001).
Conclusions: The results demonstrate that bioﬁlms are not present only in
infectious rhinopathies, but also in inﬂammatory and/or immune-mediateddi-
seases. Bioﬁlms were more frequent in patients with higher degree of nasal
obstruction as assessed by nasal endoscopy (grade III and IV adenoids and
stage-3 polyposis) and rhinomanometry. Nasal cytology, by allowing the




A 6-Week Study of the Efﬁcacy and Safety of Ciclesonide
HydroﬂuoroalkaneNasal Aerosol in theRelief of Nasal Symptoms
of Perennial Allergic Rhinitis
Dale Mohar, MD,1 William Berger, MD, MBA,2 Gordon Raphael, MD,3
Craig LaForce, MD,4 Holly Huang, PhD, MPH,5 Shailesh Desai, PhD,5
Frederick Bode,MD,5 and John Karaﬁlidis, PharmD5. 1Kerrville Research As-
sociates, Kerrville, TX; 2Allergy & Asthma Associates, Mission Viejo, CA;
3Asthma, Allergy & Clinical Research, Bethesda, MD; 4North Carolina Clinical
Research, Raleigh, NC; 5Sunovion Pharmaceuticals, Inc., Marlborough, MA.
Background: Ciclesonide hydroﬂuoroalkane nasal aerosol (CIC-HFA) is
currently in development as a potential treatment for allergic rhinitis. The
objective of this study was to determine the efﬁcacy and safety of CIC-HFA
compared to placebo in subjects with perennial allergic rhinitis (PAR).
Methods: Subjects $12 years of age with a $2 year history of PAR were
randomized in a placebo-controlled, double-blind, parallel group, multicenter
study to CIC-HFA 74 mg (N ¼ 298), CIC-HFA 148 mg (N ¼ 505), or placebo
(N ¼ 307) QD AM for 26 weeks. Subject-reported change from baseline in the
average of AM and PM reﬂective total nasal symptom score (rTNSS) and
instantaneous total nasal symptom score (iTNSS) averaged over the ﬁrst 6 weeks
of treatment period were key endpoints and were calculated as a sum of the 4
individual nasal symptoms of congestion, runny nose, sneezing, and nasal itching
each on a scale of 0 (no signs/symptoms evident) to 3 (severe symptoms). Change
from baseline in the individual reﬂective and instantaneous nasal symptom scores
over the ﬁrst 6 weeks of treatment period were also evaluated. Treatment-
emergent adverse events (TEAEs) were assessed throughout the study.
Results: CIC-HFA 74 mg and CIC-HFA 148 mg doses demonstrated a statis-
tically signiﬁcant improvement in rTNSS (LS mean change 0.70 & 0.54
respectively, P # 0.001 for both), iTNSS (LS mean change 0.58 & 0.42
respectively, P # 0.05 for both) and improvements in individual reﬂective
and instantaneous nasal symptoms (P # 0.05 for all, unadjusted for multi-
plicity) at 6 weeks from baseline. The overall incidence of TEAEs was low
and comparable between the CIC treatment groups and placebo. The most
frequently reported TEAEs ($2% of subjects in any treatment group) were
nausea, headache, sinus headache, cough, upper respiratory tract infection,
instillation site discomfort, nasal discomfort, nasopharyngitis, sinusitis, oro-
pharyngeal pain, and epistaxis.
Conclusions: In this study, once-daily treatment with CIC-HFA 74mg or
CIC-HFA 148mg demonstrated statistically signiﬁcant improvements in the
nasal symptoms of PAR. Both active treatments were well tolerated.
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3-D Visualization of the Anti-Obstructive Effect of Levocetirizine
Nils Achilles,1 Ralph Moesges, MD, FAAAAI,1 Eelaf El Hassan, MD,1
Berthold Wein, MD,2 and Wolgang Schröder3. 1Institute of Medical
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Statistics, Informatics and Epidemiology, University Hospital of Cologne,
Cologne, Germany; 2Praxisgemeinschaft im Kapuzinerkarree, Aachen, Ger-
many; 3Institute of Aerodynamics, RWTH Aachen, Aachen, Germany.
Background: Our investigation aimed to visualize the 3-D spatial distribu-
tion of nasal cavity mucosal swelling under levocetirizine prophylactic
treatment on exposure to allergens. This study made use of standard
rhinologic diagnostics such as rhinomanometry and acoustic rhinometry, as
well as 24 hours rhinometry and magnetic resonance imaging (MRI).
Methods: A suitable test subject with a history of allergic rhinitis was
identiﬁed during the symptom-free interval after the pollen season when she
showed signs of “minimal persistent inﬂammation,” consisting of pronounced
reaction to nasal challenge with allergens. Provocation with birch pollen
caused moderate symptoms of allergic rhinitis. Nasal provocation tests were
performed before and after 2 and 5 weeks of treatment with levocetirizine 5
mg OD. Long-term rhinometry was carried out to detect the progress of the
nasal cycle and relative ﬂow variances over 24 hours. Flexible air tubes
required for this new procedure made it possible to quantify relative pressure
changes. High resolution MRI was also used to capture, visualize, and pro-
cess the geometrical data of the nasal cavity immediately before and after the
challenge tests. Based upon the MRI data, we computed the nasal airﬂow
using a computational ﬂuid dynamics (CFD) nasal model to visualize intra-
nasal pressure and ﬂow. Rhinomanometry and acoustic rhinometry were
performed to validate the results.
Results: After 36 days of treatment with levocetirizine, a 16% improvement
in the nasal ﬂow relative to baseline and an increase by 3.4 cm3 of the total
nasal baseline volume were documented as compared to the allergen chal-
lenge of the untreated case. 3-D images illustrated that treatment inhibited the
allergen provocation effects on nasal airﬂow and normalised nasal ﬂow ve-
locity and pressure, including in the olfactory region.
Conclusions: Besides improving the nasal airﬂow to an almost normal
pattern, levocetirizine also helps prevents the patient from having an allergic
response, even 24 hours after last drug intake. Furthermore, it can improve
olfaction by restoring airﬂow to the olfactory region.
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Levels of F VCAM and ICAM in Patients With Allergic
Rhino-Conjunctivitis and H1 Antihistamines
Ioana Adriana Bujor, MD,1 Bocsan Ioana Corina, MD,2 and Diana Deleanu,
MD, PhD1. 1Immunology- Allergology, and; 2Pharmacology, University of
Medicine and Pharmacy, Cluj- Napoca, Romania.
Background: Soluble intercellular adhesion molecule-1 (sICAM-1) and
soluble vascular adhesion molecule-1 (sVCAM-1) play and important role
in eosinophilic inﬂammation in allergic rhino-conjunctivitis (ARC). ICAM-1
and VCAM-1 have been identiﬁed as key molecules in allergic inﬂammatory
diseases and in a few studies there was an increased value of those molecules
in patients with allergic rhinitis. Treatment with H1 antihistamines is known
to improve symptoms in allergic rhinitis and in vitro reduces the levels of
adhesion molecules.
Object: To evaluate serum levels of sICAM-1 and sVCAM-1 in pts with
ARC to grass pollen and the response to different antihistamines.
Methods: 50 pts with allergic rhino-conjunctivitis to grass pollen were
evaluated regarding levels of sICAM-1 and sVCAM-1. The serum sICAM-1
and sVCAM-1 were evaluated during pollen season before and after
antihistaminic terapy. Quantikine R&D System was used. Normal mean val-
ues in healthy volunteers were 208 ng/mL for sICAM and 557 ng/mL for
sVCAM-1. 54% of pts were women and 88% from urban area.
Results: Mean levels of sICAM-1 and sVCAM-1 were elevated before
therapy of the pts compared with mean values in healthy subjects (235 ng/mL
vs 208 ng/mL for sICAM and 966 ng/mL vs 557 ng/mL for sVCAM. 42% of
pts received desloratadine therapy and 58% of them received levocetirizine.
In both treated groups’ levels of sICAM-1 and sVCAM-1 increased after one
month of antihistaminic therapy but no statistical signiﬁcance. Was obtained:
in desloratadine group sICAM-1 (P ¼ 0.066) and sVCAM-1 (P ¼ 0.096); in
levocetirizine group sICAM-1 (P ¼ 0.681) and sVCAM-1 (P ¼ 0.4060.
Patients with high levels of sICAM-1 and sVCAM-1 at the tended to have
increased sICAM-1 and sVCAM-1 levels at one month (P ¼ 0.000). No
statistical difference was obtained between the 2 treated groups after one
month regarding the levels of sICAM-1 and sVCAM-1.
Conclusions: In patients with allergic rhino-conjunctivitis to grass pollen
levels of sICAM-1 and sVCAM-1 are higher than in healthy subjects. Levels
of sICAM-1 and sVCAM-1 in serum tend to increase during pollen season
despite antihistaminic therapy.
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Once Daily Intranasal Fluticasone Furoate Decreases Daytime
Sleepiness and Improves Cognitive Performance in Symptomatic
Seasonal Allergic Rhinitis
Alejandro Diaz, MD. Research, Western Sky Medical Research, El Paso, TX.
Background: Seasonal Allergic Rhinitis (SAR) can cause Daytime Sleep-
iness (DS) and impair Cognitive Performance (CP); therapy of SAR can
improve these symptoms.
Methods: We evaluated the effects of Fluticasone Furoate (FF) 110 mcg
given in the morning on Nasal Symptons (NS), DS, an CP in adults with
symptomatic SAR during an allergy season. 40 adults ages 18 to 55 with
a history of SAR and positive allergy skin tests to seasonal allergens. After
a 1 week placebo (PL) run in, they randomly received either FF (21) or
identical appearing PL (19) for 2 weeks. They recorded nasal sympton score
(NSS) and Eppworth daytime sleepiness score (EDDS) for the 21 days,
performed a TOVA test (Computerized test of cognitive performance) at day
7 and 21, and completed a nocturnal rhinoconjunctivitis quality of life
questionnaire (NRQLQ) at days 7, 14 and 21. Average daily weekly scores,
comparing week 1 baseline to week 3 were used for evaluation of NSS, and
EDSS/TOVA omissions, commissions and reaction times were compared, as
was NRQLQ (day 7 and day 21).
Results: Mean total NSS (TNSS) instantaneous decreased from BL 12.88 to
10.84 in the FF group, and increased in PL group from 12.64 to 13.74 (P diff
¼ .04). TNSS reﬂective decreased from 12.99 to 11.20 (FF group) and in-
creased from 13.53 to 14.02 in PL. (P diff ¼ NS). The mean EDSS decreased
from 13.83 to 10.76 (P ¼ 0.03) in FF group, and from 13.29 to 12.80 with PL
(P dif ¼ NS). TOVA commissin errors decreased by 7.13 (FF) vs 1.4 (PL)
(P dif ¼ 0.05). Omission increased in PL from 2.33 to 5.75, and 1.54 to 1.58
(FF) (P diff ¼ NS). Reaction time increased in both groups 363 to 391
milliseconds (FF), 387 to 412 milliseconds (P ¼ NS). The FF reported
a minimally clinical importance difference of 0.5 or greater on all 16 ques-
tions of NRQLQ, the PL group only in 10. (Mean change 1.01 (FF) vs .63
(PL) P ¼ 0.004).
Conclusions: Treatment of symptomatic SAR with intranasal FF decrease
daytime sleepiness, less noturnal sleep disturbance, and improved cognitive
performance.
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International Survey on the Management of Allergic Rhinitis by
Physicians and Patients (ISMAR). Physicians’ View
H. A. Badellino, MD,1 Alvaro Teijeiro, MD,2 R. M. Gomez, MD,1 Mario
Zernotti, MD, PHC,1 J. S. Croce, MD,1 M. Murrieta-Aguttes, MD,2
and Carlos E. Baena-Cagnani, MD1. 1CIMER (Centro de Investigación
en Medicina Respiratoria). Faculty of Medicine. Catholic University of
Cordoba. Fundación LIBRA Argentina, Cordoba, Argentina; 2Sanoﬁ,
Paris, France.
Background: Allergic Rhinitis (AR) is a worldwide spread disease and has
an important impact on social life, sleep quality (SQ), school and work
productivity and huge direct costs. ISMAR was designed to identify attitudes
and medical trends among physicians managing AR in different parts of the
world. This study presents the physiciansview and attitudes.
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Methods: ISMAR is an international, multicenter, non-interventional and
cross-sectional study conducted in adults and children ($6 years) with physi-
cians-diagnosed AR from 11 countries (Egypt, Mexico, Brazil, Colombia,
Guatemala, Iran, Venezuela, Argentina, Israel, Kuwait, United Arab Emi-
rates). Doctors from 4 specialties were required in each country: (i) GPs/
Family doctors/internists, (ii) pediatricians, (iii) allergologists/pulmonolo-
gists, and (iv) ENT. They were invited to participate in the study from master
lists of physicians attending patients with AR in their respective countries and
answered the Doctor Questionnaire that included questions about guidelines
awareness, relevant AR symptoms, and preference for prescribing medica-
tion, among others.
Results: Two hundred and thirty four physicians participated in the study.
Most of them were awared about ARIA (82.5%), GINA (71.4%). They
followed guidelines recommandations to classify patients severity (84.2%)
and for choosing the treatment accordingly (84.6%). Key symptoms to make
AR diagnosis were: congestion (84.8%), sneezing (79.1%), anterior watery
rhinorrhea (75.9%). SQ and AR severity were assessed mainly by clinical
history (97.1% and 98%). The main reasons to prescribe medication were:
symptom severity/frequency (97.9%), drug efﬁcacy (85.9%) and safety
(76.5%). Other less relevant raisons were: personal experience (65%), cost
(55.1%) and frequency of dosages (54.7%). The preferred medications
were oral antihistamines (OH1A) and intranasal corticosteroids (INC) [5 in
a 0–5 scale]. Other treatments (oral decongestants, leukotriene antagonists,
SCIT/SLIT), among others were considered as second level in preference.
Conclusions: Guidelines are well known and useful to physicians. Clinical
history was the main way to evaluate the patient’s sleep quality, classiﬁcation,
severity and election of treatment. Objective measures for assessment were
scarcely used. OH1A and INC were the most widely recommended treatment
for AR and were considered effective and safe.
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International Survey on the Management of Allergic Rhinitis by
Physicians and Patients (ISMAR): The Patients’ View
Alvaro Teijeiro, MD,1 H. A. Badellino, MD,2 R. M. Gomez, MD,2
Mario Zernotti, MD, PHC,2 J. S. Croce, MD,2 M. Murrieta-Aguttes, MD,2
and Carlos E. Baena-Cagnani, MD2. 1CIMER (Centro de Investigación en
Medicina Respiratoria). Faculty of Medicine. Catholic University of Cor-
doba. Fundación LIBRA Argentina, Cordoba, Argentina; 2Sanoﬁ, Paris,
France.
Background: Allergic Rhinitis (AR) is a worldwide spread illness and has an
important impact on social life, sleep quality, school and work productivity
and huge direct and indirect costs. Patient preference is becoming an
important aspect in medical care. ISMAR was designed as the ﬁrst-over
global survey to identify differences in attitudes and preference in patients
and physicians about AR. This study shows the patient’s view.
Methods: ISMAR is an international, multicenter, non-interventional and
cross-sectional study conducted in adults and children ($ 6 years) with
physician diagnosis- AR of at least 1 year of duration. Physicians recruited
consecutive patients to whom the ISMAR questionnaire was administered.
The study data collection was performed during a single visit. Other 2 addi-
tional documents (the investigator’s questionnaire and Case Record Form)
were also ﬁlled in.
Results: A total of 2776 patients from 11 countries were evaluated. Patient’s
demographics were the following: mean age 31 years, gender (F) 54%; urban
residence (86.1%), suburban (6.6%) and rural (4.9%). The main co-morbid-
ities were: sinusitis (50%), asthma (33%), conjunctivitis (36%), otitis (13%)
and nasal polyps (11%). Nasal symptoms were associated to house-dust mites
(84%), moulds (33%) animal dander (31%) and pollens (41%) exposure. At
least one current treatment was received in 91%, and recommendation to
avoid allergens or irritants in 93% of patients. 80% the patients had received
oral anti-H1 antihistamines (OH1A), 66% intranasal corticosteroids (INC),
63% oral/intranasal decongestants and 14% sub-cutaneous speciﬁc immuno-
therapy (SCIT). The patients’ preference was the following: oral route of
administration, 51%; and intranasal route 28%. The patients’ preference
mediations were: OH1A, 76%; INC, 49%; and SCIT 12%. Main factors
affecting treatment compliances were cost (32%), fear of Adverse Events
reported (18%) and frequency of doses (34%). Taking into account patients’
education, 85% of them received oral explanation on disease and only 51%
written indications.
Conclusions: OH1A and INC were the most widely used treatments for
rhinitis and were considered safe and effective. The majority of patients
preferred the oral route. Written educational material given to patients is




Patterns of Initiation and Adherence to de novo Allergen-Speciﬁc
Immunotherapy Among Adults and Children with Newly-
Diagnosed Allergic Rhinitis: Findings From Research Jointly
Funded by the AAAAI AND ACAAI
Cheryl Hankin, PhD,1 Linda Cox, MD,2 Zhaohui Wang, MS,1
and Amy Bronstone, PhD1. 1Health Economics and Outcomes Research,
BioMedEcon, LLC, Moss Beach, CA; 2Medicine, Nova Southeastern Univer-
sity, Ft. Lauderdale, FL.
Background: Although allergen-speciﬁc immunotherapy (SIT) is the only
disease-modifying treatment currently available for allergic rhinitis (AR), few
potentially appropriate United States patients initiate or sufﬁciently adhere to
treatment.1,2 We compared SIT initiation and adherence between AR-diag-
nosed children and adults.
Methods: Selected were child (age ,18 years) and adult (age $18 years)
Florida Medicaid enrollees (1997–2009) with newly-diagnosed AR (no AR
claim within 1 year preceding the ﬁrst identiﬁed AR diagnosis) who received
de novo SIT (no SIT preceding the ﬁrst AR diagnosis), had $4 years of
follow-up from ﬁrst AR diagnosis, and 6 months of follow-up from ﬁrst SIT
administration. T tests, Wilcoxon signed-rank tests, and chi-squares com-
pared differences between children and adults.
Results: Overall, 8% (330,993/4,193,986) of children and 3% (105,380/
3,330,245) of adults received $1 AR diagnosis (P , 0.0001). Among these,
2,913 children and 1,332 adults met study criteria. Adults were 3.6 times
more likely than children to immediately initiate SIT (ie on the date of their
ﬁrst AR diagnosis) (OR 3.6, 95 % CI, 3.1-4.2, P , 0.0001); children were
twice as likely as adults to receive SIT $1 year from the ﬁrst AR diagnosis
(OR 2.2, 95 % CI, 1.9-2.6, P , 0.0001). The median number of SIT admin-
istrations was 13 for children and 5 for adults (P , 0.0001). Fourteen percent
of children and 20% of adults discontinued SIT after 1 administration; 33% of
children and 52% of adults discontinued after 5 administrations. Adults were
1.6 and 2.3 times more likely than children to discontinue SIT following 1
only administration (OR 1.6, 95% CI, 1.3-1.9, P , 0.0001) and 5 adminis-
trations (OR 2.3, 95% CI, 2.0-2.6, P , 0.0001), respectively.
Conclusions: Although adults were signiﬁcantly more likely to immediately
initiate SIT, they were also signiﬁcantly more likely to discontinue treatment
within the ﬁrst 5 administrations. These preliminary ﬁndings may guide
development of future patient-speciﬁc interventions to improve SIT access
and continuity of care.
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Effect of Simvastatin on Transforming Growth Factor BETA-1-
Induced Myoﬁbroblast Differentiation and Collagen Production
in Nasal Polyp-Derived Fibroblasts
Il-Ho Park, MD, and Heung-man Lee, MD, PhD. Department of otorhino-
laryngology-head and neck surgery, Korea university college of medicine,
Seoul, South Korea.
Background: Statins are the most commonly prescribed drugs for the
treatment of hypercholesterolemia. Statins exert not only lipid-lowering but
also other cellular effects, including anti-ﬁbrotic properties. The purposes of
this study were to determine the effect of simvastatin on Transforming growth
factor (TGF)-b1-induced myoﬁbroblast differentiation and collagen produc-
tion in nasal polyp-derived ﬁbroblasts (NPDFs) and to verify the mechanism
of the effect of simvastatin in TGF-b1-induced myoﬁbroblast differentiation
in NPDFs.
Methods: NPDFs were pre-treated with simvastatin with or without
mevalonate or Y-27643 for 2 hours prior to induction by TGF-b1. The
expression of a-smooth muscle actin (SMA) and collagen type IV mRNA
was determined by a reverse transcription-polymerase chain reaction, and the
expression of a-SMA protein was determined by immunoﬂuoescent cyto-
chemical staining. Total soluble collagen production was analyzed by the
SirCol collagen dye-binding assay. Phosphorylation of Smad 2/3 was evalu-
ated by Western blot analysis.
Results: In TGF-b1-induced NPDFs, simvastatin signiﬁcantly inhibited the
expressions of a-SMA and collagen type IV mRNA and reduced a-SMA and
collagen protein levels. Pre-treatment with mevalonate reversed the effect of
simvastatin. The expression of a-SMA mRNA and protein was signiﬁcantly
decreased by pre-treatment with Y-27632. The TGF-b1-induced expression
of pSmad 2/3 protein was notably decreased by pre-treatment with
simvastatin.
Conclusions: We showed that simvastatin inhibits TGF-b1-induced myoﬁ-
broblast differentiation (expression of a-SMA) and collagen production in
NPDFs and Rho/Rock and TGF-b/Smad signaling is involved as an under-
lying mechanism. The results of our study suggest that simvastatin is a pos-
sible candidate for the suppression of nasal polyp formation.
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A 26-Week Study Evaluating the Safety and Efﬁcacy of
Ciclesonide Hydroﬂuoralkane Nasal Aerosol in Subjects With
Perennial Allergic Rhinitis
William Berger, MD, MBA,1 Dale Mohar, MD,2 Gordon Raphael, MD,3
Craig LaForce, MD,4 Holly Huang, PhD, MPH,5 Shailesh Desai, PhD,5
Frederick Bode, MD,5 and John Karaﬁlidis, PharmD5. 1Allergy & Asthma
Associates, Mission Viejo, CA; 2Kerrville Research Associates, Kerrville, TX;
3Asthma, Allergy & Clinical Research, Bethesda, MD; 4North Carolina Clin-
ical Research, Raleigh, NC; 5Sunovion Pharmaceuticals, Inc., Marlborough,
MA.
Background: Ciclesonide hydroﬂuoroalkane nasal aerosol (CIC-HFA) is
currently in development as a potential treatment for allergic rhinitis. The
objective of this study was to determine the long-term safety and efﬁcacy of
CIC-HFA compared to placebo in subjects with perennial allergic rhinitis (PAR).
Methods: Subjects $12 years of age with a $2 year history of PAR were
randomized in a placebo-controlled, double-blind, parallel group, multicenter
study to CIC-HFA 74 mg (N¼ 298), CIC-HFA 148 mg (N¼ 505), or placebo
(N ¼ 307) QD AM for 26 weeks. Subject-reported change from baseline in
reﬂective total nasal symptom score (rTNSS) and instantaneous total nasal
symptom score (iTNSS) averaged every 2 weeks over the 26 weeks of the
treatment period were secondary endpoints and were calculated as a sum of
the individual nasal symptoms of congestion, runny nose, sneezing, and nasal
itching. Change from baseline in the individual reﬂective and instantaneous
nasal symptom scores averaged every 2 weeks over the 26 weeks of treatment
period were also evaluated. Treatment-emergent adverse events (TEAEs)
were assessed throughout the study.
Results: CIC-HFA 74 mg and CIC-HFA 148 mg doses demonstrated im-
provement in rTNSS (LS mean change 0.65 & 0.52 respectively, P # 0.01
for both), iTNSS (LS mean change 0.51 & 0.42 respectively, P # 0.05 for
both), and improvements in the individual reﬂective and instantaneous nasal
symptoms (P # 0.05 for all except instantaneous sneezing for the CIC-HFA
74 mg dose) at 26 weeks from baseline. P-values were unadjusted for mul-
tiplicity. The overall incidence of TEAEs was comparable between the CIC-
HFA treatment groups and placebo. The most frequently reported TEAEs
($5% of subjects in any treatment group) were headache, nasopharyngitis,
upper respiratory tract infections, viral upper respiratory tract infections, si-
nusitis, and epistaxis.
Conclusions: In this study, once-daily treatment with CIC-HFA 74 mg or
CIC-HFA 148 mg demonstrated improvements in the nasal symptoms of
PAR. Both active treatments were well tolerated.
155
Omalizumab Improves Asthma but not Nasal Symptoms in
Japanese Patients With Severe Allergic Asthma and Rhinitis
Fuyumi Nishihara, MD, Yotaro Takaku, MD, PhD, Kazuyuki Nakagome,
MD, PhD, Takehito Kobayashi, MD, PhD, and Makoto Nagata, MD,
PhD. Allergy Center, Department of Respiratory Medicine, Saitama Medical
University, Moroyama-Machi, Japan.
Background: There is evidence that humanized monoclonal antibody against
IgE (Omalizumab) is effective in severe allergic asthma. In this study, we
examined the effectiveness of omalizumab on asthma and nasal symptoms in
Japanese patients with severe allergic asthma and rhinitis.
Methods: An open-label study that enrolled 7 patients with both severe
allergic asthma and rhinitis who visited Allergy Center, Saitama Medical
University was performed. All patients presented uncontrolled asthma despite
medication including high-dose inhalational corticosteroids, long-acting
beta2-agonist, leukotriene receptor antagonist, theophylline, and oral predo-
nisolone. Omalizumab was added on their treatments and symptoms score
using Asthma Contol Test (ACT), peak expiratory ﬂow rate (PEFR), exhaled
nitric oxide (eNO), sputum eosinophils and nasal symptoms were evaluated
before and 12 to 16 weeks after omalizumab.
Results: Omalizumab signiﬁcantly improved ACT scores especially dose of
rescue use of short-acting beta2-agonist (P , 0.05) and PEFR (P , 0.05).
Furthermore, omalizumab signiﬁcantly decreased exhaled both eNO (P ,
0.05) and the percentage of eosinophils in induced sputum. On the other
hand, nasal symptoms were not change following induction of omalizumab.
Conclusions: Clinical effectiveness of omalizumab was conﬁrmed in
Japanese population of severe allergic asthma, but not rhinitis. The
therapeutic potency of omalizumab on asthma likely involves anti-inﬂam-
matory properties such as decreasing eNO or airway eosinophilia.
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Economic Evaluation of Grass Tablets for Immunotherapy
(oralair) Compared to Placebo in Adults and Children in Italy
Amerigo Cicchetti,1 Matteo Ruggeri,1 Alessandro Fiocchi, MD,2
Sergio Bonini, MD,3 Paola Puccinelli,4 Giovanni Passalacqua, MD,5
and Franco Frati, MD6. 1Faculty of Economy, Catholic University, Rome,
Rome, Italy; 2Melloni Paediatria, Milano, Italy; 3Second University of Na-
ples, Rome, Italy; 4Stallergenes Milan, Milano, Italy; 5Allergy & Respiratory
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Diseases, Universita Degli Studi Di Genova, Genoa, Italy; 6Department of
Medical and Surgical Specialties and Public Health, Perugia, Perugia, Italy.
Background: Speciﬁc immunotherapy is based on the regular administration
over time of a maintenance dose of allergen extracts to allergic patients
in order to modify the immune response, thus achieving a decrease in
symptoms/drug intake and an improvement in quality of life, possibly on the
long-term. Grass pollen tablet, Oralair (Stallergenes, Antony Cedex, France),
were developed and registered for rhinoconjunctivitis allergy induced by
grass pollen. There is sufﬁcient evidence for the clinical efﬁcacy of the
product, but pharmaco-economy data are lacking.
Methods: An economic analysis, using a rescue medication adjusted score
(AASS) was performed, based on the available registration trialsdto assess
the magnitude of Oralair effect if patients had not taken any rescue medica-
tion. In the present study the results of an adult and a pediatric study are
pooled together with economic data in order to perform a cost–effectiveness
analysis from the third party payer perspective. Medical visits, diagnostic
exams, skin prick test, and drugs were valorized in euros according to the
National tariffs and the standard drug prices in the Italian setting. The esti-
mated ROC also enabled us to quantify the effectiveness in terms of Quality
Adjusted Life Years (QALY). A decision tree was structured in order to
model the possible outcomes and costs, according to a low, moderate and high
AASS in adults and pediatric patients. A probabilistic sensitivity analysis was
ﬁnally conducted to test the robustness of the results as well as the consistency
with an assumed cost effectiveness threshold of euros 30.000/QALY.
Results: The results showed a relative difference of 1.84 in favor of the active
treatment versus placebo in absolute value in adult study and of 1.64 in
pediatric study. The results also show how the Oralair administration costs
1024 euro/QALY with high and moderate AASS. Including also the loss of
productivity the incremental cost-effectiveness ratio (ICER) in adults is 700
euro/QALY. The 95% of the simulation performed by sensitivity analysis
shows an ICER below the threshold of 30.000 euro/QALY.
Conclusions: In conclusion our results show that Oralair grass tablet is a cost




The Post-Treatment Efﬁcacy of House Dust Mite Sublingual
Allergen ImmunotherapyTablets inAdultsWithAllergic Rhinitis
Karl-Christian Bergmann, MD,1 Pascal Demoly,MD, PhD,2 Margitta Worm,1,3
Wystke Fokkens,4 Tabar Anna,5 Nguyen Helene,6 Olivier de Beaumont,6
Michel Melac,6 Marine Frereux,6 and Robert K Zeldin6. 1Allergy-Centre-Charité,
Charité - Universitätsmedizin Berlin, Berlin, Germany; 2Allergy, University Hos-
pital of Montpellier, Montpellier, France; 3Dermatology, Charite University
Clinic, Berlin, Germany; 4Department of Otorhinolaryngology, AMC, Amster-
dam, Netherlands; 5Department of Allergy, Complejo Hospitalario de Navarra,
Pamplona, Spain; 6Stallergenes SA, Antony, France.
Background: The efﬁcacy and safety of 2 doses of sublingual allergen
immunotherapy house dust mite (HDM) tablets administered for 12 months
were demonstrated in a randomized, double-blind, placebo-controlled study
of adults suffering from HDM-related allergic rhinitis. Here we report the
efﬁcacy during the 12-month, treatment-free, follow-up period.
Methods: Of the 509 patients randomized, 412 were included in the year 2 full
analysis set (500 IR ¼ 132, 300 IR ¼ 134, Placebo ¼ 146). The primary
efﬁcacy variable was the Average Adjusted Symptom Score (AAdSS, scale
0–12) an average of the daily score based on the severity of 4 rhinitis symptoms
(sneezing, rhinorrhea, nasal pruritus and nasal congestion) and adjusted for
rescue medication usage. The AAdSS was analyzed, at the end of the post-
treatment period, using an ANCOVA and at 3, 6, 8 and 12 months after
treatment cessation in a secondary analysis, using repeated measures ANCOVA.
Results: At the end of the post-treatment period, the 500 IR group showed
a signiﬁcant improvement in AAdSS vs. placebo (P ¼ 0.021) with a LS Means
difference of –0.70 (95% CI [–1.29, –0.11]), corresponding to –19.1%. The LS
Means difference of –0.62 (95% CI [–1.20, –0.05]) between the 300 IR and
placebo groups was also signiﬁcant (P ¼ 0.034), corresponding to –17.0%. The
difference between the active treatment groups was not statistically signiﬁcant.
Eight months after treatment cessation, which corresponds to the autumn peak in
HDM, the relative LS mean difference was –20.9% (P ¼ 0.0079) for the 500 IR
and was –25.5% (P ¼ 0.0011) for the 300 IR group.
Conclusions: During the 12-month post-treatment period, house dust mite
sublingual immunotherapy tablets at doses of 500 IR and 300 IR provided
sustained symptom relief, demonstrating their efﬁcacy after treatment
cessation.
158
Efﬁcacy of Immnunotherapy with an Oral Bacterial Lysate and
Vitamin C in the Primary Prevention of Acute Respiratory Tract
Infections in Children
Miguel Socci, MD, Pablo Slullitel, MD, and Luciano Cortigiani, MD.
Sociedad Argentina de Alergia e Inmunologia, SanJusto, Argentina.
Background: Airway infections are of great importance worldwide and
nearly half of the pediatric consultations in industrialized countries are caused
by respiratory tract infections (RTIs). Acute respiratory tract infections
(ARTIs) are among the main causes of morbidity and mortality in children
and recurrent infections of the respiratory tract are the most frequent cause of
pharmacotherapy in pediatric practice. The aim of this study was to evaluate
the efﬁcacy and tolerability of immunotherapy with oral bacterial lysates 1
vitamin C in the prevention of ARTIs in children.
Methods: 109 children with ages between 4 and 16 years with frequent
respiratory tract infections (2–5 infections the previous winter) were evalu-
ated. Participants were randomly allocated in 2 groups: 52 patients (mean age
6.8 6 2.9 years; 20 males 32 females) received no preventive therapy (NPT
group) and 57 (mean age 9.0 6 3.3 years; males 36 females 21) received
immunotherapy with oral bacterial lysates 1 vitamin C (VC group) at the
recommended dosage. Patients were followed up for 6 months, including the
administration period. Primary end points were the type and number of
ARTIs. Secondary end points (after the infection occured) included: time to
clinical cure, severity of infection, absenteeism from school due to an ARTI,
number of antibiotic courses or other drugs prescribed, and duration of con-
comitant drug treatment.
Results: There were signiﬁcant differences between groups in the cumulative
number of acute infectious episodes: 170 in NPT group (141 upper ARTIs, 29
lower ARTI, and 26 otitis episodes) vs 55 in VC group (50 upper ARTIs, 5
lower ARTI and 4 otitis episodes). Patients in the NPT group received 127
antibiotic courses compared to 28 in the VC group (P , 0.0001). Patients in
the NPT group had 475 days of absenteeism from school compared to 100
days in the VC group (P , 0.0001). No adverse events related to the trial
medications were reported.
Conclusions: Immunotherapy with oral bacterial lysates and vitamin C appears
to be very effective in the prevention of infectious episodes in pediatric patients
with frequent respiratory tract infections. Future studies are needed to further
explore the role of oral bacteroial lysates in ARTIs prevention.
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Therapeutic Effect and Safety of the Sublingual Immunotherapy
With Tropical House Dust Mite Allergen Vaccines in Asthmatic
Cuban Adult Patients
Raúl Lázaro Castro Almarales, MD,1 Mercedes Ronquillo, MD,2 Alexis
Labrada, PhD,3 Mirta Alvarez Castello, MD,4 Mayda González, MD,5
José Rodríguez, MD,6 Irene Enriquez, MD,6 Bárbara I Navarro Viltres,
MD,7 Yunia Oliva DíazLic, 8 and Maytee Mateo 8. 1National Center
Abstracts WAO Journal  February 2012
S52  2012 World Allergy Organization
of Bioproducts, Member of WAO, Cuban Society or Allergy, Cuban Soci-
ety of Immunology and Cuban Society of Family Medicine, Mayabeque,
Cuba; 2Allergy Service, Univesity Hospital General Calixto García, WAO
Member, Cuban Society of Allergy Member, Cuban Society of Immunology
Member, Havana, Cuba; 3Allergen Department, Naitonal Center of Bio-
products, WAO Member, Cuban Society of Allergy Member, Cuban Soci-
ety of Immunology, Mayabeque, Cuba; 4Allergology Department,
University Hospital General Calixto García, WAO Member, Cuban Soci-
ety of Allergy, Asthma and Clinical Immunology, Member, Cuban Society
of Immunology Member, Havana, Cuba; 5Docent Policlinic Pedro Fon-
seca, Member of Cuban Society of Family Medicine, Cuban Society of
Allergy, Havana, Cuba; 6Allergy Service, Univesity Hospital General Cal-
ixto García, Member of WAO, Cuban Society of Family Medicine, Cuban
Society of Allergy, Havana, Cuba; 7Cuban Society of Allergy Member,
Havana, Cuba; 8Allergen Department, Naitonal Center of Bioproducts,
Member of Cuban Society of Immunology, Mayabeque, Cuba.
Background: Subcutaneous injection route (SCIT) is burdened with the risk
of severe adverse events; therefore, sublingual immunotherapy (SLIT) is
being increasingly investigated. The efﬁcacy of SLIT in asthma has been
reviewed in a Cochrane meta-analysis. Allergic sensitization to Dermatopha-
goides pteronyssinus (Dp), Dermatophagoides siboney (Ds) and Blomia
tropicalis (Bt) is strongly linked to respiratory allergy and asthma in Cuba (3).
These last 2 species are relevant in tropical countries or even only in the
Caribbean region (4). Nevertheless, well conducted clinical studies of
immunotherapy with standardized allergen vaccines of these particular
species are very scarce.
Objective: This study was conducted to assess the therapeutic effect and
safety of allergen therapeutic vaccines of Dermatophagoides pteronyssinus,
Dermatophagoides siboney and Blomia tropicalis House-Dust mites
(VALERGEN, BIOCEN, Cuba) by sublingual route, in asthmatic patients.
Methods: Three Double-Blind Placebo-Controlled clinical trials were
performed in 40 patients each, showing asthmatic symptoms and positive
predominant Skin Prick Test (SPT) to each mite, respectively. Half of
subjects were randomized to active group. Treatment consisted of sublingual
drops with increasing daily doses for 3 weeks and maintenance doses (2000
BU) twice a week until 12 months.
Results: Therapeutic effect was assessed after 6 and 12 months using
symptoms/medication diary cards, peak expiratory ﬂow (PEF) measures and
skin sensitivity to investigated mites. Adverse reactions were classiﬁed using
the World Allergy Organization scale. The treatment reduced signiﬁcantly
(P , 0.01) clinical symptoms (38%, 95% CI, 33-44) and medication intake
(26%, 95% CI, 21-32) with respect to placebo. The skin sensitivity to the
allergens decreased also signiﬁcantly (P , 0.01). The allergen amount
needed to induce a positive SPT increased 52-fold. PEF variability decreased
also signiﬁcantly (P , 0.05). The treatment was considered effective in 77%
of patients. A major advantage as compared to subcutaneous route was
a remarked lower frequency of adverse effects. Local reactions were noted
only in 0.43% of administrations. No systemic reactions were observed.
Conclusions: The results indicate that sublingual immunotherapy using
allergen vaccines of tropical mite species is effective and safe in mite-
sensitive asthmatic patients.
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Candidate for Response Monitoring or Prognostic Biomarkers in
Two-Year Sublingual Immunotherapy for Japanese
Cedar Pollinosis
Takashi Fujimura, PhD,1 Syuji Yonekura, MD, PhD,2 Shigetoshi Horiguchi,
MD, PhD,2 Masahiro Sakaguchi, DVM, PhD,3 Masaru Taniguchi, MD,
PhD,1 and Yoshitaka Okamoto, MD, PhD2. 1Research Center for Allergy
and Immunology, Yokohama Institute, RIKEN (The Institute of Physical
and Chemical Research), Kanagawa, Japan; 2Department of
Otolaryngology, Head and Neck Surgery, Graduate School of Medicine,
Chiba University, Chiba, Japan; 3Department of Veterinary Microbiology,
School of Veterinary Medicine, Azabu University, Kanagawa, Japan.
Background: The aims of this study were to clarify the therapeutic effects
and potential prognostic and response monitoring biomarkers of sublingual
immunotherapy (SLIT) in a randomized, double-blind, placebo-controlled
(DBPC) clinical trial for Japanese cedar (Cryptomeria japonica) pollinosis.
Methods: This trial was carried out for 2 pollinosis seasons in 2007 and 2008
in double-blind status. Carry-over therapeutic effects were analyzed in 2009
in single-blind manner. We recruited 130 participants diagnosed as Japanese
cedar pollinosis based on clinical history and the presence of IgE speciﬁc to
Japanese cedar pollen of at least class 2. Cytokine production from peripheral
blood mononuclear cells and increase of iTregs were determined before and
after 2008 pollen season. Clinical symptoms were estimated using a pollino-
sis-symptom diary and Quality-of-Life (QOL) questionnaire in 2007, 2008,
and 2009 peak pollen seasons.
Results: The ﬁnal sample size included 88 subjects for on-treat analysis
(SLIT; N ¼ 51, placebo; N ¼ 37) for the DBPC study, and a total of 63
patients completed a pollinosis-symptom diary for the single-blind follow-up
study (SLIT; N ¼ 36, placebo; N ¼ 27). The symptom-medication score
(SMS) in the SLIT group did not differ from that in the placebo group in
the 2007 peak pollen season. However, the average SMS in 2008 and 2009
peak pollen seasons were signiﬁcantly ameliorated in the SLIT group com-
pared with the placebo group (4.2 vs. 5.3, P ¼ 0.02 in 2008; 3.5 vs. 4.5, P ¼
0.03 in 2009). The ratio of Japanese cedar pollen-speciﬁc IgE to total IgE
before treatment correlated with the SMS in the SLIT group in 2008. The
patients with increased Cry j 1-speciﬁc iTregs in the SLIT group showed
a signiﬁcant reduction of QOL and QOL-symptom scores compared with
those in the placebo group.
Conclusions: SLIT can ameliorate the clinical symptoms after 2-year
administration with standardized extract of Japanese cedar pollen and the
amelioration was observed for at least one pollen season after the treatment.
The ratio of speciﬁc IgE to total IgE can be used as a prognostic biomarker
and the increase of Cry j 1-speciﬁc iTregs may serve as a biomarker to
monitor the clinical response to SLIT.
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Efﬁcacy and Safety of 300IR 5-Grass Pollen Sublingual Allergen
Immunotherapy Tablets in us Adults With Grass-Pollen
Allergic Rhinoconjunctivitis
Linda Cox, MD,1 Thomas B. Casale, MD,2 Anjuli Nayak,3 David Bernstein,
4 Peter Creticos,5 Souad Mekhaldi,6 Olivier de Beaumont,6 Michel Melac,6
Armelle Montagut,6 Laurence Ambroisine,6 and Robert K Zeldin6. 1Medicine,
Nova Southeastern University, Ft. Lauderdale, FL; 2Creighton University,
Omaha, NE; 3Sneeze, Wheeze, and Itch Associates, LLC, Normal, Normal,
IL; 4Division of Immunology, Allergy and Rheumatology, University of Cin-
cinnati College of Medicine, Cincinatti, OH; 5Johns Hopkins University,
Baltimore, MD; 6Stallergenes SA, Antony, France.
Background: Clinical trials in adult and pediatric populations in Europe have
demonstrated the efﬁcacy and safety of 300IR 5-grass pollen sublingual
allergen immunotherapy (SLIT) tablets for the treatment of grass pollen-
induced rhinoconjunctivitis. Here we present an assessment of this treatment
in the US.
Methods: 473 grass pollen allergic adults with a Retrospective Rhinocon-
junctivitis Total Symptom Score of .12 (scale 0–18) during the previous
pollen season were randomized in a DBPC study to receive 300IR SLIT tablet
or placebo, once-daily starting 4 months before and continuing through
the 2009 grass pollen season. The primary efﬁcacy variable was the daily
Combined Score (CS, scale 0–3), which integrates symptoms and rescue
medication use. Secondary efﬁcacy assessments included the daily Rhinocon-
junctivitis Total Symptom Score (RTSS), daily Adjusted Symptom Score
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(AdSS, which adjusts the RTSS for rescue medication use) and daily indi-
vidual rhinoconjunctivitis symptom scores. The primary efﬁcacy endpoint,
the daily CS during the pollen period while on treatment, was analyzed using
a repeated measures ANCOVA model, as were the above secondary efﬁcacy
endpoints. The safety of the treatment was documented by means of adverse
event reporting, laboratory data and physical examination ﬁndings.
Results: The 300IR group showed a relative improvement in daily CS versus
placebo of -28.2% (relative difference in LS Means, 95%, CI [–43.4%;
–13.0%], P ¼ 0.0003). Signiﬁcant improvements in RTSS and AdSS were
consistent with previous European studies. There were also signiﬁcant
improvements in the individual symptoms: sneezing, rhinorrhea, nasal con-
gestion, itchy eyes and watery eyes. The 300IR SLIT tablet was generally
well tolerated. The most commonly reported treatment-emergent adverse
events (TEAEs) in the 300IR group were application site-reactions: oral
pruritus, throat irritation, and nasopharyngitis. No drug-related serious
TEAEs were reported. The overall safety proﬁle of 300 IR SLIT tablet was
consistent with that observed in European studies.
Conclusions: The 300IR SLIT tablet showed clinically meaningful efﬁcacy,
with signiﬁcant improvements on the primary and secondary endpoints. The
treatment was well-tolerated. Overall, the results in United States are
consistent with European observations.
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Establishing the Effectiveness, Cost-Effectiveness and Safety of
Oral and Sublingual Immunotherapy for Food Allergy: A
Systematic Review and Meta-Analysis of Intervention Studies
Ulugbek Nurmatov, MD, MSc, PhD,1 Graham Devereux, MD, PhD, FRCP,2
and Azizx Sheikh, Aziz , FRCGP, FRCP1. 1Centre for Population Health
Sciences, Allergy & Respiratory Research Group, The University of Edin-
burgh, Edinburgh, United Kingdom; 2Department of Child Health, Royal
Aberdeen Children’s Hospital, The University of Aberdeen, Aberdeen, United
Kingdom.
Background: Oral and sublingual immunotherapy to food allergens aim to
enable the safe consumption of the foods containing these allergens.
Methods: Systematic review of intervention studies, searching 11 interna-
tional databases and contacting an international panel of experts. Studies were
critically appraised using the Cochrane approach and meta-analysed.
Results: We identiﬁed 721 potentially relevant papers, from which we
selected 16 reports of 14 eligible trials (12 randomised controlled trials and 2
controlled clinical trials). Eleven of these trials evaluated oral immunotherapy
and the remaining 3 investigated sublingual immunotherapy.Meta-analysis
revealed that immunotherapy substantially reduced the average risk of
persisting food allergy in patients (RR ¼ 0.24; 95% CI, 0.11-0.50). Pooling
of the safety data however revealed an increased average risk of systemic
adverse reactions in those receiving immunotherapy (RR ¼ 1.13; 95% CI,
1.00-1.27); the average risk of local (minor oropharyngeal/gastro-intestinal)
adverse reactions was also increased in those receiving immunotherapy (RR
¼ 1.16; 95% CI, 1.04, 1.30). Meta-analysis of immunological data demon-
strated that allergen skin prick test wheal diameter signiﬁcantly decreased in
experimental groups compared to controls (mean difference –2.96 mm; 95%
CI, –4.48, –1.45), whilst speciﬁc-IgG4 increased by an average of 19.9 mg/
mL (95% CI, 17.1, 22.6); however there was no change in speciﬁc IgE: –5.2
kU/L (95% CI, –12.39, 1.99).
Conclusions: Oral/sublingual immunotherapy substantially reduces the risk
of food allergy, this effect being mediated by immunological mechanisms.
However, because of the stringent exclusion criteria used in many of the
reviewed studies and the increased risk of systemic adverse events,
immunotherapy cannot yet be recommended for routine clinical practice.
Future research needs to focus on larger randomised controlled trials
investigating long-term clinical tolerance induction, impact on quality of life
and estimating the cost-effectiveness of treatment. Overall, this appears to be
a promising line of potentially disease-modifying treatment for people with
a range of IgE-mediated food allergies.
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The Efﬁcacy of Human Plasma-Derived C1-Inhibitor
Concentrate Used for Prophylactic Treatment in Patients With
Hereditary Angioedema Due to C1-Inhibitor Deﬁciency
Dorottya Csuka, PhD, Zsuzsanna Zotter, Erika Szabó, MD, Zsuzsanna
Kelemen, MD, and Henriette Farkas, MD, PhD, DSc, III. Department of
Internal Medicine, Semmelweis University, Budapest, Hungary.
Background: Management of hereditary angioedema (HAE) comprises the
prophylaxis and emergency treatment of edematous attacks. Our aim was to
appraise the wide variety of the prophylactic use of plasma-derived human
C1-inhibitor concentrate in HAE type I and type II patients.
Methods: 125 patients with HAE (54 males, 71 females) were included in
our study. Classical short-term prophylaxis (STP) was administered before
surgical or diagnostic interventions in the head and neck region and other
types of major surgery, as well as before endotracheal intubation. Alterna-
tively, STP was introduced before the expected and unavoidable onset of
triggering factors.
Results: Before diagnosis of HAE, 128 interventions performed on 43 out of
125 patients induced edema: dental procedures (99 interventions in forty
patients), ENT interventions (13/9 patients), surgery in the head and neck
region (2/2 patients), surgery under general anesthesia (3/3 patients), gastro-
duodenoscopy (2/2 patients), delivery (6/6 patients) and artiﬁcial abortion (3/
2 patients). After diagnosis of HAE, 500 IU of C1-INH concentrate was
administered for STP, one hour before dental intervention (to 14 patients in
26 cases), surgery on the head or neck (to 7 patients in 7 cases), surgery under
ETN (to 11 patients in 12 cases), diagnostic procedures (1 colonoscopy, 2
bronchoscopy, 4 gastroduodenoscopy, 1 cardiovascular catheterization),
artiﬁcial abortion (to 4 patients in 6 cases), or childbirth (to 11 patients in
11 cases). Thirty-three of the 125 patients received prophylactic treatment on
70 occasions altogether. The medical history was positive for oedema
provoked by medical interventions in 20 of the 33 patients undergoing STP
with C1-INH concentrate. Eight patients received alternative prophylaxis: 2
patients during airway infections, 5 others before stressful life events, and one
patient on the ﬁrst day of the menstrual cycle over 4 months. In all cases, C1-
INH concentrate prevented the occurrence of attacks.
Conclusions: STP with C1-INH concentrate was effective in preventing
angioedematous attacks in all cases. After interventions, during 48 hours
observation period, edematous attacks did not occur. Repeated adminis-
tration did not diminish its efﬁcacy. C1-INH concentrate was well
tolerated, and it was never associated with potentially treatment-related
adverse effects.
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Treatment of Acquired Angioedema with the Bradykinin
Receptor Antagonist Icatibant
Maria Concetta Siani, MD,1 Angelica Petraroli, MD,1 Maria Bova, MD,1
Stefania Loffredo, PhD,1 and Massimo Triggiani, MD2. 1Department of Clin-
ical Immunology and Allergy, University of Naples Federico II, Naples, Italy;
2Division of Allergy and Clinical Immunology and Center for Basic and
Clinical Immunology Research (CISI), University of Naples Federico II,
Naples, Italy.
Background: Complement-mediated acquired angioedema (AAE) is a rare
condition characterized by an increased degradation of C1-esterase inhibitor
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(C1-INH) associated with lymphoproliferative disorders (AAE type I) or
caused by autoantibodies against C1-INH (AAE type II). Reduced C1-INH
activity leads to uncontrolled bradykinin formation and to angioedema
symptoms. There is no established treatment for AAE. Replacement with
plasma-derived C1-INH is effective in most patients with life-threatening
attack; however, icatibant, a bradykinin B2 receptor antagonist, may represent
an alternative treatment.
Methods: We describe 2 patients with AAE who were treated with
icatibant during acute attacks. Patient 1 is an 86 year old male who reported
cutaneous and abdominal attacks of angioedema beginning 2 years earlier
with a frequency of 2 to 3 month. He had low C1-INH (antigenic and
functional) C4 levels, normal C1q levels and detectable of anti-C1-INH IgM
and anti-C1q IgA. Because of increased frequency, his attacks were
treated with icatibant (30 mg s.c.). Patient 2 is a 64 year old female who
reported angioedema of the tongue and upper limbs in the last 4 years. Her
C4, C1-INH and C1q were low. Monoclonal gammopathy (6%) and IgA anti
C1-INH were found. After the diagnosis she started icatibant for acute
attacks.
Results: The ﬁrst patient used icatibant consecutively for 20 attacks (mainly
abdominal), with rapid resolutions of symptoms and no adverse events.
Symptoms resolution began 30 minutes after administration of icatibant and
resolution was complete in 3 to 4 hours. The second patient used icatibant for
a tongue attack, a mixed cutaneous-tongue attack and a severe facial attack,
with ﬁrst symptom improvement in 25 minutes and complete resolution after
16 to 18 hours. The only adverse event was erythema at the injection site
lasting few minutes.
Conclusions: Icatibant is an effective and well tolerated treatment of acute
attacks in patients with AAE. Our data suggest that blocking bradykinin
activity could be considered a good therapeutic strategy particularly in
patients with anti-C1-INH antibodies.
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Early Versus Delayed Treatment of Swelling Attacks with
Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With
Hereditary Angioedema due to C1-INH Deﬁciency
Konrad Bork, MD, and Jochen Hardt, PhD. Department of Dermatology,
University Hospital Mainz, Mainz, Germany; Department of Medical
Psychology and Medical Sociology, University Mainz, Mainz, Germany.
Background: To compare the efﬁcacy of icatibant in early versus late treated
attacks of hereditary angioedema.
Methods: Thirty-one patients received 30 mg icatibant subcutaneously at
various times for 121 swelling attacks. The time periods between onset of
attacks and icatibant injection, icatibant injection and the ﬁrst symptom relief,
and icatibant injection and resolution of symptoms or, in some attacks, the
start of a rebound attack were compared in 3 patient groups with different
times to injection.
Results: Data are reported as mean 6 SD. In 61 attacks treated at 2 or less
hours after attack onset, the time to ﬁrst relief was 16 0.9 hours and the time
to symptom resolution was 12.9 6 11.5 hours. In 43 attacks treated at more
than 2 to 5 hours, the time to ﬁrst relief was 0.8 6 1.2 hours and the time to
resolution was 15.16 15.3 hours. In 17 attacks treated later than 5 hours after
attack onset, time to ﬁrst relief was 0.66 0.6 hours and time to resolution was
12.6 6 10.3 hours. The percentages of attacks with ﬁrst symptom relief
within 30 minutes in the 3 groups were 59%, 70%, and 64.7%, respectively.
There were no statistically signiﬁcant differences between the groups. In
a subgroup of 20 attacks treated within 1 hour after attack onset, the time
to ﬁrst relief was 0.6 6 0.3 hours and the time to symptom resolution was 10
6 12 hours. The only adverse events were injection site reactions that all
resolved without intervention.
Conclusions: Icatibant is equally effective in early and delayed treatment of
acute HAE attacks, with an early onset of relief.
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Assessment of Chronic Spontaneous Urticaria by Serum-Induced
TNF & ALPHA; and MMP-9 Release
Sidsel Falkencronec, MSc,1 Lars Poulsen, MD, PhD,2 Marcus Maurer, MD,3
Carsten Bindslev-Jensen, MD, PhD,4 and Per Stahl Skov, MD5. 1Department
of Dermatology, Allergy center, Odense University Hospital, Odense C,
Denmark; 2Region Hovestaden, Kopenhagen, Denmark; 3Department of
Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin,
Germany; 4Odense University Hospital, Odense, Denmark; 5Reﬂab ApS,
Copenhagen, Denmark.
Background: Previous studies from our group have demonstrated that IgE-
mediated basophil activation leads to release of TNFa that in turn can induce
matrix metallo-proteinase-9 (MMP-9) release from monocytes. We wished to
investigate if serum from chronic spontaneous urticaria-patients with auto-
antibodies against IgE/IgE-receptor could induce TNFa and MMP-9 release
from donor PBMCs, and if release levels could be used to assess severity and
activity of chronic spontaneous urticaria (CSU).
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood from healthy donors and basophils isolated with MACS
Basophil Isolation Kit to 97 to 99% purity. Cells were pulsed 1 hour with
or without anti-IgE or with sera from CSU-patients/healthy controls and
incubated for a total of 21 h before protein analysis of supernatants. MMP-9
and TNFa in supernatants were measured with commercial ELISAs (R & D),
and histamine release determined with HR-test from RefLab ApS.
Results: Stimulations with serum-pools demonstrated that CSU-serum, in
contrast to healthy controls, was able to induce TNFa-release from isolated
basophils. 10 sera from healthy controls and 22 sera from CSU-patients were
tested for serum-induced histamine, TNFa and MMP-9 release. The CSU
sera were grouped by reaction/no reaction in the autologous skin serum test
(ASST), each group consisting of 11 sera. Nine of the 22 CSU-sera were
found positive in the HR-test, 6 sera from ASST1 and 3 from ASST-
patients. Sera from ASST1 and ASST- patients were observed to induce
highly signiﬁcant MMP-9 and TNFa release from donor PBMCs when com-
pared to sera from healthy controls (P , 0.001). Urticaria assessment score
(UAS) did not appear to correlate with release levels for histamine, TNFa or
MMP-9 in either group but in the ASST1 group, the ASST score appeared to
be positive correlated to histamine and TNFa release and to a smaller degree
to MMP-9 release.
Conclusions: We have shown for the ﬁrst time that serum from CSU-
patients, in contrast to serum from healthy controls, can induce TNFa release
from isolated basophils, as well as TNFa and MMP-9 from donor PBMCS.
Release levels appeared to be positive correlated to ASST reaction in ASST1




Allergen Sensitization in Children with Allergic Rhinitis and
Asthma in Guatemala
Ann Michelle Rigalt, MD,1 Juan Pablo Maselli, MD,1,2 Ninotchka Alvarado,
MD,1 Paola Carpio, MD,1 Víctor Chur, MD,1 Patricia Mayén, MD,1
Edgar Morán, MD,1 Mario Pinto, MD,1 and Juan Manuel Rodríguez, MD1.
1Asociación Guatemalteca de Alergia, Asma e Inmunología Clínica, Guatemala,
Guatemala; 2Career of Medicine, Universidad Rafael Landivar, profesor of
Immunology, Guatemala, Guatemala.
Background: There are no previous studies published reporting allergen
sensitizations in the population of most Central American countries, including
Guatemala. There are many types of climates in different regions, with
variable altitude, humidity, etc. The purpose of this study was to determine
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S55
the most common allergen sensitizations in children with Allergic Rhinitis
and Asthma in 4 different regions.
Methods: The study was performed on 461 children aged 5 to 15 years, from
4 different regions in Guatemala. A questionnaire was given to record
information regarding family history of atopic disease and symptoms of
Rhinitis and Asthma. The diagnosis was made in the presence of at least 3
symptoms of each disease. Scratch testing was performed using a commer-
cially available device and a panel of 8 allergen extracts: Cypress Arizona,
Dog, Cat, Dermatophagoides farinae and pteronyssinus, Cockroach Mix,
Mold Mix and Bermuda grass.
Results: Patient average age was 8.3 years, 55% male and 45% female.
Patient distribution by region was 35% from Huehuetenango, 29% Chiqui-
mula, 18% Mazatenango and 18% Quetzaltenango. Family history of allergic
rhinitis was present in 46% of patients, asthma in 51% and atopic dermatitis
in 33%. The most common diagnosis was rhinitis in 86% of patients, 52%
had asthma and 43%, both rhinitis and asthma. 98% had a positive Histamine
Control and all a Negative Saline Control. 36% of patients had no allergy
sensitization to allergens tested and 64% showed positive skin tests. The most
frequent allergic sensitization was to Dermatophagoides pteronyssinus (44%)
and farinae (43%), followed by Cockroach (28%). We also found less
frequently, positive skin tests to grass (14%), Cat (14%), Mold (10%), Dog
(8%) and Cypress (6%). The regions with higher dust mite sensitization were
Quetzaltenango (51–55%) and Huehuetenango (45–51%).
Conclusions: The most common allergen sensitizations in children with
allergic rhinitis and asthma in Guatemala are dust mites and cockroach.
Family history of either rhinitis or asthma is present in a signiﬁcant amount of
patients (46–51%) with atopic disease and allergic sensitization, showing that
it is an important risk factor in Guatemala. In 36% of patients in this study,
allergic sensitization does not seem to contribute to their rhinitis and asthma
symptoms.
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The Impact of Breast-Feeding Duration and Mode of Delivery on
Allergic Rhinitis in Korean Children: Cohort of Allergic Rhinitis
in Korea (Coar-korea) Study
Doo Hee Han, MD, PhD,1 Jae Min Shin, MD,2 Ji-Eun Lee, MD,1
Tae- Bin Won, MD, PhD,1 Dong-Young Kim, MD, PhD,1 Chul Hee Lee,
MD, PhD,1 Yang-Gi Min, MD, PhD,1 and Chae-Seo Rhee, MD, PhD1.
1Otorhinolaryngology, Seoul National University College of Medicine, Seoul,
South Korea; 2Otorhinolaryngology, Soonchunhyang University College of
Medicine, Cheonan, South Korea.
Background: There is much interest in the possibility that environmental
factors may inﬂuence the risk of allergic rhinitis in early life. We investigated
simultaneously the effect of mode of delivery and breast-feeding duration on
the development of allergic rhinitis in Korean children.
Methods: Data from 878 children of Cohort of Allergic Rhinitis in Korea
(COAR-Korea) Study were analyzed. Children with rhinitis were recruited
from 14 centers located in 6 provinces of South Korea between April 2008
and September 2010. All subjects were divided into allergic rhinitis (AR)
group and nonallergic rhinitis (NAR) group according to skin prick test
response. Data on environmental factors, including mode of delivery and
breast-feeding duration, were collected using a questionnaire. Relationships
were analyzed using logistic regression analyses.
Results: We found that 77% of the population with rhinitis had AR,
whereas 23% had NAR. Compared with never breast-fed, breast-feeding
for $ 12 month was signiﬁcantly associated with a lower prevalence of AR
(aOR, 0.64; 95% CI, 0.41-0.99). Children who were born by Cesarean
section showed a higher prevalence of AR compared with those born by
vaginal delivery (OR, 1.48; 95% CI, 1.05-2.09). However, after adjust-
ment for confounders under study, this difference was lost (aOR, 1.40;
95% CI, 0.90-2.20). Children born by Cesarean section were shown
signiﬁcantly lower rates of breast-feeding initiation (70.5% vs. 78.9%,
P ¼ 0.005) and lower rates of longer (for $ 12 months) breast-feeding
maintenance compared with those born by vaginal delivery (35.5% vs.
48.4%, P ¼ 0.005).
Conclusions: Amongst environmental factors, longer duration (for .12
months) of breast-feeding seems to be the most powerful protective factor
against the risk of developing AR in young children. However, breast-feeding
behavior seemed to be affected by mode of delivery and must be considered
as a strong confounding factor in evaluating the correlation between environ-
mental risk factors and development of allergic diseases.
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The Efﬁcacy of a Nasal Corticosteroid Ciclesonide for the
Treatment of Serous Otitis Media in Atopic Children
Safa Nsouli, MD. Senior Clinical Research Associate, Asthma and Allergy,
Danville Asthma and Allergy Clinic, USA, Danville, CA.
Background: Since chronic inﬂammation is the histopathologic landmark of
otitis media with effusion, clinical observations led us to believe that the use
of a Nasal Corticoteroid Ciclesonide may be more effective than an oral
antibiotic in the treatment of serous otitis media in atopic children.
Methods: We studied forty pediatric patients (age 6–11 years) in a random-
ized open labeled 2-week trial to compare the efﬁcacy of the nasal cortico-
steroid Ciclesonide 50 mcg/nostril 2 sprays per nostril once a day to an oral
antibiotic Amoxicillin/Clavulanate potassium (90 mg/kg/day in 2 divided
doses every 12 hours) for the treatment of otitis media with effusion. The
efﬁcacy of the treatment options was assessed using pneumatic otoscopy,
impedance tympanometry and audiometry to monitor the clinical course of
the middle ear effusion in both treatment groups.
Results: In the group nasal corticosteroid Ciclesonide a resolution of otitis
media with effusion occurred at the 8th day. In contrast in the group treated
with the oral antibiotic the resolution of otitis media with effusion occurred on
the 14th day.
Conclusions: In conclusion, the nasal corticosteroid Ciclesonide is more
effective than an oral antibiotic. The nasal corticosteroid Ciclesonide may be
a safer and shorter therapy given the safety issues with long term use of
systemic antibiotics in atopic children.
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Combination of a Nasal Antihistamine Olopatadine and A
Leukotriene Receptor Antagonist Montelukast Sodium for the
Treatment of Seasonal Allergic Patients not Currently Controlled
on Monotherapy Intranasal Antihistamine or a Leukotriene
Receptor Antagonist
Safa Nsouli, MD. Senior Clinical Research Associate Asthma and Allergy,
Danville Asthma and Allergy Clinic, Danville, CA.
Background: For seasonal Allergic Rhinitis (SAR) patients that remain
symptomatic on an intranasal antihistamine, Olopatadine or a leukotriene
receptor antagonist Montelukast sodium, the combination of intranasal antihis-
tamine with a leukotriene antagonist Montelukast sodium may provide additional
efﬁcacy in sub-optimally controlled Seasonal Allergic Rhinitis Patients.
Methods: In this open 8-week trial 40 patients with symptomatic SAR
currently using Olopatadine 1330 mcg/nostril or Montelukast sodium, 10 mg
p.o daily were randomized to receive the combination Olopatadine 1330 mcg/
nostril BID1Montelukast sodium, 10 mg p.o QD. The end points of the trial
include: rhinomanometry, nasal symptom score (composite score of nasal
congestion, rhinorrhea, sneezing, post nasal drip, and nasal itching) and ﬂex-
ible rhinopharyngolaryngoscopy examination.
Results: Mean efﬁcacy measurements at the end of the 8-week trial revealed
signiﬁcant improvements in all parameters examined in the combination
treatment group compared to baseline measurements.
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Conclusions: In conclusion, the combination nasal Olopatadine plus
Montelukast orally is more effective than monotherapy nasal Olopatadine
or Montelukast. It appears that in the combination treatment Olopatadine and
Montelukast sodium, the primary end points (rhinomanometry and symptom
scores) are signiﬁcantly improved.
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Augmentation of cxcl10 Expression in Nasal Fibroblasts Derived
from Patients With Recalcitrant Chronic Rhinosinusitis
Associated With Bronchial Asthma
Mamoru Yoshikawa, MD,1 Tsuyoshi Yoshimura, MD,1 Daiya Asaka, MD,1
Naoko Okada, PhD,2 Hirohisa Saito, MD, PhD,2 and Hiroshi Moriyama,
MD1. 1Department of Otorhinolaryngology, Jikei University School of Med-
icine, Tokyo, Japan; 2National Research Institute for Child Health & De-
velopment, Tokyo, Japan.
Background: The prevalence of chronic rhinosinusitis (CRS) that is
refractory to traditional therapy appears to be increasing, and CRS that is
refractory to traditional therapy tends to be associated with bronchial
asthma (BA), especially, aspirin-intolerant asthma (AIA). After viral
infections, patients with CRS associated with BA usually experience
exacerbations of their CRS symptoms, including nasal polyposis, in
comparison with CRS patients without BA. Alternatively tissue ﬁbroblasts
as an important component of the epithelial mesenchymal trophic unit play
a key role in maintaining tissue homeostasis and may also have the
potential to contribute to disease pathogenesis through their contribution to
inﬂammatory responses. On the basis of these ﬁndings, we hypothesized
that CRS patients with BA are more susceptible to inﬂammation of the
nasal and paranasal mucosa depending on the antiviral response of nasal
ﬁbroblasts.
Methods: Tissue specimens were obtained from the nasal polyps of 3
groups of CRS patients, a group that did not have BA (CRS-NA group),
a group with aspirin-tolerant asthma (CRS-ATA group), and a group with
AIA (CRS-AIA group). Nasal polyp ﬁbroblasts (NPFs) were isolated
from the specimens and stimulated with poly I: C. By using a DNA
microarray and performing a hierarchical clustering analysis we were able
to identify a cluster containing genes that were up-regulated after poly I:
C stimulation. To conﬁrm the results of the analysis data, we used
quantitative real-time PCR (qRT-PCR) and an enzyme-linked immu-
noadsorbent assay (ELISA).
Results: Expression of IFN-inducible protein 10 (IP-10)/CXCL10 transcript
was higher in the NPFs of the CRS-AIA group and CRS-ATA group than in
the CRS-NA group and control group. These ﬁndings were conﬁrmed by
qRT-PCR and ELISA.
Conclusions: The results of this study suggest that the increased poly I:C-
induced CXCL10 expression in NPFs derived from the CRS patients with BA
is involved in susceptible to T helper (Th)1-type immune response in the
nasal and paranasal mucosa by viral infection compared with CRS patients
without BA.
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Correlation between CU/ZN-SOD and Macrophages or
MUC5AC in Eosinophilic Chronic Rhinosinusitis With
Nasal Polyps
Noritsgu Ono, MD,1 Takeshi Kusunoki, MD,1 and Katsuhisa Ikeda, MD2.
1Otorhinolaryngology, Juntendo University Graduate School of Medicine,
Bunkyo-ku, Japan; 2Otorhinolaryngology, Juntendo University Faculty of
Medicine, Tokyo, Japan.
Background: Recently, some researchers have reported that increases and
decreases of inﬁltrating macrophages, a mucin gene or the antioxidant as well
as inﬁltrating eosinoplils would be related to severe asthma. At present,
eosinophilic chronic rhinosinusitis with nasal polyps (ECRS) has been
considered intractable rhinosinusitis. From the point view of “one air way,
one disease,” we immunologically examined macrophages and mucin gene
(MUC5AC), IL-17A with these promotive factors and Copper-and Zinc-con-
taining superoxide dismutase (Cu/Zn-SOD). Furthermore, we discuss whether
Cu/Zn-SOD would be associated with inﬁltrating macrophages, MUC5AC
and IL-17A.
Methods: The patients were classiﬁed into ECRS and non-eosinophilic
chronic rhinosinusitis with nasal polyps (non-ECRS) groups. In addition,
normal mucosal membranes of the sphenoid sinus removed at operation for
pituitary adenoma were used as control. Part of each specimen derived from
the nasal polyps of ECRS and non-ECRS were divided and ﬁxed in 10%
phosphate buffered formalin, embedded in parafﬁn, processed routinely and
then prepared as semi-thin sections (3.5 mm). We immunohistochemically
observed Cu/Zn-SOD and macrophages by using CD68, IL-17A, and
MUC5AC.
Results: Both the numbers of macrophages (CD 68 positive cells) and IL-
17A-positive cells in the ECRS were signiﬁcantly greater than in non-
ECRS. Furthermore, there was a signiﬁcant correlation between CD 68
and IL-17A positive cells. The rate of epithelial cells with MUC5AC-
positive reaction was signiﬁcant in the comparison of ECRS with non-
ECRS. On contrast, the rate of Cu/Zn-SOD-positive epithelial cells in
non-ECRS was signiﬁcantly greater than that in ECRS. Cu/Zn-SOD was
inversely and signiﬁcantly correlated with macrophages, IL-17A, and
MUC5AC.
Conclusions: The present study suggested that the decrease of Cu/Zn-SOD in
ECRS could be increased by the inﬁltration of macrophages, the expression
of IL-17A, and MUC5AC.
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Relationship Between Allergic Rhinitis and
Dental-Facial Abnormalities
Miguel Alejandro Medina. Alergia Pediatrica Hospital General Issste Veracruz,
Colegio Mexicano De Alergia E Inmunologia Clinica, Veracruz, Mexico.
Background: Allergic rhinitis (AR) affects 10 to 25% of the general
population and is of great importance for the impact on quality of
life and school performance.1 Rhinitis has been associated with cranio-
facial abnormalities due to the high frequency of mouth breathing,
oral breathing syndrome occurs when the child replaces the correct pat-
tern of breathing caused by nasal obstruction resulting from allergic
disease.2
Objective: To establish the type of relationship between allergic rhinitis and
dental-facial abnormalities in the pediatric population of Veracruz ISSSTE
Hospital General in 2009.
Methods: A case-control study, cases (25) were patients aged 6 to 18
years of age with allergic rhinitis. Controls (25) were entitled 6 to 18
years, informed consent, were referred to the dental service, where he
underwent medical history and oral examination. For data analysis
descriptive statistics were used, and chi-square test statistic (X2) and
t test.
Results: The average age of cases was 12 6 3.5 years, mean bodyweight
44.33 kg, age of controls was 12.6 6 3.8 years, weight 48.23 kg. 16% of the
cases has any oral habit (ﬁnger, tongue), in controls 36% assumed the habit.
The predominant type of skull was normocéfalo controls (84%), where was
dolichocephalic (63%). In dental abnormalities (dry lips, deep palate, maloc-
clusion) 100% of cases had at least one, 90% have deep palate, in controls
32% had impaired and 24% with deep palate. We found a statistically sig-
niﬁcant difference P¼ 0.007, in the variable Inadequate Respirator Syndrome
Nasal.
Conclusions: There is a partnership between the patient with allergic rhinitis
and dental-facial abnormalities.
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Reduction in Allergic Rhinitis Index by Decreasing Aero-
Allergens and Malodor Causing Volatile Organic Compounds by
Luna Air Puriﬁers Using Photo-Catalytic Oxidation
(PCO) Technology
Nabarun Ghosh, PhD,1 Cristina Aguaiza,1 Alicia Guzman, BS,1
Jay Chudasama, BS,2 Jeff Bennert, PhD, CTN,3 and A. B. Das, DSc4. 1Life,
Earth and Environmental Sciences, West Texas A & M University, Canyon,
TX; 2Research and Development, LUNA US LLC, Las Vegas, NV; 3Research
& Development, Air Oasis, Amarillo, TX; 4Department of Agricultural Bio-
technology, College of Agriculture, Orissa University of Agriculture & Tech-
nology, Bhubaneswar, India.
Background: The quality of the environment within buildings is a topic of
major importance for public health. Breathing pure and clean air allows us to
think more clearly, sleep more soundly, and stay healthier. Studies show that
we receive 56% of our energy from the air we breathe, more than from water
and food combined. On average we breathe 37 pounds of air a day. It has
been established that the use of negative ions in a puriﬁcation system is an
effective means of eradicating aeroallergens in room air.
Methods: The wall-mount, Inducts and Mobile Saniﬁer air puriﬁcation units
of Luna are designed to sanitize air, to kill surface mold, bacteria, and viruses
in areas up to 26,000 cubic feet. Samples were collected from the clinic rooms
to analyze the VOC concentrations using the Luna air puriﬁers to detect
the efﬁciency in reducing the VOCs in the indoor air. We analyzed the
aroallergens and VOCs prevalent in the indoor air in the clinics at the
Coulter Animal Hospital, Amarillo, Texas. The data were correlated to
the inhalant allergy index before and after running air puriﬁers that use PCO
technology.
Results: Samples from the clinic rooms to analyze the VOC concentrations
using the Luna air puriﬁers to detect the efﬁciency in reducing the VOCs in
the indoor air. The SKC Pocket Pump and thermal desorption tubes were used
to obtain the samples from the indoor air. Pumps were set on 200 mL/min as
air ﬂow to estimate the concentration of Acetic acid, Isobutyric acid, Butyric
acid, Isovaleric acid, Valeric acid, Hexanoic acid, Phenol, p-cresol, 4-ethyl,
2-amino, Indole, and Skatole. All desorption tube samples were analyzed
using a Markes UNITY and Markes Ultra automated thermal desorber (ATD)
and a Varian 3800/Saturn 2000 GC with a MS. Slides with double sticky tape
were exposed to room air stained with 2% safranin and were observed using
a BX-40 Olympus microscope with DP-70 and Image Pro Plus software.
Conclusions: The data were correlated with the aeroallergen index and the
frequency of inhalant allergy cases that showed reduction in allergic rhinitis
index on using air puriﬁers.
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TheMissing Link!! Specialist Nurse-Led Education for Parents of
Children With Atopic Eczema
Deryn Thompson, RN BNg. Allergy and Dermatology Outpatients, Child-
ren’s Youth and Women’s Health Service, North Adelaide, Australia.
Background: Australia’s rate of children with food allergy is still on an
upward trend. In infants the earliest manifestation is usually atopic eczema.
Australian Bureau of Statistics National Health Survey (ABNHS, 2007–2008,
p.305) reported hayfever, allergic rhinitis and asthma in the top 10 most
commonly reported long-term conditions for children and young people.
Early effective management of eczema is essential. Australia’s medical model
means long wait for allergy appointments with a specialist, limiting review
appointment availability. Following diagnosis of atopic eczema and treatment
recommendations by a clinical immunologist/allergist or dermatologist,
parents report having many unanswered questions -contributing to anxiety
and confusion. They feel overwhelmed that eczema is incurable and long-
term management and constant vigilance is required. Many feel a lack of
support and despair. Education, demonstration and support by a nurse spe-
cialist in eczema management at a Children’s hospital in Adelaide has im-
proved outcomes and reduced the psychosocial burden of the condition.
Parents and children receive 30 minutes explanation, demonstration of re-
quired treatments and an individualised, written eczema action/care plan. The
education sessions use a conceptual framework based on Social Cognitive
Theory where active participation, goal setting and forward planning enhance
understanding assisting the long-term behavioural changes needed to master
eczema management effectively. The families are reviewed by the nurse
several weeks later to review progress and answer questions that have arisen
over the preceding weeks. The education sessions are tailored to the individ-
ual family needs, encourage self-management and aim for increased conﬁ-
dence to self-regulate the condition as it waxes and wanes.
Methods: Twenty-two families in a novel clinic at Children’s Youth and
Women’s Health Service, Adelaide undertook a pre-post intervention ques-
tionnaire surveys.
Results: All 22 families (2009) reported that the service had assisted their
understanding, enhanced management and compliance and called for
expansion as soon as possible. A research project is scheduled in the near
future to expand the service within the recommendations of the South
Australian Chronic Diseases Action Plan 2009-2018.
Conclusions: Specialist nurse’s support assists parents to gain the required
practical skills, understanding increased conﬁdence and compliance with their
recommended treatments.
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Sublingual Immunotherapy for Grass Pollen Allergy in Children:
A Systematic Review and Meta-Analysis
Rebecca Bryson, MSc Allergy BSc Hon, RN Dip HE,1,2. 1Women and Child-
rens Services, Wirral University Teaching Hospital Arrowe Park, Mersey-
side, United Kingdom; 2Faculty of Medicine University of Southampton, MSc
Allergy, Southampton, United Kingdom.
Background: Sublingual immunotherapy (SLIT) using grass pollen extracts
is an attractive treatment option compared with subcutaneous immunotherapy
(SCIT) for children suffering with the symptoms of seasonal allergic rhino-
conjunctivitis, with or without asthma. However, evidence for the efﬁcacy of
SLIT in children remains unclear. The objective was to undertake a systematic
review of the available literature to identify high quality paediatric studies of
SLIT for grass pollen allergy to assess the safety and beneﬁts of SLIT
compared with standard medication alone.
Methods:MEDLINE, EMBASE, CINAHL, NHSEED, DARE and Cochrane
were searched from 1st Jan 2000 to June 2010. A pre-speciﬁed inclusion
criteria was used to select studies, which were assessed for the risk of bias
using the Jadad scale. The outcomes of interest were data from the studies
including the reduction of nasal, eye and chest symptoms, use of symptom
relieving medication and safety.
Results: Nine studies met the inclusion criteria. A narrative synthesis on the
safety of SLIT found a high incidence of mild, adverse events. Outcomes
were pooled using Rev Man 5 and the random effects model. Inter-study
heterogeneity was measured using the I2 statistic and was ,70% in all meta-
analyses. The reduction of total allergic rhino-conjunctivitis symptom scores
indicated a small highly signiﬁcant reduction with non-signiﬁcant heteroge-
neity. (SMD –0.24, 95%, CI–0.38 to –0.11 P ¼ 0.0005), (I2 15% P ¼ 0.32).
The reduction in total relief medication use scores compared to placebo was
non-signiﬁcant. (SMD-0.25 CI -0.50, 0.01, P ¼ 0.06). I2 67% (P ¼ 0.006).
Conclusions: SLIT has a small beneﬁt on symptoms but does not
demonstrate a signiﬁcant reduction in medication use. This justiﬁes current
SLIT use in paediatric allergy in the UK where availability is limited to
children who remain symptomatic despite having proven concordance using
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optimised symptom relieving medication and children in whom SCIT is
contra-indicated.
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Effect of EPA-DHA Supplementation on Forced Expiratory
Volume in One Second (FEV1) and Triglycerides in Obese
Adolescents With Hypertriglyceridemia
Nancy Mendez Berreondo. 3204, Distrito Federal, Mexico.
Background: Evaluate the effect of supplementation of eicosapentaenoic
acid (EPA) and docosahexanoic acid (DHA) in FEV1 and triglyceride levels
in obese adolescents.
Methods: Single blinded, parallel, clinical trial in 2 groups of adolescents
supplemented with an intake of 3 gm/d of EPA-DHA versus 3 gm of grenetin
for 3 months. We included adolescents with exogenous obesity with Body
Mass Index (BMI) CDC . 95%. All patients underwent anthropometry, lipid
proﬁle and spirometry at baseline and study end. They were divided into 2
groups: G1: EPA-DHE obese and G2: Grenetin obese. Samples analyzed by
T Student (paired and independent).
Results: Adolescents were recruited with hypertriglyceridemia . 150 mg/dl,
female 45.5%, male 54.5% mean and SD 12 6 1.3 years. There were 34
patients in G1 and G2: 40 patients. The initial values averages the baseline IC
95% FEV1 G1 102.27 (106.06–98.48), G2 102.18 (106.12–98.26), Tiffaneau
Index G1: 0.87 (0.90–0.84), G2 0.85 (0.83–0.88) Triglycerides G1 221.71
(246.10–197.32), G2 190.91 (206.90–174.92), Cholesterol G1 169.29
(179.35–159.23), G2 157.09 (169.90–144.28), HDL G1 32.96 (35.58–
30.36), G2 33.85 (36.55–31.06). After 3 months, FEV1 G1 100.39
(104.99–95.79), G2 100.80 (105.88–95.74), Tiffaneau Index G1 0.83
(0.85–0.81), G2 0.86 (0.86–0.83) Triglycerides G1 101.00 (117.64–84.36),
G2 127.09 (149.87–104.31), Cholesterol G1 169.88 (181.70–158.06), G2
163.32 (176.00–148.64), HDL G1 35.95 (40.25–31.66), G2 35.81 (38.93–
32.71). Supplementation with EPA-DHA and grenetine for 3 months in tri-
glyceride basal levels had only one signiﬁcant value (P , 0.05), without
a signiﬁcant in FEV1.
Conclusions: Supplementation with EPA-DHA and grenetine for 3 months is
helpful for reducing basal levels of triglycerides.
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A Pilot Study of Caregiver’s Recall of Their Child’s Skin Test
Results and Environmental Remediation Education
Kristen Townsend, BSN,1 James Corry, MD,2 Beth Quigley, MSN, RN,3
and Maureen George, PhD, RN, AE-CFAAN3. 1University of Pennslyvania
School of Nursing, Philadelphia, PA; 2Allergy and Immunology, Children’s
Hospital of Philadelphia, Philadelphia, PA; 3Family and Community Health,
University of Pennslyvania School of Nursing, Philadelphia, PA.
Background: Allergic asthma is common in urban minorities and evidence
suggests that environmental remediation is an effective management strategy.
However, remediation requires complex interventions. The purpose of this
pilot study, therefore, was to examine caregiver’s recall of their child’s skin
test results and the accuracy of planned remediationw4 months after testing.
Methods: A Q-sort was used to determine caregiver’s knowledge of the
appropriate remediation for their child’s allergic status. Using this method,
caregivers sorted cards into piles: important for my child’s asthma, not im-
portant or unsure. Each of the 52 cards represented one intervention for
a common indoor allergen. Three of the 52 cards were speciﬁc to cat allergen,
3 for dog, 10 for mold and 23 for dustmite. Unlike typical Q-sorts, these cards
used pictures and low-literary language. Caregivers were then instructed to
place each card on a continuum of highest to lowest priority. At the conclu-
sion of the Q-sort, caregivers received feedback on the accuracy of their
prioritization in the context of their child’s skin test results. Acceptability
of this technique was assessed using qualitative interviews.
Results: Five African American women (mean age 33.6; 80% receiving
public assistance) caring for 5 children (4 males; mean age 7.8) were enrolled.
Caregivers recalled 4.6 positive results per child; only 4.2 positive results per
child were noted. However, no caregiver recall of skin test results was
concordant with actual results. Caregiver’s accuracy in identifying trigger
reduction strategies speciﬁc to their child’s skin test results ranged from 33
to 100% for cat, 40 to 70% for molds, 70 to 87% for dust mites, and 100% for
the 1 dog allergic child. No standard battery was performed; rather each test
was speciﬁc to the child’s history. Qualitative interviews showed Q-sort to be
an acceptable way to learn about remediation.
Conclusions: Caregivers do not accurately recall skin test results and this
may, in part, impede their ability to implement appropriate interventions. A
low literacy game-style approach is a novel strategy to provide complex
teaching that warrants further investigation.
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Evaluation and Comparison of Lung Function by
Plethysmography in Adolescents with Morbid Obesity, not
Morbid Obesity and Healthy Eutrophic Children
Luis Octavio Hernandez-Mondragon, MD, Blanca del Rio, MD,
Dino Pietropaolo-Cienfuegos, MD, Jaime Mariano del Río-Chivardí, MD,
and Miguel Angel Rosas-Vargas, MD. Pediatric Allergy and Clinical
Immunology, Hospital Infantil Federico Gomez, Mexico City, Mexico.
Background: The objective was to measure and compare lung function by
plethysmography in young healthy children, obese and morbidly obese.
Methods: Cross-sectional, prospective study in 150 adolescents from 11 to
17 years old, grouped according to their body mass index (BMI): group 1
(G1) healthy eutrophic (BMI percentile 10–84 of the boards of the CDC)
Group 2 (G2) not morbidly obese (BMI 85–98) and group 3 (G3), morbidly
obese (BMI> 99). Anthropometry was performed and plethysmography. Sta-
tistics: mean, standard deviation (SD), conﬁdence interval 95%, CI 95%.
ANOVA post hoc analysis.
Results: The mean age was 13.7 years, 46.7% women and 53.3% men. G1
had 40 children, G2 had 67 and G3 had 43. Mean values and CI 95% of vital
capacity (VC) of G1 was 104.97% (100.12–109.82), G2 114.65% (111.36–
117.94), G3 118.09% (112.71–123.47) [G1 with signiﬁcant difference com-
pared the G2 and G3 P ,0.05]. The total lung capacity (TLC) was 124.67%
G1 (105.94–143.40), G2 145.61% (114.77–176.45), G3 132.27% (125.14–
139.41) [no intergroup difference]. Functional residual capacity (FRC) of G1
was 145.95% (133.75–158.14), G2 122.41% (110.23–134.59), G3 115.74%
(103.05–128.43) [G1 with signiﬁcant difference compared with the G2 and
G3 P ,0.05]. The expiratory reserve volume (ERV) of G1 was 113.15%
(90.57 – 135.72), G2 68.64% (60.34 – 76.93), G3 67.33% (52.40 – 82.26) [In
contrast to the G1 compared to G2 and G3 P ,0.05]. Inspiratory capacity
(IC) in G1 was 76.90% (66.94–86.85), G2 102.04% (94.94–109 145), G3
115.72% (105.61–125.82) [G1 with signiﬁcant difference compared with the
G2 and G3 P , 0.05].
Conclusions: The morbidly obese have a lower FRC and ERV and increased
IC and CV.
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Selecting Primal Therapy Appropriate for the Type of
PollinosisdTopic-J Study
Kimihiro Okubo, MD, PhD, and Minoru Gotoh, MD, PhD. Department of
Otolaryngology, Nippon Medical School, Tokyo, Japan.
Background: In Japanese Guideline for Allergic Rhinitis, drugs for treatment
after the start of pollen dispersal are recommended for each type of pollinosis,
but drugs for primal therapy are not categorized by the type of pollinosis. We
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S59
examined the adequacy of different drugs for primal therapy on each type of
pollinosis.
Methods: Patients with pollinosis attending 11 otorhinolaryngology clinics in
Tokyo during part of pollen season (February 18–26) were enrolled and
assigned to either an anti-leukotriene agent (pranlukast) or an antihistamine
based on their symptoms in the previous year. During 3 months of treatment,
symptoms and quality of life (QOL) were investigated by a mail questionnaire at
7 time points (at the start of treatment, and between March 1 and May 15).
Results: Of 150 patients with pollinosis who were registered, analysis was
conducted on 144 patients (62 receiving anti-leukotriene therapy and 82
receiving antihistamine therapy), excluding those with incomplete question-
naires. In both groups, scores for symptoms of pollinosis and QOL were low,
suggesting that both drugs were effective considering the high pollen levels
season (5–9 times higher than the previous year). After deﬁning types of
pollinosis by the severity of symptoms (sneezing, rhinorrhea, or nasal block-
age), stratiﬁed analysis was conducted. This showed that antihistamine ther-
apy was effective for the sneezing/rhinorrhea type and anti-leukotriene
therapy was effective for the nasal blockage type, with no difference between
the 2 drugs the combined type. For the nasal blockage type, symptoms and
QOL improved faster with anti-leukotriene than antihistamine therapy from
the peak to the end of the pollen season. No adverse effects were observed.
Conclusions: When either an anti-leukotriene (pranlukast) or an antihista-
mine was used for primal therapy of pollinosis, both drugs improved
pollinosis symptoms and QOL. Stratiﬁed analysis showed that the antihis-
tamine was more effective for the sneezing/rhinorrhea type and the anti-
leukotriene was more effective for the nasal blockage type, with no difference
in effectiveness for the combined type. Therefore, appropriate drugs for the
type of pollinosis should be selected for primal therapy.
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Olfactory Disfunctions in Patients with Chronic Rhinosinusitis
María Victoria Sánchez Vallecillo,1,2 María Emilia Fraire,3 Carlos E. Baena-
Cagnani, MD,4,5 and Mario Zernotti, MD, PHC1. 1Otorrinolaringología,
Sanatorio Allende, Córdoba, Argentina; 2Research Centre of Respiratory
Medicine, Faculty of Medicine, Catholic University of Cordoba, Córdoba,
Argentina; 3Otorrinolaringología, Sanatorio Allende, Córdoba, Argentina;
4LIBRA Foundation, Cordoba, Argentina; 5CIMER (Centro de Investigación
en Medicina Respiratoria), Faculty of Medicine, Catholic University of
Cordoba, Fundación LIBRA Argentina, Cordoba, Argentina.
Background: There are several factors that could produce olfactory
dysfunction. The chronic inﬂammation of the upper air tract, especially
allergic rhinitis is mentioned as a trigger factor. The aim of this study is assess
the prevalence and identify clinical features associated with olfactory
dysfunction in patients with chronic rhinosinusitis.
Methods: A prospective, analytical and observational study in adult patients
(. 18 years) with chronic rhinosinusitis during the period May-October of
2010. We used the CCCRC (Connecticut Chemosensory Clinical Research
Center smell test)
Results: A total of 33 patients were investigated. In the group of patients
between 18 and 39 years, 73% of patients suffer from hyposmia and 18%
anosmia; for the group of 40 to 64 years, 63% with hyposmia and 37%
anosmia; patients older than 65 years, 67% hyposmia and 33% with anosmia.
In the smokers group the 11% of patient presented hyposmia and 13%
anosmia (P , 0.05); 5% in both cases had a history of nasal endoscopic
surgery. In patients with chronic rhinosinusitis with nasal polyps have 18%
with hyposmia and 19% with anosmia (P , 0.05). A 20% with allergic
rhinitis had hyposmia while anosmia in 22% (P , 0.05). Septal deviation
patients had 20% of hyposmia (P , 0.001) and 12% anosmia. Patients with
turbinate hypertrophy had 22% hyposmia (P , 0.001) and 13% anosmia
while in the group of patients with Asthma, the 4% had hyposmia and
16% anosmia (P , 0.001).
Conclusions: Nasal polyposis, septal deviation, turbinate hypertrophy,
smoke, allergic rhinitis and asthma are negative predictors factors of olfactory
dysfunction in patients with CRS. A previous endoscopic surgery, age and
sex would not intervene in the olfactory loss.
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Perceptions of Caregivers of Patients with Cow Milk Allergy
Regarding the Treatment
Glauce Hiromi Yonamine,1 Divanice Contim,2 Ana Paula Beltran Moschione
Castro, MD, PhD,3 Cristina Miuki Abe Jacob,MD, PhD,4 and Antônio Carlos
Pastorino,MD, PhD3. 1Division of Nutrition, Instituto da Criança, Faculdade de
Medicina do Hospital das Clínicas da Universidade de São Paulo, São Paulo,
Brazil; 2Universidade Federal do Triângulo Mineiro, Uberaba, Brazil;
3Department of Pediatrics, Instituto da Criança, Faculdade de Medicina do
Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil;
4Instituto da Criança, Faculdade de Medicina do Hospital das Clínicas da
Universidade de São Paulo, São Paulo, Brazil.
Background: To understand the perceptions of caregivers of patients with
cow milk allergy (CMA) regarding the disease and its treatment.
Methods: Qualitative study in which caregivers of children and adolescents
with conﬁrmed CMA followed, at least, for 1 year, were interviewed. They
were recruited from outpatient clinic of Allergy and Immunology Division
from a tertiary pediatric hospital in São Paulo, Brazil. The interviews were
conducted under conditions of privacy and 2 opened questions were pro-
posed: “Tell me about your experience with cow’s milk allergy treatment”
and “What do you expect from your child’s disease treatment?” Data were
audio-recorded, transcribed, analyzed using the content analysis method and
categories and subcategories were generated based on their speeches.
Results: Nine interviews were done and 3 categories with subcategories
emerged: A. Treatment and education of the patient and their caregivers (life
experiences, bases of treatment, coping with the disease). B. Resolution of the
disease (hope, gradual improvement). C. Quality of life (social inclusion,
family daily activities, costs of dietary treatment). Caregivers experienced
difﬁculties during the initial treatment but pointed out that the guidance given
during follow-up made the adjustments easier. They also compared CMA
with other chronic diseases and highlighted the importance of their children
follow-up in this institution for adequate control. They commented on the
difﬁculties about lack of cooperation from other family members regarding
the restrictive diet, their experience coping with allergic reactions, doubts
about the treatment and gaps on knowledge about the disease by other
physicians and people. The majority of relatives was satisﬁed with the gradual
improvement of patients, although there are no drugs or vaccines for
treatment, and observed a reduction on the severity of symptoms and
tolerance of milk traces. In addition, they commented on the efforts to give
a normal life for their children, the changes in their daily lives and the
difﬁculty to buy special products.
Conclusions: This qualitative study allowed us to understand how families
cope with the disease, their histories and hopes about the treatment. They feel
a great burden of the disease and need support and orientation from health
professionals.
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Incidence of Systemic Reactions (SRS) to Prick (P) and
Intradermal (ID) Tests, Response to Immediate (“STAT”)
Epinephrine IM (EPI IM) Dose versus BMI, Number of Delayed
SRS, and WAO Systemic Reaction Grade
Dona Shearer, RN,1 Richard F. Lockey, MD,2 Roger Fox, MD,2
Dennis Ledford, MD,2 and Mark Glaum, MD2. 1Division of Allergy &
Immunology, University of South Florida, Tampa, FL; 2Division of Allergy
& Immunology, University of South Florida and James A. Haley Veterans’
Hospital, Tampa, FL.
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Background: To determine the incidence of SRs to P and ID tests,
the response to stat epi IM, number of delayed SRs, the dose of epi IM
versus BMI and the World Allergy Organization (WAO) Grade (1-5) of
the SRs.
Methods: SRs were compiled from 07/2010 to 06/2011 to P and ID tests for
any combination of approximately 20 allergens (pollens, animal emanations,
molds and Hymenoptera) in 1,332 subjects. Nurses administered stat epi IM
(1:1000 v/v), 0.2 mg IM, into the arm or thigh for any signs or symptoms (SS)
of a SR, including, but not limited to, itchy eyes, nose, pharynx, or palms;
rhinorrhea, nasal congestion, sneezing; and generalized erythema, skin
pruritus, or urticaria. SS (WAO Grade), total epi IM dose, and delayed SRs
were recorded. Repeat doses of epi IM were given if SS persisted or
worsened.
Results: 31 (2%) had SRs: 24 (77%) female, 7 (23%) male; 5 (16%)
pediatric, 26 (84%) adult. Of the 31 SRs, 26 (84%) had Grade 1, 5 (16%)
Grade 2 and Grades 3 to 5. 13 (42%) experienced SS during P and 18 (58%)
during ID or at the completion of P and ID. All received stat epi IM with any
SS. 2 BMIs were not available. 28 SRs, with a mean BMI of 28.5 (overweight
range 25.0–29.9) received one epi IM, 0.2 mg, and one BMI 20.4 (normal
range 18.5–24.9) received 2 epi IM (total 0.3 mg). There were no under-
weight (less than 18.5) or obese (30.0 or greater) subjects.
Conclusions: 31 (2%) had SRs to P and/or ID tests; 30 received one epi IM
dose (0.2 mg) and one, 2 doses (0.3 mg total). There were no delayed SRs or
relationship of epi IM dose to BMI and all but one were WAO Grade 1
reactions. Stat use of EPI IM may prevent more serious SRs and delayed
reactions.
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The “Allergy Blog” and Lay Person Questions: An Interactive
Educational Experience
Jose Luiz Rios, MD,1 Fatima Emerson, MD,1 Neide Pereira, MD,2,3 and
Margareth Duque,MD1. 1Allergy, Policlinica Geral do Rio de Janeiro, Rio de
Janeiro, Brazil; 2Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil;
3Faculdade de Medicina de Petrópolis, Petrópolis, Brazil.
Background: Despite the increase of allergic diseases over the last decades,
the population ignores the basic concepts, interfering in their prevention and
treatment. The “Allergy Blog” (Blog da Alergia) has been using digital media
resources to offer new forms of dialogue and patients ethical enlightenment
since 1996. This research objective to report the interactive educational ex-
perience, through the internet on "http://www.blogdalergia.com" and to ﬁnd
out, from the audience’s questions, which are the main areas of interest about
immune-allergic diseases.
Methods: Research on 1375 e-mails randomly selected, sent to the Blog
home page, to know what were the main issues raised by the lay public. The
e-mails were analyzed, considering the gender and age of the users and the
topic searched.
Results: Since 1996, Allergy Blog answered 4,256 e-mails and 2,200
comments. Most of patients were female: 78.2%, compared with 19.9%
male and 1.9% with no information. Many users (67.65%) did not reported
their age, as there wasn’t a mandatory item for this question. But, 25.38% of
the users were parents or guardians of children with allergic disease. The
frequency of the most popular topics searched were: Urticaria (14,55%),
Doubts about drugs (12.51%), Allergic Rhinitis (10,98%), Pruritus (8,15%),
Asthma (8, 87%), Contact dermatitis (5,60%), Atopic Dermatitis (4,58%),
Drug Allergy (2,47%), Cough (3,86%), and Others (6,40%). Dermatologic
manifestations of allergy bring more questions than the respiratory ones
(32.9% versus 23.7%), and drug concerns responded for 14.9% of the doubts.
Asthma, for which there are a lot of educative campaigns, represented only
8.9% of the questions. To clarify these questions, Allergy Blog published
educational texts and interacted with the visitors through: a) Comments on
Blog posted questions, 2) Answers to doubts sent via e-mail, 3) Chat intended
for short answers.
Conclusions: The discoveConclusions: The discovery of the lay’s greatest
gaps and areas of interest can be a guideline to improve new educative actions
in Allergy and Immunology. The use of digital media and social networks
may be a prime tool for the education of allergic individuals, community
dialogue and dissemination of correct information about the various aspects
of immune-allergic diseases.
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Anaphylaxis after Anesthetic Reversal
Sendy Chugo, MD. Allergy, MIR, Navarra, Spain.
Background: Sugammadex is a new drug used for the reversal of
neuromuscular blockade by rocuronium or vecuronium, a muscle relaxant
used as fast acting.
Methods: We performed a review of a case of a patient scheduled for
osteosynthesis of the ankle with a history of bronchial asthma and
sensitization to Dermatophagoides pteronyssinus. After the surgery the
patient suffered anaphylaxis, a minute after the use of sugammadex.
Results: We evaluated the drugs used during anesthesia Prick and in-
tradermal, and we obtained positive results with Sugammadex at 1 month, 3
and 6 months. We performed the basophil activation test giving a positive
result. Tests show IgE-mediated sensitization with positive skin tests and
basophil activation test.
Conclusions: It is believed that prior sensitization may have occurred due to
ingestion of cyclodextrins which is present in many foods. The atopic status
of this patient may have had some awareness of cyclodextrins. This case has
been published as the ﬁrst documented case of anaphylaxis by sugammadex
with normal doses. Our case raises clear that the underlying mechanism of
this reaction was an IgE-mediated sensitization.
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Establishment of Reference Values for Differential Cell Counts in
Nasal Lavage of Healthy Young Adults
Yanqing Xie, PhD,1 Jiaxing Xie, PhD,1 Rongquan Huang, MD,2 Kefang Lai,1
Nanshan Zhong,MD,3 and Jing Li, MD3. 1State Key Laboratory of Respiratory
Diseases Guangzhou, Guangzhou Institute of Respiratory Disease, The First
Afﬁliated Hospital of Guangzhou Medical College, Guangzhou, China;
2Guangzhou Medical College, Guangzhou, China; 3State Key Laboratory of
Respiratory Disease, The First Afﬁliated Hospital, Guangzhou Medical College,
Guangzhou, China.
Background: Upper airway inﬂammation could be reﬂected by nasal lavage
cytology test, which is characterized by advantages of non-invasive, simple,
objective and costless. However, reference values nasal lavage cytology was
not established. To establish reference values and positive standard for nasal
lavage cytology through screening normal healthy subjects and patients with
allergic rhinitis according to strict inclusion criteria.
Methods: To establish reference values and positive standard for nasal lavage
cytology through screening normal healthy subjects and patients with allergic
rhinitis according to strict inclusion criteria.
Results: There was no statistical signiﬁcance in gender constitutional
proportion, age, height and weight among each group. 95% CI of neutrophils,
eosinophils was (0w12.61)/·200 and (0w1.70)/·200, respectively. The me-
dian (interquartile range) of neutrophils were 0(0.65)/·200 in AR group,
which showed no statistical difference (P . 0.05) with that of normal group
[0(0)/·200]. A signiﬁcant difference was found in the median (interquartile
range) of eosinophils [6.90(22.40)/·200] in AR group as compared with that
of normal control group [0(0.10)/·200, P , 0.001].
Conclusions: Establishment of reference values of nasal lavage cytology test
is helpful to discriminate normal individuals and patients with allergic
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S61
rhinitis, but also a non-invasive tool for objective reﬂection on upper airway
inﬂammation, which is of great value for scientiﬁc and clinical purposes.
ASTHMA TREATMENT
187
Reduction in Asthma Deteriorations in Subjects with Persistent
Asthma not Well Controlled on Low-, Medium-, or High-Dose
Inhaled Corticosteroids: A Pooled Analysis From Three Clinical
Trials Using Combined Mometasone Furoate/Formoterol
Steven Weinstein, MD,1 Robert Nathan,2 Eli Meltzer, MD,3 Davis Gates,4
and Hendrik Nolte5. 1Allergy & Asthma Specialists Medical Group,
Huntington Beach, CA; 2Asthma & Allergy Associates, P.C. and Research
Center, Colorado Springs, CO; 3Allergy and Asthma Medical Group &
Research Center, San Diego, CA; 4Schering-Plough Research Institute
(now Merck Research Laboratories), Kenilworth, NJ; 5Merck Research Lab-
oratories, Kenilworth, NJ.
Background: We present a post hoc analysis from 3 phase III clinical trials
examining the effects of mometasone furoate/formoterol (MF/F) combination
therapy on asthma deterioration in subjects previously not well controlled on
low-, medium-, or high-dose inhaled corticosteroids (ICS).
Methods: A 2- to 3-week run-in period with twice-daily (BID) MF 100 mg
(MF/F 100/10 mg BID study), MF 200 mg (MF/F 200/10 mg BID study), or
MF 400 mg (MF/F 400/10 mg BID study) was performed before subjects
(aged $12 years) were randomized to BID: MF/F 100/10 mg, MF 100 mg, F
10 mg, or placebo for 26 weeks (n ¼ 746; MF/F 100/10 mg BID study); MF/F
200/10 mg, MF 200 mg, F 10 mg, or placebo for 26 weeks (n ¼ 781; MF/F
200/10 mg BID study); or MF/F 200/10 mg, MF/F 400/10 mg, or MF 400 mg
for 12 weeks (n ¼ 728; MF/F 400/10 mg BID study). Assessment of asthma
deterioration (ie, 20% decrease in forced expiratory volume in 1 s [FEV1],
30% decrease in peak expiratory ﬂow [PEF] on $2 consecutive days, or
clinically judged deterioration [ie, emergency treatment, hospitalization, or
treatment with excluded medications]) was a coprimary endpoint for the MF/
F 100/10 mg BID and 200/10 mg BID studies and a secondary endpoint for
the MF/F 400/10 mg BID study. Post hoc pair-wise comparisons of pooled
MF/F vs pooled MF, F, and placebo treatment groups were performed.
Results: Sample sizes in this pooled analysis were 861 for MF/F, 620 for MF,
390 for F, and 384 for placebo. There was a signiﬁcantly lower incidence of
asthma deterioration with MF/F (17.2%) versus MF (26.1%; P ¼ 0.002), F
(49.5%; P, 0.001), and placebo (50.8%; P, 0.001). Incidence of individual
asthma deterioration criteria was 7.0% for MF/F, 10.0% for MF, 13.8% for F,
and 17.7% for placebo for FEV1 reduction; 7.5%, 12.6%, 27.2%, and 26.3%,
respectively, for PEF reduction; and 2.1%, 2.6%, 6.7%, and 5.2% for clini-
cally judged deterioration.
Conclusions: MF/F-treated subjects experienced a signiﬁcantly lower rate of
asthma deterioration compared with MF, F, and placebo in subjects
previously not well controlled on low-, medium-, or high-dose ICS.
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Efﬁcacy Comparison of Mometasone Furoate/Formoterol Versus
Fluticasone Propionate/Salmeterol Combination Therapies in
Subjects With Persistent Asthma: Noninferiority and Onset-of-
Action Findings
David Bernstein,1 Kevin Murphy, MD,2 and Hendrik Nolte,3,4. 1Division of
Immunology, Allergy and Rheumatology, University of Cincinnati College of
Medicine, Cincinatti, OH; 2Boys Town National Research Hospital, Boys
Town, NE; 3Merck Research Laboratories, Kenilworth, NJ; 4Respiratory
Research Unit, Bispebjerg Copenhagen University Hospital, Copenhagen,
Denmark.
Background: Mometasone furoate/formoterol (MF/F) combination therapy
is a new treatment recently approved by the US Food and Drug Adminis-
tration for the treatment of persistent asthma and currently under regulatory
review by Canadian authorities. We report ﬁndings from a noninferiority
study that compared effects of MF/F and ﬂuticasone propionate/salmeterol
(FP/S) combination therapies on pulmonary function and onset of action in
subjects with persistent asthma.
Methods: This randomized, active-controlled, multicenter, noninferiority trial
enrolled subjects (aged $12 years) previously treated with medium-dose in-
haled corticosteroid alone or combined with a long-acting b2-agonist. Fol-
lowing a 2- to 4-week run-in treatment period with MF administered via
a metered-dose inhaler (MDI) 200 mg twice daily (BID), eligible subjects
were randomized to MF/F-MDI 200/10 mg BID or FP/S administered via
a dry powder inhaler (DPI) 250/50 mg BID for 12 weeks. The primary
endpoint of this trial was change from baseline in area under the curve
(AUC) in forced expiratory volume in 1 second (FEV1) measured serially
for 0 to 12 hours postdose (FEV1 AUC0212h). Key secondary endpoints
included onset of action, deﬁned as change from baseline in FEV1 at 5
minutes postdose on day 1.
Results: 722 subjects were randomized to MF/F-MDI (n ¼ 371) or FP/S-DPI
(n ¼ 351). The trial’s primary endpoint was met, demonstrating that MF/F
administered via an MDI was noninferior to FP/S administered via a DPI in
the patient population investigated. Mean FEV1 AUC0212h at endpoint for
MF/F-MDI and FP/S-DPI was 3.43 versus 3.24 L · h, respectively (95%, CI,
20.40 to 0.76). Analysis of onset-of-action characteristics revealed that MF/
F’s effect on lung function occurred signiﬁcantly faster than the effect ob-
served with FP/S-DPI. MF/F-MDI was associated with a 200-mL mean in-
crease from baseline in FEV1 at 5 minutes postdose (ﬁrst scheduled
measurement) on the ﬁrst day of treatment vs a 90-mL increase for FP/S-
DPI (P , 0.001).
Conclusions: This trial demonstrated that MF/F 200/10 mg BID administered
via an MDI was noninferior to FP/S 250/50 mg BID administered via a DPI in
its effect to improve lung function as measured by FEV1 AUC0–12h. How-
ever, the onset of action for this effect was signiﬁcantly faster with MF/F-
MDI than with FP/S-DPI.
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Efﬁcacy and Safety of Two Doses of Mometasone Furoate/
Formoterol Combination Treatment in Subjects With
Severe Asthma
Steven Weinstein, MD,1 Kevin Murphy, MD,2 and Hendrik Nolte3. 1Allergy
& Asthma Specialists Medical Group, Huntington Beach, CA; 2Boys Town
National Research Hospital, Boys Town, NE, Jonathan Corren, Allergy Med-
ical Clinic, Los Angeles, CA; 3Merck Research Laboratories, Kenilworth, NJ
and Martha White, Institute for Asthma and Allergy, Wheaton, MD.
Background: Multiple strengths of mometasone furoate/formoterol (MF/F)
metered-dose inhaler combination therapy have been investigated as new
treatments for asthma. We report efﬁcacy/safety ﬁndings from an MF/F study
in subjects with severe asthma previously uncontrolled on high-dose inhaled
corticosteroids (ICS) with or without a long-acting ß2-agonist (LABA).
Methods: This was a 3-month, randomized, double-blind, parallel-group,
multicenter study with a 2- to 3-week open-label run-in period during which
subjects received mometasone furoate (MF) 400 mg twice daily (BID). Sub-
jects ($12 years) were randomized to MF/F 200/10 mg BID, MF/F 400/10
mg BID, or MF 400 mg BID. The primary endpoint was the area under the
curve (AUC) of the change in serial (0212 hours) forced expiratory volume
in 1 second (FEV1) for MF/F 400/10 mg vs MF 400 mg from baseline to week
12. Adverse events (AEs) and other clinical safety measures were recorded.
Results: 728 subjects were randomized (mean: age, 47.9 years; asthma
duration, 14.0 years; FEV1 % predicted, 66.3; reversibility, 22.9%; Asthma
Control Questionnaire score, 1.93). Improvements in mean changes
from baseline in FEV1 AUC0212h at week 12 were: MF/F 200/10 mg ¼
3.59 L · h; MF/F 400/10 mg ¼ 4.19 L · h; MF 400 mg ¼ 2.04 L · h, with
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both MF/F doses signiﬁcantly better than MF (P , 0.001). These FEV1
AUC0–12h values with MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg
correspond to average hourly increases of 0.30, 0.35, and 0.17 L, respec-
tively. MF/F was associated with a rapid (,5 minutes) and sustained im-
provement in lung function. The percentages of subjects experiencing an
asthma deterioration (ie, severe asthma exacerbation) were 12.4% (MF/F
200/10 mg), 12.2% (MF/F 400/10 mg), and 18.3% (MF 400 mg). There were
no notable differences in AEs between the groups.
Conclusions: Both the 200/10 mg BID and 400/10 mg BID doses of MF/F
combination therapy led to signiﬁcantly greater improvements in lung func-
tion compared with 400 mg BID MF monotherapy in subjects with severe
asthma previously treated with an ICS alone or in combination with LABA.
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Background: Asthmatics often report asthma-related nocturnal awakenings.
These sleep interruptions may have a signiﬁcant impact on patients’ quality of
life. We characterized the effect of mometasone furoate/formoterol (MF/F)
administered via pressured metered-dose inhaler on incidence of nocturnal
awakenings requiring short-acting b2-agonists (SABAs).
Methods:MF/F’s effect on nocturnal awakenings requiring SABA was char-
acterized across 3 phase III efﬁcacy trials (baseline ¼ number of nights with
awakenings in week before ﬁrst dose; endpoint ¼ number of nights/wk with
awakenings averaged across the 26-week treatment period). Subjects were
asthmatics previously treated with low- (n¼746), medium- (n¼781) or high-
dose (n¼728) inhaled corticosteroids at various doses. Subjects in the MF/F
100/10 mg BID study were randomized to 26 weeks of twice-daily (BID)
treatment with MF/F 100/10 mg, MF 100 mg, F 10 mg, or placebo; subjects in
the MF/F 200/10 mg BID study to 26 weeks of BID treatment with MF/F 200/
10 mg, MF 200 mg, F 10 mg, or placebo; and subjects in the MF/F 400/10 mg
BID study to 12 weeks of BID treatment with MF/F 400/10 mg, MF/F 200/10
mg, or MF 400 mg. All treatments were delivered via a metered dose inhaler.
Results: Baseline awakenings ranged from 0.84–1.05, 1.05–1.26, and 1.33–
1.61 nights/wk in the MF/F 100/10 mg BID, MF/F 200/10 mg BID, and MF/F
400/10 mg BID studies, respectively. In the MF/F 100/10 mg BID study,
nocturnal awakenings were reduced by MF/F ¼ –0.42, MF ¼ –0.21, F ¼
–0.21, and placebo ¼ 0.14 nights/wk; corresponding changes in the MF/F
200/10 mg BID study were –0.56, –0.35, 10.07 and 0.00 nights/wk, respec-
tively. In each of these placebo-controlled studies, MF/F was superior to
placebo (P , .001) and F (P #.035); MF was also superior to F and placebo.
In the MF/F 400/10 mg BID study, awakenings were reduced by –0.70, –0.70
and –0.35 nights/wk by MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg,
respectively; both MF/F treatments were superior to MF (P #0.006).
Conclusions: These results provide evidence that validates the role of MF/F
in reducing nocturnal asthma symptoms in patients with moderate to severe
persistent asthma and supports the efﬁcacy of MF/F compared with that of
placebo and F.
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Background: A major goal of asthma treatment is to improve patients’
health-related quality of life (QoL). Mometasone furoate/formoterol (MF/F)
combination therapy was recently approved for the treatment of persistent
asthma. The objective of this analysis was to examine the effect of MF/F on
health-related QoL at the approved doses.
Methods: Data from 2 phase III studies investigating the effects of MF/F 200/
10 mg (study P04334) and MF/F 400/10 mg (study P04431) were included.
All subjects were $12 yeara and not well controlled on medium dose
(P04334) or high-dose (P04431) inhaled corticosteroid (ICS). After 2 to 3
weeks of run-in on twice-daily (BID) MF 200 mg (P04334) or 400 mg
(P04431), subjects were randomized to 26 weeks of BID MF/F 200/10 mg,
MF 200 mg, F 10 mg, or placebo (PBO) in P04334; or 12 weeks of BID MF/F
200/10 mg, MF/F 400/10 mg, or MF 400 mg in P04431. The Asthma Quality
of Life Questionnaire with Standardized Activities (AQLQ [S]), consisting of
4 domains (Symptoms, Activity Limitation, Emotional Function, and Envi-
ronmental Stimuli), was used to assess QoL. AQLQ(S) score changes from
baseline were assessed; a difference$0.5 was considered clinically meaning-
ful. Study protocols were approved by IRBs; written informed consent was
provided by all subjects or a parent/guardian.
Results: In P04334 (n ¼ 781), subjects receiving MF/F 200/10mg experi-
enced signiﬁcant improvements in total score (13.1%) and the 4 domain
scores of the AQLQ (S) at endpoint vs those receiving PBO (P # 0.005)
or F 10 mg (P # 0.024). Clinically meaningful improvements in total AQLQ
(S) from baseline to week 26 were observed in patients receiving MF/F 200/
10 mg (0.61). In P04431 (n ¼ 728), subjects receiving MF/F 200/10 mg
experienced signiﬁcant improvements in total score (12.8%) and the Symp-
toms and Activity Limitation domain scores of the AQLQ (S) at endpoint vs
those who received MF 400 mg (P # 0.017). Clinically meaningful improve-
ments in total AQLQ (S) from baseline to week 12 occurred in patients re-
ceiving MF/F 200/10 mg (0.61), MF/F 400/10 mg (0.51), or MF 400 mg (0.5).
Conclusions: Patients with persistent asthma receiving MF/F had statistically
signiﬁcant, clinically meaningful improvements in QoL in 2 phase III studies.
These data suggest that MF/F combination therapy improves the health-
related QoL of patients with persistent asthma who are inadequately
controlled on medium- or high-dose ICS.
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Background: Asthma is a variable disease. Optimal control in clinical
practice often requires the use of therapy at varying doses. Availability of
treatments at multiple strengths is therefore essential. These are results from
a 6-month trial of combined mometasone furoate/formoterol (MF/F) 100/10
mg administered via a metered-dose inhaler (MDI) as treatment for asthma
deterioration (ie, severe asthma exacerbation) and bronchoconstriction in
asthmatics previously treated with low-dose inhaled corticosteroids (ICS).
Methods: In a randomized, multicenter, double-blind, placebo-controlled
study in asthma subjects ($12 years) on ICS with/without a long-acting b2-
agonist (LABA), subjects were assigned to 2 to 3 weeks of open-label MF
100 twice daily (BID), followed by 26 weeks of MF/F 100/10 mg, MF 100 F
10 or placebo (all BID). Co-primary endpoints were time to ﬁrst asthma
deterioration across the 26-week treatment period (MF/F versus F) and change
from baseline to week 12 in serial (0212 hours) forced expiratory volume in 1
second (FEV1) (MF/F vs MF). Adverse events (AEs) were monitored.
Results: 746 subjects (mean: age ¼ 38.3 years, asthma duration ¼ 14.77
years, FEV1 % predicted ¼ 75.08, reversibility ¼ 18.69%, Asthma Control
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Questionnaire ¼ 1.31) were randomized to 1 of the 4 treatment groups. MF/F
increased the time to ﬁrst asthma deterioration thus decreasing the proportion
of subjects experiencing asthma deterioration during the study (MF/F ¼
16.5%; versus MF ¼ 28.2% [P ¼ 0.006]; versus F ¼ 44.7% [P , 0.001];
and vs placebo ¼ 45.7% [P , 0.001]). Mean FEV1 AUC0–12h over baseline
at week 12 were MF/F ¼ 4.00 L · h; MF ¼ 2.53 L · h; F ¼ 3.83 L · h; and
placebo ¼ 1.11 L · h. Low rates of AEs were observed and were similar
between treatment arms.
Conclusions: In asthmatics previously treated with low-dose ICS with or
without a LABA, MF/F 100/10 mg BID was more effective than placebo,
MF, or F (all administered by MDI) in reducing asthma deteriorations and
improving lung function.
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Background: The widespread use of inhaled corticosteroids (ICS) for the
treatment of persistent asthma, although highly effective, may be associated
with local side effects. The aim of this study was to evaluate swallowing
function in patients with severe persistent asthma, by nasal ﬁbroscopy.
Methods: Sixty-four patients with severe asthma with a mean age of 55 6 11
years, using inhaled corticosteroids without spontaneous complaints related to
swallowing, participated in the study. The participants were evaluated using
nasal ﬁbroscopy. Each participant was offered diet boluses (3, 5 and 10 ml)
such as thin liquids, pasty and solids, and their swallowing function was
determined according to the following criteria: (1) premature oral leakage
to the pharynx; (2) laryngeal penetration; (3) tracheal aspiration; and (4)
pharyngeal stasis.
Results: Nineteen (25,3%) of the patients with severe asthma presented
premature oral leakage or pharyngeal stasis of the bolus after swallowing or
laryngeal penetration.
Conclusions: Patients with persistent asthma presented subclinical manifes-
tations of abnormal swallowing, when analyzed using nasal ﬁbroscopy,
possibly associated with neuromuscular dysfunction caused by inhaled
corticosteroids.
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Background: Eosinophils play an important role in inﬂammation asthma. In
asthma, the leukotrienes are implicated in pathophysiological mechanisms.
The antileukotriene montelukast inhibits proinﬂammatory cytokines and
decreases half-life of eosinophils. However, the inﬂuence of montelukast
on the activation of eosinophils is not clear yet. Therefore, the objective of
this work was to evaluate the effect of montelukast on the state of activation
of eosinophils in children with persistent asthma.
Methods: It was selected 83 asthmatic children, from 2 to 18 years old, that
were randomly assigned to treatment with montelukast or placebo for 12
weeks and 10 healthy control children. Asthma severity was assessed by the
criteria of Global Initiative for Asthma (GINA, 2010). Peripheral blood was
taken from children after parent’s informed consent. The activation of eosi-
nophils was assessed by morphological parameters after adherence to slide,
before and after 12 weeks of treatment with montelukast or placebo. The
following morphological parameters were evaluated: normal eosinophils,
spreading, rounding, presence of localized and generalized pseudopods, re-
lease of small, moderate and large quantity of granules, cytoplasmatic
vacuoles, cluster of free eosinophils granules, cell degeneration and cell
communication.
Results: The number of eosinophils with normal feature in peripheral blood
showed an inverse correlation with the severity of asthma, while the emission
of widespread pseudopods and isolated granules showed positive correlation
with the severity of asthma (P , 0.0001; Spearman correlation test). Mon-
telukast was able to reduce the number of eosinophils in peripheral blood
from 513 cells/mm3 to 485 cells/mm3 (P ¼ 0.017, paired t test) after treat-
ment, and to increase the proportion of eosinophils with normal feature from
45% to 51% (P ¼ 0.03; Wilcoxon test). The drug was also able to decrease
the median of eosinophils with rounded feature (1.5 versus 0) and that re-
leasing free eosinophil granules (2.25 versus 0.5) after 12 weeks of treatment
compared to placebo, respectively (P ¼ 0.005; Mann Whitney test).
Conclusions: Our data showed, for the ﬁrst time, that montelukast is able to
modify the activation of eosinophils correlated with clinical severity.
Parameters of eosinophil activation could be used to the follow up of
response to montelukast treatment of asthma individuals.
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Background: Bronchial asthma develops by the age of 3 years frequently in
childhood in industrialized countries. Pranlukast hydrate, leukotriene receptor
antagonists, has been shown to be clinically effective for the treatment of
hypersensitivity and childhood asthma. The generic drugs for PLK were
universally used in the market, and the effect of the drug also restrain the
bronchial asthma onset of infants having an established allergic factor
clinically, which necessitates the analysis of the mechanisms of allergic
diseases and development of the effective treatment. Therefore we examined
inﬂuence of administration of Pranlukast-EK (PLK-EK) on the symptom
onset of a mild and moderate type of bronchial asthma.
Methods: The 116 patients, who accepted at least 2 to 3 times wheeze after
birth, were enrolled ranging from 6 months to 6 years in age. They were
treated with Pranlukast-EK (7-10 mg/kg) daily (71 cases, group A) or with
suplatast tosilate as a reference (45 cases, group B). The severe and moderate
type of patients, who were continuously treated with corticosteroids were
excluded. The clinical evaluation was concerning frequency of coughing and
wheeze, and that of the b2-receptor agonist inhalation consumption in every 4
months with an asthma diary. In addition, allergic tests; eosinophile count and
IgE value were determined in every 4 months.
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Results: The frequency of the coughing decreased signiﬁcantly 12 months
later (the last 4 months) as compared to the ﬁrst 4 months in both groups.
Concerning the wheeze, the signiﬁcant change was also examined in both
groups. As for the frequency of the b2-receptor agonist inhalation consump-
tion, the signiﬁcant decrease was observed in group A and B. The meaningful
change of the peripheral blood eosinophile count was not watched in group A
and B. The serum IgE value decreased 12 months later in the subgroup of
group A, who showed the decreased frequency of symptoms, whereas such
a meaningful decrease was never recognized in group B. PLK-EK likely
restrains an increase of serum IgE value.
Conclusions: Pranlukast-EK modulates IgE production and eosinophile
count in patients with the mild and moderate type of bronchial asthma, and
has action to improve wheeze expression clinically.
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Effect of the Treatment With Montelukast in Asthmatic Patient
Roberto O. Aguila de la Coba, MD, and Castillo Méndez, MD. Allergology,
Cerro Pediatric Hospital, La Habana.
Background: Asthma is chronic inﬂammatory illness of the air roads in
which several cells playing an important rol in the development of the
bronchial hiperreactivity. The leukotriens are mediators that participate in the
inﬂammatory process being involved in the bronchoconstriction. To evaluate
the effectiveness of the Montelukast in patient pediatric and adults with
Moderate-Severe Persistent Asthma.
Methods: 201 patients were studied, 101 of 6 to 16 years of age and 100 of
17 or more years old with persistent moderate and severe asthma, without
antecedents of illnesses hematológic, hepatic or renal, to those that were
administered montelukast in dose from 5 mg of 6 to 14 years and 10 mg
to those bigger than this age, once a day during 6 months. A monthly pursuit
of its clinical evolution was taken, with control of the renal function and
liverwort to the beginning, to the 3 months and when concluding the study;
tests of breathing function were also made to the beginning and when ﬁnish-
ing the treatment.
Results: Neither of the patients worsened, 81% of them passed to stay
asymptomatics in this period and 18.9% they happened to fast. In 6 cases it
was necessary to move away the treatment for different reasons for causes
unaware to the medication.
Conclusions: The effectiveness of this medication was demonstrated and
they were not problems of intolerance or important adverse effects.
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Andrzej Emeryk, MD, PhD,1 Magdalena Kowalska,1 Iwona Czerwinska-
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Background: Short acting beta-2 agonists (SABA) inhalation is commonly
used in bronchodilatatory test, which is still an important research tool in the
diagnosis of respiratory diseases with bronchial obstruction. Bronchodilata-
tory effect of SABA depends primarily on the degree of patency of the
airway, the type and dose of SABA, as well as the type of inhaler and
inhalation technique. The aim of the study was to evaluate the spirometric
effectiveness of 2 different methods of salbutamol nebulization in asthmatic
children.
Methods: The study group included 132 children aged 6 to 18 years (mean:
11.7), 91 (69%) boys and 41 (31%) girls with partly controlled asthma treated
in the Allergy or Pulmonology Outpatient Clinics in Children’s University
Hospital in Lublin. The study was randomized and single blind design.
Patients were randomly assigned to one of 2 groups. The ﬁrst group used
2.2 mg of salbutamol (mean calculated dose) in the breath-actuated nebulizer
(BAN) (Marine, Medbryt, Poland), while the second one–5 mg salbutamol
(constans dose) in the constant-output nebulizer (CON) (Porta-Neb, MEDIC-
AID, UK). Flow-volume curve (dynamic spirometry) was measured before
and 20 minuts. after drug nebulization (bronchodilatatory test). FEV1 (expi-
ratory volume in ﬁrst second) and FEF25-75 (forced expiratory ﬂow at 25 to
75% of forced vital capacity) values were analyzed. The change in FEV1 and
FEF25-75 after treatment with respect to baseline was calculated.
Results: The mean baseline value of FEV1 was 67.4% in BAN and 70.5% in
CON group and there was no statistical difference between these groups. The
signiﬁcant improvement of measured ventilatory parameters was observed.
There was the signiﬁcant difference in the bronchodilator response to
salbutamol between 2 methods of nebulization. The value of FEV1 increased
at 16.2% in BAN group and at 12.6% in CON group (P ¼ 0,026). The value
of FEF25-75 increased in both groups at 37.7% and 32.7% respectively and
there was no statistical difference between these groups.
Conclusions: We observed greater bronchodilatatory effect of salbutamol
inhaled via breath-actuated nebulizer while delivering a double lower dose. 2.
Bronchodilatatory test using nebulized salbutamol in breath-actuated nebu-
lizer should be recommended for children.
IMMUNOTHERAPY
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AAAAI Survey on Immunotherapy Practice Patterns Concerning
Dosing, Dose-Adjustment after Missed Doses and Duration
of Immunotherapy
Désirée Larenas Linnemann, MD, FAAAAI, Dist, Int, FACAAI,1 Payel
Gupta, MD,2 Sima Mithani, MD,3 and Punita Ponda, MD3. 1Allergy, Hospital
Médica Sur, Mexico DF, Mexico; 2Allergy and Immunology department,
SUNY Downstate/Long Island College Hospital, New York, NY; 3Division
of Allergy and Immunology, NSLIJ Health System, Great Neck, NY.
Background: Several practical issues dealing with the exact application of
allergen immunotherapy (AIT) among European and US allergists are not
well known. Guidelines on AIT give recommendations and suggestions for
only some of them. We present this unique survey with worldwide response.
Methods: The AAAAI immunotherapy committee conducted a web-based
practice patterns survey (program: Survey Monkey) among all members
in&outside US on dosing, dose-adjustment after missed doses and duration
of AIT.
Results: 1201 Returned questionnaires (almost 25% response rate). 21%
were non-US-Canada members. Maintenance doses in USCan are (mean/
median): Dermatophagoides farinae (Df) combined with Dermatophagoides
pteronyssinus (Dpt): 2155/1000AU; Df solo 2484/1000AU. Dpt when com-
bined with Df 1937/1000AU; Dpt solo: 2183/1000AU.Cat 3224/2000BAU.
Grass 11,410/4000BAU. 57-65% of the dosing falls within the recommended
Practice Parameters recommended ranges. Non-USCan allergists expressed
maintenance doses in many different units making analysis impossible. Dose-
adjustment after missed doses is based on ‘time elapsed since the last applied
dose’ by 77% of USCan and 58% of non-USCan allergists and on ‘time since
missed scheduled dose’ by the rest. Doses are adjusted when a patient comes
in more than 14 d/5 wk after the last administration at build-up/maintenance
by both USCan and non-USCan colleagues. The mostly followed dose-ad-
justment schedules after 1, 2, 3 missed doses are: Build-up: repeat last dose,
reduce by one dose, reduce by 2 doses; maintenance: reduce by one dose,
reduce by 2 doses, reduce by 3 doses. 26% uses a different approach reducing
doses by a certain percentage or volume. AIT is restarted after a gap in build-
up of .30 days and of .12 weeks during maintenance in both groups
(median). Outside USCan AIT is prescribed for 3 years (Median). However,
75% of USCan allergists prescribes AIT for 5 years. Main reasons why to
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continue AIT beyond 5 years: ‘symptoms came back after stopping’ or “pa-
tient afraid to relapse.”
Conclusions: These results show regional differences on some points
(especially AIT duration) and they suggest in which direction to plan further
research in 2 areas to establish universal dose-adjustment plans for missed
applications and deﬁne the usefulness (or lack of) of long-term AIT.
Moreover, there is still room for improvement in the way AIT is dosed.
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Sur, Mexico DF, Mexico; 2Medicina, Universidad autónoma del Estado de
Hidalgo, Pachuca, Mexico; 3Pediatric Allergy and Clinical Immunology, Hospi-
tal Infantil de Mexico Federico Gomez, Mexico City, Mexico; 4State Autonomous
University of Tamaulipas, H. Matamoros, TAM, Mexico; 5Allergy and Clinical
Immunology, University Hospital UANL, Monterrey, Mexico; 6Private practice,
Playa del Carmen, Mexico.
Background: Several international guidelines exist on allergen immunother-
apy (AIT) –eg American, European, British, Spanish, Italian- but local con-
ditions that reign in each country limit their applicability. We present the
steps we followed to develop a National Guideline on AIT, taking into
account local legislation, extracts available, costs and patient preference.
Methods: Firstly a Nation-wide survey on the practice of skin testing and
AIT was undertaken among all members of Mexican Allergist Societies.
Secondly, based on the replies obtained with the survey clinical questions
were formulated on critical points and issues susceptible for improvement, as
diagnosed by the survey. Thirdly, all 6 Regional Allergist Societies were
visited to obtain the opinion of their members on the clinical questions
concerning how immunotherapy could best be practiced under local Mexican
conditions. This led to the Consensed experience. Fourthly, 6 experts looked
for the replies to the clinical questions reviewing the literature and assigning
quality of evidence to the articles on the speciﬁc issues treated by each
clinical question.
Results: To develop the ﬁnal document the GRADE approach was used. For
each clinical question both, knowledge from the local consensed experience
and the evidence-based replies were taken into account, as well as cost,
patient preference and safety to make a set of recommendations and sugges-
tions on the most crucial aspects of skin testing and AIT. Forming centers of
allergists in Mexico corrected the ﬁnal draft. The ﬁnal document came out as
the January issue of Revista Mexicana Alergia and was presented by the
authors in a National Course on Immunotherapy (May 2011), withdapart
from the lecturesda more workshop-like part to allow for practical exercising
and discussion. The updated questions on allergen immunotherapy for the
ﬁnal board exam are based on the Guideline. Allergy-residents developed
a slide-show. In 2012 Regional Allergist Societies shall be visited again.
Conclusions: We present a democratic way of how a National Guideline can
be developed, supported by evidence-based medicine and local experience in
a country where little is legislated on this respect and quality improvement
has to be stimulated by the professional community. We show how
implementation can be enhanced.
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Efﬁcacy of Mite Sublingual Immunotherapy in 130 Children with
Atopic Dermatitis
Jianping Tang, MD, PhD. Dermatology, Hunan Children’s Hospital, Chang-
sha, Hunan, China.
Background: Atopic dermatitis (AD) is a chrinic inﬂammatory skin disease
with increasing prevalence. The aim of this study was to investigate the
efﬁcacy and safety of mite sublingual immunotherapy (SLIT) in children with
atopic dermatitis (AD).
Methods: A total of 178 AD patients IgE-proved (class $3) Dermatopho-
goicles farinae sensitization. The treatment group (n ¼ 130, 87 male and 43
female, age 2.5–14, SCORAD.7) were given sublingual drops of Dermato-
phogoicles farinae. They received increasing doses and concentration. Con-
ventional treatment was added in the beginning. The 48 AD cases in the
control group were treated with conventional drugs. The treatment time of
SLIT is from 7 months to 2.5 years.
Results: In the 130 patients of treatment group, 18 cases were considered
cured, 39 got a marked effect, 58 were effective and 15 got no effect, for
a total effective rate of 88.46% (115/130). In the control group, 8 got
a marked effect, 20 were effective and 20 got no effect, the total effective rate
was 58.33% (28/48). There is a statistically signiﬁcant difference between the
treatment group and the control group (p,0.05). The patients’ status of
asthma and / or allergic rhinitis were improved after their received the sub-
lingual immunotherapy with no emergence of new allergic diseases or sig-
niﬁcant side effects.
Conclusions: SLIT appears to be an effective treatment of children with AD.
201
Clinical Efﬁcacy and Mucosal/Systemic Antibody Response
Changes After Sublingual Immunotherapy in Mite-Allergic
Children: A Randomized Double-Blind, Placebo-Controlled
Study in Brazil
Meimei Queirós, MD,1 Deise Silva, PhD,1 Isabella Simanc, BS,1
Leandro Ynouec, MSc,1 Núbia Araújoc, MSc,1 Fernando Pereira, PhD,2
Karine Almeida, PhD,2 Juliana Mirandac, MSc,2 Janethe Pena, MD, PhD,3
and Ernesto Taketomi, MD, PhD,1,2. 1Laboratory of Allergy and Clinical Im-
munology, Federal University of Uberlândia, Uberlândia, Brazil; 2Alergia e
Imunologia Clínica, Laboratório de Investigação em Alergia Ltda, Uberlândia,
Brazil; 3Division of Medical Research, Bayer Health Care, São Paulo, Brazil.
Background: This study aimed to evaluate the clinical efﬁcacy and mucosal/
systemic antibody response changes after sublingual immunotherapy (SLIT)
using Dermatophagoides pteronyssinus (Dpt) allergens with or without bac-
terial extracts in mite-allergic Brazilian children.
Methods: One-hundred and 2 patients presenting allergic rhinitis with or
without asthma were selected for a randomized double-blind, placebo-
controlled trial and distributed into 3 groups: DPT (Dpt allergen extract,
n ¼ 34), DPT1MRB (Dpt allergen plus mixed respiratory bacterial extracts,
n ¼ 36), and Placebo (n ¼ 32). Clinical evaluation and immunological anal-
yses were carried out before and after 12 and 18 months of treatment, in-
cluding rhinitis/asthma symptom and medication scores, skin prick test (SPT)
to Dpt extract, and measurements of Dpt-, Der p 1-, Der p 2-speciﬁc IgE,
IgG4, and IgG1 in serum and -speciﬁc IgA in saliva and nasal lavage ﬂuid.
Results: Clinical results showed a signiﬁcant decline in rhinitis/asthma
symptom scores in all groups, but medication use decreased only in active
DPT group at 12 months. SPT results showed no signiﬁcant changes and
SLIT was generally safe, with no severe systemic reactions. SLIT using Dpt
allergen alone induced increased serum IgG4 levels to Dpt, Der p 1 and Der p
2, and increased serum IgG1 and salivary IgA levels to Dpt and Der p 1. SLIT
using DPT1MRB was able to decrease IgE levels, particularly to Der p 2, to
increase salivary IgA levels to Der p 1, but had no changes on speciﬁc IgG4
and IgG1 levels.
Conclusions: Therefore, SLIT seems to be effective in ameliorating clinical
symptoms, but only active SLIT was able to modulate the mucosal and
systemic antibody responses. These ﬁndings support the role of speciﬁc
serum IgG4 and IgG1, in addition to salivary IgA, as protective or blocking
Abstracts WAO Journal  February 2012
S66  2012 World Allergy Organization
antibodies as well as biomarkers of tolerance that may be useful for
monitoring activation of tolerance-inducing mechanisms during allergen
immunotherapy.
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Treatment Satisfaction with Sublingual Immunotherapy in
a Real-Life Setting
Meike Hadler,1 Silvia Schnitzer,MD, PhD,2 Jörg Schnitker,3 and Jochen Sieber,
MD, PhD1. 1Medical Department, Stallergenes GmbH, Kamp-Lintfort,
Germany; 2Private Ofﬁce, Grevesmuehlen, Germany; 3Institut für angewandte
Statistik, Bielefeld, Germany.
Background: By now, the efﬁcacy and safety of sublingual immunotherapy
(SLIT) have been well established, but as for all long-term treatments,
adherence to the treatment is essential. Patient-related outcome measures,
such as the patients’ satisfaction with the treatment, have become more cru-
cial for they may affect treatment adherence.
Methods: To evaluate patient satisfaction with SLIT treatment (Staloral,
Stallergenes S.A., France) we designed a prospective, observational,
multicenter study. Treatment satisfaction was measured using the QUARTIS
questionnaire (¼ Questionnaire on Respiratory Allergies Treated by Sublin-
gual Immunotherapy). As medical parameters effectiveness and adverse
events were documented. Patients with allergic rhinitis and/or conjunctivitis
due to tree pollen, grass pollen or house dust mites were included in the study.
Results: 226 patients (94 male, 132 female, median age 37 years) participated
in this study. Treatment satisfaction: Compared to a period before treatment,
patients reported improved nasal symptoms (13.03 vs. 9.70; P , 0.0001) and
eye symptoms (6.11 versus 4.43; P , 0.0001). After treatment, the allergy
was less bothersome in everyday life (9.62 versus. 7.27; P , 0.0001). 69.2%
of treated patients experienced a better tolerability than they had expected. No
relevant differences were observed between the different allergen groups.
Effectiveness: The severity of nasal symptoms was reduced by 53.2% (2.35
versus 1.10; P , 0.0001). For eye symptoms the severity was reduced by
57.0% (2.14 versus 0.92; P , 0.0001). Only 36.1% of the patients needed
symptomatic medication in the treatment period compared to 70.1% before
treatment. 88.0% of the investigators assessed the patients’ well-being as
"much better" or "better" after treatment. Adverse events: The overall toler-
ability was assessed as "good" or "very good" in approximately 90% of the
evaluable cases. Only 11.9% of patients experienced adverse events (AEs).
The most common AEs were gastrointestinal disorders.
Conclusions: Patients treated with SLIT in a real-life setting were satisﬁed
with the treatment: It was tolerated well, patients’ symptoms improved and
their allergy had less impact on daily life. The patients’ high level of treatment
satisfaction as well as the good tolerability and effectiveness of the extract are
important factors for they may help to improve treatment adherence.
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Long-Term Clinical Efﬁcacy of Immunotherapy in
Rhino-Conjunctivitis with Pollen Extract
Carlos Nunes, and Susel Ladeira,. Center of Allergy of Algarve, Portimao,
Portugal.
Background: Evaluate long-term clinical efﬁcacy 2 years after suspension of
speciﬁc immunotherapy in patients with seasonal rhino-conjunctivitis.
Methods: During 5 years in a pre-seasonal period an extract of 7 grass pollens
by sub cutaneous route (SCIT) was administered to a group of 16 patients with
moderate and severe rhino-conjunctivitis, monosensitised to grass pollens. The
mean age of the patients was 27.1 years, with homogeneous sex distribution.
After the terminus of SCIT the group was followed during 2 more years to
evaluate symptomatology and the use of rescue medication, during pollen
season. We have compared this group with another group who did not perform
SCIT. All patients received weekly information about forecasts and grass
pollens count in their residential area. An informatics sheet was used to evaluate
daily 4 degrees of 6 parameters including nasal and eye symptoms and any use
of medication used to control the disease. As statistical method ANOVA test
and t test was used for analyse mean differences between the 2 groups. For
correlations the Spearman method was used.
Results: During the immediate 2 years after SCIT in the active group,
a signiﬁcant reduction on symptoms (42%) as well as a reduction on the use
of rescue medication (59%) were observed (P , 0.01), compared with the
control group. The eye symptoms had a higher reduction than nasal symp-
toms after the suspension of IT.
Conclusions: A signiﬁcant efﬁcacy of SCIT was veriﬁed even 2 years after
the suspension of the treatment, with reduction on symptoms and on use of
medication. The use of a daily score of symptoms and the use of rescue
medication was very useful and confortable to the majority of the patients.
Also providing regular information to patients regarding pollen count and
climatic changes by electronic mail was considered useful to both groups.
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IGE/IGG4 Ratio as a Possible Surrogate Marker of Clinical
Efﬁcacy During Allergen-Speciﬁc Immunotherapy with House
Dust Mite Vaccines
Alexis Labrada, PhD,1 Maytee Mateo,1 and Rosa Naranjo, MD2. 1Allergens,
National Center of Bioproducts, Mayabeque, Cuba; 2Alllergy, "Joaquin Al-
barran" Hospital, Havana, Cuba.
Background: Allergen immunotherapy (AIT) induces IgG4 antibodies with
blocking effect, and long-term reduction of IgE. The problem of ﬁnding
suitable surrogate paraclinical markers during AIT is currently very relevant.
The aim was to evaluate the allergen-speciﬁc IgE/IgG4 ratio as an
immunological correlate to clinical efﬁcacy during AIT with House Dust
Mite (HDM) allergen vaccines in Cuban asthmatic patients.
Methods: Three separate Double-Blind Placebo-Controlled clinical trials of
AIT were performed using standardized registered allergen extracts of 3
HDM species: Dermatophagoides pteronyssinus, and the tropical species D.
siboney and Blomia tropicalis. Each clinical trial included 40 asthmatic
patients, totalling 120 individuals. Half of them received placebo. Allergen-
speciﬁc IgE and IgG4 antibodies were measured by ELISA. Antibody titres
were normalized and averaged between the 3 trials. Size effect was calculated
as the Standard Mean Difference (SMD) between the active and placebo
groups, using meta-analysis tools.
Results: There was a signiﬁcant increase of IgG4 antibodies (P , 0.05) after
6 months of treatment. At 12 months, the IgG4 increase was even greater and
the IgE decrease achieved also signiﬁcance (P , 0.05). Thus, IgG4 induction
appeared to precede IgE changes, in agreement with the possible role of the
Treg/IL-10 response induction at the initial AIT phase. Moreover, 83% of
patients showed a decrease of the IgE/IgG4 ratio in the active groups, whereas
only 32% showed reduction in placebo groups. The IgE/IgG4 ratio was the
immunological variable with the greatest size effect value (SMD ¼ 0.81 95%
CI, 0.71-0.91), as compared to changes in IgE or IgG4 levels, alone. The size
effect value was close to the clinical effect (symptom-medication score SMD
¼ 1.2 95% CI, 0.7-1.7). Per-patient changes in IgG4 levels, as well as, in the
IgE/IgG4 ratio, were signiﬁcantly correlated to the symptom-medication vari-
able (r ¼ 0.23, P ¼ 0.04).
Conclusions: These results support the use of the IgE/IgG4 ratio as an easily
measurable marker for monitoring the allergen-speciﬁc immunity during AIT
with HDM in asthmatic patients, and possibly, for predicting patient’s clinical
improvement after 1 year of treatment.
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Allergy Training and Immunotherapy in Latin America: How
Survey-Results Lead to a Regional Overview
R. Maximiliano Gomez,1 Désirée Larenas Linnemann, MD, FAAAAI, Dist,
Int, FACAAI,2 Giovanni Passalacqua, MD,3 Sandra González-Díaz, MD,
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PhD,4 Victor H Coce, PhD,5 Giorgio Walter Canonica, PhD,6
and Carlos E. Baena-Cagnani, MD7. 1Centro Investigacion Medicina Respi-
ratoria (CIMER-UCC), Salta, Argentina; 2Latin American Society of Allergy,
Asthma & Immunology, Mexico DF, Mexico; 3Universita Degli Studi Di
Genova, Liguria, Italy; 4Latin American Society of Allergy, Asthma & Im-
munology, Monterrey, Mexico; 5Centro Investigacion Medicina Respiratoria
(CIMER-UCC), Cordoba, Argentina; 6Allergy & Respiratory Diseases, Uni-
versita Degli Studi Di Genova, Genova, Italy; 7CIMER (Centro de Investi-
gación en Medicina Respiratoria), Faculty of Medicine, Catholic University
of Cordoba. Fundación LIBRA Argentina, Cordoba, Argentina.
Background: In April 2011 a group of Latin American (LA) allergy experts,
leaders in their countries in the area of immunotherapy, met in Cordoba,
Argentina, to discuss how allergy and allergen-speciﬁc immunotherapy
(ASIT) can be improved in the region. The need for a situational sketch
was expressed.
Methods: A questionnaire on allergy training (AT), ASIT, extracts and
legislation was sent out to 22 leaders in the ﬁeld of nine LA countries to
obtain an overview of the LA situation.
Results: Results are presented with descriptive statistics. All 22 question-
naires were returned (9 countries). AT in 56% of the surveyed LA countries is
at the third-level of medical care, after a core-training of 2 to 3 years internal
medicine or pediatrics; in 3 countries it is a second-level career and in one
country there is no AT. Board certiﬁcation with exam is only mandatory in
a third of the countries; recertiﬁcation being obtained without exam. Mostly,
training is in general allergy; pediatric AT only exists in 2 countries. Both
sublingual (SLIT, only in the form of drops) and subcutaneous (SCIT)
immunotherapy are practiced in all countries, from the age of 3 years (mean,
range 1–5 years) onward. As no strict legislation exists IT can be managed by
non-allergists in 7/9 countries. Mixed extracts are used with mostly 3 to 5
allergens/vial (range 2 to 6-10 allergens/vial) and all countries have bacterial
vaccine. SCIT extracts come from US and European (89%) and 56% local
providers. SLIT extracts are almost exclusively from Europe (Spain), but in
Argentine, Brazil, and Mexico also local SLIT extracts exist. There is rudi-
mentary regulation concerning extract potency in 2 countries. IT is generally
paid for by private patients. Insurance companies reimburse IT in 56% of the
countries, the social security system in 33% and in one country selected third
level governmental hospitals supply IT. Publications on adverse events with
IT are starting to appear (3 countries) and 3 countries have their own guide-
lines on IT (one only in pediatrics).
Conclusions: A clearer picture where and how to improve AT and ASIT in
LA has been obtained; however, unmet needs on ASIT are still pending.
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Clinical Effects of Immunotherapy in Patients with Allergic
Disease in the National Institute of Respiratory Diseases
Ma del Rosario Gonzalez Galarza, MD, Ma de la Luz Garcia Cruz, MD,
Fernando Ramirez Jimenez, MD, Karla Paola Ruiz Cervantes, MD,
Carlos Guillermo Najera Villatoro, MD, and Luis Manuel Teran Juarez,
PhD. Clinical Immunology and Allergy, National Institute of Respiratory
Disease, Distrito Federal, Mexico.
Background: Previous studies have shown that after the treatment with
immunotherapy there is a reduction in the number of visits to emergency
services for asthma crisis, a signiﬁcant improvement in pulmonary function
tests: forced vital capacity (FVC), forced expiratory volume percentage in 1
second (FEV1%) and in the percentage of peak expiratory ﬂow (PEF%) and
the dose and number of drugs. There is also evidence of decreased response to
skin tests and IgE levels with immunotherapy speciﬁc to Dermatophagoides
pteronyssinus (Dpt).
Methods: The objective of this study was to evaluate the clinical effects of
immunotherapy in patients with allergic disease treated at the National
Institute of Respiratory Diseases in Mexico City, Mexico. There was a random
selection in a prospective study of 99 patients with positive skin tests and
more than 18 months of treatment with subcutaneous immunotherapy speciﬁc
to epithelia, pollens from trees, grasses and weeds; at the beginning and the
end of the immunotherapy there was an evaluation of the scale of rhinitis
symptoms and asthma control; pulmonary function tests were performed as
well (spirometry).
Results: At the initial evaluation, 97% of patients presented moderate to
severe persistent rhinitis, 80% of patients with asthma was uncontrolled; after
18 months with speciﬁc immunotherapy 80% of patients presented moderate
intermittent rhinitis and asthma control was achieved in 85% of the patients.
The FEV1 average increased from 78% at the beginning to 89% (P, 0.001).
The average bump at the beginning of the speciﬁc immunotherapy was 12 cm
for Dpt, for trees 10 cm, for weeds 8 cm and for grasses 8 cm; at the end of
the SIT the average bump for Dpt was 10 cm, trees 2 cm, weeds 1cm and
grass 0 cm (P value , 0.01).
Conclusions: The speciﬁc subcutaneous immunotherapy had beneﬁcial
clinical effects in patients with allergic disease, with signiﬁcant improvement
in pulmonary function tests and reduced positivity in skin tests, speciﬁcally
for patients who were sensitive to pollens from trees, weeds and grasses.
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Approach of Paediatric Allergists to Allergen Immunotherapy
in Severe Persistent Allergic Rhinitis
Alessandro Fiocchi, MD,1 Giovanni Passalacqua, MD,2 Sergio Bonini, MD,3
Franco Frati, MD,4 Luigi Terracciano, MD,1 Sandra Senecic, BSc,5
and Oscar Mazzina, RD1. 1Melloni Paediatria, Milano, Italy; 2Allergy &
Respiratory Diseases, Universita Degli Studi Di Genova, Genoa, Italy; 3Second
University of Naples, Rome, Italy; 4Department of Medical and Surgical Spe-
cialties and Public Health, Perugia, Perugia, Italy; 5Allegria, Milan, Italy.
Background: Hospital-based allergists manage children with allergic rhinitis
(AR) in Lombardy (paediatric population 900,000 ca). These specialists’
perception of severity in referrals was assessed by questionnaire.
Methods: During May 2011, a spreadsheet was e-mailed to 51 paediatric
allergy units, followed up by telephone interviews by trained volunteers
providing online assistance for compilation. Data were collected in pre-
schoolers (group I), school-age (group II) and adolescents (group III).
Results: Overall response was 66.6%. AR estimates among these referrals were
75.6% (70.6% in group I, 75.5% in group II and 82.9% in group III). AR alone
occurred in 18.7% (21.4%, 17.2%, and 19.1%) of cases. Co-morbidities
included asthma in 18.1% (30.1%, 14.1%, and 13.4%), conjunctivitis in
25.5% (13.8%, 27.8%, and 34.6%), or both in 13.4% (5.3%, 16.4%, and
15.7%). Specialists report intermittent AR in 51.4% (52.9%, 49.5%, and
54.7%), persistent disease in 48.6% (47.1%, 50.5%, and 45.3%), mild in 61.5%
(53.6%, 64.1%, and 63.9%) and moderate/severe in 38.5% (48.4%, 35.9%, and
36.1%) of cases. In moderate/severe persistent rhinitis (18.4%), allergy was
considered relevant for 42.2% (46.4%, 35.9%, and 36%) of cases. SIT was
considered appropriate for mild persistent grass-induced rhinitis in 22.5%
(10.1%, 29.2%, and 22.7%, respectively) and for 10.3% of moderate/severe
persistent rhinitis (3.8%, 18.9%, and 15.8%).
Relevant allergens Group I Group II Group III
Dust mites 45.9 46.2 57.3
Grass pollen 37.8 64.7 69.7
Ragweed 11.1 23.5 46.1
Tree pollen 17.1 20.2 27
Animal danders 13.3 19.7 16.8
Mould 15.6 23.5 13.5
Food allergens 5.8 2.1 0.8
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Conclusions: Rhinitis was the most frequent symptom, though rarely alone.
From the Italian ISAAC, AR affects 18.9% schoolchildren and 35.5%
adolescents, while severe persistent rhinitis affects 30,700 (3.42%) in
Lombardy. Some severe persistent rhinitis was considered indicative for
SIT in Group I, and incidence was higher in other groups. SIT is likely to be
considered particularly in the subset of patients not completely controlled by
symptomatic drugs. In the absence of clinical surveys and given referral study
limitations, epidemiological surveys are needed to quantify demand in the
pediatric population.
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Compliance and Persistence to Grass Immunotherapy Treatment
is Comparable for Allergy Immunotherapy Tablets and
Subcutaneous Immunotherapy: A Swedish Registry Study
Jakob Nørgaard Andreasen, MSc,1 Simon Lawton, MD,2 Sussi Boberg
Bæch, MSc, PhD,3 and Mikael Svärdc, BSc4. 1Market Access, ALK-Abelló,
Hørsholm, Denmark; 2Medical Advice, ALK-Abelló, Hørsholm, Denmark;
3Global Clinical Development, ALK-Abelló, Hørsholm, Denmark; 4Market
Access, ALK Nordic, Kungsbacka, Sweden.
Background: Allergy immunotherapy tablets (AITs) are administered by the
patients in their homes and the medical compliance and persistence may
therefore be poorer than for subcutaneous immunotherapy (SCIT) adminis-
tered by physicians. Purpose: to compare medical compliance and persistence
for AIT and SCIT treatments in Swedish patients with allergic rhinocon-
junctivitis (ARC).
Methods: Two products for the treatment of grass pollen induced ARC were
investigated: a SCIT treatment (Alutard SQ, Phleum pratense, 100,000 SQ-U/
mL) and an AIT treatment (Grazax, Phleum pratense 75,000 SQ-T/2,800
BAU), ALK, Denmark). Data were drawn from the Prescribed Drug Registry
2007–2009, the National Board of Health and Welfare in Sweden. Data on
patients treated and number of packages sold were used to calculate the
compliance and persistence for each of the 2 products, for patients who
started treatment in 2007.
Compliance: calculated as the duration of treatment estimated from the
number of packages sold (assuming 100% compliance), divided by the actual
duration of treatment (the time estimated from the ﬁrst to the last observed
prescription, plus the duration of the last package). Persistence: calculated as
the percentage of patients who continued their treatment in 2009 with at least
initiation of 1 treatment package or vial in 2009.
Results: Grass AIT treatment was started by 636 patients and the grass SCIT
treatment by 354 patients in 2007. The persistence of treatment in 2009 was
55% for grass AIT treatment and 57% for grass SCIT treatment. The
estimated average duration of treatment was 2.34 years for grass AIT and
2.47 for grass SCIT at cut-off 31 December 2009. The average number of
tablets used per patient during this period was 770. For grass SCIT treatment
the average number of up-dosing kits used was 1.07 and the average number
of maintenance vials was 3.26 (5 injections per vial). This corresponded to
a compliance of 90% for grass AIT and 82% for grass SCIT.
Conclusions: Compliance to treatment for grass ait and grass scit treatments
were both high (.80%) and comparable. The persistence of swedish patients




Fungal Sensitization and Its Relation to Asthma and Allergic
Rhinitis in Children Aged 6 to 7 Years
Alexander Diaz Rodriguez, MD. Department of Allergy, Medical Center,
Guira de Melena, Havana, Cuba, Cuban Society of Allergy, Asthma and
Immunology, Havana, Cuba.
Background: The purpose of the study was to determine the skin
sensitization to environmental fungi and its relation with the presence of
asthma and allergic rhinitis in children aged 6 to 7 years.
Methods: A cross-sectional and analytical study was conducted in 100 school
children aged 6 to 7 years in a primary school of San Antonio de los Baños,
La Habana, Cuba, in February-March, 2007. The ISAAC (International Study
of Asthma and Allergies in Childhood) questionnaire was applied to deter-
mine the presence of asthma and allergic rhinitis. The sensitization to envi-
ronmental fungi Penicillium, Cladosporium and Alternaria was explored by
skin prick tests. The statistical association between sensitization to each en-
vironmental fungi and the presence of asthma and allergic rhinitis was de-
termine by chi-square tests.
Results: The 27% of the selected sample suffered from asthma, 40% from
allergic rhinitis and 56% showed asthma, rhinitis or both, which was grouped
in a term called allergic respiratory disease. From these 56 children, 18 had
positive prick tests to one or more environmental fungi (32%); 9 showed
cutaneous reactivity to Cladosporium (16%), 9 to Penicillium (16%) and 5 to
Alternaria (9%). There was a signiﬁcant statistically association between the
cutaneous reactivity to Penicillium and the presence of allergic rhinitis (X2 ¼
5.46 P ¼ 0.05). There were no associations between any other fungal sensi-
tization and the presence of asthma or allergic rhinitis.
Conclusions: Allergic sensitizations to environmental fungi were relevant in
children with asthma, rhinitis or both; there was a signiﬁcant statistically
association between sensitization to Penicillium and the presence of allergic
rhinitis.
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Study on the Sensitization Rates to Airbone Pollen and Mold
in Children
So Hyun Park, MD,1 Dae Hyun Lim, MD, PhD,1,2 Byong Kwan Son, MD,
PhD,1,2 Jeong Hee Kim, MD, PhD,1,2 In Bo Oh, PhD,3 Yang Ho Kim, MD,
PhD,3 Keun Hwa Lee, PhD,4 Su Young Kim, PhD,4 and Sung Chul Hong,
PhD4. 1Department of Pediatrics, School of Medicine, Inha University, In-
cheon, South Korea; 2The Environmental Health Center, Inha University
Hospital, Incheon, South Korea; 3The Enviromental Health Center, Ulsan
University Hospital, Ulsan, South Korea; 4Enviromental Health Center, Jeju
National Universitiy Hospital, Jeju, South Korea.
Background: Aeroallergens are important causative factors for allergies such
as allergic rhinitis, allergic conjunctivitis and asthma. Previous studies for the
sensitization rate to aeroallergen were based on those patient groups who had
visited the pediatric allergy clinic. Compared to that, we inquired into the
sensitization rates based on general school aged student population group in
the city of Incheon, Jeju and Ulsan.
Methods: With informed consent, skin prick tests were performed on 5,094
students between April and June, 2010. Common 21 aeroallergens were used
on elementary school student while middle and high school students were
tested upon 28 allergens. 28 allergen list as positive control (1%Histamine),
negative control (Normal saline), D.pteronyssinus, D.farinae, Citrus red mite,
pollen (Birch, Alder, Oak, Japanese cedar, Pine, Willow, Elm, Maple, Ber-
muda grass, Timothy grass, Rye grass, Orchard, Meadow grass, Vernal grass,
Mugwort, Japanese hop, Fat hen, Ragweed, Plantain), mold (Penicillatum,
Asperugillus, Cladosporium, Alternaria) and 21 kinds of allergens that were
used on elementary school students count as same as above except Elm, Rye
grass, Orchard, Meadow grass, Vernal grass, Fat hen, Plantain.
Results: If arranged in rates of higher sensitization were D. pteronyssinus
(25.79%), D. farinae (18.66%), Mugwort (6.20%), Willow (4.07%) in
Incheon, D. pteronyssinus (33.35%), D. farinae (24.78%), Japanese cedar
(15.36%), Alternaria (7.33%) in Jeju, D. pteronyssinus (32.79%), D. farinae
(30.27%), Alder (10.13%), Birch (8.68%) in Ulsan respectively. The sensiti-
zation rate of Japanese cedar was statistically signiﬁcantly higher in Jeju. The
sensitization rate of Birch, Alder, Oak was higher in Ulsan. The sensitization
rate of Ragweed was 0.99% in Incheon, 1.07% in Jeju, 0.81% in Ulsan. The
sensitization rate of Mugwort in Incheon was 6.20% which was meaningfully
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higher in comparison to 2.32% of Jeju and 2.73% of Ulsan. The sensitization
rate of Alternaria was 2.98% in Incheon, 7.33% in Jeju, 2.39% in Ulsan and
as we can see it was higher in Jeju. The sensitization rate of Dermatopha-
goides had an increasing tendency with increasing age.
Conclusions: Changes in exposure rate to allergens with increasing ages
brings changes in sensitization rates. And because there are changes in
sensitization rates due to different regional living environmental status and
discrepancies of surrounding biologic species, this would leave us there lies
needs for subsequent studies and nationwide researches.
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Inﬂuence of Degree of Speciﬁc Allergic Sensitivity on Severity of
Rhinitis and Asthma in Chinese Allergic Patients
Jing Li, MD,1 Ying Huang, MD,2 Xiaoping Lin, MD,3 Deyu Zhao, MD,4
Guolin Tan, MD,5 Jinzhun Wu, MD,6 Changqing Zhao, MD,7 Jing Zhao,
MD,8 and Nanshan Zhong, MD,9,10. 1State Key Laboratory of Respiratory
Disease, The First Afﬁliated Hospital, Guangzhou Medical College, Guangz-
hou, China; 2The Children’s Hospital, Chongqing University of Medical
Sciences, Chongqing, China; 3The General Hospital of Shenyang Military
Command, Shenyang, China; 4Nanjing Children’s Hospital, Nanjing, China;
5The Third Hospital of Xiangya Medical University, Changsha, China; 6The
First Hospital of Xiamen, Xiamen, China; 7The Second Hospital of Shanxi
Medical University, Taiyuan, China; 8Capital Institute of Pediatrics, Beijing,
China, Michael Spangfort, ALK-Abello A/S, Asia Paciﬁc Region, Hongkong,
China; 9State Key Laboratory of Respiratory Disease, The First Afﬁliated
Hospital, Guangzhou Medical College, Guangzhou, China; 10China Alliance
of Research on Respiratory Allergic Disease Carrad, China Alliance of Re-
search on Respiratory Allergic Disease, China, China.
Background: The associations between sensitizations and severity of allergic
diseases are controversial. This study was to investigate the association
between severity of asthma and rhinitis and degree of speciﬁc allergic
sensitivity in allergic patients in China.
Methods: A cross-sectional survey was performed in 6,304 patients with
asthma and/or rhinitis from 4 regions of China. Patients completed a
standardized questionnaire related to the respiratory and allergic symptoms,
their impact on sleep, daily activities, school and work. They also underwent
skin prick tests with 13 common aeroallergens. 2,268 of them were taken
blood for serum speciﬁc IgE (sIgE) measurements for 16 common
aeroallergens.
Results: Signiﬁcantly higher percentage of patients with moderate-severe
intermittent rhinitis were sensitized to outdoor allergens while percentage of
patients sensitized to indoor allergens was increased with increasing severity
of asthma. Moderate-severe intermittent rhinitis was related to skin wheal size
and sIgE to Artemisia vulgaris and Ambrosia artemisifolia (P , 0.001).
Moderate-severe asthma was associated with increasing in skin and sIgE
response to Dermatophagoides (D.) pteronyssinus and D. farinae (P ,
0.001). Moderate-severe rhinitis and asthma were also associated with in-
creasing in number of skin and sIgE sensitized allergens.
Conclusions: Outdoor allergen sensitizations are signiﬁcantly associated with
severity of intermittent rhinitis and indoor allergen sensitizations are
signiﬁcantly associated with severity of asthma in patients in China. Number
of allergen sensitization is also related to severity of rhinitis and asthma.
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Allergic Sensitization to Domestic Mites in Santo Domingo,
Dominican Republic
Antonio Castillo, MD,1 William Muñoz,1 and Enrique Fernandez-Caldas,
PhD,2,3. 1Allergy & Asthma Center, Santo Domingo, Dominican Republic;
2Research & Development, Inmunotek SL, Madrid, Spain; 3Division of Al-
lergy and Immunology, University of South Florida College of Medicine,
Tampa.
Background: The objective of this study was to determine the prevalence of
mites sensitization in Santo Domingo.
Methods: One hundred consecutive patients (52 males and 48 females, mean
age 30.3 years; 4–68) with asthma and /or allergic rhinoconjunctivitis were
skin tested with 9 commercial extracts of mites of the following species:
Dermatophagoides pteronyssinus, D. farinae, Blomia tropicalis, B. kulagini,
Acarus siro, Lepidoglyphus destructor, Tyrophagus putrescentiae, Glycypha-
gus domesticus and Chortoglyphus arcuatus. A skin test was considered
positive when the wheal was. 3 mm with erythema. Conventional exclusion
criteria were used, in order to avoid masking a skin reaction.
Results: A positive skin test to any of the mites tested was detected in 98% of
the patients; Dermatophagoides spp. was positive in 89% of the patients; 15%
were exclusively positive to Dermatophagoides spp; 87% reacted to Blomia
spp. and 3% were exclusively positive to Blomia tropicalis spp; 80% were
sensitized to 3 or more specie.
Conclusions: The allergy sensitization to domestic mites in Santo Domingo
is high. Sensitization to several species is very common. B. tropicalis is an
important species in this region. With these results we could extrapolate that
immunotherapy with only Dermatophagoides species could not be enough
achieve clinical improvement in mite allergic patients. Other species, such as
B. tropicalis may be needed.
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Prevalence Sensitizing to Most Common Allergens in Elderly in
Western Mexico
Martín Bedolla-Barajas, MD. Servicio de Alergia e Inmunología Clínica,
Hospital Civil de Guadalajara, Guadalajara, Mexico.
Background: Allergic diseases affect a great proportion of seniors. Our
objective was to determine the prevalences of allergen sensitization in this age
group.
Methods: Retrolective study was performed during 3 years follow-up at
Hospital School in Guadalajara city, Mexico. The allergen sensitization with
a common allergen panel by a prick test was evaluated in seniors of ﬁrst
consultation in an Allergology Service.
Results: We included 60 subjects, with an average of 67.7 years old;
83.3were women. Diagnosis of allergic rhinitis was present in 60%, allergic
rhinitis plus asthma in 30%, and asthma alone in 10%. Non atopic
comorbidities were present in 56.7% of the cases. Median of serum IgE
was 124.95 UI/mL, whereas for positive prick test was 4 (minimum-
maximum, 1–21); 13.3% were sensitized to just 1 aeroallergen, and 55%
were to more than 3 aeroallergens. Sensitization to pollens was predominant,
even more to tree pollens. One by one, house-dust mite, Fraxinus sp and
Amaranthus palmeri were the most common found. To have diabetes was
associated to a minor positive prick test (P ¼ 0.021).
Conclusions: It’s recommendable to identify the allergen sensitization in
seniors with allegic disease symptoms, as part of their evaluation. The most
common sensitizing allergens are similar for other age groups proceeding
from the same area. It’s recommendable to search for more ﬁndings possibly
associated between diabetes and number of positive prick tests.
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Cross Reactivity Between Cypress Pollen and Plant Food in
Queretaro, Mexico
Alejandra Medina-Hernández, MD, Carlos Fancisco Sosa Ferreyra, PhD,
and Guadalupe Zaldívar Lelo de Larrea, PhD. Medicine Faculty, Queretaro
University, Queretaro, Mexico; Natural Sciences Faculty, Queretaro Uni-
versity, Queretaro, Mexico; Medicine Faculty, Querétaro University, Quer-
etaro, Mexico.
Background: Food allergy prevalence is growing continuously. Reasons are
unknown. It is suggested that environmental factors have a greater impact
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than genetic. The hay may be responsible for developing food allergy to
plants. The geographical and climatological condition of Querétaro city, and
having a large industrial corridor are risk factors for development allergic
problems. In Mexico there are no prevalence studies on food allergy and
therefore the most common food allergens. The objectives of the study are
to identify common allergen sensitization and to determine if there is cross-
reactivity between cypress pollen and plants most commonly consumed in
Queretaro.
Methods: We performed a correlation study in patients allergic to cypress
pollen to determine if there is cross reactivity between it and plant food by
spick prick test and speciﬁc IgE titers by inmunocap technique.
Results: Studied 45 patients, 23 (51,1%) males and 22 (48,8%) women, 43
patients had allergic rhinitis (95,5%), 23 had asthma (51,1) and 12 had atopic
dermatitis (26,6%). As background, 16 patients (35,5%) had no ﬁrst-degree
relatives with atopy, in 17 (37,7%), the father had a history of allergy, the
mother was allergic in 31,1%, and 24,4% (11) had at least one sibling with
allergy. 51,1% (23) were born by eutosia, and 22 (48,8%) via cesarean
section. 24 (53,3%) received mixed feeding, 17 (37,7%) were breastfeed and
only 4 (8,8%) received only formula. The average time of breastfeeding was
5,3 months. Person correlation coefﬁcients were found in descending order
relationship with oregano (0.69), corn (0.65), wheat (0.63), oats (0.63), bean
(0.597), melon (0.569), tomatoe (0.538), lentil (0.537), peanut (0.515),
chickpea (0.480), soybean (0.479), carrot (0.474), avocado (0.457), apple
(0.438), pepper (0.418), celery (0.187).
Conclusions: Although the literature reported association between cypress
with tomato only, we found relationship with apple, wheat, celery, peanuts,
melon, lentil, tomatoes, beans, avocados, soybeans, chickpeas, corn and
pepper.
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Study of the Allergenic Crossreactivity and Allergenic
Composition of Dermatophagoides Pteronyssinus and
Blomia Tropicalis
Barbara Cases, PhD,1 Enrique Fernandez-Caldas, PhD,1,2 Jose Ignacio Tudela,
BS,1 Eva Abel Fernandez, BS,1 Sylvie Lafosse-Marin,3 Miguel Casanovas,
MD, PhD,1 and Jose Luis Subiza, MD, PhD1. 1Research & Development,
Inmunotek SL, Madrid, Spain; 2Division of Allergy and Immunology, Uni-
versity of South Florida College of Medicine, Tampa; 3Cabinet de Inmuno
Alergologie, Fort de France, Martinique.
Background: D. pteronyssinus and B. tropicalis are the most common house
dust mite species worldwide. D. pteronyssinus and B. tropicalis are the most
prevalent species in the tropics. Twelve allergens have been described in B.
tropicalis and ﬁfteen in D. pteronyssinus. The objectives of this study were:
1) to analyze the prevalence of sensitization to B. tropicalis and D. pteronys-
sinus on the tropical Island of Martinique; 2) to evaluate the allergenic cross-
reactivity between D. pteronyssinus and B. tropicalis and 3) to identify
common, and species speciﬁc allergens, using mass spectrometry (MS).
The serum of patients sensitized to a single, or to both species, was further
analyzed by western blots.
Methods: The sera of 1,243 consecutive patients evaluated for allergic
rhinitis and/or asthma were evaluated for speciﬁc IgE using direct ELISA. All
patients resided on the tropical island of Martinique. Crossreactivity between
both species was analyzed by ELISA Inhibitions. Proteins of both species
were digested with trypsin and analyzed by MS/MS (MALDI TOF/TOF).
Different databases were used for the identiﬁcation of the proteins.
Results: Sensitization to B. tropicalis was detected in 868 sera and to D.
pteronyssinus in 919 sera; 135 were sensitized exclusively to B. tropicalis and
177 to D. pteronyssinus. Speciﬁc IgE levels to D. pteronyssinus were signif-
icantly higher than to B. tropicalis (Mean 0.67 OD 6 0.89 vs. 0.866 1.04; P
, 0.001). The correlation coefﬁcient between speciﬁc IgE levels to both
species was 0.135. ELISA Inhibition studies demonstrated minimal cross-
reactivity between both species. Western blots done with the serum of poly
or monosensitized patients revealed speciﬁc IgE binding to similar proteins.
Proteomic analysis revealed the presence of the following allergens: B. tro-
picalis: groups 2, 3, 4, 6, 9, 14 and groups 1, 2, 3, 4, 8, 11, 14, 15, 16 and 18
in D. pteronyssinus. Species speciﬁc, as well as common proteins were
detected.
Conclusions: There is limited crossreactivity between B. tropicalis and D.
pteronyssinus. Sensitization to their allergens seems to be a parallel phenom-
enon. Allergen extracts of both species are needed for the correct diagnosis
and treatment of mite allergic individuals in the Caribbean.
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Ficus Benjamina Sensitization in Adult Patients with Rhinitis
Sandra González-Díaz, MD, PhD, Alfredo Arias-Cruz, MD, Dora Valdes,
MD, Claudia Gallego, MD, Maria del Carmen Zarate, MD, PhD,
Gabriela Galindo, MD, Diego Garcia-Calderin, MD, Karla Mejia, MD,
Luis Dominguez, MD, and Maricruz Calva, MD. Regional Centre of Allergy
and Clinical Immunology, University Hospital, Monterrey, Mexico.
Background: In Monterrey there are a considerable number of Ficus benja-
mina trees, but the awareness-related information to this plant is scarce. The
objective of this study is to determine the frequency of sensitization to Ficus
benjamina in patients with rhinitis who were attended the Regional Centre of
Allergy and Clinical Immunology of Monterrey, Mexico.
Methods: Observational, transversal and descriptive study. We included
patients over 18 years old with chronic rhinitis, which completed a question-
naire to assess exposure to Ficus benjamina. Skin prick tests (SPT) to com-
mon aeroallergens in our region with extract of Ficus benjamina (Allerstand
Company) had done in all subjects.
Results: A total of 177 patients were included, mean age was 38 years, 65%
(115) were female, 135 (76%) reported contact with a Ficus benjamina tree in
their home or neighbor. 12 (17%) patients had a positive skin test to Ficus
benjamina, but up to 15% (26) had clinical manifestations when they were
close to a tree of Ficus benjamina. Most patients with positive skin test to
Ficus benjamina (76.9%, 9) had positive test more than one of the aeroaller-
gen tested. The association between Ficus benjamina and sensitization to
other aeroallergens, as well as the symptoms associated to the contact with
the tree was not statistically signiﬁcant.
Conclusions: Sensitization to Ficus benjamina is common and was similar to
that reported in European countries. To demonstrate the association between
sensitization to Ficus benjamina and symptoms should be made studies with
nasal challenge test.
REFERENCES
1. Kortekangas O, Kalimo K, Savolainen J. Allergens of Ficus benjamina
(weeping ﬁg): unique allergens in sap. Allergy. 2006;61:393–394.
2. Mahillon V, Saussez S, Michel O. High incidence of sensitization to
ornamental plants in allergic rhinitis. Allergy. 2006;61:1138–1140.
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Identiﬁcation and Statistic Analysis Related with Climatic
Variability and Transportation of the Most Abundant Spores in
Mexicali, Mexico
Silvia Ahumada, PhD. Environmental Area, Air quality, Academic, Mexicali,
Mexico.
Background: The Mexicali valley with intense agricultural and industrial
activities has among its community a high incidence of allergenic diseases
and one of the causes could be suspended particles including pollen and
spores. Unfortunately, there are not backgrounds for aerobiological analyses,
being Mexicali a city where the levels of atmospheric contamination have
exceeded the air quality standards (Reyna, 2006). This situation has led
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studies to determine the impact of concentrations of air pollutants including
spores as causal agents in allergies and respiratory diseases.
Method: Three periods of sampling have been carried out. The ﬁrst sampling
in 2005 with Rotorod equipment; the quantitative parameters were diversity,
volume, and frequency of spores, as well as its relation with meteorological
factors, like average temperature, relative humidity, and precipitation;
a second study was performed in 2008, with same parameters and equipment.
In 2011 new sampling is performed by using the Burkard sampler which
includes same parameters as the ﬁrst and second sampling.
Results: In 2005 the most abundant types were Alternaria 3,419/m3 with
greater representativeness in August (24.81%); the same to Bipolaris
1,846/m3 (22%); Stemphylium 1197/m3 with greater presence in February
(15%); temperature and relative humidity were correlated with the presence of
spores being an association linear loss; the correlation in annual tendency is
smaller, related to the seasonal monthly correlation; correlation of cold season
is greater than correlation of the warm season. A study carried out in 2008
showed, high incidence of Cladosporium, on April 57, 32%. Same month in
the ﬁrst sampling only 15.11%. In 2011 richness of Ascospora, Cladosporium
and Periconia, showed very different results the same months but sampling in
2005 and 2008.
Conclusions: The studies show different data related with type and richness
on same months. Data obtained in the ﬁrst study correlated the relationship
between air pollution caused by fungal spores and the incidence of childhood
asthma in Mexicali (de la Fuente, 2009).
AEROBIOLOGY
218
Thunderstorm-Related Asthma in Patients Sensitised to Olea
Europaea Pollen: Twenty Emergency Department Visits for
Asthmatic Symptoms in One Single Day
Laura Losappio, MD,1 Enrico Hefﬂer, MD,2 Francesco Contento, MD,1
Antonio Falco, MD,1 Cosimo Damiano Cannito, MD,1 and Giovanni
Rolla, MD2. 1Emergency Department, PO Dimiccoli Barletta, Barletta, Italy;
2Biomedical Sciences and Human Oncology, Allergy and Clinical Immunol-
ogy, University of Torino-AO Mauriziano "Umberto I", Torino, Italy.
Background: Asthma exacerbation associated with thunderstorms has been
reported in several countries. Common to all epidemics of thunderstorm-
related asthma is a signiﬁcant increase in atmospheric allergen load during
and immediately after a thunderstorm. Sensitization to Alternaria species or to
grass and parietaria pollens has been suggested to play a key role in
thunderstorm-related asthma. The only reported event of thunderstorm-related
asthma in Mediterranean area was attributed to sensitization to parietaria
pollen.
Methods: Here we describe a series of 20 patients who accessed to an
Emergency Department in Puglia (Italy) for sudden and severe dispnoea
between the 27th and the 28th of May 2010 (between 15:36 and 5:02), just
after a violent thunderstorm which occurred after a very warm morning (mean
atmospheric temperature: 298C). All patients have been subsequently visited
by an allergist and underwent a complete allergological work-up which in-
cluded skin prick tests and a careful clinical history record. Data from atmo-
spheric pollen count were recorded.
Results: In the months between 10th of May and 10th of June 2010, a total of
86 accesses to same Emergency Department were recorded for asthma
exacerbations, 20 of them during the studied day. Patients’ mean age was
44.256 18.5 years (range: 9–81), 8/20 females, 2 smokers, 16 with a previous
history of known respiratory allergy. All 20 patients were sensitized to
Olea europaea pollen, 7 of which were monosensitized. Other sensitizations
were: 10 patients to grass, 7 to parietaria, 5 to compositae, 5 to cypress, 5 to
house dust mites, 3 to dog and 1 to cat danders. Mean atmospheric pollen
count was 170 granules/m3 for Olea europaea and 60 granules/m3 for grass
pollen.
Conclusions: This is, in our knowledge, the second thunderstorm-related
asthma episode described in Mediterranean area and the ﬁrst one in which
sensitization to Olea europaea played a key-role. This result should focus the
possibility that not only the increase of molds and grass pollen load after
a thunderstorm may raise asthma exacerbations.
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The Revised Edition of Korean Calendar for Allergenic Pollens
Jae-won Oh, MD, PhD, FAAAAI,1 Joo-Hwa Kim, MD,1 Seong-Won
Kim, MD,2 Im-Joo Kang, MD,3 Bong-Seong Kim, MD,4 Myung-Hee
Kook, MD,5 Kang-Seo Park, MD,6 Ha-Baik Lee, MD, PhD,7 Kyu Rang
Kim,PhD,8 and Young-Jean Choi, PhD8. 1Pediatrics, Hanyang university Guri
Hospital, Guri, South Korea; 2Pediatrics, Busan St. Maria Hospital, Busan,
South Korea; 3Pediatrics, Daegu Fatima Hospital, Daegu, South Korea; 4Pe-
diatrics, Kangneung Asan Hospital, Kangneung, South Korea; 5Pediatrics,
Kwangju Veteran’s Hospital, Kwangju, South Korea; 6Pediatrics, Jeonju Jesus
Hospital, Jeoju, South Korea; 7Pediatrics, Hanyang university Seoul Hospital,
Seoul, South Korea; 8Applied Meteorology Research Laboratory, National
Institute of Meteorological Research, Seoul, South Korea.
Background: The old version of pollen calendar was used until this year in
South Korea. That calendar did not reﬂect current pollen distribution and
concentrations that can be inﬂuenced by changes in weather and environment.
A new pollen calendar of allergenic pollens was made based on the data on
pollen concentrations obtained in 8 regions nationwide between 1997 and
2009 in South Korea.
Methods: The distribution of pollen grains was assessed every day at 8 areas
(Seoul, Guri, Busan, Daegu, Jeonju, Kwangju, Kangneung, and Jeju)
nationwide for 12 years between July 1, 1997 and June 30, 2009. Pollen
were collected by using Burkard 7-day sampler (Burkard manufacturing Co
Ltd, Hertfordshire, UK), and the collected pollens were sent every week to
Hanyang Guri Hospital. Then pollens were strained with Calberla’s fuchsin
staining solution and were identiﬁed. The number of pollen grains per m3 was
calculated.
Results: Alder, birch and Japanese cedar started to appear in February.
Japanese cedar showed a highest pollen concentration in Jeju. Pine became
the highest pollen in May, and the pollen concentrations of oak and birch also
became high. Common ragweed appeared in the middle of August and
showed the highest pollen concentration in the middles of September.
Japanese hop showed a high concentration between the middle of August
and the end of September, and mugwort appeared in the middles of August
and its concentration increased up until early September. Birch appeared
earlier in Kangneung, and pine showed a higher pollen concentration than in
the other areas. In Daegu, Oriental thuja, alder and juniper produced a large
concentration of pollens. Pine produced a large concentration of pollens
between the middle of April and the end of May. Weeds showed higher
concentrations in September and mugwort appeared earlier than common
ragweed. In Busan where is the southeast city, the time of ﬂowering is
relatively early, and alder and Oriental thuja appeared earliest among all
areas. In Kwangju, Oriental thuja and hazelnut appeared in early February. In
Jeju which is the end of southern island, Japanese cedar showed a higher
pollen concentration than the other areas
Conclusions: New information on pollen distributions and concentrations
should be provided for the general publics or allergic patients through the
website in order to prevent the occurrence of pollinosis.
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Aerobiological Study of Anemophilous Pollens in the City of
Toluca, Mexico
Maria Cid del Prado Izquierdo,MD,1 Berenice Piedras-Gutierrez,BD,1 Horacio
Del Olmo Tellez, PhD,2 and Osvaldo Zarco Cid del Prado, MD1. 1Funda-
cion Regional Para El Estudio De Asma Y Alergia, Clinica De Asma,
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Alergia E Inmunologia, Toluca, Mexico; 2Pediatric Allergy & Clinical
Immunology, Phd In Science, Private Practice, Mexico City, Mexico.
Background: The pollen dispersal by wind is a natural event of great
biological signiﬁcance and an etiological factor in the genesis of allergic
respiratory diseases. This is the ﬁrst such study carried out in the city of
Toluca, Mexico.
Objective: To present the data of collected pollen from September 2004 to
September 2005.
Methods: The pollen was collected, using a Hirst type 7-day recording
volumetric Spore Trap. According to the British Aerobiology Federation, we
decided to read 12 sweeps in 24 hours in a transverse to have the mean pollen
count. Standard equipment used for aerobiological sampling worldwide was
used. Statistical analysis is a descriptive study using the SPSS Software.
Results:We found 14, 078.61 pollen grains, coming from 32 diferent pollinic
types in the 12 Transverse traverses in the year analized. The 6 leading taxa,
in order of abundance, were: Cupressaceae (49%), Oleaceae genus
Fraxinus sp (17%), Betulaceae genus Alnus (14%), Pinaceae (11%), Grami-
neae (6%), Asteraceae or Compositae (3%). The most prevalent months
regarding pollen counts were January and February 2005 in wich Cupressa-
ceae and Oleaceae genus Fraxinus were accounted.
Conclusions: In aerobiological terms both Cupressaceae and Fraxinus seem
to be a major risk for potential sensitized individuals due to its known aller-
genicity and its high atmospheric concentrations between late winter and
early spring, followed by Alnus, Pinaceae, Gramineae, Asteraceae, Casuar-
inaceae, Schinus, Cheno/Amp and Moraceae. This is the ﬁrst effort to create
the Mexican Aerobiological Network (REMA), and further studies are needed
to correlate clinical data.
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Allergenic Signiﬁcance of Airborne Rhizopus Stolonifer (ehrenb.)
Vuill, a Common Bread Mold
Gaurab Sircar, and Swati Gupta Bhattacharya, PhD. Division of Plant
Biology, Bose Institute, Kolkata, India.
Background: Airborne fungi, a signiﬁcant constituent of atmospheric
bioaerosol, are well-known source of allergens and can cause allergic rhinitis
and bronchial asthma in sensitive subjects. Rhizopus stolonifer, the ﬁlamen-
tous fungus is a widely distributed thread-like Mucoralean mold. Commonly
found on bread surfaces, it takes food and nutrients from the bread and causes
damage to the surface where it lives. Although a signiﬁcant exposure risk is
assumable in indoor environment, the role of this fungus in provoking allergic
symptoms in pre-sensitized individuals, however, was poorly investigated.
We conducted this study to monitor airborne R. stolonifer and to evaluate its
potential as an aeroallergen causing nasobronchial allergy in sensitized
individuals.
Methods: Seasonal periodicity of R. stolonifer was studied for 2 years
(March, 2009-Feb.11) by Andersen air sampler. The relationships between
meteorological parameters and airborne R. stolonifer concentration were ex-
plored by linear regression models. The allergic potential of R. stolonifer
extract was studied on 389 respiratory allergic patients by performing skin
prick tests (SPT) and measuring the allergen-speciﬁc IgE levels in SPT pos-
itive patient’s sera by Enzyme-linked Immunosorbent Assay. SDS-PAGE and
immunoblotting with pooled patient sera were performed to identify its IgE-
binding components.
Results: Airborne R. stolonifer concentration range was 4 to 47 CFU/m3 and
reached the peak concentration in March. Relative humidity was found to be
a signiﬁcant predictor for occurrence of R. stolonifer in air. Positive skin
reaction was observed in 105 patients (27%) including 10 (9.5%) showing
markedly high (21 to 31) skin sensitization. Crude antigenic extract of
R. stolonifer was resolved in 16 protein bands in the molecular weight range
of 12 to 72 kDa on SDS-PAGE (12% gel). Three IgE-binding protein bands
(17, 21and 67.12 kDa) were detected by immunoblot analysis.
Conclusions: Exposures to R. stolonifer in environments where it naturally
occurs may confer risk of IgE-mediated sensitization in sensitive individuals.
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Aerobiological and Immunological Studies on Coconut
Pollen Allergy
Bodhisattwa Saha, M.Sc, and Swati Gupta Bhattacharya, PhD. Division of
Plant Biology, Bose Institute, Kolkata, India.
Background: Pollen grains constitute a signiﬁcant portion of the aero-
biological ﬂora. The plant Coccos nucifera (commonly known as coconut) is
found in huge quantities in the tropical coastal areas of the world and is very
common in Kolkata, India. A 2 years aerobiological survey was carried out
using Burkard Volumetric Sampler to know the seasonal variation of Cocos
nucifera pollen. The plant ﬂower through out the year but maximum concen-
tration was found in the month of August. Allergenicity of Cocos nucifera
pollen has been reported from the Skin Prick Test, Lung function test, ELISA
from a 400 susceptible patients in and around West Bengal in India. An
immunobiological study was conducted to identify major allergens from
Coccos nucifera pollen causing hay fever, skin allergy and allergic asthma
in Kolkata population.
Methods: Proteins from pollen grains were obtained by initially defatting and
then extracted with sodium phosphate buffer with 10 mM PMSF. Total
protein was divided into 4 fractions by ammonium sulfate at 25%, 50 %, 75%
and 100% respectively. SDS PAGE was done with the 25% fraction (result
obtained from dot blotting) and subsequently western blotting was performed.
Two dimensional gel electrophoresis and immunoblotting was also done from
the crude protein.
Results: The total protein was separated on a SDS PAGE gel showed 21
prominent bands by Coomassie Blue staining. Dot -blotting the different
fractions from ammonium sulfate cut, showed a positive result in the 25%
fraction. Western blot with patient speciﬁc sera gave 3 bands out of which
a major band was obtained at 60Kd. This result was obtained in more than
65% of the patients from whom Sera was isolated. 2D gel electrophoresis of
the crude protein sample was performed which showed 120 protein spots in
the PI range of 3 to 10 and molecular weight 14Kd to 97Kd. Immunoblotting
the 2D gel with pooled patient speciﬁc sera showed 20 spots thus implying
IgE reactivity.
Conclusions: It can thus be inferred that Coccos nucifera pollen grains are
very common in the air and are important to cause allergy to susceptible
persons. More over the 60 Kd protein is responsible for allergenicity.
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Patterns of Skin Prick Test Positivity in 519 Patients with Allergic
Rhinitis and Asthma in Mexico City
Karla Paola Ruiz Cervantes, MD,1 Ma de la Luz Garcia Cruz, MD,2
Ma del Rosario Gonzalez Galarza, MD,2 Fernando Ramirez Jimenez, MD,2
Carlos Guillermo Najera Villatoro, MD,2 Luis Manuel Teran Juarez, PhD,2
and Fernando Gandhi Pavon Romero, MD2. 1Clinical Immunology and
Allergy, National Institute of Respiratory Disease Calzada de Tlalpan 4502
Col. Sección XVI, Del. Tlalpan, Mexico; 2Clinical Immunology and Allergy,
National Institute of Respiratory Disease, Distrito Federal, Mexico.
Background: There are studies in Mexico and worldwide about the patterns of
positivity of skin prick test and the most frecuently allergens were: Dermato-
phagoides pteronyssinus (DPT), tree pollens (Ash/Oak in Mexico, Oak in
U.S.A, Birch in Europe), grasses (Bermuda in Mexico, Timothy in U.S.A and
Lolium in Europe) and thirdly cat ephitelium(CE). The reactivity to allergens
was more common in males and the age groups in which there were positive
skin test with the highest prevalence was from 5 to 15 years and 21 to 40 years.
Methods: The objective is to determine the pattern of skin prick test
reactivity to aeroallergens in patients with rhinitis and asthma allergic in
Mexico city, attending in the National Institute of Respiratory Disease
(INER). This is a prospective, observational and longitudinal study based on
data analysis of skin prick test results of individuals with clinical diagnosis of
airway allergy (rhinitis/asthma). We use standardized allergens (alkalbello),
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detailed clinic history was collected in all cases. The statistical analysis was
performed with the program SPSS14.
Results: We obtained a total of 519 patients with positive skin prick test
between January 2009 and March 2011. This group comprised 47% females
and 53% male, with a mean age of 19 years between 3 to 79 years. We have
253patients with allergic rhinitis (AR) and asthma (A), 173 with RA and 93
with A. 55% of the patients reacted to one allergen extract (AE) and 45% of
the patients reacted with 2 or more AE. The most frequently indoor
allergenswith positive skin prick test were Dpt (65.1%), Dermatophagoides
farinae (Df) in 32.3%, CE(31.7%), Cockroach (11.5%). Among the outdoor
allergens ash was positive in 23.3%, Ligustrum (18.8%) oak (17.7%) birch
(13.6%) Western Juniperus (9.6%), Ulm (8.6%).
Conclusions: The most frequently positivity skin prick test were Dpt, Df, CE,
Ash, Privet, Oak. The reactivity to allergens was more common in males, and
there are 3 peaks of age of positivity on prick test (7–12 years, 25–29 years
and 36 years).
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Risk Factors and Their Impact on Development and Severity of
Allergic Diseases in the CIS-Region
Tatiana Slavyanskaya, PhD, MD,1,2. 1Allergology & Immunology, University
of Russia, Moscow, Russia; 2Department of Allergology and Clinical Immu-
nology, Institute of Immunophysiology, Moscow, Russia.
Background: This paper presents the results of inﬂuence of risk factors (RF)
on development and severity of allergic diseases (ADs) in the CIS-region
(CIS-R).
Methods: ISAAC and ARIA studies results, data on atopic dermatitis,
Republic Ministries of Health Statistical Reports as well as literature data has
been analyzed.
Results: It has been established that in industrialized areas, ADs is 2 to 3
times higher than the incidence in rural areas. The highest incidence is noted
in ecologically unfavorable regions of low mountains where suffering from
ADs is more often met. In the medium mountains ADs appear with less
intensity, in conditions of high mountains ADs are extremely rare. The
maximum prevalence of ADs has been observed at the experience of working
in hazardous conditions from 5 years and above. A high degree of
contamination airpollutions (CO2, NO2, SO2 etc.) in the industrial cities
correlated with the prevalence of respiratory allergies and other ADs were
observed. Frequent cause and signiﬁcant allergens, as identiﬁed in patients
with different ADs in CIS-R were domestic, epidermal, pollen and fungous
allergens. The main triggers which involved in the development or
exacerbation of ADs in Azerbaijan, Armenia, Russia and Uzbekistan are:
house dust mites, pollen of trees and plants, pet allergens. In Belarus,
Kazakhstan, Turkmenistan, Ukraine, Moldova, the cause-important allergens
are: pollen of trees, grasses and weeds. Among the most signiﬁcant risk F for
ADs should be noted: burdened by heredity (65,5–75,9%), high frequency of
SARS in history (16,2–77%), passive smoking (43,1–62,5%), poor social
conditions (17–42%) the presence of pets in the apartment (12,5–17%). Chil-
dren (7–8 years) were more susceptible to environmental RF as compared
with teens (13–14 years). In Tajikistan and Turkmenistan, ADs were closely
related with poor social conditions, low household income and large-family.
Conclusions: Epidemiologic studies are of great theoretical and practical signiﬁ-
cance as they provide impartial evaluation and reliable data on ADs prevalence and
the most important allergens. Climatic and geographical conditions of the
environment and ecological situation in the region are signiﬁcant RF, requiring
consideration in determining the probability of a genetic predisposition to ADs.
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Monitoring of Air-Pollutants Concentration in Children with
Allergic Diseases
Manana V. Chikhladze, and Revaz I. Sepiashvili,MD, PhD. National Institute
of Allergology, Asthma and Clinical Immunology, Georgian Academy of
Sciences, Tskhaltubo, Georgia; Department of Allergology and Clinical
Immunology, Institute of Immunophysiology, Moscow, Russia.
Background: All over the world, increases the incidence of allergy, asthma
and autoimmune diseases. Both young and elderly people are at risk.
Therefore, on time diagnostics of these changes and the improvement of
patient’s quality of life is the most important task for doctors worldwide.
Methods: Patients by random selection were interviewed and subsequently
examined: 535 schoolchildren of Kutaisi, aged 7 to 14. Stepwise diagnostics
of allergic factors included: 1. Questionnaire screening according to the
international ISAAC questionnaire. 2. To identify the speciﬁc allergens in
serum. 3. To deﬁne air pollutant concentration in the environment with the
help of Burkard Trap (Burkhard Pollen Trap donated by the WAO).
Results: Investigation included questionnaire screening with the use of the
international ISAAC questionnaire. The questionnaires for children aged 7 to
10 years were ﬁlled in by their parents; school children of 11 to 14 answered
the questions themselves. Questionnaire screening allowed select the group of
children with already diagnosed and with primarily diagnosed allergic
diseases. From mentioned above 3 groups of children: I group 57 persons
(10.7%) children with primarily diagnosed allergic diseases; II group-68
persons (12.7%) children with already diagnosed allergic diseases; III group-
410 persons (77.6%) practically healthy children with no deviations
according to ISAAC questionnaire. The next phase of the examination
consisted of ImmunoCAP100 tests in II group 68 children with already
diagnosed allergic diseases. There was determined the highest level of
Phadiatop (inhaled environmental allergens) was positive in 35% of patient.
We gave them the information and recommendation of air –pollens concen-
tration according to Burkard Trap research. The use of allows accurately
deﬁne the concentration of air pullutants in the environment including the
pollen of trees, grass and weeds in particular geographical area in different
seasons of the year.
Conclusions: Burkard Trap is committed to helping physicians identify the
causative allergens in this complex mini environment, there are necessary
condition for ﬁnal veriﬁcation of allergic diseases, which makes it posible to
form successfully the basis of preventive therapy and appropriate undertake
preventive measures.
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Analysis of anAfter-CareQuestionnaire inAllergic People toDust
Mites Using Anti-Dust Mites Bed Covers
Nabile Boukhettala, PhD, and Solveig Bourgeon. Laboratoire Protec’Som,
Valognes, France.
Background: The goal of the study was to assess in a declarative way, the
symptoms felt by the patients and the impact of micro-woven cotton (MWC)
and a non woven polyester polyamide (NWP) anti-dust mites bed covers on
allergic volunteers to dust mites.
Methods: This study is a descriptive survey based on an after-care
questionnaire handed out to a group of 419 volunteers allergic to dust mites.
109 questionnaires have been used. Regarding the allergy, we asked
questions in order to assess the most annoying symptoms. The discomfort
level felt was assessed using scores that ranged from 0 (no discomfort) to 10
(severe discomfort). Values, expressed as mean 6 SEM, were compared
using 2-way ANOVA.
Results: The discomfort level felt by the allergic volunteers to dust mites has
signiﬁcantly decreased after the anti-dust mite’s bed cover use (7.1 6 0.2
versus 2.6 6 0.2). After the anti-dust mites bed cover use, the discomfort
level noticed decreased signiﬁcantly and in a similar way no matter the age
brackets. Thus, after the use of an anti-dust mites bed cover, it ranged
between 2.1 and 2.3. The discomfort level felt after the anti-dust mites bed
cover use was similar whatever the symptom. The reduction of the percentage
of the discomfort level in volunteers having used MWC anti-dust mites bed
covers was similar to the percentage of the volunteers having used NWP anti-
dust mites bed covers (62.9 6 3.1% vs. 60.7 6 4.2%).
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Conclusions: To conclude, the use of anti-dust mites bed cover permits to
signiﬁcantly reduce the symptoms felt by allergic patients to dust mites.
Moreover, it underlines the fact that the use of MWC anti-dust mite’s bed
cover or NWP anti-dust mites bed cover had a similar efﬁciency on the
reduction of symptoms felt.
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Changing Scenario of Airborne Allergens in Bangalore, India
Anand Pendakur, MBBS, DLO1 and Balaji Ramdas, MBBS2. 1Allergy
Asthma ENT Clinic, Indian College of Allergy Asthma and Applied Immu-
nology, Bangalore, India; 2Community Medicine, Indian Academy of Allergy,
Bangalore, India. With phenomenal growth of Bangalore city and a distinct
shift of its arboriculture in the last 2 decades, change in allergen proﬁle has
been suspected. Earlier studies reported the pollen of Partheenium, Albizia,
Cassia, Ageratum and Ricinus, and dust mites D.pteronyssinus and D.farinae
to be the commonest airborne allergens (Anand P and Agashe SN, Ind Journal
Otolaryngol, Vol 36, no 2, 1984 and Channabasavanna GP, Final Report:
Research Project H Dust Mites, DST, Gov Ind June 1983). Present study
involved skin prick tests done on 134 patients of respiratory allergy with
standard protocol. 82 male and 52 female patients with moderate–severe
persistent allergic rhinitis, rhinoconjunctivitis and asthma were the study
subjects with mean age of 30.2 6 13.8 years. 30 were asthmatics and 64
were asthmatics with rhinitis. Cynodon dactylon (22.4%) and Pennisetum
typhoides (5.9%) are the commonest grass pollen allergens. Artemesia
scoparia (15.7%), Partheenium hysterophorus (8.9%), Ageratum conyzoides
(8.2%) and Helianthus annuus (8.2%) are the commonest weed pollen
allergens. Prosopis juliﬂora (14.2%), Cassia siamea (10.4%) and Ricinus
communis (8.9%) are the commonest tree pollen allergens. D.pteronyssinus
(58.9%) and D.farinae (47%) are the commonest indoor allergens. House dust
mites have remained the predominant indoor allergens even now. Present
study shows signiﬁcant change in the type of pollen allergens. Cynodon,
Artemesia and Prosopis have replaced Partheenium and Albizia as the
predominant allergens in 2 decades. Helianthus annuus and Pennisetum
typhoides, which were insigniﬁcant in the past, have emerged as signiﬁcant
allergens. Molds as airborne allergens have become very insigniﬁcant.
Bangalore has grown enormously in the last 2 decades. Innumerable vacant
lands and swampy areas covered by weeds like Partheenium, have become
buildings. Helianthus is cultivated on a large scale all around as a commercial
crop. Large outskirts around the city have become residential and, ofﬁce and
commercial hubs resulting in a considerable change in pollen allergen ﬂora.
This change in the pollen allergen proﬁle is an important guideline for allergy
diagnosis and immunotherapy. This evidence may have signiﬁcant applica-
tion to the management of allergy patients in other major cities of India like
Hyderabad, Chennai, Delhi, Mumbai and Kolkata as well.
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PCR Analysis of Microorganisms in Chronic Rhinosinusitis with
Nasal Polyps
Mikio Hirotsu,1 Katsuhisa Ikeda, MD,2 and Noritsgu Ono, MD1. 1Juntendo
University Graduate School of medicine, Bunkyo-ku, Japan; 2Otorhinolaryn-
gology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Background: Chronic rhinosinusitis (CRS) with nasal polyps is characterized
by tissue eosinophilia, which is speculated to be related to Staphylococcus
superantigen and fungus, in European and U.S patients. However, Japanese
patients with CRS with nasal polyps showed 2 distinct phenotypes of
eosinophilic and neutrophilic inﬂammation (Hirotsu et al 2011). We
attempted to analyze the microorganisms from nasal polyps of Japanese
patients by PCR method.
Methods: Eleven specimens of nasal polyps with CRS were collected for
examination by endoscopic sinus surgery. All specimens were treated with
70% ethanol and physiologic saline to eliminate microorganisms outside of
the nasal polyps. Bacterial and fungal culture was performed for 2 weeks
using 5 different culture media. We detected 16S rRNA bacteria and 18S
rDNA-ITS-26S rDNA fungus, and then identiﬁed species of microorganisms
by direct-sequence. In addition, the number of eosinophils in the nasal polyps
was counted.
Results: No bacteria or fungus were recovered from any of the nasal polyps
by culture medium. By the PCR analysis, DNA for bacteria could not be
detected, whereas 7 samples of the nasal polyps showed ampliﬁcation of
fungal DNA such as Candida parapsilosis, Candida glabrata, and Rhodotorula
etc. Grocott dyeing for the nasal polyps, however, showed no intracellular
presence of fungus. The number of the eosinophils in the nasal poly with the
patients with the presence of fungal DNA (2406 191) was signiﬁcantly (P,
0.05) higher than that in the absence (56 6 40).
Conclusions: The present study suggests the participation of fungus in
eosinophilic CRS with nasal polyps.
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Incidence of Allergy to Artemisia Vulgaris and Salsola Kali in
Sabzevar cCty
Zahra Matloobi, MA. Student of Tarbiat Modares University, Sabzevar, Iran.
Background: Artemisia vulgaris and Salsola kali are common plants in
North hemisphere (eg in Iran). The pollens of Artemisia vulgaris is major
aeroallergen in late summer usually 10 to 14% patients that suffering from
allergic rhinitis in summer have allergy to Artemisia vulgaris. The pollens of
Salsola kali is major aeroallergen in early summer. Usually 53 to 76%
patients that suffering from allergic rhinitis in summer have allergy to
Salsola kali.
Methods: In one search in Sabzevar, we studied 47 patients with allergic
rhinitis. They were tested with prick test.
Results: In this study, were known that 27 patients (58%) had allergy to
Artemisia vulgaris and 43 patients (92%) had allergy to Salsola kali.
Conclusions: This study showed that incidence of allergy to Artemisia
vulgaris and Salsola kali in Sabzevar is more common than usual.
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The Prevalence of Allergic Rhinitis in Adolescent in La Paz,
Bolivia (3600 m.s.n.m.)
Abel Marcelo Moncada Alcon, MD, and Roxana Ivon Rios Mora, MD.
Pediatric Allergy, Allergist Pediatrician, La Paz, Bolivia.
Background: Allergic Rhinitis is the most prevalent illness in allergy. We
didn’t know the prevalence about it to 3600 m.s.n.m. It exist paper about
prevalence at least altitude in 10 to 30% in different places. The purpose of
this study is showing the prevalence of the allergic rhinitis in students in the
city of La Paz, Bolivia.
Methods: We realize a question form with the methodology ISAAC in
student into 13 to 18 years old in schools of the La Paz. We choose urban
zones. We realize this study in February 2009.
Results: We get 250 questionnaires in adolescent and were completely right
only 245. Of these 245 questionnaires 64% (157) were women and 36% (88)
men. To the ﬁrst question: Any time in your life have you had a problem with
sneezing or a runny, or a blocked nose when you did not have a cold or the
ﬂu? They respond yes in the 60% (147 persons). To the second question: In
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the past 12 months, have you had a problem with sneezing, or a runny, or
a blocked nose when you did not have a cold or the ﬂu? They respond yes in
the 43% (108 persons). To the third question: in the past 12 months, has this
nose problem been accompanied by itchy-watery eyes? They respond yes in
the 56.5% (83 persons). The months more prevalent were February 11.5% (17
persons); June 18% (27 persons); July 16% (24 persons) and august 20% (29
persons). Interference in their quality of life: neither 11.5% (17 persons), little
66% (97 persons), moderately 6.5% (10 persons) and a lot of much 16% (23
persons).
Conclusions: The Allergic Rhinitis is high prevalent in citizen about 3600
m.s.n.m. 43% have Allergic Rhinitis with symptoms more prevalent in winter
season, interfere with life in 22.5% and associated with ocular problems in
66% (97 persons). We must realize allergic test to discriminate allergic of non
allergic rhinitis, because many people we had non allergic rhinitis associated
to the cold temperature. We need to study more about this pathology in high
altitude.
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Pattern of Positive Sensitization in Patient with Asthma and
Rhinitis to 3600 MSNM (La Paz, Bolivia)
Abel Marcelo Moncada Alcon, MD, and Roxana Ivon Rios Mora, MD.
Pediatric Allergy, Allergist Pediatrician, La Paz, Bolivia.
Background: In the high altitude exists very few studies about allergies, we
seek to give to know our sensitization in population with breathing problems
(asthma and Allergic Rhinitis).
Methods: They were carried out allergy tests to 94 patients between 6 and 13
years with breathing symptoms predominantly allergic rhinitis and asthma.
They were carried out allergy tests to foods like peanut, wheat, almond,
tomato, milk, ﬁsh, soya, nuts, corn egg, chocolate, dog epithelia, cat, rabbit,
feathers, horse, dermatophagoides spp, blatella, periplaneta pollens: lolium,
poa, cynodon, festuca, ambrosia, artemisa, plantago, chenopodium, rumex,
zea mays, populus, cupressus, platanus, fraxinus, schinus, dactylis, and
mushrooms like it would alternate, aspergillus and cladosporium. They took
positive all hives bigger than 3 mm of diameter.
Results: Of the 94 patients 9 gave negative to the tests, 88 positive%. In the
foods, milk prevails (lactoglobuline 39%; casein 21%), tomato 33%, ﬁsh,
almond and wheat; 23% peanut and nuts less than 10%. In the epithelia: cat
20%. Dermatophagoides 46%, pollens grasses lolium 13% and poa 14%,
other pollens important festuca, chenopodium and dactylis with 21 to 23%,
trees less than 15% and mushrooms with less than 15%. You begin handling
predominantly according to these tests to dematophagoides, poa, lolium,
festuca, dactylis, mushrooms and cat epithelium since their reactions were
similar to the positive challenge of histamine. It is necessary to mention that
the diagnoses were alone allergic Rinitis on the whole in 60%, asthma allergic
single 10% and asthma and rinitis 30%.
Conclusions: Although this is a closed population, it guides us that to 3600
m.s.n.m. the allergen more frequent is dermatophagoides, and many articles
refers that to high altitude we are liberated of the mites but it is not this way.
Another important discovery is the positive to milk, tomato and very little to
other foods that it is part of our population’s diet. They are data that deserve
the attention and we will continue advancing in ﬁnding other factors of risk,
clinic and prevalence.
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Epidemiology of Allergic Rhinitis Cases in the Allergy Service of
a Third Level Medical Center. Six Year Experience
Luis Rafael Sanchez-Gallardo, MD. Immunoallergology Service, Issemym
Ecatepec Medical Center, Ecatepec De Morelos, Mexico.
Background: The purpose of this study is to report the cases of Allergic
Rhinitis (AR) in the Allergy service from a Third level medical centre since
its creation in July 2005.
Methods: This is a descriptive, retrospective, transversal study from July
2005 to February 2011. Selected medical records of patients apply for
diagnostic criteria for an allergy disease were made. ARIA guide 2009 was
used to make diagnosis of allergic rhinitis. Patients were classiﬁed by age and
sex and ﬁnd out how many skin prick test were made in such patients, and
how many patients began immunotherapy.
Results: 13737 consultations were attended in the Allergy service between
the period mentioned above. 2337 medical records of patients were selected,
1608 patients applied for a speciﬁc diagnosis for an allergy diseases as
follows: Asthma 411, Atopic conjuctivitis 58, Atopic Dermatitis 180, Allergic
Rhinitis 869, Urticaria 90. 869 patients completed criteria for Allergic
Rhinitis. 433 (49.9%) patients were female, 436 (50.1%) patients were male.
490 (56.3%) patients were found to be in the range of 0 to 14 years. The
mayority of allergic rhinitis patients were males in the range of 5 to 14 years,
with 270 (42.5%) patients. There were an increase of AR cases in females in
the range of 20 to 40 years, with 171 (39.4%) of total female cases. In 408
(47%) patients skin prick test were made, in 305 (35%) patients were positive
and began treatment with immunotherapy.
Conclusions: In this study, AR represents the most frequent allergy disease
among children, a good diagnosis of AR is mandatory because of the
confusion of symptoms mainly related with upper respiratory tract infections,
that implies a different management, increasing the risk of complications,
such as asthma and therefore the cost of treatment, including immunotherapy.
The results of this study are helpful to improve specialized medical attention
not only in paediatric patients but also in adults.
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The Evaluation of Allergen Sensitivity in Allergic
Rhinoconjunctivitis and Allergic Asthma Patients in
Antalya, Turkey
Arzu Didem Yalcin, MD,1 Hasan Hüseyin Polat,2 Fulya Kamaci,3 Atil
Bisgin, MD, PhD,4 and Reginald M Gorczynski, MD, PhD5. 1Allergology
and Clinical Immunology Unit, Antalya Education and Training Hospital,
Antalya, Turkey; 2Cumhuriyet University, Faculty of Medicine, Depart-
ment of Public Health, Sivas, Turkey; 3Atatürk State Hospital, Antalya,
Turkey; 4Human Gene and Cell Therapy Center of Akdeniz University
Hospital and Clinics, Antalya, Turkey; 5Division of Cellular and Molec-
ular Biology, Toronto Hospital, University Health Network, Toronto, ON,
Canada.
Background: Allergic rhinitis is a common health problem which has 2
forms; seasonal and perennial. The prevalence and etiology of allergic rhinitis
varies from region to region and affect 10 to 20% of the population
approximately. The prevalences of asthma, allergic rhinitis and allergic eye
disease were detected as 8.2%, 10.8% and 7.5% respectively in Antalya, the
south coast of Turkey.
Methods: The study was conducted in Antalya between 10th of November
2009 and 20th of September 2010. 866 of 2862 patients who had allergic
rhinoconjunctivitis and asthma were enrolled in the study due to having high
total IgE levels in blood conducted at the Allergy-Immunology Division of
Antalya Research and Training Hospital. Allergen-spesiﬁc subcutaneous
immunotherapy was given 626 of 866 patients.
Results: Of the 866 patients studied, 66.1 % were females. Most of the cases
had declaired that the rhinitis symptomes were due to pollens and house dust
the second most common irritant. Also the cases have said that their
symptoms got worse with exposure to dust, smoke, heavy odors, perfumes,
and detergents. Most of the patients have said that air pollution was the most
important factor that exacerbated the symptoms of rhinitis and asthma. While
there is a comparison between the age and SPT positivity, Aspergillus
fumigatus and Dpteronyssinus sensitivity was statistically different in the
mites and fungal mixture dermal test groups. As a result, in the study group of
866 allergic rhinitis patients, only the Plantagolanceolata, Corylusavellana,
Aspergillus fumigatus, Dpteronyssinus and cockroach sensitivity was signif-
icantly varies with the age.
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Conclusions: In allergic diseases; we all know that allergens may have
regional variations. That’s why; the allergen proﬁles of the regions must be
determined and the dermal Prick tests must be prepared accordingly. Mostly
grass and cereal mixtures and mites are responsible from the allergic rhinitis
cases due to our observations in our clinic. The other important allergens that
are linked to the ﬂora and climate of the region are olive and the cockroaches.
High asthma prevalence in people living in shanties and in housewives may
be due to exposure to house dust mites.
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Allergic Disease Severity and Relations
Filipa Viveiros, MD,1 Ivone Gonçalves, MD,2 Pedro Brinca,3 Ricardo Lima,
MD,2 Raquel Duarte, MD,2 Ivone Pascoal, MD,2 João Moura e Sá, MD,2
and Aurora Carvalho, MD2. 1Pulmonology, Centro Hospitalar de Gaia/
Espinho, EPE, Vila Nova de Gaia, Portugal; 2Centro Hospitalar de Gaia/
Espinho, EPE, Vila Nova de Gaia, Portugal; 3Departamento de Economia,
Universidade de Estocolmo, Estocolmo, Sweden.
Background: Prevalence of allergic disease has increased in recent years all
over the world. Asthma and rhinitis are the most prevalent in Portugal and,
having them such a multi-factorial basis, atopy is the most important risk
factor for its development. The authors aim to evaluate mono/polisensitization
as risk factors for severity of allergic disease, if there is an impact in allergic
disease manifestations number, the different treatment response, and if there
is a relationship between VEMs, comorbilities and sensitization.
Methods: In a population of patients followed in asthma/allergology appoint-
ment were selected those with asthma and allergic rhinitis conﬁrmed by
cutaneous test and/or speciﬁc IgE. Clinical processes were reviewed and analyzed
data related to the age of beginning, manifestations, atopic proﬁle, severity,
treatment, comorbilities and functional limitation. A descriptive analysis of the
sample was made and used linear regression for variable correlations.
Results: 176 patients 30% men and 70% women, mean age 33,7 and mean
age of early symptoms 12,7 Of these, 94% had asthma and 85% rhinitis. They
were 53% monosensitized, 47% polisensisitized and 43% had comorbilities.
66,5% of patients has done speciﬁc immunotherapy (SIT). On linear
regression analysis it was found that different sensitization has not been
determinative for disease manifestations number neither of treatment
response. It was observed that severity of asthma and rhinitis correlate with
each other (P, 0,001), but no signiﬁcant differences were veriﬁed in severity
level between patients mono vs polisensitized. SIT demonstrate a positive and
statistically signiﬁcant correlation with treatment reduction (P , 0,001) and
reduction on asthma and rhinitis severity (P ¼ 0,015 and P , 0,001). SIT
patients also demonstrate a decrease in asthma severity associated to the
number of allergen sensitizations. It was found a positive correlation between
the presence and number of comorbilities and asthma and rhinitis severity (P
¼ 0,001/P , 0,001 and P ¼ 0,007/P ¼ 0,001), instead of individually, only
nasal polyposis prove to be associated with statistical signiﬁcance. Comorbil-
ities were also related with a lower FEV1 (P ¼ 0,02).
Conclusions: This study supports literature data, which says there is only one
allergic disease and that severity of disease extends to its various
manifestations. We conﬁrmed that in atopic patients, SIT has beneﬁt in the
reduction on allergic disease severity and a better disease control with minor
therapeutic use.
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Frequency of Patients With Clinical Manifestations of Allergic
Rhinitis without Evidence of Systemic Atopy and Speciﬁc
ige Sensitization
Norma de Paula Motta Rubini, PhD,1 Stephania Campregher Berti, 2
Tatiane Cristina Marques, 2 Luiz Cláudio Pereira Ribeiro, MSc,3
Cássia Cristina Alves Gonçalves, MSc,3 Rafael Teixeira Figueredo
Poleshuck, MD,2 Fernando Samuel Sion, PhD,1 and Carlos Alberto Morais
de Sa, PhD2. 1Clinical Immunology, Federal University of Rio de Janeiro
State, Rio de Janeiro, Brazil; 2Federal University of Rio de Janeiro State, Rio
de Janeiro, Brazil; 3Laboratory of Immunology, Federal University of Rio de
Janeiro State, Rio de Janeiro, Brazil.
Background: The diagnosis of allergic rhinitis (AR) is based on clinical
manifestations and supported by a positive result for skin prick test (SPT) or
serum speciﬁc immunoglobulin E (sIgE) antibodies to aeroallergens. Our
objective was to investigate the frequency of patients with clinical
manifestations of AR without evidence of speciﬁc IgE sensitization.
Methods:We evaluated patients with clinical manifestations suggestive of AR,
other causes of rhinitis excluded, aged .5 years and who had total serum IgE
and SPT or sIgE to aeroallergens measured. Skin tests were performed with
extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blo-
mia tropicalis and Aspergillus fumigatus (FDA Allergenic) and total serum IgE
and sIgE, for the same allergens, by ImmunoCAP (Phadia). Patients were sub-
divided into groups according to the results proﬁle, and comparatively analyzed
for association with asthma, severity of rhinitis and age.
Results: We evaluated 116 patients (64% female) aged between 5 and 79
years, including 34 children (29%) and 63 (54%) with bronchial asthma. The
observed proﬁles and frequencies were: high IgE levels and positivity in the
SPT or sIgE –55%; normal IgE levels and SPT or sIgE positivity –9%; high
IgE levels and SPT and sIgE negativity –3 %; normal IgE levels and nega-
tivity in the SPT and sIgE –23%. Among patients with normal levels of total
serum IgE and no evidence of speciﬁc IgE sensitization, 14% had asthma,
while in the remainder the prevalence of asthma was 34% (P ¼ 0.0009).
There was no statistical signiﬁcance in the inﬂuence of the rhinitis severity
and age in the absence of markers of atopy and allergen sensitization.
Conclusions: We observed a signiﬁcant number of patients with clinical
manifestations of AR, without evidence of systemic atopy and speciﬁc IgE
sensitization, indicating the importance of careful research of local allergic
rhinitis, as well as other causes of chronic rhinitis. Local allergic rhinitis
appears to be less frequent in patients with rhinitis and asthma. The
observation of 13% of patients with elevated levels of total IgE without
speciﬁc sensitization implies the possibility of sensitization to aeroallergens
which were not investigated, such as occupational allergens.
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H1 Antihistamines Inﬂuence on Pro-inﬂammatory Cytokines
Level in Patients With Allergic Rhinitis
Ioana Corina Bocsan,1 Ioana Adriana Bujor, MD,2 Nicolae Miron,3 Vlad
Negulescu,4 and Victor Cristea3. 1Clinical Pharmacology, University of Med-
icine and Pharmacy, Cluj Napoca, Romania; 2Immunology Allergology, Uni-
versity of Medicine and Pharmacy, Cluj Napoca, Romania; 3Department of
Immunology, University of Medicine and Pharmacy, Cluj Napoca, Romania;
4Clinical Pharmacology, University of Medicine and Pharmacy, Bucharest,
Romania.
Background: The aim of the study is to evaluate the effect of H1
antihistamines on symptoms and pro-inﬂammatory cytokines plasmatic level
in patients with persistent allergic rhinitis (PAR), after 4 weeks treatment,
during continuous exposure to allergens.
Methods: 79 patients, mean age 30.44 6 9.90 years, diagnosed with PAR
were included in the study, divided into 2 groups: 39 patients were under
treatment with Desloratadine 5 mg/day and 40 patients received Levocetir-
izine 5 mg/day for 4 weeks. The patients were evaluated before and after the
treatment, regarding rhinitis symptoms (sneezing, rhinorrhea, nasal congestion,
nasal and ocular itching), total symptoms score, type of sensitisation (indoor or
outdoor allergens), plasmatic levels of IL-6 and IL-8. The obtained data were
analised using SPSS 15 and GraphPad Prism 4 programs, using Wilcoxon
Signed Rank and Mann Whitney test, with a signiﬁcant P values , 0.05.
Results: Both Desloratadine and Levocetirizine reduce total symptoms score
(8.35 versus 1.97, P ¼ 0.0001, respectively 8.67 versus 1.97, P ¼ 0.0001),
especially nasal congestion in patients with allergic rhinitis (1.76 versus 1.02,
P ¼ 0.001 and 1.72 versus 0.87, P ¼ 0.0001). IL-6 and IL-8 have no different
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plasmatic level in patients with allergic rhinitis compared with the values obtained
in healthy volunteers. Levocetirizine reduces plasmatic level of IL-6 (1.19 versus
1.006, P ¼ 0.0097) and IL-8 (8.90 versus 6.90, P ¼ 0.0003) after 4 weeks
treatment, while Desloratadine has inﬂuence only IL-6 level (1.68 versus 1.36,
P ¼ 0.0038). The intergroup analysis revealed no signiﬁcant difference between
these 2 drugs regarding IL-6 (P ¼ 0.36) and IL-8 (P ¼ 0.25).
Conclusions: Both studied H1 antihistamines present anti-inﬂammatory
effect in patients with PAR after 4 weeks treatment.
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International Survey on the Management of Allergic Rhinitis
by Physicians and Patients (ISMAR)
R. M. Gomez, MD,1 Alvaro Teijeiro, MD,2 H. A. Badellino, MD,1 Mario
Zernotti, MD, PHC,1 M. Murrieta-Aguttes, MD,3 and Carlos E. Baena-
Cagnani, MD1. 1CIMER (Centro de Investigación en Medicina Respira-
toria). Faculty of Medicine, Catholic University of Cordoba, Fundación
LIBRA Argentina, Cordoba, Argentina; 2CIMER (Centro de Investigación
en Medicina Respiratoria), Faculty of Medicine, Catholic University of
Cordoba, Fundación LIBRA Argentina, Cordoba, Argentina; 3Sanoﬁ,
Paris, France.
Background: Allergic Rhinitis (AR) is an underappreciated disease consid-
ered to be trivial. The small group of patients taking medications for AR are
usually seen by specialists. AR is under-diagnosed and under-treated with
frequent non-adherence to treatment. There are a gap and unmet needs
regarding the management of AR at global level. ISMAR was designed as the
ﬁrst-ever global, quantitative survey to ask to patients and physicians the
same questions to identify differences in attitudes and opinions about the
treatment of AR at global level with the goal of identifying barriers to optimal
management and revealing limitations of currently available treatments.
Methods: An international, multicenter, non–interventional, cross-sectional
study was conducted in adults or children ($ 6 years). Physicians were
selected at random from a master list provided by country and combining
private and public practices. ISMAR was designed according to the most
accepted epidemiological recommendations based on the successful experi-
ence of the WAO-GAPP survey on asthma. A questionnaire addressing
patient proﬁles, diagnostic assessment, therapeutic decisions, and real-life
management was answered. The questionnaire also asked about national/local
features, medications availability/cost, laboratory test facilities, traditions,
geographical constraints, among others. The participating physicians
recruited consecutive patients with AR. Study data collection was performed
during a single visit with 3 types of documents: Investigator’s questionnaire,
Case Record Form, Patient’s questionnaire.
Results: Two-hundred and thirty four physicians were surveyed with a mean
age of 49 years (28–69), 180 of them were males (76.9%). The type of
medical practice was public sector 16.7%, private practice 41.9% and mixed
41.4%. Regarding medical specialty is a follows: GPs/family practitioners/
internists (22.2%), allergologists/pulmonologists (35.9%), pediatricians
(11.1%) and ENT specialist (30.3%). Physicians recruited 2776 patients with
AR (Egypt, n ¼ 500; Mexico, n ¼ 418; Brazil, n ¼ 351; Colombia, n ¼ 223;
Guatemala, n ¼ 216; Iran, n ¼ 207; Venezuela, n ¼ 201; Argentina, n ¼ 200;
Israel, n ¼ 176; Kuwait, n ¼ 150; UAE, n ¼ 134).
Conclusions: ISMAR has made possible the participation of physicians from
eleven countries in different regions of the world that see AR patients. The
doctors surveyed and the patients they recruited will give us the opportunity to
gain insight about different aspects of the management of AR at global level.
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Effectiveness of Sinus Surgery for Lower Airway Disease
Ryoji Kagoya, MD,1 Masanobu Shinogami,MD, PhD,1 Hirohisa Mouri,MD,1
Sayaka Suzuki,MD,1 Wakako Nakanishi,MD,2 and Hiroyoshi Yoshinami,MD,
PhD3. 1Otolaryngology, Tokyo Metropolitan Police Hospital, Tokyo, Japan;
2University of Tokyo, Tokyo, Japan; 3Otorhhinolaryngology, Saitama Medical
University, Saitama, Japan.
Background: Upper respiratory illness can adversely impact the lower
airway. This study aimed to evaluate the relationship between clinical
background and improvement in the lower airway after surgery for treatment
of chronic rhinosinusitis.
Methods: A total of 22 patients with chronic rhinosinusitis surgically treated
between January 2010 and February 2011 were included in the study. The
presence or absence of asthma and peripheral blood eosinophils count were
examined for all patients in addition to preoperative radioallergosorbent tests.
Spirometry was conducted and fractional exhaled nitric oxide (NO) was
measured at the preoperative, 1-month postoperative, and 3-month post-
operative visits.
Results: The average level of NO in the exhaled air at the preoperative,
1-month postoperative, and 3-month postoperative visits was 51.5 ppb, 42.5
ppb, and 38.0 ppb, respectively. Although the average results of spirometry
didn’t show any improvement, forced expiratory volume in 1 second percent-
age improved in 2 of 4 cases with obstructive ventilatory disturbance. There
were 10 improved cases, which were deﬁned as those showing more than 1.2-
fold difference in the ratio of preoperative NO level to the 3-month post-
operative one. The remaining 12 cases, including 4 of 6 cases with asthma,
5 of 7cases with eosinophilia, and 4 of 4 cases with animal dander allergy
were unimproved cases.
Conclusions: Chronic rhinosinusitis can cause latent lower respiratory
disease. Endoscopic sinus surgery can improve the status of the lower
airway. However, the effectiveness of surgery is signiﬁcantly less in cases of
animal dander allergy.
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Berberine Inhibits Myoﬁbroblast Differentiation in Nasal Polyp-
deroved Fibroblast via P-38 Pathway
Heung-man Lee, MD, PhD,1,2 and Il-Ho Park, MD3,4. 1Department of oto-
rhinolaryngology, Korea university college of medicine, Seoul, South Korea;
2Institute for Medical Devices Clinical Trial Center, Korea university college
of medicine, Seoul, South Korea; 3Department of otorhinolaryngology-head
and neck surgery, Korea university college of medicine, Seoul, South Korea;
4Institute for Medical Devices Clinical Trial Center, Korea University Col-
lege of Medicine, Seoul, South Korea.
Background: The alkaloid has shown pharmacological activities and
multiple biological functions such as antibiotic activity, anti-tumor, anti-
inﬂammation and anti-ﬁbrotic properties. The purposes of this study were to
examine whether berberine has any effect on phenotype change and
extracellular matrix production in nasal polyp-derived ﬁbroblasts (NPDFs)
and to investigate underlying molecular mechanism.
Methods: NPDFs were pre-treated with berberin for 2 hours prior to
induction by transforming growth factor (TGF)-b1. The expression of
a-smooth muscle actin (SMA) and collagen type I mRNA was determined
by a reverse transcription-polymerase chain reaction, and the expression of
a-SMA protein and collagen type I was determined by Westernblotting and/
or immunoﬂuoescent staining. Total soluble collagen production was ana-
lyzed by the SirCol collagen dye-binding assay. Expression of pSmad 2/3,
pp38, pERK 1/2 and pJNK was evaluated by Western blot analysis.
Results: In TGF-b1-induced NPDFs, berberine signiﬁcantly inhibited the
expressions of a-SMA and collagen type I mRNA and reduced a-SMA and
collagen protein levels. Berberine had no effect on the level of pSmad2/3,
pERK1/2 and pJNK expression in TGF-b1-induced NPDFs. However, ber-
berine suppressed the expression of phosphorylated p38 in TGF-b1-induced
NPDFs. SB 203580 (a speciﬁc inhibitor of p38 kinase) markedly suppresse
the increased expression of collagen type I and a-smooth muscle actin
(a-SMA) protein in TGF-b1-induced NPDFs.
Conclusions: Berberine exerts suppressive effects on phenotype change and
extracellular matrix production in NPDFs, through interfering of p38
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signaling pathways. Our ﬁndings provide new therapeutic options for
extracellular matrix production in nasal polyps.
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Mold Sensitization in Chronic Rhinosinusitis Patients
Radoslaw Gawlik, MD, PhD, and Eugeniusz Czecior, MD, PhD. Internal
Medicine, Allergy and Clin Immunology, Silesian University of Medicine,
Katowice, Poland; Silesian University of Medicine, Zabrze, Poland.
Background: It is estimated that about 10% of the population have IgE
antibodies to common inhalant molds. Exposure to fungal allergens could
be linked to the presence and persistence of asthma, rhinitis and atopic
dermatitis. Mold sensitization is a risk factor for development and
deterioration of upper airway allergy, especially chronic rhinosinusitis.
We addressed the incidence of mold allergy measured as speciﬁc IgE to
molds and skin prick tests in chronic sinusitis patients. We assessed
prevalence of allergic reactions to mould among surgery treated chronic
sinusitis patients.
Methods: A group of 28 chronic sinusitis patients after surgery were
included into the study. Routine medical examination, skin prick tests with
common inhaled allergens and extended mold panel (Alternaria alternate,
Cladosporium herbarium, Aspergilus fumigatus, Candida albicans, Mucor
mucedo, Botrytis cinerea, Rhisopus nigricans, Penicilliumi notatum, Fusa-
rum moniliforme Pullularia pullulans (Allergopharma, Germany), tIgE,
asIgE measurement were performed (Phadia, Sweden). All investigated
patients were consulted by laryngologist and mycological examination
was performed.
Results: We found that sensitization to at least one allergen was present
in 43.8(14/32) of sinusitis patients. The most prevalent was sensitization
to house dust mite Dermatophagoides pt., found in 21.8 % (7/32)
patients. Positive results of skin prick tests with Candida albicans we
observed in 18.8% (6/32), with Alternaria alternate in 15,6% (5/32),
Cladosporium herbarium in 6,3% (2/32), Aspergilus fumigatus in 3,13 %
(1/32). None of investigated patients presented sensitization to other
mold allergens. Microbiological methods demonstrated fungal infection
only in 2 patients.
Conclusions: Almost half of chronic sinusitis patients presented sensitization
to at least one allergen. Fungal allergy is relatively rare in chronic sinusitis
patients.
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Nasal Cytology is Important in the Classiﬁcation of Patients with
Allergic and Non-Allergic Rhinitis
Olavo Mion, Daniel Salgado, Thiago Carvalho, and Joao Mello, Jr.
Universidade de Sao Paulo, Sao Paulo, Brazil.
Background: The purpose of the study is the classiﬁcation and clinical
characterization of patients with allergic rhinitis and non-allergic and
differentiate the presence of eosinophils and neutrophils in nasal cytology.
Methods: Prospective study of 405 patients with chronic symptoms of
sneezes, pruritus, nasal congestion and rhinorrhea were evaluated by clinical
examination, skin prick test and nasal cytology. Patients with diseases and/or
treatments that could alter the outcome of these tests were excluded.
Results: 405 patients from 3 to 80 years were evaluated; 248 female patients
(61%) and 157 males (39%). The sample was divided into 2 groups according
to skin prick tests: allergic 270 (67%), 135 non-allergic (33%). The mean age
of onset of symptoms was 14.27 and 23.47 years in allergic and nonallergic
respectively. Nasal symptoms (nasal congestion, sneezes/pruritus, rhinorrhea,
postnasal secretion) and signs (turbinates color and edema, secretion and
oropharynx redness) were accessed using scores from 0 to 3, ranging from
0 to 24. In the allergic group the mean total nasal symptoms and signs scores
were 6.64 and 4.66, while in non-allergic were 5.67 and 3.52. Allergic
patients had an average 27.82% of eosinophils and 64.09% of neutrophils in
nasal smears, whereas non-allergic patients 8.38% and 85.30%. Using skin
prick test and nasal cytology we were able to diagnose allergic rhinitis in
69.6% (208) of the patients. 20.7% (62) had neutrophilic non-allergic rhinitis
(NARNA) and 9.7% (29) non-allergic rhinitis with eosinophilia syndrome
(NARES). No idiopathic rhinitis patients were found.
Conclusions: The frequencies of the types of rhinitis were: allergic rhinitis
69.6%, RENA 9.7%, NARNA 20.7% and idiopathic rhinitis 0%. Despite
the fact that each sub group of nonallergic rhinitis has particularities, in
allergic rhinitis we found early onset of complaints, signs and symptoms
more intense and a greater number of eosinophils, compared with the
nonallergic patients.
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The Examination of the Association between the Chronic
Rhinosinusitis and the Inﬂammation of the Lower Respiratory
Airway by Using the Exhaled Nitric Oxide (NO) and the
Respiratory Function Test
Hiroyoshi Yoshinami, MD, PhD,1 Masanobu Shinogami, MD, PhD,2
Ryoji Kagoya, MD,2 Masato Nakashima, MD,1 Isao Wada, MD, PhD,1
Tutumiuchi Katuhiro, MD,1 Tetsuo Ikezono, MD, PhD,1 Yasuhiro Kase,
MD, PhD,1 and Makoto Nagata, MD, PhD3. 1Otorhhinolaryngology, Sai-
tama Medical University, Saitama, Japan; 2Otolaryngology, Tokyo Metro-
politan Police Hospital, Tokyo, Japan; 3Allergy Center, Department of
Respiratory Medicine, Saitama Medical University, Moroyama-Machi,
Japan.
Background: It is said that the chronic rhinosinusitis inﬂuences the lower
respiratory airway and there is a report that a tendency to increase the
eosinophilic rhinosinusitis later, but they are still unknown.
Methods: We divided the chronic rhinosinusitis patients with the adaptation
of the operation into 4 groups and exaed whether there was a difference in the
respiratory function, exhaled NO, and the number of the blood eosinophil.
Object: 29 patients with chronic rhinosinusitis who planned the endonasal
sinus surgery.
Results: Comparing these 4 groups, it was the worst on the respiratory
function (one second rate) in the group with nasal polyps and without nasal
allergy. It was recognized the connection between the respiratory function
and the presence of the nasal polyps. It was possible that the exhaled NO
became the index to the lower airway inﬂammation.
Conclusions:We classiﬁed the chronic rhinosinusitis and evaluated the lower
airway function. It helps the pathologic understanding of the chronic
rhinosinusitis. And it leads to understand of the inﬂuence on the lower
airway inﬂammation.
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Peak Inspiratory Flow Rate is More Sensitive Than Acoustic
Rhinometry or Rhinomanometry in Detecting Nasal Obstruction
Using the Allergen Challenge Chamber
Tetsuya Terada. Otorhinolaryngology, Osaka Medical College, Takatsuki,
Japan.
Background: We prepared an allergen challenge chamber (ACC) which
facilitates quantitative pollen challenge at any time, and, so, the acquisition of
objective data. The aim of this study was to evaluate peak nasal inspiratory
ﬂow rate (PIFR) as an endpoint during allergen challenge and compare this
with rhinomanometry (Rhino) and acoustic rhinometry (AR).
Methods: The study was conducted in November, which is not in pollen
season. Subjects were exposed to Japanese cedar pollen at a concentration of
50,000 counts/m3in ACC for 120 minutes each day for 2 days. Subject
recorded nasal symptoms before challenge and every 15 minutes after
challenge initiation. Nasal symptoms (sneezing frequency, nasal blowing
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frequency, nasal obstruction) were recorded before challenge and every 15
minutes after challenge initiation. For the evaluation of nasal obstruction, we
used visual analog scales (VASs); subjects marked a site on a 10-cm line
corresponding to the symptom severity on which absence of symptoms was
designated as 0 and worst imaginable symptom as 10. PIFR was measured
using an In-check ﬂow meter and nasal resistance was measured using Rhino.
The cross-sectional area in the nasal cavity was also measured using AR
before and after challenge as an indicator of nasal obstruction.
Results:When the volunteers with cedar pollinosis were exposed to cedar pollen
in ACC, pollinosis symptoms were induced signiﬁcantly. Changes in the 3
symptoms (sneezing frequency, nose-blowing frequency, nasal obstruction) were
investigated before and after challenges on 2 consecutive days. No signiﬁcant
symptoms were induced on the ﬁrst day of challenge in the non-pollen season.
However, each of the 3 symptoms became more severe with second day of
challenge, and a signiﬁcant increase was seen in cumulative values by the second
day. In terms of the allergen challenge test, we found a signiﬁcant correlation
between nasal obstruction symptom (VAS) and PIFR, but not AR and Rhino.
Conclusions: PIFR after allergen challenge is more sensitive than AR or
Rhino in detecting nasal obstruction using the allergen challenge chamber.
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Nasal Poliposis and Allergic Disease. Dr. Salvador
Allende Hospital
Ada Castillo Méndez, MD. Alergia, MINSAP, Habana, Cuba.
Background: The edematous irritation of the corium of the pituitary
mucosa wakes it suffers a degeneration that causes what is known as nasal
polyposis, hypertrophy of the nasal mucosa as a result of a chronic
inﬂamatory process. It is said that its formation is due to infectious
processes, vascular changes as local disorders of the immunity of the nasal
mucosa. However many concide in including the allergic factors as the
cause of the nasal polypos and they give a special interest to the
constitutional factor inside the genesis of them. The investigation had as
objectives to know the relationship that there is between the nasal polyposis
and the allergic diseases, as well as to study some parameters of the
humoral and celular immunity in our patients.
Methods: 15 patients diagnosed wiht nasal polyposis were taken from the
otorhinolaryngologists and they were sent to the allergic department to be
evaluated. Patient’s charts of all of thems were made and they were indicated
some studies such as eosinophil global count, nasal exudate,sample radio-
graphic study of paranasal sinus, serology, hemogram, glycemia and minimal
clotting test, study of the humoral immunity and making determination of
IgE, IgA, IgG, IgM. The celular immunity was also studied by making a de-
termination of active and expontaneous Roseta test. And a life evaluation was
made too by means of the hypersensitivity retard tests.
Results: High ﬁgures of elevated IgE were obtained in a 67 % of the patients
studied. A control group was made for the Igs determination and the Roseta
test. No signiﬁcant difference was found in the Roseta test.
Conclusions: The elevation of the IgE in the patients studied makes us infer
that there is an evident relation ship between these 2 pathologies. There is no
evidence. That shows that there is an alteration of the celular immunity in the
sample of the patients with nasal polyposis that were studied.
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Use of the CT Navigation in the Rhinology and Head Surgery
Petra Fundova, MD,1 Daniel Kovar, MD,1 Michal Navara, MD, PhD,1,2
and Zdenek Voldrich, MD, DSc1. 1ENT Department, Central Military Hos-
pital, Prague, Prague 6, Czech Republic; 23rd Medical Faculty, Charles
University, Prague 10, Czech Republic.
Background: CT navigation is an assistant tool for identiﬁcation and location
of anatomical structures during surgery based on computer processed
preoperative CT images followed by registration. CT navigation facilitates
exact localization of particular anatomical points and at the same time also
allows determination of the exact position of a respective instrument in 3D
pictures and in 3 CT planes.
Methods: The optical CT navigation system Treon Plus (Medtronic-Xomed)
is successfully being used at the ENT Department of the 3rd Medical
Faculty Charles University and Central Military Clinic, Prague, Czech
Republic. We studied the advantages of CT navigation use on 141 patients
(257 procedures) operated from January, 1, 2007 till December, 31, 2009. The
CT navigation was used for primary sinus endoscopic surgery (81 procedures),
revision sinus endoscopic surgery (46), surgical treatment of injuries (7), and
in tumors (7). We examined the use of optical CT navigation with MRI fusion
for delimitation of extensive tumor of the tongue.
Results: In operated group of patients we observed no major per- or post-
operative complications.
Conclusions: The primary beneﬁt of the presented CT navigation is the
feasibility of higher radicality, accuracy, together with delicacy towards the
surrounding tissues.
This work was supported by grant 0801 8 8030 from the Ministry of Defence,
Czech Republic.
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Assessment of the Quality of Methodological Rigour and
Reporting of Clinical Practice Guidelines for the Management of
Allergic RhinitisdQugar Study
Agnieszka Padjas, MD, PhD,1 Holger Schünemann,2 Jean Bousquet,3
and Jan Brozek, MD, PhD2. 1Department of Medicine, Jagiellonian Univer-
sity Medical College, Krakow, Poland; 2Department of Clinical Epidemiol-
ogy & Biostatistics and Medicine, McMaster University, Hamilton, ON,
Canada; 3University of Montpellier, Montpellier, France.
Background: To assess the methodological rigour and transparency of reporting
in clinical practice guidelines for the management of allergic rhinitis (AR).
Methods: We systematically searched MEDLINE, TRIP database (including
the National Guidelines Clearinghouse) and professional society websites for
guidelines about the management of AR published after the year 2000. We
assumed that older guidelines would no longer inﬂuence current clinical
practice. If the guideline was updated after 2000 we assessed the most recent
version. We included all guidelines published in English and endorsed by an
international or national government agency or professional group, irrespec-
tive of country of origin or publication status. Two reviewers independently
screened search results using predeﬁned eligibility criteria and assessed the
rigour of development and reporting of included guidelines using the AGREE
II instrument (www.agreetrust.org).
Results: Our search revealed 432 records of which 34 full text articles were
assessed for eligibility. Nine documents fulﬁlled our criteria–3 international
and 6 national guidelines from Japan, Singapore, South Africa, UK and the
USA. Overall methodological rigour and reporting of guidelines about the
management of AR was variabledfrom fulﬁlling most AGREE II criteria to
almost none. There was no association between the methodological rigour
and time of publication or the target scope of the guideline (national versus
international). Across all guidelines the most rigorously reported domain was
“clarity of presentation” (median score 53%), mainly due to fair presentation
of different management options (item 16), followed by “scope and purpose”
(median score 42%). The least rigorously addressed was “applicability”
domain with median score of 2% across all guidelines. Median scores for
domains “stakeholder involvement”, “rigour of development” and editorial
independence” were 17%, 15% and 25%, respectively. The ARIA guidelines
(2010 update) achieved the highest scores in 5 out of 6 domains and the
lowest score on any domain was 60%.
Conclusions: Guideline users should be aware of the variability in quality of
development and reporting of guidelines for the management of AR. They
should choose higher quality guidelines to inform their practice. For many
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guidelines there is much room for improvement, in particular in the domains
of applicability and implementation.
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Health-Related Quality of Life and Prognostic Value of Acoustic
Rhinometry in Patients With Perennial Allergic Rhinitis Treated
with Fix Combination of Montelukast Plus Desloratadine
Cemal Cingi, MD, ORL & HNS,1 Fatih Oghan, MD, ORL & HNS, DPU,2
Gorkem Eskiizmir, MD, ORL & HNS,3 Aytekin Yaz, MD, ORL & HNS,4
Ahmet Ural, ORL & HNS,1 and Nagehan Erdogmus, ORL & HNS1.
1Osmangazi University, Faculty of Medicine, Eskisehir, Turkey; 2Medical
School, Kutahya, Turkey; 3Celal Bayar University, Medical School,
Manisa, Turkey; 4Tepecik Training and Research Hospital, Izmir, Turkey;
5Karadeniz Technical University, Medical School, Trabzon, Turkey.
Objective: To determine prognostic value of acoustic rhinometry in patients
with perennial allergic rhinitis (PAR) treated with montelukast in ﬁx
combination with desloratidine and to assess effectiveness of this medication
on health-related quality of life (HRQL).
Study design: A randomized, double-blind, prospective and multicentric
clinical study.
Setting: Tertiary university hospitals.
Methods: Patients 20 years of age and older with PAR were assessed over 3
months of treatment with ﬁx combination of montelukast 10 mg plus
desloratidine 5 mg once daily (n ¼ 40). Comparative acoustic rhinometric
evaluation was used to compare nasal changes in before and after treatments.
For evaluation of HRQL between before and after treatments at the ﬁrst and
third months, the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
was used.
Results: Nasal symptoms and ﬁndings including itching, sneezing, discharge,
congestion and edema and color change of turbinates have been decreased
after treatment. In acoustic rhinometry, minimum cross-sectional area (MCA)
measurements and volume results were statistically higher than in before
treatment (P, 0.001). Correlation was found that between the volume results
and nasal discharged and/or congestion in right nasal passages. In left nasal
passages, statistical relation was described between the MCA measurements
and itching and/or change of turbinate color (P , 0.05). There was a larger
decrease in the overall RQLQ score for the group using montelukast plus
desloratidine compared with the pre-treatment scores (P , 0.001). The dif-
ference between scores at baseline versus the end of the ﬁrst and third months
for all domains was statically signiﬁcant (P , 0.001). The treatment differ-
ence in change from ﬁrst month to the end of the third month was statically
signiﬁcant, in favor of the third month, for eye, nose, and non- nose/eye
symptoms, sleep, practical problems, emotions and activities that have been
limited by nose or eye symptoms, and for overall score.
Conclusions: Signiﬁcant reductions in signs and symptoms of PAR with
montelukast plus desloratadine treatment were accompanied by improved
disease-speciﬁc QOL measures. Montelukast in combination with deslorati-
dine provides improvements in acoustic rhinometric values including volume
and MCA in patients with PAR. Acoustic rhinometry should be use in
diagnostic and prognostic process in patients with PAR.
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HLA-B58 Does not Increase Allopurinol Hypersensitivity among
Patients with Hematologic Malignancy
Jae-Woo Jung, Min-Hye Kim, Woo-Jung Song, Tae-Wan Kim, So-Hee Lee,
Sae-Hoon Kim, Hye-Ryun Kang, Heung-Woo Park, Sun-Sin Kim, Yoon-
Seok Chang, MD, PhD, Sang-Heon Cho, and Kyung-Up Min. Department
of Internal Medicine, Seoul National University College of Medicine, Seoul,
South Korea.
Background: HLA-B58 is a very strong marker of allopurinol-induced
severe cutaneous adverse reactions (SCARs), especially in population with
high frequency of HLA-B58, such as Chinese, Thai, and Korean. Although
allopurinol is frequently prescribed to patients receiving chemotherapy for the
prevention of tumor lysis syndrome, the risk of allopurinol-related SCARs in
patients with hematologic malignancies is not evaluated. This study was
conducted to ﬁnd out the incidence of allopurinol-induced hypersensitivity in
patients with hematologic malignancy during chemotherapy according to
HLA-B58 and clinical usefulness of HLA-B58 as a risk marker for the
development of allopurinol-induced hypersensitivity.
Methods: We retrospectively reviewed the medical records of patients with
hematologic malignancy who ever took allopurinol and underwent serologic
HLA typing for bone marrow transplantation from January 2000 to May
2010.
Results: Among total 463 patients, 13 (2.8%) patients experienced allopu-
rinol hypersensitivity reactions which were simple maculopapular rash and
none of those were compatible with SCARs. The mean duration of
allopurinol exposure in total patients was 26.46 days (1w2,173) and the
mean duration until development of rash was 5.546 1.20 days. Fifty patients
(10.8%) had HLA-B58. However, the incidence of allopurinol induced rash
was not different according to HLA-B58 (4% (2/50) and 2.66% (11/413) in
B58 (1) and B58 (-) patients, respectively). Frequency of B58 was slightly
higher in patients with rash (15.4%) compared with tolerant patients (10.7%)
but the difference was statistically insigniﬁcant (P . 0.05).
Conclusions: The results of this study that HLA-B58 does not increase the
risk of allopurinol induced SCARs as well as simple rash among patients with
hematologic malignancy. Allopurinol can be used safely in most patients with
hematologic malignancy during chemotherapy and HLA typing does not give
additional advantage for clinical decision.
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Risk Factors Associated to Mortality in Pediatric Patients with
Hemophagocytic Lymphohistiocytosis
Armando Partida-Gaytan, MD,1 Blanca del Rio, MD,1 Gabriela Tercero-
Quintanilla, PhD,2 and Miguel Angel Rosas-Vargas, MD1. 1Pediatric Allergy
and Clinical Immunology, Hospital Infantil de Mexico Federico Gomez,
Mexico City, Mexico; 2Psychiatry and Adolescent Medicine, Hospital Infantil
de Mexico Federico Gomez, Mexico City, Mexico.
Objective: Identify risk factors associated to mortality in pediatric patients
with hemophagocytic lymphohistiocytosis.
Methods: Retrospective cross-sectional study of medical records with
discharge diagnosis of Hemophagocytic syndrome/Hemophagocytic lympho-
histiocytosis (ICD-10; D76.1/D76.2) from Jan2004-May2011 in a pediatric-
tertiary-care-center. Descriptive and risk analysis were made on SPSS
Statistics V17.0.
Results: Thirty medical records were analyzed. Median-for-age: 2 years 8
months, (range: 2 months-to-15 years). Sex distribution: 14 girls (47%), 16
boys (53%). Median of symptoms duration: 1 month (range: 3 days-to-7
years). Reported symptoms and physical signs at hospital admission: fever
n ¼ 28 (93%), asthenia/adynamia n ¼ 11 (37%), skin ﬁndings n ¼ 10 (33%),
epistaxis n ¼ 5 (17%), gastrointestinal bleeding n ¼ 4 (13%), hepatomegaly
n ¼ 27 (90%), splenomegaly n ¼ 21 (70%), lymphadenopathies n ¼ 14 (47%),
paleness n ¼ 14 (47%), purpura n ¼ 5 (17%). Laboratory ﬁndings: anemia n ¼
29 (97%), LDH elevation n ¼ 28 (93%), hypoalbuminemia n ¼ 27 (90%),
thrombocytopenia n ¼ 26 (87%), hypertransaminasemia n ¼ 25 (83%), hae-
mophagocytosis n ¼ 22 (73%), hypertrigliceridemia n ¼ 21 (70%), hypoﬁbri-
nogenemia n ¼ 20 (67%), leucopenia n ¼ 19 (63%), hyperferritinemia n ¼ 15
(50%). In 18 patients (60%) active infection was evident at hospital admis-
sion: pneumonia n ¼ 9(50%), gastroenteritis n ¼ 2 (11%), meningitis n ¼ 1
(5%), others n ¼ 6 (33%). Epstein-Barr virus infection was diagnosed in 7
patients (23%). All patients were treated according to HLH-2004 guidelines.
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Overall mortality 63% (n ¼ 19), 9(47%) died from septic-shock, 7 (36%)
haemorraghic-shock, and 1(5%) with acute liver failure. Differences between
non-survivours and survivours by (x2): hypoﬁbrinogenemia (53%versus 13%;
P ¼ 0.039), epistaxis (17% versus 0%; P ¼ 0.023), evident clinical infection
(47%versus 13%; P ¼ 0.044), elevated LDH levels (63% versus 30%; P ¼
0.039), hemophagocytosis (57% versus 17%; P ¼ 0.024). Risk factors asso-
ciated to mortality: history of epistaxis (OR ¼ 1.78, 95% CI, 1.26-2.52; P ¼
0.023), evident clinical infection at hospital admission (OR ¼ 2.41, 95% CI,
1.08-5.8; P ¼ 0.044). Normal levels of LDH showed diminished mortality
risk (OR ¼ 0.32, 95%, CI, 0.18-0.55; P ¼ 0.039).
Conclusions: The present study describes the most common clinical, physical
and laboratory ﬁndings in patients with haemophagocytic lymphohistiocy-
tosis attended in our hospital. We were able to identify risk factors associated
to mortality, and 1 protective factor.
250
The Clinical and Serological Findings in Patients with
Toxocariasis in Korea
Sungjin Choi, MD, Taehoon Yim, MD, and Kyungho Yang, MD. Allergy
and Rheumatology, Sunlin Hospital, Pohang, South Korea.
Background: We performed this study to investigate the clinical and
serological characteristics of human toxocariasis in Korea.
Methods: Total 152 patients with peripheral eosinophilia (.450 cells/mL)
were enrolled and they were divided into 2 groups based on a Toxocara
excretory-secretory IgG ELISA: 95 seropositive patients and 57 seronegative
patients. We not only compared the clinical features including age, sex, tissue
inﬁltration of eosinophil and presence of allergic asthma and rhinitis but also
serologic markers such as serum total IgE, speciﬁc IgE to Dermatophagoides
pteronyssinus (Dp) and Dermatophagoides farine (Df) by using immunoCAP
between 2 groups.
Results: The seropositive rate of toxocara was 62.5% (95/152) in the patients
with peripheral eosinophilia in whom seropositive patients were older than
seronegative patients (P ¼ 0.043), men were more than women (P , 0.01).
The serum total eosinophils (P ¼ 0.048), total IgE level (P, 0.01) and the Df
seropositive (immunoCAP .0.35 KU/L) rate (P , 0.01) were signiﬁcantly
higher in sereopositive patients than seronegative patients. The eosinophilic
tissue inﬁltration in liver (P ¼ 0.003) or lung (P, 0.01) and ingestion of raw
cow meat or liver (P , 0.01) were observed more frequently in seropositive
patients but the presence of allergic asthma (P, 0.01) and rhinitis (P, 0.01)
more frequnetly in seronegative patients. Among seropositive patients, there
were positive correlations between the serum total IgE level, total eosinophils
and the value of toxocara IgG ELISA OD (r ¼ 0.502, P , 0.01; r ¼ 0.247,
P ¼ 0.016, respectively) and the speciﬁc IgE to Df was signiﬁcantly higher
(P , 0.01) than that to Dp suggesting there might be cross reaction between
the antigen of Df and toxocara antigen.
Conclusions: The ingestion of raw cow meat or liver was closely related to
an increased risk of toxocariasis in Korea. We thought that the patients who
had highly elevated serum total IgE level, peripheral eosinophilia and
experience of ingestion of raw cow meat or liver but not allergic disease
might have human toxocariasis so should be evaluated whether eosinophils
were inﬁltrated in organs such as liver or lung.
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Interferon-Gamma Release AssaydUseful Tool for the Diagnosis
of Pleural Tuberculosis
Andrea Ondrejkova,1 and Gustav Ondrejka, MD2. 1Laboratory of Immu-
nology and Serology, PR LAB Novy Jicin, Novy Jicin, Czech Republic;
2Department of Pulmonary Medicine, Hospital Novy Jicin, Novy Jicin,
Czech Republic.
Background: Pleural tuberculosis represents a big problem to diagnose despite
of many diagnostic tools. CD41T-lymphocytes play an imprortant role in
immune response against Mycobacterium tuberculosis. They are accumulated
in pleural space affected with Mycobacterium tuberculosis and release an
inﬂammatory cytokines (interferon-g, interleukin-2). These cytokines interact
with macrophages to stimulate effective antimycobacterial actions. The pleural
ﬂuid lymphocytes and interferon-g level are elevated in many cases such as
viral infections, malignancy or tuberculosis. We decided to evaluate a beneﬁt of
utilization of antigen speciﬁc Interferon-gamma release assay (IGRA) in pleural
effusion (PE) to the diagnostics of pleural tuberculosis.
Methods:We present results of 29 patients with lymphocytic PE of unknown
cause. The total leukocytes count, lymfocyte subsets by ﬂow cytometry with
monoclonal antibodies directed against the T-lymphocyte antigens (CD3,
CD4, CD8) and HLA DR antigen as a marker of T-lymphocyte activation
were determined in PE. IGRA test was used to determine a level of speciﬁc
interferon-gamma in PE and in whole blood too. Furthermore we analysed
results of tuberculin skin test and Mycobacterium tuberculosis cultivation in
the sputum and in PE.
Results: Of the 29 lymphocytic PE was IGRA test positive in 3 cases
(10,3%). These patients had the pleural effusion with activated CD4 1 T-
lymphocytes predominance, elevated CD4/CD8 ratio. Mycobacterium tuber-
culosis cultivation was negative in both sputum and pleural ﬂuid except 1
patient with positive sputum culture. The tuberculin skin test was higher than
15 mm of all 3 patients. The clinical diagnosis of active pleural tuberculosis
was conﬁrmed in these patients. AntiTB treatment was successful of all them.
Lymphocytic PE with negative IGRA test was in 26 patients (89,7%):
malignancy in 7, heart failure effusion in 3, parapneumonic effusion in 8
and other pathological causes was in 8 patients.
Conclusions: Our results acknowledge that IGRA test applied to pleural ﬂuid
is very helpful to the diagnostics of pleural tuberculosis because the pleural
ﬂuid interferon-g level is measured after stimulation of T-lymphocytes by
tuberculous speciﬁc antigens. We conclude that another important beneﬁt of
interferon-g release assays is the differential diagnostics of CD41T-lympho-
cytic pleural effusions.
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The Parasite Echinococcus Granulosus Promotes Allergic
Response in Human
Manel Amri, PhD, and Chaﬁa Touil-Boukoffa. Cellular and Molecular
Biology, Team “Cytokines and NOSynthases”, Faculty of Biological Sciences
(FSB), University of Sciences and Technology Houari Boumediene (USTHB),
Algiers, Algeria.
Background: Helminth parasites are highly antigenic and some types favour
the generation or exacerbation of allergic responses by inducing strong Th2-
type responses (with the production of cytokines, particularly IL-4).
Moreover, recent data suggest that Arginase is involved in the pathogenesis
of multiple aspects of allergic disease. In the present work, our aim is to study
whether the parasite Echinococcus granulosus induces Th2-type response and
whether this is beneﬁcial for the host or not. Echinococcus g. infection, which
induces hydatidosis, remains a serious parasitic disease in Algeria. In human,
the larval form develops into large cysts especially in the liver and lungs.
Methods:We have investigated the effect of laminated-layer (accelullar layer
of hydatic cyst) extract (LLs) on IL-4, and IFN-g production and Arginase
activity in culture performed with mononuclear cells (PBMC). These cells are
prepared from peripheral blood of hydatic patients (before and after surgery)
and healthy donors. Of note, IFN-g (Th1 cytokine) downregulates Th2-de-
rived cytokines (like IL-4) which are the best inducer of Arginase pathway.
Finally, we have investigated the effects of LLs and IL-4 on protoscoleces
(larval form of parasite) viability in PBMC-protoscoleces coculture.
Results: We have found that LLs enhanced IL-4 production and Arginase
activity and reduced IFN-g production by PBMC. Furthermore, LLs and IL-4
also enhanced parasite survival in PBMC-Parasite cocultures. Moreover, we
have puriﬁed by chromatography one of the major antigenic protein in LLs:
the fraction 4 (F4, 12kDa). This fraction has the same effect as LLs on Th1/
Th2 balance. Interestingly, similar ﬁndings are observed in cultures and
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cocultures performed with PBMC of presurgical and postsurgical patient and
healthy donors.
Conclusions: Taken together, our results suggest that the laminated layer of
Echinococcus g. may promote allergic response in humans directly by induct-
ing the Th2 pathway. Moreover, this response allows the parasite survival.
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Use of Transfer Factor in Patients with Persistent Genital Human
Papillomavirus Infection
Blanca Maria Morﬁn-Maciel, MD,1 and Julieta Margarita Sotelo-Ortiz2. 1Al-
lergy, Hospital Angeles Mocel, Mexico City, Mexico; 2Gynecology, Hospital
Angeles Mocel, Mexico City, Mexico.
Background: Human papillomavirus (HPV) is the most common sexually
transmitted infection worldwide. About 75 to 80% of sexually active
Americans will be infected with HPV at some point in their lifetime. The
risk of HPV infection seems to be related with age at ﬁrst intercourse,
younger age and number of sexual partners. HPV infection is limited to the
basal cells of stratiﬁed epithelium of the skin or mucous membranas. There is
a wide latency period, from months to years, before squamous intraepithelial
lesions develop. Most HPV infections are cleared within 2 years by the
immune system. Only in 5% to 10% of infected women with “high risk” types
the infection persists determining a high risk of developing intraepithelial
neoplasias, as cervical cancer, vulvar cancer, penile cancer, and/or anal can-
cer. The gynecological evaluation and Papanicolau smear are the primary
screening tools for detecting HPV infection. There is currently no speciﬁc
treatment for HPV infection. The Transfer Factor (TF) or Dialyzable Leuko-
cyte Extract is an immunomodulator that has been successfully used as an
adjuvant in the treatment of intracelular infections such as recurrent herpes
virus diseases. TF induces the expression of RNAm and IFN-g and increases
CD41 cells. The IFN-g activates macrophages, neutrophils, B lymphocytes,
NK cells, and favours the differentiation of T cells into Th1 lymphocytes that
are requiried for the control of intracellular patho gens.
Methods: We used TF in a group of patients with persistent genital human
papillomavirus infection.
Results:We included 12 patients, aged 19 to 45 years old (mean 30), with 14 to
23 years at ﬁrst intercourse and a mean of 3 sexual partners in their lifetime. All
of them had persistent HPV that had been treated before with local and ablative
therapeutic options (including cervical freezing, cauterizing loop, imiquimod,
podophyllin and/or cervical conization). Transfer factor was administered daily
for 5 days, and subsequently at 7-day intervals for 5 weeks. We found an
important improvement in the gynecological evaluation of cervix and perineal
lesions and a signiﬁcant reduction in the frequency of relapses.
Conclusions: Transfer factor could be used as an adjuvant in patients with
persistent genital human papillomavirus infection.
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Experimental Heterophyiasis: Histopathological &
Immunological Study
Ahmed Daoud, PhD. Parasitology, Tanta Faculty of Medicine, Tanta, Egypt.
Background: The present study was conducted to evaluate the effect of
immunosuppression on the course of infection, the extraintestinal patholog-
ical changes and the immune complexes deposits in kidneys and brain tissues
with Heterophyes heterophyes infection in mice.
Methods: Seventy Swi-ss albino mice were divided into 4 groups; G (I) 30
immunocompetent infected mice, G (II) 30 immunosuppressed by cyclo-
phosphamide, infected mice and G (III) 5 non-infected immunocompetent
control mice and G (IV) 5 immunosuppresed non-infected. Groups I & II
were infected with 300 metacercariae / mouse orally. Two weeks post in-
fection (p.i.) 5 animals from each group were sacriﬁced at 14, 16, 18, 21, 25
and 28 days p.i., and the kidneys and brain were processed for tissue di-
gestion with KOH and histopathological and immunoﬂuorescence examina-
tion. The adult worms were counted by mucosal scraping of the intestines.
Results: The result of this study showed that the adult worm count was higher
in G (II) and G (1). The kidneys of G (I) mice showed mild congestion of the
glomeruli with lymphoid aggregates. While in G (II) mice, the glomeruli
showed variation in size with mild thickening of their walls and the blood
vessels showed moderate congestion with mild thickening of their walls. The
brain in G (I) mice showed capillary haemorrhage with focal accumulation of
endotheliocytes and histiocytes in a frame work of connective tissue. While in
G (II) mice, the brain showed congestion, oedema and hypercellularity. In
addition, gliosis accompanied with increased vascularity and endothelial
hyperplasia was also observed. No adults or ova were detected by KOH
digestion of the brains and kidneys. Mild immune complex deposits were
detected from the 3rd week p.i. in G (I). The immunoﬂourescence reaction
becomes moderate at the 4th week p.i. While in G (II) the immunoﬂourescence
reaction was mild 2 weeks p.i. and became moderate at the 3rd week p.i.
Conclusions: These results proved that the H. Heterophyes antigen or
immune complex deposits were detected in the kidneys and brain of infected
mice. These deposits play an important role in the histopathological changes
in the kidneys and brain of infected animals.
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Chronic Obstructive Pulmonary Disease and Lung Cancer Share
Inﬂammation Pathways
Kostas N. Syrigos,1 Ekaterini Politi,1 Nektaria Makrilia,1 Sotirios Tsimpoukis,1
Fotis Psarros,2 Ekaterini Syrigou,2 and Ioannis Dannos1. 1Oncology Unit, 3rd
Department of Medicine, Sotiria General Hospital, Athens School of Medicine,
Greece, Athens, Greece; 2Department of Allergy, Sotiria General Hospital,
Athens, Greece, Athens, Greece.
Background: The relationship between inﬂammation, air obstruction and
lung cancer is complex and there is still great uncertainty regarding their
underlying pathophysiology. Our aim was to investigate the inﬂammation
pathways that are implicated in both chronic obstructive pulmonary disease
(COPD) and lung cancer.
Methods: A literature search was performed in PubMed to identify relative
studies published until June 2011.
Results: The pathophysiology of both COPD and lung cancer includes
dysregulation of the inﬂammation process, but the cascade of signaling
events is not yet fully understood. Both lung cancer and COPD are
associated with cigarette smoking that induces a chronic inﬂammatory
state in the lung by generating reactive oxidant species. It is considered
that shared inﬂammatory pathways involve genetic and epigenetic changes
due to chronic tissue injury and abnormal tumor immunity in susceptible
hosts. The proposed role of chronic inﬂammation is based on the 2-stage
model of carcinogenesis. According to this model, genotoxic injury is
crucial in tumorigenesis, followed by promotional events that result in
clonal growth of modulated cells. Research has shown that chronic
inﬂammation creates the necessary environment for the development of
lung cancer, acting as a tumor promoter. This environment, in combination
with cigarette smoke, induces the upregulation of mediators of the
inﬂammatory response, such as cyclooxygenase-2. This leads to the
production of inﬂammatory cytokines through lymphocytes, such as IL-
1, IL-6, IL-8 and IL-10, as well as to the increased formation of
chemotactic factors. Some of the latter mediators may suppress cell
mediated immune response and promote angiogenesis. They also impact
cell growth, resulting in the inhibition of apoptosis. Inﬂammatory factors
promote oxidative stress, contribute to the generation of reactive oxygen,
and cause oxidative DNA base modiﬁcation. COX-2 also plays an
important role in promoting epithelial-to-mesenchymal transition, present
in both lung cancer and COPD. Thus, chronic inﬂammation plays
a pathogenic role in lung cancer by inducing preneoplastic mutations
and cellular damage.
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Conclusions: Additional research is required to understand the cellular and
molecular mechanisms that link COPD and lung cancer, in an effort to
discover new methods of prevention and treatment.
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Risk Factors of Recurrent Upper Respiratory Infections in
Children under 5 Years. Habana Vieja
Xiomara Lopez Campos,MD,1 Mirta Alvarez Castello,MD,2 and Juliette Massip,
MD3. 1Hogar Materno Leonor Pérez, Havana, Cuba; 2Allergy Society from
Cuba, Havana; 3Cuba Bioestatistics Society, Havana, Cuba.
Background: Upper Respiratory Infections are the most common diseases in
childhood. It is possible to get even with no risk factors; although, if there are
more factors, the higher it is the probability of illness.
Methods: It was carried out an analytic study of cases and controls to identify
risk factors associated with Recurrent Upper Respiratory Infections (RURI) in
children under 5 years old from Habana Vieja municipality between January and
June of the 2008, 40 children with RURI were studied selected by convenience
sampling and 40 controls. Surveys were relatives. The group of cases was
compared with the group control and then it was analyzed if the exhibition factor
was associated to the RURI by means of the test of square chi, for that which was
considered as signiﬁcant a P ,0.05 in which case the test of odds ratio was
applied (OR) to determine if really the factor or characteristic is or not of risk.
Results: The most common was RURI was Adenoiditis with 18 cases (45%).
All the cases had personal and family history of allergy, compared with
37.5% and 62,5% respectively in controls; (OR¼ 25.4 P ¼ 0.0001 and OR¼
16,3 P ¼ 0.001). The adequate breastfeeding was more frequent in controls
(OR ¼ 2.5 P ¼ 0.048). 70% of the cases were exposed to the smoke of the
tobacco, and controls only 25% (OR ¼ 8.2). 92.5% of the homes of the cases
and 70% of the controls had animals, especially dogs. The cold (92.5%),
temperature changes (80%) and humidity (80%) were considered environ-
mental risk factors in this study (OR ¼ 14.5 P ,0.001; OR ¼ 16.5 P ,
0.001, OR ¼ 13.2 P ,0.002).
Conclusions: Risk factors affecting the RURI are: personal and family
history of allergy, inadequate breastfeeding, exposure to the smoke of tobacco
and the presence of domestic animals, cold, changing weather and humidity.
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Long Term Asbestos Exposure as a Cause of Eozinophilic
Pleural Effusions
Biserka Jovkovska Kaeva, MD, PhD, and Zoran Arsovski, MD, MSc.
Outpatient Department, Clinic of Pulmonology and Allergy, Skopje, Mace-
donia; Allergy and Clinical Immunology, Clinic of Pulmonology and Allergy,
Skopje, Macedonia.
Background: Exposure to asbestos can cause several different types of
pleural disease: ﬁrst diffuse malignant mezothelioma, plural plaques or
calciﬁcation, loculated pleural abnormality called “rounded atelectasis” and
benign pleural effusions (PE).
Objective: To determine the frequency of various pleural diseases related to
asbestos exposure.
Methods: A retrospective analysis of 6 cases of PE related to the
occupational asbestos exposure (AE) was made, after exclusion of other
possible causes of PE. They were evaluated in the period of 7 years.
Results: All cases were male and almost all were more than 60 years old. All
cases had more then 30 years from the ﬁrst occupational AE (5 in building
construction and sixt in mine). All of them reported pleuritic chest pain, or
feeling heavy in their chest. The chest radiographs showed small to moderate-
sized PE, which was bilateral by tree patients (pts) by the others with pleural
caliﬁcations in one of them. One of the pts had 3 episodes of PE and evidence
of parenhimal asbestosis. PE was serous exudate and serosanguineous in 2
pts, with polymorphonuclear leucocytes, mononuclear cells and eosinophils
(EO). We have evaluated the number of EO in the pleural ﬂuid (PF), from the
smear of PF colored by May-Grunwald-Giemsa. The PF differential WBC
consisted predominately EO and mononuclear cells. At 4 pts more than 30%
EO were found in the PF and 21% and 17% in other 2 pts respectively.
During the follow up period of 3 years no other cause of PE has been found
and there has been no evidence of mesothelioma in all the pts.
Conclusions: Exposure to asbestos can cause PE with predominant presence
of Eo cells.
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A Novel Therapeutical Option in Resistant Ganglionar and
Cutaneous Tuberculosis
Laura Vidal,1 Damián Palafox,2 Araceli Hernández-Lagunes,3 and José
Palafox4. 1Immunology and Allergy, Hospital Ángeles Xalapa, Xalapa,
Mexico; 2Surgery, General Hospital of Mexico, Mexico City, Mexico;
3Pathology Department, CEMEV, Xalapa, Mexico; 4Pneumology and Tho-
racic Surgery, Hospital Ángeles Xalapa, Mexico.
Background: Transfer factor was ﬁrst described in 1955 and constitutes
a Dialyzable Leukocyte Extract. It has been widely used in several infectious
diseases and malignancies with satisfactory results. Although not yet fully
clariﬁed, among the mechanisms of action the most accepted is the
enhancement of the cellular immunity.
Methods: We tested transfer factor in a 1 year old and 3 months patient
diagnosed with Ganglionar Tuberculosis. 1 week after the administrarion of
the Bacillus Calmette-Guérin vaccination, the present developed fever, cer-
vical, submandibular, supraclavicular, inguinal and axillary lymphadenopa-
thy. Later on the patient devoloped cutaneous clinical manifestations of
tuberculosis such as scrofuloderma, ﬁstulas, hypertrophic scars and ulti-
mately, queloids. The patient had previously undergone short-term strictly
supervised treatment for tuberculosis with very poor results. When the treat-
ment was ﬁrst administered, the patient had the following data: Total White
Blood Count 12.9 Lymphocytes: 29% (12–46) CD3: 26.3% (59–90) T helper
Cells (CD3/CD4) 21.6% (42–58) Cytotoxic T cells (CD3/CD8) 5.1% (17–33)
Natural Killer Cells (CD56) 2.1% (3–7) B cells (CD19) 67.6 % (0–10).
Results: At the end of the treatment, the patients immune system was en-
hanced in terms of cell count and improval of skin manifestations. Total
White Blood Count 6.5 Lymphocytes: 51.3% CD3: 48.5% T helper cells
(CD3/CD4) 31.2% Cytotoxic T Cells (CD3/CD8) 14.6% Natural Killer cells
(CD56) 12.2% B cells (CD19) 985%. Cicatrization process was improved,
with involution of skin lesions os scrofuloderma and ﬁstulas. Lymphadenop-
athy was no longer encountered. We have followed the patient for a year and
half and no relapses have been encountered.
Conclusions: We consider Transfer Factor a valuable option as adyuvant
therapy in cases of ganglionar and cutaneous tuberculosis refractory to
conventional treatments. To our knowledge, this is the ﬁrst report of a case of
the disease treated satisfactorily with transfer factor.
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Penicillin Allergy Evaluation: Experience from a Drug Allergy
Clinic in Kuwait
Mona Al-Ahmad, FRCPC,1 Nermina A. Arifhodzic,MD, PhD,2 Ali Al-Onizi,
3Nasser Fakim,3 and Nasser Al-Ahmed, MD, ABIM, FRCPC4.
1Allergy, AL-Rashed allergy Centre, Kuwait, Kuwait, Kuwait; 2Department
of Allergy Clinical Immunology, Kuwait Allergy Centre, Kuwait city, Kuwait;
3Allergy Department, Kuwait Allergy Center, Kuwait, Kuwait; 4Department
of Allergy, Al-Rashed Allergy Centre, Ministry of Health, State of Kuwait,
Kuwait city, Kuwait.
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Background: To evaluate a cohort of patients with a suspected beta-lactam
allergy history.
Methods: 42 patients with suspected beta-lactam hypersensitivity reactions
were evaluated at a drug allergy clinic at a tertially allergy center. Skin prick
tests (SPT) with major determinants (PPL), minor determinants (MDM),
penicillin G, ampicillin, amoxicillin, intradermal tests (ID) and speciﬁc IgE
determination were done. If all tests were negative, a drug challenge was
performed.
Results: 42 patients were enrolled (mean age 39 years, 71.4% female and
28.6% males). History of atopy was present in 59.5%. The offending antibiotics
were amoxicillin and amoxicillin/clavulanic acid in 28 (66.6%), penicillin in 10
(23.8%), and ampicillin in 4 (9.5%). Speciﬁc IgE to penicillin was negative in
almost all patients with history of penicillin allergy (41 patients, 97.6%). SPT
and ID tests were positive in 11 patients (26.1%) as follows: 3 patients (7.1%)
had positive SPT to PPL, 1 patient (2.4%) SPT to MDM, 2 patients (4.8%) SPT
to Penicillin G, 1 patient (2.4%) SPT to Ampicillin, 1 patient (2.4%) SPT to
Amoxicillin, 8 patients (19%) ID to PPL, 3 patients (7.1%) ID to Penicillin G, 3
patients (7.1%) ID to Ampicillin. Only 1 patient had both positive speciﬁc IgE
and skin tests. The remaining 31 patients (73.8%) underwent a drug challenge
with the culprit antibiotic with no reported reactions.
Conclusions: One fourth of patients with history of beta-lactam hypersen-
sitivity reactions were conﬁrmed after testing. A combination of skin testing,
speciﬁc IgE and drug challenge is necessary since none has sufﬁcient
sensitivity to be used alone.
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Association Between Genetic Polymorphisms of ABCC2
Transporter and the Susceptibility to Maculopapular Eruption
Induced by Antituberculosis Drugs
Sang-Hoon Kim, MD, PhD,1 Sang-Heon Kim, MD,2 Jae-Hyung Lee, MD,1
Byoung-Hoon Lee, MD,3 and Young-Koo Jee, MD, PhD4. 1Internal Medi-
cine, Eulji Hospital Eulji University School of Medicine, Seoul, South Korea;
2Department of Internal Medicine, Hanyang University College of Medicine,
Seoul, South Korea; 3Eulji Hospital Eulji University School of Medicine,
Seoul, South Korea; 4Internal Medicine, Dankook University College of
Medicine, Cheonan, South Korea.
Background: ATP-binding cassette (ABC) transporter proteins play an
important role in drug disposition. Polymorphisms of ABC transporter genes
(ABCC2 and ABCB1)may be risk markers for maculopapular eruption (MPE)
induced by unusual accumulation of antituberculosis drugs (ATD) itself or
metabolites.
Methods: We compared genotype distributions of single nucleotide poly-
morphisms and haplotypes in ABCC2 and ABCB1 genes between 62 ATD-
induced MPE cases and 159 ATD-tolerant controls using multivariate logistic
regression analysis.
Results: Among the 7 selected SNPs of ABCC2, -1549G.A in promoter and
IVS3-49C.T in intron were associated with ATD-induced MPE (P ¼ 0.032
and P ¼ 0.029, respectively). ABCC2 haplotype1 [G-C-C-G] was signiﬁ-
cantly associated with ATD-induced MPE (P ¼ 0.032, OR ¼ 0.35, 95%
CI, 0.29-0.95). However, there was no signiﬁcant association between other
genetic polymorphisms in ABCB1 and ATD-induced MPE.
Conclusions: These results suggest that genetic variations of ABCC2 are
a potential risk factor for ATD-induced MPE.
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The Real Use of Beta-Lactams after "Penicillin Allergic"
Label Removal
Shai Cohen, MD,1 Areen Khateeb-Alabbasi, MHA,2 David Nusem, MD,3
and Josef Panassof, MD3. 1Allergy Clinic Lin Medical Center, Bruce Rappa-
port Faculty of Medicine, Technion-Israel Institute of Technology, Haifa,
Israel; 2Allergy Clinic Lin Medical Center, School of Public Health, Univer-
sity of Haifa, Haifa, Israel; 3Allergy Clinic Lin Medical Center, Haifa, Israel.
Background: The "penicillin allergic" label becomes very common, thus
preventing from many patients the use of one of the most efﬁcient antibiotic
drugs, with the lowest cost and toxic effects. However, approximately 80% of
patients with a history of penicillin allergy have negative results if they are
skin tested and can actually use this drug class. We sought to determine
whether in real life, removal of the label is implemented to the treatment of
beta-lactams when it is required.
Methods: A retrospective study that includes all penicillin allergy history–
positive/penicillin skin test–negative/oral amoxicillin challenge-non reactive
individuals who had been tested in advance of need between the years 2000
toi 2009 at one medical center (n ¼ 140). To uncover late reactions, they were
offered after the test a 5 day course of amoxicillin. The study tool was
a phone-questionnaire assessing the patients’ conﬁdence in their test results,
and whether they have used penicillin since testing.
Results: 106 patients (76%) agreed to participate in the survey. Ninety-nine
patients (93%) chose to take the 5 day course of amoxicillin. From this group
of patients twenty-seven (27.2%) answered that they feel intermediate
insecurity and fourteen (14.1%) that they feel complete insecurity to receive
penicillin. Since having the test seventy 2 (72.7%) of the 99 needed penicillin.
Sixty-two (86.1%) indeed took a beta-lactam while 10 patients (13.9%) chose
to receive another antibiotic class due to their or their physician’s disbelief in
the test. All the patients (n ¼ 7) who chose not to take the course of amox-
icillin after the test stated that they feel complete insecurity to receive pen-
icillin. Four (57.1%) of these patients had a disease that requires a beta-lactam
antibiotic and actually, none of them agreed to take one (P ¼ 0.01).
Conclusions: A negative penicillin test done in advance of need even when
includes an oral challenge may not be enough to convince patients that they
can use beta-lactams. Our study suggests that giving a 5 day course of
amoxicillin after the test increases the patients’ conﬁdence in the results.
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Hypersensitivity to Beta-LactamAntibiotics Evaluation Using the
European Network Drug Allergy (ENDA) Algorithm
Tânia Maria Gonçalves,MD,1,2 Emmanuel Martins,MD,1,2 Alfredo Alves Neto,
MD,1,2 Nathalia Delcourt, MD,3,2 João Rios, MD,1,2 Luiz Arcanjo, MD,1,2
and José Luiz Rios,MD,3,2. 1Policlinica geral do rio de janeiro, Rio de janeiro,
Brazil; 2Faculdade de medicina de petropolis, Petropolis, Brazil; 3Policlinica
Geral do Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Hypersensitivity to beta-lactam antibiotics are usually deﬁned
only by the history of suspected previous reaction to these medicines. This
deﬁnition, however, can erroneously restrict the use of these important
therapeutic resources if not assessed by the proper tests. The objective was to
assess the presence of hypersensitivity to beta-lactams through adequate testing.
Methods: Thirty-three patients were referred to our allergic clinic for testing
of penicillin hypersensitivity in the period from 2008 to 2011: 22 (66.6%)
females and 11 (33.4%) males, with ages ranging from 8 to 88 years. The ﬁrst
24 (72.7%) patients were tested using only penicillin G, in the form of a prick
test followed by an intradermal test with immediate reading, according to the
Brazil Ministry of Health protocol (group I). The remaining 9 (27.3%)
patients (group II) were subjected to the adaptations of standards-based
assessment of hypersensitivity reactions to beta-lactam antibiotics, according
to the algorithmic recommendations of the European Network Drug Allergy
(ENDA), which includes a prick test and intradermal test with penicillin G,
amoxicillin and the suspected beta-lactam, such as clavulanic acid or
cephalosporins, with immediate and delayed readings. Patients who had
negative skin tests results underwent a provocation test, which is considered
the gold standard in determining drug hypersensitivity. In-vitro tests available
in Brazil (speciﬁc IgE to penicillin and amoxicillin) were performed in
patients with a history more suggestive of adverse reactions. It was respected
the ENDA recommendation of not subjecting patients with severe reactions to
this protocol.
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Results: Of the 33 patients, 28 (84.8%) had negative results for the tests. One
patient in group I showed inconclusive results. Four patients (12.2%) in group
II had positive tests, including 3 for penicillin G and one for amoxicillin.
Conclusions: The results demonstrated that the clinical history collected by
medical questionnaires is not the determining factor in conﬁrming a patients’
reaction to penicillin, and shouldn’t be the only parameter used to exclude
potential future prescriptions. In addition, the results denote that hypersensi-
tivity to other beta-lactam antibiotics should be evaluated in a more proper
way for a fuller understanding of each case.
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Clinical Features of Drug Rash with Eosinophilia and Systemic
Symptoms Syndrome Caused by Antituberculous Medications
Sang-Ha Kim, MD, Shun Nyung Lee, MD, Seok Jeong Lee, MD,
Chong Whan Kim, MD, Won Yeon Lee, MD, Suk Joong Yong, MD,
and Kye Chul Shin, MD. Department of Internal Medicine, Yonsei University
Wonju College of Medicine, Wonju, South Korea.
Background: Drug rash with eosinophilia and systemic symptoms (DRESS)
syndrome is one of severe adverse drug reactions. Aromatic anticonvulsants
and sulfonamides are the most common causes of DRESS syndrome.
However, there have been only 2 case reports of DRESS syndrome induced
by antituberculous medication. This study was aimed to observe the clinical
features of patients with DRESS syndrome caused by antituberculous
medications.
Methods: We retrospectively revealed the clinical and laboratory data of the
patients from September 2006 to August 2010 at a University Hospital. Our
patients were diagnosed as DRESS syndrome if 3 criteria were present: (1)
cutaneous drug eruption, (2) peripheral eosinophilia.1,500/mL, (3) systemic
involvement (lymphadenopathy, hepatitis or fever).
Results: Nine patients (5 men, 4 women; mean age 50.5 years) were enrolled
DRESS syndrome induced by antituberculous medications. The most
common causative agent was ethambutol which was identiﬁed as the cause
in 8 of 9 patients (88.9%). In the other patient, streptomycin was considered
as the causative agent. Two out of 8 patients with DRESS syndrome caused
by ethambutol were induced by rifampicin as well. Drug eruption developed
6.9 weeks after antituberculous drugs were ﬁrst used. Skin eruptions were
involved on the whole body in 8 patients and on only upper trunk in 1 patient.
Diffuse maculopapular eruption was the most common type of skin lesions
that was observed in 8 of 9 patients. Other types of skin eruption were
identiﬁed; 4 exfoliative eruptions, 3 facial edema and 1 urticaria. The mean
value of peripheral eosinophil counts was 3,354/mL. The cervical, axillary or
inguinal lymphadenopathy was observed in 7 patients and fever was detected
in 6 patients. Hepatitis was developed in 3 patients. All patients with DRESS
syndrome recovered after corticosteroid therapy and the elimination of the
culprit drugs.
Conclusions: The most common cause of DRESS syndrome induced by
antituberculous medications was ethambutol in our study. Diffuse maculo-
papular eruption on the whole body was the most common type of eruption
and lymphadenopathy was the most common involvement of internal organ
in patients with DRESS syndrome caused by antituberculous drugs.
ANAPHYLAXIS
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Basophil-Mediated Anaphylaxis Triggered by Drug-Activated
Complement Alternative Pathway Without Mastocyte’s nor
Immunoglobulins Involvement
Giacomo Manfredi, MD, Pierluigi Traetta, MD, and Massimo Errico, MD.
Allergology and Clinical Immunology Unit, Department of Clinical Medicine,
General Hospital Miulli, www.miulli.it, Acquaviva (BA), Italy.
Background: It’s well known that drugs may induce complement alterna-
tive pathway’s activation. On the other hand there is evidence that anaphy-
laxis may occur in absence of IgE and IgG antibodies (so-called
non-immune anaphylaxis). We determined the tryptase, complement and
circulating immune complexes (CIC) levels to understand the nature of
anaphylaxis occurred in a woman during high rate infusion of high con-
centrated iron.
Methods: A 46 years-old woman was admitted to our department because of
mixed anemia, iron and cobalamin deﬁciency-related, started after a surgical
intervention (bilio-pancreatic derivation) for heavy obesity occurred 7 years
ago (starting Hgb ¼ 7g/dl). Ev. hydroxicobalamin and iron infusions were
planned, but during high rate (100 gtt/m’) infusion of high concentrated (0,5
mg/mL) iron, the patient suffered from discomfort, sweat and drop in blood
pressure (BP 60/30). Blood samples were taken to evaluate tryptase, comple-
ment and CIC levels; standard treatment of anaphylaxis was started (im.
epinephrine, inhaled O2 with steroids and beta-agonists, ev. electrolyte solu-
tion and vital parameters continuous evaluation). The shock resolution was
gained in 3 hours.
Results: The level of tryptase was normal (4 mcg/mL; N.R.-Normal Range-¼
1–20), while C3 and C4 were impaired (C3 ¼ 65 mg/dl; N.R. ¼ 75–165; C4
¼ 12 mg/dl; N.R. ¼ 20–55). The search for CIC IgG, IgA, IgM was negative.
Six months later the low rate (30 gtt/m’) low concentration (0,25 mg/mL) iron
infusion was well tolerated by the patient, so excluding any IgE sensitization.
Conclusions:We describe here for the ﬁrst time a case of human anaphylaxis
without mastocyte nor IgE involvement. The high infusion rate and hyper-
osmolality of hyperconcentrated drug caused complement alternative path-
way’s activation. The only cell type able to release anaphylaxis mediators
other than mastocytes are the basophils, having anaphylotoxins receptors. So,
we conclude that drug-induced complement alternative pathway’s activation
with consequent basophil’s involvement was responsible for the patient’s
“non-immune” anaphylaxis.
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Wait at Least 60 Minutes After Eating
Stella Gandhi, MD, Megan Woodruff, LPN, Hillary Halley, Samir Patel,
DPM, and Summit Shah, MD. Premier Allergy, Dublin, OH.
Background: We will describe 2 unique cases of Food Dependent Exercise
Induced Anaphylaxis.
Methods: Patients underwent a complete history, physical exam, and skin
prick testing by classical method.
Results: Case 1: A 23 year old Asian Male presented with anaphylaxis
following cashew ingestion and post prandial exercise. This was the ﬁrst
episode of anaphylaxis despite previous exposure to cashews and exercise
independently. Patient ingested cashews and went for a jog 30 minutes
later. His symptoms of anaphylaxis included urticaria and ocular swelling.
Skin prick testing generated positive results to cashew, with measurements
of 10 mm/30 mm (wheal/ﬂare). Controls of histamine and saline measured
were 10 mm/30 mm and 0 mm/0 mm, respectively. Case 2: A 42 year old
Caucasian Male presented with anaphylaxis following shrimp ingestion and
post prandial exertion. This was the ﬁrst episode of anaphylaxis despite
previous exposure to shrimp and exercise independently. Patient ingested
shrimp and went for a brisk walk 30 minutes later. His symptoms of
anaphylaxis included full body urticaria and shortness of breath. Skin prick
testing generated negative results to shrimp and shellﬁsh mix, with
measurements of 0 mm/0 mm and 0 mm/0 mm (wheal/ﬂare). Controls of
histamine and saline measured were 10mm/30mm and 0mm/0mm,
respectively.
Conclusions: The previous cases describe anaphylactic reactions after food
ingestion followed by post prandial exercise. The precise pathophysiology of
this rare syndrome is poorly understood, however it is believed that allergen
absorption is increased in a post-exercise state. The contrast in our patients’
results of their skin prick tests demonstrate that patients may or may not have
food-speciﬁc IgE but still can experience food dependent exercise induced
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anaphylaxis. Mainstay treatment for food dependent exercise induced ana-
phylaxis is recommending exercising only on an empty stomach. The con-
sideration of food dependent exercise induced anaphylaxis in cases of
unexplained anaphylaxis is important as reactions can be life threatening
and clinicians should be reminded of the importance of thorough history
taking.
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First Report of Anaphylactic Shock Caused by the Ingestion of
Mite-Infested Flour in Panama
Olga Melcina Barrera de Pino, MD,1 Ingrid Murgas Entomologist, 2
and Roberto J. Miranda2. 1Institute of Pneumology and Allergy, San Fer-
nando Hospital, Panama City, Panama; 2Gorgas Memorial Institute, Pan-
ama City, Panama.
Background: To report the ﬁrst case of an anaphylactic shock, almost lethal,
in the Republic of Panama, produced by ingestion of pancakes contaminated
by mites.
Methods: A 21 year-old male patient was evaluated due to an anaphylactic
shock after the ingestion of pancakes, eggs and milk. The patient had
a background of a moderate allergic rhinitis. Not asthma. Skin prick test was
performed on the patient with standardized extract of mites and food items,
including, ﬂour, milk and egg. After twenty minutes the results were read and
considered positive since the wheal was 2 mm larger than the control
(histamine 1 mg/mL). The Total IgE was determined by the chemilumines-
cence method. The determination of the speciﬁc IgE for mites and food was
performed by the enzyme immunoassay technique. The counting and
identiﬁcation of the mites in the pancake samples that were eaten by the
patient were placed in a microscopic slide using a Hoyer medium and
analyzed in a stereomicroscope.
Results: The skin prick test performed was considered positive for Blomia
tropicalis, Dermatophagoides pteronyssinus and negative for ﬂour, milk and
egg. The total IgE was increased and the speciﬁc IgE resulted positive for
Dermatophagoides pteronyssinus and Blomia tropicalis, but negative for
ﬂour, egg and milk. The microscopic examination of the pancake wheat
showed 3 different species of mites: Blomia tropicalis, Blomia sp. and
Dermatophagoides pteronyssinus, the ﬁrst one in major proportion.
Conclusions: The anaphylactic shock of the patient was produced by the
ingestion of a commercial pancake contaminated by mites to which the
patient was sensitized. Flour kept in open containers becomes a fertile ground
for the growth of mites in tropical climates. Allergic patients should be
warned of the danger of anaphylaxis in such conditions.
REFERENCE
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Recurrent Aanaphylaxis in Cow Milk Allergy: What Is Wrong?
Marcela Asanuma Odaira, MD,1 Deborah Geraldi Rezende de Oliveira, MD,1
Letícia Aki Watanabe, MD,1 Andrea Keiko Fujinami Gushken, MD,1
Ana Cláudia Brandão, MD,1 Antônio Carlos Pastorino, MD, PhD,2
Cristina Miuki Abe Jacob, MD, PhD,1 and Ana Paula Beltran Moschione
Castro, MD, PhD1. 1Allergy and Immunology Unit, Pediatric Department,
Hospital das Clínicas Faculdade de Medicina da, Universidade de São Paulo,
São Paulo, Brazil; 2Instituto da Criança da Faculdade de Medicina do Hos-
pital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Background: Food allergens are one of the most important triggers of
anaphylaxis in pediatric population and all efforts must be done to avoid new
episodes.
Objective: To determine some factors associated to recurrent anaphylaxis
induced by cows milk (CM) in pediatric patients with a previous anaphylactic
episodes.
Methods: This is a retrospective study based on medical records from all
CM anaphylactic patients, from a Brazilian reference center for food
allergy. The anaphylaxis criterion used was based on the Second sympo-
sium on the deﬁnition and management of anaphylaxis. Patients and
parents had received orientation regarding prevention of new episodes,
including information about hidden allergens, label reading, and synony-
mous terms.
Results: It was included 53 patients (33M: 20F), median age of the ﬁrst
episode of anaphylaxis was 6 months (range 1–87 month) and in 56. 6% the
ﬁrst episode occurred until the age of 6 months. Fifty episodes were observed
in 22 patients during the follow up. Twelve patients presented 2 or more
episodes and 2 patients presented 6 episodes. It was not possible to detect the
trigger food in 17 episodes and these situations were related to ingestion of:
appetizers (4), margarine (3), bread (2), pizza (2), juice with casein (1), pasta
(1), cake (1), chips (1), Italian sausage (1). Two episodes were challenged by
accidentally skin contact and 2 by inhalation. Among the settings of episodes,
the majority occurred at home. Other places included: school, restaurants and
bakery.
Conclusions: This study showed that it is very difﬁcult to reach success only
with the orientations regarding anaphylaxis prevention. It is necessary to
betake of other strategies to improve the measure to avoid new episodes of
anaphylaxis such as: folders, visual midia and interactive activities.
Furthermore, the continuous education is essential to reinforce the knowl-
edge.
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Epidemiology of Anaphylaxis in Adults Treated in the Emergency
Department, of the University Hospital of Monterrey n.l Mexico,
During 2005–2010
Maricruz Calva, MD,1 Sandra González-Díaz, MD, PhD,1,2 Alfredo Arias-
Cruz, MD,1 Alejandra Macías-Weinmann, MD,1 Lucía Leal, MD, PhD,1
Arya González, MD,1 Claudia Gallego, MD,1 Diego Garcia-Calderin, MD,1
Karla Mejia, MD,1 and Luis Dominguez, MD1. 1Regional Centre of Allergy
and Clinical Immunology, University Hospital, Monterrey, Mexico; 2Re-
gional allergy center, University California San Diego, Monterrey, CA, Mex-
ico; 3Allergy and Clinical Immunology, University Hospital UANL,
Monterrey, Mexico.
Background: The risk of anaphylaxis ranges from 0.2 to 0.7%. The objective
of this study was to describe the causes, clinical features and complications of
patients with anaphylaxis treated in the emergency department of our
hospital.
Materials and Methods: A prospective, observational and descriptive survey
was conducted for assessing adult patients with a diagnosis of anaphylaxis
from March 2005 to 2010. Information was obtained from the medical
records and from a questionnaire was that completed for the patients and
a relative. The information included, triggers, demographics, allergy history
and clinical characteristics of the current episode. All the cases were followed
to their outcome.
Results: We documented 45 cases of anaphylaxis. 26 patients (58%) were
male. The most common causes of anaphylaxis were: drug (49%) food
(20%) and poison hymenoptera venom (16%). The most common clinical
signs ando symptoms included: dyspnea (69%), nausea (58%) and
hypotension (56%). 44% of patients came to emergency departments in
the course of 30 minutes after onset of symptoms while the 29% took 30
minutes to 1 hour and 27% more than 1 hour. Among the associated
diseases, hypertension was 13% and rhinitis (11%). In 85% of the cases,
patients remained under observation for 3 to 12 hours were the most
frequent discharged. 7 patients were hospitalized and 4 sent to intensive
care later were discharged without complications.
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Conclusions: Anaphylaxis is not uncommon in our environment. Drugs are
the most common cause as reported in the literature. The most frequent
clinical manifestations are respiratory and gastrointestinal.
ANTI-IGE
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Refractory Chronic Urticaria Treated with Omalizumab
Martinez Saenz, NP, Ramírez Del Pozo, ME, Lopez Tiro JJ, and
Javier Gomez Vera, MD. Alergia e inmunologia clínica, Hospital Regional
Lic. Adolfo Lopez Mateos, Distrito Federal, Mexico.
Background: Chronic urticaria (CU) is a common disorder characterized by
recurrent episodes of urticaria pruritic erythematous lesions, associated with
angioedema1. It affects 0.1% of the population, it is estimated that approxi-
mately 15 to 25% of the population will have hives at some point in their
lives.2 About 80% of UC patients are diagnosed as idiopathic chronic urti-
caria and that no cause is identiﬁed, 3 experiencing deterioration in their
quality of life affecting your work, social relationships, schemes requiring
multiple medications and doses higher than usual. This study proposes Oma-
lizumab (anti-IgE humanized antibody) as a treatment for Refractory Chronic
Urticaria (RCU)
Object: Demonstrate Omalizumab’s effectiveness in the treatment of Refrac-
tory Chronic Urticaria.
Methods: A clinical study, was carried out to evaluate the effectiveness of
the Omalizumab’s treatment on RCU diagnosed patient, including male
and female patients ages 12 to 50 diagnosed with RCU, with Scorad
higher tan 30 points. We made a questionnaire to know about the patient’s
family background, skin symptoms beginning, administration of drugs
such sistemic steroids, inmunosupresors, calceurine inhibitors, presence
of inmunotherapy and age of start. Omalizumab was administered on
doses according patient’s weight and IgE levels, bimonthly or monthly
according to treatment guides. Severeness level was calculated with
scorad every 1 month, with IgE seric level measurement and life quality
questionnaire.
Results: 5 patients diagnosed with RCU were included in the group of
Omalizumab and 5 patients in the control group (placebo). All patients were
female. A gradual decrease on the life quality score and in Score, with
a signiﬁcant P under 0.05 was observed on all patients treated with
omalizumab compared with patient in the group with placebo.
Conclusions: Treatment with Omalizumab progressively decreases the
severeness level on RCU, with a signiﬁcant improvement on the patient’s
life quality.
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Clinical Experience in Allergic Asthma Patients: Omalizumab
with Immunotherapy
Arzu Didem Yalcin, MD,1 Sukran Kose,2 and Reginald M. Gorczynski,
MD, PhD3. 1Allergology and Clinical Immunology Unit, Antalya Education
and Training Hospital, Antalya, Turkey; 2Infectious Diseases and Clinical
Microbiology, Clinical Allergy and Immunology, Tepecik Educational and
Research Hospital, Izmir, Turkey; 3Division of Cellular & Molecular Biol-
ogy, Toronto Hospital, University Health Network, Toronto, ON, Canada.
Background: To evaluate the therapeutic efﬁcacy of omalizumab and
speciﬁc subcutaneous immunotherapy (SCIT) as a treatment modality in
patients with more than one allergic-type condition.
Methods: In the ﬁrst group (Group A), 2 males and 7 females with severe
persistent asthma and a mean age of 34.2 years received omalizumab and
SCIT. In the second group (Group B), 4 males and 2 females with severe
persistent asthma and a mean age of 52.7 years received omalizumab only. In
the third group (Group C), 1 male and 3 females with severe persistent asthma
and a mean age of 28.8 years received omalizumab followed by SCIT. All
patients were followed for 2 years and comparisons were made using pulmo-
nary function tests and asthma control tests.
Results: The patients studied had severe persistent asthma for periods ranging
from 2 to 10 years, and in addition had been diagnosed as allergic asthmatics
for 5 to 40 years. The mean IgE levels were as follows: Group A: 553.9 IU/
mL; Group B: 422.3 IU/Ml; and Group C: 383.5 IU/mL. In all 3 groups
results in the asthma control test increased by 2.5 fold over the period of
study.
Conclusions: After the addition of SCIT to omalizumab therapy at 48
week of our study, no change was detected in urticarial attack rates. In
another 17 year old male patient with moderate allergic rhinoconjuncti-
vitis, asthma and atopic dermatitis, omalizumab administration with SCIT
at the same time, increased the severity of atopic dermatitis. We stopped
the immunotherapy than the skin lesions lost.omalizumab therapy is
continued.
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Evaluation of Adverse Events Associated to Administration
of Omalizumab
R. Maximiliano Gomez, 1,2 Miguel Vinuesa, MD, PhD,3 Alvaro Teijeiro,
MD,4 Juan Carlos Ivancevich, 5 Edgardo Jares,5 and Carlos E. Baena-
Cagnani, MD,6,7. 1Ayre Foundation, Salta, Argentina; 2Allergy and Asthma
Unit, Hospital San Bernardo, Salta, Argentina; 3Instituto de Inmunología y
Alergia, Sanatorio Britanico, Rosario, Argentina; 4Hospital Pediatrico, Cor-
doba, Argentina; 5LIBRA Foundation, Buenos Aires, Argentina; 6Centro de
Investigación en Medicina Respiratoria, Faculty of Medicine, Catholic Uni-
versity of Cordoba, Fundación LIBRA Argentina, Cordoba, Argentina; 7LI-
BRA Foundation, Cordoba, Argentina.
Background: Anti IgE therapy is the ultimate therapeutic option for severe
atopic conditions, not controlled by conventional treatment. Its efﬁcacy and
safety was described in several peer reviewed publications. Here we report on
the events temporally related to the administration of almost 4 hundred doses
of the only monoclonal Anti IgE antibody approved in our country for the
treatment of severe asthma.
Methods: Descriptive retrospective analysis of clinical charts of patients
receiving omalizumab because of Severe Uncontrolled Asthma, considering
those events presented in the 72 hours after administration of it, which was
not present before the procedure or as a concomitant condition of the patient.
Vital signs, respiratory and cardiovascular evaluation, and dermatological
inspection were performed in the hour after administration of corresponding
doses. Patients having any kind of complaint were evaluated in unscheduled
visits.
Results: 384 doses of 150 mg omalizumab were given to from April 2007 to
June 2011, to nine severe asthmatic patients. One of them received treatment
for over 4 years, and two for over 3 years.
Conclusions: Our records from patients receiving omalizumab have not
registered severe adverse events in almost four hundred doses given. The
moderate adverse events of nausea and tachycardia resulted in discontinuation
Events related to omalizumab administration
YES NO
Local erythema and edema: 0.78%-mild Muscle pain: 1%-moderate
Nausea: 0.26%-moderate Bruises: 0.52%-mild
Sinusal Tachycardia: 0.26%-moderate Headache: 0.26%-mild
Ear pain: 0.26%-mild
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of treatment in this unique patient. Overall, omalizumab demonstrated a very
acceptable safety proﬁle in our patients.
Funded by Fundación Ayre (Salta), Fundación LIBRA (Córdoba), CIMeR
(U.C.Córdoba), Argentina.
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Gender and Different Prevalence in Asthma Treatment With
Anti-IGE (Omalizumab)
Vincenzo Patella, MD,1 Giovanni Florio,2 and Carmine Oricchio, MD3. 1Di-
vision of Clinical Immunology and Allergy, General Hospital, ASL Salerno,
Agropoli (SA), Italy; 2Division of Clinical Immunology and Allergy, General
Hospital, ASL Salerno, Salerno, Italy; 3Division of Immunohaematology,
General Hospital, ASL Salerno, Agropoli (SA), Italy.
Background: General opinion on pathogenesis and prevalence of bronchial
asthma indicates that age and sex are the major risk factors. Detailed
physiological mechanisms of the changing sex ratio are not fully known.
Aims and objectives: Investigate the inﬂuence the asthmatic patients treated
with anti-IgE with different gender.
Methods: Here, we pooled data from ten published studies from 1999 with
more of our unpublished data of patients with severe persistent asthma treated
with omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody.
Static analysis was used to ﬁnd gender risk factors as the ratio of treatment
effect (omalizumab: control) on the standardized exacerbation rate per year.
Results: The studies included 3270 patients (treated with omalizumab), whose
had severe persistent asthma according to the Global Initiative for Asthma
(GINA) classiﬁcation. Analysis of 2 groups male versus female showed that the
efﬁcacy of omalizumab on asthma exacerbations was unaffected by patient age,
gender, baseline serum IgE (split by median) or by 2- or 4-weekly dosing
schedule, although a more large number of women were treated (1921/1349; 59
% women vs 41% men; P , 0.001) and beneﬁt in absolute terms appeared to
be greatest in women patients which had a more severe asthma, deﬁned by
a lower value of percentage predicted forced expiratory volume in 1 second
(FEV1) at baseline, this subgroup showed odds of being a responder (composite
deﬁnition) 1.25 times higher (95% CI, 1.18-3.01) than men.
Conclusions: These results suggest that in population of asthmatics treated
with anti-IgE the number of women is shown higher than men, it conﬁrms
that asthma should be considered with different approach by the gender for
being adequately controlled on current therapy.
273
Fetal Loss in SevereAsthmaandPosteriorHealthyPregnancy and
Birth with the Use of OmalizumabdCase Report
Fábio Kuschnir, PhD,1 Fatima Emerson, MD,2 Nelson Cordeiro, MD,2
Michele Viegas Rocha, MD,2 Silvio Lima Filho, MD,2 and Jose Luiz Rios,
MD2. 1Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil; 2Allergy,
Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Pregnancy may aggravate asthma and result in life-threatening for
both mother and foetus. The humanized monoclonal antibody omalizumab has
proven to be effective in controlling severe asthma. The purpose of this case
report is to present the effectiveness and safety of this medicine during pregnancy.
Methods: Case report of a severe asthmatic pregnant woman who had
a previous foetal loss due to asthmatic exacerbation, and obtained a sub-
sequent successful pregnancy and delivery with omalizumab use.
Results: KRF, 35, female, housewife, presented bronchial asthma associated
with allergic rhinosinusitis since childhood with periods of remission and
exacerbations. Since 15 years old, she presented progressive worsening of the
disease with increased intensity and frequency of the attacks. In 2005 she
became pregnant, progressing with severe attacks, emergency visits and hospital
admissions, and requiring courses of systemic corticosteroids, despite continued
treatment including combined of long-acting beta agonist (LABA) and inhaled
corticosteroids (IC), besides Montelucast and Bamiphylline. Nevertheless, the
pregnancy was interrupted at 8 months, due to the fetal death. Despite using
regularly Formoterol (24 mcg/day) and Ciclesonide (640 mcg/day), the
exacerbations became frequent, requiring continuous oral prednisolone, 20
mg daily, to achieve asthma control. Other risk factors for severe asthma were
ruled out through extensive investigation. Omalizumab, 300 mg monthly, was
introduced in July 2006, resulting in important improvement of the asthma
control, allowing the discontinuation of systemic corticosteroids in 2 months,
and subsequent reduction of Ciclesonide and formoterol doses. Discontinuation
in Omalizumab use resulted in asthma worsening, despite the increment in the
other medications doses. When omalizumab administration was restored, 8
months later, the asthma control was achieved again. In November 2010, she
became pregnant and the same treatment plan for asthma was maintained. Only
one episode of a mild exacerbation of asthma occurred due to a respiratory
infection. The pregnancy reached full-term with a cesarean section in May 2011
with mother and newborn presenting satisfactory health conditions.
Conclusions: Omalizumab has shown efﬁcacy and safety in the control of
severe asthma during pregnancy, reducing the risk of injury to health for both
mother and newborn.
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Vasculitic Urticaria Treated with Omalizumab. Case Report
María Elena Ramírez Del Pozo, MD, Nancy Paola Martínez Saenz, MD,
Javier Gomez Vera, MD, and Jesus Lopez Tiro, MD. Alergia e inmunologia,
Hospital Regional "Lic. Adolfo López Mateos" ISSSTE, Distrito Federal, Mexico.
Background: Vasculitic urticaria (UV) is a condition characterized by hives
lasting more than 24 hours, itchy and burning with residual hyperpigmen-
tation. Histopathology is characterized by leukocytoclastic vasculitis, peri-
vascular inﬁltrate and ﬁbrin deposits. The incidence is approximately 2%,
prevalence in women (5:1). The treatment includes steroids, immunosup-
pressants, and has suggested the use of monoclonal antibodies. We report
a patient treated with omalizumab.
Methods: Female 51 years old, his mother died of complications from Lupus
Erythematosus (SLE). 10 years ago was diagnosed with SLE by criteria
haematological and immunological joints treated with azathioprine, chloroquine
and deﬂazacort, with control of lupus, immunosuppressive suspended and
continuing low-dose steroids. Have hives as secondary reaction to netilmicin
and penicillin. Two years ago shows like lesions papules and burning and
itching rash on chest and limbs, with no peeling hyperpigmented macules,
managed with systemic steroids (prednisone) and antihistamines, with a decrease
of the same but has l month after similar injuries, and macula, adjust the dose of
steroid 1 mg/kg with a decrease in events with exacerbations and remissions,
until 3 months course again with increasing symptoms with erythematous,
violaceous, painful to the touch did not disappear in extremities lower, upper
abdomen and chest, with no improvement after systemic steroids, antihist-
amines, and immunosuppressants, laboratories report 4.600 leukocytes, eosi-
nophils 100/mcl, 90.1 mgU/dl C3, C4 8.6 mg/dL of 169 I U IgE/mL,
leukocytoclastic vasculitis biopsy reports, deciding Omalizumab use was
calculated based on weight and IgE, showing signiﬁcant improvement with
disappearance of the lesions, without pain or itching with hives.
Results: Gradual decrease was observed of Score of 6 to 1 and score-related
quality of of life with a 84.37 to 42.36 CUQ2oL after 3 applications, with
a signiﬁcant P by comparing the results and statistical analysis.
Conclusions: We conclude that Omalizumab may be useful in the treatment
of vasculitic urticaria, although it requires clinical trials that include a greater
number of patients and be compared with conventional treatment.
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Efﬁcacy of Omalizumab in the Treatment of Urticaria-Vasculitis
Associated to Churg-Strauss Syndrome: A Case Report
Gilda Varricchi, MD, Aikaterini Detoraki, MD, PhD, Bianca Liccardo, MD,
PhD, Giuseppe Spadaro, MD, Amato de Paulis, MD, Gianni Marone, MD,
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PhD, and Massimo Triggiani, MD. Division of Allergy and Clinical
Immunology and Center for Basic and Clinical Immunology Research (CISI),
University of Federico II, Naples, Naples, Italy.
Background: Churg-Strauss Syndrome (CCS) is a rare systemic necrotizing
small vessel vasculitis associated with bronchial asthma, peripheral blood
eosinophilia and eosinophilic lung inﬁltration. Skin changes compatible with
vasculitis are present in about 75% of patients. Previous reports suggest that
patients with CSS can be treated with anti-IgE (omalizumab) in addition to
conventional therapy to achieve asthma control. Here we report the efﬁcacy
of a 6-month treatment with omalizumab in a patient with CSS characterized
by severe asthma and urticarial vasculitis.
Methods: A 44 year old Caucasian female with a 5 year history of severe
asthma, chronic urticaria and mild eosinophilia (1100/mL) was evaluated for
possible CSS. Total serum IgE was 662 KU/l with positive skin prick tests for
dust mites. Bronchial asthma was not controlled and FEV1 was 60% despite
treatment with budesonide (640 mcg/die) and formoterol (18 mcg/die). Dif-
fuse and conﬂuent urticarial rash occurred in the last 6 months before eval-
uation and responded neither to prednisone (10 mg/die) and rupatadin (10
mg/die) nor to immunosuppressive agents (cyclosporin 200 mg/die or aza-
thioprin 100 mg/die). The patient was treated, as add-on therapy, with oma-
lizumab (300 mg s.c. every 2 weeks) accordingly to total IgE and weight
parameters reported in the drug information leaﬂet.
Results: After 6 months of treatment the patient reported a signiﬁcant
improvement in asthma control with 50% reduction of nocturnal awakenings
and asthma exacerbations and a major FEV1 improvement (101% at 16 weeks
and 103% at 24 weeks). Eosinophil count was reduced to 600/mL. A 75%
reduction of oral prednisone was registered after 8 weeks of treatment. Impor-
tantly, urticarial lesions disappeared after the ﬁrst injection of omalizumab.
Omalizumab injections were well tolerated and no adverse event was recorded.
Conclusions: This case suggests that omalizumab can be beneﬁcial and safe
in patients affected by CSS with severe asthma and urticarial vasculitis. In
addition to its effect on serum IgE, efﬁcacy of omalizumab in CSS may be
related to an inhibitory effect on blood eosinophilia.
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A 4-Year Follow-up in Children With Moderate/Severe Asthma
after Withdrawal 1 Year Omalizumab Treatment
Alvaro Teijeiro, MD,1 H. A. Badellino, MD,1 R. Maximiliano Gomez,1,2
Giorgio Walter Canonica, PhD,3 and Carlos E. Baena-Cagnani,MD1. 1Centro
de Investigación en Medicina Respiratoria, Faculty of Medicine. Catholic
University of Cordoba, Fundación LIBRA Argentina, Cordoba, Argentina;
2Allergy, Asthma and Immunology, ALAS Medical Institute, Salta, Argentina;
3Allergy & Respiratory Diseases, Universita Degli Studi Di Genova, Genova,
Italy.
Background: Asthma guidelines include omalizumab in the step up
management in those patients with severe non-controlled asthma despite
the use of the inhaled corticosteroids (ICS) at the highest dose recommended
and/or oral corticosteroids (OCS) courses. This communication describes the
4 year follow up of children with moderate/severe allergic asthma treated for
1 year with add-on omalizumab after discontinuation.
Methods: 7 children (6 to ,12 years) with moderate/severe uncontrolled
asthma following strict inclusion/exclusion criteria. The patients completed
a 1 year treatment with omalizumab according to the DBPC CIGE025 clinical
study protocol. Four years follow up after discontinuation of the study med-
ication was performed. It included clinical assessment, different asthma-re-
lated outcomes and lung function in outpatient hospital ofﬁce
Results: All patients that received xolair during the study period achieved
good asthma control and high dose ICS (mean dose ﬂuticasone 500 mcg)
were could be discontinued. Surprisingly, the 7 patients that received Xolair
for one year were completely free of asthma symptoms during the ﬁrst 3 years
of follow up. They did not use any additional asthma medication. After the
third year of follow up, only 2 out of 7 (28%) patients begun with persistent
asthma symptoms and exacerbations. These patients have required rescue
medication and then regular controller medication (budesonide 400 mcg). We
could not identiﬁed any risk factor helping in predicting those who had
symptoms relapsing. Lung function, number of exacerbation, number of
hospitalization, eosinophilia, IgE levels or previous treatments with OCS
Conclusions: Most of these patients 5 out of 7 still remain asymptomatic 4
years after discontinuation Xolair without regular ICS treatment. They are
still not using any controller medication only 2 patients had exacerbations and
at present show persistent mild asthma controlled with medium ICS therapy.
This follow up would generate the hypothesis that omalizumab could have
a potential as a modiﬁer of the natural history of asthma beyond the
improvement of symptoms control in children with moderate/severe un-
controlled asthma. Further studies are needed to test this hypothesis.
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Serum Soluble Trail Levels in Patients With Severe Persistent
Allergic Asthma: Its Relation to Omalizumab Treatment
Arzu Didem Yalcin, MD, Atil Bisgin, MD, PhD, Aysegul Kargi, MD, and
Reginald M. Gorczynski, MD, PhD. Allergology and Clinical Immunology
Unit, Antalya Education and Training Hospital, Antalya, Turkey; Human Gene
and Cell Therapy Center of Akdeniz University Hospital and Clinics, Antalya,
Turkey; Oncology Unit, Denizli Education and Training Hospital, Denizli,
Turkey; Division of Cellular & Molecular Biology, Toronto Hospital, Univer-
sity Health Network, Toronto, ON, Canada.
Background: The pathogenesis of allergic asthma and other allergic conditions
are believed to be closely interrelated because of the similar dynamics of
allergy-inducing cells and molecules, and the independent evidence for their
clinical overlap. In this study we compare the diseases and the effect of
Omalizumab treatment on the dynamics of cell apoptosis regulating molecules.
Methods: In the ﬁrst group, 6 males and 8 females (a total of 14 patients) were
selected with severe persistent asthma with a mean age of 42.4 years (Table I).
All patients received omalizumab therapy for 4 months, with treatment
administered every 2 weeks. Symptoms and severity of allergic reactions were
recorded before and after treatment with omalizumab. Clinical changes and
adverse effects were assessed and recorded at each patient visit. The second
group consisted of 14 newly diagnosed allergic asthma patients with mean age
was 43.8 years. All of these patients were followed up in the Immunology
Allergy Clinic of the Antalya Education and Training Hospital, and were
evaluated by clinical status. The third group consisted of 14 healthy volunteers,
with no difference in age and sex (mean age was 43,3 years. Serum sTRAIL
levels in all individuals (patients and healthy controls) were measured by
a sandwich enzyme-linked immunosorbent assay (Diaclone, France).
Results: There were no differences between the healthy controls, newly
diagnosed allergic asthma patients and non-treated severe persistent allergic
asthma patients during the active phase (P, 0.05). Interestingly, the variance
levels in patients who received omalizumab treatment were signiﬁcantly
lower than the healthy controls.
Conclusions: In summary, we speculate that the physiological functions of
sTRAIL in allergic conditions, and the elucidation of the molecular
mechanisms by which sTRAIL: TRAIL receptor signals cells, will be of
signiﬁcant interest to the scientiﬁc allergy community in the coming years.
Our study provides a novel perspective on severe persistent allergic asthma
and the effect of omalizumab treatment on cell apoptosis, using serum
sTRAIL measurements.
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Total Antioxidant Capacity, Hydrogen Peroxide,
Malondialdehyde and Total Nitric Oxide Concentrations in
Patients With Severe Persistent Allergic Asthma: Its Relation to
Omalizumab Treatment
Arzu Didem Yalcin, MD,1 Reginald M. Gorczynski, MD, PhD,2
Gizem Esra Parlak, MSc,3 Aysegul Kargi, MD,4 Atil Bisgin, MD, PhD,5
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Emel Sahin, PhD,3 Sukran Kose,6 and Saadet Gumuslu, PhD3. 1Allergology
and Clinical Immunology Unit, Antalya Education and Training Hospital,
Antalya, Turkey; 2Division of Cellular & Molecular Biology, Toronto Hos-
pital, University Health Network, Toronto, ON, Canada; 3Department of
Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey;
4Oncology Unit, Denizli Education and Training Hospital, Denizli, Turkey;
5Human Gene and Cell Therapy Center of Akdeniz University Hospital and
Clinics, Antalya, Turkey; 6Infectious Diseases and Clinical Microbiology,
Clinical Allergy and Immunology, Tepecik Educational and Research Hos-
pital, Izmir, Turkey.
Background: There is no data available to adequately explain the alterations
in total antioxidant capacity, hydrogen peroxide, malondialdehyde and total
nitric oxide concentrations in severe persistent asthma and newly diagnosed
allergic asthma patients. In the study below we have examined changes in
total antioxidant capacity, hydrogen peroxide, malondialdehyde and total
nitric oxide levels in severe persistent asthma and newly diagnosed allergic
asthma patients and the association(s) between these variables.
Methods: The ﬁrst group of patients included 6 male and 8 female subjects
with severe persistent asthma, having a mean age of 42.4 years. A second
group of subjects consisted of 14 newly diagnosed allergic asthma patients
with a mean age of 43.8 years. All patients were followed in our clinic, and
were evaluated by clinical status. A third group of 14 age-sex matched
healthy controls were also included. Serum samples were collected and stored
at –70 until use for the determination of total antioxidant capacity, hydrogen
peroxide, malondialdehyde and total nitric oxide concentrations. Serum IgE
levels, ANA, RF, hepatitis markers, C3, C4 and eosinophil levels were eval-
uated in all patients. All assays were carried out in duplicate.
Results: Total antioxidant capacity levels of Group IB, group II and group III
were lower than the IA group. Total antioxidant capacity levels of groups II and
III were higher than in group IB. Hydrogen peroxide concentrations in group IB
were lower than in group IA, while concentrations in group II were higher than
in group IB. The malondialdehyde concentration of group IB was lower than in
all other groups. The malondialdehyde concentration of group III was higher
than all other groups. The malondialdehyde concentration of group II was lower
than in group III. The total nitric oxide level of group IB was lower than all
other groups. The total nitric oxide level of group III was higher than all other
groups, while that of group II was higher than for both groups IA/IB.
Conclusions: To monitor the omalizumab treatment efﬁcacy in the severe
allergic asthma patients; total antioxidant capacity, hydrogen peroxide,
malondialdehyde and total nitric oxide concentrations might be new markers.
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Near-Fatal Asthma Treated with Omalizumab
Elvia Angelica Contreras Contreras,1 María Elena Ramírez Del Pozo, MD,2
Javier Gomez Vera, MD,2 and Jesus Lopez Tiro, MD2. 1Alergia e Inmuno-
logia clinica, ISSSTE, Ciudad de México, Mexico; 2Alergia e inmunologia,
Hospital Regional "Lic. Adolfo López Mateos" ISSSTE, Distrito Federal,
Mexico.
Background: Near-fatal asthma treated with Omalizumab. The near-fatal
asthma is a severe form of asthma that threatens the life of patients and is
associated with poorly controlled chronic asthma, accounting for limitations
in the quality of life. Presents with ongoing chronic inﬂammation and
irreversible changes in the airway. Treatment is difﬁcult, however with the
use of omalizumab can decrease the risk of mortality in these patients.
Objective: Evaluating clinical improvement, spirometric and income to the
emergency hospitalization and intensive care unit, as well as near-fatal asthma
episodes in patients with uncontrolled asthma in treatment with con
Omalizumab.
Methods: We evaluated 4 patients with poorly controlled asthma and near-
fatal episodes of asthma who were administered doses of omalizumab and
IgE established according to weight, evaluating clinical, spirometric well as
income to the emergency room and hospital intensive care unit.
Results: There was a signiﬁcant clinical improvement in 4 patients after
treatment with omalizumab with improved daytime symptoms by 75% and
68% nocturnal P # 0.001, as well as 100% improvement in revenue and
hospitalizations to ﬂoor, well as income to the ICU with P # 0.001. No
further episodes of near-fatal asthma. In addition to decreased use of systemic
steroids 90% (P 0.003) and inhaled steroids 60% (P 0.005).
Conclusions: Omalizumab is a good treatment option in patients with poorly
controlled asthma with near-fatal asthma episodes.
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Use of Omalizumab in Chronic Moderate to Severe Persistent
Asthma-an Indian Experience
Qamar Ansari, MBBS, DTCD, FAMS, FCCP, and Chest Diseases, Apollo
Hospitals, Hyderabad, India.
Background: The worldwide prevalence of asthma is high and increasing. In
India prevalence of asthma is variable from 4% to 20%. Despite ICS plus
LABA therapy 72% of asthma patients were uncontrolled or not well controlled
in INSPIRE study. Immunoglobulin-E plays a central role in inﬂammatory
cascade. To study the efﬁcacy of omalizumab in Indian patients with moderate
to severe persistent asthma in terms of quality of life (QOL) improvement,
reduction in severe exacerbation, ED visits and loss of working days.
Methods: 52 patients aged from 121 years to 86 years (23.3 % females, avg
age: 33.6, avg S.IgE: 283) fulﬁlling omalizumab indication criteria were
given 150 mg subcutaneously once in 2 or 4 weeks for 16 to 24 weeks during
March 2007 till date. QOL assessment 52 weeks after treatment in terms of
following parameters were studied: Asthma symptoms (Cough, wheezing,
tightness in the chest) Night Symptoms (frequent awakening, sleep disturban-
ces) Rescue medication use Loss of working days/school days Emergency
visits.
Results: 94% of patients were able to reduce or discontinue regular OCS use.
72% reduction in exacerbations, 76% reductions in emergency visits ICS/
LABA dose was maintained/reduced inw 93 % patients. –54% improvement
in working/school days in the age group of 12 to 40 years. 60% improvement
in uninterrupted sleep hours best improvement in QOL was observed in 12 to
40 years age group.
Conclusions: Omalizumab is well tolerated and effective as an add-on
therapy in patients of moderate to severe persistent Asthma and offers
a therapeutic and economic beneﬁt to patient. Its potential as disease modiﬁer
and early intervention in treatment guidelines needs further studies.
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Use of Monoclonal Antibody Omalizumab in the Treatment of
Urticaria Chronic
Jorge Vargas Correa, MD. Internal Medicine, H. R. Merida Issste, Merida,
Yucatan, Mexico.
Background: The chronic Urticaria is a real problem of health and a frequent
problem in the consultation of the allergist, which the treatment is not to
satisfactory. Some Urticaria can be for autoimmunity where the antibody
involved is IgE. Omalizumab is an monoclonal antibody against the C3
domain of the epsilon heavy chain of the antibody IgE (domain C3 of the
IgE), involved, in allergic problems, which has proved a great utility in
asthma off difﬁcult control.
Method: Five patients of both genders were studied aged between 30 and 45
years, carriers of chronic Urticaria at least of ten years duration. Theirs control
was not satisfactory, with the treatment habitual. They were not used
glucocorticoids. The clinical evaluation and test of laboratory stated Chronic
Urticaria idiopathic. The total IgE was below 100 U. I. The monoclonal
antibody Omalizumab applying it for 6 month accorded to habitual schedule.
According to dose schedule monoclonal antibody Omalizumab apply the
antibody to them, calculating the dose habitual schedule applying for 6
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month. According to dose schedule the monoclonal antibody Omalizumab
apply to them, it applying for 6 month.
Results: All the patient improved their Urticaria between weeks 3 and fort of
application of the drug, getting the control of the symptoms between the
month 2 and 3 in the 5 patients, without requiring other drugs for their
control, and remained asymptomatic for 3 and forth months discontinuity the
product up to 6 months, not reactivity the Urticaria, the older case takes now 1
year without activity of his disease.
Conclusions: Omalizumab must be considered to be another therapeutic
alternative in patients with idiopathic Urticaria.
ASPIRIN-EXACERBATED RESPIRATORY DISEASE
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Successful Treatment of Severe Nonallergic Asthma by
Omalizumab. An Observation
Karl-Christian Bergmann, MD,1 and Torsten Zuberbier, MD2. 1aAllergy-Cen-
tre-Charité, Charité Universitätsmedizin Berlin, Berlin, Germany; 2Clinic for
Dermatology, Venereology and Allergology, Charité–Universitätsmedizin
Berlin, Berlin, Germany.
Background: Omalizumab (Oma) is used in Europe for treatment of severe
allergic asthma we describe the use of anti-IgE for severe nonallergic aspirin-
induced asthma.
Methods: A non-smoking woman with negative family anamnesis, negative
skin prick test (28 allergens), no speciﬁc IgE antibody and IgE of 107 kU/l
developed a chronic rhinitis with anosmia, sinusitis and severe asthma at the
age of 31 years. She suffers from nasal polyps (7 operations) and intolerance
to aspirin and ibuprofen as well as alcohol; both leading to severe
breathlessness. She was treated over years without success with oral steroids,
ICS, LABA’s and montelukast. The asthma was not under control and un-
stable. Therefore, we decided to try Oma as an additional medication. Since
25.08.2010 she is receiving 150 mg Oma/month without any change in other
medication. After only 2 months she reported a remarkable reduction in their
bronchial and nasal symptoms including improved smell and that she can
drink small amounts of alcohol and also stands aspirin. We performed appro-
priate provocation tests to prove this observation.
Results: The FEV1 increased from 1.4 L on the 25.08.2010 to 2.4 L after only
2 months of treatment with Oma and was stable at this normal level for the next
12 months (till October 2011). The severity of symptoms (night and day) were
dramatic reduced and the quality of life increased signiﬁcantly (asthma-control-
test normalized from 11 to 21 points). A double-blind placebo-controlled
(DBPC) test with 125, 250, and 500 mg aspirin (cumulative dose 875 mg) was
negative (all-day well-being, no changes in lung function). The DBPC-test with
3 doses of alcohol (sum of 10 g) was also negative.
Conclusions: A severe, difﬁcult-to treat nonallergic asthma with nasal
polyposis, ASS, and alcohol-intolerance (Samter’s syndrom) was successfully
treated with additionally given Oma. The injection of 150 mg Oma per month
induced a clearly improved quality of life, “an asthma under control”, im-
proved the lung function with respect to FEV1 and leads to an unexpected
tolerance against ASS and alcohol. To our knowledge this is the ﬁrst reported
observation on successful treatment of a Samter’s syndrome using Oma.
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Relationship between Aeroallergen Sensitization and Asthma
Severity in Patients with Aspirin-Exacerbated
Respiratory Disease
Chihiro Mitsui, MD,1 Masami Taniguchi, MD, PhD,2 Noritaka Higashi, MD,
PhD,3 Emiko Ono, MD, PhD,3 Keiichi Kajiwara,3 Hidenori Tanimoto, MD,3
Kentaro Takahashi,MD, PhD,2 Chiyako Oshikata,MD,2 Kiyoshi Sekiya,MD,3
Takahiro Tsuburai, PhD,3 Naomi Tsuirikisawa, PhD,2 Kenji Minoguchi, PhD,2
Akio Mori, PhD,3 Maki Hasegawa,3 Kazuo Akiyama, MD,3
and Yuma Fukutomi, MD2. 1Clinical Research Center for Allergy and Rheu-
matology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan;
2Sagamihara National Hospital, Sagamihara, Kanagawa, Japan; 3Clinical Re-
search Center for Allergy and Rheumatology, National Hospital Organization
Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
Background: The pathogenesis of aspirin-exacerbated respiratory disease
(AERD) is presumed to involve the aspirin/non steroidal anti-inﬂammatory
drug (NSAID)-induced abnormal metabolism of arachidonic acid, resulting in
the production of 5-lipoxygenase metabolites, particularly leukotriene C4.
Aspirin intolerance occurs around the same time as asthma onset, and a few of
the patients with AERD had suffered from pediatric asthma. Although atopy
is not associated with the pathogenesis of AERD, some of the patients with
AERD have aeroallergen sensitization. There are few studies in which the
association between the pathogenesis of AERD and atopy has been clariﬁed.
Methods: Ninety AERD patients, whose aspirin sensitivity was determined
by the aspirin challenge test, and 100 aspirin-tolerant asthma (ATA) patients,
whose age and sex were adjusted, participated in this study. Atopy was
deﬁned as a positive reaction in an intradermal test to one or more of 19
common aeroallergens, or a positive reaction above class one in Immuno
CAP RAST. We analyzed the relationships between aeroallergen sensitiza-
tion and clinical settings of AERD patients.
Results: The atopic and non atopic AERD groups showed median serum total
IgE concentrations of 464 and 130 IU/l (P value ¼ 0.004), respectively. The
asthma of atopic patients with AERD was milder than that of non atopic
patients with AERD. (P value ¼ 0.05) The Lund-Mackay score of atopic
patients with AERD was lower than that of non atopic patients with AERD.
(P value ¼ 0.02)
Conclusions: Two-thirds of the patients with AERD showed aeroallergen
sensitization. The asthma and sinusitis in atopic patients with AERD were
signiﬁcantly milder than those in non atopic patients with AERD. Aero-
allergen sensitization might prevent the worsening of asthma in patients with
AERD.
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Persistence of Nasal and Bronchial Symptoms in Patients with
Samter’s Syndrome with Treatment Medical and Surgical in a 2
Year Period
Hugo Alberto Azuara Trujillo, MD,1 and Jose Ruben Velez Martinez, PhD2.
1Allergy and Clinical Immunology, Mexican Social Security Institute, Gen-
eral Hospital, 2, IMSS, Hermosillo Sonora, Mexico; 2Health investigator,
Medical Family Unit 37, IMSS, Hermosillo Sonora, Mexico.
Background: Know the causes of nasal and bronchial symptoms persistence
in patients with Samter’s syndrome under treatment in a period of time.
Methods: Cohort study. Inclusion criteria: Patients with asthma diagnoses,
hypersensitivity to aspirin and nasal polyps. Exclusion criteria: Other kind of
asthma, COPD. Twelve patients were followed from June 2009 to June 2011.
Nasal and bronchial symptoms were assessed every 6 months using the
Visual Analogue Scale of severity (VAS) from EPOS guidelines and
spirometry from GINA. All were treated with intranasal mometasone furoate
200 mcg at day, montelukast 10 mg at day, salmeterol plus ﬂuticasone 50/100
powder 2 inhalation every 12 hours, ﬂuticasone spray 150 mg every 12 hours,
loratadine tablet 10 mg if was necessary, with modiﬁcations of doses every 3
months.Patients diagnosed at 6 months with sinusitis and nasal polyposis
were administered amoxicillin plus clavulanate 1.5 g daily for 5 weeks. The
patients without response at 6 and 18 months were prescribed clarithromycin
400 mg daily for 4 weeks. All patients underwent CT of the sinuses through
the Lund-Mackay system, chest CT scan, skin prick test. Evaluated by
otolaryngology at the 6, 12, and 18 months.
Results: In the 98, 2% had negative skin prick tests. At 6 months, 58.3% had
nasal symptoms with VAS ,7. At 33.3% reported bronchial relapses with
FEV1 ,80. At year nasal symptoms increased, with WAS. 7 in 66.6%. The
bronchial relapse decreased to 16.6%. At year and a half it increased nasal
Abstracts WAO Journal  February 2012
S92  2012 World Allergy Organization
symptoms in 75% of patients, with VAS. 7. At 41.6% had obstruction of
100% and pansinusitis. They needed antibiotic scheme. At 2 years in 83.3%
had a VAS.7. At 58.3% had pansinusitis. The bronchial relapse did not
increase. We determined the presence of VAS. 7 and pansinusitis (OR ¼
4). The bronchial relapse did not inﬂuence with increasing VAS (OR ¼ 1).
Conclusions: Nasal symptoms persistent were secondary to the nasal polyps
and pansinusitis with higher levels of VAS. It was determinated a 4-fold risk
over pansinusitis with a VAS. 7 (OR ¼ 4). It should be stressed the palli-
ative surgical treatment in earlier stages and desensitization protocols.
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Clinics andLaboratoryCharacteristics ofAsthmatic Patientswith
Aspirin Exacerbated Respiratory Disease (AERD)
Marice Guterrez Roso,MD, Giordana Portela Lima,MD, Jorge Kalil, MD, PhD,
Pedro Giavina-Bianchi, MD, PhD, and Rosana Camara Agondi, MD, PhD.
Clinical Immunology and Allergy, Sao Paulo University, São Paulo, Brazil.
Background: Clinics and laboratory characteristics of asthmatic patients with
aspirin exacerbated respiratory disease (AERD): asthma, polyposis and
aspirin hypersensitivity.
Methods: Asthmatic patients with AERD history were evaluated. They were
evaluated about asthma severity, rhinitis severity, history of polypectomy,
and atopy. Some complementary exams were performed: total and speciﬁc
IgE, serum eosinophilia, spirometry and nasal ﬁbroscopy.
Results: Forty-seven patients concluded the study. The mean age of the patients
was 53.1 years old and eighty-ﬁve percent were women. All patients had nasal
polyposis and 23 patients (49%) had performed polypectomy. Thirty-nine patients
(83%) had moderate/ severe persistent rhinitis and thirty-6 patients (77%) had
moderate or severe persistent asthma and all of them were in inhaled corticosteroid
treatment. The spirometry was classiﬁed as mild obstructive ventilatory disturbed
(FEV1 3 60%) in 31 patients (66%). The mean value of total IgE was 427 IU/mL.
The mean number of eosinophils was 477 cell/mm3. The speciﬁc IgE to inhaled
allergens was present in 22 patients (47%), who also had family history of atopy.
Conclusions: AERD is clinic syndrome related to chronic and severe in-
ﬂammation of superior and inferior respiratory tracts, and is complicated with
chronic rhino sinusitis, recurrent polyposis and asthma. In this study, thirty-six
patients (77%) had history of rhino sinusitis and 50% had moderate and severe
asthma. Atopy was conﬁrmed in 47% of the patients. Polypectomy was performed
as therapeutic treatment in 23 patients (49%). The prevalence of AERD in
asthmatic patients is around 40%, and therefore, an early diagnosis is essential.
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Association Analysis of Member RAS Oncogene Family Gene
Polymorphisms with Aspirin Intolerance in Asthmatic Patients
Myung ok Kim,1 Choon-Sik Park,2 and Tae-Hoon Kim3. 1Genome research
center for allergy and respiratory disease, buchun, South Korea; 2Respira-
tory and allergy, Soonchunhyang University Bucheon Hospital, Bucheon,
South Korea; 3Soonchunhyang University Hospital Genome Research Center
for Allergy and Respiratory Disease, Bucheon, South Korea.
Background: Member RAS oncogene family (RAB1A) converts small G
protein to rab1 protein, a inﬂammation of blood eosinophils. Thus, functional
alterations of the RAB1A gene may contribute to Aspirin exacerbated respi-
ratory disease (AERD).
Methods: Asthmatics (n ¼ 1277) were categorized into Aspirin exacerbated
respiratory disease (AERD) and aspirin-tolerant asthma (ATA). 8 SNPs were
genotyped. Messenger RNA expression of the RAB1A gene by peripheral
blood mononuclear cell is measured by Real time PCR and reverse transcrip-
tase polymerase chain reaction (RT-PCR). Human PBMC culture supernatant
expression of 11-dehydrothromboxane B2. Protein expression of the RAB1A
gene by PBMC is measured by RNAi (Knock down) analysis.
Results: The logistic regression analysis showed that the rare allele frequency of
141170 C.G on intron 5 was signiﬁcantly lower in the AERD group (n¼ 261)
than in the ATA group (n ¼ 1016) (P ¼ 0.002). The linear regression analysis
revealed a strong association of 141170 C.G with the aspirin challenge in-
duced-FEV1 fall (P ¼ 0.00008). RT-PCR and real time PCR revealed an exon-
4-deleted variants. The level of full-length RAB1A mRNA did not differ, but the
variants was signiﬁcantly higher in 141170 G homozygotes than in 141170 C
homozygotes (P ¼ 0.002). Intron based PCR was was used to amplify transcripts
of PBMC pre-mRNA in which intron-5 had been removed (mRNA) while an-
other set of primers was used to amplify intron 5-containing pre-transcripts (pre-
mRNA). Knock down analysis of RAB1A Transcripts level in hPBMC. Throm-
boxane B2 were increased in the siRNA treated when compared those of scramble
and control. After knock down analysis, the levels of thromboxane B2 were
signiﬁcantly decreased in PBMC culture supernatant.
Conclusions: The rare allele of 141170 C.G may play a protective role
against aspirin hypersensitivity via a lower catalytic activity of the RAB1A
gene attributed to the increase of a non-functioning variants of RAB1A.
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Nasal Nitric Oxide Levels after Lysine Aspirin Nasal Challenge in
Subjects with Aspirin Induced Asthma
Damian Tworek, MD, PhD,1 Malgorzata Bochenska-Marciniak, MD, PhD,2
Izabela Kuprys-Lipinska, MD, PhD,1 Wioletta Pietruszewska, MD, PhD,3
Ewa Zielinska-Wyderkiewicz, MD, PhD,2 and Piotr Kuna, MD, PhD1. 1De-
partment of Internal Medicine, Asthma and Allergy, Barlicki University Hos-
pital, Lodz, Poland; 2Department of Pneumonology and Allergy, Barlicki
University Hospital, Lodz, Poland; 3Department of Otolaryngology, Barlicki
University Hospital, Lodz, Poland.
Background: Changes in nasal nitric oxide (nNO) levels after nasal lysine
aspirin (lys-ASA) challenge have not been determined.
Methods: Fourteen patients with aspirin induced asthma (AIA) with or
without nasal polyps with aspirin were included to the study. Hypersensitivity
had to be conﬁrmed by positive result of oral aspirin challenge Ten healthy
subjects served as the control group. 12 mg of lys-ASA were applied
unilaterally. Nasal symptoms were assessed using visual analogue scale
(VAS) and nNO and peak nasal inspiratory ﬂow (PNIF) measurements were
performed before and 1, 2, 4 and 24 hours after the challenge. The result of
the challenge was considered as positive when at least 20% fall of PNIF as
well as 20% increase of total VAS score were observed.
Results: Ten patients (71.4%) had clinically positive result of the challenge. We
observed signiﬁcant fall in nNO levels in AIA patients after 1 and 2 hours after the
challenge (653. 1 6 420. 2 at baseline versus 490. 3 6 456. 0; P ¼ 0.0029 and
439. 9 6 556. 4 ppb; P ¼ 0.0076; respectively). The decrease in nNO level
was more pronounced in patients with clinically positive result of the challenge
(510. 16 212. 5 at baseline versus 283. 36 173. 4; P ¼ 0.005; 159, 66 166,1;
P ¼ 0.005 and 331. 0 6 312.0 ppb; P ¼ 0.037 after 1, 2 and 3 hours, respec-
tively). In 4 subjects with clinically negative result of the challenge we noticed
a trend towards higher nNO concentrations after lys-ASA challenge (1010. 8 6
625. 2 at baseline vs 1341. 36 670. 5 ppb after 4 hours). No signiﬁcant changes
in nNO levels after the challenge were observed in healthy controls.
Conclusions: NO levels decrease after lys-ASA nasal challenge in subjects
with AIA and clinically positive nasal provocation. An unexpected trend
towards increase in nNO levels was observed in subjects with AIA and
clinically negative provocation Potential usefulness of nNO measurement in
aspirin nasal provocation needs further evaluation.
288
IL1B but not IL8 Polymorphisms Are Increased in Aspirin
Exacerbated Respiratory Disease Patients Versus Aspirin
Tolerant Asthmatics
Fernando Gandhi Pavon Romero,MD,1 Ramcés Falfán-Valencia, PhD, HLA,2
Angel Camarena, MSc, HLA,3 Ma de la Luz Garcia Cruz, MD,4 and
Luis Manuel Terán-Juarez, PhD1. 1Allergy, National Institute of Respiratory
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Disease, Mexico City, Mexico; 2Laboratory, National Institue of Respiratory
Disease, Mexico City, Mexico; 3National Institue of Respiratory Disease,
Mexico City, Mexico; 4Clinical Immunology and Allergy, National Institute
of Respiratory Disease, Distrito Federal, Mexico.
Background: Aspirin exacerbated respiratory disease (AERD) is a syndrome
characterized by chronic hyperplastic rhinosinusitis, nasal polyposis, asthma
and aspirin sensitivity. The mechanisms by which produce these manifes-
tations of intolerance are not fully deﬁned, the current research involve
alterations in the metabolism of arachidonic acid, cyclooxygenase 1 (COX-1)
inhibition and its deviation from substrate to the lipoxygenase (LO) pathway,
inducing increased synthesis of leukotrienes (LT). Biological plausibility of
this fact has led to the search for polymorphisms in genes responsible for LT
synthesis however others factors such as genetics polymorphisms in pro-
inﬂammatory cytokines like, IL1B and IL8 could be associated.
Methods: 78 patients with AERD, 135 aspirin-tolerant asthma (ATA) and
134 healthy control subjects participated. All participants who underwent
a simple spirometry, methacholine challenge and nasal challenge with
Lysine-aspirin (L-ASA), both tests performed according to international
guidelines. Peripheral blood was drawn by venipuncture, genomic DNA was
obtained using the commercial BDtract DNA isolation kit. We selected 2
polymorphisms in 2 genes related to chronic inﬂammation rs16944 in IL1B,
and rs4073 in IL8, Allelic discrimination of SNPs was performed by Real
Time PCR (PCR-RT) on a 7300 Real Time PCR Systems. Statistical analysis
was performed between groups of cases (AERD and ATA) versus control
group with Epi-info v.6.04 by x2 test to identify the difference between the
allele and genotype frequencies of each polymorphism made, considering
a signiﬁcant P value ,0.05, in addition to the calculation of odds ratios
and conﬁdence intervals of 95%.
Results: We ﬁnd no association between IL1B (rs16944) to GG and GA
genotypes in ATA patients versus control group neither AERD versus control
group. Interestingly, the AA genotype showed increased frequency in the
AERD patients versus the ATA patients (FG ¼ 0.19 versus 0.07), this asso-
ciation remained signiﬁcant (P ¼ 0.018, OR 2.98, CI, 1.17-7.82).
Conclusions: This is the ﬁrst observation that IL1B polymorphisms are
involved in AERD, suggest that patients carrying out the IL1B-511 polymor-
phism (rs16944 AA genotype) may show enhanced susceptibility to develop
AERD.
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Fatty Acid Binding Protein 1 is Related with Development of
Aspirin-Exacerbated Respiratory Disease
Tae-Hoon Kim,1 and Choon-Sik Park2. 1Soonchunhyang University Hospital
Genome Research Center for Allergy and Respiratory Disease, Bucheon,
South Korea; 2Respiratory and allergy, Soonchunhyang University Bucheon
Hospital, Bucheon, South Korea.
Background: Aspirin-exacerbated respiratory disease (AERD) refers to the
development of bronchoconstriction in asthmatics following the ingestion of
aspirin. Although alterations in eicosanoid metabolites play a role in AERD,
other immune or inﬂammatory mechanisms may be involved. We aimed to
identify proteins that were differentially expressed in nasal polyps between
patients with AERD and aspirin-tolerant asthma (ATA).
Methods: Two-dimensional electrophoresis was adopted for differential
display proteomics. Proteins were identiﬁed by liquid chromatography-
tandem mass spectrometry (LC-MS). Western blotting and immunohisto-
chemical staining were performed to compare the amount of fatty acid-
binding protein 1(FABP1) in the nasal polyps of patients with AERD and
ATA.
Results: Fifteen proteins were signiﬁcantly up-(7 spots) or down-regulated in
the nasal polyps of patients with AERD (n ¼ 5) compared to those with ATA
(n ¼ 8). LC-MS revealed an increase in 7 proteins expression and a decrease
in 8 proteins expression in patients with AERD compared to those with ATA
(P ¼ 0.003-0.045). FABP1-expression based on immunoblotting and immu-
nohistochemical analysis was signiﬁcantly higher in the nasal polyps of
patients with AERD compared to that in patients with ATA. FABP1 was
observed in epithelial, eosinophils, macrophages, and the smooth-muscle
cells of blood vessels in the polyps.
Conclusions: Our results indicate that alterations in 15 proteins, including
FABP1, may be related to the development of AERD.
ASTHMA
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The Correlation of Cholesterol Lowering Statin Drugs and
Worsening Asthma Control in Mild Persistent Asthmatics
Safa Nsouli, MD. Senior Clinical Research Associate Asthma And Allergy,
Danville Asthma And Allergy Clinic, USA, Danville, CA.
Background: To show that pharmacological agent statins use, adversely alter
the immunomodulatory activities that promote the worsening of the clinical
course of allergic diseases such as asthma.
Methods: Two groups of 20 asthmatics patients each were compared from
baseline values. Twenty patients with extrinsic asthma (group A) were
prescribed statins for their lowering of their cholesterol necessity, and 20
patients (group B) were controls who did not receive statins. Group A and
group B were designed to compare FEV1, exacerbation asthma rates, beta
agonists use, nocturnal awakenings, and daytime symptoms from baseline
values.
Results: Statins treated asthmatic patients group A had signiﬁcant worsening
of FEV1 at 3 months, 6 months and 12 months, to almost no change in
control asthmatic patients group B. Statins treatment patients group A were
associated with more frequent use of rescue medication (albuterol inhaler),
increased nocturnal awakenings, and increased daytime asthma symptoms,
compared to group B.
Conclusions: Statin drugs may worsen asthma control in mild persistent
asthmatics. Statins may cause possible immune alteration that promotes
allergic diseases such as asthma.
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Studies on the Relationship between Airway Inﬂammatory
Responses in Patients With Asthma or Not-yet Onset Asthma and
Air Pollution
Mariko Yamaura, MD,1 Toshiyuki Kogane, MD,1 Hikari Koyama, MD,1
Oji Obayashi, MD,1 and Hajime Takizawa, MD, PhD2. 1The Fourth Depart-
ment of Internal Medicine, Teikyo University School of Medicine, Mizonoku-
chi Hospital, Kawasaki, Japan; 2Department of Respiratory Medicine,
Kyorin University School of Medicine, Mitaka, Japan.
Background: Substantial data have demonstrated that air pollution is
associated with cardiopulmonary mortality and morbidity in the world.
Among a variety of pollutants, particulate components, particularly PM2.5,
are especially suggested to be harmful to our lung health. Diesel exhaust
particles (DEPs) are the major component of PM2.5, and therefore the
relationship between PM2.5 or PM10 and airway inﬂammatory responses of
asthmatic and people of not-yet asthma onset is important to be investigated.
Recent ﬁndings suggested that susceptibility to DEPs is dependent upon
certain genetic variations of anti-oxidative stress enzymes such as GSTP1,
which is largely regulated by a transcription factor Nrf2. By preliminary
experiments, we found that exhaled breath condensates (EBC) are safely and
repeatedly obtained from both disease and health persons, and that several
biomarkers including growth factors, cytokines and oxidant stress markers
could be measured.
Methods: In the present study, we attempted to study the airway in-
ﬂammatory/ﬁbrogenic responses from patients with asthma, and further, those
from people who have suggestive, but not yet deﬁnite symptoms of asthma.
Participants are asked to present exhaled breath condensates (EBC) by
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R-tubes during spontaneous breathing for 5 minutes, which are processed to
measure several inﬂammatory/ﬁbrogenic markers.
Results: These molecules, including vascular endothelial growth factor
(VEGF), hepatocyte growth factor (HGF), basic ﬁbroblast growth factor
(FGF), IL-1 receptor antagonist, IL-8 and epidermal growth factor (EGF)
tended to be increased in asthmatic group. These markers were signiﬁcantly
increased in severity step 4 patients as compared to mild asthmatics. There was
a signiﬁcant correlation between the PM10 concentration 1 month before the
sampling of EBC and EBC EGF concentration. NO2 concentration and several
markers in EBC in patients with asthma correlated with each other. EBC pH
showed a signiﬁcant relationship with the distance from main trafﬁc roads.
Conclusions: These results suggested that mass screening using simple
methods such as EBC and appropriate biomarkers might facilitate the
progress in the prophylaxis against hazardous health effects of DE exposures
in subjects with high susceptibility to DEPs.
This work was supported in part by a grant from Environmental Restoration
and Conservation Agency of Japan.
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The Relationship Between Maternal Atopy and
Childhood Asthma
Salome Abbott, MD, and Robin Green, PhD. Department of Paediatrics,
University of Pretoria, Pretoria, South Africa.
Background: The diagnostic difﬁculty of childhood asthma leads to
widespread under-diagnosis, which negatively affects the quality of life of
asthmatic children. The presence of atopy in children is often used as
a clinical tool to assist in making the diagnosis. However, local studies have
demonstrated that atopy occurs in fewer asthmatic children than previously
thought. This brings into question the association between allergy and
asthma. The purpose of this study was to determine if a family history of
allergy is predictive of atopic asthma in children, by comparing allergy,
history of asthma and allergic symptoms, in mothers of atopic versus non-
atopic asthmatic children.
Methods: A random sample of children and their mothers attending the
Children’s Chest and Allergy Clinic at Steve Biko Academic Hospital were
enrolled. Skin-prick testing or radioallergosorbent test results, of the children
were obtained from the child’s hospital records. Mothers completed a detailed
questionnaire which included demographic details, a history of symptoms
suggestive of ‘atopy’ and allergic diseases and a history of asthma. Skin prick
testing was performed on the mothers.
Results: 100 children and their parents were enrolled. 64 mothers to atopic
children were used as the study group and 36 mothers to non-atopic children
were used as the control group. Of the 48 mothers with a positive skin prick
test, 30 (64%) had atopic children (P ¼ 0.836). Of the 16 mothers with
asthma, 14 (88%) had atopic children (P ¼ 0.045). Of the 70 mothers with
a history of symptoms suggestive of an allergic disease, 45 (64%) had chil-
dren with atopic asthma (P ¼ 1.0). Of the 77 mothers who were considered to
be allergic, 50 (65%) had children with atopic asthma (P ¼ 0.806).
Conclusions: Both maternal skin prick positivity and a history of symptoms
suggestive of allergic disease, are poor predictors of atopic asthma in children.
This is true even in the mothers were considered to be allergic. However
maternal asthma is a speciﬁc predictor of childhood atopic asthma with a good
positive predictive and a high odds ratio. Further studies need to be conducted to
compare the epidemiology of allergic asthma in different population groups.
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Sensitization of Severe Allergic Asthma Patients
Priscila Takejima,1 Jorge Kalil, MD, PhD,2 Rosana Camara Agondi, MD,
PhD,2 and Pedro Giavina-Bianchi, MD, PhD2. 1Division of Clinical Immunol-
ogy and Allergy of University of São Paulo Medical School, Sao Paulo, Brazil;
2Clinical Immunolgy and Allergy, Sao Paulo University, Sao Paulo, Brazil.
Background: The prevalence of asthma is high, the worldwide average being
estimated at 10%, which makes it a public health problem. Many studies
show a clear relationship between asthma and speciﬁc allergens. With
sensitization to aeroallergens identiﬁed as a dominant risk factor for asthma.
Objective: The present study of asthma reports the allergic sensitization of
patients with severe persistent asthma followed in the Division of Clinical
Immunology and Allergy of University of São Paulo Medical School.
Methods: A total of 61 patients with severe persistent asthma deﬁned
according to the criteria of the Global Initiative for Asthma (GINA) were
enrolled. Total IgE levels (IU/mL) were measured in serum and levels up to 120
IU/mL were considered within normal range. A battery of 7 aeroantigens
(Dermatophagoides pteronyssinus, Blomia tropicalis, Aspergillus fumigatus,
Penicillium nonatum, Lolium perenne, Felis domesticus, Canis familiaris, Bla-
tela germanica and Periplaneta americana) was used in skin prick tests (SPTs),
which were performed in each subject, on the volar side of the forearm. His-
tamine hydrochloride and normal saline solutions were used as positive and
negative controls, respectively. The SPTs were read after 15 minutes and,
a wheal at least 3 mm greater than the negative control was considered positive.
Results: The asthmatic patients had a mean age of 48 years and 75% were
female. We found that mean total serum IgE levels were 518.4 IU/mL (be-
tween 17 and 4720 UI/mL). SPTs positivity was 91.8% for D pteronyssinus,
67.2% for Blomia tropicalis, 4.9% for P nonatum and A fumigatus, 6.5% L
perene and Felis domesticus, 16.3% for Canis familiaris, 21.3% Blatela
germanica, 13.1% for Periplaneta americana. Twelve patients were mono-
sensitized and 23 patients were polysensitized to 3 or more allergens.
Conclusions: Most patients with severe allergic asthma were polysensitized,
and dust mites, followed by cockroaches, were the main allergens.
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ReferenceValues and Inﬂuencing Factors of ExhaledNitric Oxide
in Healthy Korean Adults
Min-Suk Yang, MD,1 Yoon-Jung Kim, MD,1 Woo-Jung Song,1 Min-
Hye Kim,1 Gyu-Young Hur,2 Tae-Bum Kim, MD, PhD,3 Sang-Heon Kim,
MD,4 Hae-Sim Park, MD, PhD,5 Young Joo Cho,6 Suk-Il Chang, MD,7
Tae-Wan Kim,1 Sae-Hoon Kim,8 Hye-Ryun Kang,1 Heung-Woo Park,1 Sun-
Sin Kim,1 Yoon-Seok Chang, MD, PhD,8 Sang-Heon Cho,1 Kyung-Up Min,
1 and You-Young Kim, MD, PhD9. 1Department of Internal Medicine, Seoul
National University College of Medicine, Seoul, South Korea; 2Internal Med-
icine, Korea University College of Medicine, Seoul, South Korea; 3Depart-
ment of Allergy and Clinical Immunology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, South Korea; 4Department of Internal
Medicine, Hanyang University College of Medicine, Seoul, South Korea;
5Department of Allergy & Clincal Immunology, Ajou University School of
Medicine, Suwon-si, South Korea; 6Allergy and Clinical Immunology, Inter-
nal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South
Korea; 7Department of Internal Medicine, Sungae General Hospital, Seoul,
South Korea; 8Department of Internal Medicine, Seoul National University
Bundang Hospital, Seongnam, South Korea; 9Department of Internal medi-
cine, division of allergy and clinical immunology, National Medical Center,
Seoul, South Korea.
Background: Fractional exhaled nitric oxide (FeNO) is widely used as an
inﬂammatory marker for asthma. However, reference values and inﬂuencing
factors of FeNO using Niox Mino, which is the only device achieving US
FDA approval, are not well described in healthy Asian adults. This study
aimed to suggest the reference values and inﬂuencing factors of FeNO in
healthy Korean adults.
Methods: Subjects who were over 19 years old and did not have any history
of rhinitis, asthma or recent respiratory symptoms were enrolled. FeNO levels
were measured using Niox Mino. Age, gender, body mass index (BMI),
smoking status and lung function were also measured to analyze factors
associated with FeNO levels.
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Results: The mean value of FeNO was 16.14 6 10.04 ppb. The reference
value of FeNO, which was deﬁned as the value of 95% in distribution curve,
was same or less than 34 ppb. In a univariate analysis, FeNO levels were not
associated with age, BMI and smoking history. However, atopy status (18.2
6 11.8 for atopy and 15.16 8.5 for nonatopy groups, P ¼ 0.008) and gender
(17.8 6 10.2 for male and 14.8 6 9.8 for female groups, P , 0.001) were
positively associated with FeNO levels. In stratiﬁed analysis, the signiﬁcance
of both variables remained unchanged (P , 0.001).
Conclusions: Our data suggested that the reference value of FeNO in healthy
Korean adults seemed to be same or less than 34 ppb. Reference values of
FeNO in Korean adults are inﬂuenced by gender and atopy status. This study
was supported by a grant of Korea HealthCare technology R&D project,
Ministry of Health and Welfare, Republic of Korea (A092076).
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Association of Feno with IgE Levels in Patients with
Allergic Asthma
Joselit Torres, MD,1 Elianny Chavez, MD,1 Mayra Martínez, MD,1
Durnes García, MD,2 and Aura Pellizzeri, MD1. 1Inmunology and Allergolgy,
Resident, Caracas, Venezuela; 2Inmunology and Allergolgy, Teaching Co-
ordinator, Caracas, Venezuela.
Background: Asthma is a chronic multifactorial disease characterized by
inﬂammation with multiple triggers. Inﬂamation of the airways is the main
pathologic pathway in asthma, and not only determines the diagnosis and
severity of symptoms, but is also useful to establish treatment and predict
potential complications. By measuring FeNO levels, an indirect level of
pulmonary inﬂammation can be obtained since it is produced by alveolar
macrophages in response cytokines. One of the main known causes of this
inﬂammatory response is an allergic reaction. This allergic reaction sets off
a cascade of biochemical events that leads to the expression of inﬂamatory
mediators, preformed or de novo, and IgE being the principal of such
mediators. The objective was to evaluate the relationship between levels of
FeNO and IgE to inﬂammation and allergy severity.
Methods: 50 patients (72% female and 28% male) aged 12 to 50 years old,
diagnosed with asthma were taken from the Allergy and Immunology
department. A complete medical history was performed, and the diagnosis
was conﬁrmed through a clinical history and spirometric criteria, according to
GINA 2010. All medications that could alter the inﬂammatory process were
taken away for 15 days. Lastly, total serum IgE levels were measured with
electrochemiluminescence technique and the FeNO with standard procedures.
The data was further analyzed using a Pearson’s correlation test.
Results: 21% of the participants showed normal IgE values (,100 UI/Ml)
and 33% of the participants had normal FeNO measurements (,20 ppm). A
0.29 coefﬁcient was measured using a Pearson’s correlation test, which sug-
gests a low positive correlation between the 2 observed variables.
Conclusions: The results showed a low correlation between the IgE and
FeNO levels. This result does not allow for a correlation between both
parameters; which leads to a conclusion that high levels of IgE from an
allergic reaction is not necessarily going to lead to a high FeNO, thus
a pulmonary inﬂammation. Additionally, it emphasizes the importance of the
allergists and pneumonologists to work together when treating an asthma
patient, given the multidisciplinary nature of this pathology.
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The Relationship of Fractional Exhaled Nitric Oxide (FeNO) and
Acute Exacerbation of Childhood Asthma
Yeong Ho Rha, MD, Myung-Sung Kim, MD, and Sun Hee Choi, MD. 1De-
partment of Pediatrics, Kyung Hee University Hospital, Seoul, South Korea;
2Department of Pediatrics, Idream Children’s Hospital, Daegu, South Korea;
3Department of Pediatrics, Gangdong Kyung Hee University Hospital, Seoul,
South Korea.
Background: Asthma is a chronic inﬂammatory disorder in the airways.
Measurement of FeNO (fractional exhaled nitric oxide) is a non-invasive tool
for measuring airway inﬂammation. The aim of this study was to investigate the
relationship of FeNO and acute asthmatic exacerbation in children and to decide
whether measurement of FeNO could predict acute exacerbation of asthma.
Methods: Thirty eight children with mild to moderate persistent asthma aged
from 3 to 15 years were included. Patient’s data were based on out-patient
records. FeNO was measured thorough chemiluminescence analyzer. Pro-
spectively, the patients were followed for 6 month. The FeNO levels of
asthma exacerbation group and non-exacerbation groups were evaluated.
Results: Mean age of the patients is 5.4 years. There were no difference of
peripheral blood total eosinophil count, serum IgE, age, sex between asthma
exacerbation group and non-exacerbation group. In the range of abnormal
FeNO level (more than 10 ppb), there was signiﬁcant difference of FeNO
level between exacerbation group and non-exacerbation group (P ¼ 0.004).
There was also signiﬁcant correlation between FeNO level and acute asthma
exacerbation (P ¼ 0.003).
Conclusions: Measurement of FeNO can be a useful tool to predict asthma
exacerbation in mild to moderate persistent asthmatic children.
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Relationship Between Exhaled Nitric Oxide and Levels of Asthma
Control in Asthma Patients Treated with Inhaled Corticosteroid
Ho Joo Yoon,MD,1 Sang-Heon Kim,MD,1 Tae Hyung Kim,MD,1 Jang Won
Sohn, MD,1 Dong Ho Shin, MD,1 Sung Soo Park, MD,1 and Suk-Il
Chang, MD2. 1Department of Internal Medicine, Hanyang University College
of Medicine, Seoul, South Korea; 2Department of Internal Medicine, Sungae
General Hospital, Seoul, South Korea.
Background:While asthma control is deﬁned as the extent to which the various
manifestations of asthma are reduced by treatment, current guidelines of asthma
recommend assessment of asthma control without consideration of airway
inﬂammation. Our aim was to investigate the relationships between fractional
exhaled nitric oxide (FeNO), a reliable marker of airway inﬂammation, and
levels of asthma controls in patients treated with inhaled corticosteroid (ICS).
Methods: We enrolled 71 adult patients with asthma, who had been treated
with ICS more than 4 months. Asthma control was assessed by the physician
based on the Global Initiative for Asthma guidelines, and by the patients and
by using Asthma Control Test (ACT). Statistical analyses were performed to
analyze the relationships between FeNO and measures of asthma control and
clinical indices for asthma manifestations.
Results: There was no signiﬁcant difference in FeNO levels between 3 groups
according to levels of asthma control (controlled, partly controlled and un-
controlled) determined by the physician (P¼ 0.81) and by the patients (P¼ 0.81).
In addition, FeNO values were not correlated with the ACT scores (r¼ 0.031, P¼
0.807), while FeNO showed peripheral blood eosinophil counts (P , 0.001).
Conclusions: These ﬁndings demonstrated that FeNO levels are not related
with the measures of asthma control in patients treated with ICS. Information
of airway inﬂammation from FeNO concentrations seems to be discrepant
from levels of asthma control.
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Relationship between Aeroallergen Sensitization and Asthma
Severity in Mexican Children
Blanca Maria Morﬁn-Maciel, MD, Trinidad Hernández-Venegas, MD,
Blanca Maria Castillo-Morﬁn, MD, Maria Rosario Perez-Chavira, MD,
and Nora Martinez-Aguilar, MD. Allergy, Hospital Angeles Mocel, Mexico
City, Mexico.
Background: Asthma is the most common chronic disease in children. The
aim of this study was to assess the association between asthma severity and
skin test reactivity to common inhalant allergens.
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Methods: With informed parenteral consent, we included children with
asthma, who attended for the ﬁrst time to Allergy Department and collected
data on clinical history, respiratory function and allergic sensitization.
Asthma severity was classiﬁed using the GINA guide. We integreted the
data into regression models to identify allergen sensitization most strongly
associated with asthma severity.
Results: We included 260 children with ages ranging from 3 to 18 years old
(mean 11.5 6 2.85). Male/female ratio: 1.4:1. 72.3% had mild asthma; 23.8%
moderate asthma and 3.8% severe asthma. Skin prick testing with aeroallergens
was performed. Most of the children were sensitized to at least one aeroallergen
(89.6%). Male gender and the number of positive skin tests correlated to asthma
severity. Among allergic children 72.1% had more than one allergic disease.
Total serum IgE did not correlate with the number of sensitizing aeroallergens,
neither with asthma severity. Dust mite was the most frequent sensitization. Cat
and molds were associated with a greater risk of having moderate and severe
asthma. We found a progressive sensitization with age.
Conclusions: Sensitization to some perennial indoor allergens, particularly
cat and molds, were strongly associated with asthma severity.
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Association of Asthma and IGE Levels
Joselit Torres,MD,1 Mayra Martínez,MD,1 Elianny Chavez,MD,1 Durnes García,
MD,2 and Ana Antelo, MD3. 1Inmunology and Allergolgy, Resident, Caracas,
Venezuela; 2Inmunology and Allergolgy, Teaching Coordinator, Caracas,
Venezuela; 3Inmunology and Allergolgy, Attending, Caracas, Venezuela.
Background: Asthma is a multifactorial chronic inﬂammatory disease that
presents with varying degrees of bronchospasm which can be triggered by
multiple causes. One of the best known triggers is allergies, or contact with
allergens that have different immunological mechanisms leading to activation
of the inﬂammatory process characteristic of asthma. Immunoglobulin E is
a protein that normally rises in the allergic process and used as a marker.
Objectives: To assess the prevalence of IgE as a key factor in asthma and to
estimate the incidence of non IgE-mediated asthma.
Methods: 50 Patients (72% female and 28% male) aged 12 and 50 years old,
diagnosed with asthma who met the inclusion and exclusion criteria, were taken
from the Allergy and Immunology department. A complete medical history was
performed, and the diagnosis was conﬁrmed through a clinical history and
spirometric criteria, according to GINA 2007. Subsequently, total IgE in serum
were measured by electrochemiluminescence using the Cobascore equipment.
Results: 72% of the patients in the study, had an elevated total IgE which
suggests that this group has an allergic cause as a trigger for their disease,
meanwhile the cause for the remaining patients were due to other causes.
Conclusions: Evaluation of serum IgE levels should be considered in
asthmatic patients in order to determine the speciﬁc etiologic treatment.
Additionally, these results enhance the importance of a multidisciplinary
working diagnosis, and management of this condition, considering that up to
a quarter of asthma patients may have Non-IgE mediated etiology
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The Method of Antigen Speciﬁc Damage of Leucocytes by Food
Additives in Patients with Bronchial Asthma
Nadya Titova. Allergy, Belarussian Medical Academy of Post Graduate
Education, Minsk, Belarus.
Background: Diagnosis of adverse reactions to food additives is difﬁcult due
to a variety of mechanisms involved and the lack of sufﬁciently reliable
methods for their determination. The diagnosis of intolerance to food
additives is still based only on placebo-controlled oral provocation.
Methods: The aim of this study was to determine the incidence of intolerance
to ponceau 4R (E124), indigo carmine (E132), azorubine (E122), tartrazine
(E102), sunset yellow (E110) and sodium benzoate (E211) among patients
with bronchial asthma. We studied 114 patients with bronchial asthma using
clinical and laboratory methods. Also we used the method of antigen speciﬁc
damage of leucocytes by food additives. After the incubation of leucocytes
with solutions of food additives to leucocytes was added 0.05 mL of trypan
blue and counted the percentage of stained (damaged) granulocytes with the
food dye and in control tests. If damaging leucocytes were more than 20% in
comparison with controls - the test considered positive.
Results: It was found that positive to ponceau 4R were 6 of 114 patients, to
indigo carmine–3 of 73, to sodium benzoate–4 of 73, to azorubine–11 of 114,
to tartrazine–7 of 114 and to sunset yellow–9 of 114. There was a correlation
between the results obtained and data history. Between experienced and
control group (the patients without allergic diseases) were the reliable differ-
ences (P , 0.05).
Conclusions: 1. Under inﬂuence of the food additives leukocytes of patients
with bronchial asthma are damaged and painted by trypan blue. 2. The method
of antigen speciﬁc damage of leucocytes by food additives can be used for
diagnostics of the allergies to food dyes, sodium benzoate and other gaptens.
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Effect of Ascorbic Acid on Aiway Hyperresponsiveness in
Bronchial Asthma
Young S. Hwang, MD,1 Jong D. Lee, MD,1 Ho C. Kim, MD,1 Yu J. Cho,
MD,1 and Se Hwa Yoo, MD, PhD2. 1Internal Medicine, Gyeongsang Uni-
versity Hospital, Jinju, South Korea; 2Internal medicine, Korea University
Medical Center, Seoul, South Korea.
Introduction: Ascorbic acid has been reported to have a role in the decrease
of airway responsiveness in animal models. This data has been based on the
regulation of airway tone and modulation of airway reactivity by ascorbic
acid. Human studies show that ascorbic acid has a protective effect against the
increase in bronchial responsiveness induced by ozone, and nitrogendioxide.
We hypothesized that ascorbic acid may attenuate bronchial hyperresponsive-
ness in bronchial asthma.
Methods: We studied 15 mild asthma patients and 13 healthy non smoker
controls. These patients were measured plasma ascorbic acid levels with 2, 4-
DNPH (dinitrophenyhydrazine) method and checked methacholine challenge
with Chi method before and 1 hour after ascorbic acid intake (3 gm). To
assess chronic effect of ascorbic acid on airway responsiveness, these
participants were checked again plasm ascorbic acid and methacholine
challenge after daily intake of ascorbic acid (1 gm) for 2 weeks.
Results: There were no signiﬁcant differences in plasma ascorbic acid levels
in asthma patients and controls. Bronchial hyperresponsiveness was de-
creased after ascorbic acid intake (3 gm) in asthma patients, but not
statistacally signiﬁcant. This decrease was persisted with daily 1 g of
ascorbic acid intake for 2 weeks. PC20FEV1 were not correlated to plasma
ascorbic acid levels in asthma patients.
Conclusions: In mild bronchial asthma, Airway hyperresponsiveness may be
ameliorated by ascorbic acid supplementations. But further studies are necessary
to address the question of the effectiveness of ascorbic acid in bronchial asthma.
ASTHMA AND CO-MORBID CONDITIONS
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Screening for Allergic Bronchopulmonary Aspergillosis in
Patients with Aspergillus 1 Asthma From 2000 to 2010
Paul Greenberger, MD. Feinberg School of Medicine, Northwestern Univer-
sity, Chicago, IL.
Background: Approximately 25% of patients with persistent asthma have
immediate skin reactivity to Aspergillus species. The purpose of this study
was to screen all patients with immediate hypersensitivity to Aspergillus for
evidence of Allergic Bronchopulmonary Aspergillosis (ABPA).
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Methods: All patients with asthma underwent immediate cutaneous testing
including prick (epicutaneous) with a mix of Aspergillus species and if
negative, intradermal at 1000 PNU/mL, Aspergillus fumigatus (Af). Sera
were analyzed for total IgE (elevated is $417 kU/L) by Phadia Immuno-
Cap, anti-Af IgE and anti-Af IgG (ABPA range $ 2.0) ELISA, and pre-
cipitating antibodies. HRCT of the lungs was ordered next if serology was
positive (diagnostic criteria for ABPA required total IgE $ 417 kU/L and
both anti-Af IgE and IgG $ 2.0 compared to sera from skin test 1 patients
with asthma without ABPA). To avoid bias from patients examined by the
author, data were compared using screening from 5 other faculty in the
same clinic.
Results: From 2000 to 2010, 864 skin test 1 patients underwent serologic
testing for ABPA from which 81 (9.4%) were diagnostic for ABPA, and in
this group, precipitins were positive in 42/81. To address referral bias in
screened patients of the author, diagnostic criteria were positive in 49/208
(23.5%) patients of the author versus 32/656 (4.8%) of other allergy-immu-
nology faculty. In addition, some 74/884 (8.6%) patients had total IgE $ 417
kU/L and either anti-Af IgE or IgG $ 2.0, implying an overall at risk for
ABPA population of 155/864 (17.9%). The highest total IgE recorded in
a non-ABPA patient with asthma was 192,100 kU/L.
Conclusions: Using total IgE and ELISA determinations to discriminate
ABPA from skin test1 asthma sera, 9.4% of patients had diagnostic evidence
for APBA. Using data from faculty, presumably with less referral bias than
the author, results in 4.8% patients with classic diagnostic criteria. This rate
conservatively translates into a minimum of approximately 1.2% of patients
with persistent asthma having APBA in the upper Midwestern US. The
combination of elevated total IgE and precipitins but not elevated anti-Af
IgE or IgG in this population has little/no value in diagnosis.
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Sleep-disordered Breathing in Obese and Eutrophic Adolescents,
Asthmatics and not Asthmatics, in the Hospital Infantil of Mexico
Federico Gómez
Alexander Morales, MD. Immunology and allergy, Distrito Federal, Mexico.
Background: Sleep-disordered breathing (SDB) has been studied in obese
adults but there are few studies on adolescents. This study analyzed the
frequency of SDB in obese adolescents and controls with and without asthma.
Methods: A cross-sectional comparative study, 27 obese adolescents 10 to 18
years old with body mass index (BMI) $ 95th percentile, of whom 17 (43%)
had mild intermittent asthma (MIA) according to GINA 2005 guidelines and
23 (57%) without asthma, plus a group of 20 eutrophics adolescents (BMI ¼
percentile 50th–84th), 50% (n¼ 10) with MIA and 50% (n ¼ 10) healthy. All
patients underwent overnight polysomnography, primary snoring (PS) was
diagnosed with recording of snoring and apnea/hypopnea index (AHI) ,1
and sleep apnea /hypopnea syndrome (SAHS) with an AHI $ 1 plus oxygen
desaturations .4% baseline, bradycardia or tachycardia. We obtained meas-
ures of central tendency, dispersion and t student test for different groups.
Results: In obese adolescents with and without asthma SAHS was found in
72.5% (n ¼ 29), PS was diagnosed in 20% (n ¼ 8) and the subgroup analysis
of obese show that same number of asthmatic and non asthmatic had SAHS
(70.5%, 74%, respectively). The subgroup analysis of asthmatics and healthy
eutrophic had SAHS (60% (n ¼ 6), 0% (n ¼ 0) respectively. Globally AHI in
the obese group was 2.05 6 3.48 compared to healthy eutrophic (0.40 6
0.26) with P ¼ 0.0016, signiﬁcant differences were obtained in the analysis of
subgroups: the IAH in obese adolescents with asthma (3.41 6 3.47) and
obese without asthma (2.60 6 2.55) with P ¼ 0.7017. In the eutrophic group
differences there were signiﬁcant differences: eutrophic asthmatics (IAH:
2.15 6 0.26) and 0.40 6 0.26 healthy eutrophic P ¼ 0.0047.
Conclusions: SDB is more common in obese adolescents. In eutrophic
asthmatic adolescents SAHS was more frequent than in healthy, probably by
the presence of co-morbidities such as rhinitis, hypertrophy of tonsils and all
patients were classiﬁed as MIA. Adolescents who are obese have an increased
risk of SDB compared with the group of healthy adolescents.
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Dyspnea in Chronic Fatigue Syndrome (CFS): Comparison of
Two Prospective Cross-sectional Studies
Murugan Ravindran, MBBS,1 Oluwatoyin Adewuyi, MS,1 Yin Zheng, MS,1
Uyenphuong Le, MD,2 Christian Timbol, MS,1 Samantha Merck, BA,3
Rania Esteitie, MD,1 Michelle Cooney, RT,4 Charles Read, MD,4
and James Baraniuk, MD1. 1Medicine-Section of Rheumatology, Allergy,
and Immunology, Georgetown University, Washington, DC; 2Section of
Rheumatology, Allergy and Immunology, Medicine, Washington, DC; 3Med-
icine, Section of Rheumatology, Allergy and Immunology, Washington, DC;
4Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown
University, Washington, DC.
Background: Chronic Fatigue Syndrome (CFS) subjects have many systemic
complaints including shortness of breath. Dyspnea was compared in two CFS
and control cohorts to characterize potential pathophysiological mechanisms.
Methods: Cohort 1 of 257 CFS and 456 control subjects were compared
using the Medical Research Council chronic Dyspnea Scale (MRC Score;
range 0–5). Cohort 2 of 106 CFS and 90 controls answered a Dyspnea
Severity Score (range 0–20) adapted from the MRC Score. Subsets of both
cohorts completed CFS Severity Scores, fatigue, quality of life, and systemic
complaints questionnaires. Cohort 2 also responded to other Dyspnea, affec-
tive and anxiety instruments. A subset had pulmonary function and total lung
capacity (TLC) measurements.
Results:MRC Scores were equivalent for females and males in Cohort 1 CFS
(1.92 [1.72-2.16]; mean [95% conﬁdence interval]) and controls (0.31 [0.23-
0.39]; P , 0.0001 by 2-tailed, unpaired Student’s t tests with Bonferroni
corrections). Receiver-operator curves identiﬁed 2 as the threshold for posi-
tive MRC Scores in Cohort 1. This indicated 54% of CFS, but only 3% of
controls, had signiﬁcant Dyspnea. In Cohort 2, the threshold Dyspnea Sever-
ity Score of 4 indicated shortness of breath in 67% of CFS and 23% of these
controls. Cohort 2 Dyspnea Scores were higher for CFS (7.80 [6.60-9.00])
than controls (2.40 [1.60-3.20]; P , 0.0001). CFS had signiﬁcantly worse
fatigue, other CFS deﬁning criteria and quality of life compared to controls.
Although CFS had worse depressive affect and anxiety scores, only the con-
trols showed correlations with Dyspnea Score. Pulmonary function was nor-
mal in CFS, but Borg scores and sensations of chest pain and dizziness were
signiﬁcantly greater during testing than controls. TLC was normal except for
2 of 16 CFS who had hyperinﬂation. A general linear model of Cohort 2 CFS
responses linked Dyspnea Scores with rapid heart rate, chest pain and
dizziness.
Conclusions: Sensory hypersensitivity without airﬂow limitation contributed
to Dyspnea in CFS. Correlates of Dyspnea in controls were distinct from CFS
suggesting different mechanisms.
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Incidence of Allergy in Patients With Benign Lesions of the Vocal
Cords: Preliminary Report
Hulya Eyigor, MD,1 Ustun Osma, MD,1 Arzu Didem Yalcin, MD,2
Mustafa Deniz Yilmaz, MD,1 and Irfan Pirtik, MD1. 1ENT Head and Neck
Surgery, Antalya Training and Research Hospital, Antalya, Turkey; 2Aller-
gology and Clinical Immunology Unit, Antalya Education and Training Hos-
pital, Antalya, Turkey.
Background: Allergic inﬂammation commonly affects the upper and lower
airways concurrently. Although allergic nasal and pulmonary effects have
been well described, laryngeal effects are not well understood. In this study
we investigated the incidence of allergy in patients with benign lesions of the
vocal cords and types of allergens causing these reactions.
Methods: The study was approved by the local ethics committee, and written
consent was obtained from all patients. A questionnaire made by the investi-
gators taking the latest literature data into consideration were used during the
study. Laryngeal examination was done with videolaryngostroboscopy and
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the lesions of each patients was recorded. Serum IgE levels and eosinophil
levels were evaluated in all patients. All assays were carried out in duplicate.
Skin prick tests on the forearm were performed in all patients using
standardized latex extract containing high ammonia natural rubber latex,
and a full set of 35 common. In addition, venom SPT was performed on
one patient based on the subject’s clinical history. Positive tests were counted
as wheals of 3 mm in diameter after 20 minutes. Commercial extracts used
were manufactured by Alyostal ST-IR. None of intradermal tests were
performed.
Results: The group of 30 patients included 10 male and 20 female subjects
with vocal cord pathology, having a mean age of 39.87 years. Sixteen (53.3%)
patients had vocal polyp, 10 (33.3%) had nodule, 4 (13.3%) had Reinke edema.
The mean IgE levels was 133.73 IU/mL, and mean eosinophil levels was
10,728.3. Dermal prick tests were found to be positive in 66.7% of the patients):
The most common allergen was mite (53.3%) and grass pollen (52.3%).
Conclusions: In conclusion skin Prick tests were found to be highy positive
in patients with bening lesions of vocal cords compared to normal population.
Thus we can speculate that allergy may play a role in pathopysiology of these
lesions. Further research is needed to identify the underlying pathways
mediating the laryngeal response to allergy so that improved diagnostic and
therapeutic techniques can be developed.
306
Eechocardiographic Findings in Obese Adolescents with and
without Asthma
Lizette Montejano-Elías, MD. Hospital Infantil de México Federico Gómez,
Distrito Federal, Mexico.
Background: To detect echocardiographic alterations in the diameter of the
aorta in relation to the diameter and ventricular volume in obese adolescents
with or without intermittent asthma as well as in eutrophic adolescents with or
without asthma.
Methods: Cross-sectional, prospective study in 10 to 17 year old adolescents.
They were stratiﬁed into 4 groups based on the intermittent asthma diagnosis
(GINA classiﬁcation) and in the Body Mass Index [BMI] (Obesity: BMI higher
than the percentile 95%; eutrophic: BMI percentile 10 to 85% according to
CDC). Anthropometry and echocardiogram tests were done on all adolescents.
Measures of central tendency were obtained (mean and 95% conﬁdence interval
[CI]) and data were analyzed through corrected ANOVA post HOC.
Results: One hundred and ninety-four subjects were studied and divided into 4
groups: obese with intermittent asthma (OA) [N ¼ 72], obese without asthma
(OnA) [N ¼ 73], eutrophics with intermittent asthma (EA) [N ¼ 22], eutrophics
without asthma (EnA) [N¼ 27]. Expressing the mean values and the 95% CI, we
obtained the relation of the aorta with the left ventricular diastolic diameter
indexed to the body surface (millimeters [mm]) in OA ¼ 1.105 (1.047–1.164),
OnA ¼ 1.130 (1.06–1.192), EA ¼ 0.921 (0.885–0.988), EnA ¼ 0.967 (0.873–
1.061) [P, 0.05 EA vs OA y OnA]. For the aorta in relation to the left ventricular
diastolic volume in mm/milliliters [mL] the values were: OA ¼ 0.648, (0.624–
0.673), OnA ¼ 0.645 (0.623–0.666), EA ¼ 0.649 (0.620–0.679), EnA ¼ 0.650
(0.615–0.684) [P. 0.05]. The aorta values in relation to the stroke volume [mm/
mL] were: AO¼ 0.573 (0.530–0.617), OnA¼ 0.553 (0.511–0.594), EA¼ 0.596
(0.526–0.666), EnA ¼ 0.595 (0.525–0.665) [P . 0.05].
Conclusions: The diameter of the aorta in relation to the left ventricular
diastolic diameter was lower in eutrophic adolescents with intermittent
asthma. There was no difference in the diameter of the aorta of the obese
adolescents with and without intermittent asthma.
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Asthma Prevalence and Body Mass Index in Children
Olf Herbarth,1 Matthias Richter,2 and Thomas Richter3. 1Environmental
Medicine and Hygiene, Faculty of Medicine, University of Leipzig, Leipzig,
Germany; 2Helmholtz-Center for Environmental Research, Leipzig, Ger-
many; 3St. Georg Hospital, Leipzig, Germany.
Background: Overweight seems to be a growing problem associated with
diseases which are increase during the last decades. As an example both
the BMI (Body Mass Index) and the asthma prevalence are increasing. The
question is whether a link exists between these changes or whether the
increase is independent of each other.
Methods: In the frame of a longitudinal repeated cross-sectional epidemio-
logical study 4925 children in total have been medical checked up. A
questionnaire was ﬁlled out by the parents. Among other things data were
gathered concerning anamnesis, physical measurements, and physician
diagnosed diseases, like asthma. Describing the overweight in children’s
age until 15 years the BMI was divided in percentiles ,10%, 10 to 25%,
25 to 75%, 75 to 90%, .90% respectively .97%. The full data set was
available for 3946 children (80.1% of all participants).
Results: Descriptive: The lifetime prevalence of asthma was 7.1% (age group
until 15 years). The BMI was for the overweight group of 6/8/15 year old kids;
18.1/20.1/24.5 kg/m2 and in the adiposity group 20.2/22.4/27.7 kg/m2 respec-
tively. Frequent air way infections and parental predisposition enhance the risk
for asthma (4.1 vs 10.9%); boys are more affected than girls (8.1 vs 6.1%).
Starting with the 10%-BMI-percentile the asthma prevalence increases using the
above mentioned intervals from 3.6% up to 8.3% for children with overweight
(.90%-BMI-percentile). Analytical: The logistic regression adjusted for rele-
vant confounders (gender, smoking and passive smoking, parental predisposi-
tion, pets (like cats), duration of breastfeeding, socioeconomic status) conﬁrms
the descriptive results. The BMI dependent adjusted Odds Ratio (aOR) (range)
for asthma was 1.6 (95% CI, 1.0-2.7; P ¼ 0.048).
Conclusions: The results clearly show that within the group of higher BMI
more asthma will detected. Contrary to other studies this study may not
conﬁrm that the dependence on asthma from the BMI is bimodal since no
higher asthma prevalence was observed in the lower and lowest BMI classes.
Up to now this pilot study does not answer the question about the underlying
processes.
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Evaluation and Comparison of Lung Volumes and Capacities in
a Group of Morbid Obese, Obese and Eutrophic Adolescents
Jeannette Mendiola Marin, MD. Allergy and Immunology, Instituto Mexicano
del Seguro Social, Mexico City, Mexico.
Background: Obesity is a major health issue in the world. It is associated
with a range of adverse consequences and its prevalence appears to be
increasing among children and adolescents. The effects of ventilatory
function have been widely studied in adults but there are scarce studies in
children and even more, in speciﬁc population as inmorbid obese adolescents.
Knowledge of early complications on the lung by pulmonary function tests
allow the development of new management strategies aimed at the sporting
activity in patients with morbid obesity.
Objective: To measure and compare pulmonary function tests in morbid
obese, obese and eutrophic.
Methods: Transversal prospective protocol, in a group of morbidly obese, obese
and eutrophic adolescents, aged between 11 and 17 years, divided into 3 groups:
1) Eutrophic adolescents (BMI , p85); 2) obese adolescents (BMI . p95 and
,99); and 3) Adolescents with morbid obesity (BMI . 35 or BMI . P99). All
of them underwent complete medical history, measurements and pulmonary
function tests (plethysmography) using a Sensor Medics VMAX plethysmograph.
Results: We used descriptive stadistics, measurement of standar deviation,
standar error, conﬁdence interval95%, we analized in groups using analysis of
variance (ANOVA) with a Tukey post hoc analysis. Signiﬁcance was taken as
P , 0.05 for all tests. Funtional Residual Capacity (FRC) and Expiratory
Reserve Volume (ERV) decrease sharply comparing the 3 groups: FRC P ,
.032 eutrophic versus obese and P , .031 eutrophic versus morbid obeses.
ERV P , .001 eutrophic versus obese and P , .003 eutrophic versus morbid
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S99
obese. We also found a decrease in FEV1 comparing the 3 groups with a P,
.011 morbid versus eutrophic and P , .049 morbid versus obese.
Conclusions: Our results conﬁrm the ﬁndings of others, who have shown that
lung volumes especially FRC and ERV decrease as body weight increases.
Obese patients have a combination of mechanical and inﬂammatory effects
that result in pulmonary disability.
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Difﬁcult-to-treat Asthma with Idiopathic Chronic
Eosinophilic Pneumonia
Norbert Pauk, PhD, MD. Department of Pneumology, Faculty Hospital Na
Bulovce, 3rd Faculty of Charles University, Prague, Czech Republic.
Background: Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare
disorder of unknown cause characterised by subacute or chronic respiratory
and general symptoms, alveolar and /or blood eosinophilia, and peripheral
pulmonary inﬁltrates on chest imaging. Interestingly, some but not all patients
diagnosed with ICEP have a history of asthma, whilst others may develop
asthma after a dignosis of ICEP has been made.
Methods: We present this rare and interesting case, because ICEP is a rare
complication of asthma, although it is seldom mentioned in reviews ant
textbooks on asthma. Asthma in patients with ICEP is relatively severe and
get worse after diagnosis of ICEP.
Results: A 70-year-old woman with a history of asthma and chronic rhinitis
with polyps (diagnosed in 2003), nonsmoker, history of allergies negative.
She suffered from frequent exacerbations of asthma (7 times a year with
repeated courses of oral corticosteroids). In 2006 she had sudden fever,
weight loss, malaise and impaired dyspnea with productive cough, mild chest
pain on sternum and respiratory failure. A chest radiograph demonstrated
bibasilar inﬁltrates. Peripheral blood smear showed a newly developed,
marked eosinophilia, and a chest X-rays and HRCT scan revealed a diffuse
patchy nodular inﬁltrate in all lung ﬁelds. Serum-precipitating antibodies
against Aspergillus antigens negative, no cutaneous reactivity to Aspergillus
antigen, negative ﬁndings for parasitic infections, no central bronchiectasis on
previous HRCT, ANCA, ANA, ENA negative. She received an intensive
course of corticosteroids with complete resolution of symptoms and the
eosinophilia, as well as decreased inﬁltrates on chest radiograph. Doses of
corticosteroids slowly reduced a maintained until June 2009. Her asthma
often exacerbates so far and needs intermittent courses of corticosteroids, is
difﬁcult- to-treat, but without any relapses of ICEP.
Conclusions: Clinicians should consider pulmonary eosinophilia in the
differential diagnosis of patients treated for asthma who develop pulmonary
inﬁltrates with dyspnea.
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Diagnosis and Management of Post-radiation Pneumonitis in
Patients with Asthma
Ekaterini Syrigou,1 Maria Ralli,2 Fotis Psarros,1 Nektaria Makrilia,2
Andriani Charpidou,2 Ioannis Dannos,2 and Kostas N. Syrigos2. 1Department
of Allergy, and; 2Oncology Unit, 3rd Department of Medicine, Sotiria Gen-
eral Hospital, Athens School of Medicine, Athens, Greece.
Background: Lung cancer remains the leading cause of cancer-related deaths
among men and women in the civilized world. A notable number of patients
undergo radiation in various stages of the treatment process and its main
respiratory side effect is pneumonitis. Our aim was to investigate the
diagnostic and treatment methods of post-radiation pneumonitis particularly
in asthma patients.
Methods: A literature search was performed in Pubmed to identify relative
studies published until June 2011. Lung cancer, post-radiation pneumonitis,
therapy and asthma were the key words used for the search.
Results: Post-radiation pneumonitis is a clinical situation demanding early
diagnosis in asthma patients, but the latter is often underestimated. Pneumonitis
is clinically revealed by dyspnea, cough, fever and usually begins up to 12 weeks
after the start of radiation treatment. Radiographically, it appears as diffuse or
patchy consolidation and/or ground glass opacities. Pulmonary function decline
is correlated to decreased values of forced expiratory volume in the 1st second
(FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO). The
effects on normal tissue may mimic or hide tumor recurrence. Smoking cessation
causes changes of total lung capacity and vital capacity and this may have
consequences on lung volume results in dose volume histogram analysis,
targeting precision, oxygenation changes, tumor biology (gene expression) and
prognosis. NCI Common Toxicity Criteria (CTC) V3.0 assessments are usually
preformed weekly during radiotherapy and at regular follow-up visits. Compli-
cation rates vary with dose, fractionation, schedule duration, technique, photons’
energy, irradiated volume, dose escalation, accelerated fractionation schemes,
ﬁelds, co-morbidities and concurrent chemo-radiotherapy.
Conclusions: The crucially deteriorating on therapy effect of pneumonitis
leads to the realization that alertness and constant attention is not only
strongly advised, but compulsory in asthma patients.
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Pathogenesis of Radiation-induced Pneumonitis in Patients with
Chronic Obstructive Pulmonary Disease
Ekaterini Politi,1 Maria Tolia,1 Nektaria Makrilia,1 Fotis Psarros,2 Ioannis
Dannos,1 Kostas N. Syrigos,1 and Ekaterini Syrigou2. 1Oncology Unit, 3rd
Department of Medicine, and; 2Department of Allergy, Sotiria General Hos-
pital, Athens, Greece, Athens, Greece.
Background: Chest radiation is a common therapeutic approach in the mana-
gement of lung cancer, as well as in other malignancies, rendering radiation-
induced pneumonitis a rather commonly reported adverse event. A large proportion
of patients undergoing radiation have underlying chronic obstructive pulmonary
disease (COPD). We aim to elucidate the pathogenetic pathways implicated in
radiation-induced pneumonitis particularly in this subgroup of patients.
Methods: A literature search was performed in PubMed to identify relative
studies published until June 2011.
Results: The incidence of radiation-induced pneumonitis after conventional
irradiation in COPD is about 7 to 10% in the moderate although symptomatic
forms and about 1 to 3% in the severe forms. Radiation-induced pneumonitis
seems to be an acute-phase reaction, taking primarily place in the most
radiosensitive subunit of the lung, the alveolar/capillary complex. Reactive
oxygen species, generated by radiation, initiate a cascade of molecular events
that alter the cytokine milieu of the microenvironment, creating inﬂammation
and chronic oxidative stress. COPD is characterized by a chronic inﬂammatory
state in the lung, also generating reactive oxidant species. Biological markers
intrinsic to the patient, such as early variations of certain cytokines (IL-6, IL-10,
TGF-b) seem to be implicated and studies are under way to determine their role.
The standard dose-volume metrics, such as V20, V13 and mean lung dose, are
major factors inﬂuencing the clinical course of radiation-induced pneumonitis.
Conclusions: Understanding the underlying pathogenesis of radiation-
induced pneumonitis may help improve optimal delivery of treatment
plans, minimize the risks and increasing the therapeutic ratio in patients
with COPD.
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Medication Responses in Chronic Fatigue Syndrome (CFS) and
Non-CFS Subjects
Rania Esteitie, MD,1 Oluwatoyin Adewuyi, MS,1 Murugan Ravindran,
MBBS,1 Yin Zheng, MS,1 Samantha Merck, BA,2 Christian Timbol, MS,1
Cristina Di Poto, PhD,2 Rakib Rayhan, MS,2 and James Baraniuk, MD1.
1Medicine-Section of Rheumatology, Allergy, & Immunology, Georgetown
University, Washington, DC; 2Medicine, Section of Rheumatology, Allergy
& Immunology, Washington, DC.
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Background: There is a clinical perception that Chronic Fatigue Syndrome
(CFS) subjects have greater drug sensitivity and “allergy” than the rest of the
population. This perception was tested by assessing the symptoms associated
with medication use in a group stratiﬁed by CFS status and gender.
Methods: 194 subjects answered a binary (yes-no) questionnaire (Simon GE
et al, 1993) to determine if “medications” (not further subdivided by drug
class) caused any of 25 symptoms from the neurological (6 symptoms);
musculoskeletal (5); airways (7); gastrointestinal (5); and skin (2) systems.
Subjects used our CFS Severity score to estimate the severity of fatigue and
the 8 minor criteria for the previous 6 months.
Results: The subgroup of ALL CFS females had more frequent nausea (32%
vs 13%; P ¼ 0.013) and visual changes (19% vs 4%; P ¼ 0.018) than ALL
non-CFS females. ALL CFS males had nausea (26%; P ¼ 0.003) and dizzi-
ness (23%; P ¼ 0.006) compared to zero in ALL non-CFS males. However,
these differences were misleading because many individuals had no symp-
toms, and so would not have adverse complaints or contact their physicians.
Therefore, the 47% of CFS and 72% of non-CFS subjects with zero symp-
toms were removed.The remaining 65 CFS subjects had 5.6 symptoms (95%
CI, 4.2- 7.0). The 20 non-CFS subjects had 3.5 symptoms (1.8 to 5.2; not
signiﬁcant by t test). Females in these subsets had no signiﬁcant differences in
symptoms frequencies. However, CFS males (n ¼ 22) had more nausea
(54.5% vs 0%; P ¼ 0.067) and dizziness (50% vs 0%; P ¼ 0.091) for
non-CFS males (n ¼ 4).
Conclusions: The apparent higher prevalence of medication-related symp-
toms in CFS than non-CFS was biased by the large number of subjects with
zero symptoms. When subjects with no complaints were excluded, there was
no difference between CFS and non-CFS females, but a trend for CFS males
to have had more gastrointestinal and neurologic symptoms than the non-CFS
males. Overall, the equivalence of symptoms in CFS and non-CFS suggests
that Multiple Chemical Sensitivity (MCS) may be an independent syndrome.
These methods will direct our analysis of other irritants in this multiple
chemical sensitivity questionnaire.
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Psychogenic Intractable Sneezing. Case Report
Sandra González-Díaz, MD, PhD, Alfredo Arias-Cruz,MD, Karla Mejia, MD,
Claudia Gallego, MD, Diego Garcia-Calderin, MD, Maricruz Calva, MD,
and Luis Dominguez, MD. Regional Centre of Allergy and Clinical Immunol-
ogy, University Hospital, Monterrey, Mexico.
Background: Sneezing is a coordinated protective respiratory reﬂex which
occurs due to stimulation of the upper respiratory tract, and frequently
accompanies allergic or nonallergic rhinitis. Sneezing can also arise due to
bright light or sun (ACHOO syndrome), physical stimulants of the trigeminal
nerve, psychogenic or central nervous system pathologies, sexual ideation
and psychogenic sneezing. There are few case reports in the literature of
patients with psychogenic sneezing.
Methods: 14-year-old girl who had incessant sneezing for over 4 days. The
patient was initially seen in a rural hospital, were it was prescribed prednisone
and antihistamines but the patient did not show any improvement. She was
refered to 3rd level Hospital and treated with nasal steroids, antihistamines,
and isotonic sodium chloride solution nasal spray; sneezing remitted in 2
hours. During a follow up visit nasal endoscopy was normal. Had a similar
episode a month after that, and was referred to our service. She didnt have
either personal or family history of allergies.
Results: There were not abnormalities in physical examination but obesity;
nasal cytology and skin tests to aeroallergens were negatives. Received the
same management with isotonic sodium chloride solution nasal and the
symptoms remitted. Consultation with psychiatry is requested by probable
psychogenic sneezing. The interrogation relates to the loss of father 3 years
also suffered from bullying for obesity. Combined treatment was initiated by
psychiatry and psychology.
Conclusions: Psychogenic Sneezing is a rare disorder, but should be
considered in the differential diagnosis of sneezing. May have suspect if
inspiratory phase is quite short and the amount of nasal mucosal secretion
expelled very low. Eyes may remain open during sneezing. It usually develops
due to psychogenic factors and is refractory to medical treatment. It is important
to assess the patient in a holistic manner through a medical history and physical
examination. Psychosocial environmental conditions should be investigated,
and once identiﬁed the trigger requires a multidisciplinary treatment.
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GERD Screening by the Use of F-Scale and Allergy Screening for
Diagnosis and Treatment of Chronic Cough
Ryuichi Nishihira, MD, Shigeru Komatsu, MD, Takeshi Shinohara, MD,
Akihiro Tagawa, MD, Takashi Ogura, MD, and Hiroshi Takahashi, MD.
Department of Respiratory Disease, Kanagawa Cardiovascular and Re-
spiratory Center, Yokohama, Japan.
Background: Allergy and gastro-esophageal reﬂux (GERD) are main causes
of chronic cough, and simple, easy and rapid screening is desired for
diagnosis of these symptoms.We used F-scale (Frequency Scale for
Symptoms of GERD: FSSG) for GERD screening, developed by Japanese
gastro-enterologist, did general allergy screenings, and investigated clinical
outcome after treatment retrospectively.
Methods: GERD was screened by F-scale questionnaire, composed in
twelve questions concerned with reﬂux symptoms, and scored 5 grades in
each symptom. General allergy screening was deﬁned as asking history of
allergy, serum immnogloblin E (IgE) test (total, fourteen kinds of speciﬁc
allergens) and measuring fraction of exhaled nitric oxide (FeNO),its
positive range was greater than or equal to 20 ppb. Allergy positive was
deﬁned as at least one positive ﬁnding of allergy screening test. GERD was
treated with proton pump inhibitor (PPI), and allergy was treated with
inhaled corticosteroid or histamine H1 receptor blocker or leukotriene
receptor antagonist.
Results: Fifty-four consecutive chronic cough patients were screened in
GERD and general allergy screening. Thirty-seven patients (69%) were F-
scale positive and 43 patients (80%) were positive in general allergy
screening. Thirty patients (56%) were positive in both F-scale and general
allergy screening. All patients were treated with allergy medicine or PPI, or
both medicines. In all patients screened and treated with both GERD and
allergy concurrently, cough improved within 2 weeks, and in patients whose
positive ﬁnding was either GERD or allergy, cough improved by treatment
with PPI or allergy drugs similarly. Delayed screening or treatment of either
GERD or allergy was related to delayed improvement of cough. Cough
ﬁnally improved in all patients in visit within 3 times.
Conclusions: In examination of chronic cough, adding GERD screening by
use of F-scale to general allergy screening is beneﬁcial to proper diagnosis,
treatment and rapid improvement of symptom.
315
Diagnosis of Gastroesophageal Reﬂux Disease in Patients with
Chronic Cough
Rosana Camara Agondi, MD, PhD, Jorge Kalil, MD, PhD, and Pedro
Giavina-Bianchi, MD, PhD. Clinical Immunology and Allergy, University
of Sao Paulo, Sao Paulo, Brazil.
Background: A major cause of chronic cough is gastroesophageal reﬂux
disease (GERD). Its diagnosis is based on symptoms and diagnostic tests, such as
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upper gastrointestinal endoscopy (UGE), 24-hour pH monitoring and manom-
etry. Many patients also present chronic posterior laryngitis in ﬁbronasolaryngo-
scopy (FNL). The objective of the present study was to evaluate the diagnosis of
esophagitis, by FNL and UGE in patients with chronic cough.
Methods: Patients followed up for chronic cough, over 18 years of age, were
asked about the presence of GERD symptoms and submitted to the FNL and
UGE, some of them with esophageal biopsy.
Results: Fifty-one patients participated in the study. The average age was
56.8 years (613.2 years), 90.2% were female and the average duration of
cough, 12.2 years (614.9 years). Of these, 46 (90.2%) had dyspepsia, and
partial or complete improvement of symptoms of cough with proton pump
inhibitor. Of the 46 symptomatic patients, only 18 (39.1%) had esophagitis on
UGE; however, 36 patients (78.3%) had posterior laryngitis on FNL. Seven-
teen patients also underwent esophageal biopsy, and 15 examinations identi-
ﬁed esophagitis. Nine (60%) of these patients had only posterior laryngitis on
the FNL (UGE without esophagitis).
Conclusions: Fibronasolaryngoscopy was more sensitivity than upper
gastrointestinal endoscopy to conﬁrm gastroesophageal reﬂux disease.
Although the indication for biopsy of esophagus follows standardized criteria,
this study suggests that in patients with chronic cough, if there is an indication
for the performance of UGE, it would be interesting to complement with
biopsy of the esophagus.
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Botox Injections in Larynx as a Treatment for Vocal
Cord Dysfunction
Juan Esteban Perez, Thanai Pongdee, MD, and Juan Guarderas, MD. Allergy
and Pulmonary Medicine, Mayo Clinic, Jacksonville, FL.
Background: Vocal Cord Dysfunction (VCD) is a respiratory condition in
which vocal cords restrict airﬂow by closing during inspiration. Symptoms
include shortness of breath, coughing, chest tightness and wheezing. These
symptoms are commonly reduced with breathing exercises to relax the
chest and throat. VCD is often misdiagnosed as asthma and treated as such.
Studies have shown that steroids used to treat asthma are not beneﬁcial in
the treatment of VCD, and are therefore unnecessary. Recent studies
suggest that Botox injections to relax the thyroarythenoid muscles
surrounding vocal cords resulting in an improvement in the patient’s
airﬂow.
Methods:We followed a 56-year-old female patient over the course of a year
who had a history of upper espiratory infections, sinusitis, allergic rhinitis and
asthma reporting an increase in the severity of respiratory symptoms even
though successfully undergoing immunotherapy treatment and following
a regimen of asthma medication. Her symptoms included shortness of breath,
wheezing and trouble sleeping.
Results: Pulmonary function testing done elsewhere revealed that the patient
had a reduced lung capacity. After a consult with a speech pathologist, VCD
and Spastic Dysphonia (SD) were diagnosed. The symptoms where initially
treated with speech therapy. Four months later the patient noted a slight
improvement in her symptoms, but also attributed this to the fact that she had
developed behavioral ways to cope with symptoms. The possibility of Botox
injections was mentioned and the patient agreed to follow with this treatment.
Two 2.5 unit injections of Botox were administered in the thyroarythenoid
muscles via an EMG guided needle, without any complications. The results
from the procedure were very favorable. All her symptoms improved
signiﬁcantly. Lung function tests appeared normal, and she was able to
reduce the use of most asthma control medications. She received another dose
of Botox injections 6 months following the ﬁrst, and continues to do very
well.
Conclusions: Botox injections in the thyroarythenoid muscles are a successful
treatment option for VCD patients with dysphonia. With this treatment
patients are able to minimize respiratory symptoms and inhaled steroid use. A
larger, randomized study with patients diagnosed with VCD alone should be
considered.
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Myasthenia Gravis and Asthma, Relationship between Two
Different Disorders of the Immune System
Andrea Aida Velasco-Medina,MD, Adriana Barreto-Sosa,MD, Aida Gonzalez-
Carsolio,MD, Andres-Leonardo Burbano-Ceron,MD, and Guillermo Velázquez-
Sámano,MD. Servicio de Alergia e Inmunología Clínica, Hospital General de
México, Mexico City, Mexico.
Background: Myasthenia gravis is an autoimmune disease caused by absence
of neuromuscular transmission due to antibodies directed against the nicotinic
AChR located at the neuromuscular junction. The main symptoms include
muscle weakness in the affected muscles, which is worse after its use. Diagnosis
is made upon clinical manifestations and ﬁnding of IgG. Only 80 to 90% of
patients with generalized disease are positive to these antibodies, and 30 to 50%
with ophthalmologic manifestations. Other immunological alteration found in
these patients is an overexpression of the low afﬁnity IgE receptor (CD23).
Asthma is characterized by shortness of breath, cough, wheezing and chest
tightness caused by inﬂammation and a reversible contraction of bronchial
smooth muscle. Immunologically is associated with a Th2 cytokine proﬁle,
mainly Il-4, Il-5, Il-13 and an increased IgE.
Methods: Allergic and autoimmune diseases represent an altered response of
the immune system. Here we discuss the case of a patient who presented with
an allergic disease at ﬁrst then years later developed an autoimmune disease.
Results: Our patient had been diagnosed with persistent allergic rhinitis and
asthma since 1992. He had been treated with inhaled corticosteroids,
bronchodilators, intranasal corticosteroids, antihistamines and speciﬁc im-
munotherapy with control of symptoms. In June 2010 he noticed diplopia,
palpebral ptosis and muscle weakness in upper extremities diagnosed with
Myastenia gravis and started treatment with piridostigmine with adequate
control of muscular symptoms. No thymoma was identiﬁed.
Conclusions: It has been noted the possible relationship between allergic and
autoimmune diseases since in both there is an alteration in the regulatory
mechanisms of the immune system. In this patient, we found the association
between asthma and 19 years later the development of myasthenia gravis.
Some of the explanations for this kind of association is the expression of
CD23 in myasthenia gravis, which is a receptor found in B cells, among
others, responsible of the increased production of IgE. Besides, autoimmune
and allergic diseases share some pathogenic characteristics such as their
inﬂuence by viral infections. They are one of the main factors associated with
asthma exacerbations and it is suggested that they cause tissue damage,
exposure to self-antigens and molecular mimicry.
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Immunological Characteristics of Patients withBronchialAsthma
and Obesity
Anna Konischeva, Valentina Gervazieva, MD, and Ekaterina Lavrentyeva.
Mechnickov Research Institute for Vaccines and Sera, Moscow, Russia.
Background: The problem of obesity-related diseases is current and
worldwide increasing. We aimed to estimate the relationship between obesity,
it’s biomarkers and immunological features of bronchial asthma (BA) in
obese patients as compared to healthy people with different BMI.
Methods: Body mass index (BMI) was evaluated in 57 adult patients with
atopic BA, 23 patients with allergic rhinitis (AR) and 25 healthy people.
Spontaneous production of TNF-a and IL-4 from blood lymphocytes and
levels of C reactive protein (CRP), total IgE and leptine were detected in
serum samples using ELISA kits. Levels of IgE- autoAbs to keratin, III and
VI collagen types and elastin that showed association with BA severity in our
previous data were also measured by ELISA.
Results: Atopic patients with BMI . 30 kg/m(2) in groups with AR and
with BA had elevated levels of C-reactive protein (744 6 28 ng/mL) and
high spontaneous production of TNF-a (456 4 ng/mL) and IL-4 (9.56 2.8
ng/mL) in comparison with normal-weight patients and healthy (7.3 6 2.7
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ng/mL, 3 6 0.6 ng/mL and 1.7 6 0.3 ng/mL accordingly). BMI was
considerably associated with BA severity (R ¼ 0.4) and IgE-autoreactivity
only in obese asthmatics (R ¼ 0.58; P ¼ 0.01), which showed raised IgE-
autoAbs to keratin (11.6 6 2 IU/mL) and collagen III (1.03 6 0.3 IU/mL)
in comparison with preobese (6.7 6 1.5 IU/mL, 0.3 6 0.01 IU/mL) and
nonobese patients. The levels of total IgE in all groups showed no associ-
ation with BMI and serum leptine concentration. Leptine level correlated
with CRP (R ¼ 0.59) and BMI (R ¼ 0.4) and appeared to be overproduced
in obese (57 6 7.1 ng/mL) via non-obese (23 6 6 ng/mL) asthmatics, as
compared with AR patients and healthy subjects independently from BMI
(6.1 6 0.3 ng/mL) and therefore was associated with BA but not atopy in
overweight patients.
Conclusions: In obese patients with atopy the adipose mass represents an
important source of inﬂammatory cytokines whereas it’s mediators, such as
leptine appears to impact especially in pathogenesis of BA in comparison
with AR. Obesity is attended with higher generation of autoIgE-Abs, which
elevated levels can indicate the disturbance of normal immune regulation. So
asthmatics with higher BMI, show a special phenotype of disease which
needs to be managed and treated distinctly.
ASTHMA DIAGNOSTIC TOOLS
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Bronchial Hyperresponsiveness in Obese Adolescents
Gabriela Ramírez, MD, and Blanca del Rio, MD. Pediatric Allergy and
Clinical Immunology, Hospital Infantil de México Federico Gómez, México
City, Mexico.
Background: Identify the frequency of bronchial hyperresponsiveness in the
obese and morbid obese adolescent. Compare the results of the direct
challenge with gender and BMI.
Methods: We analyzed 215 bronchoprovocation challenges of adolescents
from 10 to 18 years old in the period 2006 to 2010. We classiﬁed them in 3
groups: eutrophic (BMI , p85), obese (BMI p90–99) and morbid obeses
(BMI . p99) without smoking contact of pulmonar disease. A basal spirom-
etry was performed according to the ATS guidelines. If the FEV1 was above
80% for age and gender we performed the methacholine challenge. We use
the dosimeter method with the following methacholine dilutions: 0.0625 mg,
0.25 mg, 1 mg, 4 mg and 16 mg. When a provocation concentration caused
a 20% FEV1 reduced was considered a positive challenge for bronchial
hyperresponsiveness (BHR).
Results: Of the 215 adolescents in this study: 40 were eutrophic, 116 obese
and 59 morbid obese. The methacholine challenges were positive in 12% of
eutrophic, 22% of morbid obese and 25% of obese. But there were not
a statistically signiﬁcant difference. Gender was not associated as a risk factor
for bronchial hyperresponsiveness. The positive bronchoprovation challege in
women was observed in 27.6% of morbid obese, 23.7% of obese and 5% of
eutrophic; in men 26.3% of obese, 20% of eutrophic and 16.7% of morbid
obese. There was not a stadistically signiﬁcant difference.
Conclusions: It is necessary a larger number of patients to concluded that
BMI and gender are not associated with increased bronchial hyper-
responsivess.
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Development of a Questionnaire for the Assessment of Bronchial
Hyperresponsiveness in Korea
Seong Yong Lim, MD, PhD,1 Kwang HA Yoo, MD, PhD,2 Jae-Jeong Shim,
MD, PhD,3 and Kwan Hyung Kim,MD, PhD4. 1Internal Medicine, Kangbuk
Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul,
South Korea; 2Internal Medicine, Konkuk university medical center, Seoul,
South Korea; 3Internal Medicicne, Korea Univesity College of Medicine,
Seoul, South Korea; 4Internal Medicine, Catholic University Medical Col-
lege, Uijeongbu, South Korea.
Background: Bronchial hyperresponsiveness (BHR) is an important
pathophysiological feature of asthma. In addition to the diagnostic
signiﬁcance, BHR is associated with the severity of airway inﬂammation
and BHR- based treatment approaches has been shown to be effective.
Nevertheless, challenge tests are time consuming, inconvenient to
patients, and are not accessible in every primary care physicians. We
aimed to develop a questionnaire for the assessment of BHR in Korean
subjects.
Methods: From the 24 University-afﬁliated hospitals, we recruited 149 adults
between age 20 and 40 years with more than one asthmatic symptom (cough,
sputum or dyspnea) and who had bronchial provocation test. A list of 33
symptoms, past history of allergy or smoking and 10 provoking stimuli were
selected for the BHR questionnaire. After a methacholine challenge test
patients were asked to complete each questionnaire. For each item of
questionnaire, diagnostic odds ratios for the presence of BHR were calculated
and multiple logistic regression analysis was performed to select ﬁnal
questionnaire items. Receiver operating characteristic (ROC) curve analysis
was used to evaluate the sensitivity and speciﬁcity of the selected
questionnaire items.
Results: Methacholine challenge test was positive in 36 patients (24.2%).
Eleven symptoms and 2 provoking stimuli items were statistically
signiﬁcant by the results of diagnostic odds ratio. According to the result
of multiple logistic regression analysis, 4 items were ﬁnally selected for the
signiﬁcant BHR questionnaire: the presence of wheezing episode, past
history of physician-diagnosed asthma, family history of asthma. The
psychiatric stress was negatively associated provoking stimuli item for the
presence of BHR. The area under the ROC curve was 0.80 (95% CI, 0.72-
0.86). Sensitivity was 84.9% (95% CI, 68.1-94.9) and speciﬁcity was
65.5% (95% CI, 55.8-74.3).
Conclusions: Four BHR questionnaire items including wheezing episode,
past history of physician-diagnosed asthma, family history of asthma and
psyachiatric stress stimuli were able to assess the presence of BHR in Korean
adults.
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Clinical Analysis of Salbutamol Responsiveness after
Acetylcholine-induced Bronchoconstriction in ChildhoodAsthma
Tomio Kondo, MD, PhD,1 Yoshiki Nakashima, MD, PhD,2 and Hiroaki
Shikano, MD, PhD2. 1Department of Pediatrics, Hirano General Hospital,
Gifu-city, Japan; 2Department of Pediatrics, Ogaki Municipal Hospital,
Ogaki-city, Japan.
Background: The bronchodilator is usually inhaled after the acethylcholine
(Ach) inhalation test for asthmatic patients. We investigated clinical
characteristics of asthma about the response to a inhalation of salbutamol
after the Ach provocation test.
Methods: Asthmatic patients from 6 to 18 years old were examined. They
inhaled aerosol with increased concentration of Ach to produce 20% or more
decrease in FEV1.0 (RT-Ach point). After then they inhaled salbutamol, and
respiratory function was examined after 0, 5, 10, and 15 minutes. We divided
the patient into 4 groups (G0,G5,G10,G15) by the recovery time up to
baseline FEV1.0 after inhalation of salbutamol.
Results: Pre-provocated baseline FEV1.0, the rate of actual FEV1.0 /pre-
dictive FEV1.0, RT-Ach and FEV1.0 at the point of RT-Ach were lower in
the G0 than other groups signiﬁcantly. Complication of exercise induced
asthma (EIA) and increased rate of FVC after the inhalation of salbutamol
were higher in the G0. Serum IgE, eosinophil count of peripheral blood was
not different in these groups.
Conclusions: We investigated about the response to salbutamol after the
provocation of Ach for childhood asthma. Bronchial constriction and
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hyperresponsiveness exit prior to challenge Ach in the group of early
response to b2-agonist after the provocation test.
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Preoperative Cardiopulmonary Exercise Testing (CPET) in
Severe Asthma Patients
Ekaterini Syrigou,1 Anastasios Kallianos,2 Sotirios Tsimpoukis,2 Nektaria
Makrilia,2 Ioannis Dannos,2 Fotis Psarros,1 and Kostas N. Syrigos2. 1Depart-
ment of Allergy, and; 2Oncology Unit, 3rd Department of Medicine, Sotiria
General Hospital, Athens School of Medicine, Athens, Greece.
Background: Lung resection is still the only potentially curative therapy for
patients with localised non-small lung cancer (NSCLC). However, the
presence of cardiovascular comorbities and pulmonary function impairment
increase the risk of perioperative death and postoperative complications.
Various studies have evaluated the use of different preoperative tests aiming
to identify asthma patients at greater risk for complications.
Methods: A literature search was performed in Pubmed to identify relative
studies published until June 2011.
Results: Postoperative complications are associated with prolonged hospital
stays and excessive morbidity and mortality especially in this group of
patients. According to the ACCP/BTS guidelines, patients without known
underlying lung disease with a preoperative FEV1 in excess of 2 L, generally
tolerate pneumonectomy whereas those with FEV1 greater that 1.5 L, tolerate
lobectomy. Although spirometric values strongly correlate with the severity
of obstruction, they do not provide direct information regarding the degree of
gas exchange impairment or the status of cardiovascular function. Cardio-
pulmonary exercise testing (CPET) is a preoperative test suggested before
lung resection in patients with known underlying cardiovascular or lung
disease. It is based on the interactions among pulmonary function,
cardiovascular function and oxygen absorption from the peripheral tissues.
Patients with maximal oxygen consumption (VO2 max) ,10 mL/kg/min or
those with VO2 max, 15 mL/kg/min and both postoperative predicted FEV1
and DLCO,40% are considered to be at high risk of perioperative death and
cardiopulmonary complications postoperatively. Studies have shown that ox-
ygen uptake efﬁciency slope, oxygen pulse and heart rate at peak exercise are
correlated with better postoperative outcome.
Conclusions: Further research is required to elucidate the role of CPET in the
preoperative evaluation of this group of patients.
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Annual Change of Peak Expiratory Flow Rate in Asthma
and COPD
Kwang H. A. Yoo, MD, PhD, and Kye Young Lee, MD, PhD. Internal
Medicine, Konkuk University Medical Center, Seoul, South Korea.
Background: Peak Expiratory Flow Rate (PEFR) is a useful measurement for
the follow-up examination in a chronic airway disease because it has the
advantage of simple measuring and repetitive examination. The aim of this
study is to examine the annual decrease of PEFR in asthma and COPD
patients and to conﬁrm the factors which inﬂuence the annual decreasing rate
of PEFR.
Methods: From May, 2003 to September, 2010, the annual decreasing rate of
PEFR is obtained from the asthma and COPD patients attending an outpatient
pulmonary clinic. PEFR was measured using Mini-Wright (Clement Clarke
International Ltd. UK). We conducted an analysis of the factors to inﬂuence
on the change of PEFR and the average of it.
Results: The result indicated decrease of 3.72 6 12.55 L/min annually in the
asthmatic patient and decrease of 8.69 6 8.87 L/min annually in the COPD
patient. In the asthma, age and FEV1 are the predictive factor to inﬂuence on
the change, on the other hand, age, FEV1, smoking and the number of
aggravation are the factors in the COPD.
Conclusions: We could conﬁrm the annual decreasing rate in patients of
chronic airway disease and similar factor with FEV1 to inﬂuence on the
change.
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Evaluation of Chest Computed Tomography in Patients
with Asthma
Fernanda Guerra Montenegro, MD,1 Ana Príscia Castro-Coelho, MD,1 Carla
Bisacione, MD,2 Marcelo Vivolo Aun, MD,1 Jorge Kalil, MD, PhD,1
Pedro Giavina-Bianchi, MD, PhD,1 and Rosana Camara Agondi, MD, PhD1.
1Clinical Immunology and Allergy, University of Sao Paulo, Sao Paulo,
Brazil; 2University of Sao Paulo, Sao Paulo, Brazil.
Background: Asthma is an inﬂammatory disease of the airways. The
pathophysiological effects of airway obstruction include air trapping and
dynamic hyperinﬂation. The investigation of asthma is usually performed
through pulmonary function tests. The assessment of asthma by radiological
methods is required to rule out other causes of bronchospasm or out
complications. The aim of this study was to evaluate the changes found in
the chest computed tomography (CT) in patients with persistent asthma.
Methods: Sixty-nine patients of both genders and above 18 years of age,
accompanied by persistent asthma, participated in the study. The charts were
analyzed for severity and onset of symptoms of asthma, spirometry, search of
speciﬁc IgE and chest tomography.
Results: The mean age was 55.7 years, 71% female. Asthma began in
childhood in 55.8% of patients. All patients had persistent asthma, divided
into 66.7% of severe asthma, 29% moderate and only 4.3% mild. Only 14.5%
of spirometry was normal. Atopy, assessed by clinical history and research of
speciﬁc IgE was observed in 75.8% of patients. Regarding CT scans of the
chest, the primary ﬁndings were bronchial wall thickening in 70% of patients,
nodules in 25%, and atelectasis in 25%. The bronchiectasis was present in
20% of CT scans of the chest, and signs of emphysema in 10% of them.
Conclusions: In this trial, the CT scans of the chest were primarily indicated
for patients with severe persistent allergic asthma. Bronchiectasis was found
in 20% of tests, suggesting that CT scan of the chest should be required for
patients with partial response to conventional treatment, mainly in patients
with severe asthma.
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Exercise-induced Airway Obstruction and Vitamin D Deﬁciency
Davide Varenni, MD,1 Enrico Hefﬂer, MD,2 Martina Papurello, MD,1
Beatrice Culla, MD,1 Luisa Brussino, MD,3 Giuseppe Guida, MD,3
Caterina Bucca, MD,1 and Monica Masoero, MD1. 1Department of Clinical
Pathophysiology, University of Turin, Turin, Italy; 2Biomedical Sciences and
Human Oncology, Allergy and Clinical Immunology, University of Torino,
AO Mauriziano Umberto I, Torino, Italy; 3Department of Biomedical Science
and Human Oncology, University of Turin, Turin, Italy.
Background: Exercise-induced (EI) symptoms may be associated with
bronchospasm (EI-B), or laryngospasm, that is a paradoxical VC adduction
(VCD) mimicking asthma. We previously found that vitamin D deﬁciency
(Ddef) favours the occurrence of VCD during hyperventilation test (HV),
particularly in hypocapnic conditions. We evaluated the occurrence of EI-B
and EI-VCD during HV in relationship with Ddef, in 37 non smoking young
athletes (24 males, 13 females, age: 13–25 years).
Methods: Each subject underwent HV (5 runs of one minute) either in
isocapnia (HViso, obtained breathing CO2 enriched air) or in hypocapnia
(HVhypo, obtained breathing normal air) in randomized order, one week
apart. Exhaled CO2 pressure was controlled breath by breath by a capnograph.
A 10% decrease in FEV1 was used as EI-B marker, a 25% decrease in MIF50
as EI-VCD marker.
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Results: Sixteen subjects (43%) were atopic, 6 (16%) reported past diagnosis
of asthma. No subject was assuming drugs or had suffered from respiratory
infections in the last month. All subjects had normal lung function tests. With
HViso 10 subjects had EI-B and 12 had EI-VCD. With HVhypo 8 subjects
had EI-B and 15 EI-VCD. Eighteen subiects (49%) had Ddef (serum 25-
hydroxycholecalcipherol , 25 ng/mL). Serum levels of vitamin D were
signiﬁcantly lower in athletes with than in those without EI-VCD, either with
HViso (19.1 6 1.8 vs 25.7 6 1.5 ng/mL; P ¼ 0.013) or with HVhypo (20.2
6 1.9 vs 26.2 6 1.8 ng/mL; P ¼ 0.029). No inﬂuence of vitamin D on EI-B
could be demonstrated. Vitamin D levels were signiﬁcantly related to the
decrease in MIF50 (as % of baseline) during the test (HViso: r ¼ 0.41; P
, 0.015 and HVipo: r ¼ 0.42; P ¼ 0.017).
Conclusions: Our young athletes had a high prevalence of paradoxical vocal
cord adduction during HV, which was strongly associated to Ddef. The high
prevalence of Ddef was expected, since the study was conducted during
winter in a town located beyond 458 latitude. Vitamin D deﬁciency may
favour laryngospasm by decreasing calcium availability, ATP production
and Ca-ATPase pump activity in the striate muscle cell, with consequent
tetanic contraction and delayed relaxation. The fact that alkalosis worsens
hypocalcemia accounts for the higher prevalence of laryngospasm observed
during HVhypo.
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Lung Age/Chronological Age Index as Indicator of Clinical
Improvement or Severity in Asthma Patients
Isabel Castrejon-Vázquez, MD,1 Maria Eugenia Vargas,2 Raúl Cicero Sabido,3
and Jorge Galicia Tapía3. 1Inmunologia Clínica y Alergia, Centro Medico Nacio-
nal ISSSTE, Distrito Federal, Mexico; 2Anﬁtriones Nacionales APR S.A. de C.V.,
Mexico, Distrito Federal, Mexico; 3Mexico.
Background: Spirometry is a very useful clinical test to evaluate pulmonary
function in asthma. However pulmonary function could be affected by the
sex, time of clinical evolution, lung age (LA) and chronological age (CA).
The aim of this study was to evaluate LA/CA as index of clinical
improvement or severity in asthma patients.
Methods: The tenets of the Declaration of Helsinki were followed, and all
patients gave their informed consent to participate in this study. Asthma
severity was evaluated according with GINA classiﬁcation. Spirometry was
performed at the beginning of this study, at 46 days, 96 days, 192 days and
after 8 months. Statistical analysis was performed using t test, 2-way
ANOVA test, correlation and multiple regression models as well as ROC
curves were also performed, a P , 0.05 was considered as signiﬁcant.
Results: 70 asthma patients were included (22 male and 48 female), mean CA
was 35-years old; mean LA was 48-years with a LA/CA index ¼ 1.4, time of
clinical evolution was 13 years. A LA/CA index ¼ 1 (range 0.5 to 0.9) was
observed in asymptomatic patients. LA/CA index over 1 were related with
airway inﬂammation, and a LA/CA index more than 2 correlated with GINA
step 3. Interestingly when we analyzed CA and LA, we observed that in
female group more than 10 years of difference between CA and LA, (GINA
Step2 and 3); while in male we observed (GINA Step1, Step2 and Step3).
LA/CA index # 1 was considered as normal.
Conclusions: LA/CA index is a good as clinical indicator of clinical
improvement or severity in asthma patients in with excellent correlation of
pulmonary function and age.
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Transition from Cough Variant Asthma to Asthma With
Reduced FEV1
June-Hyuk Lee,1 Sung Woo Park,2 An-Soo Jang,1 DoJin Kim,1 and Choon-
Sik Park1. 1Respiratory and allergy, Soonchunhyang University Bucheon
Hospital, Bucheon, South Korea; 2Division of Respiratory and Allergy Med-
icine, College of Medicine, Soonchunhyang University Hospital, Bucheon,
South Korea.
Background: Cough variant asthma (CVA) is one of the most common
causes of chronic cough. It may have been thought to be as a pre-asthmatic
condition. Some CVA patients show decreased lung function after diagnosed
as a CVA. This study aimed to see differences of clinical characteristics
between CVA with preserved FEV1 and CVA with reduced FEV1 after
diagnosis of CVA.
Methods: We searched medical records from January 2007 to May 2011.
Thousand six hundred sixty two patients were diagnosed as CVA. Among
1662 CVA patients, 284 patients were revisited to hospital with symptom of
chest tightness.
Results: Among 284, ﬁfty two (18.3%) patients showed reduced FEV1.
Mean interval between diagnosis of CVA and reducing of FEV1 was 305.5
days. There was no signiﬁcant difference of level of PC20 or other pulmonary
functional values between FEV1-reduced group and -preserved group.
Conclusions: Only small portion of CVA patients was transformed to asthma
with reduced FEV1, and most of CVA still preserved their lung function.
ASTHMA EPIDEMIOLOGY
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Epidemiology of Asthma Cases in the Allergy Service of a Third
Level Medical Center. Six Year Expirience
Luis Rafael Sanchez-Gallardo, MD. Immunoallergology Service, Issemym
Ecatepec Medical Center, Ecatepec De Morelos, Mexico.
Background: The creation of an Allergy service was required because of the
high frequency of allergic diseases among paediatric population in the general
consultation of a third level medical centre.
Objective: The purpose of this study is to report the cases of asthma
diagnosed in the Allergy service from a Third level medical centre since its
creation in July 2005.
Methods: This is a descriptive, retrospective, transversal study from July
2005 to February 2011. Selected medical records of patients apply for
diagnostic criteria for an allergy disease. GINA guide 2009 was used to make
diagnosis of asthma. Patients were classiﬁed by age and sex and ﬁnd out how
many of them skin prick test were made and also how many patients began
treatment with immunotherapy.
Results: Thirteen thousand seven hundred thirty seven consultations were
attended in the Allergy service between the time period mentioned above.
Two thousand three hundred thirty seven medical records of patients were
selected, 1608 patients applied for a speciﬁc diagnosis for an allergy disease
as follows: Asthma 411, Atopic Conjunctivitis 58, Atopic Dermatitis 180,
Allergic Rhinitis 869, Urticaria 90. Four hundred eleven patients completed
criteria for Asthma. Two hundred thirteen (51.8%) patients were female, 198
(48.2%) patients were male. Two hundred twenty seven (55.2%) patients
were found to be in the range of 0 to 9 years, 141 (62.1%) of them were
between 5 to 9 years. The majority of asthma patients were males in the range
of 5 to 9 years. Some increase in asthma cases were found in females between
30 and 40 years of age, 75 (35.2%) of total female cases, about 18% of total
cases of asthma. Skin prick test were made in 164 (40%) asthma patients. In
134 were positive to a speciﬁc allergen and began immunotherapy.
Conclusions: Asthma represents the second highest incidence in allergy
diseases among children. However, it is the main cause of hospitalization
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among allergy diseases because of the presence of crises that increases the
cost of medical attention. It is very important therefore to make a good
diagnosis of asthma early on in order to bring adequate treatment, including
immunotherapy. Education to these patients is also an important task, mainly
in children.
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Latin America Asthma Insight and Management (LA AIM): A
Survey of Asthma Patients in 5 Latin American Locales
Sandra González-Díaz, MD, PhD,1 Jorge Maspero, MD,2 Jose Jardim, MD,3
Alvaro Aranda, MD,4 and Paolo Tassinari, MD5. 1Hospital Universitario,
Medical School, Universidad Autónoma de Nuevo León, Monterrey, Mexico;
2Allergy and Respiratory Research Unit, Fundacion CIDEA, Buenos Aires,
Argentina; 3Pulmonary Department, Heart Institute, University of São Paulo
Medical School, São Paulo, Brazil; 4Hospital Auxilio Mutuo, San Juan, PR;
5Hospital de Clínicas Caracas, Caracas, Venezuela.
Background: In 2011, we conducted a comprehensive asthma survey in
Latin America with a 3-fold purpose: to explore the realities of living with
asthma, to identify the disconnect between expectations in asthma manage-
ment and the patient experience, and to identify unmet needs in asthma
management. The Latin America Asthma Insight and Management (LA AIM)
survey was modeled on similar programs in the US, Europe and Canada, and
the Asia-Paciﬁc region.
Methods: Face-to-face interviews of approximately 35 minutes’ duration
were conducted with respondents drawn from a national probability sample.
The survey was designed to include 2000 patients (400 patients/location)
across countries in Latin America (Argentina, Brazil, Mexico, Venezuela)
and the Commonwealth of Puerto Rico. Survey questions were organized
under the topics of asthma burden; impact of asthma on patients’ activities,
lifestyles, and work productivity; emotional burden; deﬁning and character-
izing symptoms; seasonal inﬂuences on symptoms; triggers; most bothersome
symptoms; and patient perceptions about current levels of control.
Results: The results from the LA AIM survey will become available in
November 2011. In the 2009 US AIM survey,1 2500 asthma patients aged
$12 years (adults, n ¼ 2186, and parents of adolescent respondents) were
interviewed by phone. Participants had a diagnosis of asthma, had taken
asthma medication, or experienced an asthma attack within 12 months of
the survey. Respondents in the patient sample were predominantly female
(69%, n ¼ 1732), aged $35 years (73%, n ¼ 1819), and had “not well-
controlled” or “very poorly controlled” asthma (71%), using National Asthma
Education Prevention Program guideline criteria. One in 4 respondents expe-
rienced symptom worsening at least weekly over the past 12 months: 11%
reported asthma exacerbations most days; another 14% reported them at least
twice weekly.
Conclusions: The US AIM survey provides a comprehensive depiction of the
current state of asthma burden and patient perceptions in the United States.
The LA AIM survey provides a view of the state of asthma across 5 distinct
Latin American cultures.
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Understanding ofAsthmaTerminology byPatients Interviewed in
the Latin America Asthma Insight and Management (LA
AIM) Survey
Jose Jardim, MD,1 Sandra González-Díaz, MD, PhD,2 Jorge Maspero, MD,3
Paolo Tassinari, MD,4 and Alvaro Aranda, MD5. 1Pulmonary Department,
Heart Institute, University of São Paulo Medical School, São Paulo, Brazil;
2Hospital Universitario, Medical School, Universidad Autónoma de Nuevo
León, Monterrey, Mexico; 3Allergy and Respiratory Research Unit, Funda-
cion CIDEA, Buenos Aires, Argentina; 4Hospital de Clínicas Caracas, Ca-
racas, Venezuela; 5Hospital Auxilio Mutuo, San Juan, PR.
Background: Patients often do not clearly understand the terminology
regularly used by their physicians to describe asthma symptoms and their
worsening, such as “attacks,” “exacerbations,” and “ﬂare-ups”, among others.
The Latin America Asthma Insight and Management (LA AIM) survey,
a large and comprehensive asthma survey being conducted in 2011, explores
differences across regions in the understanding of terminology to describe
asthma symptoms, asthma deteriorations, and other asthma-related concepts.
Methods: Adult participants aged $18 years with asthma responded to sur-
vey questions during 35-minute face-to-face interviews. The survey was con-
ducted in 4 Latin American countries (Argentina, Brazil, Mexico, and
Venezuela) and the Commonwealth of Puerto Rico. A sample size of 2000
patients (400 patients/location) was determined to provide an accurate na-
tional representation of the opinions and views of asthma patients. The survey
question on asthma terminology was designed to reveal respondents’ famil-
iarity with and understanding of asthma terms, such as “exacerbation,” “ﬂare-
up,” and “attack.”
Results: Results from the LA AIM survey will become available in
November 2011. In the US AIM survey,1 conducted via telephone with
2500 respondents (adults, n ¼ 2186, and parents of adolescent respondents),
only 24% of asthma patients participating in the US survey were familiar with
the term “asthma exacerbation.” In contrast, most asthma patients (97%) were
familiar with the term “asthma attack,” and 71% of them recognized the term
“asthma ﬂare-up.” Perceptions of the meaning of “asthma ﬂare-up” were less
varied across groups.
Conclusions: Distinctions exist in patients’ understanding of asthma ﬂare-ups
and asthma attacks; however, asthma exacerbations, the phrase used most
regularly by physicians, may not be well enough understood by asthma
patients for effective communication with them. The LA AIM survey was
designed to determine whether physicians and patients currently communi-
cate in a mutually understood terminology.
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AsthmaManagement in LatinAmerica: Learnings from the Latin
America Asthma Insight and Management (LA AIM) Survey
of Patients
Jorge Maspero, MD,1 Jose Jardim, MD,2 Sandra González-Díaz, MD, PhD,3
Alvaro Aranda, MD,4 and Paolo Tassinari, MD5. 1Allergy and Respiratory
Research Unit, Fundacion CIDEA, Buenos Aires, Argentina; 2Pulmonary
Department, Heart Institute, University of São Paulo Medical School, São
Paulo, Brazil; 3Hospital Universitario, Medical School, Universidad Autón-
oma de Nuevo León, Monterrey, Mexico; 4Hospital Auxilio Mutuo, San Juan,
PR; 5Hospital de Clínicas Caracas, Caracas, Venezuela.
Background: In 2003, the Asthma Insights and Reality in Latin America
(AIRLA) survey assessed, in part, perception, knowledge, and attitudes
related to asthma.1 In 2011 the Latin America Asthma Insight and Manage-
ment (LA AIM) survey was designed to ascertain the realities of living with
asthma, disconnect between expectations in asthma management and patient
experience, and unmet needs. Using results from our survey, we investigated
the advances made in asthma care and the challenges that remain for Latin
American patients with asthma.
Methods: Asthma patients aged $18 years from 4 Latin American countries
(Argentina, Brazil, Mexico, Venezuela) and the Commonwealth of Puerto
Rico responded to survey questions during 35-minute face-to-face interviews.
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A sample size of 2000 patients (400 patients/location) provided an accurate
national representation of the opinions of asthma patients. Questions probed
respondents’ views on topics such as patient-reported levels of asthma con-
trol, frequency and duration of exacerbations in the past year, and current and
recent use of asthma medications. Participants in both surveys had a diagnosis
of asthma, had taken asthma medication, or had an asthma attack within 12
months of the survey.
Results: Results from the LA AIM will be available November 2011. A total
of 2184 adults or parents of children with asthma took part in AIRLA by
phone or face-to-face interviews.1 In AIRLA, 54.0% of respondents reported
their disease as well- or completely controlled. However, only 2.4% met all
guideline criteria for asthma control. Further, 6% of AIRLA respondents
reported their asthma as severe; however, when guideline criteria were ap-
plied, 21% had severe asthma.
Conclusions: The responses in LA AIM shed light on whether there have
been meaningful changes since the 2003 AIRLA survey in patient perception
of their asthma control and that control as deﬁned by guideline criteria.
Because asthma morbidity is largely preventable, additional education is
required to teach patients that by more closely following asthma management
strategies outlined by current guidelines, more patients can achieve adequate
asthma control.
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Project for Prevention&Control of Asthma andAllergic Diseases
in Korea
Eun Hee Chung, MD, PhD,1 Seung-Hee Seo, MA,2 Hye-Jin Seo, MA,2 Hye-
Mee Jou, MA,2 Yun-A Kim, PhD,2 and Young Taek Kim, MD, PhD2.
1Pediatrics, National Medical Center, Seoul, South Korea; 2Division of
Chronic Disease Surveillance, Korea Centers for Disease Control and Pre-
vention, Osong, South Korea.
Background: The prevalence rate of allergic disease, one of chronic diseases,
has been recently increased due to changes of life style and numerous
environmental factors. In May 2007, the Ministry of Health and Welfare of
Korea established the comprehensive countermeasures to prevent and control
asthma and allergic disease in Korea and has pushed ahead with this project
related associations and academic experts together.
Methods: To improve the quality of life, reduce social and economic burden
through getting over allergic diseases, the evidence based healthcare policy
should be established about prevention and control of allergic diseases ; 1)
Campaign & education 2) Proper treatment & control 3) Construction of
environment friendly living 4) Construction of investigation, monitoring
and alert systems 5) Support the disadvantaged patients.
Results: This project has moved ahead according to each 5 major program ;
1) Establish and provide guideline for prevention & control, promote pre-
vention & control measures by cooperating with the private sector, operate an
education & information center for asthma and allergic disease, 2) Provide &
educate standard treatment guidelines, program development for a patient’s
self-treatment & control, 3) Create asthma and allergic disease friendly
school, improve the living environment to control the trigger of asthma and
allergic disease, 4) Establish an surveillance and monitoring system for
asthma and allergic disease, study on asthma & allergic diseases; cohort
study, develop and forecast an asthma index, 5) Support the patients of the
disadvantaged with treatment, improve the living environment of the disad-
vantaged patients
Conclusions: We expect that evidence based healthcare policy about
prevention and control of allergic diseases would improve the quality of life
by reduction inducing factor for allergic diseases, and minimize the
recurrence and aggravation by realization of the proper treatment and control
the trigger for asthma and allergic diseases.
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Asthma in the CIS-region: The Prevalence and Peculiarities of
the Course
Tatiana Slavyanskaya, PhD, MD,1,2 and Revaz I. Sepiashvili, MD, PhD1.
1Department of Allergology and Clinical Immunology, Institute of Immuno-
physiology, Moscow, Russia; 2Allergology & Immunology, University of Rus-
sia, Moscow, Russia.
Background: In this study there has been analyzed the data from
epidemiological studies on the prevalence and peculiarities of the course of
bronchial asthma (BA) among the adult (Ad), children (Ch) and teenagers
(Tg) in the CIS-region (CIS-R) over the past 5 to 10 years.
Methods: There has been used the results of studies of ISAAC, Statistical
Reports (SR) of the Republic Ministries of Health and Medical facilities; the
literature data.
Results: It has been established that BA is dominated in the structure of
allergic diseases (ADs) of the CIS-R. BA, on average, suffer from 7 to 48.3%
Ad and from 4 to 31% Ch. The highest incidence of BA among the
population, especially Ad is observed in Armenia, Belarus, Moldova,
Ukraine, Kyrgyzstan, Russia, Tajikistan. The actual incidence among Ch
and Tg was 21 to 40%, for the Ad-23 to 48%. In this case, the diagnosis of
BA was recorded by the SR in only 2.3% of children (Tg-3.2%, Ch-1.5%),
and Ad-less than 1%. In the structure of the severity of BA among Ch and Tg,
and Ad are dominated by mild forms of the disease (60 to 90% and 35 to 55%
respectively) as mild intermittent or mild persistent BA, which in most cases
are not diagnosed and do not receive adequate, timely assessment. The share
of severe and moderate BA according to the age accounted for between 2 and
48%. The structure of BA recorded by statistical morbidity, dominated the
moderate or severe forms of BA.
Conclusions: Thus, an analysis of existing data revealed that the mild forms
of BA were dominated. The true incidence is much higher, as the uptake to
the doctor takes place only in cases of the disease formed, earlier symptoms
often go undetected. Often BA has been diagnosed at later stages with severe
disease and complications. Uniﬁed account of the early features of ADs in
a particular region will not only develop a National Prevention Program of
ADs in the CIS-R, identify the main ways of their implementation, but also
will allow to plan Allergic service in each region, important element of which
is education and training of primary care physicians to identify early
symptoms of ADs.
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Asthma in the Elderly: A Mexican Point of View
Maria Rosario Perez-Chavira, MD. Clinic Of Asthma, Instituto Nacional De
Enfermedades Respiratorias, Mexico, D.F., Mexico.
Background: Asthma has been considered as mainly a childhood disease,
however, 4 to 8% of the aged population suffer from it. In the National
Institute of Respiratory Diseases (Instituto Nacional de Enfermedades
Respiratorias, INER) Asthma’s Clinic, in the year 2010, 1056 medical atten-
tion appointments were attended for patients of this group of age, representing
12.7% of total medical consults for asthma.In this study we describing the
characteristics of elderly patients with asthma of INER’s Asthma Clinic.
Methods: Descriptive, transversal, retrospective research. One hundred sixty
eight patients with asthma diagnosis were included, 60 years old and more,
subjects with other respiratory diagnosis were excluded, as those with tobacco
smoking of more than 10 packs, and those with exposure to other types of
smoke.
Results: 86% of the study group were women average age of 68.7 years old,
the Forced Expiratory Volume in the ﬁrst second (FEV1) average was of
76%. The 8.8% of patients had asthma diagnosed since childhood, and the
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rest onset with asthma symptoms at adulthood. Only 32% were submitted to
skin prick tests; 4.5% suffered difﬁcult asthma control; 56% of patients had
overweight or obesity; 17.8% suffered Diabetes Mellitus type II, 37.5% had
Arterial Systemic Hypertension and 3.75% had Ischemic Cardiopathy; 60%
of patients had Gastroesophageal reﬂux symptoms, and 5% presented
Obstructive sleep apnea. Most of the patients had a good control in Asthma
Control Test (ACT).
Conclusions: Asthma can initiate at any age, the advanced age is not directly
associated to certain changes in airway remodeling, or not major disease severity.
There’s a high persistence of co-morbilities. This study shows that it’s necess-
ary to study this age group further, a group that is gradually on the increase.
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Control of Asthma and Its Relationship to Quality of Life
in Adolescents
Camila Macca,1 Caroline Adachi,1 Iraí Santana,2 Ana Paula Beltran
Moschione Castro, MD, PhD,3 Cristina Miuki Abe Jacob, MD, PhD,1
and Antônio Carlos Pastorino, MD, PhD3. 1Instituto da Criança - Faculdade
de Medicina do Hospital das Clínicas da Universidade de São Paulo, São
Paulo, Brazil; 2Faculdade de Medicina do Hospital das Clínicas da Univer-
sidade de São Paulo, São Paulo, Brazil; 3Department of Pediatrics, Instituto
da Criança - Faculdade de Medicina do Hospital das Clínicas da Universi-
dade de São Paulo, São Paulo, Brazil.
Background: Asthma in adolescence is an important cause of morbidity,
affecting signiﬁcantly the quality of life. In order to facilitate the management
of asthma control and allow a better assessment of quality of life, symptoms
can be evaluated with questionnaires that reﬂect the multifactorial nature of
the disease.
Objective: Assessing asthma control and its impact on quality of life in
adolescents followed up in specialized ambulatory.
Methods: A cross-sectional study included 120 patients from a center of
reference, between 10 and 20 years, with a mean age of 13.8 years and 66%
male. Asthma was classiﬁed according to the GINA (2009) and 8% of
patients had intermittent asthma, 9% mild, 64% moderate and 19% severe
persistent asthma. At the time of consultation were applied two questionnaires
previously validated in Brazil: Asthma Control Test (ACT) and Pediatric
Asthma Quality of Life Questionnaire Adapted (PAQLQ-A). The ACT
included 5 items that assess asthma symptoms, use of rescue medication,
inﬂuence of disease on daily activities and patient perception of control of the
disease, giving a maximum score of 25. Patients with a score .18 were
considered controlled. The PAQLQ-A is composed of 23 questions, divided
into 3 areas: limitation of activities, symptoms and emotional function. The
responses are evaluated using a 7-point scale, with higher value indicating the
minimum commitment. In this study the data were statistically analyzed by
Spearman correlation, with signiﬁcant value , 0.05.
Results: Comparisons were made between the areas of PAQLQ-A versus
results of the ACT. Thus, correlating ACT and the area of symptoms was
found an r ¼ 0.7. In the emotional function was found an r ¼ 0.55 and in
limitation of activities an r ¼ 0.49. The 3 correlations were statistically
signiﬁcant with P , 0.001.
Conclusions: The use of questionnaires to assess quality of life and
evaluation of disease control showed great potential to improve health care
in chronic patients. Questionnaires are easy to apply and may allow a broader
assessment of disease and better recognition of the patient’s perception re-
garding their limitations and symptoms.
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The Leukotriene C4 Synthase (A-444C) Promoter Polymorphism
in Venezuelan Individuals with Asthma
Ingrid Quintana Quintero, MD,1 Juan de Sanctis, PhD,2 Jenny Garmendia,
MD,2 Mercedes Fernandez Mestre, PhD,1 and Dolores Moreno, MD3.
1Centro de medicina experimental, Instituto venezolano de investigaciones
cientiﬁcas, Caracas, Venezuela; 2Facultad de Medicina, Instituto de Inmu-
nologia de la UCV, Caracas, Venezuela; 3Servicio de Neumologia, Hospital
Universitario de Caracas, Caracas, Venezuela.
Background: Asthma affects approximately 300 million individuals of all
ages and ethnic groups worldwide. Previous studies have reported weak
associations between leukotriene C4 synthase (LTC4S) promoter poly-
morphism with the asthma phenotype, bronchial responsiveness to meth-
acholine, and the severity of asthma regardless of aspirin sensitivity. The
aim of the present study was to study the association between leukotriene
C4 synthase A–444C promoter polymorphism and susceptibility to
asthma.
Methods:Whole blood was collected from 144 ethnically mixed Venezuelan
subjects, classiﬁed in 2 groups: patients with asthma (n ¼ 90) and healthy
individuals (n ¼ 54). The LTC4S A-444C polymorphism was analyzed by
PCR-RFLP by using MspI restriction endonuclease. Frequencies were de-
termined by direct counting and Fisher’s exact test was applied to determine
frequency differences between groups.
Results: No difference in the distribution of the frequencies LTC4S (A-444C)
variants among control and patients was found. However, although no sig-
niﬁcant, the genotype AC of LTC4S was increased in control group (20%)
compared with asthma patients (12%) (P ¼ 0.09, OR ¼ 0.54, 95% CI,
0.2181-1.3583).
Conclusions: These preliminary results suggest that LTC4S polymorphisms
are not associated with the development of asthma and further studies are
needed to determine the role of genetic factors in this disease.
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Allergic Disorders Prevented by Helicobacter Pylori Colonization
Olf Herbarth,1 Stefan Roeder,2 Ulrike Rolle-Kampczyk,2 Matthias Richter,2
and Thomas Richter3. 1Environmental Medicine and Hygiene, University of
Leipzig, Faculty of Medicine, Leipzig, Germany; 2Helmholtz-Center for En-
vironmental Research, Leipzig, Germany; 3St. Georg Hospital, Leipzig,
Germany.
Background: Previous studies suggest that an association exists between
microbiological colonization and allergic disorders. The derived hygiene
hypothesis postulates that the increase in atopic diseases may in part be due to
diminished exposure to microorganisms. The study should contribute to clear
up whether the association exists focused on chronic microbial colonization/
infection and which type of infection does render the expected protection.
Methods: As part of a 3 times repeated cross-sectional epidemiological study
4925 children in total have been medical checked up. Gastrointestinal and
respiratory types of infection where considered: (1) gastrointestinal coloni-
zation (Helicobacter pylori detection using in vivo [13C] urea breath test) and
(2) respiratory infections (physician-diagnosed lower (bronchitis) and upper
(common cold) respiratory tract infections). Physician diagnosed allergic
asthma, atopic eczema, rhinitis allergica and allergic symptoms were selected
as allergic target variables.
Results: Descriptive: Whereas respiratory infections lead to higher
prevalence of the allergic disorders (not infected/infected: asthma 3/
10%, eczema 10/24%, hay fever 6/12%) Helicobacter pylori colonization
protects against allergies (not infected/infected: asthma 6/3%, eczema 16/
7%, hay fever 8/7%). Analytical: The descriptive results could be
conﬁrmed using a logistic regression adjusted for relevant confounders
(gender, smoking and passive smoking, parental predisposition, pets (like
cats), number of older siblings, duration of breastfeeding, socioeconomic
status) except and not signiﬁcant for rhinitis allergica. Related to asthma/
eczema/hay fever the adjusted odds ratios (aOR) for Helicobacter pylori
colonization were 0.58 (P ¼ 0.05)/0.48 (P , 0.01)/1.07 (P ¼ 0.75).
Contrary respiratory tract infection shows an amplifying effect on
asthma/eczema/hay fever of aOR 3.75 (P , 0.01)/1.96 (P , 0.01)/2.07
(P , 0.01).
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Conclusions: Helicobacter pylori colonization seems to protect against aller-
gic disorders in comparison with the effect of respiratory tract infections. The
hygiene hypothesis may be better explained when this kind of gastrointestinal
and respiratory tract infections are subtly differentiated.
ATOPIC DERMATITIS
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Early Clinical Differential Diagnosis between Infant Atopic
Dermatitis and Seborrheic Eczema
Rubens Marcelo Souza Leite, MD,1 and Adriana Aragao Craveiro Leite,
MD2. 1Departamento Medico, Camara dos Deputados, Brasilia, Brazil;
2Allergy, Instituto Saint Louis, Brasilia, Brazil.
Background: Clinical differential diagnosis between atopic dermatitis and
seborrheic eczema is sometimes difﬁcult. Early differential diagnosis is
important, since atopic dermatitis can be more difﬁcult to treat and may be
associated with asthma and allergic rhinitis.
Methods: In a cohort study, 96 infants with high risk for atopic dermatitis
were followed up from the maternal ward until they completed one year of
age. The infants were submitted to complete skin examination, monthly, for
a 1 year period. A full skin examination was performed and any sign of
eczema was registered. Therapy with hydrocortisone 1% cream was pre-
scribed. Eczema onset time, skin distribution, response to therapy and the
presence of pruritus were evaluated.
Results: 87 (96%) infants fulﬁlled the study criteria (physical examination at
least 10 months). Fivty four (62%) infants had signs of eczema during one year
follow up. Atopic dermatitis was diagnosed in 14 (16%) patients and seborrheic
eczema in 30 (34.5%) infants, with 10 (11.5%) classiﬁed as: both eczemas.
Atopic eczema onset was mainly between 2 and 4 months and seborrheic
eczema between 1 week and 3 months, with an important coincident period.
Facial eczema had similar onset and semiological aspect for both diseases in its
beginning. Head eczema was present in 40 (74%) eczema infants, 33 (82.5%)
with a posterior diagnosis of seborrheic eczema and 7 (17.5%) with atopic
dermatitis. After 3 to 5 months, axillar and groin folds eczema were the main
signs of seborrheic dermatitis diagnosis, while face, neck and limbs were the
main eczema sites in atopic dermatitis. The 10 infants with dubious eczema just
after 6 months could have a more accurate eczema diagnosis. Haniﬁn et Rajka
diagnostic criteria for infants showed to be useful just after 6 months, since
some of its criteria are evolutive. All patients improved with hydrocortisone
cream, but seborrheic eczema infants had a better response and prognosis, with
complete eczema resolution until 8 months. The presence of pruritus could be
securely established just after 6 months of age.
Conclusions: Continuous follow up is indispensable for Infant atopic
dermatitis differential diagnosis with seborrheic eczema. Eczema distribution
and therapy response are the best predictors for differential diagnosis in infant
eczema.
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Sensitization to Contactants in Patients with Atopic Dermatitis
Fausto Matsumoto,1 Cleide Alessandra Terada, 2 Marcia Mallozi, PhD,3
and Dirceu Solé, PhD4. 1Allergy and Clinical Immunology, UNIFESP/Fed-
eral University of São Paulo, São Paulo, Brazil; 2UNIFESP, São Paulo,
Brazil; 3Pediatrics, UNIFESP, São Paulo, Brazil; 4Department of Pediatrics,
Federal University of São Paulo, São Paulo, Brazil.
Background: Atopic dermatitis (AD) is a chronic inﬂammatory pruritic skin
disease with extensive interindividual variation and multiple internal and
external factors. In this study, we evaluated whether the atopic dermatitis
severity (SCORAD index), gender, age, age onset or the presence of Allergic
rhinitis (AR), Allergic conjunctivitis (AC) or Asthma has an inﬂuence on
contact sensitization to common contactant allergens.
Methods: 30 AD patients were evaluated in the Division of Allergy of
Federal University of São Paulo. AD was diagnosed according to the Haniﬁn
and Rajka’s criteria and all patients were currently under regular treatment.
Questionnaire (age, gender, age at onset, presence of AR, Asthma or AC),
clinical examination and skin patch tests were carried out on all patients at the
beginning of the study. Patients in regular use of oral CE; topical CE and/or
calcineurin inihibitor use or having active AD lesions in the back were
excluded from the study. Patch test was applied onto the upper back with 8
mm chambers attached with hypoallergenic tape and removed after 48 hours.
The interpretation of the test reactions was performed at 48th and 96th hour.
Results: Positive Patch-test reaction occurred in 14/30 (46.6%). Among those
with positive patch-test, Nickel was responsible for 42.8% and Thimerosal for
28.5%. All patients ﬁnished the study and no adverse reactions occurred.
Positive and negative Patch-test groups found no statistically signiﬁcant
difference (P . 0.05) when comparing: SCORAD index, sex, age, age of
onset and presence of AC, AR or asthma.
Conclusions: According to our results, sensitization to common contact
allergens in AD patients was more frequent than in normal subjects. Although
we did not found an explanation to these ﬁndings, indiscriminate exposure to
topic products should be avoided so that new sensitization or risk of
deteriorating AD occurs. The beneﬁts of avoidance to the contactants
considered positive should be evaluated in the follow-up of these patients.
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Sensitization to Aeroallergens and Risk of Respiratory Allergy in
Atopic Dermatitis Children
Natalya Migacheva, MD, PhD, and Tatiana Kaganova, MD, PhD. Paediat-
rics, Samara State Medical University, Samara, Russia.
Background: Infants and young children with atopic dermatitis (AD) are at
grate risk of developing respiratory allergy later in life with rhinitis, eye
symptoms, and sometimes asthma. The aim of our study was to describe the
sensitization patterns to inhalants in our young patients with AD and to assess
the relation between early sensitization to aeroallergens and the development
of respiratory allergy.
Methods: 80 children diagnosed of AD, aged from 11 to 34 months, were
included (51 male and 29 female). Seventy two of these 80 were followed up
to 7 years of age. Except a clinical examination, total IgE level was
investigated by ELISA, and analysis of speciﬁc IgE antibodies to aeroaller-
gens was performed with MAST CLA Allergen speciﬁc IgE Assay.
Nonparametric tests were used in comparative analysis.
Results: 79% of our infants with AD had increased level of total IgE (mean:
387 kU/L). Sensitization to inhalant allergens was determined in 52 atopic
dermatitis children (65%). The most relevant results were: 39 patients
(48.8%) were sensitized to pets, 36 patients (45.0%) were sensitized to
house-dust mites, 25 patients (31.3%) were sensitized to pollen, 17 patients
(21.5%) were sensitized to molds. During the follow up, 48% of patients
developed asthma and 52% allergic rhinitis. The mean age of respiratory
allergy onset was 29.8 6 3.9 months. At the end of our study the cumulative
prevalence of respiratory allergy symptoms was signiﬁcantly higher in chil-
dren with inhalant sensitization compared to children without sensitization to
aeroallergens (71% vs 18%, P, 0.001). The risk of asthma in that group also
was signiﬁcantly higher (68% vs 14%, P , 0.001).
Conclusions: Early sensitization to aeroallergens in AD children is associated
with increased risk of development of respiratory allergic symptoms later in
life.
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Quality of Life in Pediatric Patients with Atopic Dermatitis
Xiomara Lopez Campos, MD. Hogar Materno Leonor Pérez, Havana, Cuba.
Background: Atopic dermatitis (AD) is a common skin condition. The aim
of this study was to evaluate the impact of AD on the quality of life of
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children and their families establishing correlations with scores of disease
severity.
Methods: It was carried out an observational study of the correlations
between clinical indicators of severity and a questionnaire on quality of life:
IDQOL. The study also included scoring of eczema severity – ISAAC. One
hundred seventeen children with AD, fulﬁlling established diagnostic criteria,
and 396 children with no dermatologic diseases were investigated for
the effect of eczema on quality of life. Pearson’s correlation was used for
the correlation analysis and the comparison between the groups was carried
out using the Mann-Whitney test.
Results: Data analysis demonstrated signiﬁcant differences between the
scores for the 2 groups. The mean score in the eczema group was 9.2 (range
1–19) for IDQOL. The highest scoring questions for IDQOL referred to
itching and scratching, mood changes and problems caused by treatment.
For the ISAAC, the highest impact domains were treatment-related expendi-
ture and sleep disturbance affecting family members.
Conclusions: AD has a negative impact on the quality of life of pediatric
patients and their families. The individuals dealing with AD and their
families need more than just the physical treatment of symptoms.
Educational and psychological support for patients and their families in
addition to medical treatment of AD may improve their long-term physical
outcomes.
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Epidemiology of Atopic Dermatitis in the Allergy Service of
a Third Level Medical Center
Luis Rafael Sanchez-Gallardo, MD. Immunoallergology, Issemym Ecatepec
Medical Center, Ecatepec De Morelos, Mexico.
Background: The creation of an Allergy service was required because of the
high frequency of allergic diseases among paediatric population in the general
consultation of a third level medical centre.
Objective: The purpose of this study is to report the cases of Atopic
Dermatitis (AD) in the Allergy service from a Third level medical centre since
its creation in July 2005.
Methods: This is a descriptive, retrospective, transversal study from July
2005 to February 2011. Selected medical records of patients, some records
supplied by the Dermatology service, applied for diagnostic criteria for an
allergy disease. The EAACI/AAAI/PRACTALL/ 2006 guide was used to
make diagnosis of AD. Patients were classiﬁed by age and sex and ﬁnd out
how many skin prick test were made in such patients, and how many patients
began immunotherapy.
Results: Thirteen thousand seven hundred thirty seven consultations were
attended in the Allergy service between the time period mentioned above.
Two thousand three hundred thirty seven medical records of patients were
selected, 1608 patients applied for a speciﬁc diagnosis for an allergy diseases
as follows:
• Asthma 411; atopic conjuctivitis 58; atopic dermatitis 180; allergic
rhinitis 869; and urticaria 90.869 patients completed criteria for al-
lergic rhinitis.
• From 180 patients with diagnosis of AD, 111 (61.6%) patients were
female, 69 (38.4%) patients were male. Ninety six (53.3%) patients
were found to be in the range of 0 to 9 years. The mayority of atopic
dermatitis patients were females in the range of 0 to 14 years, with 82
(45.5%) patients.
• There was an increase of atopic dermatitis cases in females in the range
of 30 years compared with males (F 10/ M 3). In 111 patients with DA
skin prick test were made, only in 76 (42%) patients were positive and
began treatment with immunotherapy.
Conclusions: In this study, AD represents the third cause of allergy disease in
frequency among children. AD requires interdisciplinary management
because of dermatological and allergological aspects for treatment, including
immunotherapy. Education of parents and patients is also an important task in
the treatment of AD. The results of this study are helpful to improve
specialized medical attention in paediatric patients and adults with AD.
343
Gene-environment Interactions on the Development of Atopic
Dermatitis in Preschool Children: Mold is the Main
Environmental Factor
Hyung Young Kim, MD, and Soo-Jong Hong, MD, PhD. Department of
Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center, College
of Medicine, Ulsan University, Seoul, South Korea.
Background: Genetic factor and environmental exposure are recognized risk
factors for atopic dermatitis (AD) in children. It is known that fungus is the
representative environmental factor of AD. However, the relative and the
overall contributions of fungal exposure remain unexplored.
Methods: During July to August 2010 population-based cross-sectional
survey, we investigate 986 preschool children from 16 kindergartens of Seoul
and Gyeonggi-do province in Korea using a modiﬁed International Study of
Asthma and Allergies in Childhood (ISAAC) questionnaire. We investigated
5 mold exposure items (dampness stain, dampness damage, visible mold,
mold odor, house repair) in this survey. Multivariate regression analysis was
applied to determine impact of mold exposure as risk factor for AD.
Results: The prevalence of AD was as follows: lifetime symptoms, 28.0%;
symptoms in the past 12 months, 28.7%; lifetime diagnosis by questionnaire,
35.1%; treatment in the past 12 months, 16.6%; current AD (which was
deﬁned as lifetime diagnosis by questionnaire together with symptoms in the
past 12 months), 21.5%; and diagnosis by doctor’s examination on the spot,
14.6%. A parental history of AD and mold exposure and environmental
factors were independent risk factors for AD in preschool children. The co-
existence of a parental history of AD and mold exposure together was syn-
ergistically related to AD prevalence. When children with a parental history
of AD were exposed to mold (ex. mold odor), the risk for AD prevalence
increased up to 7 times. (OR 6.956, 95% CI, 2.599-18.615)
Conclusions: This investigation provides a high prevalence of AD and
a close relationship with mold. High prevalence of AD was detected by the
combined effect parental history of AD and mold exposure at infancy. These
ﬁndings suggest that early avoidance from mold exposure is important to
prevent the development of AD especially in the susceptible children.
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FcRg-mediated ImmuneResponsesModulate theExacerbation of
Clinical Symptoms in Atopic Dermatitis of NC/TND Mice
Kumiko Oida, DVM, Keisuke Oku, DVM, Keitaro Ohmori, DVM, PhD,
Akira Matsuda, DVM, PhD, Akane Tanaka, DVM, PhD, and Hiroshi
Matsuda, DVM, PhD. Tokyo University of Agriculture and Technology, Fuchu,
Tokyo, Japan.
Background: Although elevated speciﬁc IgG and IgE are observed in sera of
patients with atopic dermatitis (AD), their involvement in the pathogenesis of
AD remains to be determined. In this study, we investigated the contribution
of the immunoglobulin in AD by using Fc receptor common g-chain (FcRg)-
deﬁcient NC/Tnd mice.
Methods: NC/Tnd mice spontaneously develop the AD skin lesion when
they are raised in air-unregulated conventional circumstances, but not when
maintained under air-regulated speciﬁc pathogen-free conditions. We estab-
lished FcRg - NC/Tnd mice; those mice lacked FcRg-mediated immune
responses initiated by speciﬁc IgG and IgE. The clinical skin severity score
and scratching behavior were evaluated in FcRg-deﬁcient mice and wild-type
(WT) littermates. To examine histological features and distribution of mast
cells, tissue sections of the lesional skin were stained with hematoxylin-eosin
and toluidine blue, respectively. With regard to inﬂammatory cytokine pro-
duction, the mRNA expression was detected in the dorsal skin and the axil-
lary lymph node by real-time RT-PCR.
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Results: Although the absence of FcRg did not affect production of the
immunoglobulin, the clinical skin severity scores were lower in FcRg-/-
NC/Tnd mice by half than in conventional WT mice. On the other hand,
there were no differences in both scratching behavior elicited by dermatitis
and Th1/Th2 cytokine production between 2 groups of mice. In the skin
lesion of FcRg null mice, mild epidermal hyperplasia and immune cell in-
ﬁltration were observed. Particularly, mast cell numbers and their degranula-
tion were signiﬁcantly decreased in the skin of FcRg-deﬁcient mice.
Conclusions: FcRg was not critical to the onset of AD, because FcRg-de-
ﬁcient mice exhibited moderate dermatitis and scratching behavior compara-
ble to WT. On the other hand, although scratching behavior induced the
mechanical destruction of skin barriers and mast cell activation, the absence
of FcRg markedly attenuated the skin severity, immune cell recruitment in-
cluding lymphocytes, and mast cell degranulation. These results indicated that
the FcRg-mediated immune response by speciﬁc IgG and IgE regulate the
exacerbation of clinical symptoms in AD.
AUTOIMMUNITY
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Autoimmune Diseases and Risk of Stroke
Anita Arsovska, MD, PhD,1 Zoran Arsovski, MD, MSc,2 and Ante Popovski,
MD, PhD3. 1University Clinic of Neurology, Skopje, Macedonia; 2Allergy
and Clinical Immunology, Clinic of Pulmonology and Allergy, Skopje,
Macedonia; 3Private Neuropsychiatry Practice, Dr A. Popovski, Skopje,
Macedonia.
Background: To determine the frequency of patients (pts) with autoimmune
diseases who developed stroke and to analyse the associated risk factors.
Methods: We made a retrospective analysis of 251 pts with stroke,
hospitalized during 1 year period at the Department for Urgent Neurology.
Of them, we selected 7 pts with a history of autoimmune diseases.
Results: Three patients had systemic lupus erythematosus (SLE), 2 pts had
M. Behcet, one patient was diagnosed with Sneddon sy and one patient had
Vascullitis allergica leucocytoclastica. All pts were females, except one male
pt with M. Behcet. The average age was 49 6 11 years. Two patients with
massive ischemic stroke had a lethal outcome. Hypertension was found as an
independent risk factor for stroke in all pts (P , 0.01). Other risk factors
included chronic renal failure, antiphospholipid antibodies, hypercoagulable
state and symptomatic seizures.
Conclusions: The incidence of autoimmune diseases in patients with stroke
was 2.7% in our material. Hypertension was an independent risk factor for
subsequent stroke.
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Clinical Effects of Tocilizumab, a Humanized Anti-interleukin-6
Receptor Antibody, on Patients with Autoimmune and
Allergic Diseases
Toshio Tanaka, MD, PhD,1 Atsuyoshi Morishima, MD,1 Yoshihiro Hishitani,
MD,1 Yuji Yoshida, MD,1 Akihiko Nakabayashi, MD,1 Masako Ogawa,1
Mari Kawai, MD, PhD,1 Toru Hirano, MD, PhD,1 Keisuke Hagihara, MD,
PhD,1 Yoshihito Shima, MD, PhD,1 Masashi Narazaki, MD, PhD,1
Atsushi Ogata, MD, PhD,1 Tadamitsu Kishimoto, MD, PhD,2
and Atsushi Kumanogoh, MD, PhD1. 1Department of Respiratory Medicine,
Allergic and Rheumatic Diseases, Osaka University Graduate School of
Medicine, Suita City, Japan; 2Osaka University Graduate School of Frontier
Biosciences, Suita City, Japan.
Background: A humanized anti-interleukin-6 receptor, tocilizumab, has been
approved as a biological drug for the treatment of rheumatoid arthritis, systemic
juvenile idiopathic arthritis and Castleman’s disease. Since dysregulation of
IL-6 production also plays a pathologic role in other various autoimmune
and allergic diseases, we tested whether tocilizumab might have beneﬁcial
effect on refractory autoimmune or allergic diseases to conventional treatment
regimens.
Methods: After informed consent by patients and approval by the Ethics
Committee of Osaka University Hospital were obtained, patients were treated
with tocilizumab at 8 mg/kg every 4 weeks.
Results: The diseases for which off-label use of tocililizumab was performed
included amyloid A amyloidosis, relapsing polychondritis, systemic sclerosis,
HLA-B27 positive spondyloarthritis such as reactive arthritis and psoriatic
arthritis, polymyalgia rheumatica and polymyositis. After 3 injections of
tocilizumab amyloid ﬁbril deposits in the colon disappeared in a patient with
gastrointestinal AA amyloidosis, who was resistant to anti-TNF drugs and
disease-modifying antirheumatic drugs. In 2 patients with refractory relapsing
polychondritis, the continuous tocilizumab treatment for more than 3 years
could ameliorate clinical symptoms related to upper and lower airways and
stabilize the disease activity. The skin sclerosis of 2 patients with systemic
sclerosis became softened with reductions of 52 and 23% in the modiﬁed
Rodnan total skin score by the tocilizumab treatment. Two administrations of
tocilizumab led to the disappearance of joint swelling, pain and complete
resolution of symptoms in a patient with refractory reactive arthritis to several
therapeutic regimens for 4 years, whereas 2 patients with severe psoriatic
arthritis did hardly respond to tocilizumab. In a patient with polymyalgia
rheumatica, the tocilizumab treatment caused a reduction of the disease
activity score (PMR-AS) from 22.14 to 0.74, indicating remission. Creatine
phosphokinase normalized by 2 patients with polymyositis who had been
resistant to corticosteroids and immunosuppressive drugs, in association with
the disappearance of the high intensity zones in the thigh muscles on MR
images.
Conclusions: These clinical effects of tocilizumab suggest that it may be an
optional treatment for refractory autoimmune or allergic diseases although
further clinical trails will be essential.
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Association between Autoimmune Reactions, Herpes Infection
and Severity of Atopic Dermatitis in Children
Pavel Samoylikov,1 Valentina Gervazieva, MD,2 and Sergey Kozhevnikov3.
1Allergology, Mechnikov Research Institute of Vaccines and Sera, Moscow,
Russia; 2Mechnikov Research Institute of Vaccines and Sera, Moscow, Rus-
sia; 3Research Institute of pediatrics and pediatric surgery, Moscow, Russia.
Background: Atopic dermatitis (AD) is a chronic skin disease predominately
with the beginning in childhood. One hundred autoantigens and more are
capable of binding with autoantibodies in AD patients, including autoantigens
with common epitopes of EBV. Aim of study was to reveal IgE- and IgG-
autoreactivity to some tissue proteins and IgG-abs to some herpes viruses and
to compare the received dates with the severity of AD.
Methods: In the sera of 157 children with AD (from 1 to 17 years old) the
levels of IgG- and IgE-abs to keratin, collagen III and VI, elastin, myosin and
basic myelin protein were determined in adapted ELISA. The levels of IgG-
abs to HSV, CMV and EBV were determined using commercial kit of
ELISA. The level of total IgE and IgE-antibodies to allergens were detected
using an autoanalyzer.
Results: In all age groups of patients (with light AD, middle AD and severe
AD) elevated levels of total IgE were revealed, especially in children with
severe AD (Me ¼ 360 KU/L (80 – 1160); P , 0.05). An increased contents
of IgE-abs to keratin (Me ¼ 2.71 ME/mL (1.4–13.69); P , 0.05) and elastin
(Me ¼ 2.69 ME/mL (1.4–2.78); P , 0.05) and IgG-abs to keratin (Me ¼
296.21 mg/mL (127.88–342.01); P , 0.05) were revealed in children with
severe AD in comparison with healthy children. Whereas in children with
light AD the levels of these antibodies were not signiﬁcantly increased (P .
0.05), but were being increased in proportion to a severity of AD. We
revealed a correlation between the levels of total IgE and the levels of IgE-abs
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S111
to keratin in children with severe AD (r ¼ 0.35; P , 0.05). In addition we
revealed that the levels of IgG-abs to HSV were being increased in proportion
to a severity of AD. Maximal increased level of IgG-abs to HSV was in
children with severe AD (Me ¼ 2.93 units of OD (0.14–3.15); P , 0.05).
Conclusions: The detection of the elevated levels of the autoantibodies,
especially against the background of herpetic infection, ampliﬁes the
phenotypic and diagnostic criteria of severity of AD and allows the clinician
to choose the most adequate and effective treatment of AD patients.
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Immunomodulatory Effects of Extracorporeal
Photochemotherapy in Systemic Sclerosis
Margit Zeher,1 Gábor Papp, MD,1 Ildikó-Fanny Horváth, MD,1 Sándor
Baráth, PhD,1 Edit Gyimesi, PhD,1 Judit Végh, PhD,1 and Péter
Szodoray, PhD2. 1Clinical Immunology Division, Debrecen, Hungary; 2Institute
of Immunology, Rikshospitalet, University of Oslo, Immunologist, Oslo,
Norway.
Background: The aim of the present study was to evaluate the clinical and
immunomodulatory effects of extracorporeal photochemotherapy (ECP) in
systemic sclerosis (SSc).
Methods: In the study, we enrolled 16 patients with diffuse cutaneous SSc,
who received 12 ECP treatments in total. Skin involvement was assessed by
modiﬁed Rodnan skin score and high-resolution ultrasonography. Blood
samples were taken prior to the ﬁrst therapy and 6 weeks after each cycle.
Samples were also obtained from 16 healthy controls. Lymphocyte subgroups
were quantiﬁed by ﬂow cytometry, autoantibodies were determined by
ELISA technique, and levels of 17 circulating cytokines were measured by
multiplex cytokine assay. We used in vitro test to assess the changes in
suppressor capability of CD41CD251 Treg cells.
Results: After ECP treatments, the dermal thickness reduced and the
mobility of the joints improved. Internal organ involvement did not
deteriorate. Initially, patients had lower numbers and percentages of
peripheral NKT, Th1, Tr1 and CD41CD251 Treg cells, compared to
control values. Moreover, the suppressor activity of Treg cells was lower.
During the therapy, the values of Tr1 and Treg cells elevated, and the
suppressor capacity of Treg cells improved. Initially, patients had higher
numbers and proportions of NK and Th17 cells, compared to control
values. During the therapy, values of Th17 cells decreased. Levels of
CCL2 and TGF-beta decreased, while the concentration of IL-1Ra,
IL-10 and HGF increased during ECP.
Conclusions: ECP contributes to the restoration of the balance between
regulatory and effector immune mechanisms, leading to the deceleration of
disease progression.
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Detection of Anti-nucclear Antibodies (ana) Used for Diagnostic
Approach of Systemic Autoimmune Diseases. Correlation with
Double Stranded DNA (DSDNA) and Extractable Nuclear
Antigen (ENA) Antibodies
Ekarerini Anastasiou,MD, Anastasia Vakaloudi,PhD, Georgios Papadopoulos,
MD, Styliani Mavridou, MD, and Asimoula Koteli, MD. Immunology
Laboratory, General Hospital “Agios Pavlos”, Thessaloniki, Greece.
Background: To determine the correlation between the titer of ANA and
anti-dsDNA and anti-ENA antibodies and the contribution of ANA detection
to the diagnosis of connective tissue diseases (CTD).
Methods: Our samples consisted of 516 specimens, from Rheumatology
Department, collected during January 2010 – July 2010. The detection of
ANA was performed using indirect immunoﬂuorescence (IFA) and the de-
tection of anti-dsDNA and anti-ENA using ELISA.
Results: Of the 364 (70.54%) samples with negative ANA 4 (1%) had
positive anti-ENA and 2 (0.5%) had positive anti-dsDNA while positive
anti-ENA and anti-dsDNA were detected in the 44.73% (n ¼ 68) and 21%
(n ¼ 32) of the specimens with positive ANA respectively. The probability
of detecting positive anti-ENA and anti-dsDNA rises proportionately to the
titer of ANA. Speciﬁcally, the correlation between the probability of detect-
ing positive anti-ENA and the titer of ANA is 0.577 (P , 0.001) while the
correlation between the probability of detecting positive anti-dsDNA and
the titer of ANA is 0.18 (P ¼ 0.003). Probability calculations on the basis of
the ANA titer showed that samples with low titer ANAs (1:160 or less) had
low probabilities for positive anti-ENA. The receiver operating (ROC)
curves of the ANA titer for anti-ENA had a larger under the curve area
compared to the ROC curve for anti-dsDNA, indicating that ANA titer is
better for predicting anti-ENA than anti-dsDNA. The sensitivity of positive
ANA in the prediction of the anti-ENA and anti-dsDNA was 94.40% and
94.10%, the speciﬁcity was 81% and 75.10%, the positive prognostic value
was 44.70% and 21.10% and negative prognostic value was 98.90 and
99.50%.
Conclusions: The detection of ANA using indirect IFA has high sensitivity in
predicting the presence of specialized antibodies and may be used as
a screening method for the diagnosis of CTD. It is cost and time effective
too. Our study also shows that the ANA titer is useful in predicting anti-ENA.
Samples with low titer ANAs (1:160 or less) may not need a further test for
anti-ENA unless an ANA-associated disease is highly suspected. However
a test for anti-dsDNA should be considered in positive ANA samples at any
titer including low titers.
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The Vasculitis Induced by the Cerebrovascular Coil
Seido Ooka, MD, PhD,1 Satoshi Ozaki, MD, PhD,2 Hiromasa Nakano, MD,
PhD,1 Yukiko Takakuwa, MD,3 Hisao Nakamura, MD, PhD,4
Hidetaka Onodera, MD,5 Hidehiro Yamada, MD, PhD, and Shoichi Ozaki,
MD, PhD1. 1Division of Rheumatology and Allergy, Department of Internal
Medicine, St. Marianna University School of Medicine, Kawasaki, Japan;
2Neurosurgery, Yokohama Sintoshi Neurosurgery hospital, Yokohama, Ja-
pan; 3Division of Rheumatology and Allergy, Department of Internal Medi-
cine, Machida Municipal Hospital, Machida, Japan; Departments of
4Radiology, and; 5Neurosurgery, St. Marianna University School of Medi-
cine, Kawasaki, Japan.
Background: The treatment of a cerebrovascular coil is the popular
treatment for the cerebral aneurysm. It is treatment to insert a metal coil
in aneurysm. It is not reported the allergy of cerebrovascular coil. In Dec,
2019, a 57-year-old Japanese woman came to the neurosurgery hospital.
The cerebral aneurysm was treated by coil embolization. Two days later,
she was returned to hospital by left facial paralysis. Vasculitis was detected
on the peripheral artery of the coil by MRI (magnetic resonance imaging). It
was treated by prednisolone 60 mg/d, and paralysis was improved, although
slightly remained sequelae.
Object: To understand of necessity of long term steroid therapy, we
investigated metal allergy for coil.
Methods: The steroid was tapered and discontinued. The MRI was checked
every 3 months. When vasculitis recurs, tapering is canceled. Three kinds
of coils were used by embolization. Their coil consists of platinum and
tungsten mainly, but it is unknown about the other component metal. After
the steroid was discontinued, a patch test for 3 coil and LTT (lymphocyte
transformation test) for the contrast medium was indicated. It was
interpreted using ICDRG (INTERNATIONAL CONTACT DERMATITIS
RESEARCH GROUP) criteria. It was given her informed consent to this
study.
Results: After treatment of steroid, only Potassium bichromate was positive
and other 17 metals, including the platinum was negative by the patch test.
Two coils of the same type, was positive. The contrast medium was negative
by LTT. One month later, new lesion of vasculitis was detected on the
peripheral artery of the coil by MRI.
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Conclusions: It is a metal coil at risk of causing vasculitis. When it was
treated by coil embolization, the check of the allergy to metal is
recommended, because it was possible to experience permanent sequelae.
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Prevalence of Thyroid Peroxidase Autoantibodies (ANTI-TPO) in
Women with Autoimmune Connective Tissue Diseases (ACTD)
Georgios Papadopoulos, MD, Anastasia Vakaloudi, PhD, Eirene Koutsika,
MD, Ekarerini Anastasiou, MD, and Asimoula Koteli, MD. Immunology
Laboratory, General Hospital Agios Pavlos, Thessaloniki, Greece.
Background: Chronic autoimmune thyroiditis, manifested by positive test
for antithyroid antibodies, is common in the general population, occurring in
10 to 20 percent of women. The aim of the study was to determine whether
Anti-TPO is more prevalent in women with ACTD, compared to the general
population.
Methods: Anti-TPO was determined in 290 women diagnosed with ACTD
based on ACR (American College of Rheumatology) criteria and in 50
healthy women (control group). Among ACTD patients, 121 were diagnosed
with Rheumatoid Arthritis (RA), 44 Systemic Lupus Erythematosus (SLE),
43 Sjogren’s Syndrome (SS), 42 Systemic Scleroderma (SScl) and 40 Psori-
atic Arthritis (PsA). Anti-TPO was measured by Chemiluminescent Micro-
particle Immunoassay (CMIA) on Architect i2000SR (ABBOT Laboratories).
Results: The prevalence of Anti-TPO in separate groups of patients had as
follow: RA 28.93%, SLE 29.55%, SS 27.91%, SScl 23.81%, PsA 30% and
control group 12%.
Conclusions: ACTD and thyroid autoimmune diseases often overlap with each
other. Increased Anti-TPO may be most common among women patients with
ACTD. On the other hand, these systemic diseases are often present in
Hasimoto’s thyroiditis subjects. Therefore it is clinically important to screen
women patients with ACTD for the co-existence of thyroid disorders.
REFERENCES
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Anticardiolipin Antibodies in Patients with Acute Myeloid
Leukemia: Prevalence and Clinical Signiﬁcance
Maryam Ayatollahi,1 Mani Ramzi,2 Maryam Zakerinia,2 and Mehdi Dehghani2.
1Transplant Research Center, Shiraz University of Medical Sciences, Shiraz,
Iran; 2Bone Marrow Transplantation Center, Nemazi Hospital, Shiraz Univer-
sity of Medical Sciences, Shiraz, Iran.
Background: Leukemia in general is known to be associated with
coagulopathies. The presence of antiphospholipid antibodies was associated
with several medical problems, including recurrent spontaneous abortion,
arterial and venous thromboses, and thrombocytopenia. A number of studies
report the prevalence of anticardiolipin (ACL) antibodies in acute myeloid
leukemia (AML). This study was designed to explore the prevalence and the
clinical and prognostic signiﬁcance of ACL antibodies in patients with acute
myeloid leukemia (AML).
Material and Methods: The study includes 28 AML patients .15 years old
and with no evidence of infection at the time of enrollment. The previous
history of thromboembolism, recurrent abortion, and autoimmune disease was
given from patients. Serum level of ACL antibodies was determined by in-
direct enzyme immunoassay.
Results: ACL antibodies were found in 9 patients (32.14%). None of the
patients had high positive titers (.40 GPL). Two patients had moderately
positive (20–40 GPL), while 7 patients had low positive (10–20 GPL) ACL
antibody titers.
Conclusions: ACL antibody positivity was not correlated with the risk of
thromboembolism, fetal loss, and autoimmune disease. These preliminary
results demonstrate a prevalence of ACL antibodies in AML patients and
suggest that serum ACL antibodies may have a role in some haematological
malignancies. The correlation of ACL antibodies with predicting, relapse, and




Alopecia as a Symptom of Neonatal Lupus: A Report of Case
Aura Pellizzeri, MD, Durnes García, MD, Joselit Torres, MD, Mayra
Martínez, MD, Elianny Chavez, MD, and Diana Briceño, MD. Inmunology
and Allergolgy, Caracas, Venezuela.
Background: Neonatal Lupus is a rare disease, described in 1954, which
only occurs in children of mothers with antibodies to speciﬁc antigens of
Systemic Lupus Erythematosus (SLE). Such antigens pass, transplacentally
during gestation and is characterized by cutaneous manifestations such as
rash, erythematous macules, papules or plaques which tend to coalesce; less
frequent are blood disorders including aplastic anemia, neutropenia, throm-
bocytopenia, hemolytic anemia, pancytopenia; liver disorders with elevated
liver enzymes and cholestasis; central nervous system disease such as
mielopaias, convulsions; pulmonary as pneumonitis, and gastrointestinal
tract such as bloody diarrhea. Alopecia is a common symptom in SLE but has
not been reported in the literature in neonatal presentation.
Methods: Case report: A 1 month and 4 day old infant female, who
presented 3 days after birth with a persistent bloody diarrhea, without
mucus also presents dehydration and metabolic acidosis that warrant
intravenous correction. An infectious etiology is discarded and is referred
to an allergist for study of a possible lactose intolerance which is discarded
initially. However, the physical ﬁnding of hair loss is evident with areas of
alopecia which together with the persistence of the diarrhea and rash is
suspect of a possible immunological etiology. Therefore, it was decided to
test Anti-Ro autoimmunity in the infant and his mother; given a positive
results.
Results: With the Anti-Ro test the presence of Neonatal Lupus is conﬁrmed.
A treatment with EV-dose methylprednisolone was initiated, which had little
clinical response, meriting a treatment with azathioprine with a good clinical
response, which improved and reduced Anti-Ro values.
Conclusions: The importance of clinical observation is evident when there
are unusual features which allows for a rare diagnosis. This striking case,
given the unusual presentation with alopecia which together with the clinical
observations was indicative of this disease, and not of other syndromes
characteristic of this age, like sepsis.
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Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding
to Interferon/Ribavirine Therapy
Michal R. Pijak, MD, and Veronika Csibova2. 1Department of Internal Med-
icine, Slovak Medical University, University Hospital, Bratislava, Slovakia;
2Department of Long Term Care, Medical Faculty Hospital, Bratislava,
Slovakia.
Background: Latent autoimmune hepatitis (AIH) triggered during interferon
(IFN) treatment in patients with chronic hepatitis C (CHC) is well known.
Here, we report for the ﬁrst time improvement of AIH using IFN and ribavirin
(RBV) in a patient initially incorrectly diagnosed as having CHC.
Methods: Case report
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Results: 32 years old female was referred because of ﬂuctuating elevations of
aminotransferases (AT) (4- to 19-fold normal) known last 6 months. She had
positive HCV-RNA by RT-PCR an untypable genotype. Liver biopsy
revealed chronic active hepatitis grade 2, stage 2. She also had Hashimotos
thyroiditis with high titres of antithyroid antibodies. After 12 weeks of treat-
ment with Intron A 3MU TIW and RBV 1000 mg/d, HCV RNA was negative
and AT ﬂuctuated between normal and 2-fold normal. One week after com-
pleting 48 weeks of treatment, AT showed 11-fold increase, but HCV
remained negative. Indirect immunoﬂuorescence became positive for ASMA
(31) and ANA (41). A repeated liver biopsy showed no improvement. A
therapeutic trial with RBV was started and within 11 weeks of this treatment
her symptoms markedly improved and AT decreased to 2-fold. Unfortu-
nately, cessation of RBV resulted in immediate reversion of symptoms and
elevation of AT to its previous state. After restarting RBV therapy no re-
sponse was observed within 2 weeks and the treatment was stopped. She was
then put on prednisone 30 mg/d and azathioprine 50 mg/d. Within 6 weeks
her symptoms resolved and AT and IgG became completely normal. The
patient remains in remission with prednisone 5 mg and azathioprine 50 mg/
d. A re-evaluation of the primary diagnosis of hepatitis C was warranted
because of unusually high AT activity and repeatedly negative anti-HCV
using a third generation assay.
Conclusions: This case may provide support for the hypothesis that RBV
may dampen autoimmune reaction induced by IFN alpha and potentiate its
anti-inﬂammatory effects.
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Ocular Muscles Myopathy Associated with Autoimmune
Thyroiditis. Case Reports
Eugenia Vargas-Camaño, MD, Isabel Castrejon-Vázquez, MD, Sara I Plazola-
Hernández, MD, and Silvia Moguel-Ancheita, MD. Servicio de Inmunología
Clínica, CMN 20 de Noviembre, Mexico, Mexico.
Background: Thyroid-associated orbitopathy is commonly associated with
Graves’ disease with lid retraction, exophthalmos, and periorbital swelling,
but rarely with autoimmune thyroiditis or euthyroid state. We reviewed 3
cases from our hospital whose antibodies to anti-receptor of TSH were
normal.
Methods: Case 1: 60 year-old non-diabetic woman with bilateral glaucoma in
treatment, recurrent media otitis and euthyroidism, acute onset of painless
diplopia, and lid ptosis in the left eye. MRI of orbit showed increased size of
the III right cranial pair and high levels of thyroid autoantibodies (Tab) anti-
tiroglobulin (ATG) 115.1, anti-thyroid peroxidase (ATPO) 1751 U/mL. She
started oral deﬂazacort 30 mg each 3 days. Sixty days later, complete
remission of eye symptoms correlated with lower auto-antibodies level (ATG
19 ATPO 117). Case 2: 10 year-old girl. At age 8, she had diplopia, lid ptosis
and limitations of upper gaze in the left eye. The neurological study discarded
ocular myasthenia; with thyroid goitier, and hypothyrodism, she started oral
levothyroxin. At age 10 with normal IRM Botulinic toxin was injected,
without change. High levels of Tab were found, ATG 2723, ATPO 10.7. She
started oral deﬂazacort 30 mg each 3 days, azathioprin 100 mg, daily.
Actually, Tab levels are almost normal, but she remains with ocular
alterations. Case 3: 56 year-old woman, Graves disease with exophtalmos
in 1990, treated with I131 and immunosupression, with good outcome; obe-
sity, hypertension and bilateral glaucoma in treatment. She suddenly pre-
sented diplopia and IV pair paresia of the right eye. A year later, ATb
were found slightly elevated, ATG 100 years ATPO 227; despite prednisone
50 mg, each 3 days and azathioprin 150 mg/daily treatment, a surgical pro-
cedure was required for relieve the ocular symptoms.
Results: We found only 3 cases previously reported with this type of eye
thyroid disease. Is important to note that awareness of this atypical form of
orbitopathy
Conclusions: Early recognition facilitates successful treatment (Case 1) or
persistent disease when diagnosis is delayed (Cases 2 and 3).
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PulmonaryArterialHypertensionAssociated toAntiphospholipid
Syndrome in an Infant
Raul Dorbeker, MD, Daniela Lopez Ortiz, MD, Luisa Gamez, MD,
and Alonso Gutierrez Hernandez, MD. Allergy and Immunolgy clinic,
National Institute of Pediatrics, Mexico Distrito Federal, Mexico.
Background: Antiphospholipid syndrome (APS) is a systemic autoimmune
disorder characterized by a combination of arterial or venous thrombosis and
recurrent fetal loss. It may be primary or in association with an underlying
systemic disease, particularly systemic lupus erythemathosus.The diagnostic
criteria include vascular thrombosis, complications during pregnancy with
recurrent losses, positive titers of anticardiolipin and lupus anticoagulant
antibodies.Vascular thrombosis can occur anywhere in the body, including
lung vessels. The association of APS with pulmonary arterial hypertension
has been estimated between 1.8% and 3.5%.
Methods: Case Presentation: We present an 18 month old male boy, who was
admitted to our hospital with a history of 3 previous episodes of pneumonia,
at arrival with pulse saturation of 69% without oxygen, improving to 100%
with oxygen. Pulmonary arterial hypertension was documented with
echocardiogram resulting in 100 mm Hg without structural abnormalities.
An autoimmune etiology was suspected, resulting with high titers of
anticardiolipin (IgG 34.6 mg/dL) and anti-b2 glicoprotein (IgG . 200 mg/
dL, IgA 53 mg/dL).
Results: Treatment with acenocumarine, hydroxichloroquine and prednisone
was initiated. Nowadays he has evolved with clinical improvement, on its last
echocardiogram the pulmonary arterial tension resulted in 65 mm Hg, without
evidence of thrombosis.
Conclusions:We report an infant with pulmonary arterial hypertension as the
only manifestation of antiphospholipid syndrome, with clinical improvement
with anticoagulant and steroid therapy.
CONJUNCTIVITIS
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Tear IL-4 is Decreased in Allergic Conjunctivitis Patients with
Negative Skin Test After Dialyzable Leukocyte
Extracts Treatment
Gustavo Aguilar-Velazquez, MD, PhD,1 Concepcion Santacruz, MD,2
Pedro M Hernandez, MD,1 Raul Chavez, MD, PhD,3 Sergio Estrada-Parra,
PhD,4 Mayra Perez-Tapia, PhD,5 and Maria C Jiménez-Martínez,MD, PhD3.
1Research Unit, Department of immunology, Institute of Ophthalmology
"Conde de Valenciana", Mexico, Mexico; 2Department of Cornea, Institute
of Ophthalmology "Conde de Valenciana", Mexico, Mexico; 3Department of
Biochemistry, Faculty of Medicine, UNAM, Mexico, Mexico; 4Molecular Im-
munology Lab-I, National School of Biological Sciences, IPN, Mexico, Mex-
ico; 5Unidad de desarrollo e investigacion de biologicos, National School of
Biological Sciences, IPN, Mexico.
Background: It has been suggested that sublingual immunotherapy induces
immune regulation, however in patients with clinical ophthalmological
diagnosis as allergic conjunctivitis with negative skin test reactivity (ACNST)
this treatment is not useful. Dialyzable leukocyte extracts (DLE) have been
used in atopic dermatitis and asthma. The aim of this work was to evaluate
treatment of ACNST with DLE and to analyze the microenvironment
provided by tear and serum cytokines in patients before and after DLE
treatment.
Methods: 10 ACNST-patients with negative skin test were included in this
study. ACNST diagnosis was based on a clinical history and full ophthalmo-
logic examination according to the diagnosis standards of the American
Academy of Ophthalmology. Coproparasitoscopic negative for parasites was
documented This study was approved by Scientiﬁc and Ethics Committees if
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Institute of Ophthalmology “Conde de la Valenciana “, Mexico City an all
subjects gave their informed consent to obtain samples. Tear and Serum Sam-
ples were collected to determine cytokines IL2, IL-4, IL-5, IFN-g, TNF-a, IL-10
by cytometric bead arrays (CBA), following manufacturer’s instructions.
Results: Patients showed lower signiﬁcant levels of L-4 after 6 months of
treatment, without changes in IL2, IL5, TNFa and IL10. Signiﬁcant Clinical
improvement was also observed since 3 months of treatment and was
maintained until the end of 6 months.
Conclusions: DLE could be an excellent therapeutic tool to improve the
clinical outcome in ACNST patients; it is possible that clinical improvement




Histochemical Study of Allergic Inﬂammation in Conjunctiva
From Ovalbumin Sensitized Rabbits after Ocular or
Nasal Challenge
Rocio Batle, Miguel Vinuesa, MD, PhD, Norberto Bassan, MD, Adriel
Martinez, Florencia Giacomozzi, Soledad Chaparro, MD, Valentin Torres,
and Florencia Acebal,MD. Catedra Histologia, Facultad de Ciencias Medicas,
UNR, Laboratorio Inmunohistoquimica, Rosario, Argentina.
Background: We previously demonstrated that subcutaneous sensitization with
ovalbumin (OVA) induce generation of speciﬁc IgE antibodies and quantitative
modiﬁcations in immune cells populations from different mucosal sites in rabbit.
The aim of the study is characterization of eosinophil inﬁltration in conjunctival
mucosa from OVA sensitized and ocular and nasal challenged rabbits.
Methods: Animals were divided into 4 groups: G1 (n ¼ 9): normal control; G2
(n ¼ 10): subcutaneous sensitized with OVA; G3 (n ¼ 10): subcutaneous sensi-
tized and conjunctival challenged with OVA; G4 (n ¼ 9): subcutaneous sensitized
and nasal challenged with OVA. Four hours after challenge animals were sacri-
ﬁced and obtained samples were processed for histochemistry with cromotrope 2R
for eosinophil detection. Cells were counted in 200 high power ﬁelds per group.
Results: Data were expressed as positive cells per high power ﬁeld.
Conjunctival mucosa: G1: 2.3; G2: 3.4; G3: 12.2; G4: 3.3 (G3 vs G1, G2
y G4 P , 0.001). Speciﬁc anti-OVA-IgE levels were evaluated by positive
passive cutaneous anaphylaxis test (PCA) at 160 fold dilutions.
Conclusions:We observed an increase in the number of eosinophils-positive
cells after local challenge in conjunctiva as compared to normal controls
and sensitized and nasal challenged animals. We conclude that systemic
sensitization with soluble antigen and conjunctival challenge induces
modiﬁcations in number of eosinophil populations in conjunctiva but not in
nasal challenged rabbits.
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Prevalence of Allergic Conjunctivitis in Childhood
Marcos Geraldini, MD, Herberto Jose Chong Neto,MD, PhD, Carlos Antonio
Riedi, MD, PhD, and Nelson Rosario, MD, PhD. Allergy and Immunology,
Federal University of Paraná, Curitiba, Brazil.
Background: The prevalence of allergic conjunctivitis (AC) has not been
established. Estimates suggest that ocular allergies affect 15 to 20% of the
worldwide population yet most epidemiological studies encompasses nasal
and ocular allergy symptoms together and have not been speciﬁc with respect
to AC. The aim of this study was to verify the prevalence of ocular allergy
symptoms in adolescents.
Methods: Adolescents were selected from a sample of schools and self-
completed in classrooms a previously validated questionnaire on symptoms
of AC. AC was considered when more than 3 episodes of ocular itching were
reported in the past 12 months. Related symptoms as tearing, photophobia,
foreign body sensation, impact on daily activities, and diagnosis of allergic
conjunctivitis were analyzed.
Results: Questionnaires from 3120 adolescents (mean 13.36 1.1 years) were
analyzed. Ocular itching in the past 12 months occurred in 1,592 (51%). The
most frequent associated symptom was tearing (74%) followed by photopho-
bia (50.1%) and foreign body sensation (37.1%). The prevalence of allergic
conjunctivitis was 20.7% affecting more females (56.1% vs 45.9%; P ,
0.01). Moderate and severe interference in daily activities were reported by
66% and 21%, respectively. Diagnosis of AC was reported by 47% of them.
Conclusions: Symptoms of ocular allergy are common and cause great impact
on daily activities in adolescents. Accessing risk factors and the allergic status of
these patients should be the focus of future epidemiological studies on AC.
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Effects of Omalizumab in Children with Atopic
Keratocojunctivitis: A New Treatment for Severe Ocular
Allergies?dReport of Two Cases
Fábio Kuschnir, PhD,1 Fatima Emerson, MD,2 Nelson Cordeiro, MD,2
José Luiz Rios, MD,1 Silvio Lima Filho, MD,2 and P Bicudo, MD2. 1Poli-
clinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil; 2Allergy, Policlinica
Geral do Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Keratoconjunctivitis is a severe form of ocular allergy, difﬁcult
to control and with poor prognosis. The purpose of this study was to verify
the clinical efﬁcacy of humanized monoclonal antibody omalizumab
treatment in children with this condition.
Methods: Report of 2 cases of children with severe vernal keratoconjunc-
tivitis poorly controlled by the conventional therapeutic scheme that were
submitted to treatment with Omalizumab.The disease was scored according to
the severity by ophthalmologic evaluation (amount of viscous mucus, giant
papillae .1 mm, aspect of cornea/keratitis) and graduation of allergic symp-
tons (itching, tearing, photophobia), before and after the last subcutaneous
administration of Omalizumab.Evaluation by Parents/ guardians using the
same score, regarding to itchy eyes, runny eyes and photophobia, after
Omalizumab application, was also requested.
Results: Case 1: MPOS (7 years) with vernal keratoconjunctivitis and atopic
dermatitis since childhood, both with progressive severity. Recalcitrant ocular
itching and photophobia, in addition had other atopic conditions such as mild
asthma, rhinitis and egg allergy. Total IgE ¼ 1323 IU/mL. Ocular manifes-
tations poorly controlled with topical use of antihistamines, cromolyn, tacro-
limus and cyclosporine. The use of topical corticosteroids was frequent, but
resulted in brief improvement.Case 2: HCS (6 years) with vernal keratocon-
junctivitis since 3 years age, and mild asthma and moderate persistent rhinitis.
Continued use of topical tacrolimus 0.03% showed an initial improvement,
but subsequent relapses resulted in frequent use of systemic prednisolone and
eye drops antibiotics to control symptoms. Total IgE ¼ 1530 IU/mL.After the
second Omalizumab application, good or excellent improvement in ocular
symptoms of both children was observed by allergists and parents.
Ophthalmologic evaluation showed moderate improvement in the amount
of slime and little or no improvement in the structural changes of the eye
(cornea and appearance of giant papillae).
Conclusions: There are few reports about the use of Omalizumab in allergic
keratoconjunctivitis. Our work points to the need for further research in this
area as the Anti-IgE may become a promising therapy for this difﬁcult to
control condition.
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Giant Papillary Conjuntivitis without Associated Triggers.
Report of Two Cases
Aida Gonzalez-Carsolio, MD, Adriana Barreto-Sosa, MD, Andres-Leonardo
Burbano-Ceron, MD, Andrea Aida Velasco-Medina, MD, and Guillermo
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Velázquez-Sámano, MD. Servicio de Alergia e Inmunología Clínica, Hospi-
tal General de México, Mexico City, Mexico.
Background: Giant papillary conjunctivitis is associated with soft and rigid
contact lens wearing, ocular prostheses, exposed sutures, extruded scleral
buckle, ﬁltering blebs, band keratopathy, corneal foreign bodies, limbal
dermoids, and cyanoacrylate tissue adhesives. Patients present decreased lens
tolerance, increased lens movement and awareness, mucus, irritation, redness,
burning, and itching. Is bilateral and 10% unilateral. The upper tarsal
conjunctiva shows inﬂammation, papules .0.3 mm, bulbar conjunctival in-
jection, superior corneal pannus or opacities. Fluorescein noted papillary re-
action. Histopathology: Mast cells, basophils and eosinophils were found in
the epithelium and substantia propia. Histamine, Ig, IgG, IgM, C3, Factor B,
C3 anaphylatoxin, Eotaxin, Neutrophilic chemotactic factor elevated in tears.
Lactoferrin is decreased. Pathophysiology: The cause is unknown, factors as
immunologic disease, mechanical trauma or irritation inﬂuence. Contact
lenses become coated that serves as an antigen so the increased proteins in
the tear ﬁlm result in further coating. Treatment: Nonsteroidal anti-inﬂamma-
tory agents, topical mast cell stabilizers or mast cell stabilizer-antihistamines.
Replacement lenses at 2 weeks to 3 months. Daily lens disinfection with
hydrogen peroxide and unpreserved saline solution. Severe should stop wear-
ing their contact lenses for .4 weeks or reﬁt with rigid gas-permeable lenses.
Methods: A 7 year-old female presents 6 months ago redness, pruritus,
forgein body sensation, eyelid inﬂammation without improvement with
treatments. On examination with conjunctival hyperemia, hypertrophy of
papillae and epiphora.A 22 year-old male presents at 7 years old conjunctival
burning, foreign body sensation, conjunctival hyperemia, hyaline secretion
treated with topical antibiotics and steroids with minimal and temporal
improvement. On examination, conjunctival hyperemia, giant papillae on
superior tarsal bilateral predominantly left. Stool negative.
Results: We found 2 patients affected without common triggers and early
onset of severe clinical manifestations and refractory to usual treatment.
Conclusions: We present 2 clinical cases of unusual presentation since both
of them were pediatric presentation and Giant papillary conjunctivitis has its
peak of incidence in the adult population. Besides, both patients lacked an
initial trigger such as contact lens wearing or ophthalmologic surgery. Both of
them had a poor response to treatment. This disease should be considered in
pediatric population and start treatment inmediately to avoid complications
such as loss of vision.
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Contact Allergy Due to Ophthalmic Drugs in Uruguay
Valeria Pomies, MD, and Iris Ale, MD. Allergy Unit and Department of
Dermatology, University Hospital, Republic University of Uruguay, Mon-
tevideo, Uruguay.
Background: The external eye is exposed to a large number of environ-
mental, cosmetic and pharmacological allergens and the frequency of external
eye diseases related to the prolonged use of ophthalmic medications and
contact lens wear is increasing. Predisposing factors for contact allergy are:
high exposure to topical drugs (eyelids & eye), high percutaneous absorption
in eyelids, high potential for concomitant irritation and hand transfer of
allergens due to frequent rubbing.
Methods: Ninety three patients 56 women and 37 men, age range 10 to 81
years old, mean age 43 years old with a clinical picture compatible with
ocular allergy were referred to our Allergy Unit by the Department of
Ophthalmology at the University Hospital for allergological evaluation,
including a thorough history, complete clinical examination as well as
laboratory techniques and skin testing. Patch-testing was performed with the
standard series, an ophthalmic series of allergens developed at our unit, as
well as additional allergens according to the clinical situation.
Results: Contact allergy was more frequently caused by topical antibiotics
and preservatives and occasionally by mydriatic agents and topical drugs for
glaucoma. The allergens more frequently implicated were Neomycin (10.7%),
Bacitracin (9.6%) Thimerosal 8 (8.5%) Benzalconium chloride 5 (5.3%)
Phenylephrine hydrochloride 3 (3.2%), local anesthetics 3 (3.2%), Chloram-
phenicol (3.1%), Polymyxin (2.1%), Kanamycin (2.1%), Gentamicin (2.1%),
Tobramycin (2.1%), Beta-blockers 1 (1.7%), and others (6.1%).
Conclusions: Patients with a clinical picture compatible with ocular allergy
should be referred for allergologic evaluation. A comprehensive approach
will often provide clues for a presumptive diagnosis and appropriate
management. When a contact allergy is found it is mandatory to avoid
contact with the precipitating substance. This may simply be a case of
stopping or altering an ophthalmic medication. The proper use of
ophthalmic preparations should decrease the incidence of allergic contact
reactions.
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Increased Frequency of gd T Cells in Patients with
Allergic Conjunctivitis
Miguel E Alonso-Sánchez, MD,1 Jorge Galicia-Carreón, MD, MSc,1 Raul
Chávez, MD, PhD,2 Atzin Robles-Contreras, MSc,1 and Maria C Jiménez-
Martínez, MD, PhD,1,2. 1Research Unit and Department of Immunology,
Institute of Ophthalmology, México D.F., Mexico; 2Department of Biochem-
istry, Faculty of Medicine, UNAM, México D.F., Mexico.
Background: It is well known involvement of CD41 T cells in the mainte-
nance of allergic immune response at conjunctiva; recently, it was suggested
in the mouse model that gd T cells are needed for the ocular allergic response
maintenance; however contribution of gd T cells in human allergic conjunc-
tivitis is still unknown. The aim of this study was to evaluate the frequency of
gd T cells in AC patients.
Methods: Patients with AC diagnosis were included. All participants gave
their informed consent for blood sampling after written information was
provided. Peripheral blood mononuclear cells (PBMC) were separated on
a Ficoll density gradient, after that PBMC were stained with mAb against
human CD3-PeCy5 and gd-PE. The cells were analysed for marker expres-
sion by collecting 10,000 events using a FACScan ﬂow cytometer (Becton
Dickinson, CA, USA) and CellQuest Pro software. To analyse cell surface
marker staining, a gate was drawn around the lymphocyte population based
on their physical properties (forward and side scatter). Data were analyzed
with t test and differences were considered statistically signiﬁcant with P ,
0.05.
Results: We observed a higher frequency of gd T cells in patients with AC,
gd T cells were increased 11.9 times in AC-patients (22.63 6 2.9%) than
healthy donors (1.9 6 1.9%) (P ¼ 0.002).
Conclusions: gd T cells are increased in allergic conjunctivitis patients.
These data suggest that lipids antigens could be involved in pathogenesis
of allergic conjunctivitis in humans and possibly implicated in chronic
responses at ocular level, as has been suggested in the mouse model of
allergic conjunctivitis.
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Zero Itch in Eyes Treated With Olopatadine Hydrochloride
Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen
Challenge Studies
Michael S. Blaiss, MD, and Maria Tort, PhD2. 1University of Tennessee
Health Science Center, Memphis, TN; 2Global Medical Affairs, Alcon Re-
search, Ltd, Fort Worth, TX.
Purpose: To further assess the prevention of ocular itching with olopatadine
hydrochloride ophthalmic solution, 0.2% (OLO) in patients with allergic
conjunctivitis.
Methods: This was a post-hoc analysis of 85 patients participating in 2
prospective, randomized, double-masked bilateral conjunctival allergen
challenge (CAC) studies. Patients received OLO in one eye and placebo
(vehicle) in the contralateral eye. Ocular itching was self-assessed by patients
and rated on a scale of 0 (none) to 4 (severe). To assess onset of action,
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eligible patients were challenged with antigen 27 minutes after dosing. To
assess duration of action, patients were challenged with allergen 16 hours
after dosing. The percentage of eyes with zero itching in both studies was
assessed at 3 minutes post allergen challenge.
Results: The percentage of eyes with zero itch at the 3 minutes timepoint
after the onset of action allergen challenge was 60.0% for OLO-treated
eyes compared with 5.9% for vehicle-treated eyes (P , .0001, OLO vs
vehicle). The percentage of eyes with zero itch at 3 minutes post allergen
challenge following the 16-hour dosing was 59.8% for OLO-treated eyes
compared with 22.0% for vehicle-treated eyes (P , .0001, OLO vs
vehicle).
Conclusions: In bilateral CAC studies, ocular itching was prevented in
a higher percentage (P , .0001) of eyes treated with 0.2% olopatadine
hydrochloride ophthalmic solution when compared with vehicle as early as
30 minutes and for at least 16 hours post dosing.
CONTACT DERMATITIS
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Patch Testing Results in Contact Dermatitis from the
Allergist’s Perspective
Marcella Aquino, MD,1 Mary Ann Michelis, MD, FAAAAI,2 Sebastian
Lighvani, MD,3 Mark Davis-Lorton,1 and Luz Fonacier, MD, FAAAAI,1,4.
1Rheumatology, Allergy & Immunology, Winthrop University Hospital,
Mineola, NY; 2Department of Allergy & Immunology, Hackensack University
Medical Center, Hackensack, NJ; 3New York Allergy and Asthma, Weill
Cornell Medical College, New York, NY; 4Medicine, Winthrop University
Hospital, Mineola, NY.
Background: Contact Dermatitis (CD) is a frequently encountered skin
disease by allergists and dermatologists that results from contact with external
allergens. Patch Testing (PT) remains the gold standard in the diagnosis of
allergic CD. Studies evaluating PT from allergy practices are lacking.
Methods: A multi-center, retrospective chart review of PT within the last 5
years at allergy practices in 3 institutions. We report PT results using
allergens in the Thin-Layer Rapid-Use Epicutaneous Test (TT) and additional
supplemental allergens [North American Contact Dermatitis (NACD) Panel,
Dormer Cosmetic Panel, hairdresser’s panel, corticosteroid panel and per-
sonal products]. Additionally, patient characteristics including age, gender,
occupation, dermatitis site, history of atopic disease and ﬁnal diagnosis were
also obtained.
Results: A total of 427 patients (mean age ¼ 49.8 years) were patch tested,
82% were female, 54% reported an atopic history (history of asthma,
atopic dermatitis, allergic rhinitis or food allergy), 30% were tested with
TT, 60% with NACD panel, 30% with cosmetic series, 15% with cortico-
steroid series and 35% with personal products. The 5 most common
positive PT allergens were nickel sulfate, fragrance mix I, P-phenylenedi-
amine, thimerosal and cobalt chloride. The most common dermatitis sites
were eyelid/periorbital (31%), facial (25%) and trunk (21%). 56.9% of
patients were positive to at least one TT allergen. 25.6% of patients were
positive to both a TT and a supplemental allergen (these patients would
have been “partially evaluated” with TT allergens alone as they are pos-
itive to at least 1 TT allergen and 1 supplemental allergen). 12.5% of
patients were negative to a TT allergen and positive to at least 1 supple-
mental allergen only (these patients would have been “missed” as they are
negative to all TT allergens, but positive to at least 1 supplemental
allergen).
Conclusions: Nickel remains the most common allergen. When evaluating
patients with CD, testing with TT allergens alone would miss 12.5% of
patients while 25.6% of patients would be only partially evaluated. As half of
our patients were positive to at least 1 TT allergen, the TT remains an
adequate screening tool but a more comprehensive panel may be needed to
fully evaluate contact dermatitis.
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Contact Allergy to Medicaments in Consecutively Patch-tested
Patients in Uruguay
Valeria Pomies, MD, and Iris Ale, MD. Allergy Unit and Department of
Dermatology, University Hospital, Republic University of Uruguay, Mon-
tevideo, Uruguay.
Background: Allergic contact dermatitis (ACD) to topical medicaments is
common. Medicaments are responsible for approximately 30% of all cases of
ACD. The most common drugs associated with ACD include topically
applied antibiotics, antiseptics, antihistamines, anesthetics, nonsteroidal
antiinﬂammatory drugs, and corticosteroids.Certain body areas are particu-
larly susceptible (ie, genital and perianal areas, ears, eyes, face and lower
legs)Predisposing factors are: occlusion (skin folds, use of bandages),
application in damaged skin (stasis dermatitis & leg ulcers, and other chronic
dermatitis) and long-lasting use of multiple medicamentsThe aim of our study
was to study the prevalence of ACD to topical medicaments in patients with
suspected ACD attending the Unit of Allergy at the University Hospital in
Montevideo.
Methods: 1175 consecutive patients; 781 F (63%) 394 M (37%) with
suspected ACD were patch tested with the standard series and the topical
medicament series, as well as other allergens according to the clinical
situation.
Results: The most frequent allergens were: Neomycin (7.1%), Thiomersal
(3.8%), Benzocaine (1.9%), Bacitracin (1.9%), Propolis (1.5%), Gentamycin
(1.2%), Tixocortol (1.1%) and Budesonide 24 (0.8%).
Conclusions: Contact allergy to topical medicaments is common in patients
studied by a suspected ACD in Uruguay. In these cases the topical
medicaments that the patient is using should be included when patch testing.
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Evaluation of Allergen Sensitivity in Patients with Contact
Dermatitis in Antalya
Arzu Didem Yalcin, MD,1 Cekin Ayhan Hilmi,2 Saadet Gumuslu, PhD,3
Hasan Hüseyin Polat,4 Sukran Kose,5 and Ramazan Cetinkay6. 1Allergology
and Clinical Immunology Unit, and; 2Gastroenterology and Hepatology unit,
Antalya Education and Training Hospital, Antalya, Turkey, Antalya, Turkey;
3Department of Biochemistry, Faculty of Medicine, Akdeniz University, Ant-
alya, Turkey; 4Department of Public Health, Faculty of Medicine, Cumhur-
iyet University, Sivas, Turkey; 5Infectious Diseases and Clinical
Microbiology, Clinical Allergy and Immunology, Tepecik Educational and
Research Hospital, Izmir, Turkey; 6Division of Nephrology, Antalya Educa-
tion and Training Hospital, Antalya, Turkey.
Background: Allergic contact dermatitis (ACD) is a delayed type of induced
sensitivity (allergy) resulting from cutaneous contact with a speciﬁc allergen
to which the patient has developed a speciﬁc sensitivity. This allergic reaction
causes inﬂammation of the skin manifested by varying degrees of erythema,
edema, and vesiculation. In this study, the socio-demographic characteristics,
patch test were evaluated in treated patients diagnosed with Allergic contact
dermatitis
Methods: The study was conducted in Antalya between 10th of November
2010 and 20th of July 2011. A questionnaire made by the investigators taking
the latest literature data into consideration were used during the study. The
total IgE levels were made by ﬂuoroenzyme immunoassay method via use of
ImmunoCAP kit for patch test was used. The statistical data derived were
evaluated by using 14.00 SPSS software. Ki-Square test and percent ratios
were used for data analysis. A P value less than 0.05 was assumed for
statistical signiﬁcance.
Results: During the study 457 patients (211 male, 246 female) were included.
Among patients 52% belonged to 40 to 49 years age group, and 29% had
University degree graduate. The total duration of the ACD was 10.116 3. 45
years. The total Ig E level was 112.6 6 10.2 Ku/L. The most common
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allergen was nickel, and fragrances. In this study, Allergic contact dermatitis
is more common in women than in men.
Conclusions: Approximately 25 chemicals appear to be responsible for as
many as one half of all cases of allergic contact dermatitis. These include
nickel, preservatives, dyes, and fragrances. in this study Allergic contact
dermatitis is more common in women than in men. This predominantly is
a result of allergy to nickel, which is much more common in women than
in men in most countries. In elderly individuals, the development of
allergic contact dermatitis may be delayed somewhat, but the dermatitis
may be more persistent once developed. Individuals may develop new
allergies.
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Better Protection from Eczema Among Turkish Migrants’
Children Carries Over from Preschool Age to Adolescence
Christoph Grüber, MD, PhD, Paolo Matricardi, MD, PhD, Christopher
Theissen,MD, and Ulrich Wahn, Prof. Dr. Pediatric Pneumology/Immunology,
Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background: In a cross-sectional study of preschool children born in
Germany we found signiﬁcantly reduced rates of atopy, eczema and asthma
among Turkish migrants’ children than among their domestic peers (Clin
Exp Allergy. 2002;32:526–531). About 10 years later we re-examined
children from this study population in order to investigate whether better
protection from atopy among Turkish migrants’ children persists into
adolescence.
Methods: The setting of the original survey was screening for school
eligibility in an inner-city district of Berlin/Germany. The participants were
preschool children with double German or double Turkish citizenship. The
main outcome measures were IgE to common aeroallergens (CAP system
Phadia, Phadiatop 3 0.35 kU/L) and 1-year prevalence of allergic disease
symptoms (ISAAC questionnaire in German and Turkish language). All
available adolescents from the ﬁrst survey were included in the follow-up
survey.
Results: 147 German and 154 Turkish adolescents were included. Rates of
allergic sensitization tended to be lower among Turkish migrants’ children
than among domestic children at preschool age (7.0% vs 13.8%) and in
adolescence (33.1% vs 41.7%). Likewise, lower rates of eczema among
Turkish migrants’ children at preschool age (7.8% vs 18.4%; P ¼ 0.010)
carry over to adolescence (8.7% vs 22.4%, P ¼ 0.008). Rates of asthma also
tended to be lower at preschool age (2.6% vs 6.1%) and in adolescence
(14.0% vs 16.3%). By contrast, hay fever at any time point was not lower
among the Turkish migrants’ children (preschool age, 3.9% vs 3.4%; adoles-
cent, 19.1% vs 16.1%).
Conclusions: This prospective study demonstrates that rates of allergic
sensitization and of allergic diseases emerging earlier in life (eczema, asthma)
tend to be persistently lower among Turkish migrants’ children than among
their German peers growing up in a very similar inner-city macro-environ-
ment. Further study is under way to examine potential allergy-protective
factors in this cohort.
DIAGNOSTIC TEST FOR ALLERGIC RHINITIS
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Comparison of Skin andConjunctival Reactivity to Aeroallergens
Elizabeth Maria Mercer Mourão, MD, MSc, and Nelson Rosario, MD, PhD.
Allergy and Immunology, Federal University of Paraná, Curitiba, Brazil.
Background: Diagnosis of allergic conjunctivitis (AC) is based on symptoms
and positive skin prick test (SPT) to common aeroallergens. Allergens identiﬁed
by SPT may not be clinically relevant to the eye. This study aims to compare
the skin and conjunctival allergic responses to dust mites and grass pollen.
Methods: 56 subjects (29 6 11.4 years) with ocular allergy and sensitized
to dust mites and/or grass pollens were recruited for the study. Standardized
extracts of Dermatophagoides pteronyssinus (Der p 1 83.8 mcg/mL), Blo-
mia tropicalis (Blo t 5 462.5 ng/mL) and Lolium perenne (Phl p 5 399.2
mcg /mL) were used for skin test end point titration. Increasing 2-fold
allergen dilutions were tested in forearms until no skin reaction was eli-
cited. The end point was considered the dilution immediately above that
one. Conjunctival provocation test (CPT) was performed with progressive
doses of allergen (1:32, 1:16, 1:8, 1:4, 1:2) to the involved allergen. All
tests were performed after obtaining written informed consent and out of
grass pollen season. Subjects should be assymptomatic and off antiallergic
medication.
Results: Of 82 conjunctival tests (30 Lp; 26 Bt; 26 Dp), 76% (62/82)
occurred with 1:8 to 1:2 dilutions, 18% (15/82) with 1:32 to 1:16 dilutions
and 6% (5/82) were negative. CPT were positive in 76% of subjects with Der
p 1 (10.5–41.9 mcg/mL), Blo t 5 (57.8–231.3 ng/mL) and Phl p 5 (49.9–199.6
mcg/mL). SPT were positive for allergens with 1:1024 to 1:128 dilutions in
22% (18/82), with 1:64 to 1:16 dilutions in 63% (52/82) and with 1:8 to 1:2
dilutions in 11% (9/82). Three subjects had negative SPT. Allergen threshold
dose to trigger a response in the skin was lower than in the eye for all 3
allergens tested (P , 0.0001).
Conclusions: Reactivity to aeroallergens in provocation tests requires higher
allergen dose for CPT than SPT. Positive SPT with standardized allergenic
extracts is predictive of clinical relevance in the diagnosis of allergic
conjunctivitis.
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Correlation Between Skin Prick Test andMast Results in Patients
with Chronic Rhinitis
Young Ha Kim, MD, and Jin Hee Cho, MD, PhD. Department of
Otolaryngology-HNS, Yeouido St. Mary’s Hospital, Seoul, South Korea.
Background: Among methods to conﬁrm the allergic causes of chronic
rhinitis, the most common and the most reliable method is skin prick
test, followed by MAST, which is reported to be compatible to skin prick
test, with acceptable sensitivity and speciﬁcity. This study was desig-
ned to conﬁrm whether MAST is reliable test in diagnosing allergic
rhinitis.
Methods: Retrospective chart review was conducted with chronic rhinitis
patients who visited Yeouido St. Mary’s Hospital between January 2010 and
June 2011. Subjects were selected with whom the results of skin prick test
and MAST were found.
Results: One hundred and ninety three subjects, 111 male and 82 females,
were included and the mean age was 30.08 (range 6w77). MAST was
performed for 42 inhalant allergens and skin prick test was performed for
56 allergens including histamine and control.Subjects who have one or
more positive allergen in skin prick test were 132, and positive in MAST
were 104. Sensitivity was 63.16%, speciﬁcity was 65.57% and efﬁciency
was 63.92%.Number of positive allergen in skin prick test was 2.42 in
average and among positive subjects, 3.53. In MAST, positive allergen
count was 2.1 in average and among positive subjects, 4.0. Positive rates
per common allergens in skin prick test were as follow; Dermatophagoides
farinae 79.69% (106 subjects), Dermatophagoides pteronyssinus 68.42%
(91 subjects), oak pollen 12.78% (17 subjects). Positive rates per common
allergens in MAST were as follow; Dermatophagoides farinae 69.52% (73
subjects), Dermatophagoides pteronyssinus 59.05% (62 subjects), house-
dust 50.48% (53 subjects).Skin prick test result was analyzed as from
negative to 61, according to relative size of the allergen wheal compared
with histamine wheal and MAST result was analyzed as from negative to
class 6, according to the concentration of the solution. When we deﬁned
correlation as difference between positive count in skin prick test and class
in MAST were less than 2, the correlation rate in Df was 65.80%, 59.07%
in Dp.
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Conclusions: The correlation between MAST and skin prick test is not high
enough to use MAST as a diagnostic test for allergic rhinitis. The more study
to conﬁrm the reliability of MAST should be conducted.
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Cutaneous Response to Patch Tests with Dermatophagoides
Farinae and Dermatophagoides Pteronyssinus in Patients with
Chronic Rhinitis
Diego Garcia-Calderin, MD,1 Sandra González-Díaz, MD, PhD,1,2 Alfredo
Arias-Cruz, MD,1,3 Alejandro Rojas, MD,4 Marisela Hernandez, MD,1
Claudia Gallego, MD,1 Karla Mejia, MD,1 Maricruz Calva, MD,1
and Luis Dominguez, MD1. 1Regional Centre of Allergy and Clinical Immu-
nology, University Hospital, Monterrey, Mexico; 2Regional allergy center,
University California, San Diego U.C.S.D., Monterrey, CA, Mexico; 3Allergy
and Clinical Immunology, University Hospital UANL, Monterrey, Mexico;
4CRAIC, Hospital Universitario, Monterrey, Mexico.
Background: Rhinitis is characterized clinical by chronic runny nose,
sneezing, nasal itching, congestion and postnasal discharge, among other
symptoms. Its classiﬁed as allergic and non allergic. Skin prick testing is the
principal diagnosis method for allergic rhinits. However, there is a group of
patients with chronic rhinopathy that have negative skin tests, the objective of
this study was to determine the cutaneous response to patch tests with Der-
matophagoides farinae and Dermatophagoides pteronyssinus in patients with
chronic rhinitis.
Methods: It was a cross-sectional, observational and descriptive study. We
included patients over 18 years old. They were divided into 3 groups; Group A
patients who came for the ﬁrst time with a history of chronic rhinopathy over 18
months of evolution and positive skin tests for aeroallergens; group B patients
with chronic rhinitis with at least one year of evolution and negative skin tests;
group C healthy volunteers. Patch test with farinae and pteronisyinnus were
done in the subjects of all 3 groups, with readings at 48 and 72 hours.
Results: A total of 37 patients were studied, mean age 26.1 years. Twenty
two were male subjects (60%). The mean lenghtof chronic rhinophaty was
10.8 years. Six patients had positive patch test to any of the mites tested; 2
(33%) in group A, 2 (33%) in group B and 2 (33%) of the control group, but it
was not statistically signiﬁcant (P . 0.05).
Conclusions: Although the results were not statistically signiﬁcant, there
were patients with chronic rhinitis wich had positive patch test for mites. This
sensitization could be clinically signiﬁcant for those patients.
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Skin Prick Test Reactivity Compared to Serum Speciﬁc IGE by
ISAC in Patients With Rhinitis
Laura Araujo, MD,1 Cinthya Thom, MD,1 Herberto Jose Chong Neto, MD,
PhD,1 Paola Palazzo,2 Marina Liso,2 Adriano Mari,MD,3,4 and Nelson Rosario,
MD, PhD1. 1Allergy and Immunology, Federal University of Paraná, Curitiba,
Brazil; 2IDI IRCCS, Rome, Italy; 3CMA, Rome, Italy; 4Instituto Dermopatico
dell’Immacolata, Rome, Italy.
Background: Microarray technique is promising in allergy diagnosis. The
aim of this study was to compare SPT with speciﬁc-IgE by microarray in
a group of patients with rhinitis.
Methods: Cross-sectional study, 101 participants with rhinitis diagnosed
according to ARIA (89.1% with asthma); age range 6 to 15 years. SPT was
done with Dermatophagoides pteronyssinus (Dp), Blattella germanica (Bg),
cat and dog allergenic extracts (IPI ASAC Brasil); a mean wheal diameter of
$2 mm greater than the negative control was considered positive. Sera were
analysed for allergen speciﬁc IgE antibodies to Dp (Der p 1, Der p 2), Bg (Bla
g 1, Bla g 2, Bla g 4, Bla g 5), cat (Fel d 1, Fel d 2) and dog (Can f 1, Can f 2)
allergens using a microarray system (ImmunoCAP ISAC, PMD, Austria),
considered positive $0.3 ISU (ISAC standardized units). Categorical
variables were shown as percentage and differences between the 2 methods
veriﬁed by chi-square test; P , 0.05 was considered signiﬁcant.
Results: SPT was positive to Dp in 88.1% whereas ISAC was positive to Der
p 1 in 74.2% (P , 0.001) and Der p 2 in 73.3% (P , 0.01) respectively.
Sensitivity of SPT was 97% and speciﬁcity was 38%. The remaining aller-
gens caused less SPT reactions (cockroach 25.7%, cat 22.8%, dog 27.7%) and
these were associated with lower detection of speciﬁc-IgE by ISAC respec-
tively Bla g 1 (0.9%, P ¼ 0.09), Bla g 2 (0%), Bla g 4 (0%), Bla g 5 (0.9%,
P ¼ 0.55); Fel d 1 (16.8%, P , 0.01), Fel d 2 (0.9%, P ¼ 0.06); Can f 1
(4.9%, P ¼ 0.53), Can f 2 (2.9%, P , 0.001).
Conclusions: SPT remains the favored method to detect IgE-mediated
sensitivity to aeroallergens. SPT was highly sensitive for Dp though less
speciﬁc in comparison with the IgE microarray to Der p 1 and Der p 2 allergens.
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Alteration of Smell in Patients with Persistent Allergic Rhinitis
Susana De Barayazarra,MD,1 S Corelli, MD,1 S Cornaglia, MD,1 A Zanacchi,
MD,1 S Sosa, MD,1 E Herrera, MD,1 Alvaro Teijeiro, MD,2 Giorgio Walter
Canonica, PhD,3 Carlos E. Baena-Cagnani, MD,4 and Mario Zernotti, MD,
PHC2,5. 1CIDI, Allergy and Immunology Division, Nuevo Hospital San Roque,
Cordoba, Argentina; 2CIMER (Research Center for Respiratory Medicine),
Faculty of Medicine, Catholic University of Cordoba, Cordoba, Argentina;
3Allergy & Respiratory Diseases, Universita Degli Studi Di Genova,
Genova, Italy; 4CIMER (Centro de Investigación en Medicina Respirato-
ria), Faculty of Medicine, Catholic University of Cordoba, Fundación
LIBRA Argentina, Cordoba, Argentina; 5Otorrinolaringologia, Sanatorio
Allende, Córdoba, Argentina.
Background: A high percentage of patients with moderate-severe persistent
allergic rhinitis (PAR) also show symptoms related to impaired smell (21–
23%).Olfactory dysfunction can have a signiﬁcant impact on quality of life
(QoL) in these patients. The high frequency of this subjective condition not
always reﬂect the magnitude of the problem experienced by PAR-patients in
real life and usually goes unnoticed. The aim of this study was to assess the
olfactory dysfunction in patients with PAR and seek the association with the
PAR-severity, sleep disturbance and QoL.
Methods: We studied 50 patients with physician-diagnosed PAR consulting
a tertiary medical centre, 33 (66%) were female and 17 (34%) male. Mean age
43 years old, compared with 20 healthy volunteers. Clinical history and
assessment of severity based on ARIA criteria, skin prick tests with mite mix,
mould and pollens, QoL questionnaire for allergic rhino-conjuntivitis (Juniper
RQLQ) were done. In addition the Epworth Sleepiness Scale (ESS) and the
Connecticut smell test (CST) were performed in every patient.
Results: In patients with PAR, 30% had mild PAR and 70% the moderate/
severe form.48% of the patients studied had abnormalities of smell. We found
an alteration of smell in 18% of mild-PAR and 60% in the severe/moderate
patients (P , .006).There was no statistically signiﬁcant relationship between
olfactory impairment and sleep disturbance with the ESS (P , .85), nor in the
alteration of smell in patients with polyps detected at physical examination (P,
.57) or the relationship between impaired smell and smoking (P, .36).Patients
with moderate/severe PAR also had alterations in QoL. Nasal obstruction was
the most important parameter (70%) associated with the QoL worsening.
Conclusions: This study shows the impact of PAR on the olfactory
dysfunction. An association between smell impairment and the severity of
nasal symptoms was found. Smell impairment plays an important role in
worsening QoL. CST is a tool that could be used in patients with PAR.
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Effectiveness of an Educational Intensive Course on A/I Clinical
and Diagnostic Procedures
Araceli Elizalde, MD,1 Elena Perez, MD, PhD,1 Panida Sriaroon, MD,1
Doanh Nguyen, MD,1 Richard F. Lockey, MD,2 and Morna Dorsey, MD,
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MMSc1. 1University of South Florida, College of Medicine, Saint Petersburg,
FL; 2Division of Allergy & Immunology, University of South.
Background: The U.S.A. Accreditation Council for Graduate Medical
Education (ACGME) requires that graduate medical education programs in
A/I prepare specialists to provide expert medical care for patients with A/I
disorders. The A/I intensive education course (boot camp) program was
implemented at the University of South Florida (USF) to facilitate fellows’
education of common clinical and diagnostic procedures conducted in the
specialty. Educational methods included PowerPoint presentations and dem-
onstration of clinical and diagnostic procedures by faculty and senior fellows
and hands-on participation by the fellows-in-training. The topics covered
included: anaphylaxis, spirometry, exhaled nitric oxide determination, routine
and special skin testing, prescribing and administering immunotherapy,
asthma education and inhaler technique, management of atopic dermatitis,
food challenge, patch testing, antibiotic desensitization and challenge, prin-
ciples of treatment with intravenous and subcutaneous gammaglobulin, and
special immunology testing.
Methods: Six A/I fellows (four 1st and two 2nd year) participated in the boot
camp on July 22, 2011. All completed a 49-item multiple-choice pre-test
followed by the boot camp, after which same questions were administered as
post-test. Scores were compared by paired t test.
Results: Six participants completed the study. The average number of correct
answers increased from 26.3/49 to 39.0/49 with pre- and post-test mean
scores of 53.8% and 79.6%, respectively (P ¼ 0.009). There was a signiﬁcant
difference between 1st and 2nd year fellows in test results when comparing
pre- and post-test scores (P # 0.05).
Conclusions: An educational boot camp approach integrating theory and
practice about A/I clinical and diagnostic procedures signiﬁcantly increased




Non-steroidal Anti-inﬂammatory Drugs Hypersensitivity:
Patterns of Reaction
Luis Felipe Chiaverini Ensina, MD,1,2 Renata Parrode Bittar, MD,3
Luciana Kase Tanno, MD,3 Marcelo Vivolo Aun, MD,3 Jorge Kalil,
MD, PhD,3Pedro Giavina-Bianchi, MD, PhD,3 and Antonio Abilio Motta,
MD,PhD3. 1Rheumatology, Allergy and Immunology, University of Santo
Amaro, Sao Paulo, Brazil; 2Rheumatology, Federal University of Sao Paulo,
Sao Paulo, Brazil; 3Clinical Immunology and Allergy, University of Sao
Paulo, Sao Paulo, Brazil.
Background: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are one of
the most frequently groups of medications involved in hypersensitivity drug
reactions. The aim of this study is to describe a group of patients with
suspected hypersensitivity reactions to non-steroidal anti-inﬂammatory drugs.
Methods: A retrospective study of patients with a suspected history of
hypersensitivity to NSAIDs, between years 2005 to 2010, was done. The
drugs involved, the clinical features and interval between drug intake and
clinical manifestation were studied. Drug provocation tests were carried out in
some cases to conﬁrm the diagnosis and in others to provide a safe therapeutic
alternative drug.
Results: A total of 310 patients considered to have had hypersensitivity
reactions to NSAIDs were analyzed (mean age ¼ 39 years old; females ¼
247). Immediate reactions were reported in 209 subjects. Non-selective res-
ponders were 214. The most important suspected drugs were pyrazolones
(228), paracetamol (144), acetic acid derivatives (122) and acetyl salycilic
acid (120). Pyrazolones were the most important suspected drugs for the
selective responders. The most frequent clinical manifestations were angioe-
dema (162), airway involvement (96) and urticaria (66). Isolated angioedema
was seen in 79 patients. Atopy was reported in 138 (44.5%) patients and
chronic urticaria in 26 (8.3%). Family history of drug hypersentivity was
reported by 37 patients. Drug provocation tests (DPT) for diagnosis were
performed with paracetamol in 37 subjects (2 positive), and pyrazolone in
one subject (negative). DPT were also performed with selective COX-2
inhibitors (31 tests) and benzydamine (45 tests) to assess their safety as
therapeutic alternative drugs for those non-selective responders and for those
who had a suspected history of reactions to paracetamol, respectively. Posi-
tive results were observed in 3 patients tested with COX-2 inhibitors and in
one patient tested with benzydamine.
Conclusions: NSAIDs hypersensitivity was more prevalent in females and
immediate reactions were more common than non-immediate ones. A great
number of subjects were non-selective responders. Pyrazolones were the most
commonly suspected culprit drugs. DPT is important not just for diagnosis
but also to provide safe therapeutic options.
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Epidemiology of Immediate Type Adverse Drug Reactions and
Rashes Elicited by Nsaid
Tamar Kinaciyan, MD,1 Nergis Ghanim, MD,1 Franziska Roth-Walter,
PhD,2 Leyla Ghanim,1 Stefan Woehrl, MD,1 Georg Stingl, MD,1
and Erika Jensen-Jarolim, MD3. 1DIAID, Department of Dematology, Med-
ical University of Vienna, Vienna, Austria; 2Department of Pathophysiology
and Allergy Research, Medical University of Vienna, Vienna, Austria; 3Inst.
of Pathophysiology and Allergy Research, Medical University Vienna,
Vienna, Austria.
Background: NSAID are frequently used and can often cause adverse drug
reactions (ADR) ranging from generally mild to sometimes severe and life-
threatening reactions. ADRs are in most cases interpreted as pseudo-allergic,
presumably non immunologic, but their dynamics and appearance in a sub-
group of patients is suggestive for an IgE-mediated mechanism.
Methods: In this study, we retrospectively analysed data of 501 patients from
our outpatient clinic population of the past 7 years with ADR to NSAID. Data
was evaluated regarding the culprit drug or drugs, type and severity of
reactions, age, gender, atopy, number of co-medication, co-morbidity and
infections etc. as risk factors. Further, skin test and provocation test results
were reviewed for their clinical relevance and reliability.
Results: Acetylsalicylic acid (ASA), paracetamol, diclofenac, mefenamic
acid and propyphenazone were found as top ﬁve of causative drugs for ADR.
The most common symptoms were angioedema, urticaria, pruritus, exan-
thema and dyspnea. ASA caused dyspnea, angioedema and urticaria in the
majority of the cases. Diclofenac was found to be the most common culprit
for severe anaphylactic reactions, followed by paracetamol and propyphena-
zone. Sixty percent of the NSAID reactors suffered from an atopic disease or
had an atopic predisposition. There was a signiﬁcant association between
proven hypersensitivity reactions and reaction initiation after drug intake
regarding the time interval.
Conclusions: Our data suggest that -atopic predisposition is a risk factor for
intolerance reaction to NSAID, -ASS accounts for non-immunologic,
intolerance reactions, whereas severe anaphylactic reactions to diclofenac
and/or propyphenazone seem to be IgE-mediated, -a shorter time interval
between drug intake and appearance of symptoms is supportive for clinical
relevance and could be an indicator for IgE-mediated ADR. Acknowledge-
ments: FWF project L467-B05.
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Test in Vitro to Investigate the Cytotoxicity and Cellular
Nonspeciﬁc Stimulation of Basophils with Indomethacin
Zamir Calamita, PhD,1 Roseli N. S Antunes, PhD,2 Odilon M Almeida Filho,
PhD,3 Wilson Baleotti Junior, PhD,4 Josianne T Fukasawa, 5 Debora A
Cavaretto,5 and Andrea B. P Calamita6. 1Allergy and Immunology, Medical
School of Marilia, São Paulo, Brazil; 2Hematology, and; 3Immunology,
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Medical School of Marilia, Marilia, Brazil; 4Clinical Pathology, Medical
School of Marilia, São Paulo, Brazil; 5Flow Citometry, and; 6Dermatology,
Medical School of Marilia, Marilia, Brazil.
Background: The prevalence of hypersensitivity to nonsteroidal anti-in-
ﬂammatory drugs (NSAIDs) is high and its in vitro diagnostic is a challenge.
The basophil activation test with determination by ﬂow cytometry (FC), of
the expression rate of CD63 molecules has been much studied today. NSAIDs
several have been evaluated by this technique, which still didn’t happen with
indomethacin; however, that we may study it is necessary to assess their
effects, concentration dependants, on cell viability. We studied the viability
of indomethacin dissolved in propylene glycol, analyzing the nonspeciﬁc
stimulation and cytotoxicity, using in this case the basophil activation test
with the use of FC.
Methods: First it was studied the safe concentration of propylene glycol for
dilution of indomethacin, incubating basophils from atopic donor with this
diluent. In the second phase, the indomethacin was diluted in the following
concentrations: 10 mcg/mL, 1 mcg/mL, 0.1 mcg/mL and the CD63 intensity
molecules expression was analysed by FC.
Results: Regarding the toxicity of propylene glycol, concentrations less than
or equal to 0.5% are safe. For indomethacin, the used concentrations (10 mcg/
mL, 1 mcg/mL e 0.1 mcg/mL) were viable showing absence of cytotoxicity or
nonspeciﬁc stimulation.
Conclusions: Propylene glycol as a diluent of indomethacin is necessary to
make at concentrations less than or equal to 0.5%. The indomethacin at
concentrations of 10 mcg/mL, 1 mcg/mL and 0.1 mcg/mL proved to be not
cytotoxic and without nonspeciﬁc stimulant action to basophils.
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Aspirin Desensitization Treatment: A Case Report
Mirta Alvarez, MD,1 Lludenich Osoria, MD,2 Mercedes Ronquillo, MD,1 Raúl
Castro, MD,3 Doguerti Perez,4 José Rodríguez, MD,1 and Catalina Irarragorri,
MD4. 1Allergology Department, University Hospital Calixto García, Havana
City, Cuba; 2Cardiology, Calixto García University Hospital, Havana City,
Cuba; 3Allergens, National Center of Bioproducts, Havana City, Cuba;
4Calixto García University Hospital, Havana City, Cuba.
Background: Aspirin (ASA) is one of the best known and most widely used
drugs in the world. Patients with coronary artery disease require prolonged
treatments with this drug, which is denied to those patients with histories of
adverse reactions to it.
Methods: In a rapid desensitization protocol a patient with a history of ASA-
induced urticaria-angioedema was treated with escalating doses of aspirin
administered orally every 25 minutes.
Results: The patient completed the desensitization protocol in few hours
without complications, and currently is able to take 125 mg of ASA per day
without adverse reactions.
Conclusions: This report describes the ﬁrst desensitization treatment with
aspirin carried out in our hospital. No other case was found in the national
bibliography.
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Adverse Drug Reactions to Anti-asthmatics in Patients with
Bronchial Asthma
Cheol-Woo Kim, MD, PhD,1 Jae-Hwa Cho, MD, PhD,2 Eun-Hee Jung,3
and Hye-Kyung Lee4. 1Department of Internal Medicine, Inha Regional
Pharmacovigilance Center, Inha University Hospital, Incheon, South Korea;
2Department of Internal Medicine, Inha University Hospital, Incheon, South
Korea; 3Inha Regional Pharmacovigilance Center, Inha University Hospital,
Incheon, South Korea; 4Department of Pharmacy, Inha Regional Pharmaco-
vigilance Center, Inha University Hospital, Incheon, South Korea.
Background: The number of self-reported adverse drug reactions (ADRs)
has been rapidly increased with the active pharmacovigilance activities in
Korea. However, there has been few data on ADRs to anti-asthmatics in
Korea. This study was conducted to investigate the clinical characteristics of
ADRs to anti-asthmatics in adult patients with bronchial asthma.
Methods: ADRs to anti-asthmatics reported to Regional Pharmacovigilance
Center of Inha University Hospital by 2 physicians were collected from
January 2011 to April 2011. Causality assessment of adverse events was
performed by using WHO-UMC criteria and Naranjo’s probability scale.
Clinical information was additionally collected from electronic medical
records.
Results: Twenty ﬁve ADRs to anti-asthmatics were reported in 19 (male 5,
female 14) out of 228 patients with asthma. The most common offending
anti-asthmatics were inhaled glucocorticoids combined with inhaled long-
acting beta agonist (LABA) (12 of 19 subjects, 63.2%), theobromine
(10.5%), oral LABA (10.5%), doxofylline (5.3%), acetylcysteine (5.3%),
and montelukast (5.3%). Severity of ADRs was mild in most patients (13
of 19, 68.5%), and no severe ADR was detected. By frequency, oral LABA
was the commonest drug associated with ADRs (2 in 17 prescription,
11.8%). ADR frequency was not different according to asthma control
status. But ADRs to simultaneously prescribed drugs were more frequently
detected in patients with combined upper airway diseases (ADRs to
antihistamines) or patients with combined infection (ADRs to anti-
infective drugs, mucolytics, oral LABA, or to SABA), or older patients
with asthma.
Conclusions: Although the severity is usually mild, ADRs are relatively
common in patients with bronchial asthma. Physician should monitor
ADRs to anti-asthmatics or related drugs in patients with asthma, especially
in older patients or in patients with multiple drug treatment for combined
conditions.
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Presentation of Three Cases of Allergic Reactions to Triptorelin
Maria Cristina Diaz, MD,1 Alberto Jorge Lavrut, MD,2 and Silvia Susana
Spinelli, MD2. 1Unidad de Alergia, Hospital General de Niños Pedro de
Elizalde Casa Cuna, Buenos Aires, Argentina; 2Unidad Alergia, Hospital
de Niños Pedro de Elizalde, Buenos Aires, Argentina.
Background: Triptorelin is a drug that is frequently used in pediatrics to treat
precocious puberty -an often condition in childhood endocrinology services.
Despite its widespread use, there is not much research on hypersensitivity
reactions to this drug. We found 3 patients that have suffered allergic reaction
during the treatment with Triptorelin.
Methods: We treated three 8 year old girls diagnosed with precocious
puberty that have suffered allergic reaction during the treatment with
Triptorelin.Patient 1: An hour after the ﬁrst dose the patient broke out in
a rash over her face, trunk and upper limbs. She also showed general
paleness, conjunctival erythema, arthralgia and joint swelling in both knees
with functional impotence of the lower limbs.Patient 2: Five minutes after the
second dose the patient showed anaphylactic reaction.Patient 3: Two hours
after the second dose the patient showed generalized urticaria and
tachycardia.
Results: Once overcome those events. We started to provoke the reaction by
doing the progressive-controlled triptorelin test. Finally we could conﬁrm the
hypersensitivity reaction to this drug
Conclusions: The triptorelin is a drug that may cause hypersensitivity
reaction. So, after the ﬁrst application, we recommend to monitor the patient
and also plan some actions to avoid a possible anaphylactic shock event.
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Adverse Drug Reactions in Hospitalized Patients
Marisa Rosimeire Ribeiro, MD, Pedro Giavina-Bianchi, MD, PhD, Jorge
Kalil, MD, PhD, and Antonio Abilio Motta, MD, PhD. Clinical Immunology
and Allergy, University of Sao Paulo, Sao Paulo, Brazil.
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Background: To describe adverse drug reactions (ADRs) in hospitalized
patients.
Methods: A cross-sectional study with a questionnaire for adverse drug
reactions based on European Network for Drug Allergy (ENDA) was
performed. Hospitalized patients older than 12 years of age were included.
Results: A total of 150 patients were studied, 84 being female. Their ages
ranged from 14 to 94 years, with an average of 55 years. The average number
of medications per patient was 7.5. Fifteen ADRs were reported during
hospitalization (10%). Five ADRs were classiﬁed as hypersensitivity,
including 2 IgE-mediated reactions that were observed in 2 patients
hospitalized for desensitization (anti-rabies vaccine and insulin). The pro-
cedure had to be suspended in these patients. Three non-IgE-mediated
hypersensitivity reactions occurred: rash after non-steroidal anti-inﬂammatory
drug (NSAID) intake, coughing and itching with angiotensin converter
enzyme inhibitor (ACEI) and rash with iodinated contrast. The remaining
patients (10) had common side effect reactions to several drugs. Twenty-eight
patients have had prior hypersensitivity reaction, being ﬁve IgE-mediated
(two with beta-lactam antibiotics, one with non beta-lactam antibiotic, one
with insulin and the last one with rabies vaccine) and 23 non-IgE-mediated (8
with NSAIDs, 5 with ACEI, 3 with beta-lactam antibiotics, 3 with non beta-
lactam antibiotics, 2 with iodinated contrast and 2 with other drugs). Most
hypersensitivity reactions were cutaneous. In 3 patients, previous hypersen-
sitivity reactions were not mentioned at the time of hospitalization.
Conclusions: The average number of medications administered per patient
during hospitalization is high. Adverse drug reactions are very common and
have great clinical relevance. Ten percent of patients presented ADRs during
hospitalization and one third of them had hypersensitivity reactions, what is in
accordance with literature.
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An Unusual Reaction to Intravenous Iron Sucrose
Michael Balduzzi, MD, Daanish Rashid, Ahmed Butt, MD, Richard F.
Lockey,MD, and Dennis Ledford, M.D. Division of Allergy & Immunology,
University of South Florida and James A. Haley Veterans’ Hospital,
Tampa, FL.
Background: Intravenous (IV) iron dextran, the original parenteral iron
formulation, is associated with a high incidence of non-IgE mediated
hypersensitivity. Newer formulations of IV iron therapies include low
molecular weight iron sucrose (IS) and sodium ferric gluconate complex
(SFGC) without dextran, reducing severe adverse reactions by 93%. A case of
a rare reaction to IV IS associated with generalized skin pruritus and difﬁculty
in breathing is reported.
Methods: A 62-year-old Caucasian male with multiple gastric surgeries,
secondary to recurrent gastric ulcers and gastric outlet obstruction, presented
with severe iron deﬁciency anemia (IDA) requiring IV iron therapy.
Results: Chronic malnutrition and malabsorption, associated with difﬁculty
in tolerating oral and jejunostomy tube (J-tube) feedings, resulted in a two
month 30 pound weight loss. Oral iron supplementation via a J-tube did not
improve the IDA. Prior administrations of IV iron dextran resulted in
ﬂushing, generalized urticaria and angioedema associated with pruritus of
the face and extremities within ten minutes of infusion.The allergy/
immunology service was consulted. Premedication with IV diphenhydra-
mine, 50 mg, prednisone via J-tube, 32 mg, and IV ranitidine, 50 mg, was
followed with slow administration of a test dose of IS, 25 mg, at 1.6 mg/
min. Within 30 minutes of the IV IS infusion, symptoms of nausea,
ﬂushing, and generalized pruritus, and difﬁculty in breathing were noted.
The infusion was stopped and treatment with IV methyprednisolone, 125
mg, resulted in resolution of the reaction over several hours. No
eosinophilia or elevated liver transaminases occurred. Subsequently, the
infusion was reattempted: pre-medications consisted of IV methylprednis-
olone, 60 mg, IV diphenhydramine, 50 mg, and IV ranitidine, 50 mg, 75
minutes prior to the infusion of IS, 275 mg, 1.5 mg/min. Treatment was
tolerated without adverse effects.
Conclusions: A rare systemic reaction to IV IS is reported. Pretreatment with
methylprednisolone, diphenhydramine and ranitidine 75 minutes before IS
infusion was successful.
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Urticaria and Arthralgias in a Nine-Year-Old with Recurrent
Urinary Tract Infections
Ahmed Butt, MD, Daanish Rashid, Roger Fox, MD, and Richard F. Lockey,
MD. Division of Allergy & Immunology, University of South Florida and
James A. Haley Veterans’ Hospital, Tampa, FL.
Background: Serum sickness is a type III immune complex hypersensitivity
reaction occurring after exposure to foreign antigens, most commonly
medications. Symptoms typically begin 1 to 3 weeks after initial exposure
to the offending agent and include fever, malaise, urticarial or morbilliform
rashes and arthralgias which may progress to arthritis, nephritis, neuropathy
or vasculitis. We report a case of drug-induced serum sickness in a patient
who had previously tolerated trimethoprim/sulfamethoxasole (TMP/SMX)
for treatment of recurrent urinary tract infections.
Methods: A 9 year-old female presented with a pruritic, erythematous rash
that began 2 days after completing a 10 day course of TMP/SMX for
a urinary tract infection. TMP/SMX had previously been prescribed to treat
recurrent urinary tract infections without adverse side effects.
Results: Initially she developed a fever and a blotchy rash with patches of
erythema which started on the torso and progressed to generalized urticaria
over a 24 hour period. Associated symptoms included fatigue, lethargy,
generalized myalgias and arthralgias with swelling limited to the left knee,
ankles and ﬁngers. No mucosal lesions, nausea, vomiting or diarrhea were
present. Pertinent ﬁndings on physical examination included mild edema of
the left knee without associated erythema or warmth and proximal and distal
interphalangeal joints of the hands, wrists, knees and ankles absent of an
effusion, but tender to palpation with full range-of-motion. Urticarial lesions
with serpiginious borders and central clearing were noted on the trunk and
extremities including the palms but not soles. Hyperpigmented areas at sites
of previous urticarial lesions were present. Prednisone, 10 mg 3 times daily,
and cetirizine, 10 mg daily, was prescribed and within 24 to 48 hours, all
symptoms improved. No further laboratory studies were obtained. Prednisone
was tapered over a 2 week period and cetirizine was discontinued
simultaneously without recurrence of symptoms. The patient was advised
to avoid TMP/SMX indeﬁnitely.
Conclusions: Medications are the most common cause of serum sickness
with TMP/SMX being frequently implicated. Immune complex reactions
generally occur a few weeks after initial exposure to a medication; however,
drug -induced serum sickness should still be considered in cases to which an
agent may have been previously tolerated.
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Jessner-kanoff Lymphocytic Inﬁltrate as a Side Effect
of Immunotherapy
Arzu Didem Yalcin, MD,1 Atil Bisgin, MD, PhD,2 Reginald M Gorczynski,
MD, PhD,3 Ayse Akman,4 Gülgün ErdoÐan,5 and Olcay Yegin6. 1Aller-
gology and Clinical Immunology Unit, Antalya Education and Training
Hospital, Antalya, Turkey; 2Human Gene and Cell Therapy Center of Ak-
deniz University Hospital and Clinics, Antalya, Turkey; 3Division of Cel-
lular & Molecular Biology, Toronto Hospital, University Health Network,
Toronto, Ontario, Canada; Departments of 4Dermatology; 5Pathology,
and; 6Immunology and Allergy, Akdeniz University Faculty of Medicine,
Antalya, Turkey.
Background: Allergen immunotherapy has been used in the management of
allergic diseases for nearly 100 years. It is the only speciﬁc treatment for
hymenoptera venom anaphylaxis. Various venom immunotherapy schedules
have been designed to treat anaphylaxis. Although the effect of venom
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immunotherapy is well documented, there is also an increased risk of side-
effects in bee-venom-treated patients and in those with rapid dose increase.
Methods: This report describes the ﬁrst case of a patient in the literature with
Jessner’s Lymphocytic inﬁltration as a side effect of venom immunotherapy.
This is a chronic, benign, T cell pseudolymphoma characterized by the oc-
currence of recurrent, asymptomatic, smooth, erythematous, non-scaling pap-
ules or plaques. However, the exact cause of Jessner’s Lymphocytic
Inﬁltration is unknown.
Results: The case here reported was a 61 year-old male pediatrician, who
has been followed by at our Immunology Service because of an immediate
allergy to a bee sting managed with venom immunotherapy. His chief
complaint was an anaphylactic reaction after 5 minutes of a bee sting. The
onset of his symptoms was gradual and began just 25 minutes after the
sting. The venom immunotherapy regimen was planned and the protocol
immediately began without premedication. But during the initial phases of
treatment, on the third dose of immunotherapy, he reported severe itching.
After complaining of itching, many erythematous papules and plaques on
his chest were developed. The lesions ﬂared up for 3 days period just after
injection and decreased afterwards. The type of lesions and their location
supported the diagnosis of Jessner disease, which had also a histopatholog-
ical conﬁrmation.
Conclusions: We herein report this case to call attention to this side effect of
VIT that there may be more similar cases never reported.
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Improvement of Oral Lichenoid Reaction Symptoms after
Removal of Amalgam Restorations: An Anusual Case of Type
IV Hypersensitivity
Yasar Meric Tunca, PhD,1 Ozlem Ucok, PhD,2 Cumhur Aydin, PhD,1 Hakan
Avsever, PhD,3 Kaan Orhan, PhD,3 and Oguzhan Yildiz,MD, PhD4. 1Endodon-
tics; 2Oral Diagnosis and Radiology, and; 3Oral Diagnosis and Radiology,
Gulhane Military Medical Academy, Ankara, Turkey; 4Medical Pharmacology,
Gulhane School of Medicine, Ankara, Turkey.
Background: Chemical and mechanic iritations may play causative role in
development of lichenoid reactions in oral mucosa, similar to skin, in
predisposed patients. It has recently been reported that lichenoid reactions
and Wickham striae with papular/reticular characteristics are observed in
mucosal regions which are in direct contact with amalgam restorations (1).
A 38-year-old male patient admitted initially to the Department of Oral
Diagnosis and Radiology, chieﬂy complaining of bilateral buccal pain and
itching. In his intraoral inspection, hyperkeratotic white lesions at his molar
teeth level at both right and left buccal mucosa were observed. The purpose
of this study is to ﬁnd out the nature and decide on the management of these
buccal lesions.
Methods: In dental inspection of the patient, large amalgam restorations and
white lesions in buccal surface in direct contact with amalgam were observed
in left ﬁrst and second, and right second molar teeth region. A 4-mm punch
biopsy from buccal mucosa was performed. In addition, a skin patch test with
amalgam was done in back region of the patient.
Results: In punch biopsy, histopathological features were compatible with
lichenoid mucositis. In addition, skin patch test results indicated a very strong
positive reaction to amalgam. The lesion healed up after replacement of
restorations with composite ﬁlling material. The patient, his family and his
dental practitioner were strictly advised to use alternative restorative materials
in case of a need for restoration.
Conclusions: Amalgam and its components may cause type IV hyper-
sensitivity reactions (1) and, very unusually, immediate hypersensitivity
(2). The clinician should be aware of all possible pathological etiologies
of white lesions. If there is any doubt about the diagnosis and
management of an anusual oral lesion, referral to appropriate specialists
is mandatory.
REFERENCES
1. Am J Dermatopathol. 2010;32(1):46–48.
2. Br Dent J. 2008;205(10):547–550.
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Hypersensitivity Reactions to Interferon Based Treatment for
Hepatitis C: A Single Center 20-Year Experience
Ioannis Sidiropoulos, MD, Athanasios Beltsis, MD, Elena Gigi, MD,
Anna Sykla, MD, Aristea Bellou, MD, and Maria Raptopoulou-Gigi, MD.
Allergy, Ippokration Hospital, Thessaloniki, Greece.
Background: BA Interferon (IFN)-based therapy for chronic hepatitis C
(CHC) is associated with adverse hypersensitivity reactions (HRs). However,
data on HRs to IFN in every-day clinical practice are lacking. We conducted
a retrospective study to identify the incidence, management and outcome of
such reactions.
Methods: A review of the electronic ﬁles of all CHC patients followed in our
tertiary referral center from January 1990 to November 2010 was conducted
to identify patients submitted to IFN-based treatment and HRs to such
treatment.
Results: During the study period, 832 CHC patients were identiﬁed, 545
(65.5%) of whom received IFN-based treatment. Overall, 221 (40.5%) patients
received at least one treatment cycle with IFN-a 6 ribavirin (RBV), 170
(31.2%) patients received at least one treatment cycle with pegylated (PEG)-
IFN a2a1 RBV and 189 (34.7%) patients received at least one treatment cycle
with PEG-IFN a2b 1 RBV. Fifty-ﬁve treatment cycles were complicated by
HRs in 54 patients (female 20, median age 39 years, range 22–65 years).
Presenting symptoms of HRs were: skin rash in 46 patients (pruritic in 20),
generalized pruritus in 7 patients and aphthous mucosal ulcers in 2 patients.
HRs occurred in 9 patients treated with IFN-a (4.1%), 23 patients treated with
PEG-IFN a2a (13.5%) and 23 patients treated with PEG-IFN a2b (12.1%) (P ¼
0.002). Management of HRs included no intervention in 18 (32.7%) cases,
topical treatment in 10 (18.2%) cases, antihistamine administration in 15
(27.3%) cases, temporary cessation of treatment or dose reduction in 3
(5.5%) cases, switch from PEG-IFN to IFN-a in 4 (7.3%) cases and immediate
termination of treatment in 5 (9.1%) cases. The outcome was complete remis-
sion of the HR in 33 (60%) cases, remission sufﬁcient to allow continuation of
treatment in 13 (23.6%) cases and treatment termination in 8 (14.5%) cases,
while one (1.8%) patient was lost to follow-up after the HR. Overall, 2 (0.9%)
patients discontinued IFN-a, 3 (1.8%) PEG-IFN a2a and 3 (1.6%) PEG-IFN a2b
due to HRs (P ¼ 0.737).
Conclusions: Hypersensitivity reactions to IFN-based and especially to PEG-
IFN based treatment regimens are occasionally encountered in CHC patients
and may rarely lead to treatment termination.
DRUG ALLERGY 2
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Hypersensitivity Syndrome Associated with Phenytoin Sodium
Elizabeth Mendieta. Mexico City, Mexico.
Background: The drug-induced hypersensitivity syndrome (DIHS) is
a systemic reaction for drug-induced idiosyncratic. We report 1 in 1000 to
1 in 10,000 exposures to aromatic anticonvulsant. In the case of phenytoin is
estimated at 2.3 to 4.5 per 10,000 exposures. There is a deﬁcit of microsomal
epoxide hydroxylase causing accumulation of toxic metabolites. Occurs
between 2 weeks to 3 months after drug exposure; it is characterized by
maculopapular rash, erythema midface, fever, lymphadenopathy, with
alteration of the hematologic system with eosinophilia, peripheral or atypical
lymphocytosis. Described reactivation of herpes virus (HHV-6 and 7).
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Comorbidities during the syndrome such as type 1 diabetes, encephalitis, and
long-term sequelae such as thyroid dysfunction, systemic lupus erythemato-
sus, etc.1
Methods: We report a 39 year old female with history of traumatic brain
injury (TBI) received proﬂaxis with phenytoin sodium 100 mg 1vo c/8 hours,
4 weeks after starting with fever, malaise, sore throat, cervical lymphade-
nopathy, appeared itchy rash in face, neck. Admitted with malaise,
generalized rash, edema midface, cheilitis, jaundice, cervical lymphadenop-
athy, axillary and inguinal and hepatomegaly.We continued to study probable
hypersensitivity syndrome asking paraclinical studies including blood count,
liver function tests.We initiated 1 mg/kg/d prednisone for 6 weeks and
subsequent dose reduction. Exit after 5 days of hospitalization for clinical
improvement.Continuous current monitoring by the outpatient department of
our hospital and late complications that can occur in this syndrome.
Results: Liver function tests as well as the count of the white series was
abnormal, with the following report: AST (177 U/L), ALT (154 U/L), WBC
(12.430 mm3), eosinophil (1.310 mm3). Biopsy report unavailable.
Conclusions: Aromatic anticonvulsants (phenytoin, carbamazepine and
phenobarbital) are frequent causes of DIHS. Treatment involves discontin-
uation of the drug involved, admission to intensive care and systemic steroids
at doses of 0.5 to 1 mg/kg/d and intravenous immunoglobulin 2 g/kg.
REFERENCES
1. Kano Y, Shiohara T. The variable clinical picture of drug-induced hyper-
sensitivity syndrome (DIHS) in relation to the eliciting drug. Immunol
Allergy Clin North Am. 2009;29(3):481–501.
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DrugHypersensitivity Reactions inHospitalized Patients:What is
the Role of the Allergist?
Luciana Kase Tanno, MD,1 Simone Valadão Curi,1 Fátima Fernandes, MD,2
Michel Dracoulakis, MD,2 Wilson T Aun, MD,1 and João Ferreira Mello,
PhD1. 1Allergy and Immunology, Hospital do Servidor Público Estadual
de São Paulo, São Paulo, Brazil; 2Allergy, Hospital Servidor Público Estad-
ual de São Paulo, São Paulo, Brazil.
Background: Ten-to-twenty percent of hospitalized patients experience drug
adverse reactions. There are few epidemiological data of drug hypersensitiv-
ity in inpatients in brazilian population. Our aim was to analyze the main
clinical and epidemiological data of drug hypersensitivity reactions in
hospitalized patients and to assess the importance of the allergist’s evaluation.
Methods: A prospective study was developed in an Allergy Clinic of
a Service in São Paulo, Brazil, from January 2010 to January 2011. We
evaluated the cases in which the allergist was assessed. The patients were
studied based on history of hypersensitivity reactions to drugs (HRD) using
an adapted ENDA (European Network of Drug Allergy) questionnaire. We
analyzed clinical and epidemiological data of drug hypersensitivity reactions
and assessed differences of the allergist evaluation.
Results: Of all 80 cases in which the allergist was assessed, 65 (81%) were
for HRD. The mean age was 57 years, 49 (75%) were women. Fifty (89%)
experienced non-immediate reactions, 8 of them were severe adverse
cutaneous reactions. Eight (12%) had just positive history of HRD, without
reaction at the time of the evaluation. Neurosurgery (15), Infectious
Diseases (11), Vascular surgery (8) were the main Clinics who assessed
our specialty. Non-steroidal anti-inﬂammatory drugs (21), antiepileptics
(16) and non-b-lactams antibiotics (15) were the most important pharma-
cological groups. Thirty (46%) patients were in use of more than 5 drugs at
the time of the reaction, but in 46 (70%) evaluations there was 01 culprit
drug suspected by the allergist. There was discordance between the allergist
and the non-allergist opinion about the suspected drug in 13 (20%) cases.
In 50% of cases other Clinics were assessed for the same reason.
Eleven (17%) patients had history of HRD with the same pharmacological
group before.
Conclusions: HRD is the main cause why the allergist is assessed. The
pharmacological groups related to these HRD were different from the
previously described. The history of HRD is still not appropriate asked from
the non-allergists. The evaluation of the allergist can help to manage HRD
properly.
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Allergic Reactions to Local Anesthetics: Detection by Skin Tests
and Subcutaneous Provocation. Analysis of 160 Cases
Luiz Arcanjo, MD,1,2,3 Tania Maria Gonçalves Tavares, MD,1,2,3 Nathalia
Delcourt, MD,1,2 Juliana Baroni, MD,1,2 João Rios, MD,1,2,3 and José Luiz
Rios,MD,1,2,3,4. 1Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil;
2Faculdade de Medicina de Petropolis, Petropolis, Brazil; 3Alergistas Col-
igados, Rio de Janeiro, Brazil; 4Thorax Disease Institute, Federal University
of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Adverse reactions to local anesthetics (LA) are frequent and
often referred to as allergic. Although immune-mediated reactions are rare, it
should be investigated for suspected cases. The objective of this study was to
determine the frequency of positive skin test to these drugs in patients with
a suspected history of allergic reactions and describe the main socio-
demographic characteristics of these individuals.
Methods: Retrospective study of medical records of patients attended at
Policlínica Geral do Rio de Janeiro Allergic Clinic, between 2008 and 2011.
The parameters evaluated were the test indication and the patient ages and
gender. The drug tested was that the patient had a history of suspicion.
Patients underwent skin prick and intradermal tests and subcutaneous prov-
ocation. Descriptive statistical analysis of the data was performed.
Results: It was performed 160 tests (125 female). Three of this total was
excluded due to inconclusive results. In women, the highest proportion of
tests was in the age group from 41 to 60 years (43%), while in males the
higher concentration was at a youngest age group: 21 to 40 years (41%).The
most common indication (103 cases, 65%) for the tests was a previous
suspected anaphylactic reaction by LA. Seven of 157 tests had a positive
result (4.4%), 6 of them occurred in women (4.8%). Only one test resulted in
a type of anaphylactic reaction response (0.67%).All patients who presented
positive response to the test had a history of per-anesthetic reaction that
suggested an immune-mediated mechanism.
Conclusions: In patients with a history of previous reaction to local
anesthetics, the skin tests with these drugs have a key role in the prevention
of anaphylaxis, and on guidance for adequate anesthetic procedures.
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Protamine Allergy
Christine Hafner, MD,1,2 Daniel Blagojevic, MD,1,2 and Franz Trautinger,
MD.1,2 1Department of Dermatology, General Hospital St.Poelten, St.Poel-
ten, Austria; 2Karl Landsteiner Institute for Dermatological Research, St.
Poelten, Austria.
Background: An anaphylactic reaction to protamine sulfate during cardiac
surgery is a rare but known entity. Preoperative prediction and outcome of
such a reaction is still unclear. A 68-year-old man presented for elective
coronary artery bypass grafts. His medical history included hypertension and
he was non-diabetic. Review of his angiogram indicated 2-vessel coronary
artery disease. According to the patient’s notes, he had a known allergy to
shellﬁsh and avoids ﬁsh due to personal discomfort, although the exact nature
of his reaction to ﬁsh was not well described. The information prompted the
thoracic surgery team to alert the allergologist to perform an allergological
checkup before thoracic surgery.
Methods: Skin prick tests were performed with standard solutions for shrimp,
ﬁsh-mix, mackerel and salmon (Bencard, Munich, Germany). Protamine
sulfate (CP Pharmaceuticals Ltd, Wrexham, UK) was pricked undiluted and
was tested intradermally diluted 1:10. Physiological saline and 0.01%
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histamine solution served as controls. A wheal with a diameter .3 mm in
comparison with the negative control was scored as positive. Furthermore, in
vitro allergy testing using the Phadia CAP system for speciﬁc IgE against
shrimp, ﬁsh-mix, rainbow trout, rCyp p 1 and protamine sulfate was
performed.
Results: Skin prick tests were positive to shrimp, ﬁsh-mix, mackerel, salmon
and protamine sulfate. Intradermal testing with protamine showed a wheal
diameter of 7 mm. Analysis of a blood sample showed elevated total IgE
(2600 kU/L) and speciﬁc IgE to shrimp (2.94 kU/L), ﬁsh-mix (0.53 kU/L),
rainbow trout (0.39 kU/L), rCyp p1 (0.53 kU/L) and protamine sulfate (0.77
kU/L).
Conclusions: Protamine sulfate is a polycationic peptide used to reverse the
anticoagulant effects of heparin during cardiac surgery. It is commercially
produced from the sperm of salmon and it is considered that persons who
have an allergy to ﬁsh could be at risk of protamine reactions. The exact
mechanisms by which it causes anaphylaxis are not fully understood. Due to
a clear sensitization to ﬁsh proteins and protamine sulfate and a known
allergy to shellﬁsh we disapproved the standard anticoagulation protocol with
heparin/protamine. Bivalirudin was used as an anticoagulant and the surgery
proceeded without any untoward events.
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Description of Drug Allergy Study Conducted in a Teaching
Hospital between October 2007 and March 2011
Consuelo Fernanda Rodríguez Martínez, and Alicia Sciarafﬁa Rubio. Inmuno-
logía, VIH y Alergias, Universidad de Chile, Santiago, Chile.
Background: The World Allergy Organization (WAO) in 2003 deﬁned ‘drug
allergy’ as an immunologically mediated drug hypersensitivity reaction. The
mechanism of drug allergy may be either IgE or non-IgE mediated. The true
incidence of drug allergy is not known. There are only few studies/datasets
using standardized clinical questionnaires and validated in vivo or in vitro
tests to conﬁrm the diagnosis of drug allergy. Here we have analyzed the
obtained results of in vivo test in suspected drug allergy patients.
Methods: Data from the Centre of Allergies of the Clinical Hospital of the
Universidad de Chile between the months of October 2007 and March 2011
was obtained. The information of the protocols of drug executed, by deﬁning
as Protocol the study of a probable allergy by 2 or more procedures, which
can be: Prick Test, intradermal reaction, speciﬁc IgE and/or Test Patch.
Results: For a total of 126 drug protocols, 25% of them were trivírica vac-
cine, 24% b-lactams, 21% local anaesthetics and 10% to general anesthesia
(inductors, muscle relaxants and Latex). Of the total of patients undergoing
protocols the most of them were women, there is no clear difference between
the number of children and adults. The temporal distribution of protocols was
stable between the months of October 2007 and March 2009 (15 protocols/
semester), to then become variable, reaching values between 10 and 29 every
6 months. Of total protocols, 30.1% were positive; only one patient presented
a mild adverse reaction (local welt). The b-lactams being most often the
positive drugs. Protocols involving pethidine 100% was positive, diclofenac
33%, dipyrone, ketoprofen and hydrocortisone each one 25%. The most
accomplished protocol was trivírica vaccine, resulting in 100% negative.
Of all negative protocols 58% went to provocation, resulting in a 8% positive,
including one provocation to the trívirica vaccine.
Conclusions: Methodologicall study is very important for a possible drug
allergy, because history is not enough to certify the diagnosis. To do
a provocation test to a negative protocol is crucial.
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Lung Toxicity Induced by Novel Antineoplastic Therapies in
Cancer Patients
Kostas N. Syrigos,1 Dimitrios Vassos,1 Nektaria Makrilia,1 Sotirios Tsimpoukis,
1 Ekaterini Politi,2 Ioannis Dannos,1 and Ekaterini Syrigou2. 1Oncology Unit,
3rd Department of Medicine, Sotiria General Hospital, Athens School of Med-
icine, Athens, Greece; 2Department of Allergy, Sotiria General Hospital,
Athens, Greece.
Background: Pulmonary toxicity and respiratory failure are major adverse
events complicating the use of novel antineoplastic agents in the treatment of
lung cancer. We aim to investigate the risk and characteristics of cytostatic-
induced pulmonary toxicity caused by agents currently used to treat lung cancer.
Methods: A literature search was performed in PubMed to identify relative
studies published until June 2011.
Results: Almost all categories of antineoplastic agents have been associated
with some kind of pulmonary complications. Taxanes have been linked to
acute pneumonitis, pleural effusion and reactions during infusion. Nucleoside
analogs can cause diffuse alveolar damage, bronchospasm and acute
respiratory distress syndrome (ARDS). Monoclonal antibodies are associated
with pulmonary hemorrhage and hemoptysis. Acute pneumonitis and
hypersensitivity reactions have been reported with podophyllotoxins, while
diffuse interstitial pneumonia has been attributed to pemetrexed. Tyrosine
kinase inhibitors of the epidermal growth factor receptor have been associated
with acute pneumonitis, diffuse alveolar damage and pulmonary ﬁbrosis. The
exact incidence of lung toxicity caused by these agents remains unclear,
although it seems relatively low. Clinical manifestation includes cough, fever,
dyspnea and hypoxemia. Chest imaging reveals diffuse or patchy, unilateral
or bilateral, ground-glass opacities or consolidations. It is important that other
possible causes of respiratory failure be excluded when treating a lung cancer
patient receiving chemotherapy.
Conclusions: Physicians should be aware of the potential of lung toxicities
from antineoplastic agents, especially when they are combined with other
cytotoxic drugs or radiation.
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Redness of Skin: SSSS in a 10 Month Old Healthy Baby
Agnes Nemeth, MD, MSc,1 Maria Ablonczy, MD,1 Palma Sillo, MD,2
and Renata Kun, MD3. 12nd Department of Pediatrics, and; 2Department
of Dermatology, Venerology and Dermatooncology, Semmelweis University,
Faculty of Medicine, Budapest, Hungary; 3Pediatric Department, Jahn Fer-
enc South Pest Hospital, Budapest, Hungary.
Background: Infections are caused by staphylococcus bacteria commonly
found on the skin or mucosal membranes of healthy patients. These bacterias
can turn into blood stream and cause severe life-threatining conditions: severe
erythema multiforme-like eruption of skin and lesions of the oral, genital and
anal mucosa associated with fever, arthralgia and neurological symptoms. To
ﬁnd the correct diagnosis among mucocutaneous diseases sometimes difﬁcult
but is important for choosing the proper medication.
Methods: A 10 month old boy with symptoms starting 2 days before with
upper airway tract infection, external otitis and some urticarial eruption on his
body without fever. He was put on oral antihistamin and antibiotic treatment.
He was reffered to our Department because of high fever, conjunctivitis,
stomatitis and redness of his skin all over his body with some blister
formation. He was unable to eat, he was in pain, but sleepy. After a few hours
of his admission his fever became 398C, severe exfoliation occured, and some
large ﬂaccid bullaes appeared and erupted, drained an amber-colored liquid
and spreaded to cover extensive areas of his body revealing denuded skin. His
history and symptoms suggested allergic reaction for his medication or auto-
immun/ mucocutaneous disorder, but interestingly his laboratory tests were in
the normal range. In spite of these to prevent a bacterial superinfection after
bacterial culturing of throat, nose, skin, and blood, we introduced iv amox-
icillin/clavulanic-acid therapy, cyclesonide eye drops, antiseptic local treat-
ment of mouth (chlorhexidine digluconate) and skin (unguentum
antisepticum). After 2 days his fever stopped and the top layer of his skin
started to come off, partly powdery scales formed.
Results: The symptoms started to resolve slowly and the child became
symptome free after 10 days. Bacterial culturing results conﬁrmed the
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diagnosis of SSSS. The antibiotic treatment was completed on the tenth
day.
Conclusions: Symptomes and appearence of the disease suggested several
diseases but the laboratory tests were normal, making the diagnosis more
difﬁcult, the supposed diagnosis did not ﬁt properly for the patient age.
Careful observation of patients and the disease, exfoliative cytology and
a biopsy, microbiological investigations allow the diagnosis, ruling out
erythema multiforme and drug-induced toxic epidermal necrolysis, both
which are similar to SSS Syndrome.
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Desensitization Protocol to Methotrexate
Jonathan Maya, MD, Blanca del Rio, MD, Alexander Morales, MD,
and Miguel Angel Rosas-Vargas, MD. Pediatric Allergy and Clinical
Immunology, Hospital Infantil de Mexico Federico Gomez, Mexico City,
Mexico.
Background: A 17 year old patient was referred to Allergy outpatient clinic
with history of recent anaphylaxis (wheezing, breathlessness, nausea, vomit
and hypotension) to methotrexate (MTX) during the induction treatment of
ALL L2. The diagnostic conﬁrmation consisted in a skin test, with a positive
response at 1:100 dilution. The case was discussed together with Pediatric
Oncology service, and was agreed that MTX was necessary for the patient
survival, because of that we performed the following desensitization protocol.
Objective: Evaluate the effect and safety of a desensitization protocol to
methotrexate in an adolescent with acute lymphoblastic leukemia L2 (ALL
L2) and allergy to methotrexate.
Methods: Desensitization protocol consisted in 2 phases. First phase
consisted in premedication with hydrocortisone (IV) 1 mgkgdo, cetirizine
(PO) 0.2 mgkgdo, chlorpheniramine (IV) 0.35 mgkgdo and montelukast (PO)
10 mgdo at 13, 7 and 1 hour prior to desensitization phase which consisted in
an 8 hour scheme of IV infusion of 12 dilutions with increasing concen-
trations starting at 1:1,000,000 at 30 minutes intervals up to the full dose was
completed.
Results: Patient was admitted to pediatric intensive care unit and was
successfully desensitized, the full protocol was completed as expected,
including pre-medication, the desensitization phase lasted 8 hours; at the
second dilution (1:100,000) the patient presented nausea, requiring one extra
dose of chlorpheniramine, no other adverse reactions were presented in the
next 48 hours observation period. He was maintained with 50 mg/m2 IV
MTX weekly for the full anti-leukemia treatment duration (1–2 years) using
the same protocol and stayed out of MTX-related adverse reactions. Today he
is followed as an outpatient by our service.
Conclusions: This 12 steps MTX-desensitization protocol was effective and
safe. In selected cases of severe allergic reactions to chemotherapeutic agents
there where no other equally effective treatment option available, desensiti-
zation is effective and safe.
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Clinical Features of Dress Syndrome in 42 Patients
Mi-Ran Park, MD,1 Ki-Ho Kim, MD, PhD,2 Su-Min Park, MD,1 Il- Hwan
Jeong, MD,1 Neul-Bom Yoon, MD,1 Sung- Woo Lee, MD,1 Soo-Jung Um,
MD,1 Soo-Keol Lee, MD, PhD,1 and Choon-Hee Son, MD, PhD1. 1Internal
Medicine, and; 2Dermatology, College of Medicine, Dong-A University,
Busan, South Korea.
Background: The clinical features of DRESS syndrome are complicated, and
the incidence this condition is very low.
Methods: This study was a retrospective analysis of prospectively collected
data in 42 consecutive patients with DRESS syndrome diagnosed between
September 2009 and April 2011. We investigated the clinical features,
response to treatment, and outcome of 42 patients.
Results: Study patients consisted of 18 men (42.9%) and 24 women (57.1%).
The most common causative drugs were antibiotics (33.3%) and anticonvul-
sants (26.2%), followed by antituberculosis drugs (11.9%), allopurinol
(7.1%), nonsteroidal anti-inﬂammatory drugs (NSAIDs) (7.1%), undeter-
mined agents (7.1%), others (7.1%). The latency period ranged from 2 to 60
days, with a mean of 16.6 days. The longest latency period was noted in the
antituberculosis drug group, 35.8 6 16.2 days. Atypical lymphocytosis was
noted in 16 patients (38.1%), and thrombocytopenia in 7 patients (16.7%).
Hepatic involvement was noted in all study patients. Additionally, lung in-
volvement was noted in 2 patients (5.8%), CNS involvement was in 1 patient
(2.4%). Systemic corticosteroids were administered to 8 patients (19.0%).
Complete recovery was noted in 40 patients (95.2%). Two patients had poor
outcomes; one died due to opportunistic infection secondary to long-term
systemic corticosteroids treatment and the other showed prorgressive deteri-
oration of liver damage, although the ﬁnal outcome is not known.
Conclusions: Drugs associated with DRESS syndrome were variable and
most frequently included antibiotics and anticonvulsants. DRESS syndrome
was more common than generally recognized, and most of patients with this
disease showed better clinical out outcome than that has been generally
expected.
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Risk Factors Associated to Mortality in Mmexican Children with
Stevens-Johnson Sndrome/Toxic Epidermal Necrolysis
Luis Octavio Hernandez-Mondragon, MD,1 Blanca del Rio, MD,2 Armando
Partida-Gaytan, MD,2 Eduardo Almeida-Gutierrez, MD, PhD,3 and
Miguel Angel Rosas-Vargas, MD2. 1Pediatric Allergy and Clinical Immunol-
ogy, Hospital Infantil Federico Gomez, Mexico City, Mexico; 2Pediatric
Allergy and Clinical Immunology, Hospital Infantil de Mexico Federico
Gomez, Mexico City, Mexico; 3UMAE Cardiologia - Centro Medico Nacional
Siglo XXI - IMSS, Mexico City, Mexico.
Background and Objective: Identify risk factors associated to mortality
in Mexican children with Stevens-Johnson Syndrome/Toxic Epidermal
Necrolysis.
Methods: Cross-sectional analytical study. We reviewed the medical records
of patients with hospitalization and primary diagnosis of Stevens-Johnson
syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) from January 1995 to
May 2011. Our study variables have been previously described. We describe
median (interquartilar range: IR) and percentage. Exact Fisher test, Mann
Withney U and binary logistic regression were used.
Results:We obtained 51 medical records: 24 male (47.1%), 27 female (53%).
Median age was 5 years (IR 2–8). Thirty eight (76%) corresponded to SJS,
four (7.8%) to SJS-TEN overposition and nine (15.7%) to TEN. Mortality
was seen in 9 patients (17.6%, 6 male [66.8%] and 3 female [33.3%], P .
0.05). Twenty two cases (43%) were attributed to anticonvulsive drugs,
twenty (39%) to antibiotics, two (4%) to non-steroid anti-inﬂammatory drugs,
two (4%) to infection, one (2%) to chemotherapeutic drugs, and in two (4%)
no trigger factor was identiﬁed. Risk factors associated to mortality were:
denudation of .30% Body Surface Area (BSA) (7.1% vs 55.6% P , 0.001),
concomitant malignancy (0% vs 22.2% P , 0.028), moderate leucopenia
(,1,000 cells/mL) (0% vs 33.3%, P , 0.001), leucocytosis (.20,000
cells/mL) (7.3% vs 22.2%, P , 0.001), hypokalemia (,3.5 mEq/L) (5.6%
vs 33.3%, P , 0.011), hyperkalemia (.5.0 mEq/L) (5.6% vs 22.2%, P ,
0.011). Total bilirrubin concentration .3.6 mg/dL has tendency to associate
with mortality, P ¼ 0.08. Six patients (11.7%) were treated with steroids,
ﬁfteen (29.4%) with IV human immunoglobulin and one (1.9%) with both
drugs, no statistical difference was observed, though the steroid-treated group
showed a tendency towards mortality increase. Some variables were not able
to analyze due incomplete medical records.
Conclusions: Risk factors associated to mortality in patients with SSJ/
TEN identiﬁed in this study are: skin denudation .30% BSA, concomitant
malignancy, leucopenia, leukocytosis, hypokalemia and hyperkalemia. Total
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bilirrubin concentration.3.6 mg/dL has tendency to associate with mortality,
although not statistically signiﬁcant.
DUST MITE ALLERGY
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Standardization and Characterization of Dust Mite Extracts
Manufactured in the USA
Greg Plunkett, PhD. ALK-Abello, Round Rock, TX.
Background: Standardized Dermatophagoides dust mite extracts are pro-
duced in the US from puriﬁed whole bodies. Growth media and the processes
for separating mites from media vary among manufacturers. The FDA
requires that mite extracts are standardized and labeled in AU/mL. Potency
is determined using a laboratory ELISA competition method to compare the
product with an FDA reference. The method measures binding of IgE from an
FDA supplied sera pool to antigens bound to an ELISA plate and AU is
calculated from the ability of the test extract to inhibit the binding relative to
the 10,000 AU/mL FDA reference. Since this is the only FDA requirement
for potency, the purpose of this study was to compare mite extracts from
different US manufacturers for protein complexity, major allergen, and
potency using various biochemical characterization techniques.
Methods: Der group 1 and 2 allergens were measured in mite extracts from
several manufacturers produced over the last 8 years using validated ALK
immunoassays. Competition IgE binding was performed using FDA refer-
ences and sera pools. The effect of the immobilized extract on the relative
potency compared to the FDA reference was determined. Protein proﬁles
were determined using SDS-PAGE.
Results: The average Der 1 and Der 2 levels and ratio in 10,000 AU/mL
products varied considerably (Der 1: 25–140 mg/mL, Der 2: 2–140 mg/mL).
The ratio of Der 1/Der 2 was manufacturer related and ranged from 1:1 to
more than 10:1. The extract used to coat the ELISA plates had a marked
impact on Relative Potency (RP) with up to a 3-fold difference. RP deter-
mined by competition IgE binding was correlated with major allergen content
but the difference in potency was obtained by coating with different batches
of 10,000 AU/mL mites.
Conclusions: Often called a “total” IgE test, the competition IgE ELISA is
highly dependent on the allergen used to coat the plastic microplate. US mite
extracts with the same AU/mL can have very different Der 1 and 2 content.
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Detection of DERP 2 in theHouse Dust andCorrelation withMite
Number in an Environmental Survey
Jaw-Ji Tsai, MD, PhD, YI-Hsueh Lin, MS, and En-Chih Liao, PhD.
Department of Medical Research, Taichung Veterans General Hospital,
Taichung, Taiwan.
Background: Aeroallergen avoidance has been promoted in order to prevent
sensitization and the correlation between the level of allergen exposure and
sensitization has been reported. The aims of this study were to monitor the
environmental mite infestation and design a Der p 2 detection kit to estimate
the number of mites in house dust samples.
Methods: House dust samples were collected from 6 carpets and 2 mattresses
monthly from April 2010 to March 2011. The total number of mites was
counted under microscopes and Der p 2 concentrations were measured using
Der p 2 ELISA kit. The detection kit was constituted using Der p 2 speciﬁc
mouse monoclonal antibody as capture antibody, and rabbit polyclonal
antibody as detection antibody. Both Der p crude extract and rDer p 2 were
used as internal standard.
Results: The number of mites in the dust samples was signiﬁcantly higher in
the mattresses in comparison with that in the carpets and the total number
of dust mites was higher in the summer than any other seasons. The
concentration of Der p 2 component in Der p crude extract was analyzed and
the result showed that each gram of Der p crude extract contained 25.53 mg
of Der p 2. When the number of mites and Der p 2 concentration were
measured for the correlation analysis the results showed that there was a good
correlation between Der p 2 and number of mites with R2 ¼ 0.9652.
Conclusions: Dust mites were signiﬁcantly increased in the dust samples
collected from mattresses especially in the summer. The good correlation
between Der p 2 concentration and mite numbers indicated that the
measurement of Der p 2 can be used to replace direct mite count. Using
the Der p 2 detection to monitor environmental mite infestation may be
beneﬁcial for allergic subjects to prevent disease activation.
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Daily Vacuum Cleaning Signiﬁcantly Reduces House Dust Mite
Allergen, Endotoxin and b-glucan Content of Mattresses
Francis Fu-Sheng Wu,1,2 Rob Siebers,2 Mei-Wen Wu,3 Nevil Pierse,2
and Julian Crane2. 1Show Chwan Memorial Hospital, Changhua City, Tai-
wan; 2University of Otago, Wellington, New Zealand; 3Changhua Christian
Hospital Hospital, Changhua City, Taiwan.
Background: House dust mite allergic patients are advised to cover their
mattresses with occlusive coverings; however, these are not cheap. We
investigated whether daily vacuum cleaning of mattresses reduces house dust
mite allergens, bacterial endotoxin and fungal b-glucan content.
Methods: Twenty volunteers vacuumed their mattress daily for 8 weeks.
Dust samples, collected at two weekly intervals were analysed for house dust
mite allergens (Der p 1 and Der f 1) by double monoclonal antibody ELISA
and for endotoxin and b-glucan by the Limulus amoebocyte lysate kinetic
assay. Data are presented as geometric means with 95% CI.
Results: Total house dust mite allergens (Der p 1 1 Der f 1) signiﬁcantly
reduced from a geometric mean (95% CI) of 4.07 mg (2.44-6.79) at the start
to 0.42 mg (0.21-0.81) at week 8. Total endotoxin and b-glucan were also
signiﬁcantly reduced from 13.6 EU (8.6-21.4) to 3.4 EU (2.3-5.0) and from
94.4 mg (57.1-156.2) to 19.7 mg (10.2-37.9) respectively (P for trend
.0.0001). Percentage reductions in total house dust mite allergens, endotoxin
and b-glucan after 8 weeks of daily vacuum cleaning were 85.1% (80.1-
90.1), 71.0% (70.4-81.0) and 75.7% (70.4-81.0) respectively. This was
mainly due to a 77.7% (70.8-84.7) reduction in total dust.
Conclusions: Daily vacuum cleaning of mattresses over time signiﬁcantly
reduces house dust mite allergens, endotoxin and b-glucan. This gives house
dust mite allergic patients a practical and cheap alternative to reduce their
exposure to indoor bio-contaminants.
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Differences in Indoor Allergen Quantiﬁcation in Hispanic/Latino
Children Living in Miami to Those Living in Latin America
Miguel J Lanz, MD,1 Benjamin Efaw, CT,2 and Ronald Harbeck, PhD3.
1Allergy and Asthma, AAADRS Clinical Research Center, Coral Gables,
FL; 2Clinical Immunology Lab; 3Advanced Diagnostics Lab, National Jewish
Health, Denver, CO.
Background: Higher levels of indoor allergens can induce in children more
susceptiblity to atopy and possibly asthma.
Methods: Indoor allergen sampling was collected by families of allergic
children referred to our Allergy clinic. Two groupings were based on location
of residence, either locally, Miami Florida (MF), or from Latin America (LA).
LA children were from Dominican Republic, Ecuador, Venezuela, or Central
America. All MF children were of Hispanic/Latino descent, ﬁrst or second
generation, from similar countries. A dust collection device, (Duststream,
Indoor Biotechnologies, Charlottesville) was used to vacuum the bedroom
samples. These samples came from the mattress, pillows, ﬂoors, rugs, and
A/C vents. After collecting, samples were weighed, extracted, vortexed, and
incubated. For allergen detection, MARIA (Indoor Biotechnologies) was used
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to quantify levels of dust mite (DM) allergens, (Dermatophagoides pteronys-
sinus, Der p 1; Dermatophagoides farinae, Der f 1), and Felis domesticus (Fel
d 1), Canis familiaris (Can f 1), Blattella germanica (Bla g 2). Quantiﬁcation
of these allergens was performed on a multiplexing instrument, Luminex 200,
(Luminex Corporation, Austin, TX).
Results: Samples from 63 MF and 69 LA were returned. There was
a statistical signiﬁcance in total DM levels between both locations. The
mean DM level was 118.7 ng/mL from MF and 241.0 ng/mL from LA (*P .
0.05). Both were in the moderate range for clinical exposure, 2.37 mcg/mL
and 4.82 mcg/mL. Contribution of the total DM signiﬁcance was from the DP
species. The mean DP level was 34.1 ng/mL from MF compared to 188.6 ng/
mL from LA (**P . 0.001). The clinical exposure of DP was moderate at
3.77 mcg/mL from LA, but in the low range at 0.68 mcg/mL from MF. No
signiﬁcant difference was found in DF between locations, but a minor trend
towards more DF exposures in MF rather than LA exists. There was no
difference found between locations with the other allergens tested. High cat
allergen exposure was found in MF, but with variability and miniscule levels
found in LA. Moderate dog and very low cockroach clinical exposures were
found in both locations.
Conclusions: Our study reveals intriguing indoor allergen levels based on
different environments that may contribute to the epidemiology of allergy/
asthma in Hispanic/Latino children.
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House Dust Mite Fauna and Its Relationship to Allergen Skin
Tests in Six Mexican States
Bárbara Isabel Ferández Duro, MSc,1 Naomi Cuervo Pineda, MSc,2
Jesús Alberto Rodríguez Alvízar, MSc,3 Rodolfo Celio Murillo, 3
Tila María Pérez Ortiz, PhD,4 and Daniel Juárez Anaya 3. 1Allergens
Laboratory, National Center of Bioproducts, Havana, Cuba; 2Zoología,
IES, Havana, Cuba; 3Allergens Laboratory, Rocel, Puebla, Mexico;
4Coleccion Nacional de Acaros, Unam, DF, Mexico.
Background: House Dust Mites (HDM) are important respiratory allergens
all over the world. In Mexico, there have been only few studies describing the
HDM fauna, and mostly limited only to Mexico City. This study aimed to
asses the HDM fauna and its relationship to allergen sensitization in different
cities with climatic variations in Mexico.
Methods: A total of 60 dust samples were collected from mattresses in 6
Mexican states: Oaxaca, Tamaulipas, Veracruz, Puebla, Chiapas and
Campeche; during a period from February to August 2010 and in May
2011. Mites were isolated under a stereomicroscope using lactic acid - 0.9%
NaCl solution (1:1). Identiﬁcation was performed on ﬁxed slides prepared
with Hoyer solution. Skin Tests were performed with allergen extracts of
different HDM species in the 60 mattress’ owners, which had previously been
diagnosed with respiratory allergy.
Results: The Pyroglyphidae family was predominant, being found in 100%
of dust samples. Dermatophagoides pteronyssinus (Dp) and Dermatopha-
goides farinae (Df) were the species most frequently found (in over 90%
of samples). These ﬁndings were in agreement with the Skin Tests results,
where 100% of patients were positive to Dp whereas 70% was positive to Df.
It was evidenced for the ﬁrst time the presence of Blomia tropicalis (in
Tamaulipas, Veracruz and Campeche) and Dermatophagoides siboney (in
Campeche). Both species are important allergenic sources in tropical/subtrop-
ical climates, and the last one had been previously reported only in Cuba.
Other species found were Acarus siro, Cheyletus sp., Suidasia pontiﬁcia, and
Gamasidae and Oribatidae families.
Conclusions: These results conﬁrm the importance of pyroglyphid
HDM, as indoor sensitizers in different climatic and geographical regions
in Mexico, as well as, the relevance of tropical species, particularly Blomia
tropicalis, in certain areas. They support the need of using allergen extracts
of these mite species for improving allergen-speciﬁc diagnosis and
immunotherapy.
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Oral Mite Anaphylaxis is Caused by Mite-contaminated
Okonomiyaki Mix in Japan
Kentaro Takahashi, MD, PhD, Yuma Fukutomi, MD, Kiyoshi Sekiya, MD,
Masami Taniguchi, MD, PhD, and Kazuo Akiyama, MD. Clinical Research
Center for Allergy and Rheumatology, National Hospital Organization
Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
Background: Anaphylaxis after the ingestion of foods contaminated with
mites has recently been reported. It is an immediate and potentially life-
threatening reaction in patients with previous allergic rhinitis and/or asthma
following the ingestion of mite-contaminated foods. Case series and case
reports thus far have shown that mite-contaminated wheat ﬂour is the major
cause of oral mite anaphylaxis. However, we have encountered 8 cases of oral
mite anaphylaxis in our hospital not caused by mite-contaminated wheat ﬂour
but by mite-contaminated okonomiyaki mix.
Methods: To review the current literature, in addition to our patients, we
performed a MEDLINE search of articles on oral mite anaphylaxis in Japan
up to June 2011 and collected patient characteristics, interview contents,
results on speciﬁc IgE against mites, wheat, and pollen and other antigens,
results of skin prick tests including those using extracts from mites and/or
culprit ﬂours, and microscopic examination results.
Results:We found thirty oral mite anaphylaxis patients in Japan twenty-eight
(93.3%) of whom ingested okonomiyaki or takoyaki, prepared at home using
okonomiyaki mix (24 patients) or takoyaki mix (4 patients), respectively,
which was previously opened and stored for months at ambient temperature.
Takoyaki mix is similar to okonomiyaki mix, which is composed of ﬂour,
dried scallop, bonito, and mackerel. The other 2 patients ingested pancake
mix. Microscopic examination of thirteen patients’ mixes revealed contami-
nating mites. Thyreophagus putrescentiae, Dermatophagoides pteronyssinus,
Dermatophagoides farinae were found in mix samples of 4, 3, and 3 patients,
respectively. The speciﬁc IgE against each mite is generally upregulated,
which might be affected by cross-reactivities to other mites. Especially, the
speciﬁc IgEs to Dermatophagoides pteronyssinus and Dermatophagoides
farina were more than class 2 in all cases. It is suggested that mites are
attracted to the ﬂavors of okonomiyaki and takoyaki mixes and invade from
a crack in a ﬂour sack, and proliferate under favorable conditions.




International Survey on Evaluation and Management of
Eosinophilic Esophagitis
Gisoo Ghaffari, MD. Medicine/Pulmonary-Allergy and Critical Care Med-
icine, Pennsylvania State University, Hershey, PA.
Background: The criteria for diagnosis of Eosinophilic Esophagitis (EoE)
have been established; however the recommendations regarding evaluation
and management of patients have been debated. The purpose of this survey
study is to assess how providers across the world diagnose, evaluate and treat
patients with EoE and how education impacts their approach.
Methods: The link to a web-based survey was sent to the members of WAO,
ACAAI and AAAAI. From October 2010 to January 2011, the participants
were asked to respond to 24 questions. The qui-square test was used for
comparison between groups which included: practitioners from the Unites
States versus other countries, male versus female, different specialties, years in
practice, academic versus private, rural versus suburban, number and frequency
of patients, number of lectures and workshops the practitioners attend.
Results: Among the 200 respondents, 70% were from the United States.
Majority of respondents were allergists/allergolosits. The majority responded
that biopsy is required to diagnose EoE, that they do ask about personal and
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family history of atopy and they do recommend allergy evaluation via testing;
these were similar between all groups.When comparisons were made between
the groups, these areas showed statistically signiﬁcant differences:
1) Practitioners who see more patients with EoE more frequently were more likely
to perform testing for immediate hypersensitivities to aeroallergens and foods.
2) Practitioners who participate more often in workshops were less likely to
perfrom patch testing for foods.
Conclusions: Our survey reveals that allergy practitioners worldwide are
following patients with EoE. Practitioners who see more patients with EoE
more frequently are more likely to perform allergy testing in form of
hypersensitivity testing to both aeroallergens and foods. This could be
secondary to participation in educational sessions or more interest in
searching the literature. Participation in workshops has an inverse relation
to performing patch testing for foods, which may show that current education
does not support this practice. In order to have a more uniform approach to
patients with EoE, a consensus guideline is prudential.
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Allergen Speciﬁc Immunotherapy as a Treatment for
Eosinophilic Esophagitis
Juan Esteban Perez, Thanai Pongdee, MD, and Juan Guarderas, MD. Allergy
and Pulmonary Medicine, Mayo Clinic, Jacksonville, FL.
Background: Eosinophilic Esophagitis (EoE) is an inﬂammatory disease that
reduces the ability of the esophagus to pass food, often leading to dysphagia.
A relationship between EoE and food allergies has been determined.
However, there have been several documented cases in which patients had
negative prick skin testing (PST) results for food allergens and positive results
for airborne environmental allergens, and still have a conﬁrmed diagnosis of
EoE. Recently, airborne allergens have been implicated in the onset of this
condition. Studies have shown that patients sensitive to airborne allergens
such as pollen have a seasonal biannual component in which the severity of
EoE symptoms increase, coinciding with high pollen seasons.
Methods: We followed a 65-year-old man with a history of allergies
complaining of an increase in his symptoms of allergic rhinitis and asthma.
He also noted dysphagia and occasional vomiting. We noted the disease and
medication course over 5 years of treatment.
Results: The patient underwent an esophagogastroduodenoscopy with biopsy,
in which midesophageal rings as well as an 8 mm sessile polyp were found,
suggesting EoE. Histological analysis conﬁrmed EoE, having found .20 intra-
epithelial eosinophils/HPF. The patient was treated with a short term prednisone
regimen, as well as maintenance medications consisting of inhaled corticoste-
roids and antihistamines. The patient returned 6 months after the initial consul-
tation and still presented symptoms of EoE, at which point the patient was
prescribed proton pump inhibitors. In addition, allergen speciﬁc immunotherapy
was initiated for conﬁrmed airborne allergens. The patient was examined after 5
years of immunotherapy treatment. Not only did he report that his allergic rhinitis
and asthma symptoms were controlled, but his EoE symptoms had resolved.
Conclusions: Results suggest that immunotherapy for airborne allergens
could be a successful treatment for EoE. A larger study is needed to determine
if allergen speciﬁc immunotherapy is a viable treatment option for EoE in
similar cases. Such a study could include patients with EoE and conﬁrmed
airborne allergies treated with immunotherapy while monitoring a number of
eosinophilic and lymphocytic markers.
EPIDEMIOLOGY OF ALLERGIC RHINITIS
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Treatment of Nasal Allergies: Results from the Allergies Surveys
in America, Asia Paciﬁc, Latin America, and Middle East
Michael S. Blaiss, MD,1 Connie Katelaris, MD, PhD, FRACP,2 and
Hugo E. Neffen3. 1University of Tennessee Health Science Center`, Memphis,
TN; 2Immunology & Allergy, University of Western Sydney and Campbell-
town Hospital, Sydney, Australia; 3Respiratory Medicine Unit, Children’s
Hospital Orlando Alassia, Santa Fe, Argentina.
Background: The Allergies surveys have been conducted in several regions
of the world, and provide a uniquely comprehensive insight into the
prevalence and impact of nasal allergies worldwide. Here we report
speciﬁcally on treatment of nasal allergies in the Allergies in America
(AIA), Asia Paciﬁc (AIAP), Latin America (AILA) and Middle East (AIME)
surveys.
Methods: Patients who were previously diagnosed by a health care
professional with nasal allergies (hay fever, allergic rhinitis or nasal allergies,
plus sinus disease in AIAP), exhibited symptoms, and/or had received
treatment, were included. Standardized questionnaires provided by Abt
SRBI were used; individual questions and methodology varied slightly
between regions. In total, around 90,000 households were screened, including
responses from 6,081 patients.
Results: The surveys revealed that among patients receiving treatment for
nasal allergies, the proportion using a prescription nasal spray varied
regionally, from 21% in AIAP to 54% in AIME. Despite a high percentage
of patients reporting satisfaction with their prescription nasal spray, many
patients who were dissatisﬁed cited reasons such as lack of effectiveness and
lack of 24-hour relief as primary concerns. The percentage of allergy sufferers
who experienced a loss of product effectiveness over 24 hours varied
regionally from 35% in AILA to 53% in AIAP. Many patients strongly
agreed there were no truly effective treatments for nasal allergies, and 10% of
all patients in AIA chose to change their medication several times a year. The
most commonly reported side effects of prescription medications were
dripping down the throat and dryness. Bad taste was also commonly reported,
in all regions except North America, where drowsiness was the third most
commonly reported side effect. A higher proportion of patients reported side
effects with prescription sprays in the Middle East than in any other region
surveyed.
Conclusions: There is still an unmet need in treatment of patients with nasal
allergies worldwide. A low percentage receives treatment with prescription
nasal sprays, despite this form of therapy being considered the ‘gold standard’
of treatments. Patients are bothered by a range of side effects generally
different to those reported in drug information leaﬂets.
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Comorbid Allergy-related Respiratory Conditions Among
Children and Adults Diagnosed with Allergic Rhinitis: Findings
from Research Jointly Funded by the AAAAI AND ACAAI
Cheryl Hankin, PhD,1 Linda Cox, MD,2 Amy Bronstone, PhD,1
and Zhaohui Wang, MS1. 1Health Economics and Outcomes Research, Bio-
MedEcon, LLC, Moss Beach, CA; 2Medicine, Nova Southeastern University,
Ft. Lauderdale, FL.
Background: We examined rates of comorbid allergy-related respiratory
conditions among patients diagnosed with allergic rhinitis (AR) to charac-
terize AR-related disease burden.
Methods: Florida Medicaid retrospective claims data (1997–2009) were an-
alyzed to compare the likelihood of receiving targeted comorbid allergy-
related respiratory conditions among AR-diagnosed (ICD-9 477.x) children
(age,18 years) and adults (age $18 years). Targeted comorbidities included
strep throat (ICD-9 034.x), conjunctivitis (372.x), otitis media (381.x-382.x),
acute respiratory infections (460.x-466.x), other diseases of the upper respi-
ratory tract (470.x-476.x and 478.x), pneumonia/inﬂuenza (480.x-488.x),
chronic obstructive pulmonary disease/allied conditions (490–496), asthma
(ICD-9 493.x), and atopic dermatitis (691.8).
Results: Overall rates of AR were signiﬁcantly higher for children than adults
(8% vs 3%, P , 0.0001). On average, AR-diagnosed patients had signiﬁ-
cantly more comorbid allergy-related respiratory conditions than nonAR-
diagnosed patients (children, 3.7 6 1.9 vs 1.2 6 1.7 P , 0.0001; adults,
2.6 6 1.7 vs 0.5 6 1.0, P , 0.0001). Compared to nonAR-diagnosed
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patients, the likelihood of receiving the following diagnoses among AR-di-
agnosed children and adults, respectively, were: 13 and 15 times greater for
acute respiratory infection; 6 and 9 times greater for otitis media; 6 and 8
times greater for asthma; 6 and 12 times greater for upper respiratory in-
fection; 5 and 8 times greater for conjunctivitis; 5 times greater (both children
and adults) for chronic obstructive pulmonary disease/allied conditions; 5 and
8 times greater for strep throat; 4 and 3 times greater for pneumonia/inﬂuenza;
and 4 and 9 times greater for atopic dermatitis. Differences between AR-
versus nonAR-diagnosed groups and between children and adults were sig-
niﬁcant at the P , 0.001 level.
Conclusions: Compared to their counterparts who were not diagnosed with
AR, children and adults with AR had a signiﬁcantly greater likelihood
for receiving any targeted comorbid allergy-related respiratory condition.
Likelihood estimates, which were 3 to 15 times greater for AR-diagnosed
patients, varied signiﬁcantly for children and adults by speciﬁc comorbid
condition. Given a diagnosis of AR, the likelihood for comorbid respiratory
infection, asthma, otitis media, conjunctivitis, atopic dermatitis and strep
throat was substantially greater for adults; the likelihood for pneumonia/
inﬂuenza was greatest for children; and the likelihood for chronic obstructive
pulmonary disease/allied condition was roughly equivalent for the 2 age
groups.
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Survey of Rhinitis Phenotypes
Sergio Bonini, MD. Second University of Naples, Rome, Italy; Institute of
Translational Pharmacology, Italian National Research Council, Rome,
Italy.
Background: Non-infectious rhinitis (NIR) is often considered a trivial
disease, easily controlled by currently available drugs. Recently however,
adequate attention of the scientiﬁc and regulatory environment has been
called on the unmet needs of the most Severe Chronic Upper airways
Diseases (SCUADs, Bousquet J et al, J Allergy Clin Immunol 2009;124:428–
33). Object: An independent observational cross-sectional survey was promoted
by the Italian Federation of Allergy and Clinical Immunology Societies
(IFIACI) in order to identify phenotypes of NIR and the dimension, clinical
features and burden of SCUADs in Italy.
Methods: All IFIACI clinical centers answering GPC standards were
invited to collect data through a common questionnaire from up to 50 con-
secutive cases of NIR observed from January 1 to June 30, 2011 in subjects
aged over 14 years. Data management, entry and analysis were performed
through a validated procedure by IBIS, Milan, in respect of privacy
requirements.
Results: The duration of rhinitis was 6.8 6 6.7 years in the 2279 patients
studied. Rhinitis was classiﬁed as moderate/severe in 42.9% of the 511
patients with intermittent rhinitis and in 69.5% of the 1959 patients with
persistent rhinitis.81.6%of NIR had one or more positive skin tests, grass
(37.2%), Dermatophagoides pteronyssinus (26.8%) and Parietaria (19.8%)
being the allergens more frequently responsible for a clinically relevant sen-
sitization. Conjunctivitis (47.3%), asthma (34.4%), sinusitis 15.5%), sleep
disturbances (9.4%) and nasal polyps (6.0%) were the co-morbidities more
frequently associated with rhinitis, particularly in the most severe forms. The
undergoing treatment (anti-histamines in 64.4%, nasal steroids in 59.7%, anti-
leukotrienes in 14.8% and oral steroids (!) in 8.1% of cases), was considered
unsatisfactory in 19.1% of cases by the doctor and in 33.6% by the patients.
Immunotherapy was indicated in 63.9% of subjects with a clinically relevant
sensitization but it was accepted only by 51.6% of the patients, the high costs
being the major cause for non- acceptance.
Conclusions: NIR is a heterogeneous entity including several different
phenotypes. Allergic rhinitis patients with persisting symptoms, co-morbidities,
poor response to pharmacological treatment represent a not frequent pheno-
type but with high social and individual costs and still unanswered health
needs.
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Prevalence and Risk Factors Associated to Symptoms of
Rhinoconjunctivitis in Mexican School Children. A
Multicenter Study
Mayra Alondra Livano Prez, MD,1 Blanca del Rio, MD,1 Jaime Mariano
del Río-Chivardí, MD,1 Juan Valente Merida Palacios, MD,2 Sergio de
Jesus Romero Tapia, MD,3 Francisco Javier Linares Zapien, MD,4
Alberto Escalante Dominguez, MD,5 Sandra González-Díaz, MD, PhD,6
Roberto García-Almaraz, MD,7 Sergio Carvajal Abdala, MD,8
and Dino Pietropaolo-Cienfuegos, MD1. 1Pediatric Allergy and Clinical
Immunology, Hospital Infantil de Mexico Federico Gomez, Mexico City,
Mexico; 2Mexicali Health Care, Mexicali, Mexico; 3Hospital Angeles Vil-
lahermosa, Villahermosa, Mexico; 4COMPEDIA, Toluca, Mexico; 5Hospi-
tal General de Rosarito, Tijuana, Mexico; 6Hospital Universitario, Medical
School, Universidad Autónoma de Nuevo León, Monterrey, Mexico; 7COM-
PEDIA, Tamaulipas, Mexico; 8COMPEDIA, Veracruz, Mexico.
Background: According to ISAAC symptoms of allergic rhinoconjunctivitis
(RC), have a worldwide prevalence of 8.5% in school children. Multiple risk
factors had been associated with its prevalence, though little is known about
the regional variations of these risk factors.
Objective: Identify the prevalence and the main risk factors associated to the
presence of symptoms of rhinoconjunctivitis in the last 12 months in Mexican
school children.
Methods: Cross-sectional, multicenter, prospective, based in ISAAC meth-
odology of 9 registered sites in 8 cities (north, center and south of the
Mexican Republic) with a validated and standardized survey applied to tutors
of children aged 6 to 7 years old. Risk analysis was made through
multivariate logistical regression, central tendency and dispersion measures
were obtained with respective 95% conﬁdence intervals.
Results: 24,902 surveys were obtained. The prevalence and 95%CI of
symptoms of rhinitis was as follows: Monterrey 23%(21.4-24.5%), Mexicali
28.7% (26.9-30.5%), Ciudad Victoria 21.3%(19.7-22.8%), Villahermosa
39% (37-41%), North Federal District 45.6% (44.1-47.2%), Toluca-18.6%
(17.3-20%), Tijuana 24.5% (22.9-26.1%), southeast Federal District 53%
(50.7-55.4%) Veracruz 25% (23.1-26.8%) and conjunctivitis: Monterrey
8.8% (7.8-9.9%), Mexicali 13.2%(11.9-14.5%), Ciudad Victoria 7.3%(6.3-
8.3%), Villahermosa 18.7% (17-20.3%), North Federal District 20.4%(19.1-
21.7%), Toluca 7.3%(6.4-8.2%), Tijuana 8.7%(7.6-9.7%), southeast Federal
District 25.1%(23-27.1%) Veracruz 8.7% (7.5-9.9%). The prevalence de
rhinoconjunctivitis were 12.8%. Identiﬁed risk factors for the presence of
rhinitis in the last 12 months were: asthma symptoms in the last 12 months
OR-2.59 (95% CI, 2.25-2.98; P # 0.0001), wheezing ever OR-1.78 (95% CI,
1.61-1.96; P # 0.0001), eczema symptoms in the last 12 months OR-1.61
(95% CI, 1.35-1.93; P # 0.0001), atopic dermatitis ever OR-2.97 (95% CI,
2.52-3.51; P # 0.0001). Identiﬁed risk factors for the presence of
conjunctivitis in the last 12 months were: wheezing ever OR-1.88 (95% CI,
1.64-2.16; P # 0.0001), asthma symptoms in the last 12 months OR-2.97
(95% CI, 2.52-3.51; P # 0.0001) eczema symptoms in the last 12 months
OR-1.95 (95% CI, 1.58-2.41; P # 0.0001), atopic dermatitis ever OR-2.14
(95% CI, 1.81-2.54; P # 0.0001).
Conclusions: The highest prevalence of rhinoconjunctivitis in Mexican
School Children is in the southeast of the Federal District.The presence of
asthma symptoms in the last 12 months, wheezing ever, eczema symptoms in
the last 12 months, atopic dermatitis ever, risk factors are present symptoms
of rhinoconjunctivitis.
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Oral Allergy Syndrome and United Airways Disease: Is There
a Functional Connection?
Carlo Lombardi,1 Giovanni Passalacqua, MD,2 and Giorgio Walter Canonica,
PhD2. 1Allergy Unit, Department of Internal Medicine, Sant’Orsola Hospital,
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Sant’Orsola, Italy; 2Allergy & Respiratory Diseases, Universita Degli Studi
Di Genova, Genoa, Italy.
Background: The airways and the upper digestive tract have a common
embrional origin, and in sensitized subjects they can respond to allergens with
an immediate reaction (asthma, rhinitis or oral allergy syndrome). We
investigated the possible functional connection between respiratory tract
and upper digestive tract by means of speciﬁc oral allergen challenges.
Methods: Patients sensitized to birch and apple were subdivided in GROUP
A (N ¼ 12; asthma and rhinitis due to birch and OAS due to apple) GROUP
B (N ¼ 10; OAS due to apple without asthma/rhinitis); GROUP C (N ¼ 8;
asthma and rhinitis due to birch without OAS). Healthy subjects represented
the control group D (N ¼ 6). Oral provocation test with apple was performed
out of the pollen season. Visual analog scale for eye, nose and mouth symp-
toms, spirometry, nasal eosinophil count and exhaled nitric oxide were
assessed before and 6 hours after challenge.
Results: There was no change in nasal and ocular symptoms before versus
after challenge in all groups. On the contrary, in groups A and B the oral
scores signiﬁcantly increased after challenge (P , .001), whereas no change
was seen in groups C and D. Exhaled nitric oxide and nasal eosinophils
showed no change before versus after challenge in all groups. Nitric oxide
was higher before and after challenge in groups A and C versus groups B and
D. No change was een as well in forced vital capacity and forced expiratory
volume in one second.
Conclusions: In the case of birch-apple syndrome, eating apple does not
functionally or clinically affect the respiratory tract.
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Epidemiological and Clinical Characteristics of Allergic
Conjunctivitis Patients in a Reference Center of Mexico City
Atzin Robles-Contreras, MSc,1 Julio Ayala-Balboa, MD,1 Miguel E
Alonso-Sánchez, MD,1 Iris Estrada-Garcia, PhD,2 and Maria C Jiménez-
Martínez, MD, PhD,1,3. 1Research Unit and Department of Immunology,
Institute of Ophthalmology, México D.F., Mexico; 2Departamento de Inmu-
nologia, Escuela Nacional de Ciencias Biologicas-IPN, Mexico City, Mexico;
3Department of Biochemistry, Faculty of Medicine, UNAM, México D.F.,
Mexico.
Background: In our country (Mexico) there are few reports about
epidemiological characteristics of allergic conjunctivitis patients; despite
these studies give us some information about patient proﬁle, in most cases
these studies are not always comparable due to the use of different
methodologies, that is, Include only a portion of the population (elderly,
infants) or there are limited to one region of the city. The purpose of this
study was to know the epidemiological and clinical characteristics of allergic
conjunctivitis (AC)-patients in the biggest reference center of ocular diseases
in Mexico (Institute of Ophthalmology “Conde de Valenciana”)
Methods: Data were obtained from clinical records. Six hundred ﬁfteen
patients with diagnosis of AC were included. Epidemiological characteristics
included sex, age, residence; clinical-immunological characteristics included
atopy, coexistence of other allergies, total IgE, cutaneous reactivity to skin
prick test (SPT), sixty allergens were evaluated. Descriptive statistics were
performed to obtain frequencies and t test was used to ﬁnd signiﬁcant differ-
ences, P , 0.05 was considered statistically signiﬁcant.
Results: AC-Patients who received medical consultation at the Institute of
Ophthalmology where predominantly from State of Mexico (47.25%),
Mexico City (37.5%), and in less frequency Hidalgo, Puebla, Tlaxcala,
Michoacan, Veracruz, Oaxaca, Guerrero, Chiapas and Guanajuato. 88% of
AC-patients were positive to SPT (SPT1), while 12% were negative to SPT
(SPT-). Age of diagnosis was signiﬁcant different between SPT-AC-patients
and SPT1AC-patients (14.5-years vs 17.9-years, P ¼ 0.02). Male SPT-
AC-patients were diagnosed younger than male SPT1AC-patients (P ¼
0.001). IgE concentration was signiﬁcant increased in male SPT1AC-patients
than female SPT1AC-patients (P ¼ 0.006). The most common skin reactivity
was against Dermatophagoides sp (59.1%), Aedes sp(54.55%) and Blatella-
Periplaneta sp.(31.14%); we did not observe signiﬁcant differences in skin
reactivity between male or female SPT1AC-patient.
Conclusions: It was considered that AC-patients were negative to SPT;
contrary to reported, this study showed that most of AC-patients were positive
to some allergen; this result is relevant because open the possibility to offer
speciﬁc desensitization as conventional treatment instead anti-histamine drugs
in SPT1 population. This is the ﬁrst study covering the central and southern
part of our country.
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The Classiﬁcation of Allergic Rhinitis and Its
Cytological Correlate
Matteo Gelardi,1 Cristoforo Incorvaia, MD,2 Giovanni Passalacqua, MD,3
Maria Luisa Fiorella,1 and Franco Frati, MD,4,5. 1University Department of
Otolaryngology, Bari, Bari, Italy; 2Allergy/Pulmonary Rehabilitation Unit,
ICP Hospital - Milan, Milano, Italy; 3Allergy & Respiratory Diseases, Uni-
versita Degli Studi Di Genova, Genoa, Italy; 4Department of Medical and
Surgical Specialties and Public Health, Perugia, Perugia, Italy; 5Medical
and Scientiﬁc Department, Stallergenes Milan , Milano, Italy.
Background: The ARIA document introduced a new classiﬁcation of allergic
rhinitis, based on its duration and severity, which is graded on the basis of the
impact of AR on daily activities and quality of life. Nasal cytology is a simple
and reliable diagnostic tool to identify the presence and type of inﬂammation
in rhinitis. Thus, we assessed severity of AR by nasal cytology on the basis of
the ARIA classiﬁcation.
Methods: Patients suffering from AR caused by grass pollen only, and
healthy subjects were studied. The severity of rhinitis was deﬁned according
to ARIA. All subjects underwent nasal cytology, using a Rhino-probe.
Scrapings were air-dryied and stained by May-Grunwald-Giemsa. Differen-
tial cell count was expressed as % of the total leukocytes. Unpaired t test was
used for comparisons.
Results: Sixty-two grass-allergic patients (34 men, mean age 35.2 years) and
18 healthy subjects (10 men, mean age 32) were studied. 67.8% of patients
had intermittent AR (33.9% mild and 33.9% moderate-severe) and 32.2% had
persistent AR (14.5% mild and 17.7% moderate-severe). The patients with
moderate-severe AR had signiﬁcantly more mast cells and lymphocytes than
those with mild AR, with a relatively smaller number of neutrophils and
eosinophils. Mast cells and/or lymphocytes could be detected in only 3/30
patients with mild rhinitis, and in 19/32 patients with moderate/severe rhinitis.
No difference in cell counts was found when comparing intermittent and
persistent AR.
Conclusions: Moderate/severe allergic rhinitis displays a cytological in-
ﬂammatory pattern different from mild rhinitis.
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Incidence ofAllergicDiseases onChildren under 5Years in Juarez
Hospital Mexico
María Isabel Rojo Gutiérrez,1 Adrian-Jair Ortega-Vargas, MD,2 Jaime
Mellado-Abrego, MD,1 and Mario-Alberto Bermejo, MD3. 1Allergy; 2Pedi-
atrics, Juarez Hospital, Mexico city, Mexico; 3allergy and immunology,
Juarez Hospital, Mexico.
Background: Allergic diseases such as asthma, atopic dermatitis and allergic
rhinitis are common disorders that have increased its prevalence over the past
thirty years. Atopic diseases have a genetic basis, with expression of different
phenotypes associated with chromosome 5 (5q23-25, IL-4, IL-5, IL-9, IL-13
and GM-CSF), 6 (molecules of class I and II human leukocyte antigen) 11
(11q13: b subunit of high afﬁnity receptor for IgE) and 12 (12q: IFN-gamma,
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nitric acid synthase). Asthma is deﬁned as a chronic inﬂammatory disease of
airway and is the most common chronic disease in children characterized by
wheezing. Wheezing may occur even once it is up to 50% of all infants and
children under 3 years old and topic dermatitis affecting over 10% of
children.
Objective: To deﬁne incidence and prevalence of asthma and others allergic
diseases in population of less than 5 years of age in Juarez Hospital Mexico.
Results: We evaluated 11,346 allergic patients on 4 years period (January
2007 to December 2010). Two thousand three hundred ninety six were #5
years (21.11%); 10.2% a year old or younger, 16.7% 2 years old, 18.5% had 3
years, 24.7% of 4 years and 30% 5 years old. Nine hundred ninety two
patients (41.4%) were females and 1.404 (58.6%) male. One thousand two
hundred thirty eight patients (51.7%) had only one diagnostic ﬁnding as most
frequent cause of consultation allergic rhinitis (59.6%), followed by asthma
(23%), atopic dermatitis (5.1%), prurigo by insect (4.3), immunodeﬁciency
(1.2%) the rest had various pathologies such as contact dermatitis, gastro
esophageal reﬂux, oral allergy syndrome, and others. The remaining patients
48.3% (1158) had more than one diagnostic. The most common associations
were asthma and rhinitis 716 (30%), 72 patients (3%) with asthma and atopic
dermatitis, 48 patients (2%) with some immune deﬁciency and asthma and/or
rhinitis, 12 (0.5%) with prurigo and atopic dermatitis, 8 (0.3%) with urticaria
and 11 patients (4.5%) with other diagnoses such as reﬂux or infections.
Conclusions: Allergic diseases are common on pediatric population and




Effect of Hydrolysis and Polymerization on Bovine Beta-
lactoglobulin Immunoreactivity
Mariana Battaglin Villas-Boas, 1 Isabele Serimarco Sabadin, 1 Ricardo de
Lima Zollner, PhD,2 and Flavia Maria Netto, PhD1. 1Food and Nutrition;
2Medical Science, University of Campinas (UNICAMP), Campinas, Brazil.
Background: Enzymatic treatments such as hydrolysis with proteases and
polymerization using transglutaminase (TG) have been studied to reduce the
immunoreactivity of b-Lactoglobulin (b-Lg). Bromelain is a cisteine protease
that is not usually used for production of hypoallergenic hydrolysates. TG is
an enzyme that catalyses the formation of inter and intramolecular isopeptide
bonds between glutamine and lysine residues. The present study is aimed at
investigating the antigenic response of b-Lg polymerized by TG pre or post
hydrolysis with bromelain.
Methods: b-Lg (donated by Davisco Inc), was hydrolyzed with bromelain
(3% protein w/w in distilled water, 25 U enzyme g21 of substrate, pH 7.5,
240 min) and then polymerized by TG (7% hydrolysate, 10 or 25 U TG g21
protein, 508C/180 min). When polymerization was carried out pre hydrolysis,
b-Lg (7% w/w) was polymerized by TG (10 U TG g21 protein, 508C/180
min) in 0.1 M Cys or after heat treatment (808C/60 min), and then hydrolyzed
under the same conditions previously described. The hydrolysis reaction was
monitored by pH-stat method and the samples were evaluated by SDS-PAGE/
tricine. Antigenicity was evaluated by Immunoblotting and ELISA assays
using sera from mice sensitized with b-Lg (IgE anti-b-Lg).
Results: The treatment with TG (10 or 25 U TG g21), post hydrolysis, lead to
formation of products with a wide molecular weight (MW) distribution (3 to
26 kDa), and other products with high MW, indicating partial polymerization.
The samples obtained from polymerization pre hydrolysis showed bands with
low MM (,6.5 kDa) and also products .26 kDa, indicating a partial hydro-
lysis of the polymers. Immunoblotting analysis showed no reaction towards
speciﬁc IgE with any of the samples. ELISA assay showed that the IgE-
binding response to sample polymerized by TG post or pre hydrolysis with
bromelain were signiﬁcantly reduced (IgE # 35.21 ug mL21) as compared to
untreated b-Lg (IgE 216.20 ug mL21 6 27.58) (P , 0.05).
Conclusions: These results suggested that hydrolysis with bromelain
combined with polymerization by TG was capable of reducing the
antigenicity of b-Lg, being a potential method for modifying the antigenic
properties of proteins.
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Immunoreactivity of Polymerized and Digested Beta-
lactoglobulin to IgE from Milk Allergic Patients
Mariana Battaglin Villas-Boas,1 Sara Benedé,2 Flavia Maria Netto, PhD,1
Ricardo de Lima Zollner, PhD,3 and Elena Molina, PhD2. 1Food and Nutrition,
University of Campinas (UNICAMP), Campinas, Brazil; 2Institute of Food
Science Research, Madrid, Spain; 3Medical Science, University of Campinas
(UNICAMP), Campinas, Brazil.
Background: Beta-lactoglubulin (b-Lg), is one of the most important aller-
gens in bovine milk. The allergenicity is mainly associated to its stable
structure, resistant to heat and digestive processes. With the purpose of
decreasing its allergenicity, some processes have been studied, including
enzymatic treatments using transglutaminase (TG), an enzyme that catalyses
the formation of inter and intramolecular isopeptide bonds between glutamine
and lysine residues which could alters both the structure and antigenic sites in
the protein. The allergenicity of b-Lg hydrolysates obtained after a simulated
gastrointestinal digestion (GI) and previously polymerized by TG enzyme
was studied.
Methods: The b-Lg (7% w/v), donated by Davisco Inc., was modiﬁed by 2
different methods (1) heat treated (808C/60 min) and polymerized by TG (10
U g21 protein), and (2) polymerized by TG in the presence of the reducing
agent Cysteine - Cys (0.1 mol L21). After modiﬁcation the samples were
submitted to in vitro digestion, simulating gastric and duodenal conditions
(Moreno, 2005; Martos et al, 2010). The characterization of the samples was
performed by electrophoresis (SDS-PAGE) and Reversed-phase high perfor-
mance liquid chromatography (RP-HPLC). The allergenicity of the protein
was measured by ELISA, using sera of milk allergic patients.
Results: The untreated b-Lg was resistant to pepsin while the samples
polymerized by TG showed an increased in the susceptibility to pepsin, since
a predominance of low molecular mass (MM) peptides, 3.0 to 6.0 kDa (by
SDS-PAGE) and peptides with low hydrophilicity (by RP-HPLC) were
detected. After duodenal digestion, the polymerized samples showed an
increased in the intensity of the peaks with high hydrophilicity, indicating
a potential susceptibility of polymerized b-Lg to GI digestion. Immunoreac-
tivity to IgE from sera of allergic patients was retained for b-Lg polymerized
after heat treatment, even after in vitro gastric digestion; while for the sample
polymerized in presence of Cys it decreased considerably after pepsinolysis.
After duodenal digestion, both polymerized samples showed an important
decrease in the immunoreactivity response, compared to untreated b-Lg.
Conclusions: These ﬁndings showed that the polymerization alters the
susceptibility of b-Lg to GI digestion and could have implications in the
allergenic characteristics of this protein.
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Identiﬁcation of Novel Allergens in the Fish Parasite
Anisakis Simplex
Christiane Fæste Kruse, PhD,1 Maaike Dooper, PhD,1 Alvaro Daschner,
MD,2 Wolfgang Egge-Jacobsen, PhD,3 and Eliann Egaas, PhD1. 1Norwegian
Veterinary Institute, Oslo, Norway; 2La Princesa University Hospital,
Madrid, Spain; 3University of Oslo, Oslo, Norway.
Background: The nematode Anisakis simplex is a marine parasite that causes
allergy as well as anisakiasis in human. Here, we describe the identiﬁcation of
4 novel allergens in anisakis.
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Methods: Binding of human IgE to anisakis and house dust mite proteins was
investigated by immunoblot with serum from individuals sensitized to
anisakis or shrimp. IgE binding patterns in the immunoblots were used for
the identiﬁcation of major Anisakis allergens, which were analysed by mass
spectrometry-based proteomics in ESI-Orbitrap, after separation on SDS-gel.
Results: Four new allergen candidates were identiﬁed. The ﬁrst identiﬁed
allergen was enolase, which is related to the cockroach allergen enolase.
The other allergens were Heat Shock Protein-70 (HSP 70), tubulin, and
glutathion-S-transferase, which are also present as allergens in house dust
mite.
Conclusions: Here we describe the identiﬁcation of 4 novel IgE binding
allergens in anisakis. The allergens might explain IgE cross-reactivity
between anisakis and house dust mite or cockroach.
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Milk Components as a Tool in Predicting Tolerance in Cow’s
Milk Allergy
Cristiane Santos, MD, Claudia Garcia, MD, Ana Paula Beltran Moschione
Castro, MD, PhD, Andrea Gushken, MD, Antônio Carlos Pastorino, MD,
PhD, Cleonir Beck, MD, Ana Cláudia Brandão, MD, and Cristina Miuki Abe
Jacob,MD, PhD. Department of Pediatrics, Instituto da Criança - Faculdade
de Medicina do Hospital das Clínicas da Universidade de São Paulo, São
Paulo, Brazil.
Background: One important point in cow’s milk allergy (CMA) is to stablish
predicitve factors in acquiring tolerance. The aim of this study is to evaluate
if a ratio of milk components: alpha-lactalbumin (a), beta-lactoglobulin (b),
casein (C) and whole milk (WM) can contribute to predict tolerance
development.
Methods: It was a retrospective study that included patients with previous
diagnosis of CMA evaluated at 6 years old. CMA was deﬁned as a positive
double blind placebo-controlled food challenge, open challenge or conﬁrmed
anaphylaxis plus positive speciﬁc IgE to cow’s milk (higher than 3.5 kU/L or
positive skin prick test), and tolerance was deﬁned as acceptance of cow milk
without previous symptoms. Speciﬁc IgE analysis to WM, a, b, and C were
performed through Immunocap (Phadia AB). Ratios of milk components and
whole milk (a /WM, b/WM, C/WM) were calculated and compared the
results in 2 study groups: tolerant and persistent at 6 years old. Since values
from both a /WM and b/WM ratios didn’t follow a normal distribution,
Mann-Whitney test was used to compare groups. For C/WM ratios, Student’s
t test was used as values were normally distributed.
Results: It included 49 patients (27 male/22 female), 24 tolerant and 25
persistent. Average age of Immunocap test was 2.7 years (SD ¼ 1.4). Com-
paring the results from 2 groups, persistent and tolerant it was detected: no
difference in a /WM (P¼ 0.055, Mann-Whitney test), higher levels of b/WM
in persistent group (P ¼ 0.023, Mann-Whitney test) and also higher levels of
C/WM in persistent group (P ¼ 0.004, Student’s t test).
Conclusions: Higher ratios involving beta-lactoglobulin or casein compo-
nents were detected in persistent patients. Thus, evaluating these markers
precociously can be helpful in predicting CMA evolution.
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Uncommon Occupational Allergy to Rice: as a Food Allergen
María Socorro Pérez-Bustamante,1 David Gonzalez-de-Olano,1 Dario Antolín-
Amérigo,MD,2 Mar Gandolfo-Cano,1 and Eloína González-Mancebo1. 1Allergy
Unit, Fuenlabrada Hospital, Madrid, Spain; 2Allergy Unit, Alcalá de Henares
Hospital, Madrid, Spain.
Background: Rice (Oryza sativa) belongs, with other cultivated cereals, to
different tribes of the Poaceae family. It is one of the most widely produced
and consumed cereals in the world but hypersensitivity reactions to this grain
are uncommon Most reports describe an immunologically-mediated urticaria
due to contact with raw rice or reactions after the inhalation of rice fumes,
whereas reports of immediate hypersensitivity reactions after ingestion of rice
are scarce.
Methods: Patient 1 (P1): A 40-year-old-man, a professional cook, presented
2 episodes of generalized urticaria minutes after rice ingestion. He tolerated
the inhalation of vapours during rice-boiling, but reported icthy skin and
erythema after rice handling. Patient 2 (P2): A 30-year-old-woman, pizzeria
worker for the last 10 years, complaint of sneezing and rhinorrhea after
handling rice for the last 2 years, and presented diarrhea and dysphagia after
rice ingestion during the last year. One week before consulting she presented
eyelid angioedema, chest tightness and abdominal cramping after doing
exercise right after eating rice. None of the patients reported any additional
atopic background. Skin prick tests with common inhalants and cereals
extracts, Pru p 3 extract, prick-by-prick test with rice and rice ﬂour and
speciﬁc IgE determinations to rice were carried out in both patients.
Results: Skin prick tests to rice were positive in both patients (wheal diameter
.3 mm). Skin prick-by-prick with rice and rice ﬂour was also positive in
patients 1 and 2. Serum speciﬁc IgE determinations against rice showed
values of 0.8 kU/L and 1.48 kU/L for P1 and P2, respectively, out from a total
IgE of 32.8 UI/mL and 23.7 UI/mL, respectively. SPT to common inhalants,
to the rest of the cereals and to Pru p 3, showed a negative result.
Conclusions:We present 2 work-related cases of rice allergy with an unusual
display and different clinical manifestations (urticaria, rhinitis and anaphy-
laxis) in 2 patients without atopic background and who worked handling rice
and rice ﬂour. No cross-reactivity with usual panallergens as LTP seemed to
be involved.
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Frequency of Food Hypersensitivity Mediated by IGG in Patients
Received in a Venezuelan Laboratory During 2011
Cristina Najm Lic, 1 Lorena Benarroch,2 Natacha Camacho,1 Daniela
Figueroa,1 Jhonarly Guzmán,1 Angel Perdomo,1 Nirsen García,1 and
Noel A. Silva1. 1Corpodiagnosticas Laboratory, Caracas, Venezuela; 2Hos-
pital de Clinicas Caracas, Caracas, Venezuela.
Background: Foods could cause adverse reactions, which manifested with
similar symptoms that could complicate the diagnosis, that is, gastrointestinal
disease, rashes, edema, eczema, asthma, anaphylaxis, others; these reactions
may be mediated or not by immunological processes. In the past years there
were many research studies related with different types of immunological
reactions, like for example those mediated by IgG, which are characterized
with delayed and insidious manifestations. These reactions could appear in
hours or days after ingestion of a particular food. The intake of “toxic food”
can lead to immunological reactions, which includes the formation of immune
complexes, able to increase the development of gastrointestinal, dermatolog-
ical, neurological, muscular and respiratory disorders. The objective of this
study was to evaluate the frequency of signiﬁcant speciﬁc IgG titers against
some foods in patients referred to Corpodiagnostica Laboratory, (Caracas,
Venezuela, an ISO 9001:2008 certiﬁed laboratory) from January to August
2011.
Methods: There were a total of 148 patients referred for serum speciﬁc IgG
evaluation against foods. We measured patient’s speciﬁc IgG titers against 45
foods using a commercial direct ELISA method (Dr. Fooke Labs, Germany),
which is designed for the detection and quantiﬁcation of speciﬁc IgG.
Results: We found detectable levels of speciﬁc IgG titers in highest
frequency for: milk 69%, cheese 67%, egg 64%, gluten 54%, sugar cane
51%, followed by wheat meal, rye Meal, and other foods in smaller
proportions. Moreover, in 46 patients with known clinical history, including
gastrointestinal symptoms, respiratory symptoms, pervasive developmental
disorder (PDD) and autism, we detected levels of speciﬁc IgG to a signiﬁcant
number of foods simultaneously.
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Conclusions: The Speciﬁc serum IgG determination against foods could be
a interesting tool to help the diagnosis of non type I Allergy reactions, and
there are many published studies that have been established that the decrease
or even disappearance of speciﬁc IgG titers against foods are related to the
improvement of the initial clinical manifestations on some patients, but
further investigations need to be performed to clearly understand the different
mechanisms involved and to rule out false positive results for this test in
patients without symptoms.
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IGE-mediated Responses Towards Fish Parasite Anisakis, Crab
and House Dust Mite in Norwegian Shrimp Allergic Individuals
Maaike Dooper, PhD,1 Heidi Myrset,1 Eliann Egaas, PhD,1 Thien van Do,
MD, PhD,2 and Erik Florvaag, MD2. 1Norwegian Veterinary Institute, Oslo,
Norway; 2Haukeland University Hospital, Bergen, Norway.
Background: The present study investigated to what extent shrimp allergic
individuals were IgE-sensitized to anisakis, crab and house dust mite and
whether tropomyosin was responsible for IgE cross-reactivity.
Methods: 29 Individuals with self reported shrimp allergy were recruited by
advertisements in local and national news-papers in Norway. Anamnesis was
taken, skin prick tests (SPT) were performed and positive responders to
shrimp were studied further with basophile activation test (BAT), Immuno-
CAP analyses and western blotting.
Results: Of the 29 persons studied, 10 (34%) had positive SPT against
shrimp and house dust mite, 9 (31%) against shrimp tropomyosin and 3
(10%) against anisakis. Individuals with positive SPT to shrimp all showed
positive basophilic responses to house dust mite, while 43% responded to
shrimp, 25% to anisakis and 36% to crab in BAT. Moreover, SPT, BAT as
well as ImmunoCAP analyses showed a positive correlation of IgE-reactivity
between anisakis and shrimp, house dust mite and crab. Immunoblot studies
indicated that these responses are not completely explained by cross-
reactivity towards tropomyosin.
Conclusions: The current study indicates a positive correlation between IgE-
mediated reactions to shrimp, anisakis, house dust mite and crab, which may
not be completely explained by cross-reactivity against tropomyosin.
FOOD ALLERGY CASE REPORTS
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Lentil Allergy: First Report from Venezuela
Carlos Albarran, and Arnaldo Capriles Hulett, MD. Hospital San Juan de
Dios, Allergology Unit, Caracas, Venezuela.
Background: Allergy to lentils is infrequent in Latin America: this a ﬁrst
case report from Venezuela. A 5 year old female preschooler attended our
allergology clinic with chief complaint of generalized giant urticaria
inmediately after ingestion of cooked lentils; clinical history revealed frequent
(.3) emergency visits, since the age of one year, with facial angioedema and
generalized urticaria even from inhalation of vapors while cooking of lentils
at home; moreover, also symptoms described ocurred while eating foods
containing chick peas; lentils, as other beans (black, red, chick), belong to
the leguminosa family along with peanuts and coconut.
Methods: Prick lancetter skin tests (H-S) to a panel of 25 inhalant and food
allergens (Diater Labs, Argentina) were performed along with Prick to Prick
tests to raw and cooked lentils, chickpeas, black beans, navy beans and
coconut. A papule .3 mm and read at 10 minutes was considered positive.
Results: All other allergens tested were negative, that is, epithelia, molds,
cockroach, grasses, mosquito, milk, egg, wheat, ﬁshmix, shrimp and other
seafood, nuts, hazelnut, almond, coconut and blackbeans.
Conclusions: 1. Prick to Prick testing conﬁrms speciﬁc IgE presence to
Lentils; our patient could tolerate peanuts and cocunut. Positive prick test to
peanuts likely represent a cross reaction1; 2. Lupin ﬂour (Lupinus Albus),
from the Leguminosa family, is found increasingly used in industrially pre-
pared foods and could elicit symptoms due to cross reactions, and advice to
family was given accordingly2; 3. This is the ﬁrst case report from Venezuela.
REFERENCES
1. Monneret-Vautrin DA, Gyuerin L, Kanny G, et al. Croos allergenicity of
peanut and lupine: the risk of lupine allergy in patients allergic to peanuts.
J Allerg Clin Immunol. 1999;104:883–888.
2. Wassenberg J, Hofer M. Lupine induced anaphylaxis in a child without
known food allergy. Case report. Ann Allerg Asthma Immunol.
2007;98:589–590.
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Cow’s Milk Allergy and Persistent Changes in a Multiple Food
Allergy, A Case Report
Pia Zañartu, MD, and Bastías Carla. Resident, Immunology, University of
Chile, Santiago, Chile.
Background: Cow’s milk allergy (CMA) is the most common food allergy.
Clinical manifestations are mediated immediate hypersensitivity and delayed.
The allergy study include: speciﬁc IgE, prick and patch test. Regarding treat-
ment, this is based on the exclusion diet and the replacement of cow’s milk
hydrolysates extensive. Virtually all infants who have cow’s milk allergy
develop this condition in the ﬁrst year of life, with clinical tolerance devel-
oping in about 80 percent by their ﬁfth birthday.
Methods: Describe the case of a child with CMA, which moves without
tolerance and also become sensitized to other foods.
Results: Female with 6 years of age. At 9 months presents watery diarrhea,
weight loss and intermittent rash. Initial study (2006): Upper endoscopy:
Duodenitis chronic nonspeciﬁc, total IgE: 72.60 IU/mL, IgE speciﬁc to cow’s
milk 10.40 IU/mL (Class III) and prick test positive. Exclusion diet starts to
cow’s milk, its derivatives and beef. Patient improvement. At 2 years, begins
with rhinitis and diarrhea reappears with low weight. Colonoscopy (2007):
Subacute nonspeciﬁc colitis histology. At 3 years old facial angioedema,
throat and rash are associated with eating chicken, turkey, carrot and orange
juice. New tests: speciﬁc IgE cow’s milk, 24. 7 IU/mL (class IV), class II
chicken. Prick test positive. At 4 years enter kindergarten, restarts with
diarrhea and occasional angioedema. Cow’s milk speciﬁc IgE (January
2009): 66, 6 IU/mL (class V). January 2010: 5 years post anaphylactic shock
milk pudding. Besides diarrhea 10 times a day, intermittently throughout the
year. Year 2011: intermittent diarrhea and speciﬁc IgE to cow’s milk is kept
in class V.
Conclusions: In this case the patient with CMA which evolved
atypically because it has not been able to acquire tolerance. Moreover,
awareness is added to other foods during their evolution. A recent study
indicated a lower rate of development of clinical tolerance. As assessed by
passing a milk challenge, 5 percent were tolerant at age 4 and 21 percent at
age 8. Patients with persistent milk allergy have higher cow’s milk sIgE levels
in the ﬁrst 2 years of life. Approximately 35 percent developed allergy to
other foods.
Papules Size (mm) Erythema (mm)
Mite (50/50) 3 mm 10 mm
Blomia Negative Negative
Chickpeas 5 mm 15 mm
Navy Beans 3 mm 5 mm
Lentils (raw/cooked) 10 mm 20 mm
Peanut 3 mm 5 mm
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A Rare Case of Food-induced Anaphylaxis to Pink Peppercorns
John Kim, MD,1 and Neil Minikes, MD,1,2. 1Division of Allergy and Immu-
nology, North Shore-Long Island Jewish Health System, Great Neck, NY;
2Department of Pediatrics, Columbia University College of Physicians and
Surgeons, New York City, NY.
Background: The incidence and prevalence of food allergies appear to be on
the rise over the past 20 years. The most common foods to produce an IgE
mediated hypersensitivity reaction in adults include peanut, tree nuts, and
seafood. The increased use of spices in the U.S. has resulted in a growing
number of patients presenting with hypersensitivity reactions.
Methods: We report a case of a 26 year-old-female who developed
anaphylaxis after ingesting pink peppercorn seasoning. The patient was
diagnosed with a tree nut allergy at 18 years of age when she developed hives,
vomiting and throat closure after ingesting cashews. More recently, she had 3
similar anaphylactic episodes requiring epinephrine and emergency room care
when she unknowingly consumed tree nuts contained in foods while dining
out (veggie burger, pesto sauce, almonds in Indian food). She again had
similar symptoms while eating a home prepared meal in which tree nuts were
not included. Intramuscular epinephrine was administered and she was
subsequently treated with oral steroids and antihistamines. It was later
determined that a new peppercorn medley with pink peppercorns was used for
seasoning. The reaction did not occur when she ate the same meal without
pink peppercorn seasoning. Food speciﬁc IgE testing revealed an elevated IgE
for cashews (2.52 kUA/L) and pistachios (2.85 kUA/L).
Results: Pink peppercorn is not a true pepper, but dried roasted berries
derived from Schinus terebinthifolius, a ﬂowering plant in the family Ana-
cardiaceae, native to South America. Common names include Brazilian Pep-
per, Rose Pepper and Christmasberry. Pink peppercorns are used as a spice to
add a mild pepper-like taste to foods. It may potentially cause an irritating
skin effect and has been associated with atopic dermatitis in canines. Inter-
estingly, S. terebinthifolius is a member of the family Anacardiaceae, which
include plants in the genus Anacardium (cashew nut) and Pistacia (pistachio).
No allergens from this plant have been characterized but there is potential for
cross-reactivity among different members of the Anacardiaceae family.
Conclusions: This is the ﬁrst reported case of a patient developing
anaphylaxis after pink peppercorn ingestion. Patients with tree nut allergies
may need to be educated regarding this potential allergen.
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Multiple Manifestations of Food Allergy in a Patient with
a Change of Eating Habits
Paola Toche, MD, Jessica Salinas, MD, and Carla Bastías. Resident,
Immunology, University of Chile, Santiago, Chile.
Background: Food-induced allergic reactions are responsible for a variety of
symptoms and disorders involving the skin, gastrointestinal and respiratory
tracts and can be attributed to IgE-mediated and non–IgE-mediated (cellular)
mechanisms. Food allergy frequency varies according to age, local diet, and
many other factors. The diagnosis of food allergy is based on clinical history,
skin prick test (SPT), food speciﬁc IgE and more recently atopy patch tests
(APT). If needed the use of an oral food challenge to conﬁrm allergy or
tolerance.
Methods: Describes the case of a patient with multiple manifestations of food
allergy after eating habit change.
Results: Man 20 years with a history of food allergy to egg in childhood (at
date in remission) asthma and rhinitis and urticaria in contact to cats. He
presents an atopic dermatitis, recurrent abdominal pain and diarrhea 18
months after change in eating habits (he became vegetarian). He also presents
oral syndrome with cow’s milk. The patient had 4 episodes of anaphylaxis
post prandial grade 3. In 3 of them the patient ate goat cheese and the other
cow cheese. Also 2 of the episodes were associated with exercise. Skin prick
tests with goat`s cheese: 13 mm, cows milk: 8 mm wheat: 3 mm, corn 3 mm,
chicken 3.5 mm, egg yolk: 3.5 mm, avocado and rice 3 mm. Atopy patch test:
(1 1) goat`s milk (1) peanuts and coffee. Total IgE 686 IU/mL. Foods with
positive results were excluded from the diet and a complete remission of
atopic dermatitis, abdominal pain, diarrhea and anaphylaxis was observed.
All foods were reintroduced successfully except milk of goats and cows milk.
The patient is currently asymptomatic.
Conclusions: The literature describes different kinds of manifestations of
food allergy: immediate hypersensitivity (IgE mediated), delayed hypersen-
sitivity (T lymphocytes mediated) and mixed. Highlights in this case an adult
patient with a history of atopy who makes changes in eating habits,
developping a food allergy to goats and cow s milk, with immediate (ana-
phylaxis, oral syndrome) and delayed manifestations (atopic dermatitis and
chronic diarrhea).
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Wheat-dependent Exercise-induced Anaphylaxis Occurred in
OAS Patient after Using Soap Containing Hydrolyzed Wheat
Proteins: Effect of Soap on Keratinocyte Inﬂammasome
Aya Tanaka, MD, PhD,1 Saori Itoi, MD,1 Mika Terao, MD, PhD,1 Saki
Matsui, MD,1 Mamori Tani, MD,1 Takaaki Hanafusa, MD,1 Ken Igawa,
MD, PhD,1 Hiroyuki Murota, MD, PhD,1 Ichiro Katayama, MD, PhD,1
Yuko Chinuki, MD, PhD,2 and Eishin Morita, MD, PhD2. 1Osaka University
School of Med., Suita-shi, Japan; 2Shimane University Faculty of Medicine,
Izumo, Japan.
Background: We present a case of Wheat-dependent Exercise-induced
anaphylaxis (WDEIA) occurred in a patient previously suffering from atopic
dermatitis (AD), pollen allergy and Oral allergy syndrome (OAS) after using
face soap containing hydrolyzed wheat proteins (HWP) .
Methods: A 16-year old woman had contact urticaria after using face soap
containing HWP and developed urticaria and dyspnea after ingestion of wheat
products. We performed skin prick test, provocation test and serum IgE
analysis by Western blotting.
Results: Provovation test, skin prick test for soap solution and HWP were
positive and serum IgE molecules reacting to HWP were detected in the
patient’s sera.
Conclusions: WDEIA in this patient was considered to be induced after
percutaneous sensitization with HWP in the soap. OAS is a Class 2 food
allergy which is often shown in AD patients, and it is suggested that these
patients have possibility to develop food allergy by percutaneous sensitization
with various hydrolyzed food protein in cosmetics. We also examine the
direct effects of the soap solution on keratinocytes inﬂammasome in vitro to
explain the formation of percutaneous sensitization in this case.
FOOD ALLERGY DIAGNOSIS AND TREATMENT
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Possible Prenatal Sensitization: "The Case of the Hidden Cake"
José Antonio Ortega Martell, MD,1 Rosa Elena Huerta Hernández, 2 and
Marlene Ruiz-Castillo, MD3. 1Mexican College of Pediatricians Specialized
in Allergy and Clinical Immunology, Pachuca, Mexico; 2CoMPEDIA,
Pachuca, Mexico; 3Gastroenterología, Hospital del Niño DIF, Pachuca,
Mexico.
Background: To discuss the clinical case of an infant with food allergy and
probably sensitization during pregnancy and/or breast-feeding.
Methods: Case report with clinical description of signs and symptoms,
pictures from his skin prick tests and correlation with in vitro studies (Total
IgE and speciﬁc IgE to casein, soy and egg).
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Results: 7 month old boy with history of gastroesophageal reﬂux since 2
months old; product of the ﬁrst pregnancy of a young mother with history of
asthma during childhood, obtained by cesarean section. He received maternal
human milk combined with normal infant formulae since birth to 5 months of
age when he started other foods. He presented skin perioral rash with the
ingestion of apple and sometimes with infant formulae and gastroenterologist
changed to extense hydrolized formulae but the parents decided to give partial
hydrolized formulae because of cost and taste. In his white blood cell count
marked eosinophilia was noted (700/mL), elevation of total IgE (170 UI/mL;
normal # 15 UI/mL) and speciﬁc IgE (chemiluminiscence by immunoCap
system) positive to Egg white (.300) (Class IV), Egg yolk (110) (Class III),
Soy (260) (Class III) and Casein (21) (Class II). Skin prick tests reported
(papules): negative saline control ¼ 0 mm, positive histamine control ¼ 5
mm, Soy ¼ 4 mm, Cow’s Milk ¼ 12 mm, Egg ¼ 34 mm. The boy had
received cow’s milk in infant formulae, soy in cookies given since 5 months
of age and egg in cakes eaten by the mother in great amounts during preg-
nancy and breast-feeding.
Conclusions: Recomendations to avoid soy, egg and cows milk products were
given to the parents, changing to an extense hydrolized formulae with good
clinical results. The present case suggests that sensitization during pregnancy
and breast-feeding to several foods can be present in high risk infants.
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The Evaluation of Allergen Sensitivity in Food Allergy Patients in
Antalya, Turkey
Arzu Didem Yalcin, MD,1 Ayhan Hilmi Cekýn, MD,2 Hasan Hüseyin Polat,3
Ramazan Cetinkaya,4 and Reginald M Gorczynski, MD, PhD5. 1Allergology
and Clinical Immunology Unit, and; 2Gastroenterology Unit, Antalya Educa-
tion and Trainin Hospital, Antalya, Turkey; 3Department of Public Health,
Faculty of Medicine, Cumhuriyet University, Sivas, Turkey; 4Division of Ne-
phrology, Antalya Education and Training Hospital, Antalya, Turkey; 5Division
of Cellular & Molecular Biology, Toronto Hospital, University Health Network,
Toronto, ON, Canada.
Background: In this study, the socio-demographic characteristics, skin prick
test were evaluated in treated patients diagnosed with Food allergies.
Methods: The study was conducted in Antalya between 10 November 2009
and 20 September 2010. A questionnaire made by the investigators taking the
latest literature data into consideration were used during the study. The total
and speciﬁc IgE levels were made by ﬂuoroenzyme immunoassay method via
use of ImmunoCAP kit. For dermal prick tests Alyostal ST-IR standard
allergen extracts were used. The statistical data derived were evaluated by
using 14.00 SPSS software. Ki-Square test and percent ratios were used for
data analysis. A P value less than 0.05 was assumed for statistical
signiﬁcance.
Results: During the study 173 patients: 116 female (67%), 57 male (32.9%)
were included. Among patients 42% belonged to the 20 to 29 years of age
group and 39% were University degree graduates. The total duration of
the food allergy was 3.126 0.39 years. The total Ig E level was 103.66 11.5
Ku/L. The most common allergen was orange and kakao.
Conclusions: Food allergies are the most common cause of anaphylaxis and
no pharmacologic treatments are available to prevent a reaction. The
emergency use of epinephrine, antihistamines, and steroids are usually
successful in treating a systemic reaction that is already underway. That’s
why; the allergen proﬁles of the regions must be determined and the dermal
Prick tests must be prepared accordingly.
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Clinical Correlation of Prick and Prick-to-Prick Skin Tests to
Food in a Group of Children with Allergy Symptoms
G Ricartti-Humarán, MD,1 Blanca del Rio, MD,2 Jaime Mariano del Río-
Chivardí, MD,2 Miguel Angel Rosas-Vargas, MD,2 Jonathan Maya, MD,2
and Armando Partida-Gaytan, MD3. 1Alergia e Inmunologia Clinica Pedia-
trica, and; 2Pediatric Allergy and Clinical Immunology, Hospital Infantil de
Mexico Federico Gomez, Mexico City, Mexico; 3unknown, unknown, Mexico.
Background: The food hypersensitivity IgE-mediated in children is of 1.6%
to 6%. It can be manifested clinically as allergy in different devices and
systems. Skin prick tests have a positive predictive value of less than 50% and
95% of negative predictive value. Prick-to-Prick tests have not been studied
extensively.
Objective: To clinically correlate food hypersensitivity to Prick and Prick-to-
Prick tests in a group of children with allergy symptoms in the skin, the
gastrointestinal tract and the respiratory system.
Methods: A retrospective study done in the department of Pediatric Allergy
of a Children’s Hospital from June 2008 to May 2011. Data was taken from
the records of 100 patients who gave positive to Prick and Prick-to-Prick food
tests. We also looked for the clinical setting referred to by the patient. The
frequency and CI 95% were analyzed by Chi2. Out of the 100 patients, 48
were female and 52 male. These patients were grouped by age range. Fifteen
patients fall within 1 to 2 years range, 15 patients fall within the 3 to 5 year
range and 26 patients within the over-6-years range. Twenty patients pre-
sented asthma, 16 allergic rhinitis, 24 atopic dermatitis, 33 food allergy, 5
gastrointestinal eosinophilia, and 2 children presented other reactions. The
tests were done with extracts of IPI ASAC Laboratories and fresh food. We
considered that the tests that were positive were those with a wheal diameter
greater than 3 mm over the negative control.
Results: 10%(95% CI, 4.12-15.88) of the patients had a reaction after the
Prick test and presented clinical symptoms of which 30% were cutaneous and
70% gastrointestinal. Thirty six percent of the patients had a reaction after the
Prick-to-Prick test (95% CI, 26.59-45.40)[P ¼ 0.005] of which 17% devel-
oped respiratory symptoms, 22% skin, and 61% gastrointestinal. The main
fresh foods with which the patients gave positive were: milk 16% (95% CI,
8.81-23.18), egg 10% (95% CI, 4.12-15.88), and wheat 7% (95% CI, 1.99-
12.00). Prick tests like milk, eggs and corn could not be assessed properly by
the sample size.
Conclusions: Prick-to-Prick tests are more effective than Prick to detect
patients with food clinical reactions.
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Comparison Skin Prick Test Using Commercial and Native
Extracts of Allergens in Diagnosis of Food Allergy
Zbigniew Bartuzi, PhD,1 Katarzyna Napiórkowska, 1 and Magdalena
_Zbikowska-Gotz 2. 1Department Allergology; 2Allergy, Clinical Immu-
nology and Internal Diseases, Collegium Medicum Nicolaus Copernicus
University, Bydgoszcz, Poland.
Background: Patients with the birch pollen allergy frequently develop
hypersensitive reactions to certain plant food. These reactions result from the
similarity of allergen proteins structure, which are sometimes unbound
phylogenetically. The aim of this study was to investigate the diagnostic
value of immunoblotting method for patients with pollinosis.
Methods: Fifty eight patients were included in the study. The clinical history:
the positive result of the skin prick test with the birch extract and symptoms
after consumption plant food were the condition for qualiﬁcations. The
immunoblotting was performed for the patients with the positive value of
birch, apple, celery and/or carrot speciﬁc IgE to conﬁrm the cross-reactivity.
Results: Sera of 13 patients (18 patients were analyzed) revealed positive
results in the immunoblotting method. Sera of only 12 patients revealed the
reaction against the birch pollen protein with a molecular weight 17 to 18 kDa
corresponding to the main birch allergen Bet v 1. Sera of only 2 of these
patients revealed the presence of antibodies cross-reacting with the apple
protein with the same molecular weight, which may indicate the main
allergens of these foods – Mal d 1. Serum of 6 patients revealed the presence
of antibodies cross-reacting with apple and celery protein with the same
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molecular weight, which may indicate the main allergens of these foods –Mal
d 1 and Api g 1. Serum of only one patient revealed the presence of anti-
bodies cross-reacting with the apple, celery and carrot protein with the same
molecular weight, which may correspond the main allergens of these foods –
Mal d 1, Api g 1 Dau c 1. Additionally sera of 6 persons demonstrated the
presence of antibodies reacting with apple protein with the molecular weight
10 kDa which may correspond to the lipid transfer protein (LTP). Among
some of the patients, antibodies which have not been identiﬁed so far reacted
with birch, apple and celery proteins.
Conclusions: Although the immunoblotting is an effective method conﬁrm-
ing the existences of the cross-reactivity, it still remains the method of
verifying and supplementing other diagnostic tests, and a negative result
doesn’t exclude the existence of this kind of allergy.
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Natural History of Food Allergy in Childhood -3 Years’ Follow up
of Pediatric Food Allergy Patients
Miho Hasegawa,1 Takatsugu Komata, MD,2 Takanori Imai, MD, PhD,2
Kiyotake Ogura, MD,2 Makiko Goto, MD,2 Katsuhito Iikura, MD,2
Tomohiro Utsunomiya, MD,2 Sakura Satou, MD,1 Morimitsu Tomikawa,
MD,2 Akinori Shukuya, MD, PhD,2 and Motohiro Ebisawa, MD, PhD1.
1Department of Allergy, Sagamihara National Hospital, Clinical Research
Center for Allergy and Rheumatology, Sagamihara, Japan; 2Department of
Pediatrics, Sagamihara National Hospital, Sagamihara, Japan.
Background: Food allergy (FA) is prevalent among children however natural
history of FA is not fully clariﬁed.
Methods: We sought to investigate the natural course of childhood FA. To
follow up the transition of same patients, we collected clinical records of
patients with 3 years’ interval from 2008 to 2010. Four hundred ninety-one
patients (male 321 and female 170) were recruited to this study.
Results: The onset of FA was at the age of 5 months 6 1 year 3 month
(mean 6 SD). The clinical type at the onset was with infantile atopic eczema
(84.1%), and followed by immediate reactions without eczema (14.9%). The
initial diagnosis age was 10 months 6 1 year 4 months, and the ﬁrst visit to
our department was 1 year 11 month 6 2 years 5 months. Current age of the
patients was 7 years 5 months6 2 years 11 months, and 444 patients (90.4%)
had experienced immediate reactions. The number of eliminated foods
decreased from 2.4 6 1.5 items/patient (n ¼ 1191) to 1.9 6 1.6 items/patient
(n ¼ 926) in 3 years. The ratio of stopping elimination of major allergens was
35.9% (121/337 patients) for hen’s egg, 25.6% (52/203 patients) for cow’s
milk and 47.8% (44/92 patients) for wheat. Fourteen patients (2.9%) had
developed new food allergies, and 2 of them had experienced anaphylaxis
by tree nuts. Newly diagnosed allergens were only 0.1 6 0.3 items/patient
(n ¼ 32), and nuts (n ¼ 6) and peanut (n ¼ 5) were the most frequent.
Seventy-nine patients (16.1%) had developed complete remission of FA in
3 years, and 21.5% of them (17 patients) had never developed immediate
reactions.
Conclusions: Most of pediatric FA started during infancy with atopic
eczema, and developing tolerance is expected with aging. In some patients,
persistent FA is troublesome for school age children.
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Comparative Analysis of Patients with Birch Pollinosis and
Patients with Associated Plant Food Allergy
Zbigniew Bartuzi, PhD,1 Katarzyna Napiórkowska,1 and Magdalena _Z
bikowska-Gotz 2. 1Department Allergology; 2Allergy, Clinical Immunology
and Internal Diseases, Collegium Medicum Nicolaus Copernicus University,
Bydgoszcz, Poland.
Background: Even 70% patients allergic to pollens of plants are developing
undesirable symptoms after eating foods of the plant origin. It is most often
a result of the cross-allergy between these allergens. The aim of the study was
to compare the group of patients with pollinosis with patients with pollinosis
and food allergy.
Methods: Fifty eight patients at the age above 16 were included in the study.
Patients were divided into 2 groups. Patients included in the ﬁrst group were
birch allergic without any symptoms after eating food (23 persons). Patients
in the other group had birch pollen allergy and they had reported clinical
symptoms after eating foods such as: apple, celery, carrot, tomato, banana,
peach, peanut and hazelnut (35 persons). The skin prick tests with pollen and
food allergens (commercial and native) and serum IgE concentration (total
and speciﬁc) were determined for all individuals. The immunoblotting was
performed for the patients with the positive value of birch, apple, celery and/
or carrot speciﬁc IgE to conﬁrm the cross-reactivity.
Results: Patients with pollinosis and symptoms after eating plant foods were
characterized by a signiﬁcantly larger percentage of positive skin tests with
the hazel allergen. In the ﬁrst group patients revealed positive results of skin
tests with food allergens, although they didn’t reported the problem after
consumption of them. No difference in total IgE levels was found between
the 2 groups (271.5 6 403.8 IU/mL vs 242.5 6 340.9 IU/mL). Patients with
birch allergy and hypersensitivity to food allergens showed signiﬁcantly higher
birch pollen speciﬁc IgE levels (11.8 6 14.1 IU/mL vs 4.1 6 6.6 IU/mL).
Conclusions: Sixty percent of all the patients with birch pollinosis reported
manifestations symptoms after eating certain kind of food. These patients had
most often clinical symptoms after eating apples, hazelnuts and of peaches,
and less frequently symptoms after eating carrots, celery, peanuts, tomatoes
and bananas. Although it seems that false positive results of skin tests with
food allergens in the control group and the high level of the birch speciﬁc IgE
might be the predictive factor of the allergy which may develop later; they
require further studies.
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Frequency and Characterization of Oral Allergy Syndrome in
Mexican Adults with Nasal Pollinosis
Martín Bedolla Barajas, MD. Servicio de Alergia e Inmunología Clínica,
Hospital Civil de Guadalajara, Guadalajara, Mexico.
Background: Oral allergy syndrome (OAS) is a common cause of food
allergy in adults. Our objectives were to determine the frequency and to
describe its clnical features in Mexican people with nasal pollinosis.
Methods: Diagnosis of OAS was made through the clinical history and
a fresh-food-prick-by-prick test. The sample to estimate the frequency
consisted in 100 consecutive subjects with a diagnosis of nasal pollinosis,
whereas to describe its clinical featuring, we look for the ﬁndings in 30
patients with OAS from a Second Level Hospital. Statistical analysis included
descriptive measures and Spearman’s Rho Test for a correlation between
clinical variables.
Results: The frequency for OAS was 13%. Mean age 29.9 years. By gender
26 women. Median for serum IgE was 160 UI/mL, while the average for total
eosinophils was 278.2. The most common symptoms were oropharyngeal
pruritus, followed by lip edema; the symptoms started in most of the cases
within the ﬁrst minute after eating the food. Predominant sensitizing
aeroallergens corresponded to trees, among them, oaks. Twenty three
different foods related to OAS were detected in total, mainly, peach (23
cases), apple (18 cases), pear (8 cases) and almond (7 cases). By anamnesis, 2
patients identiﬁed up to 8 foods. Evolution time of OAS correlated
signiﬁcantly to the evolution time of allergic rhinitis (Rho ¼ 0.49; P ¼
0.006) and duration of OAS symptoms (Rho ¼ 0.37; P ¼ 0.05). Evolution
time of allergic rhinitis and duration of OAS symptoms also correlated be-
tween them (Rho ¼ 0.52; P ¼ 0.003).
Conclusions: In a birch-free zone and sensitization to oaks and alders, as
Guadalajara, in Mexico, OAS should be suspected as related to foods from
Rosaceae family. The longer the evolution time of nasal pollinosis and OAS,
the longer the duration of OAS symptoms.
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Patterns of Sensitization to Common Food and inhalant Allergens
and Allergic Symptoms in Preschool Children
Man Yong Han, MD. Pediatrics, CHA University College of Medicine,
Seoul, South Korea.
Background: The prevalence of sensitization to allergens and symptoms of
allergic disease differ with regard to age, but the relationship is poorly
understood. This study aimed to investigate the patterns of allergen
sensitization and allergic symptoms with regard to age in early childhood.
Methods: A cross-sectional study was conducted on 629 children. Current
allergic symptoms were assessed using the Korean-language ISAAC ques-
tionnaires adapted for preschool-aged children. The sensitization to ﬁve aero-
and 3 food- allergens was evaluated by skin prick test.
Results: The prevalence of current asthma decreased (20.5%/8.2%), current
rhinitis increased (36.1%/56.1%) with increasing age from 3 to 6 years, while
no change in the prevalence of current eczema (16.9%/15.3%). Similarly, as
age increased, sensitization rates to inhalant allergens increased (21%/33%),
those to food allergens decreased (10%/2%). The prevalence of polysensi-
tized children increased (8%/22%), monosensitized children decreased (18%/
11%) with age, but atopic state did not change with age (27%/33%). The
agreement rate between sensitization to dust mite and atopic state increased
with age, showing a rate of 93% at 6 years (P ¼ 0.05). The presence of atopic
dermatitis in the ﬁrst 2 years of life (aOR ¼ 4.1, 2.2–7.6, P , 0.001) and
polysensitization (aOR ¼ 3.0, 1.4–5.0, P , 0.005) were signiﬁcant risk
factors for current rhinoconjunctivitis. In contrast, monosensitization was
a risk factor for current asthma (aOR ¼ 2.1, 1.1–4.1, P , 0.024) and current
eczema (aOR ¼ 2.1, 1.0–4.3, P , 0.042).
Conclusions: These data showed that the type and numbers of sensitization
and allergic symptoms changed with age in early childhood. Polysensitization
may play an important role in allergic march.
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Sensitization to FoodAllergens inPatients of theAllergy Service of
the University Hospital of Monterrey, Mexico
Luis Dominguez, MD,1 Alfredo Arias-Cruz, MD,2 Sandra González-Díaz,
MD, PhD,3 Arya González, MD,1 Claudia Gallego, MD,1 Diego Garcia-
Calderin, MD,1 Karla Mejia, MD,1 and Maricruz Calva, MD1. 1Regional
Centre of Allergy and Clinical Immunology, University Hospital, Monterrey,
Mexico; 2Allergy and Clinical Immunology, University Hospital UANL, Mon-
terrey, Mexico; 3Regional Allergy Center, University California San Diego
U.C.S.D., Monterrey, CA, Mexico.
Background: Food allergy occurs between 2 and 8% of the population and
sensitization to food allergens be detected by skin prick test (SPT). To assess
the frequency of sensitization to food allergens in patients attended in an
allergy service of Northeast of Mexico.
Methods:We reviewed the records of patients in whom SPT were performed
with food allergens extracts, from January 2008 to December 2010. The
extracts were applied on the back surface with multitest in patients under
8 years old and with duotip in those over 8 years. According to age,
patients were divided into 4 groups: I # 2 years, II 3 to 5 years, III 6 to
18 years, IV . 18.
Results: 565 records were reviewed 56.8% of patients were female. 73.3%
had at least one positive SPT. The most common diagnoses were allergic
rhinitis (74.4%) and urticaria (10.4%). The most common positive SPTs in
total group were: shrimp 61 (10.8%), cheese 58 (10.2%), beans 58 (10.3%),
almond 57 (10.1%), Chile 53 (9.2%). According to the age groups, the most
common positive SPTs were: I egg yolk in 12 patients (12.1%) and tuna 11
patients (11.1%), II peach 9 patients (11.4%) and tomatoes 8 patients
(10.1%), III cheese 16 patients (13.4%), shrimp 15 patients (12.6%), almond
15 patients (12.6%), and IV shrimp 40 patients (14.9%), almond 34 patients
(12.7%), beans 33 patients (12.3%).
Conclusions: Sensitization to food allergens were very common in our allergic
patients. The most common sensitizing foods were shrimp, cheese, beans, and
oats, although food sensitization varies among the different age groups.
REFERENCES
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Frequency of Food-sensitization by Prick-to-Prick Test andAtopy
Patch Test in Allergic Children
Jonathan Maya, MD, Miguel Angel Rosas-Vargas, MD, and Blanca del Rio,
MD. Pediatric Allergy and Clinical Immunology, Hospital Infantil de Mexico
Federico Gomez, Mexico City, Mexico.
Background: Food-allergy is a substantial and evolving health issue. We
evaluate the frequency of food sensitization by prick-to-prick and atopy patch
test (APT) in allergic children in a tertiary pediatric care center.
Methods: Cross-sectional retrospective study of prick-to-prick and APT tests
made in atopic children attending to the Pediatric Allergy and Clinical
Immunology outpatient clinic aged 6 months to 19 years. Patients were
stratiﬁed in 4 groups according to age (,1, 1–5, 6–10 and.11 years), and by
atopy-related diagnosis (asthma, rhinitis, food allergy, atopic dermatitis and
eosinophilic gastroenteropathy).
Results: Total of 170 prick-to-prick with fresh foods were made, 135 were
positive with the next distribution: milk 28.8%, (95% CI, 21.3-36.3%), egg
white 20.1% (95% CI, 13.5-26.8%), banana 19.4% (95% CI, 12.8-26%).
Sensitization to milk was most common in children aged 1 to 5 years old with
26.9% (95% CI, 17.1-36.8%) compared with corn, nuts and peanuts P , 0.05.
Sensitization to milk was the most frequent in the food allergy diagnosis group
with 27.1% (95% CI,15.8-38.5%) compared with wheat, corn and peanuts P ,
0.05. A total of 140 APT tests were made, 105 were positive with the next
distribution: soybeans 53.3% (95% CI,43.8-62.8%), peanut and chocolate both
with 50.5% (95% CI,40.9-60,.0). This ﬁnding was sustained in patients with
atopic dermatitis with soybean 55.6% (95% CI,36.8-74.3) compared to egg
yolk. Sensitization to soybeans was most common in children aged 1 to 5 years
old with 52.1% (95% CI,40.6-63.6) compared to rice and egg yolk P, 0.05. A
different distribution was found for the 6 to 10 years old aged group: peanut
41.9% (95% CI,27.1-56.6) compared with egg yolk P , 0.05.
Conclusions: Milk is the most common food-allergen found by prick-to-
prick in children independent of age or allergic diagnosis, with statistical
signiﬁcant difference, when compared to other food-allergens, in the group of
food-allergy diagnosis and in the 1 to 5 years old age-group. Soybean is the
most common food-allergen found in atopy patch test in the groups,1, 1 to 5
and .11 years old, independent of atopy related diagnosis, with statistical
signiﬁcant difference, when compared to other food-allergens in the group of
atopic dermatitis and in the 1 to 5 years old age-group. For the 6 to 10 years
old group peanut was the most common food-allergen found by APT,
independent of atopy related diagnosis
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Increasing Incidence of Food Allergy in Zimbabwe
Elopy Sibanda, MD. Clinical Immunology and Allergy, Asthma, Allergy and
Immune Dysfunction Clinic, Harare, Zimbabwe.
Background: Data relating to allergic diseases in general and food allergies
in particular in the Central African region is scant. Despite observations by
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the ISAAC studies that airborne allergen sources were common, little has
been reported about food allergens. We reviewed data from our laboratory
and outpatient records of patients consulted to estimate the magnitude of the
disease in our population.
Methods: Patients attending the only specialist allergy diagnostic facility in
the country (Asthma, Allergy and Immune Dysfunction Clinic) were offered
semi-quantitative allergen speciﬁc IgE antibody determination as part of their
diagnostic work-up. Alongside skin-prick testing, the Euroimmun immuno-
blots were used to establish IgE reactivity to a variety of allergen sources.
Results: Six hundred thirty ﬁve patients were enrolled between January 2009
and April 2011. These were born between 1931 and 2010. IgE reactivity to
egg, codﬁsh, cows milk, wheat ﬂour, rice, soya bean, peanut, hazelnut, carrot,
potato and apple was investigated using the immunoblot technique. Results
were scored negative or positive. The grades of positive were weak (6), low
(1), moderate (11) and high (111). Overall, 47% of the patients reacted
to one or multiple allergen sources. Across the age spectrum, allergen speciﬁc
IgE reactivity was most frequent against potato (16%) and peanut (15%) and
lowest against milk (2.7%) and codﬁsh (2.7%), others were intermediate. Egg
white reactivity was highest in those below the age of 5 years (7%). IgE
reactivity in patients born before 1959 was less than 1%. This increased to
3.4%, 4.8% and 64% respectively in those born before 1969, 1979 and 1989.
Nineteen (19%) of patients born in 1990 to 1999 were reactive to a variety of
food allergen sources. Likewise, 12% of those born between 2000 and 2011
were reactive. Food allergen reactivity paralleled inhalant allergen source
sensitisation in all age groups.
Conclusions: In this sample of symptomatic patients we have shown that
allergen speciﬁc IgE reactivity to dietary sources was high. An exponential
increase in IgE reactivity in patients born between 1990 and 2011 was
a surprising observation. Possible explanations include urbanisation, life-style
and dietary changes in this predominantly urban population. The results call
for a systematic investigation of the predisposing factors.
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Ten Years Follow up of Japanese Survey on Immediate Type
Food Allergy
Takanori Imai, MD, PhD,1 Chizuko Sugizaki,2 and Motohiro Ebisawa, MD,
PhD2. 1Pediatrics, Sagamihara National Hospital, Sagamihara, Japan;
2Clinical Research Center for Allergy and Rheumatology, National Hospital
Organization, Sagamihara National Hospital, Sagamihara, Japan.
Background: The food labeling system for food allergens was introduced
from April 2002 in Japan. To conﬁrm the effectiveness of the system, we
regularly conduct a nationwide food allergy survey every 3 years.
Methods: The survey was conducted in cooperation with over 1000 volunteer
doctors in Japan at 200112002, 2005 and 2008. We have sent questionnaires
to contributing doctors every 3 months based on the previous survey system,
and contributing doctors were asked to report immediate type food allergy
cases seen by those doctors. In this survey, immediate type food allergy was
deﬁned as the patients who had developed symptoms due to food allergic
reaction within 60 minutes after intake of causative foods. The details of
questionnaire consisted of age, sex, cause of food allergy, symptoms, anti-
gen-speciﬁc IgE, and type of onset.
Results: A total of 8581 immediate type food allergy cases were reported by
the doctors in these surveys. The most common causative foods were hen’s
egg (39.0%), milk products (18.0%), wheat products (9.4%), fruits (5.3%),
crustacean (4.6%), peanuts (3.7%), ﬁsh egg, buckwheat and ﬁsh (3.6%). The
most common clinical symptom was observed on skin (89.7%) followed by
respiratory system (29.6%). Interestingly, the causes of food allergy were
completely different from infancy (egg, milk, and wheat) to adulthood
(wheat, crustacean and fruits). Anaphylactic shock was observed in 10.9%
of the total reported cases. The cases of anaphylactic shock were due to hen’s
egg (27.1%), milk products (21.4%) and wheat (18.1%). Eleven percentages
of patients had been hospitalized.
Conclusions: We could clarify the detail of the immediate type food allergy
cases seen in Japan for a recent decade. Based on these data, countermeasures
against food allergy have been conducted in collaboration with the Ministry
of Health, Labour, and Welfare in Japan in order to improve quality of life of
patients with food allergy.
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Association between Cows Milk Allergy and Gastroesophageal
Reﬂux Disease on Mexican People
Fernando Ramirez Jimenez, MD, Ma de la Luz Garcia Cruz, MD, Ma del
Rosario Gonzalez Galarza, MD, Karla Paola Ruiz Cervantes, MD,
Carlos Guillermo Najera Villatoro, MD, and Luis Manuel Teran Juarez,
PhD. Clinical Immunology and Allergy, National Institute of Respiratory
Disease, Distrito Federal, Mexico.
Background: The World Allergy Organization estimates 520 million people
with food allergy on the world. The data that support the prevalence ﬂuctuate
in relation of the method employed to obtain these, for example, question-
naires, measurements of IgE-speciﬁc, oral challenges; the last one is
considerate the gold standard. Similar situation occur to allergy to cows milk
(CMA), the prevalence reported is 1 to 17.5% in preschoolers, 1 to 13.5% in 5
to 16-year-olds, and 1 to 4% in adults. About 40% of infants referred for
specialist management of Gastroesophageal Reﬂux Disease (GERD) have
CMA. This situation increases to 56% in severe cases. These allergic reac-
tions are typically not IgE-mediated. The gold standard for GERD is the pH
measurement in 24 hours (speciﬁcity 100%), exist other test more accessible,
with considerable sensivity (80%) like scintigraphy.
Methods: The objective was determinate the frequency of GERD in patients
with IgE-mediated CMA. We evaluated retrospectively 20 patients with IgE-
mediated CMA of a group of 47 patients with food allergy between 6 months
to 39 years aged. They had one or more IgE-speciﬁc to proteins that are
considered major allergens: casein, beta-lactoglobulin (BLG) or alpha-
lactalbumin (A-LA). All the patients had study to discard GERD, through
by scintigraphy (study with more access in our Institute). Patients with CMA
and negative scintigraphy, had pH measurement. We made 3 groups each one
to represent the positivity of IgE-speciﬁc to major allergens and these were
associated with the presence or absence of GERD.
Results: GERD was found in 80% of patient with CMA. 77.8% of patients
with IgE to casein had GERD diagnosed by scintigraphy (P , 0.008) Likeli-
hood ratio obtained for this relationship was 7; 70% of patients with IgE to
A-LA have GERD (P , 0.03), the likelihood ratio was 4. No signiﬁcant
difference was found between the presence of IgE to BLG and GERD.
Additionally, we found that 40% of patients with food allergy without
CMA presented GERD.
Conclusions: We found high association between IgE-mediated CMA and
evidence of GERD on Mexican people opposed to previous literature.
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An Investigation of Food Choice Behaviour of Food Allergic and
Non-food Allergic Children
Isolde Sommer, MPH, Heather Mackenzie, PhD, Carina Venter, PhD,
and Taraneh Dean. University of Portsmouth, Portsmouth, United Kingdom.
Background: Childrens food choice behaviour is inﬂuenced by a number of
family and social factors. About 20% to 30% of the population modiﬁes their
diet for a suspected adverse reaction to food. Since avoidance is the mainstay
of managing food allergy, it can be assumed to signiﬁcantly affect food
choices. It is therefore important to understand if and to what extent food
allergy inﬂuences the way parents and children make their food choice
decisions.
Methods: The research project has utilised an innovative observational
approach in the form of a board game to investigate parental-child
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communication and food choice behaviour. Parents/guardians and children
were given a problem-solving task related to food choice behaviour. Each
session lasted up to 15 minutes and was conducted with 5 food allergic and 7
non-allergic children (aged 4–8 years) and their parents/guardians. The ses-
sions were videotaped and analysed by constructing a 4-category scheme,
which classiﬁes parental utterances along 2 dimensions, food choice behav-
ioural control and food choice recognition. Observational categories were
compared between the 2 groups.
Results: Preliminary ﬁndings indicate considerable variability in how
parents/guardians and children with and without food allergy communicate
when making food choice decisions. In general, children with food allergies
seem to be more cautious and appear to have less responsibility when
choosing their foods than healthy children of the same age.
Conclusions: Given the preliminary ﬁndings, this study will illuminate how





Probiotic Effect of the Regulation of Innate Immune Response, dc
and Adaptive Cellular Immune Response and the Balance TH1,
TH2, TREG Through Sensors TLR-2 AND TLR-4, on the
Intestinal Mucosa in BALB/C Health Status and Balb/C Status of
Exposure to LPS
Azwin Lubis, MD,1 Anang Endaryanto,2 Subijanto Marto Sudarmo,3 I.G.
M. Reza Gunadi Ranuh, 3 and Alpha Fardhah Athiyyah 3. 1Child health,
Pediatric allergy immunology, Surabaya, Indonesia; 2Division of Pediatric
Allergy Immunology-Child Health Department, and; 3Division of Pediatric
Gastroenterology-Child Health Department, Faculty of Medicine, Airlangga
University-Soetomo Hospital, Surabaya, Indonesia.
Background: The concept of improving host defense as a preventive effort in
the face of exposure to pathogens through the gut mucosal immune system
must be developed where the normal intestinal ﬂora plays an important role.
Probiotics through various research can improve intestinal mucosal immune
system, but so far the effect of probiotics on the regulation of innate immune
responses of dendritic cells and adaptive cellular immune response as well as
the balance of TH1, TH2, TREG through TLR-2 sensors and TLR-4 on
intestinal mucosa Balb/c healthy status and Balb/c LPS exposure status is
unclear. The purpose is to examine the effect of probiotics against dendritic
cells regulation of innate immune responses and adaptive cellular immune
response as well as the balance TH1, TH2, TREG through TLR-2 sensors and
TLR-4, on the intestinal mucosa in Balb/c health status and Balb/c status of
exposure to LPS.
Methods: Male Balb/c divided into 4 treatment groups. Two groups given
probiotics for 21 days, one group will be given exposure to LPS on day 15.
One group will exposure by LPS alone and one group as control group
without treatment. All groups terminated after a day-to-21. Immunohisto-
chemical examination of ileal mucosa using monoclonal antibodies speciﬁc
for dendritic cells, TLR-2, TLR-4, IL-1, IL-2, IL-4, IL-6, IL-10, IL-2, TNFa
and TGFß.
Results: In LPS group there were downregulation both innate and cellular
immune system indicates the occurrence of adaptive homeostasis disorders.
In the group receiving probiotics there were upregulation both innate and
cellular immune system is adaptive to indicate an alert. When the probiotic
group exposured by LPS, it was still maintained by the improvement of the
balance indicate TREG immune system remains in a state of homeostasis.
Conclusions: Probiotics can improve alertness status innate and cellular
adaptive immune mucosa in healthy mice and can maintain the balance of
TH1, TH2 and TREG so that homeostasis is maintained.
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Gluten Induced Systemic Disease (GISD) with Distinct Clinical
Phenotype Different from Celiac Disease
Nataliya M. Kushnir, MD. Allergy & Immunology Clinic of East Bay, Berke-
ley, CA.
Background: Patients who have complex presentation involving multiple
organs are difﬁcult to diagnose. Non-infectious diseases that present with
similar clinical patterns yet test negative to the known markers often arise due
to certain change in environment or exposure. Such syndromes and diseases
require careful study and call for new diagnostic modalities.
Methods: Patients who have complex presentation involving multiple organs
are difﬁcult to diagnose. Non-infectious diseases that present with similar
clinical patterns yet test negative to the known markers often arise due to
certain change in environment or exposure. Such syndromes and diseases
require careful study and call for new diagnostic modalities.
Results: Average length of symptoms prior to diagnosis was 5 years. Of 42
patients 34 were previously treated for 3 or more health issues. None of the
patients were previously diagnosed with celiac disease, 7 patients underwent
diagnostic endoscopy with biopsies. Most prevalent symptom (94%) was
severe fatigue. Following symptoms were reported on questionnaire: sleep
problems requiring medications, concentration/memory problem, constipa-
tion, depression, headaches/migraine, gastroesophageal reﬂux, nocturnal
muscle spasms, abdominal distension, joint pain, rashes, and gum recession.
Most common laboratory abnormality was positive ANA with homogenous
pattern. All but 2 patients tested negative to tTG, gliadin and endomyseal
antibodies. Of 17 patients screened for food allergy 94% were positive for
1014 foods by skin test. Hundred percent of patients reported signiﬁcant
improvement at 1 month interval with complete resolution of above listed
clinical symptoms at 6 months. Best recovery was achieved in patients when
treatment regimen included supplemental therapy with CoQ10, ﬁsh oil and
digestive enzymes based on papain. Of 25 patients attempted gluten intro-
duction after complete clinical recovery 100% reported relapse of symptoms
within 48 hours following gluten challenge.
Conclusions: We report the emergence of new clinical phenotype of non-
celiac gluten induced systemic disease (GISD). Although recent publications
specifying existence and possible explanation of this condition arise,
mechanism is not understood. Thus further studies are needed to facilitate
recognition, testing and understanding of GISD.
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Patterns of Food Allergens in Kenyan Children
Rose Kamenwa, MD,1 and Tula Bowry, PhD2. 1Pediatrics & Child Health,
Aga Khan University Hospital, Nairobi, Kenya; 2Nairobi Diagnostic Labo-
ratory, Upperhill Medical Centre, Nairobi, Kenya.
Background: To determine the patterns of food allergens in children
presenting to pediatric gastroenterology clinic at the Aga Khan University
Hospital, Nairobi.
Methods: This data includes children evaluated from March to November,
2010. All the children presenting for evaluation of various gastrointestinal
symptoms and who had positive history of atopy in at least one ﬁrst degree
relative were included. History of reccurent cough was sought and the skin
was examined for eczema. Skin Prick Test was perfomed by an expert in
allergy and immunology. Prick to Prick Test was done for local foods where
commercial antigens were not available. Positive tests were followed by an
exclusion and rechallenge progamme but this was excluded from analysis due
to poor compliance. Analysis was performed to determine frequencies and
associations of the different gastrointestinal symptoms and food allergens.
Both skin Prick and Prick to Prick results were analysed together.
Results: The commonest food allergens in order of frequency were cow milk
(65%), egg (35%), beef (26%), beans (14%), chicken, corn, wheat, soya and
rice (9%), ﬁsh (8%) and peanut (5%). Common local infant complementary
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foods including potatoes, bananas and vegetables all tested positive in 4% of
the children. Pumpkin tested positive in one infant who had presented with
rectal bleeding. Majority of the children had positive tests to multiple foods.
Only 14% of the children had negative tests. The commonest gastrointestinal
(GI) symptoms were abdominal pain (38%), constipation (36%), vomiting
(14%), diarrhoea (11%), failure to thrive (9%) and colics (3%). Majority of
the children had multiple GI symptoms. Eczema and cough were associated
symptoms in 9% and 3% of the children respectively.
Conclusions: The prevalence of food allergy as suggested by this study is
high in Kenyan children and contributes signﬁcantly towards gastrointestinal
morbidity. While cow milk, egg and beef are the commonest allergens, the
emerging allergy to local infant complementary foods is also signiﬁcant. The
high frequency of multiple allergens partly contributed to poor compliance in
the exclusion rechallenge programme due to lack of options on alternative
foods.
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Coincidence of Celiac Disease and Gluten Allergy
Katarzyna Markiewicz, PhD,1 Gra_zyna Rowicka, MD, PhD,2 and Maria
Go1ebiowska-Wawrzyniak, MD, PhD3. 1Immunology; 2Nutrition Depart-
ment; 3Department of Clinical Immunology, Institute of Mother and Child,
Warsaw, Poland.
Background: The type I or IV of hypersensitivity reactions according to Gell
and Coombs classiﬁcation may be responsible for clinical symptoms
observed after ingestion of gluten - containing products. The mechanisms
of these reactions are either IgE-dependent or IgE-independent. Celiac disease
based on IgE-independent mechanism is classiﬁed as gluten hypersensitivity.
Clinical manifestation of celiac disease and gluten allergy is often similar.
Correct diagnosis of this disease is particularly important due to the different
long-term therapeutic procedures. We would like to asses of the incidence of
celiac disease in children with gluten allergy.
Methods: The study involved 50 children with abdominal pain, chronic
diarrhea, recurrent respiratory and ears inﬂammation and skin lesions -
patients of the Immunological and Gastroenterology Outpatient Clinic of
Institute of Mother and Child. The allergy to gluten was conﬁrmed on
the basis of positive peripheral blood lymphocytes blast transformation
test and detection of allergen-speciﬁc IgE antibodies to gluten (f79). In
all children plasma concentration of immunoglobulin classes A, G M
and IgA or IgG antibodies against tissue transglutaminase (tTGA) were
measured.
Results: In children on the study group the type IV of hypersensitivity
reaction to gluten was diagnosed. In 3 children speciﬁc IgE antibodies to
gluten was also conﬁrmed (f79 - I type hypersensitivity). Anti-tissue trans-
glutaminase antibodies both IgA and IgG were detected in 2 children in whom
the concentration of IgA and IgG in serum remained within normal range for
age. In these children celiac disease was conﬁrmed by jejunal biopsy.
Conclusions:
1. The predominant frequency of type IV of hypersensitivity reactions in
children in response to the gluten antigen should be taken into account
in diagnosis of food allergy.
2. In children diagnosed with gluten allergy the test for celiac disease
should be performed.
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Immunoreactivity of ß-Lactoglobulin and Identiﬁcation of the
PeptidesGenerated after SimulatedOrogastrointestinal Digestion
Sara Benedé,1 Iván López-Expósito, PhD,1 Elena Alonso, MD,2 and Elena
Molina, PhD1. 1Institute of Food Science Research, Madrid, Spain; 2Hospital
Gregorio Marañon, Madrid, Spain.
Background: The aim of the study was to evaluate the allergenicity of one of
the main allergens from cow milk, b-lactoglobulin (b-Lg) after being
digested through a simulated orogastrointestinal digestion and to identify
those peptides generated during the digestion process.
Methods: The digestion was performed in 3 steps by using simulated oral,
gastric and duodenal ﬂuids. Digestibility of b-Lg was assessed by SDS-
PAGE and RP-HPLC. IgE binding of native b-Lg and hydrolysates was
evaluated by indirect ELISA, using the sera from 6 milk-allergic patients.
The peptides produced during the orogastointestinal digestion, were identiﬁed
by liquid chromatography tandem mass spectrometry analysis.
Results: Results showed that b-Lg was progressively degraded during the
digestion. Intact b-Lg was observed after the gastric phase and in the ﬁrst
stages of the duodenal digestion. However, no residual b-Lg was observed at
the end of the duodenal phase. Immunoassays showed that during the in vitro
gastric and duodenal digestion immunoreactivity decreased progressively
with an EC50 value increased 150 times at the end of the digestion. Among
the products of digestion, 146 peptides were identiﬁed. No peptides were
found in the oral phase. Forty ﬁve peptides were detected in the gastric phase,
71 in the duodenal, and 30 were common in both phases. Between those
identiﬁed peptides, 4 of them with the sequences LIVTQTMK, GLDIQK,
IDALNENK, and VLVLDTDYK had been previously described as epitopes
of b-Lg.
Conclusions: b-Lg is progressively degraded during the digestion process.
Similarly, b-Lg allergenicity is reduced through the simulated digestion with
a severe reduction at the end of the duodenal stage. From the digestion
products, 147 peptides have been identiﬁed. Studies are underway to evaluate
the ability to cross the intestinal barrier and to bind to human-IgE of the most
relevant identiﬁed peptides.
HEALTH OUTCOMES FOR ASTHMA
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Associations between Self-reported Adherence to Asthma Anti-
inﬂammatory Therapy and Risk Factors for Non-adherence (NA)
in Pediatric Patients
Andrew Weinstein, MD,1 Jean-Phillipe Laurenceau, PhD,2 and Jacqui Vok,
BS3. 1Allergy/Immunology, Thomas Jefferson Medical College, Newark, DE;
2Psychology, University of Delaware, Newark, DE; 3Asthma and Allergy
Foundation of America, Landover, MD.
Background: Identifying patient adherence status and reasons for non-
adherence are important components of asthma management. GINA 2008
Guidelines have identiﬁed risk-factors associated with poor adherence
Methods: Three hundred sixty one parents of children with intermittent and
persistent asthma (59.6% male; 64.1% Caucasian; mean age 8.07 years)
completed the AsthmaPACT, a 96-item asthma survey hosted by the Asthma
and Allergy Foundation of America website. The AsthmaPACT identiﬁes risk-
factors for not following treatment recommendations as well as medication use.
Asthma surveys were completed from August 2009 thru June 2011.
Results: Descriptive statistics indicated that 259 of the sample reported giving
their child one or more of the anti-inﬂammatory medication prescribed. Of these,
69 (27%) were diagnosed as NA, operationalized as whether a parent reported
giving the child anti-inﬂammatory medication "less than prescribed by their
physician." During the 4 weeks prior to completing the survey, 43.0% were
having symptoms daily and 39.4% were using albuterol MDI daily. In this
cross-sectional data set, items intended to relate risk factors to NA were
examined using chi square (x2). Parents who claimed that their child receive
less anti-inﬂammatory medication than prescribed, were more likely to report: 1)
symptoms from emotional states: crying x2(df ¼ 2) ¼ 8.643 P ¼ 0.013;
frustration x2(df ¼ 2) 6.202 P ¼ 0.045; anger x2(df ¼ 2) ¼ 11.029 P ¼
0.0042); Parent more likely to see child as anxious or a worrier x2(df ¼ 2) ¼
6.527 P ¼ 0.038; 2) Child’s Quality of Life (QoL): is more likely to be effected
at school x2(df ¼ 2) ¼ 12.963 P ¼ 0.002; and interfere with family activities x2
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(df ¼ 2) ¼ 8.856 P ¼ 0.012; 3) Parent’s QoL is more likely to interfere with
work x2 (df¼ 2)¼ 16.517 P, 0.001; recreational activities x2 (df¼ 2) 17.759
P , 0.001 and family activities x2 (df ¼ 2) ¼ 16.517 P , 0.001; 4) Parents
are more likely not to agree regarding asthma management x2 (df ¼ 2) ¼ 7.677
P ¼ 0.022; not to agree with relatives/caregivers on how to manage asthma
x2 (df ¼ 2) ¼ 9.853 P ¼ 0.007; lack conﬁdence in teachers/school personnel to
manage asthma at school x2(df ¼ 2) ¼ 20.216 P , 0.001.
Conclusions: The AsthmaPACT provides an assessment of 1) risk-factors for
non-adherence and 2) patient self-report of adherence, and is readily available
as a tool to individuals with asthma who have access to the Internet. Findings
in this study are consistent with GINA 2008 Guidelines regarding common
risk-factors for non-adherence and speciﬁcally to the child’s emotional state
and QoL for both the child and parent. The AsthmaPACT might be consid-
ered for symptomatic patients to identify barriers to treatment and diagnose
adherence status.
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Inability of Medical Students to Use of Three Types of Inhaler
Jae-Won Jeong, MD. Internal Medicine, Inje University Ilsan Paik Hospital,
Gyeongki-do, South Korea.
Background: Several studies have demonstrated that a signiﬁcant percentage
of health care professionals are deﬁcient in both knowledge and skill
regarding the inhalers. But no data is available about the assessment of
inhaler technique and knowledge among medical students in Korea. The aim
of this study was to evaluate the proﬁciency and knowledge of medical
students in proper use of 3 kinds of inhalers (metered dose inhaler, turbuhaler,
and diskus).
Methods: We enrolled 40 third-year medical students who are on hospital
training course. The participants received 25 to 35 minutes of instruction from
a trained nurse educator for asthma. Three month later, we assessed their
knowledge and skill regarding inhaler use. They were asked to discriminate
each type of 3 devices and to demonstrate the use of each device using
placebo inhalers. Also, they were asked about the prevention and manage-
ment for local adverse reaction induced by inhaled corticosteroids (ICS).
Participants’s inhaler skill was assessed into 3 levels as good, inadequate, and
poor for each device type.
Results: Only 12.5% (5/40) of medical students could explain the merits of
inhalation therapy compared to oral route. 67.5% (27/40) of participants
could not discriminate all types of inhaler devices. With regards to prevention
and treatment option for ICS-related local side effects, only 22.5% (9/40)
answered correctly. Subjects with good performance grade were found in
12.5% for metered dose inhaler, 40.0% for turbuhaler, and 57.5% for diskus.
Conclusions: We conclude that large percent of medical students were
deﬁcient in knowledge and proﬁciency regarding the inhalers. A brief
educational session with demonstration by trained asthma nurse was not
effective in enhancing inhaler technique or increasing knowledge on inhaler
treatment.
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Impact of Providing Physical Education Teachers with
Information about Asthma When Training Children and
Adolescents with This Disorder
Dania Fabré,MD,1 Arelys Eligio,MD,2 Tania Reyes,MD,2 Rafaela Andina,MD,2
Juana Maria Rodriguez, MD,2 Guadalupe Pérez,MD,2 and Lidice Galán, PhD3.
1Allergy Department, Juan Manuel Márquez Pediatric Hospital, Havana, Cuba;
2Pediatric Hospital Juan Manuel Marquez, Havana, Cuba; 3Cuban Neuroscience
Center, Havana, Cuba.
Background: To assess the impact of providing physical education teachers
with information about asthma and the progression of this disorder when
training children and adolescents with this disorder.
Methods: A descriptive, applied, prospective, longitudinal and evaluation
study was conducted with the participation of 160 children, with ages
ranging from 9 to 12 years and 320 children aged 13 to 14 years from 4
different schools. Two subgroups for each age were established with
a similar number of members. A subgroup with 80 students and another
with 160 students were headed by 2 teachers instructed in handling
students with asthma while the 2 remaining subgroups were headed by 2
teachers who did not have any knowledge about asthma. The following
aspects were assessed: prevalence and severity of asthma, exercise-
induced asthma, physical ﬁtness and maximum expiratory ﬂow at the
beginning of the study and 6 months later.
Results: An 18.5% prevalence of asthma was observed among the 480
students; 28.1% in children from 9 to 12 years and 13.7% from 13 to 14
years. In the group of asthmatic children from 9 to 12 years, signiﬁcant
differences were observed in favor of asthmatic students whose teacher
had received instruction with regards to: decreasing the severity of
asthma (P ¼ 0.000), lower incidence of exercise-induced asthma (P ¼
0.0001), increase in the results of physical ﬁtness tests (P ¼ 0.009). In the
group of asthmatic children from 13 to 14 years old, statistically
signiﬁcant differences were also reported in favor of students whose
teachers had received training with the following results: drop in
exercise-induced asthma (P ¼ 0.000116), higher values in the physical
ﬁtness tests of all students (P ¼ 0.00000) and also in students with
asthma (P ¼ 0.009436). At the end of the study, both groups exhibited
a signiﬁcant increase in the maximum expiratory ﬂow measurements of
students in the group aged 9 to 12 years (P ¼ 0.000) and in the group
aged 13 to 14 years old (P ¼ 0.001).
Conclusions: Teachers with knowledge about asthma had a positive impact
on physical ﬁtness and lowed exercise-induced asthma in students.
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Asthma Knowledge among Parents and/or Caregivers of
Asthmatic Children Attending a Practical Allergy Course
Eunice Sandoval-Ramírez, MD,1 Mayra Alondra Livano Prez, MD,2
Gabriela Tercero-Quintanilla, PhD,3 Miguel Angel Rosas-Vargas, MD,2
Blanca del Rio, MD,2 and Jaime Mariano del Río-Chivardí, MD2. 1Pedi-
atric allergy and clinical Immunology, and; 2Psychiatry and Adolescent Med-
icine, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Background: Asthma is one of the most frequent chronic diseases, with
worldwide prevalence of 1 to 18%. Patient and the patient’s family education
is considered by all International Guides fundamental to achieve this disease
control. The aim of this study is to asses the asthma knowledge among
parents and/or caregivers of pediatric asthmatic patients before and after
attending to a Practical Allergy Course given at Hospital Infantil de Mexico
Federico Gomez by the Pediatric Allergy Department.
Methods: Transversal Study that included 115 persons attending to a Practical
Allergy Course that answered the previously validated instrument to asses the
asthma knowledge among parents or caregivers NAKQ (Newcastle Asthma
Knowledge Questionnaire); its Spanish version consisting in 31 questions; be-
fore and after the practical course. A descriptive annalysis was made; usefullness
of the course was determinated by x2. Stadistical packagge used was SPSS 17.
Results: A total of 115 questionnaires were applied, only 99 were properly
answered and were included in the analysis; from these 35 were male and 64
female; 80% with high-school and middle school schooling; 92% were small
families with 1 to 3 children; 90% of the families had only one child with
asthma; 63% was receiving the practical course for the ﬁrst time. Before
attending the practical course the mean answered questions was 30 and after
attending the mean answered questions was 31 (LR ¼ 57.465; P , 0.000);
for the ﬁrst evaluation the mean correct answers was 19 and the latter 22
correct answers, ﬁnding statistical signiﬁcant differences (LR ¼ 30.253;
P , 0.000).
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Conclusions: We found improved asthma knowledge among parents and
caregivers of asthmatic children after attending to a Practical Allergy Course.
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Ezhengtricity 2010: a Free Novel Way to Conﬁdentially
Administer, Track, Receive and Score Medical
Questionnaires Instantly
Yin Zheng, MS,1,2 Murugan Ravindran, MBBS,2 Oluwatoyin Adewuyi,
MS,2 Cristina Di Poto, PhD,2 Christian Timbol, MS,2 Rania Esteitie,
MD,2 Rakib Rayhan, MS,2 and James Baraniuk, MD2. 1University of South
Florida College of Medicine, Tampa, FL; 2Medicine-Section of Rheumatol-
ogy, Allergy, & Immunology, Georgetown University, Washington, DC.
Background: Medical questionnaires are important for assessing allergy
patients. However, current methods of administering questionnaires are
cumbersome, expensive, and laborious to accurately administer, track and
score. eZhengtricity is a simple Google Documents based workﬂow, coupled
with customized Excel formulas, that allow researchers to create, collect and
score conﬁdential health questionnaires that are globally accessible, with
minimal setup time and maintenance.
Methods: eZhengtricity utilizes a Google Documents account as a platform
to create online questionnaires. Google automatically hosts the online
questionnaire with a unique URL that can be provided to patients. The
researcher provides patients with a unique study ID that is used to submit
questionnaire responses. By using a unique study ID, researchers ensure
conﬁdentially of questionnaire data. Patient questionnaire responses are
instantly submitted online to a secured “Cloud” database. In the Cloud data-
base, the data is automatically sorted, scaled and scored by custom Excel
formulas. Researchers can instantly access the database and download results
in a variety of formats including PDF and XLS for further analysis using the
researcher’s statistical software of choice.
Results: eZhengtricity provided questionnaire scores from submitted ques-
tionnaires instantly, while paper versions required manual double entry and
manual sorting of patient data for analysis. Better overall quality of patient
responses was obtained with eZhengtricity compared to paper questionnaires.
Submitted responses to eZhengtricity had 100 percent completion while
submitted paper responses had incomplete responses. Patient compliance for
eZhengtricity was comparable to paper questionnaires. eZhengtricity also
allowed monitoring of patient’s progress on completing questionnaires.
Conclusions: The ﬂexibility and robustness of eZhengtricity complement
longitudinal and cross-sectional studies. Compared to paper questionnaires,
eZhengtricity is a cost effective, logistically easy, and superior way to
administer conﬁdential questionnaires.
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Usefulness of Asthma Control Test Questionnaire, FEV1 and
Exhaled Nitric Oxide Level (FENO) for the Clinical Assessment of
Elderly Asthma
Yong Ho Roh, MD, PhD. Pulmonary care, Seoul Veterans Hospital, Seoul,
South Korea.
Background: Asthma remains a prevalent disease with signiﬁcant morbidity
and mortality, therefore numerous markers or measurements for the
evaluation of its severity are available. Functional parameters, clinical
assessment and biomarkers of inﬂammation are the most used. Also the
diagnosis and treatment of asthma are often focused on young patients. This
study was intended to determine the usefulness of patient-based question-
naire, Asthma Control Test score (ACT), forced expiratory volume in 1
second (FEV1) and exhaled nitric oxide (FeNO) for clinical assessment of
elderly asthma patients.
Patients and Methods: Sixty seven (67) patients with a diagnosis of asthma
more than 65 of age were enrolled. They performed spirometry, FeNO
measurement and answered the ACT questionnaire. ACT is scored on a scale
from 5 to 25 with higher values reﬂecting better control. Spirometry measures
that met the American Thoracic Society criteria were included. FeNO was
measured with values$35 ppb indicating probability of airway inﬂammation.
Qui-square test was used for statistical analysis.
Results: 67 patients (15% female), mean age of 72.3 (65–89) were included.
25 patients (37.3%) were very poorly controlled, ACT # 15 and mean values
of FEV1 81.5121.5 (% predicted) and mean FeNO of 41 6 35 ppb. Thirty
patients (44.8%) were not-well-controlled, ACT 16 to 19, FEV1 89%6 16.8,
FeNO of 40 6 36 and 12 patients (17.9%) were well-controlled, ACT $ 20,
FEV1 93.3 6 16.8 and FeNO of 44 6 35. FEV1 as .80% of predicted in
62.4% of patients (ACT 7–25) and 75% of patients with ACT $ 20 had
FEV1 . 80%. The relation between ACT and FEV1 in this study was
statistically signiﬁcant (P ¼ 0.014). There was no correlation when we eval-
uated ACT/FeNO and FEV1/FeNo variables (P ¼ 0.45, 0.41 respectively).
Conclusions: A good correlation was found between ACT and FEV1, with
higher ACT scores reﬂecting less bronchial obstruction. FeNO values had no
correlation with ACT or FEV1, indicating that this marker of inﬂammation
had less interest for assessment of asthma control in these elderly patients. In
spite of these data, we still advise that the clinical assessment of asthma
should be based on a combined approach that involves clinical aspects, func-
tional parameters and biomarkers of inﬂammation, because elderly patients
may have reduced symptom perception and have multiple co-morbidity.
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Systematic Review of the Recommendations on the Prevention of
Allergic Manifestations in Children
Patrick Detzel, PhD,1 Joerg Spieldenner, MD,1 Monika Heil-Ruess, PhD,2
Vincent Navarro, DPharm,3 Jade Berbari, BSC,4 and Michael Iskedjian,
DPharm4. 1Health Economics, Nestlé Nutrition Institute, Vevey, Switzerland;
2MHR Nutrition Marketing Services, Lausanne, Switzerland; 3PharmIdeas
Europe SAS, Lyon, France; 4PharmIdeas Research and Consulting Inc.,
Ottawa, Ontario, Canada.
Background: A systematic review of the literature was performed to gather
all ofﬁcial recommendations on the prevention in infants of allergic
manifestations (AM), and, more speciﬁcally, atopic dermatitis (AD), by
using hydrolyzed infant formulas (HF) whether partially or extensively
hydrolyzed (PHF; EHF).
Methods: OVID MEDLINE and the grey literature were searched by 2
reviewers using the keywords AM, AD, prevention and guidelines. A third
person acted as adjudicator in case of disagreement. Of interest were
recommendations pertaining to the prevention of AM issued by national or
regional associations of medical professionals.
Results: This review yielded 11 sets of guidelines published for Australia,
France, Germany, Spain, Switzerland (all n ¼ 1), Europe and the US (both n
¼ 3), 1999 to 2010. Most guidelines included AD either speciﬁcally (n ¼ 3)
or within AMs. Most guidelines recommended a period of exclusive breast-
feeding ranging from 4 to 6 months, and mentioned it as a major component
of the primary prevention of allergic manifestations. Six guidelines (of which
2 recommended PHF over EHF) endorsed the use of HFs for the prevention
of AM in “at risk” infants when exclusive breastfeeding was not or no longer
possible. Two other publications did not recommend speciﬁc HFs, but for-
mulas with documented reduced allergenicity. The need for an appropriate
level of nutritional support was stressed in one publication. Five guidelines
acknowledged that not all HFs have the same clinical protective beneﬁt. Four
publications underlined the importance of sound clinical evidence when de-
termining the preventive efﬁcacy of HFs and questioned the process leading
to the development of national recommendations. None of the guidelines
based their recommendations on recent evidence from meta-analyses of a spe-
ciﬁc brand of PHF.
Conclusions: HFs, speciﬁcally PHFs, is endorsed for the prevention of AMs,
but not consistently. The need for a strong validity of the clinical evidence is
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acknowledged by national or regional medical associations without however
speciﬁc steps for relying on all the published evidence. Hence, recent
evidence regarding the preventive efﬁcacy of a speciﬁc brand of PHF, based
rigorous clinical research, should provide the basis for new evidence-based
recommendations.
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TheRelationship BetweenEmotional Cognition and the Symptom
Gap inPatientswithBronchialAsthma: theEffects ofAlexithymia
and Empathy
Sonomi Nakajima. Clinical Psychology, Graduate School of Human
Sciences, Osaka University, Suitashi, Japan.
Background: When symptoms are poorly controlled, patients with bronchial
asthma may show a symptom gap: a cognitive divergence between the true
severity of symptoms and the severity evaluated by the patients themselves.
The aim of this study was to determine which factors (emotional cognition of
the self and others) are associated with this symptom gap.
Methods: Forty-two patients with bronchial asthma, who were found with the
Comprehensive Asthma Inventory (a bronchial asthma symptom question-
naire) to have psychosocial factors associated with a deep concern about the
onset of asthma attacks, were studied by means of validated scales for
alexithymia (the Toronto Alexithymia Scale-20) and for empathy (the
Interpersonal Reactivity Index: IRI) and questions about how patients
evaluate the severity of asthma.
Results: Of the patients, 42.5% showed a cognitive divergence regarding
asthma symptoms. The scores for “perspective taking” on the IRI were sig-
niﬁcantly higher in patients who felt symptoms were less severe than they
actually than in patients who felt symptoms were more severe than they
actually were. No association was found between alexithymia and the symp-
tom gap.
Conclusions: The results show that empathy, the ability to understand the
emotions of others, is associated with a symptom gap in patients with
bronchial asthma and that high scores for “perspective taking” on the IRI may
indicate problems of treatment and symptom control in asthma.
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Asthma Control and Quality of Care of Adult Asthma Patients in
Primary Health Care Facilities in Saint-Petersburg, Russia
Alexander Emelyanov,1 Inessa Tsukanova,1 Gleb Fedoseev,2 Galina Sergeeva,
MD,1 Natalia Lisitsyna,2 Lubov Bakanina,2 and Ekaterina Nikitina2. 1Depart-
ment of Respiratory Disease and Allergy, Postgraduate Medical Academy,
Saint-Petersburg, Russia; 2Pavlov Medical University, Saint-Petersburg,
Russia.
Background: This study was performed to assess the control asthma and
quality of care of asthmatic patient in primary health care facilities in Saint-
Petersburg, the second largest city in Russia.
Methods: We conducted telephone interviews with 205 asthma outpatients
(aged 24 to 90 years). Asthma control was assessed by using the Asthma
Control Test (ACT).
Results: During the past 12 month spirometry were performed in 26.8%.
Only 2% of outpatients were consulted by allergist and 26.8% - by respiratory
physicians. Inhaled corticosteroids were prescribed to persistent asthma
patients in 79.1%, oral steroids for maintenance therapy were used in 7.3%
of outpatients. Fixed combination of budesonide/formoterol and ﬂuticasone/
salmeterol were used in 45.4%. Asthma was uncontrolled for 72.2% of
patients.
Conclusions: Quality of diagnostics and treatment of asthma in primary
health care is not sufﬁcient and should be improved.
HEREDITARY ANGIOEDEMA
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A 26-Year Review of Long-term Safety of a Human Pasteurized
C1 Inhibitor Concentrate
Konrad Bork, MD,1 Gerhard Korger, MD,2 and Wolfhart Kreuz, MD, PhD3.
1Department of Dermatology, University Hospital Mainz, Mainz, Germany;
2Global Clinical Safety & Pharmacovigilance, CSL Behring, Marburg, Ger-
many; 3Center of Pediatrics III, Department of Hematology, Oncology and
Hemostasis, Comprehensive Care Center for Thrombosis and Hemostasis, J.-
W. Goethe-University Hospital, Frankfurt a. M., Germany.
Background: Hereditary angioedema (HAE) is a rare disorder characterized
by C1 inhibitor (C1-INH) deﬁciency, resulting in periodic attacks of acute
edema. C1-INH replacement therapy is recommended as ﬁrst-line therapy for
treatment of acute HAE attacks, demonstrating rapid onset of symptom relief
within 30 minutes or less. CSL Behring’s human pasteurized C1-INH con-
centrate has been marketed since 1985 for the treatment of acute HAE attacks
in Germany and numerous other countries.
Methods: We reviewed spontaneous reports of adverse drug reactions
(ADRs) received by CSL Behring for its human pasteurized C1-INH
concentrate, covering the 26-year period from 1985 until 31 December 2010.
Results: During the reporting period, human pasteurized C1-INH concentrate
representing more than 550,000 treatments was distributed. A total of 101
cases of suspected ADRs were reported worldwide, with 62 cases covered by
the product’s known safety proﬁle: allergic- or anaphylactic-type reactions
(11; in very rare cases involving shock), chills and fever (4), lack of effect
(26), suspected virus transmission (6; not attributed to the product), and
thrombosis (16). Only 2 cases of thrombosis occurred when the product
was used in the labelled indication; causality was assessed as unlikely in both
cases (pre-existing cerebromalacia in 1 patient, and unspeciﬁed underlying
pro-thrombotic condition in a second patient with morbid obesity). The other
14 cases of thrombosis occurred during off-label use of the product (sub-
stantially higher doses than indicated). Three reports were no ADRs (product
exposure during pregnancy, administration failure). Of 36 cases involving
isolated reports of varying symptoms not covered by the known product
safety proﬁle, causality to the product was established for only 1 case (light-
headedness and dizziness). According to the Council for International Organ-
izations of Medical Sciences criteria, the overall ADR reporting rate for
human pasteurized C1-INH concentrate is “rare”.
Conclusions: Human pasteurized C1-INH concentrate has a well-established
safety proﬁle based on 26 years of post-marketing experience with more than
550,000 treatments. The product is safe and well tolerated when used at the
recommended dosage in the treatment of acute HAE attacks.
454
Efﬁcacy of Icatibant Versus Fresh Frozen Plasma for Attacks of
Hereditary Angioedema: Analysis of Indivudual Symptoms by
Attack Site
Alicia Lara, MD,1 and M Esthela Hernandez, M.E.Mondragon, MD2. 1Aler-
gia e Inmunlogia Clinica, UMAE 25, Centro Medico Nacional del Noreste.
IMSS, Monterrey N.L., Mexico; 2IMSS, Veracruz, Mexico.
Background: Hereditary angioedema (HAE) is a rare disorder characterized
by funcional deﬁciency of C1 inhibitor (C1-INH) resulting in unpredictable,
acute swelling attacks at varied locations. Icatibant, a selective bradikinin B2
receptor antagonist, is a novel treatment for acute attacks of HAE. The aim of
the present study was to compare the efﬁcacy beteween icatibant and fresh
frozen plasma (FFP) in the acute attacks of HAE.
Methods: We performed a retrospective analysis of acute attacks of HAE in
a tertiary hospital. We compared the efﬁcacy of icatibant with fresh frozen
plasma as control group. Efﬁcacy was measured as the median time to onset
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of symptoms relief and the improvement of HAE and the median time to end
of the attacks. Safety was assessed in terms of adverse events. All participants
gave written informed consent.
Results: There were 21 acute attacks, 14 for icatibant and 7 for FFP. The
median time to onset of symptoms relief was 27 and 45 minutes for icatibant
and FFP respectively (P ¼ 0.106). The median time to complete resolution of
all simptoms was 240 and 2880 minutes respectively for icatibant and FFP (P
¼ 0.002). All patients with Icatibant experienced generally mild transient
injection-site reactions (erythema and swelling, and pain) wich resolved spon-
taneously without intervention. No drug-related serious adverse events were
observed with icatibant and administration of FFP was not associated with
infections of human inmunodeﬁciency virus, or hepatitis virus.
Conclusions: Icatibant was effective and generally well tolerated, providing
rapid regression of symptoms associated with acute HAE attacks at all
anatomic sites.
REFERENCES
1. Zuraw BL. Hereditary Angiedema. N Engl J Med. 2008;359:1027–1036.
2. Icatibant Cicardi M. A New Bradykinin-Receptor Antagonist, in Hered-
itary Angioedema. N Engl J Med. 2010;363:532–541.
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Characterization of the Factors Triggering an Edematous Attack
in Hereditary Angioedema
Zsuzsanna Zotter, Dorottya Csuka, PhD, Erika Szabó, MD, George
FustDSc, MD, PhD, Lilian Varga, PhD, and Henriette FarkasDSc, MD, PhD.
3rd Department of Internal Medicine, Semmelweis University, Budapest,
Hungary.
Background: Hereditary angioedema due to C1-inhibitor deﬁciency (HAE-
C1-INH) is characterized by recurrent attacks of subcutaneous and/or
submucosal edema. The mechanisms involved in the development of
edematous attacks are being researched extensively and thus, abundant
information is available. By contrast, only a few surveys have been conducted
on the triggering factors of attacks.
Methods: Data recorded between 2004 and 2010 by 97 HAE patients in their
diaries have been analyzed.
Results: Eighty-nine of these 97 patients could identify possible factors,
potentially related to the onset of attacks. Events associated with an increased
propensity for having an attack were physical exertion in 64, mental stress in
53, and mechanical trauma in 53 of these patients. The average number of
triggering factors recognized by patients was 2.7 in males and 4 in females.
Based on the records of patient diaries, 3176 attacks were diagnosed and
patients could identify the triggering factor in 30 per cent of these. The
leading provoking factor was mental stress (21%). Analyzing interim
distribution during a year showed a higher-than-average number of attacks
in March, May, October, and December in almost all the 7 years studied.
Clustering of the attacks in March was particularly typical of males and of
attacks with an unknown provoking factor. Attacks triggered by stress
clustered in the spring and in the autumn. Examining the trigger factors based
on the location revealed different patterns among the trigger factors.
Conclusions: According to our results, 92% of patients can identify a factor
that triggers an attack – this proportion is higher than that published in the
literature. It is important to explore triggering factors, because avoiding these
may reduce the number of apparent attacks. Physical exertion was the most
common provoking factor. A possible triggering factor could be identiﬁed in
almost one-third of the attacks. The seasonal clustering of stress-induced
attacks shows similarity with the acute exacerbations of psychosomatic dis-
orders. This suggests that psychological support may positively inﬂuence the
course of the disease.
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Hereditary Angioedema: Report of TenMexican Patients atWest
National Medical Center in Guadalajara City
Ileana Madrigal, MD. UMAE-HECMNO-IMSS, Guadalajara, Jalisco, Mexico.
Background: Hereditary angioedema (HAE) is an autosomal dominant
inherited condition characterized by swelling of the skin, subcutaneous tissue,
and the walls of almost all organs, including upper respiratory and
gastrointestinal systems. The aim of this paper is to show the medical
community clinical characteristics of 10 Mexican patients with HAE.
Methods:We reviewed medical records of 10 patients with hereditary angioedema.
Results: All are women, mean age 36 years; 4 of them with C4 0 mg/dL and
the rest with serum levels less than 7 mg/dL. In all patients, C1 INH was
determined quantitatively with low serum levels. It was also carried out
qualitative determination of C1 INH with negative results in all patients. In 1
patient it was diagnosed also systemic lupus erythematosus.
Conclusions: All patients presented here have HAE type I and the diagnosis
was made according to the criteria deﬁned by Cicardi Zingale. They have
been long-term treated with danazol with different response, dose range of
100 to 400 mg daily, depending of clinical response in each patient. In only 2
of them was used a selective bradykinin B2 receptor antagonist icatibant with
good response.
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Clinical Features and Outcome of 82 Patients with
Hereditary Angioedema
Fabricio Loffredo D’Ottaviano, MD, Pedro Giavina-Bianchi, MD, PhD,
Antonio Abilio Motta, MD, PhD, and Marcelo Vivolo Aun, MD. Clini-
cal Immunology and Allergy, University of Sao Paulo, Sao Paulo, Brazil.
Background: Hereditary angioedema due to C1 inhibitor deﬁciency is
clinically characterized by relapsing skin and mucosal swelling, abdominal
pain and life threatening upper airway obstruction. It still is a disease poor
known by physicians and underdiagnosed.
Methods: We analyzed the clinical features and outcome of patients with
Hereditary Angioedema from the Clinical Immunology and Allergy Division
of University of São Paulo and compared them with literature.
Results: A total of 82 Hereditary Angioedema patients have been studied, 59
female and 23 male, with ages between 9 and 67 years. They belonged to 33
families and usually had begun to present clinical symptoms within the second
decade of life. Diagnosis had been made from 06 months to 59 years after ﬁrst
symptoms. Spontaneous swelling was frequent, but attacks were also pre-
cipitated by trauma, pressure and emotional stress. Skin swellings were
presented in 77 patients and abdominal pain attacks were related by 56 patients.
Respiratory symptoms were experienced by 45 patients, 31 of them presented
laringeal edema. Low levels of C4 had been noticed in all patients. Ninety
percent of the patients presented quantitative deﬁciency. Prophylactic treatment
with attenuated androgens was administered in low doses to 50 patients and was
totally effective in 45, without signiﬁcant side effects. Sixteen patients presented
few or none manifestations without prophylactic medications.
Conclusions: The described patients are similar to those reported in literature
and the prophylactic treatment with attenuated androgens has been effective
in controlling manifestations. The diagnosis is still late for some patients.
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Differences of Complement Activation Proﬁle between Type I and
Type II of Hereditary AngioedemaDue to C1-inhibitor Deﬁciency
Dorottya Csuka, PhD, Zsuzsanna Kelemen, MD, Lilian Varga, PhD,
George Füst, MD, PhD, DSc, and Henriette Farkas, III, MD, PhD, DSc.
Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Background: In hereditary angioedema (HAE), diverse mutations in the C1-
inhibitor gene may produce either normal C1-inhibitor protein in insufﬁcient
WAO Journal  February 2012 Abstracts
 2012 World Allergy Organization S145
quantities (HAE type I), or a dysfunctional protein in normal or even
excessive amounts (HAE type II). Previously, we have found strong
association between baseline level of functional C1-inhibitor and severity
of HAE. Our aim was to investigate complement activation products in HAE,
during a follow-up period, and to analyze the relationship between these
products and severity of disease.
Methods: 107 HAE patients (96 HAE type I, 11 type II) and 113 healthy
control subjects were included. C1rC1sC1-INH, C3bBbP, and SC5b-9 levels
were determined using ELISA methods in single EDTA-plasma samples of
controls and in 4 samples from patients taken in 4 subsequent years. Between-
group differences were evaluated with the Mann-Whitney test, and correlations
were calculated using non-parametric Spearman’s correlation coefﬁcients.
Results:Median levels of C1rC1sC1-INH (60 U/mL [40–113] vs 8 U/mL [4–
10]; P , 0.0001) and SC5b-9 (0.6 U/mL [0.4–1.2] vs 1.8[0.9–2.8]; P ,
0.0001) differed between patients and controls. Signiﬁcant differences were
found between HAE type I and type II as regards median C1rC1sC1-INH
level (54 U/mL [33–97] vs 31 U/mL [21–49], P , 0.0001), and in an
opposite manner with C3bBbP median levels (6 U/mL [4–12] vs 10 U/mL
[8–17], P ¼ 0.0002). Level of C1rC1sC1-INH correlated with the number of
attacks (r ¼ 0.3546, P ¼ 0.0004) in HAE type I, but not in HAE type II.
Dividing the patients into 2 subgroups based on danazol therapy, signiﬁcant
association (r ¼ 0.3705, P ¼ 0.0026) was found between level of C1rC1sC1-
INH and annual attack number only in patients not treated with danazol.
Similar results were found as regards the number of C1-inhibitor vials ad-
ministered, which correlated with the level of C1rC1sC1-INH only in HAE
type I (r ¼ 0.4288, P , 0.0001) and in patients not treated with danazol (r ¼
0.4783, P , 0.0001).
Conclusions: Monitoring the level of C1rC1sC1-INH is mostly informative
in HAE type I patients, who are not treated with danazol. No correlation was
found in HAE type II patients between level of C1rC1sC1-INH and disease
severity markers. As this observation may be explained by the small number
of HAE type II patients, multicenter studies are needed, including more HAE
type II patients.
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Peculiarities of HIV-speciﬁc Immune Response in
Discordant Couples
Evgenia Zhukova,1 Alexander Pronin, MD,2 Grigory Kaminsky, MD,2
Georgy Gudima,3 and Igor Sidorovich4. 1Clinical Department, Moscow re-
gional Center of AIDS and Infectious Diseases Prevention and Treatment,
Moscow, Russia; 2Moscow regional Center of AIDS and Infectious Diseases
Prevention and Treatment, Moscow, Russia; 3Laboratory of Physiology of
Immunity and Allergy, Institute of Immunology, Moscow, Russia; 4AIDS
Immunobiology Department, Institute of Immunology, Moscow, Russia.
Background: In HIV discordant couples (one parther is HIV-infected,
another is HIV-uninfected) HIV-negative partners often remain uninfected for
a long time despite long, stable, often unprotected sexual contacts with HIV-
infected partner. The increase of time of living together accompanying the
decrease of the incidence of HIV infection in HIV-negative partner. The
features of HIV-speciﬁc immune response in HIV discorgant couples was
investigated.
Methods: Thirty-three HIV discordant couples from Moscow region living
together,1 year (2 couples), 1 to 3 years (18 couples), 4 to 5 years (9 couples),
6 to 10 years (4 couples) were included in the investigation. Sera of 33 HIV-
uninfected partners from HIV discordant couples (17 men and 16 women) were
tested for HIV-speciﬁc antibodies by enzyme immunoassay and immunoblot.
Viral load was estimated by polymerase chain reaction (PCR).
Results: Antibodies against HIV gp160 were detected in 3 persons (9,1%),
against p68/66din 3 persons (9,1%), against p52/51din 3 persons (9,1%),
against g34/31din 3 persons (9,1%); totaldin 6 persons (18,2%). All of
them were deﬁned as HIV-uninfected by PCR. In 4 of 6 persons HIV-speciﬁc
antibodies were not detected after ﬁnishing of risk behavior.
Conclusions: It is possible to suggest that detected antibodies against HIV
gp160, p68/66, p52/51, p34/31 in HIV-uninfected people are caused by
contact with HIV (according to literature data, non-speciﬁc stimulation may
cause the appearance of antibodies binding the other HIV antigens: p55, p24/
25 and g18) and may contribute to maintainance of HIV-negative status of
uninfected partners in HIV-discordant couples. The cohort of high exposed
but HIV-uninfected people was formed during immunological monitoring of
HIV discordant couples in Moscow region. This cohort is available for
systematic observation and is perspective for further investigation of
mechanisms of resistance to HIV infection and correlates of immune
protection. Now the cohort is expanded.
HIV-RELATED PROBLEMS
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Detection of Dengue Virus in HIV-1-infected Patients during the
Epidemic in 2009 in Colima, Mexico
Uriel A. López-Lemus, MS,1,2 Salvador Valle-Reyes, BS,1 Rodolfo Ochoa-
Jiménez, MD, MS,3 Ivan Delgado-Enciso, PhD,1 Clemente Vásquez-
Jiménez, MD, PhD,2 and Francisco Espinoza-Gómez, MD, PhD1. 1School
of Medicine, and; 2Center for Biomedical Research, University of Colima,
Colima, Mexico; 3Internal Medicine Department, Regional Hospital of
Colima, Colima, Mexico.
Background: This study reports a case series of HIV-1-infected patients that
had dengue infection during the outbreak in 2009 in Colima, Mexico and it
analyzes the effect of the interaction in relation to the progression of HIV
disease.
Methods: Whole blood samples from 22 HIV-1-infected patients who were
suspected to have dengue infection were analyzed. The diagnosis of dengue
infection was conﬁrmed through the detection of NS1 antigen using SD
Bioline Dengue Duo Rapid Test. Dengue virus serotype was determined by
RT-PCR technique. Amplicons were cloned and submitted for automated
sequencing for both strands. Comparison of the sequences with all of those
published in GenBank (NCBI) was done using Blast Software. Written
informed consent was obtained under the protocol approved by the Ethical
Review Committee of the Center for Biomedical Research, University of
Colima.
Results: We tested 22 whole blood samples from HIV-1-infected patients in
our laboratory, and 7 were positive for Dengue virus type 1. Two strains of
DEN1 were identiﬁed in these infections. The strains were DENV-1/MX/
BID-V3664/2006 (GenBank: GQ868499) and DENV-1/MX/BID-V3744/
2008 (GenBank: GQ868529) with a similarity of 99% each. CD41 cells
remained at normal levels and it was not observed an accelerated progression
of HIV disease.
Conclusions: This is the ﬁfth and largest report dealing with a coinfection
among HIV and Dengue virus in the world, and the ﬁrst report documented in
Mexico. The lack of complications associated with this interaction suggests
that this combination is relatively benign. Little has been documented about
the interaction among these pathogens and further research is needed to
understand the biology of HIV reproduction in the context of coinfection with
Dengue virus. Furthermore, this report supports the circulation of multiple
genetic variations of DEN1 in hyperendemic areas which may complicate the
epidemiological panorama of the disease in those areas.
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HPV, HSV2, HIV AND Chlamydia Trachomatis Infections as
a Potential Accompanying Factor for Immunodeﬁciency and
Development of Allergic Processes. Final Results
Katarzyna Markiewicz, PhD. Clinical Immunology, Institute of Mother and
Child, Warsaw, Poland.
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Background: Infections caused by various microbes may induce immuno-
deﬁciency and allergies.
Methods: Clinical and laboratory tests were conducted on 579 potentially
healthy people (172 women and 407 men, between 25 and 30 years),
performed twice: in a diagnosis and after 6 to 12 months. Lymphocytes and
NK cells from peripheral blood were assessed using cytometry. G, A, M
immunoglobulin concentrations were determined by the turbidimetry. IgE
concentration was measured by ELFA. HSV2, HIV and Chlamydia tracho-
matis infections were detected on the basis of presence of IgM and IgG
antibodies tested by ELISA. For the assessment of HPV infections, DNA
from the urinary-tract, squamous, and epithelial cells was tested through
PCR. The statistical analysis was undertaken using regression analyses.
Results: In 579 people in the case of 65 people HPV infections were
conﬁrmed 10% men, 14.8% women. In 65 patients, in 1 case concentration of
IgA was decreased, in 7 cases IgM. In 21 cases, there were higher
concentrations of IgE. During the cytometric analyses a decreased number
of T CD31 was found in 3 cases, BCD191 in 5, TCD41 in 5, T CD81 in 4,
and NK cells in 8 cases. The check for HSV2 was positive for 17 people:
1.5% men, 6.4% women. In this group in 3 cases the concentration of IgA
was decreased; in 2 cases IgM was lowered, in 4 cases there were higher
concentrations of IgE. Decreased number of lymphocytes CD191 was ob-
served for 1 person and for 1 person NK cells. Chlamydia trachomatis infec-
tions were positive in 10 cases: 1.5% men, 2.3% women; in this group 1
person had lower IgA and 2 persons had increased concentrations of IgE. HIV
infection was negative for all the groups. The examination was repeated for
171 out of 579 people after 6 months. HPV infections were positive in 12.9%
cases: 14.9% men, 10.8% women; HSV2 in 11 persons: 2.3% men, 10.7%
women; Chlamydia trachomatis in 4 cases: 2.3% men 2.4% women.
Conclusions: No signiﬁcant correlation was observed between HPV, HSV2,
HIV and Chlamydia trachomatis infections and a relevant deviation from the
norm of the investigated immunological parameters.
HYMENOPTERA ALLERGY
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When Honeybees Attack: Adrenal Insufﬁciency as a Late
Consequence of Massive Exposure
David Robinson, MD. Asthma, Allergy and Clinical Immunology, Virginia
Mason Medical Center, Seattle, WA.
Background: Evaluations of massive envenomation events have not
commonly shown an increased risk for adrenal insufﬁciency.
Methods: A 77 year old woman and her 80 year old husband live part of the
year in Bolovia where they have kept hives of Africanized honey bees for
many years. Neither of them had shown evidence of bee sting hypersensi-
tivity in the past. While tending their hives in a remote area, both were
exposed to a massive number of stings (he . 600, she . 200) and barely
survived. They are both wondering if they have become sensitized as a result
of this event. After discharge from the hospital in Bolivia, she began to
experience lethargy and was hospitalized again in Seattle with nausea, vomit-
ting and eosinophilia. Abdominal CT scans showed bilateral adrenal enlarge-
ment/masses. Medline, PubMed and Google Scholar searches were performed
looking for reports of adrenal insufﬁciency and bee sting anaphylaxis/
exposure.
Results: Evaluation showed evidence of adrenal insufﬁciency and she has
responded to replacement therapy. Subsequent abdominal CT scans have
shown shrinkage and involution of both adrenal glands. Both husband and
wife were evaluated for stinging insect hypersensitivity and found to be
allergic only to honey bee venom and have begun desensitization. They
intend to continue to keep honey bees in Seattle but not in Bolivia.
Conclusions: A single publication of 3 autopsy studies (Huang, I et al, JACI
1971) looking at venom-speciﬁc IgE in tissues showed intense localization in
the serum and myocardium in 3 of 3 subjects and adrenal glands in 2 of 3
subjects all of whom died following a single honey bee sting. This would
suggest that adrenal insufﬁciency may be a delayed complication of near-fatal
massive envenomation and may play a role in immediate fatal events.
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Efﬁcacy of Immunotherapy With Allergenic Extract of Aedes
Aegypti in the Treatment of Large Local Reaction to Mosquito
Bites in Children
Maria Amelia Manrique,MD, Sandra González-Díaz,MD, PhD, Alfredo Arias-
Cruz, MD, Marisela Hernandez, MD, Claudia Gallego, MD, Diego Garcia-
Calderin, MD, Karla Mejia, MD, Maricruz Calva, MD, and Luis Dominguez,
MD. Regional Centre of Allergy and Clinical Immunology, University Hospital,
Monterrey, Mexico.
Background: Allergic reactions to insects are a global problem. The
objective of this study was to assess the efﬁcacy of immunotherapy with
allergenic extract of Aedes aegypti for the treatment of large local reactions
(LLR) to mosquito bites in children.
Methods: Experimental, comparative, prospective, longitudinal and random-
ized none blinded study was conducted. We included 2 to 15 year old
children with a history of large local reactions to mosquito bites. Sensitization
was conﬁrmed by a positive prick test. One group was treated with
subcutaneous immunotherapy with extract of Aedes aegypti during 5 months
and a second group received only antihistamine as needed. Diary symptoms
and medication use were recorded in each case. The presence of adverse
reactions to immunotherapy was also documented.
Results: A total of 35 patients from August 2009 to September 2010.
Twenty-eight patients completed the study (16 male were included, with
mean 7 6 2.5 years) 15 in the immunotherapy group and 13 in the control
group. The immunotherapy group showed a decrease in the diameter of
the wheal and ﬂare as well as the duration of the reaction and the use
of drugs, from the third month of treatment, compared with the control group
(P , 0.001).
Conclusions: Our results suggest that immunotherapy with extract of Aedes
aegypti, could modify the natural history of LLR to mosquito bites in chil-
dren. Additional studies are needed to determine the optimal length treatment
of the scheme and its long-term effects.
REFERENCES
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tice parameter update. J Allergy Clin Immunol. 2004;114:869–867.
2. Golden D, Kelly D, Hamilton R, Craig T. Venom immunotherapy reduces
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Speciﬁc Venom Ige Decrease during 5 Years of Venom
Immunotherapy (VIT): Clinical Relevance in Stung and Not
Stung Patients
Valerio Pravettoni, MD,1 Marta Piantanida, MD,1 Laura Primavesi, PhD,1
and Stella Fortic, BSc2. 1Clinical Allergy and Immunology Unit; 2Audiology
Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan,
Italy.
Background: As the question of how long VIT should last in order to
provide long-term protection is a long-standing issue, we evaluated the
speciﬁc venom IgE decrease throughout 5-years-long VIT in 3 groups of
yellow jacket (YJ) venom-allergic patients: stung during the ﬁrst 3 years of
VIT (SP3), during the last 2 years (SP5) and patients not stung (NS).
Methods:We retrospectively evaluated 232 patients submitted to 5-year-long
VIT. Speciﬁc venom IgE levels were determined at the baseline, after 3 and 5
years of VIT (CAP method, Phadia, Italy). All stung patients were clinically
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protected. ANOVA analysis evaluated differences among CAPs and in each
CAP value among the 3 groups. MANOVA multivariate analysis evaluated
differences in overall CAPs and the effects of age, gender, Mueller grade and
stings number. A P , 0.05 was considered statistically signiﬁcant. Data were
analysed by ‘SPSS’ 13.0 (SPSS Inc., Chicago, IL). We called NS patients to
check if they were stung after VIT discontinuation.
Results: We selected 84 NS, 72 SP3 and 76 SP5 patients. Speciﬁc YJ-IgE
levels decreased during VIT, as CAPs are statistically different at time 0, 3
and 5 (P , 0.001). Considering CAP levels at the ﬁrst control (CAP3), NS
patients presented lower values than SP3 patients (P ¼ 0.002); no signiﬁcant
difference was found between NS and SP5 patients. At the last control
(CAP5), CAP values of NS and SP5 patients were different (P ¼ 0.002) as
well as between SP3 and SP5 patients (P ¼ 0.014). No signiﬁcant difference
was found between NS and SP3 patients. By MANOVA, IgE decrease was
inversely correlated with Mueller grade (P ¼ 0.012) and age (P ¼ 0.002). We
recalled all NS patients by phone, 7/84 (8.3%) patients related one well
tolerated sting, as they did not develop any allergic reaction.
Conclusions: In everyday practice if a patient never stung during VIT fulﬁls
the temporal criterion, but speciﬁc IgE are not negative, a decrease of IgE
levels ranging from 57 to 70% in respect to baseline might be a satisfactory
parameter for stopping VIT. As a further conﬁrmation of our conclusions,
even if not statistically signiﬁcant, all not stung patients were clinically
protected after VIT discontinuation.
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Skeeter Syndrome, a Case Report and Literature Review
Diego Garcia-Calderin,MD,1 Sandra González-Díaz,MD, PhD,1 Alfredo Arias-
Cruz,MD,1,2 Alejandra Macías-Weinmann,1 Jose Antonio Buenﬁl-Lopez,MD,3
Maricruz Calva, MD,1 Karla Mejia, MD,1 Luis Dominguez, MD,1
and Claudia Gallego,MD4. 1Regional Centre of Allergy and Clinical Immunol-
ogy, University Hospital, Monterrey, Mexico; 2Allergy and Clinical Immunol-
ogy, University Hospital UANL, Monterrey, Mexico; 3University Hospital,
Monterrey, Mexico; 4Regional Center of Allergy and Clinical Immunology,
University Hospital, Monterrey, Mexico.
Background: The worldwide prevalence of allergic reaction to mosquito
bites is unknown. Some patients who suffer from local reactions have also
systemic symptoms.
Methods: A 3 year old female who suffered from mosquitoes bites in her left
lower extremity, had a large local reaction with erythema, edema, itching,
pain and blisters of 5 · 6 cm. It was accompanied by fever of 38.58C and
emesis. She had a positive skin prick test for Aedes aegypti with diagnosis of
Skeeter Syndrome. The patient was treated with antihistamine during 10 days
and analgesics for 3 days. She was given antihistamine treatment for 10 days
and analgesics for 3 days.
Results: Skeeter syndrome is deﬁned as a large local reaction induced by
mosquito bites associated with systemic symptoms (fever and vomiting) with
speciﬁc IgE for mosquito identiﬁed by skin testing. The primary management
of Skeeter syndrome is prevention of mosquito bites, the use of repellents and
protective clothing. It is also important the symptomatic management control
of pruritus with the use of antihistamines or if necessary topical steroids.
Overall children with Skeeter syndrome remain healthy, except for the
recurrence of large local reactions to mosquito Stings.
Conclusions: The early recognition of Skeeter syndrome is important to give
the right management and to prevent unnecessary diagnostic tests and
treatments that can increase the risk of adverse reactions and costs.
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Bee venom Immunotherapywith StandardizedExtract, TwoCase
Comunication and Clinical Progress
Aristoteles Alvarez Cardona, MD,1 Leticia Hernandez Nieto, MD,2 and
Alvaro Pedroza Melendez, MD2. 1Allergy and Clinical Immunology, Star
Medica Aguascalientes, Aguascalientes, Mexico; 2Allergy and Clinical Im-
munology, Instituto Nacional de Pediatria, Mexico DF. 04530, Mexico.
Background: Bee venom immunotherapy is a safe and effective treatment,
indicated in patients with previous history of severe systemic reactions to bee
venom, demonstrating succesful desensitization in more than 90% of cases
with standardized extract. Currently in Mexico there is no standardized
extract commercially available for treatment, despite of having high activity
of beekeeping and occupational exposure with at least 17,478 registered
stings per year and an annually honey production of nearly 70 tons.
Methods:We present the clinical progress of 2 patients with history of severe
systemic reactions to bee venom and occupational exposure, both with
demonstrated sensitization by speciﬁc IgE and who underwent speciﬁc
immunotherapy with standardized extract (Alk-US) reaching a maintenance
weekly dose of 100 mcg (PLA2) for the last 4 years.
Results: Both patients sufered of accidental stings after reached the
maintenance dose presenting mild local reactions to stings. Both patients
had very different clinical course presenting a wide variety of adverse
reactions during desensitization protocol; from mild local to generalized
reactions all generally well tolerated allowed to reach the maintenance dose
with succesful desensitization proved by accidental exposure without severe
systemic reactions.
Conclusions: Bee venom speciﬁc immunotherapy with standardized extract
is a well tolerated and efective treatment preventing the development of life
threathening reactions in sensitized patients. It is important to promote the use
and availability of standardized extract in developing countries with poor
safety measures and high occupational exposure.
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Clinical Case. Bee Venom Anaphylaxis
Adriana Barreto-Sosa, MD, Andrea Aida Velasco-Medina, MD, Andres-
Leonardo Burbano-Ceron, MD, Aida Gonzalez-Carsolio, MD, and
Guillermo Velázquez-Sámano, MD. Servicio de Alergia e Inmunología
Clínica, Hospital General de México, Mexico City, Mexico.
Background: Skin testing remains the principal conﬁrmatory test for
sensitization to hymenopteravenoms. Mechanisms on how venom induces
vascular permeability in the skinfollowing intradermal testing are elucidated
and how tolerance is induced followinghigh-dose venom exposure. For
management, venom immunotherapy remains the mosteffective treatment.
Use of immunotherapy in large local reactors to reduce morbidity is
discussed. Baseline serum tryptase levels have been identiﬁed as one potential
markerfor severe systemic reactions to a subsequent sting. Bee venom
immunotherapy is effective in most patients immediately after the conven-
tionalmaintenance dose has been reached. In the minority of patients who are
not protected withthis dose, an increased maintenance dose will provide
appropriate protection immediately after itis achieved usually by 3 to 6
months withstandarding protocols. Thus, the dosage of the maintenance dose
seems to be the major factor affectingprotection from re-stings rather than the
accumulated venom dose or the durationon the Maintenance Dose. A rush
protocol would be recommendedif the patient’s risk of being stung againbe-
fore standard immunotherapy could work wereconsidered high. Although
immunotherapy is oftenadministered by allergists, it may be deliveredby
any practitioner who is willing to observe the patientand to treat anaphylaxis
if it should occur.
Methods: A 17-year-old man reported being stung by a bee in his workplace.
He had been stung several times before, with no clinical manifestations. This
last time, he developed face edema, respiratory distress, dyspnea, vomiting
recieveing treatment with hydrocortisone. Some time later, he was stung
another time, presenting more severe symptoms including dyspnea, stridor,
altered mental status, hives, so he was taken to a local clinic where he
received epinephrine, dextrose, was hospitalized 4 hours until clinical
remission. How should his case be managed subsequently?
Results: Intradermal test was positive with a dilution 1:200000.
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Conclusions: For patients with a clear history of anaphylaxis such as the one
described in the vignette, information should be provided on avoidance and
on the use of emergency treatment with epinephrine auto-injectors. Patients
should be advised to carry an auto-injector and to wear a medical alert
bracelet.
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Urticarial Vasculitis After Bee-sting Therapy
June-Hyuk Lee,1 Sung Woo Park,2 An-Soo Jang,1 DoJin Kim,1 and Choon-
Sik Park1. 1Respiratory and allergy, Soonchunhyang University Bucheon
Hospital, Bucheon, South Korea; 2Division of Respiratory and Allergy Med-
icine, Soonchunhyang University Hospital, College of Medicine, Bucheon,
South Korea.
Background: Bee-sting therapy is one of the oriental traditional medical
therapies. Some chemical components of bee venom have been known to
have anti-inﬂammatory effects. Recently, traditional therapists use one
chemical component (e.g. Apitoxin) for injection therapy using a syringe,
instead of sting method with bee itself as to be known traditional method. 31-
year-old woman had a lower back pain because of mild HIVD in lumbar
spine for 5 months. She had bee-sting therapies for several times for 4
months. During this period, she didn’t have any side effects and pain was
improved. Her back pain recurred 4 weeks ago and had bee-sting therapy
again. The traditional doctor performed intramuscular injections of 1 mL of
Apitoxin on her lower back muscle. After 4 days, reddish skin lesions and
swelling developed on her legs and spread to trunk. She was transferred and
treated with systemic corticosteroid and antihistamine.
Methods: Serum speiciﬁc IgE and IgG were measured by immunoCAP for
and skin biopsy performed accompanied with managements.
Results: High levels of speciﬁc IgG but negative of IgE to honey bee venom
were observed by immunoCAP. Skin biopsy was revealed as an urticarial
vasculitis.
Conclusions: We report the case that suspicous to be serum sickness
developed after bee-sting therapy.
IGE
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Levels of IL-4, INF-&GAMMA; Total IGE and IGG4 in Serum of
Allergic Children within Areas of Risk of Lead Exposure in
Torreon Coahuila, Mexico
Karen Giselle Chavez Villarreal,1 Jahzeel Avila Hernandez,1
Raquel Concepción Goytia Acevedo, PhD,2 Rocio Meza Velazquez,
PhD,2 Mario Rivera Guillen, PhD,3 Michelle Gomez Jurado,1 Guadalupe
García-Arenas, PhD,1 and Aurora Maravilla-Domínguez, MD1. 1Investigation
Department, Facultad de Medicina UJED Gómez Palacio, Gómez Palacio
Durango, Mexico; 2Investigation Department, Universidad Juárez Del
Estado De Durango, Gómez Palacio, Durango, Mexico; 3Dirección, Centro
de Atención A Metales Pesados, Torreón Coahuila, Mexico.
Background: There are precedents to suggest that lead exposure may
increase the severity of allergic disease in children. In Torreon Coahuila is
known the problem of lead contamination and its association with the body
burden in children. The aim of this study was to evaluate clinical and
biochemical characteristics of allergic disease in children living in areas at
risk of lead exposure.
Methods: We included children between 6 and 11 years old with clinical
diagnosis of allergy, who were attending by allergic consultation in the Center
of attention Heavy Metals in Torreon, Coahuila, Mexico. Medical evaluation
was performed following the diagnostic criteria described by ARIA, Global
Initiative for Asthma and the Haniﬁn and Rajka criteria for atopic dermatitis.
Skin tests were applied to 47 common allergens in the region. Were quantiﬁed
in serum, the levels of IL-4, IFN-g and IgG4 by ELISA, total IgE levels by
chemiluminescence and lead in blood by spectrophotometry AA.
Results: We present the results of 33 patients (16 girls/17 boys) aged 8 6
1.38. The main risk factors for allergy were current animal contact (66.7%),
past animal exposure (60.6%) and passive smoking (51.5%). The predomi-
nant allergy diseases: rhinitis (97%), conjunctivitis (43.8%) and atopic der-
matitis (33.3%). The allergens with the higher prevalence of responses were:
thickets (91.2%) and grass (88.2%). The average blood lead level was 4.36
mg/dL 6 2.13 and median total IgE 660 IU/mL. We present the analysis of
the levels of cytokines, total IgE and IgG4 according to the types of allergy,
severity and frequency of the disease.
Conclusions: IgE levels according to the type of allergic disease, severity and
frequency seem to be related to the balance IL-4/INF g. The IgG4 seems to be
positively related to total IgE levels in rhinitis, conjunctivitis and dermatitis
and negatively with Asthma and other allergies. No association was found
between blood lead levels and total IgE.
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Relationship of Blood Lead Levels with Total Ige in Teenagers
with Environmental Exposure in Torreon Coahuila, Mexico
Rocío Meza-Velazquez, MD,1 Raquel Concepción Goytia Acevedo, PhD,1
Guadalupe García-Arenas, PhD,1 Emma S. Calderon Aranda, PhD,2
Manuel Rosales Gonzalez, PhD,1 Marisela Rubio-Andrade, MD,1 Aurora
Maravilla-Domínguez, MD,1 Mariano Enrique Cebrian, PhD,3 Jorge Luis
Rosado, PhD,4 Rebeca Stoltzfus, PhD,5 and Gonzalo Gerardo García
Vargas, PhD1. 1Investigacion, Universidad Juarez del Estado de Durango, Gomez
Palacio, Dgo, Mexico; 2Toxicologia, CINVESTAV-Mexico, D.F., Mexico;
3Toxicologia, Centro de Investigación y de Estudios Avanzados del IPN,
DF, Mexico; 4Facultad de Ciencias Naturales, Universidad Autónoma de
Querétaro, Queretaro, Mexico; 5Division of Nutritional Sciences, Cornell
University, Ithaca, NY.
Background: There are precedents that suggest gender differences in the
relationship of lead in blood with serum total IgE. The aim of this study was
to evaluate in a population of teenagers attending 9 schools in Torreon,
Coahuila, the relationship of lead in blood with total IgE and their
dependence on gender.
Methods: We included 230 teenagers (105 females, 125 males) between 11
and 14 years of age, from a cohort of children evaluated for its history of lead
exposure since 2000. Clinical diagnosis was performed to detect allergies;
skin tests were applied for 47 common allergens in the region. IgE levels were
quantiﬁed in serum by chemiluminescence and the blood lead levels by
spectrophotometry AAS.
Results: The average blood lead levels in allergic group were of 4.86 6 2.9
mg/dL and in the non-allergic group 5.1 6 2.7 mg/dL. There were not gender
differences between allergic group versus non allergic group, however,
among the types of allergic diseases, a higher percentage of males had rhi-
nitis, conjunctivitis and asthma, compared with the females. The blood lead
level in males was signiﬁcantly higher (5.61 6 3.3 mg/dL) compared with
females (4.22 6 2.1 mg/dL) and the regression analysis between blood lead
levels with total IgE was signiﬁcant in males and not in females.
Conclusions: Gender differences observed appear to be explained by blood
lead levels, however, we should consider the contribution of other variables in
the model.
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IgE from Birch Pollen Allergic Patients Cross-reacts with Two
Distinct Bet V 1 Related Proteins in Mung Beans: VIG R 1 and
Cytokinin-speciﬁc Binding Protein
Eva Guhslc, MSc,1 Barbara Gepp,1 Gerlinde Hofstetter,1 Nina Balazs,1
Wolfgang Hemmer,2 Heimo Breiteneder, PhD,1 and Christian Radauer, PhD1.
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of Vienna, Vienna, Austria; 2Floridsdorfer Allergiezentrum, Vienna, Austria.
Background:Mung beans (Vigna radiata) contain 2 Bet v 1 related proteins:
Vig r 1, a member of the PR-10 subfamily, and cytokinin-speciﬁc binding
protein (CSBP), a protein with low sequence identity (31%) to Bet v 1. We
aimed to compare Vig r 1 and CSBP to Bet v 1 regarding biochemical and
immunological properties.
Methods: Percent surface identity between Bet v 1, CSBP and Vig r 1 was
calculated based on structural alignments using an algorithm considering
backbone conformations and identities of aligned residues. The allergens
were expressed in Escherichia coli and puriﬁed by metal chelate afﬁnity and
ion exchange chromatography. Secondary structures were compared using
circular dichroism (CD) spectroscopy. Binding and cross-reactivity of IgE
from Bet v 1-sensitized patients’ sera to rCSBP, rVig r 1.0101 and rBet v
1.0101 were examined by ELISA and ELISA inhibition.
Results: Structural comparison of the 3 proteins revealed that 29% of the
solvent-accessible surface area of CSBP was identical to Bet v 1, while Vig r 1
and Bet v 1 shared 50% surface area. In addition, 2 surface patches, conserved
between Bet v 1 and CSBP, were identiﬁed as potential cross-reactive epitopes.
30% and 79% of Bet v 1-sensitized birch pollen allergic patients’ sera (n ¼ 33)
showed IgE binding to CSBP and Vig r 1, respectively. Of 12 Bet v 1-sensitized
patients, who reported reactions or had positive prick-to-prick tests to mung
bean sprouts, 10 showed IgE binding to Vig r 1 and 7 to CSBP. Bet v 1
completely inhibited IgE binding to CSBP and Vig r 1. Furthermore, CSBP
showed inhibitory activity on IgE binding to Vig r 1 and vice versa.
Conclusions: This study demonstrates IgE cross-reactivity between Bet v 1
and CSBP, despite their low sequence identity. In addition to Vig r 1, a PR-10
subfamily member, IgE binding to CSBP might contribute to allergic
reactions in mung bean sprouts.
The study was supported by grants P-B11 (CR) and SFB-01802 (HB) from
the Austrian Science Fund.
472
Heterogeneity of the Ige Response to Allergenic Determinants of
Cefotiam in SerumSamples FromPatientswithCefotiam-induced
Occupational Allergy
Jeong-Eun Kim,1 Soo-Keol Lee, MD, PhD,2 Seung-Hyun Kim,3 Hyun-
Jung Jin, MD,3 Young-Hee Nam, MD,3 Young-Min Ye,3 and Hae-
Sim Park, MD, PhD3. 1Department of Internal Medicine, Samsung Chang-
won Hospital, Sungkyunkwan University School of Medicine, Changwon,
South Korea; 2Internal Medicine, College of Medicine, Dong-A University,
Busan, South Korea; 3Department of Allergy & Clinical Immunology, Ajou
University School of Medicine, Suwon, South Korea.
Background: Exposure to cefotiam could cause IgE-mediated occupational
allergies in hospital personnel. However, the clinically available serologic test
has not been widely accepted, and the antigenic determinant of this drug is
unclear. We investigated patterns of the IgE response to cefotiam in patients
with occupational allergies to cefotiam.
Methods: A total of 161 health care workers and 86 nonatopic healthy
controls, never exposed to antibiotics, were recruited from a single tertiary
hospital and the general population. A questionnaire regarding work-
related symptoms associated with cefotiam was administered. Serum
speciﬁc IgE antibodies to cefotiam-human serum albumin (HSA) conju-
gate was measured by enzyme-linked immunosorbent assay (ELISA).
Patients with work-related symptoms to cefotiam and positive speciﬁc IgE
antibody to cefotiam were selected and ELISA inhibition studies were
performed using sera of these patients. The inhibitors included various
concentrations of free and conjugated cefotiam, ceftriaxone, ceftizoxime,
and HSA alone.
Results: Four patients showed work-related upper respiratory symptoms and
high levels of serum speciﬁc IgE to cefotiam-HSA conjugate compared to
controls. Signiﬁcant inhibition patterns to free cefotiam and cefotiam-HSA
conjugate were noted in patient 1 on ELISA inhibition testing, while minimal
inhibitions to the other cephalosporins, both free and conjugated, were noted.
In the other 3 patients, signiﬁcant dose-dependent inhibitions were noted with
additions of cefotiam-HSA conjugate, while minimal inhibitions were noted
with free cefotiam. Among the patients, patient 2 showed minimal inhibitions
with the other cephalosporins, both free and conjugated, while patient 3 and 4
showed marked dose-dependent inhibition with ceftriaxone-HSA and cefti-
zoxime-HSA respectively.
Conclusions: The speciﬁc IgE response to cefotiam-HSA conjugate in
patients with occupational allergies occurs against the hapten or new
allergenic determinant in which heterogeneity of the antigenic determinant
were noted depending on the individual.
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Evaluating Total Serum IgE Levels in Patients with Chronic
Hepatitis B and C
Sükran Köse, MD,1 Süheyla Serin Senger, MD,1 Arzu Didem Yalcin, MD,2
Gülsün Cavdar, MD,1 Sabri Atalay, MD,1 and Gürsel Ersan, MD1. 1Clinic of
Infectious Diseases and Clinical Microbiology, Clinical Allergy and Immu-
nology, Izmir Tepecik Education and Research Hospital, IZMIR, Turkey;
2Allergology and Clinical Immunology Unit, Antalya Education and Training
Hospital, Antalya, Turkey.
Background: Liver disease has been considered a prominent cause of IgE
elevation. Signiﬁcant differences may be observed depending on the cause of
liver damage. For viral hepatitis, increased IgE concentrations have been
observed during acute hepatitis A and B. Chronic hepatitis B carriers may
also have high IgE levels. But no data on serum IgE levels in chronic hepatitis
C and hepatitis B patients have been reported. The aim of the study was to
evaluate serum IgE levels in patients with chronic hepatitis C and hepatitis B
and to corelate with atopic patients.
Methods: Serum IgE levels were determined in 568 adult patients with
chronic hepatitis B, in 47 patients with chronic hepatitis C, and 311 patients
with atopic diseases.
Results: The averages of serum IgE levels were 103,9 IU/mL in chronic
hepatitis C, 95,1 IU/mL in hepatits B patients, and 126,6 IU/mL in atopic
patients. There was no statistically signiﬁcant difference between hepatits B
and hepatits C patients. Total serum IgE levels were lower in patients with
either chronic hepatitis C or hepatitis B than the atopic group.
Conclusions: According to the results presented, chronic hepatitis C and
hepatitis B are not prominent causes of increased serum IgE values. Further
studies are needed to clarify the differences and signiﬁcance of IgE levels
between hepatitis and atopic patients.
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Relationship Between Total Serum IgE, Atopy, and Obesity in
Children With or Without Family History of Atopic Disease
Budi Setiabudiawan, MD, Reni Ghrahani, MD, Gartika Sapartini, MD,
Putria Rayani, MD, Citra Amelinda, MD, and Abdurachman Sukadi.
Department of Child Health, Hasan Sadikin Hospital/School of Medicine
Universitas Padjadjaran, Bandung, Indonesia.
Background: Prevalence of obesity and atopy had been increased simulta-
noeuosly. The relationship between obesity, atopy, and total serum IgE had been
estimated. The aim of this study is to ﬁnd out the relationship between total serum
Ig E, atopy, and obese children with or without family history of atopic disease.
Methods: This was a cross sectional study. There were 160 children aged 6 to
11 years which were divided into 4 groups: obese children with and without
family history of atopic disease and normal weight children with and without
family history of atopic disease. Atopic was deﬁned by positive result of one
of allergens skin prick test and ECLIA method were done for total serum IgE.
Signiﬁcancy for categorical data used Chi-Square test. Logistic regression
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model were used to examine the relationship between obesity, total serum
IgE, and atopy.
Results: We measured the total serum IgE of 155 children. The number of
obese and normal weight children with family history of atopic disease who
had high level of total serum IgE were 30 and 25 respectively, whereas these
children who had normal level of total serum IgE were 6 and 15 respectively
[OR ¼ 1.9 (95% CI 0.9-3.9)]. On the other hand, obese and normal weight
children without family history of atopic disease who had high level of total
serum IgE were 21 and 11 respectively, whereas these children who had
normal level of total serum IgE were 18 and 29 respectively [OR ¼ 1.7
(95% CI 1.1-2.7)]. The number of obese and normal weight children without
family history of atopic disease who had atopy were 38 and 9 respectively,
whereas these children who had non-atopy were 2 and 31 respectively [OR ¼
13.3 (95% CI 3.5-52)], but there was no relationship between atopy and
obesity in group with family history of atopic disease (P ¼ 0.314).
Conclusions: There were relationship between high level of total serum IgE
and obesity in group with and without family history of atopic disease and
also relationship between atopy and obesity in group without family history
of atopic disease.
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The Candidate Peptides in IgE for Allergy Vaccine Design
Gholam Ali Kardar, PhD,1 Tina Shahandashtic, MSc,2 and Ahad Zarec,
MSc1. 1Immunology Asthma & Allergy Research Institute, Tehran University
of Medical Sciences, Tehran, Iran; 2Department of Biology, Science and
Research Branch, Islamic Azad University, Tehran, Iran.
Background: The World Allergy Organization in 2011 estimated that 30 to
40% of the world population is now affected by one or more allergic conditions.
Since the IgE plays a central role in the expansion and regulation of allergic
response that seems the IgE elimination is the best approach in the control of
asthma and allergic diseases. Now, an anti-IgE antibody as a drug (Xolair) is
available and efﬁcient but is expensive with short half-life. As good and more
efﬁcient substitution IgE peptide-based vaccines has been proposed.
Methods: In this study, we analyzed all potential antigenic peptides on the
constant region of the Ig epsilon chain (Fce). For determination of B cell
immunodominant epitope, we used the antibody epitope prediction tools. In
continuing candidate peptides were done BlastP to avoid nonspeciﬁc antibody
reactions with other human proteins in the NCBI database. And then, to
preparation of vaccines, peptides were synthesized and conjugated by Tetanus
toxoid (TT). To immunogenicity analysis of vaccines, the rats are being
immunized with vaccines or TT as control.
Results: By Kolaskar and Tongaonkar antigenicity algorithms 20 peptides
with putative epitopes were selected. Homologous sequences and also
previous studies peptides were excluded, 13 peptides remained that used
for vaccine preparation. The produced vaccines are being analyzed for their
effect on induction of anti-IgE antibody production. Peptides based on
antibody production or not, were divided in 2 groups.
Conclusions: Active immunization by IgE peptide based vaccines can be
triggering production antibodies against self-IgE that are effective in preventing
and control of IgE levels as an important factor in asthma and allergic diseases.
IMMUNODEFICIENCY
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Severe Autoimmunity with Polyarticular Joint Disease Requiring
Anti-TNF Therapy and T1B-NK1 Immunodeﬁciency in
a Family with Small Stature and Intermediate
Radiation Sensitivity
Troy Torgerson, MD, PhD, Hans Ochs, MD, and Jun Lu, MD. Allergy &
Immunology and Rheumatology, University of Washington, Seattle, WA.
Background: We have identiﬁed a family in which 3 of 4 children are
affected with signiﬁcant autoimmunity and immunodeﬁciency that does not
ﬁt any of the known disorders. We have embarked to characterize their defect
and describe a completely new disorder.
Methods: Whole Exome Sequencing, T and B Cell Immunophenotyping,
Radiation Sensitivity, Bacteriophage.
Results: The oldest affected child is female with severe polyarticular arthritis
(treated with etanercept), eczema, diarrhea, short stature and numerous
infections including pneumonia. She is s/p bone marrow transplant using
a matched sibling donor, is fully engrafted and doing well. The second
affected child was also female and had numerous episodes of pneumonia,
bronchiolitis, otitis media and conjunctivitis. She died at 11 months from
presumed fulminant CMV hepatitis. The third affected child is male with
hypothyroidism, chronic diarrhea, alopecia totalis, eczema, multiple food
allergies, reactive airway disease and short stature. All had normal CD41 and
CD81 T cell and NK cell numbers but marked B cell lymphopenia. T cell
immunophenotyping demonstrated a modest decrease in effector memory T
cells. Mitogens were normal. B cell immunophenotyping demonstrated a dra-
matic block in B cell development at the transition from immature to mature
B cells suggesting a defect in immunoglobulin gene rearrangement. All af-
fected patients were hypogammaglobulinemic. Immunization with bacterio-
phage FX174 to more thoroughly evaluate humoral immune responses
demonstrated a poor immunoglobulin response with only modest ampliﬁca-
tion and markedly decreased immunoglobulin class switching. Radiation sen-
sitivity testing using skin ﬁbroblasts was performed and demonstrated an
intermediate radiation sensitivity. Sequencing of the RAG1, RAG2, and Ar-
temis genes was normal. Evaluation via western blotting of other components
of the DNA repair machinery that lead to defective immunoglobulin gene
rearrangement and radiation sensitivity was normal.
Conclusions: The overall clinical and laboratory picture of severe autoim-
munity with a T1B-NK1 phenotype is unusual and does not ﬁt any known
immune defect. The CMV susceptibility suggests that even though T cell
numbers and proliferation are normal, there may be a subtle defect in T cell
function. We are currently in the process of whole exome sequencing and
optimistic we will ﬁnd a novel defect in DNA repair.
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Autoimmunity in Patients with Allergy and Immunodeﬁciency: as
Result of the Immune Chronic Inﬂammation
Julia Mendez-Inocencio, MD,1 and Joseph Bellanti, MD2. 1Clinical Immu-
nology and Allergy, Hospital Angeles Lomas, Huixquilucan Edo de Mexico,
Mexico; 2Immunology Center, Georgetown University Medical Center,
Washington, DC.
Background: Autoimmunity is present in several patients that have allergy
and immunodeﬁciency; however there are few reports that correlate these 3
immunological problems. Our objective was to study the association of these
3 problems where the deregulation of the T reg cells has a roll in triggering
a chronic inﬂammation and the clinical expression.
Methods: We included 8 patients with symptoms of autoimmune disease,
such as autoimmune hypothyroidism, dermatomiositis, systemic vasculitis,
autoimmune uveitis, Wegeners granulomatosis, antiphospholipid syndrome,
Kawasakis disease and SLE with allergic disease and T and B lymphocytes
immunodeﬁciency. We did the clinical history, skin test and also immuno-
logical evaluation with immunoglobulins, IgG subclasses, T lymphocytes
absolute numbers and speciﬁc antibodies, all of them had diagnosis of allergy,
with immunodeﬁciency and autoimmune disease.
Results: There were included 8 patients, with moderate to severe allergy and
recurrent infections, from 3 to 66 years of age, 1 child (12.5%) and 7 adults
(87.5%), 7 women (93.3%), 1 men (12.5%) with allergic rhinitis 8 (100%),
combination of allergic rhinitis and other allergic disease 2 (25%), asthma 1
(12.5%), atopic dermatitis 1 (12.5%). Also all the 8 patients had humoral,
cellular immunodeﬁciency and autoimmune problems, 7 of them received
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IVIG therapy on the basis of the immunodeﬁciency, with evident improve-
ment, 1 did not received and had some improvement of their symptoms.
Conclusions:We found out that the 8 patients with autoimmunity had allergy
and also mixed T and B immunodeﬁciency. We conclude that the physicians
should be aware of the correlation in chronic inﬂammation and the presence
of the 3 immunological clinical problems to give appropriate treatment and
improve the prognosis of these patients.
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HPV, HSV2, HIV AND Chlamydia Trachomatis Infections as
a Potential Accompanying Factor for Immunodeﬁciency and
Development of Allergic Processes. Final Results
Maria Go1ebiowska-Wawrzyniak, MD, PhD,1 Katarzyna Markiewicz, PhD,1
Artur Jakimiuk, MD,2 Maciejewski Tomasz, MD, PhD,3 Agata Kozarc, MS,1
Krzysztof Rytwinski, MD,1 and Zbigniew Wawrzyniak, PhD4. 1Clinical
Immunology, Institute of Mother and Child, Warsaw, Poland; 2Obsterics
and Ginecology Department, Central Clinical Hospital of Ministry of Inte-
rior, Warsaw, Poland; 3Ginecology and Obstetrics Department, Institute of
Mother and Child, Warsaw, Poland; 4Faculty of Health Science, Medical
University of Warsaw, Warsaw, Poland.
Background: Infections caused by various microbes may induce immuno-
deﬁciency and allergies.
Methods: Tests were conducted on 579 potentially healthy people (172
women and 407 men, between 25 and 30 years), performed twice: in
a diagnosis and after 6 to 12 months. Lymphocytes and NK cells from
peripheral blood were assessed using cytometry. G, A, M immunoglobulin
concentrations were determined by the turbidimetry. IgE concentration was
measured by ELFA. HSV2, HIV and Chlamydia trachomatis infections were
detected on the basis of presence of IgM and IgG antibodies tested by ELISA.
For the assessment of HPV infections, DNA from the urinary-tract, squa-
mous, epithelial cells were tested through PCR. The statistical analysis was
undertaken using regression analyses.
Results: In 579 people in the case of 65 people HPV infections were
conﬁrmed 10% men, 14.8% women. In 65 patients, in 1 case concentration of
IgA was decreased, in 7 cases IgM. In 21 cases, there was higher
concentration of IgE. During the cytometric analyses a decreased number
of T CD31 was found in 3 cases, BCD191 in 5, TCD41 in 5, T CD81 in 4,
and NK cells in 8 cases. The check for HSV2 was positive for 17 people:
1.5% men, 6.4% women. In this group, in 3 cases the concentration of IgA
was decreased, in 2 cases IgM was lowered, in 4 cases there were higher
concentrations of IgE. Decreased number of lymphocytes CD191 was ob-
served for 1 person and for 1 person NK cells. Chlamydia trachomatis infec-
tions were positive in 10 cases: 1.5% men, 2.3% women, in this group 1
person had lower IgA and 2 persons had increased concentrations of IgE. HIV
infection was negative for all the groups. The examination was repeated for
171 out of 579 people after 6 months. HPV infections were positive in 12.9%
cases: 14.9% men, 10.8% women; HSV2 in 11 persons: 2.3% men, 10.7%
women; Chlamydia trachomatis in 4 cases: 2.3% men 2.4% women.
Conclusions: No signiﬁcant correlation was observed between HPV, HSV2,
HIV and Chlamydia trachomatis infections and a relevant deviation from the
norm of the investigated immunological parameters.
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A 3Year-old Child with Speciﬁc AntibodyDeﬁciency andAllergic
Rhinitis. A Case Report
Maria Edith Gonzalez Serrano, MD, MSc,1 and Miguel Angel González
Cruz, MD2. 1Immunodeﬁciency Research Unit, National Institute of Pediat-
rics, México City, Mexico; 2Escuela de Medicina, Universidad Autónoma
Metropolitana, México City, Mexico.
Background: Speciﬁc antibody deﬁciency (SAD) is a humoral immunode-
ﬁciency characterized by normal levels of IgG, IgA, IgM and IgG subclasses
but a failure to polysaccharide antigens, manifested with recurrent bacterial
respiratory infections. To establish the SAD diagnosis an inadequate IgG
antibody response to more than 50% of pneumococcal serotypes after
unconjugated pneumococcal immunization are needed. An adequate response
is deﬁned as a post-immunization titre of $1.3 mg/mL or $4 times the
preimmunization value.1,2
Methods: The record of 1 patient was review and relevant clinical data was
collected. A review of the literature about SAD was made.
Results: A 4-year old male with family history of atopic disease, esophageal
reﬂux at 3-months, he began with recurrent upper respiratory tract infections
at 1-year old, 1 to 2 events per month, fever (39–408 C), persistent cough and
hyaline rhinorrhea, nasal itching and sneezing he was treated with multiple
antibiotics, inhaled and oral corticosteroids with mild clinical recovery be-
tween episodes. A normal blood cell count and normal levels of IgG 1219
mg/dL, IgA 146 mg/dL, IgM 98 mg/dL and IgG subclasses were determined.
Allergic rhinitis and asthma were diagnosed at 3-years old, percutaneous
prick skin test was positive to Dermatophagoides farinae, Salsola pestifer,
Phleum pratense, Heliantus sp. and speciﬁc immunotherapy was started.
Despite of treatment he continued with recurrent infections so speciﬁc anti-
body response to polysaccharide pneumococcal antigens was evaluated, he
responded less than 50% to 14 pneumococcal serotypes after 23-valent un-
conjugated pneumococcal vaccine, so SAD was diagnosed and treated with
prophylactic antibiotic, pneumococcal polysaccharide conjugated vaccine
(10-valent) and speciﬁc immunotherapy. He showed clinical improvement,
with few mild infections, and controlled rhinitis and asthma.
Conclusions: There are several Primary Immunodeﬁciency Diseases related
to allergic diseases as IgA deﬁciency and SAD. In the atopic patient that does
not improve in spite of speciﬁc immunotherapy further investigations are
needed to exclude them.
REFERENCES
1. Yong PF, Chee R, Grimbacher B. Hypogammaglobulinaemia. Immunol
Allergy Clin North Am. 2008;28:691–713. vii.
2. Boyle RJ, Le C, Balloch A, Tang ML. The clinical syndrome of speciﬁc
antibody deﬁciency in children. Clin Exp Immunol. 2006;146:486–492.
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Silvery-gray Hair Patient with neurologic deterioration
Luisa Gamez, MD,1 Yamazaki-Nakashimada Marco Antonio, MD,2
Saul Lugo-Reyes, MD,2 Raul Dorbeker, MD,1 and Victor Hernandez,
MD2. 1Allergy and Immunolgy clinic, National Institute of Pediatrics, Mex-
ico Distrito Federal, Mexico; 2National Institute of Pediatrics, Mexico.
Background: Griscelli syndrome is a rare autosomal recessive condition
characterized by pigmentary abnormalities, particularly greying of the hair.
Type 1 is associated with severe neurological impairment and type 2 with
immunological problems, whereas type 3 is limited to the pigmentary
phenotype.
Methods: We describe the presentation of a 3 year old female silvery-gray
hair patient with neurological deterioration.
Results: A 3 year-old Mexican female was refered to our hospital. Relevant
history: Consanguinity parents, 2 males from father side died in infancy, both
presented grayish hair. Normal development milestones until 2 and a half
years of age. (Including bladder and bowel control). Immunizations up to
date. No prior history of infections. At 11 months of age cutaneous lesions
leaving atrophic scars, with a chronic evolution. At 2 years 6 months old she
started presenting demential picture, with impaired language, abnormal gait,
with a signiﬁcant decline of previous level of functioning. Hospitalized in
another state hospital with diagnosis of Infection of central nervous system.
Due to worsening evolution despite treatment she was refered to our
institution. She was admitted to Intensive Care Unit, requiring mechanical
support due to a pneumonia. On physical examination the most striking
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feature was an unusual silvery-gray pigmentation of her hair, eyebrows and
eyelashes, crackles in both lungs, no adenomegalies, no hepatosplenomegaly.
Analysis of hair shafts was carried out at the time of hospital admittance and
showed abnormal clumping of the pigment granules, as seen in Griscelli
syndrome. During her clinic evolution the neurological deterioration was
progressive. Serial exams for haemophagocytic syndrome (accelerated phase)
were negative (ferritin, transaminases, CBC, triglycerides etc). Her condition
deteriorated during the following days. Treated at the Intensive Care Unit
with multiple broad spectrum antibiotics, she developed respiratory in-
sufﬁciency, refractory shock, multiorgan dysfunction, and died on her 23rd
hospital day. A cerebral biopsy reported necrosis and chronic inﬂammatory
inﬁltrate.
Conclusions: The results of molecular analysis is in process: griscelli type 2
(rab27a mutation) or elejalde syndrome (myo5a mutations) are the 2
considerations.
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Differences in Humoral and Cellular Immunity in Young and
Old Individuals
Arzu Didem Yalcin, MD,1 Reginald M Gorczynski, MD, PhD,2 Munevver
Sarigul, Msc,3 Mehtap Ulker,3 and Ender Terzioglu, MD3. 1Allergology and
Clinical Immunology Unit, Antalya Education and Training Hospital,
Antalya, Turkey; 2Division of Cellular & Molecular Biology, Toronto Hos-
pital, University Health Network, Toronto, ON, Canada; 3Akdeniz University,
Antalya, Turkey.
Background: The immune system changes with the age. In this study we
characterized immune changes by performing immunologic screening proﬁles
on aging individuals (graduation thesis).
Methods: This study was performed at Akdeniz University, in the Faculty of
Medicine, Dept. of Immunology. Healthy volunteers consisted of a young
group (22 donors) and an older group (45 individuals). Using ﬂow cytometry
analysis, CD3, CD4, CD8, CD16, CD19, CD28, CD40, CD45, CD56, CD80,
CD86, CTLA-4 and with ELISA IL-1 b, IL-2, IL-6, IL-10, IFN-g, TNF-a
expression were evaluated, along with and NK activity and induced cytokine
expression (by bioassay/ELISA respectively).
Results: No statistical differences were observed between the 2 groups in
expression of CD3, CD8, CD19, CD80, CD86, CD16, CD 56 or CD28. A
higher frequency of expression of CD4, CTLA-4, CD40 and CD45 was seen
in older subjects by comparison with young subjects. Cytokine proﬁles
expressed by stimulated monocytes from the 2 groups showed no difference
in IL-1 b, IL-2, IL-6, IL-10, TNF-a and IFN-g production levels. Cytokine
proﬁles expressed by stimulated lymphocytes from the 2 groups showed no
difference in IL-1 b, IL-2, IL-6, IL-10, TNF-a and IFN-g production levels.
Conclusions: We found increased expression levels of CD40 and CD45 levels
in healthy older (.55 years old) versus young individuals (media age 28 years).
CTLA-4 expression levels were also higher in elderly subjects, with no differ-
ence in CD28 expression levels between young/elderly individuals.
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Analysis of the Immune Status in the Acute Phase of Viral
Respiratory Infections in Children
Olga Bede, PhD,1 Sándor Sipka,PhD,2 Gabriella Terhes,PhD,3 Judit Deák,PhD,3
and Dóra Nagy, MD1. 1Department of Pediatrics, University of Szeged, Faculty
of Medicine, Albert Szent-Györgyi Medical and Pharmaceutical Centre, Szeged,
Hungary; 2Immunological Laboratory, University of Debrecen, Medical and
Health Science Centre, Debrecen, Hungary; 3Department of Microbiology, Uni-
versity of Szeged, Faculty of Medicine, Albert Szent-Györgyi Medical and Phar-
maceutical Centre, Szeged, Hungary.
Background: Viral infections can cause severe symptoms in the upper and
lower respiratory tract. These are very common in childhood and occasionally
seem to be an intractable problem. The aim of our study was to investigate the
serum cytokine levels and other inﬂammatory parameters in the acute phase
of viral respiratory infections and after 1 month.
Methods: We investigated the peripheral blood cell, leukocyte counts, C-
reactive protein (CRP) levels, serology of respiratory viruses and serum IL-1,
IL-2, IL-4, IL-6, IL-10, IL-13, IFN-gamma and TNF-a levels in children
suffered from acute viral infection (group 1, N ¼ 40) and in healthy controls
(group 2, N ¼ 20).
Results: Based on serology and direct identiﬁcation of viruses from
nasopharyngeal secretion RSV was detected in 40%, adenovirus in 20%,
parainﬂuenza in 33% and EBV in 7%. In acute phase of infection the patients
had moderately elevated leukocyte (9729 6 658 vs 7405 6 416, P , 0.05),
monocyte count (8.48 6 0.58% vs 5.84 6 0.34%, P , 0.001), CRP levels
(9.62 6 3.14 mg/L vs 1.66 6 0.58 mg/l, P , 0.05) and decreased eosinophil
count (2,15 6 0,34% vs 5,25 6 0,81%, P , 0,05) and elevated IL-6 (4.28 6
0.77 pg/mL vs 1.50 6 0.25 pg/mL, P , 0.01), IL-10 (9.17 6 2.86 pg/mL vs
1.476 0.28 pg/mL P, 0.05), IL-13 (9.566 2.15 pg/mL vs 1.386 0.24 pg/
mL, P , 0.01), IFN-g (25.36 6 9.73 pg/mL vs 1.11 6 0.08 pg/mL, P ,
0.05) and IFN-g /IL-4 ratio (22.13 6 9.56 vs 1.03 6 0.08, P , 0.05)
compared with controls. One month after the acute phase most inﬂammatory
parameters normalized, monocyte count (8.48 6 0.58% vs 5.05 6 0.52%, P
, 0.05), IL-6 (4.28 6 0.77 pg/mL vs 0.80 pg/mL, P , 0.001) and IFN-g
(25.36 6 9.73 pg/mL vs 5.14 6 1.8 pg/mL, P , 0.05) levels decreased and
eosinophil counts (2.15 6 0.34% vs 3.62 6 0.48%, P , 0.05) increased.
Conclusions: Our results show that the protective proinﬂammatory cyto-
kines, such as IFN-gamma (induced by TNF-a from monocytes) and IL-13,
in association with an anti-inﬂammatory cytokine, IL-10, and mildly elevated
other inﬂammatory parameters are increased in children with acute viral in-
fection. A single parameter, elevated monocyte count, can indicate the viral
origin of the infections.
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Immunomodulatory Effects of Human Bone Marrow-derived
Mesenchymal Stem Cells
Maryam Ayatollahi,1 Frogh Zariﬁ,1 Maryam Zakerinia,2 Alireza Rezvani,2
and Mani Ramzi2. 1Transplant Research Center, and; 2Bone Marrow Trans-
plantation Center, Nemazi Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran.
Introduction: Human mesenchymal stem cells (MSCs) have great plasticity
and the potential for therapeutic applications1 Due to the fact that MSCs
could reduce the incidence severity of graft versus host disease2 We have
investigated the immunologic properties of human marrow-derived MSCs.
Material & Methods: Bone marrow was obtained from healthy human
donors of bone marrow to a related patient at Bone Marrow Transplantation
Center, Nemazi Hospital, after obtaining approval of the Ethics Committee
and Written informed consent. The Mononuclear cells derived over the
Ficoll-Paque density-gradient, and plated in tissue cultures dish. The adherent
cells expanded rapidly and maintained with periodic passages until a relatively
homogeneous population was established. The MSCs were characterized by
immunophenotyping and differentiation into osteoblast and adipocytes.
Alloreactivity was studied after adding the MSCs to allogeneic lymphocytes
in mixed lymphocyte reaction cultures.
Results: Flow cytometric analysis, and the differentiation potential into
osteoblast and adipocytes showed that more than 90% of human MSCs were
positive by speciﬁc markers and functional tests. Indeed, The MSCs
expressed CD90, and CD73. But not CD80, CD40, and HLA class II. They
also were negative for the hematopoietic markers CD34, and CD45. The
MSCs do not induced proliferation of allogenic lymphocytes and suppressed
them.
Conclusion: The human marrow-derived MSCs do not elicit alloreactive
lymphocyte proliferation. The results suggest that these cells have potentials
for allogenic transplantation.
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Allergen Standardisation in Allergens and
AllergoidsdChallenges and Considerations
Murray Skinner, PhD, Alan Bullimore, Simon Hewings, and Nicola Swan,
MSc. R&D, Allergy Therapeutics, Worthing, United Kingdom.
Background: The range of therapeutics and dosing schedules for allergen
preparations and allergoids produced and used clinically are considerable.
Standardisation of allergy immunotherapies is considered a positive step;
however there are difﬁculties in identifying universal metrics for stand-
ardisation. Many advocate the use of major allergen content whilst others
advocate total allergenicity. Additionally as a compounding argument, where
major allergen is used, many disagree on what the major allergen is for certain
species.
Methods: Major allergen content measurement allows a consistent recog-
nised measure, and IgE responses of a serum pool are often dominated by IgE
against major allergens. However issues such as speciﬁcity of different assays
toward isoforms and other variants of single allergens often results in
diverging allergen contents that can cause unexpected and misleading
disparity. Other aspects that increase complication are the relevance to
modiﬁed allergens, use of adjuvants and differing dosing regimes.
Results: The major allergen content of key products in different therapeutic
formats has been measured.
Conclusions: This has been performed in conjunction with techniques
such as total allergenicity, as allergy treatments and therapeutics require
careful characterisation to allow supply of consistent, safe and efﬁcacious
products.
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by Subcutaneous Route in Allergic Asthmatics Patients
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Labrada, PhD,6 Bárbara I Navarro Viltres, MD,7 Yunia Oliva Díaz, 8
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Cuba; 4Univesity Hospital General Calixto García, WAO Member, Cuban
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Cuba; 5Docent Policlinic Pedro Fonseca, Cuban Society of Family Medicine
Member, Cuban Society of Allergy Member, Cuban Society of Immunology,
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Background: Allergen-speciﬁc subcutaneous immunotherapy (SCIT) is
presently recognized as a biological response modiﬁer, as it is the only
available treatment able to inﬂuence the natural course of allergic disease.
Extensive clinical evidence supports its efﬁcacy. Safety concerns are related
to the risks of anaphylactic reactions during treatment. Standardization of
allergen vaccines in terms of allergenic activity allows a more precise control
over the administered doses and can be, therefore, very relevant for both
efﬁcacy and safety of SCIT. House Dust Mites (HDM), particularly Derma-
tophagoides pteronyssinus (Dp), Dermatophagoides siboney (Ds) and Blomia
tropicalis (Bt) have been described as very relevant allergen sources in Cuba,
with a strong association to respiratory allergy symptoms.
Objective: To asses the efﬁcacy and safety of standardized allergen vaccines
of these 3 mite species (Valergen, Biocen, Cuba) in Cuban asthmatic patients.
Methods: Three Double-Blind Placebo-Controlled clinical trials were
performed in 40 patients each, showing asthmatic symptoms and positive
predominant Skin Prick Test (SPT) to each mite, respectively. Half of patients
received the active treatment consisting of subcutaneous injections with
increasing doses, up to 6000 BU.
Results: The total 1 year cumulative dose was 63035 BU, in an average of
20.5 injections. The treatment was effective in the reduction of clinical
symptoms (up to 32%, 95%CI: 28-36%; P ¼ 0.0006) and medication in-
take (23%, 95%CI:18-28%), as compared to control treatment. The skin
sensitivity to the allergens decreased signiﬁcantly (P ¼ 0.0001), with regard
to the beginning of the treatment. The allergen amount needed to induce
a positive SPT increased 297-fold. An improvement of the lung function
was observed, expressed in a modest Peak-Expiratory-Flow increase (P ,
0.05) and reduction of PEF daily variability. SIT was considered effective in
71% of patients. The frequency of local adverse reactions was 2.4 % of
injections.
Conclusions: The results indicates that immunotherapy, using standardized
House Dust Mite vaccines, including tropical species, is effective and safe for
the control and amelioration of the asthma in our population.
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Therapeutic Effect and Security in Asthmatics Adult Patients
Treated with Dermatophagoides Pteronyssinus Allergen
Sublingual Immunotherapy
José Rodríguez, MD,1 Raúl Castro, MD,2 Alexis Labrada, PhD,3 Mirta
Alvarez, MD,1 Mercedes Ronquillo, MD,1 Mayda González, MD,4 Bárbara
Navarro, MD,3 Maytee Mateo,3 Yunia Oliva,3 Iris García, MD,1 and Irene
Enriquez, MD1. 1Allergology Department, University Hospital Calixto García,
Havana City, Cuba; 2Allergens, National Center of Bioproducts, Havana City,
Cuba; 3Allergens, National Center of Bioproducts, Mayabeque, Cuba; 4Pedro
Fonseca Docent Policlinic, Havana City, Cuba.
Background: The speciﬁc active immunotherapy, employing vaccine of
allergen of mite is a treatment considered as effective for the respiratory
allergy and asthma. The sublingual route has minor risk of systematises
reactions. The objective of this study was to determine the therapeutic effect
and security of sublingual immunotherapy (ITSL) employing the standard
vaccine VALERGEN-DP (BIOCEN, CUBA) in a population of asthmatic
Cuban patients.
Methods: A phase II Clinical Trials double blind, placebo controlled in
a total of 40 adult patients with mild or moderate asthma and speciﬁc
sensibility preponderant to this mite. Half of patients received drops by
sublingual route with growing doses up to 2000 UB.
Results: The treatment was effective in the reduction of clinical symptoms
and medication intake as compared to conventional treatment in control
group. The cutaneous sensibility to this mite was signiﬁcant reduced,
increasing in 1.9 log; the amount of necessary allergen to provoke a positive
Prick Test. An improvement of the lung function was observed with
a signiﬁcant reduction (P , 0.05) of expiratory pick ﬂow variability. The
frequency of local reactions were only 0.58% of administration.
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Conclusions: The VALERGEN-DP vaccine is an effective treatment and
proﬁtable against asthma in our population and guarantee its generalization in
the Allergy Services of our health system.
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Safety of Sublingual Immunotherapy with Standardized Vaccines
of Domestic Mites
Mirta Alvarez, MD,1 Raúl Castro, MD,2 Daniel Gutierrez, MD,3 Alexis
Labrada, PhD,2 Irene Enriquez, MD,1 Mercedes Ronquillo, MD,1 José
Rodríguez, MD,1 and Iris García, MD1. 1Allergology Department, University
Hospital Calixto García, Havana City, Cuba; 2Allergens, National Center of
Bioproducts, Havana City, Cuba; 3Allergology, University Hospital Calixto
García, Havana City, Cuba.
Background: Allergen-speciﬁc immunotherapy consists of administering grad-
ually increasing doses of the allergen, to which the patient is sensitized, aiming at
achieving tolerance to it and decreasing clinical symptoms. The sublingual
immunotherapy (SLIT) was introduced as an alternative to subcutaneous route. Its
use is being increased in the world and in Cuba, using standardized vaccines
owing to greater safety. The objective of this study was to determine the safety of
sublingual standardized vaccines of 3 domestic mite species (Valergen, Cuba) and
its adverse events in allergic patients from the Calixto García University Hospital
in Havana, as well as the frequency of its prescription.
Methods: Descriptive and cross sectional study design, which included 130
patients with treatment of SLIT with VALERGEN-DP (Dermatophagoides
pteronyssinus), VALERGEN-DS (D. siboney) and VALERGEN-BT (Blomia
tropicalis) (BIOCEN, Cuba), who attended the Allergy Service in the period
January-September 2010. Age distribution: mean 19.6 years (range 1–75),
40.7 % was younger than 18 years.
Results: The multiallergen vaccine was the type of vaccine most used
(63.8%). The most common allergen was D. pteronyssinus followed by B.
tropicalis. 71.55% of administered allergens vaccines were in maintenance
phase. We found 4 adverse events (3.1% of patients), all local, mild, and not
requiring treatment or change of vaccination dosing schedule.
Conclusions: The Valergen vaccines by sublingual route are safe and well
tolerated in Cuban allergic patients.
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The Effect of Speciﬁc Immunotherapy on the Clinical Response in
Patients with Grass-pollen Induced Rhinoconjunctivitis
Zoran Arsovski, MD, MSc,1 Biserka Jovkovska Kaeva, MD, PhD,2 Miroslav
Gavrilovski,MD, PhD,2 Tome Stefanovski, MD, PhD,2 Sava Pejkovska, MD,2
Suzana Arbutina, MD,2 Irfan Ismaili,2 Tatjana Caparoska, MD, PhD,2 and
Dejan Dokic, MD, PhD2. 1Allergy and Clinical Immunology, Clinic of Pulmo-
nology and Allergy, Skopje, Macedonia; 2Clinic of Pulmonology and Allergy,
Skopje, Macedonia.
Background: Speciﬁc immunotherapy (SIT) has a signiﬁcant potential in the
treatment of allergic rhinitis and allergic conjunctivitis. The aim of the study
was to evaluate the effect of speciﬁc immunotherapy (SIT) in patients with
grass-pollen induced allergic rhinitis and allergic conjunctivitis.
Methods: Twenty-six patients with pollen induced rhinoconjunctivitis and
positive history for more than 2 years were included in our study. They had
skin prick test of $ 5 mm, age range from 18 to 44 years and all underwent
conjunctiva provocation tests before and after 1 year of SIT. Clinical severity
score of nasal and conjunctiva symptoms during the season was assessed by
4-point arbitrary rating scale from 0 to 3. Conjunctiva provocations were
performed out of the season until allergic symptoms occurred, achieving
the allergen threshold dose (ATD).
Results: After 1 year of SIT, we have noticed reduction of clinical symptoms
present in allergic conjunctivitis: burning, itching, lacrimation and hyperemia
(P , 0,05). We have found also reduction in clinical symptoms of allergic
rhinitis: secretion, irritation, itching and nasal blockade (P , 0,01). The
patients tolerated signiﬁcantly higher allergen doses in provocation tests after
1 year of SIT, reaching new ATD.
Conclusions: SIT reduces the clinical symptoms of allergic rhinoconjuncti-
vitis and modiﬁes the inﬂammatory response after speciﬁc allergen challenge.
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Does Sublingual Immunotherapy Work with an Immune
Deviation Mechanism?
Laura Giovanna Sensi,MD, Elisa Panﬁli, Arianna Latini, Francesco Marcucci,
and Giuseppe Di Cara, MD. Medical-Surgical Specialities and Public Health,
University of Perugia, Perugia, Italy.
Background: We aimed at ﬁnding out the immunological mechanisms of
SLIT by studying the activity of IgE speciﬁc for the epitopes of Phleum in
patients treated with SLIT for grass allergen and in a control group.
Methods: 30 patients allergic to grass were included in the study:
• 15 patients carried out a pre-seasonal SLIT for 2 years with the 5 grass
mix extract from Stallergenes.
• 15 patients were not treated with SLIT.
Eligible patients: Clear symptoms of seasonal rhinoconjunctivitis during the
past year, positivity to Phleum skin prick tests (111-) and speciﬁc IgE (3.5
kU/L). Prick tests were performed with extracts from Stallergenes; serum
speciﬁc IgE for Phleum and rPhlp1, rPhlp2, rPhlp5, rPhlp6, rPhlp7, and
rPhlp12 were determined through the Unicap system 100 IgE FEIA (Phadia
Usala, Sweden). Wilkoxon and Fischer method were performed. Rast Inibi-
tion rpPhlp1/rpPhlp1, rpPhlp1/rpPhlp2 and rpPhlp1/rpPhlp4 were evaluated.
Results: IgE for rPhlp7 and rPhlp12 present only in some patients did not
show signiﬁcant modiﬁcations. Most patients treated with SLIT for 2 years,
and all those showing improvement in symptoms, showed a less evident
increase of speciﬁc IgE for rPhlp1 and rPhlp5 if compared with that of minor
allergens, ie, rPhlp2, rPhlp4, rPhlp6. This difference was absent in control
patients and in patients not showing clinical improvement. In patients
showing clinical improvement the IgE ratio rPhlp5/rPhlp2 was signiﬁcantly
decreased (P ¼ 0.02). A RAST inhibition study showed no cross-reactivity
between rPhlp1/rPhlp2 and rPhlp1/rPhlp4.
Conclusions: After 1 and 2 years of SLIT, the data show the following
results:
• a signiﬁcant increase of speciﬁc IgE for minor allergens and a less
evident increase of speciﬁc IgE for major allergens in patients showing
a clinical response to SLIT
• a drastic decrease in IgE ratio for rPhlp5/rPhlp2. These results suggest
that SLIT not only induces a TH2-TH1 isotypic switch, but also can act
with a mechanism of immunological replacement. In fact, the produc-
tion of speciﬁc IgE for minor allergens (rPhlp2, rPhlp4, rPhlp6) tends to




Immunotherapy (IT) Training in Canada: Perspectives of
Fellows-in-training on the First Immunotherapy
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Center, University of Manitoba, Winnipeg, MB, Canada; 2Department of
Health Policy, Management and Evaluation, Faculty of Medicine, University
of Toronto, Toronto, ON, Canada; 3Department of Medicine, University of
Western Ontario, McMaster University, Kitchener, ON, Canada; 4Depart-
ment of Medicine, University of Western Ontario, London, ON, Canada;
5Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Allergen immunotherapy (IT) is a key component of allergy
practice, however fellows state that there is inadequate IT exposure during
their training. In response, the Canadian Society of Allergy and Clinical
Immunology (CSACI) unveiled the ﬁrst ever IT Training Manual for fellows-
in-training at the annual 2010 CSACI meeting. The manual was distributed
during a faculty-led teaching session. This was a pilot investigation to
determine the perspectives of fellows in training about the IT training manual.
Methods: Canadian fellows-in-training in Allergy and Clinical Immunology
(list derived from CSACI) were contacted via email to complete a survey (using
survey monkey), both quantitative (Likert scales) and qualitative, to assess their
opinion on the faculty-led session on IT and the IT Training Manual.
Results: Sixty-nine Canadian fellows-in-training were invited to complete the
survey and 16 (23%). Fifty-four percent of 13 respondents were in their ﬁrst
year of fellowship. Seven respondents (58% of 12 respondents) attended the
2010 CSACI fellow-in-training session and received the IT Training Manual.
One respondent commented that it was “more information than we’ve had in
all of our fellowship!” The same 7 respondents “somewhat liked” or “liked”
the large group format, but felt that the experience could be improved in the
future with the addition of cased-based learning in smaller groups. One re-
spondent commented that “as in intro, it was good in a larger setting.” All 7
respondents felt that their understanding of IT was positively impacted by the
faculty-led session. Eighty-six percent of 7 respondents indicated that the
Training Manual “somewhat impacted” to “very much impacted” their un-
derstanding of IT. One commenter stated that “it is the basis of my knowledge
thus far.” Most respondents (86%) preferred the current paper booklet format
of the IT Training Manual.
Conclusions: The results of this pilot survey demonstrate that some fellows-
in-training found the faculty-led session on IT and the IT Training Manual
useful. Future studies will help to further elucidate the utility of these 2
educational interventions.
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Immunotherapy (IT) Training in Canada: Current Experience
of Fellows-in-training
Teresa Pun, HBSc, MD, FRCPC,1 Monika Kastner, PhD,2 Harold Leeyonge
Kim, MD, FRCPC,3 D. William Moote, MD, FRCPC,4 and Susan
Waserman, MD, FRCPC5. 1Adult Allergy and Clinical Immunology, Health
Sciences Center, University of Manitoba, Winnipeg, MB, Canada; 2Department
of Health Policy, Management and Evaluation, Faculty of Medicine, University
of Toronto, Toronto, ON, Canada; 3Department of Medicine, University of
Western Ontario, McMaster University, Kitchener, ON, Canada; 4Department
of Medicine, University of Western Ontario, London, ON, Canada; 5Depart-
ment of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Allergen immunotherapy (IT) is a key component of allergy
practice of allergy. Canadian fellows-in-training have expressed concern that
they receive inadequate exposure to IT in their training programs.
Methods: Canadian fellows-in-training in Allergy and Clinical Immunology,
identiﬁed through the Canadian Society of Allergy and Clinical Immunology
(CSACI), were contacted via email to complete a pilot survey (using survey
monkey) to assess their exposure to, experience with, and comfort level in
using IT.
Results: Sixty-nine Canadian fellows-in-training were invited to complete the
survey and 16 (23%) completed at least part of the survey. Fifty-four percent
of 13 respondents were in their ﬁrst year of fellowship. Fifty percent of 12
respondents were internal medicine trained. Eighty-three percent of 12
respondents acknowledged exposure to IT during their training. Eighty
percent of 10 respondents had previously written a prescription for IT; 71%
and 43% of 7 respondents had written 1 to 5 prescriptions for aeroallergen
and stinging venom IT, respectively. Only 50% of 12 respondents felt
comfortable prescribing IT. The most common reason cited was lack of
experience; however, one respondent wrote that he/she would feel un-
comfortable prescribing IT without using the standardized hospital IT form.
Sixty-seven percent of 12 respondents had previously administered IT to
a patient. Sixteen percent of 12 respondents felt uncomfortable administering
IT due to lack of experience. Fifty percent of 12 respondents had treated
a patient having an allergic reaction to IT and 100% of these same
respondents felt "somewhat comfortable" to "very comfortable" in responding
to an allergic reaction to IT. Seventy-ﬁve percent of 12 respondents agreed
that a formal clinical rotation in IT would be helpful.
Conclusions: The results of this pilot survey demonstrate that Canadian
fellows-in-training in Allergy and Clinical Immunology are not receiving
adequate exposure and training in IT. Future studies will help to explore this
subject in more detail.
INCIDENCE AND PREVALENCE OF FOOD ALLERGY
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Nationwide Survey of Immediate Type Food Allergy in Japan
Takanori Imai, MD, PhD,1 Chizuko Sugizaki,2 and Motohiro Ebisawa, MD,
PhD3. 1Pediatrics, National Sagamihara Hospital, Kanagawa, Japan; 2Na-
tional Sagamihara Hospital, Kanagawa, Japan; 3Clinical Research Center
for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara,
Japan.
Background: The food labeling system for food allergens was introduced
from April 2002 in Japan. To conﬁrm the effectiveness of the system, we
regularly conduct a nationwide food allergy survey every 3 years.
Methods: The survey was conducted in cooperation with over 1000 volunteer
allergists in Japan at 2001, 2002, 2005 and 2008. We sent questionnaire to
contributing doctors every 3 months based on the past survey system, and
contributing doctors were asked to report immediate type food allergy cases
seen by those doctors. In this survey, immediate type food allergy was
deﬁned as the patients who had developed symptoms due to food allergic
reaction within 60 minutes after intake of offending food. The details of
questionnaire consisted of age, sex, cause of food allergy, symptoms, CAP
system, and type of onset.
Results: A total of 8581 immediate type food allergy cases were reported by
the doctors. The most common offending foods were hen’s egg (39.0%), milk
products (18.0%), wheat (9.4%), fruit (5.3%), crustacean (4.6%), peanuts
(3.7%), ﬁsh egg, buckwheat and ﬁsh (3.6%). The most common clinical symp-
tom was observed on skin (89.7%) followed by respiratory system (29.6%).
Interestingly, the causes of food allergy were completely different from infancy
(egg, milk, and wheat) to adulthood (wheat, crustacean and fruits). Anaphylactic
shock was observed in 10.9% of the total reported cases. The cases of anaphy-
lactic shock were due to hen’s egg (27.1%), milk products (21.4%) and wheat
(18.1%). Eleven percentages of patients had been hospitalized.
Conclusions: We revealed the current condition of the immediate type food
allergy cases seen in Japan recent decade. Based on these data, counter-
measures against food allergy are ongoing in collaboration with the Ministry
of Health, Labour, and Welfare in Japan in order to improve quality of life of
patients.
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Service Centre, China, Zhuhai, China; 3Children Hospital, Zhejiang Univer-
sity, School of Medicine, Hangzhou, China.
Background: To estimate the prevalence and clinical features of food allergy
in children aged 0 to 2 years.
Methods: From January to February, 2009 and January to May, 2010, all
well-infants and young children between the age of 0-2 years attending
routine health visits at the Department of Primary Child Care, in Chongqing,
Zhuhai and Hangzhou were invited to participate the study. Parents
completed questionnaires and all children were skin prick tested to a panel
of 10 foods (egg white, egg yolk, cow milk, soybean, peanut, wheat, ﬁsh,
shrimp, orange and carrot). Based on the results of SPT and medical history,
the subjects should undergo the suspected food elimination and oral food
challenge under medical supervision. Food allergy was conﬁrmed by the food
challenge test.
Results: There were 1,687 children recruited by the consent of their parents.
Of 1,687 children approached, 1,604 (550 for Chongqing, 573 for Zhuhai and
481 for Hangzhou) fulﬁlled the study criteria for diagnosing food allergy. 100
children were conﬁrmed to have challenge-proven food allergy in 3 cities (40
for Chongqing, 33 for Zhuhai and 27 for Hangzhou). The prevalence of food
allergy in 0 to 2 years old children in Chongqing was 7.3%, in Zhuhai was
5.8% and in Hangzhou was 5.5%. There was no signiﬁcant difference in the
prevalence of food allergy in children under 2 years among the 3 cities, and
the average prevalence for food allergy in children under 2 years was 6.2%.
Egg was the most common allergen, followed by cow milk.
Conclusions: The prevalence of food allergy in 0 to 2 years old children in
China was 5.5% to 7.3%. There was no signiﬁcant difference in the
prevalence of food allergy in children under 2 years among the 3 cities.
Egg was the most common allergen, followed by cow milk.
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Skin Sensitization to Carmine Before Onset of Systemic Allergy to
Ingested Carmine
Yoshinori Katada, MD, PhD,1 Yoshinori Harada, MD, MS,1 Naoto
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and Toshio Tanaka, MD, PhD5. 1Allergy and Clinical Immuology, NHO
Osaka-minami Medical Center, Kawachinagano, Japan; 2Rheumatology, Hy-
ogo College Of Medicine, Nishinomiya, Japan; 3Clinical Immunology, NHO
Osaka-minami Medical Center, Kwachinagano, Japan; 4Clinical Investiga-
tion, NHO Osaka-minami Medical Center, Kawachinagano, Japan; 5Depart-
ment of Respiratory Medicine, Allergic and Rheumatic Diseases, Osaka
University Graduate School of Medicine, Suita City, Japan.
Background: Allergic sensitization to food can occur through skin exposure.
We investigated anaphylactic cases due to carmine, a food additive extracted
from Dactylopius coccus.
Methods: Screening all patients, who visited our department from January
2000 to December 2009, we identiﬁed 2 new such cases. Both had history of
rash induced by certain cosmetics containig carmine. We further investigated
previous case reports of carmine allergy, whether skin sensitization antedated
food allergy or not.
Results: Case 1: A 26-year-old woman visited our hospital because of
anaphylaxis occurred within 5 minutes after ingesting a Japanese YOKAN
(sweetened and jellied bean paste). IgE antibodies against common food
allergens including beans and wheat were all negative. As the paste contains
carmine, we tested speciﬁc IgE antibody, which was positive. She had been
avoiding using certain cheeks and lips for 2 years, since they cause erythema.
These cosmetics emerged as containing carmine. Abstaining from the food
additive made her free from anaphylaxis. Case 2: A 30-year-old woman came
to our hospital for dyspnea, uriticaria, and bilateral blepharedema, immedi-
ately after drinking Campari soda. Her past history was prominent, as she had
4 episodes of anaphylaxis in 4 years, requiring emergency transport twice.
All anaphylactic episodes occurred in Italian restaurants when she drank
cocktails, which might contain carmine in Campari soda. She had been also
sensitive to certain rouges since several years before the ﬁrst onset of
anaphylaxis. It became clear that the rouges contained carmine. In literatures,
we found 22 cases with allergy to ingested carmine. It is surprising that all
cases were women (aged 25 to 52), while occupationally sensitized patients
are predominantly men. As far as we could know, 85.7 % of (6/7) mentioned
cases had previous history of sensitization to cosmetics containing carmine.
Conclusions: In many cases with allergy against ingested carmine, the route
of ﬁrst sensitization was not via intestine but skin. This is similar to suspected
peanut sensitization mechanism and might be a paradigm of food allergy. As
allergic reaction to carmine mainly directed to impurities, using highly
puriﬁed carmine is desired not only for foods but also for cosmetics.
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Milk, the Most Commonly Undeclared Food Allergen Causing
Unexpected Allergic Reactions in Sweden between 2004 and 2011
Monica Ferm, and Ylva Sjogren-Bolin, PhD. Science Department, National
Food Administration, Uppsala, Sweden.
Background: Allergy to milk proteins is a common allergic manifestation,
especially among children. Different types of food products could be a risk
factor for milk allergic individuals. According to the European Community
Directive 2000/13/EC the list of ingredients shall include all the ingredients of
the foodstuff, however with some exceptions. In 2003 Directive 2003/89/EC
entered into force stating that milk and other ingredients, which are common
elicitors of food allergic reactions, shall always be declared in the labeling.
Objective: To investigate which undeclared food allergen that most
commonly has caused unexpected allergic reactions in Sweden between
2004 and 2011, ie, since 2003/89/EC entered into force, and to compile data
regarding the reactions to this food allergen.
Methods: The medical care, school personnel and control authorities have
since 1990 been encouraged to report allergic reactions to foods, which do not
declare the ingredient causing the allergic reaction, to the Swedish National
Food Administration. Also, the suspected foods have been provided for
analyses. Food allergens, e.g. caseins (a group of milk proteins), were
analyzed with Enzyme Linked Immunosorbent Assay and/or Rocket
Immunoelectrophoresis.
Results: Forty-eight cases of unexpected allergic reactions to foods, in which
the causing food allergen was detected, were reported between 2004 and
2011. The most commonly detected food allergen was milk (21) followed by
peanut (9), egg (6) and wheat (5). The persons who suffered from unexpected
allergic reactions to milk were all children or teenagers. Mild symptoms were
reported as well as anaphylactic reactions. One death was most likely caused
by an allergic reaction to bread contaminated with milk. The lowest doses
eliciting allergic reactions were calculated to be 2 to 6 mg casein. The types of
foods causing the reactions were chocolate, ready-made meals, meat
products, sauces, bread and a vegetarian milk substitute. The unexpected
allergic reactions to milk were caused by mislabeling in 7 cases and to
contamination in 14 cases.
Conclusions: Although rare, allergic reactions to undeclared food allergens
may occur. Milk was the most commonly undeclared food allergen causing
allergic reactions in Sweden between 2004 and 2011.
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Cross Sectional Study of 1,822 Pediatric Food Allergy Patients
Takatsugu Komata, MD,1 Miho Hasegawa,2 Kiyotake Ogura, MD,1
Katsuhito Iikura, MD,1 Makiko Goto, MD,1 Tomohiro Utsunomiya, MD,1
Sakura Satou, MD,2 Takanori Imai, MD, PhD,1 Morimitsu Tomikawa, MD,1
Akinori Shukuya, MD, PhD,1 and Motohiro Ebisawa, MD, PhD2. 1Depart-
ment of Pediatrics, Sagamihara National Hospital, Sagamihara, Japan;
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2Department of Allergy, Sagamihara National Hospital Clinical Research
Center for Allergy and Rheumatology, Sagamihara, Japan.
Background: The aim of this study is to clarify the cross section of pediatric
food allergy patients. We investigated the proﬁles of food allergy (FA)
patients seen in our department.
Methods: The number of food allergy patients seen in our department from
January to December in 2010 was a total of 1,822 (male: 1207, female: 615,
mean age: 5.86 3.8 year). We collected and analyzed the clinical information
of these patients from our medical record. We obtained information on the
age of FA onset & FA diagnosis, clinical types of FA at the onset, causative
food allergens, other allergic complications, and application of oral immuno-
therapy (OIT).
Results: The average age of FA onset was 8 months, and that of diagnosis
was 1 year old, respectively. The most common clinical types of FA at the
time of onset were infantile atopic dermatitis (AD) type with food allergy
(66.4%) followed by immediate type (30.8%). Food allergens avoided by the
patients were the total number of 4,203 items (2.1 items as average). The most
common eliminated food was hen’s egg (1,245 cases; 29.6%), followed by
cow’s milk (786 cases; 18.7%), peanut (449 cases; 10.7%), and wheat (407
cases; 9.7%). Food-dependent exercise-induced anaphylaxis (FDEIA) was the
total of 18 cases, and the most common causative food for FDEIA was wheat
(10 cases) followed by peach (4 cases). One hundred and seventy ﬁve cases
(9.6%) were currently receiving OIT. Main causative foods under OIT were
hen’s egg (63 cases), cow’s milk (80 cases), and wheat (30 cases). The
average starting age of OIT was 7.1 years old. Regarding complications of
allergic diseases other than FA, 1119 (61.4%) had atopic dermatitis, and 541
(29.7%) bronchial asthma.
Conclusions: We were able to clarify the cross section of food allergy
patients in our department and to obtain the basic data to follow continuous
transition of these patients.
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Surface Plasmon Resonance Imaging: New Tool for
Immunodiagnostics of Food Allergy
Oussama Abou Chakra,PhD,1,2 Nathalie Vollmer,PhD,2 Souhir Boujday, PhD,3
Pascal Poncet, PhD,1,4 Hélène Chardin, MD,1 Gabriel Peltre, Pr,1 Claire-Marie
Pradier,Pr,3 and Hélène Sénéchal, PhD,1,5. 1LSABM - Allergy and Environment,
ESPCI ParisTech, Paris, France; 2GenOptics SA, Horiba Scientifc, Chilly-
Mazarin, France; 3LRS, UPMC, Ivry sur Seine, France; 4Infection and Epide-
miology, Institut Pasteur, Paris, France; 5CSS 5, INSERM, Paris, France.
Background: Food allergy affects as many as 5 to 8% of children and 2 to
3% of adults. The milk is an important source of food allergens. The Surface
Plasmon Resonance imaging (SPRi) is an optical technique used for
measuring simultaneously several hundreds of biomolecular interactions
(about 400 interactions) in real-time and in a label free environment. The
aim of our study was to measure avidity of milk allergens with their
antibodies by the SPRi.
Methods: The biochip gold surface was functionalized by mixed layers of
acid and alcohol. Milk allergens (b-lactoglobulin and a-lactalbumin) and
ovalbumin (used as negative control) were then immobilized by covalent
bonds on the biochip surface. After saturation step, some solutions with
different concentrations of polyclonal antibodies - whole serum and puriﬁed
antibodies - were injected in the SPRi-plex system (Horiba Scientiﬁc,
Genoptics). The surface coverage and the detection limits of the target anti-
body were measured. The avidity of the couple antigen/antibody was then
calculated.
Results: For the couple b-lactoglobulin and whole serum from rabbit sensi-
tized with this allergen, the surface coverage of antibody increased from 0.7
to 1160 pg/mm2, when we injected 4 and 340 nM of antibody, respectively.
The avidity of this couple is 0.7 nM. The detection limits are 2 and 0.8 nM
by SPRi and ELISA, respectively. For the couple a-lactalbumin/puriﬁed
anti-a-lactalbumin antibody, the surface coverage of antibody increased from
20 to 1000 pg/mm2, when we injected 10 nM and 100 mM of antibody,
respectively. The avidity of this couple is about 5.2 nM and 60 nM by SPRi
and capilary electrophoresis, respectively. The rate of antibody detection limit
obtained by SPRi compared to what is obtained by ELISA is 35%.
Conclusions: A Good proportionality of SPRi and ELISA signals was
observed according to antibody concentrations. A high speciﬁcity binding
and an excellent avidity between allergens and their antibodies was also




Mastocytosis and IgE-dependent Sensitization: Report of 2 Cases
Paola Toche, MD, and Carla Bastías. Resident, Immunology, University of
Chile, Santiago, Chile.
Background: Mastocytosis is a heterogeneous disease, with abnormal
accumulation of mast cells in one or more organs. Hyperplasia is often
found in the bone marrow and peripheral sites such as skin, gastrointestinal
mucosa, liver and spleen. The clinical manifestations are due to release of
mast cell mediators and tissue inﬁltration; however, there is no direct
relationship between total mast cell mass and symptoms of liberation.
Methods: Describe 2 cases of mastocytosis that manifest with anaphylactic
shock and also have IgE-dependent allergy.
Results: Case1: Man of 62 years consulting for intraoperative anaphylaxis
with an expected elevated serum tryptase (54 mg/L) during episode. The skin
test were positive to vecuronium, rocuronium and Izofran and the other drugs
and latex were negative. Speciﬁc IgE to quaternary ammonium latex and
beta-lactams were negative. The tryptase remains elevated (23 mg/L) 6 weeks
after surgery. Bone marrow biopsy showed mast cell inﬁltration of 10% CD
34 staining less than 1% and 10% CD117. Co-CD25 and CD117 were 25%
compatible with mastocytosis. CT neck, thorax, abdomen and pelvis were
normal. The upper and lower endoscopy revealed polyps in gastric antrum,
the histology was nodular foveolar hyperplasia. Case 2: Female, 38 years
consulted for 3 episodes of anaphylaxis following the ingestion of ﬁsh,
shellﬁsh and quinoa. The skin prick test was positive to white ﬁsh and
shrimp, speciﬁc IgE were positive to white and blue ﬁsh and shrimp. The
initial serum tryptase was 11 mg/L, 3 months was 14 mg/L. Later, patient had
a new anaphylaxis episode, after unnoticed consumption of ﬁsh. Bone
marrow biopsy compatible with mastocytosis. The study with lower and
upper endoscopy with chest and abdominal CT scan ruled out visceral
involvement.
Conclusions: Both cases of systemic mastocytosis show an IgE sensitization
to drugs and to food whose main manifestation was anaphylactic shock. In the
literature, anaphylaxis was reported in up to 22% of mastocytosis, mostly
men, associated with different triggering stimuli such as muscle relaxants, but
not food. Therefore it is essential to rule out the presence of mastocytosis in
patients complaining of anaphylaxis even in those with allergy study showing
IgE-dependent sensitization.
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Mastocytosis: Importance as Differential Diagnosis in Skin
Diseases. Report of Two Cases
Aida Gonzalez-Carsolio, MD, Adriana Barreto-Sosa, MD, Andres-Leonardo
Burbano-Ceron, MD, Andrea Aida Velasco-Medina, MD, and Guillermo
Velázquez-Sámano, MD. Servicio de Alergia e Inmunología Clínica, Hospital
General de México, Mexico City, Mexico.
Background: Is a heterogeneous disorder characterized by clonal pro-
liferation of mast cells (MCs) leading accumulation in different organs.
Pathologic activation of KIT due to a mutation in codon 816 replacing
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aspartic acid for valine: KIT-D816V (.93%) has been identiﬁed. Cutaneous
Mastocytosis (CM), Classiﬁed in Urticaria Pigmentosa (UP), solitary mastocy-
toma, diffuse, and telangiectasia macularis eruptiva perstans (TMEP). The most
common is the Urticaria Pigmentosa as ﬁxed, reddish brown macular or papular,
urticate in physical irritation (Darier’s sign). WHO Diagnostic Criteria for cuta-
neous Mastocytosis: Presence of at least 1 of skin lesions with Focal dense MC
inﬁltrates (.15 MCs per cluster) or diffuse (.20 cells per high-power ﬁeld).
Methods: We report 2 cases of patients with this disease who were not
diagnosed at ﬁrst. A 51 years old female, who noticed 20 years ago, the
appareance of itchy "spots” in thorax, abdomen and extremities, progressively
increasing in number and size, receiving unspeciﬁed treatments without im-
provement. On examination, we found brown macules with sharp borders, 0.3
to 0.5 cm erythema and Dariers sign, disseminated lesions on thorax, should-
ers and extremities. A 45 year old female, who noticed 2 years ago, the
appareance of freckles in neck, arms, thorax and legs progressively increasing
in number, who in stress are itchy. Receiving multiple treatments without
improvement. On examination disseminated brown macules with sharp bor-
ders ,0.5 cm with Dariers sign.
Results: In both patients, the biopsies taken had ﬁndings compatible with
mastocytosis (inﬂammatory inﬁltrate with perivascular lymphocytes, histio-
cytes and mast cells). Mast cells were not quantiﬁed. We realized a genetic
study in search of c-kit mutation. Once the diagnosis was considered and
treated accordingly, they had a good control of symptoms.
Conclusions: Mastocytosis is diagnosed by clinical features and histological
inﬁltrate of mast cells. The skin is the organ most frequently affected. These
patients previously received multiple treatments with no clinical improvement
suggest inadecuate diagnosis. Histologically, compatible although no quanti-
ﬁcate mast cells, but a mutation of c-kit was found. It is important to consider
this disease in the differential diagnosis of pruritic skin disorders since an
appropriate treatment with an improvement in quality of life also must be
aware of the risk of anafylaxis and its potential triggers.
MECHANISMS OF ASTHMA AND ALLERGIC
INFLAMMATION
500
Human Mononuclear Phagocytes Are Regulated by a Cross-talk
with Epithelial Cells
Ilja Striz, MD, PhD,1 Eva Brabcova, MSc,1 Libor Kolesar, MSc,1 Alena
Sekerkova, MSc,1 Marcela Jaresova, MSc,1 and Stephen I. Rennard, MD2.
1Institute for Clinical and Experimental Medicine, Prague, Czech Repub-
lic; 2Pulmonary and Critical Care, University of Nebraska Medical Center,
Omaha, NE.
Background: Cell-cell interactions are particularly important for modulating
the monocyte to macrophage transition in tissue compartments. Both cell
membrane contacts and soluble signals from the environment might be
involved in these interactions. The aim of our study was to characterize gene
expression proﬁles of human mononuclear phagocytes induced by a co-
culture with epithelial cells.
Methods: Human THP-1 macrophages were co-cultured with A549 epithelial
cells either directly or separated by a ﬁlter insert. At different time points,
THP-1 cells were aspirated and the mRNA expression was evaluated by
multiplex Real-time RT-PCR, the release of selected cytokines was evaluated
by Luminex technology or ELISA. The phenotype of both cultured cells was
evaluated by ﬂow cytometry.
Results: Co-culture with epithelial cells induced a number of cytokine genes
(IL-1 beta, IL-6, IL-10, TNF alpha, IL-19, GM-CSF,.etc) together with upre-
gulation of genes associated with NFkappaB activation including REL, RELB,
transcription co-activator BCL3, MALT gene, and NFKB1 subunit. Our recent
study has conﬁrmed the role of NFkB signalling by inhibition of IL-6 release
from co-cultured cells by p65 siRNA transfection1. Phenotypic pattern of THP-1
cells co-cultured with epithelial monolayers showed maturation and activation
associated changes such as CD14 upregulation associated with higher release of
the soluble form (sCD14) from macrophage membrane.
Conclusions: Our data suggest that properties of human mononuclear
phagocytes in tissues are highly inﬂuenced by their immediate interactions
with other, e.g. epithelial cells. These factors might be of particular
importance in ﬁnal steps of differenciation of monocytes/macrophages into
fully competent effector cells.
REFERENCE
1. Striz I, Brabcova E, Kolesar L, Liu XD, Brabcova I, et al. Epithelial cells
modulate genes associated with NF kappaB activation in co-cultured human
macrophages. Immunobiology. In press. doi:10.1016/j.imbio.2011.04.009.
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Activation of PAR-2 Induces Myoﬁbroblast Transformation via
a TGF-b and GSK-3b/b-catenin Dependent Pathway in Tissue
Remodeling in the Asthmatic Lung
Tomoko Suzuki, MD, PhD,1 Gregory Downey, MD,2 Kazuyuki Nakagome,
MD, PhD,3 Makoto Nagata, MD, PhD,3 and Koichi Hagiwara, MD, PhD1.
1Saitama Medical University, Moroyama-machi, Japan; 2National Jewish
Health, Denver, CO; 3Department of Respiratory Medicine, Allergy Center,
Saitama Medical University, Moroyama-Machi, Japan.
Background: Asthma is a chronic inﬂammatory lung disease, and airway
remodeling denotes the pathophysiologic modiﬁcations of normal airway wall
structure, including changes in the composition and organization of the airway
wall’s cellular and molecular constituents. These structural alterations are largely
irreversible in chronic severe asthma and lead to symptoms associated with
chronic airﬂow limitation. However, the pathogenetic mechanisms leading to
these responses remain unclear. According to recent reports, lung-resident ﬁbro-
blasts and smooth muscle cells have been implicated in the pathogenesis of
airway remodeling. Myoﬁbroblasts are proposed to be the primary effector cells
of lung ﬁbrotic responses and are characterized by expression of a-smooth
muscle actin (a-SMA) stress ﬁbers. Transforming growth factor (TGF)-b is
known to induce the transformation of ﬁbroblasts to myoﬁbroblasts. Protease
activated receptor (PAR)-2, a G-protein-coupled receptor activated by serine
proteases such as trypsin and mast cell tryptase has been recognized as a key
molecule in inﬂammation and ﬁbrotic changes. We hypothesized that activation
of PAR-2 induces TGF-b and a-SMA expression and hence may be one of the
potential mechanisms of airway remodeling in asthma.
Methods: Cultured human lung ﬁbroblasts (MRC5) were exposed to trypsin
(5 nM) or a speciﬁc activating peptide, PAR-2AP. Secreted TGF-b was
measured using ELISA. Cell associated a-SMA was assessed by Western
blot analysis and immunostaining and activation of downstream signaling
pathways was assessed by Western analysis.
Results: Activation of PAR-2 by trypsin or PAR-2AP induced TGF-b secre-
tion that peaked between 4 and 8 hours. These were correlated with activa-
tions of c-fos and c-jun. Induction of a-SMA expression peaked between 4
and 24 hours. Treatment with trypsin or PAR-2AP also induced phosphory-
lation of GSK-3b on serine 9 and nuclear translocation of b-catenin.
Conclusions: Activation of PAR-2 induces TGF-b secretion through the AP-
1 transcription factor complex leading to myoﬁbroblast transformation via the
GSK-3b/b-Catenin Pathway.
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Plasminogen Activator Inhibitor-1, Fibrinogen and Lung
Function in Adolescents with Asthma and Obesity
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Background: Obesity promotes a low-grade systemic inﬂammatory state that
may act on the lung to exacerbate asthma. There is little information on the
relationship between systemic inﬂammation and lung function in children and
adolescents.
Methods: One hundred and seventy eight adolescents (boys and girls) were
involved, 4 groups were divided according to their diagnosis: non-obese and
non-asthmatic controls (n ¼ 38), non-obese asthmatics (n ¼ 31), obese non-
asthmatics (n ¼ 62), obese asthmatics (n ¼ 47). The levels of PAI-1 and
ﬁbrinogen were determined in blood samples. The lung function was evalu-
ated by measuring forced expiratory ﬂow in 1-second (FEV1) and forced vital
capacity (FVC1).
Results: Compared to healthy controls, obese adolescents with or without
asthma showed higher levels of ﬁbrinogen (328.4 6 54.9, 324.9 6 68.9 and
289.2 6 61.5 mg/dL, respectively) and PAI-1 (36.0 6 17.3, 53.2 6 22.3 and
52.6 6 24.7 ng/mL, respectively) and reduced FEV1/FVC ratio (87.7 6 7.7,
81.6 6 8.6 and 81.7 6 6.9, respectively). In the whole studied subjects,
FEV1/FVC ratio showed signiﬁcant inverse correlation with PAI-1 (r ¼
-0.185), ﬁbrinogen (r ¼ -0.157), BMI (r ¼ -0.303), insulin(r ¼ -0.198) and
HOMA (r ¼ -0.173). In the 78 asthmatic subjects, FVC correlated positively
with BMI, no signiﬁcant correlation was observed between FEV1/FVC ratio
and BMI, HOMA, PAI-1 or ﬁbrinogen.
Conclusions: Our data demonstrated that the degree of systemic inﬂamma-
tion and the degree of obesity in the whole studied groups correlated to the
reduced lung function. Further studies are needed to identify the pathophys-
iologic mechanism for such association.
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Peculiarities of Immune Response in Young Children with
Recurrent Wheezing
Olga Gromadina, MD, Olga Zaytseva, PhD, and Irina Shklyaeva, MD.
Department of Pediatrics, Moscow State University of Medicine and
Dentistry, Moscow, Russia.
Background: Wheezing is a very common symptom in young children.
However some questions of immune response are unclear for subsequent
prediction in recurrently wheezy children. We studied immunological status
of kids with recurrent wheezing.
Methods: 31 children with acute episode of wheezing were included in this
study (24 male, 7 female) aged from 1 to 5 years, admitted in Vladimir
Children Clinical Hospital. These children were the main group. Control
group included 6 children with no signs of chronic and acute inﬂammatory
diseases. Examination included studying clinical data, detecting in blood
serum subpopulations of lymphocytes, expression of Toll-like receptors
(TLR-2, TLR-4) on surface of monocytes (rMFI) and number of pro-
inﬂammatory monocytes (CD141CD161).
Results: We revealed high frequency of bronchial obstruction (more than 5
episodes) at 30% of children in main group. 30% of children had allergic
diseases (atopic dermatitis, allergic rhinitis) in history. In group of children
with recurrent wheezing revealed increased levels of pro-inﬂammatory
monocytes (9,44 6 1,55% vs 5,39 6 0,79%) and expression of receptors
TLR-2 (8,28 6 0,44 conventional units vs 6,59 6 0,98). In children with
recurrent wheezing an inverse correlation was found between frequency of
respiratory infections and level of expression of TLR-2. For frequency of
acute respiratory infection up to 6 times in year the level of expression of
TLR-2 was 9,11 6 0,31 and for children with monthly episodes of acute
respiratory infections level was 7,6 6 0,25 (r ¼ -0,380, P , 0,05). Expres-
sion of TLR-4 was also tended to lower level in sickly children (2,2 6 0,16
and 2.7 6 0,14), however, no signiﬁcant differences weren’t revealed (r ¼
-0,370, P . 0.05). At the same time in patients with allergic diseases showed
signiﬁcant reduction in expression levels of TLR-4 compared with patients
without atopy (P , 0,05).
Conclusions: Increased levels of pro-inﬂammatory monocytes and expres-
sion of TLR-2 correspond to local inﬂammatory reaction and adequate
immune response against background of acute respiratory illness in children
with relapsing course of bronchial obstruction. Changes of TLR-2 and TLR-4
in group of children with recurrent wheezing conﬁrm, on the one hand, risk of
bronchial asthma in children with predisposition to atopy. On the other hand
these changes can be the result of oppression of innate immunity in children
with persistent character of bronchitis.
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Participation of Invariant NKTCells (Va24Ja18) during Asthma
Exacerbation in Children
Juan Carlos Carpio-Pedroza, MSc,1 Blanca Estela del Rio-Navarro, MD,2
Jaime Mariano del Río-Chivardí, MD,2 Amelia Morales-Flores, Biol,1
Luis Antonio Jiménez-Zamudio, PhD,3 Martha Moreno-Lafont, PhD,4
Sigifredo Pedraza-Sánchez, PhD,5 Juan Gilberto Vaughan-Figueroa, PhD,6
and Alejandro Escobar-Gutiérrez, PhD6. 1Investigaciones Inmunologicas, In-
stituto de Diagnostico y Referencia Epidemiologicos, Mexico City, Mexico;
2Alergia e Inmunologia Clinica, Hospital Infantil de Mexico Federico Go-
mez, Mexico City, Mexico; 3Inmunología, Escuela NAcional de Ciencias
Biológicas, Mexico City, Mexico; 4Inmunología, Escuela Nacional de Cien-
cias Biológicas, Mexico City, Mexico; 5Bioquímica, Instituto Nacional de
Nutrición y Ciencias Médicas Salvador Zubirán, Mexico City , Mexico; 6In-
vestigaciones Inmunologicas , Instituto de Diagnostico y Referencia Epide-
miologicos, Mexico City, Mexico.
Background: Invariant NKT cells (or type 1 NKT cells) co-express CD3
marker and NK receptors (CD56, CD161) and use a single type of TCRa
chain (Va24Ja18 for humans), comprising CD4-CD8-, CD41 and CD81
subsets. Participation of these cells and their cytokines in asthmatic children,
in stable conditions and under exacerbation, was studied.
Methods: Three groups on children (6–12 years old) were selected: 1) asth-
matics under exacerbation attack (AE) within the ﬁrst 24 hours after the attack
and before starting any treatment; 2) asthmatics with stable asthma (SA),
without symptoms for at least a month before bleeding; and 3) healthy con-
trols (HC) without history of asthma, atopy and with normal lung function
were selected in the Allergy and Clinical Immunology Service, Hospital
Infantil de Mexico. Invariant NKT cells and subset levels as well as intracel-
lular cytokines were evaluated in whole blood by 4-color ﬂow cytometry
(antibodies against CD3, CD4, CD8, CD161, Va24, IL-4 and IFN-g).
Results: Proportion of iNKT cells among total CD31 cells in HC group
was 0.9%, while in SA patients they were increased up to 2.6%; interest-
ingly, during exacerbation such cells were dimished (1.8%). Concerning
iNKT CD41 cells were 0.6% in HC, 1.8% in SA, and 0.7% in AE, while
iNKT CD81 cells were 0.1% in HC, 0.7% in SA, and 0.4% in AE. Both
iNKT cell subsets expressed intracellular IFN-g and IL-4 cytokines in AE,
SA and HC but predominantly IFN-g in iNKT CD81 cells from AE
patients.
Conclusions: iNKT cells participation in asthma pathogenesis was con-
ﬁrmed. Increase of IFN-g production in patients with exacerbations, may
provide a regulatory environment to stabilize the condition.
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Cytokine Proﬁle Characterization in Patients Infected with
AH1N1 Inﬂuenza Virus
Nadia L Lopez-Espinosa,1 Lizet Vizuet-Garcia,1 Atzin Robles-Contreras, MSc,2
Maria C Jiménez-Martínez, MD, PhD,2,3 and Victor M Bautista-de Lucio,
PhD1. 1Research Unit, Institute of Ophthalmology, D.F., Mexico; 2Research
Unit and Department of Immunology, Institute of Ophthalmology, D.F., Mexico;
3Department of Biochemistry, Faculty of Medicine, UNAM, D.F., Mexico.
Background: In 2009, an outbreak of severe respiratory infection caused
by inﬂuenza AH1N1 virus affected Mexican people, previously in 1996 in
Guangdong province (China) an outbreak of H5N1 inﬂuenza started
spreading throughout Asia and the western Palearctic in 2004 to 2006.
Chinese patients were studied and it was observed a deleterious immune
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response related to cytokine storm, mainly characterized by higher levels of
IFN and other proinﬂammatory cytokines causing fatal infections or severe
clinical outcome. Until now, is unknown the cytokine proﬁle involved during
AH1N1 infection, thus it was the aim of this study.
Methods: Serum samples were obtained from 39 infected patients and their
close contacts from the ﬁrst wave outbreak of inﬂuenza AH1N1 and were
storage at –808C until cytokine determination, Human Inﬂammatory and Th1/
Th2/Th17 Cytometric Bead Array Kit was used to determine cytokine concen-
tration in serum samples. Cytokine protein arrays were performed to know
relative expression of 36 cytokines with the Proﬁler Array Membrane from
R&D Systems. The results are reported on relative units (RU). It was performed
with ANOVA test, considering P , 0.05 as statistically signiﬁcant.
Results: We did not ﬁnd signiﬁcative statistical differences between patients
and their close contacts in IFN-g, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, 12p70,
IL-17A, and TNF evaluated with cytometry. However, the proteomic analysis
showed a signiﬁcant increased (P , 0.05) in G-CSF, I-309, sICAM-1, IL-
1Ra. IL-16, IL-23, IL-27, I-TAC, MIP-1a, and E1-Serpin compared with the
closed contacts.
Conclusions: AH1N1 patients showed higher levels of IL-27. We observed
more RU of sICAM expression in patients and closed contacts, possibly due
to the IL-27 signaling. IL-23 were increased in AH1N1 patients, this cytokine
is involved in the IFN-g secretion and in the generation of memory CD4 T
cells. These results suggest that AH1N1-patients developed an immune re-
sponse characterized by IL-27 and IL-23. We need more studies to determine
if this cytokines are related with the memory response induction.
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Basal T Cell Subpopulations of Normal Humans Vary by Stress
Hormone Receptor Polymorphisms
Kristina Rehm, PhD, Lianbin Xiang, MD, and Gailen Marshall, MD, PhD.
Medicine, University of Mississippi Medical Center, Jackson, MS.
Background: Psychological stress has been correlated with allergy and
asthma activity although there are clearly individual differences in the
responses to the same stressor. These individual differences could be
inﬂuenced by stress hormone receptor binding afﬁnity, which could be
altered by single nucleotide polymorphisms (SNPs).
Methods: We categorized differences in immunoregulatory proﬁles from
peripheral blood mononuclear cells (PBMC) of 207 normal volunteers
according to various glucocorticoid (GCR) and beta-2 adrenergic receptor
(B2AR) polymorphisms. Subjects were genotyped for SNPs by real time RT-
PCR, and Th1, Th2, Th1/Th2 ratio, and CD31CD41CD25hiFoxp31 cell
numbers were measured using ﬂow cytometry. Each immune parameter in the
SNP groups was compared to the wild-type (WT) gene.
Results: Signiﬁcant differences were observed in B2AR SNPs Gly16Arg for
Th2 (means: WT gly/gly, 1.89; arg/arg, 2.58; P ¼ 0.003) and Th1/Th2 ratio
(medians: WT gly/gly, 10.18; arg/arg, 6.89; P ¼ 0.004) and Gln27Glu for
Th1 (means: WT gln/gln, 17.21; gln/glu, 19.4 P ¼ 0.031; glu/glu, 19.82 P ¼
0.049). No differences were observed based upon GCR SNPs tested (BCL1;
NC363S; TTh1111; A3669G).
Conclusions: These data suggest that SNPs from various components of the
stress-immune network (such as hormone and cytokine promoters and receptors)
may be useful for subgrouping of immune responses to more accurately evaluate
psychoneuroimmunological components of stress risk in individual subjects.
This approach has signiﬁcant clinical potentials in identifying those patients who
may be most susceptible to stress effects on their immune balance.
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The Protective Effects of Exogenous IGFBP-3 on Allergic Airway
Inﬂammation through Blockade of vegf Production
Seung Yong Park, MD, PhD, Kyung Hwa Choi, MD, PhD, Chi Ryang
Chung, MD, So Ri Kim, MD, PhD, Seoung Ju Park, MD, PhD, Heung Bum
Lee, MD, PhD, Yang Keun Rhee, MD, PhD, and Yong Chul Lee, MD, PhD.
Department of Internal Medicine, Chonbuk National University Hospital,
Jeonju, South Korea.
Background: Bronchial asthma is a chronic airway inﬂammatory disease that
is usually accompanied by increased vascular leakage, resulting in plasma
exudation. Vascular endothelial growth factor (VEGF) plays as a pro-
inﬂammatory mediator as well as a vascular permeability factor in bronchial
asthma. Insulin-like growth factor (IGF)-I is also involved in the inﬂamma-
tory process associated with bronchial asthma and it has been demonstrated to
stimulate VEGF expression. The IGF binding proteins (IGFBPs) are
a complex family of proteins which bind IGFs with high afﬁnity. IGFBPs,
especially IGFBP-3, display distinctive properties and can interfere with
various biological processes. However, there are little data on the effect and
the molecular basis of IGFBP-3 on allergen-induced bronchial inﬂammation
and airway hyper-responsiveness.
Methods: This study was aimed to investigate the related signaling regarding
the action of IGFBP-3 on bronchial inﬂammation and airway hyper-
responsiveness in allergic airway disease of mice.
Results: In this study with an ovalbumin (OVA)-induced murine model of
allergic airway disease, the increases of HIF-1a/HIF-2a activity and VEGF
protein levels in lungs after OVA inhalation were blocked substantially by the
administration of IGFBP-3. We also showed that the increased numbers of
inﬂammatory cells of the airways, airway hyper-responsiveness, and in-
creased levels of IL-4, IL-5, IL-13, and vascular permeability in lungs after
OVA inhalation were signiﬁcantly reduced by the administration of IGFBP-3.
Conclusions: These results indicate that IGFBP-3 may attenuate antigen-
induced airway inﬂammation and hyper-responsiveness through the modu-
lation of vascular leakage and VEGF expression mediated by HIF-1a/HIF-2a
in allergic airway disease of mice.
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Antioxidants Attenuate Airway Remodeling by Regulating NF-
ÊB, NRF2, and HIF in a Murine Model of Chronic Asthma
Seoung Ju Park, MD, PhD, Seung Yong Park, MD, PhD, So Ri Kim, MD,
PhD, Yang Keun Rhee, MD, PhD, and Yong Chul Lee, MD, PhD.
Department of Internal Medicine, Chonbuk National University Medical
School, Jeonju, South Korea.
Background: Reactive oxygen species (ROS) play a crucial role in the
pathogenesis of acute and chronic respiratory diseases. Antioxidants have
been found to ameliorate airway inﬂammation and hyperresponsiveness in
animal models employing short-term exposure to allergen. However, little
data are available on the effect of antioxidants on airway remodeling and
signaling pathways in chronic asthma.
Methods: In the present study, we used a long-term exposure murine model
of allergic airway disease to evaluate the inﬂuence of an antioxidant, L-2-
oxothiazolidine-4-carboxylic acid (OTC) or a-lipoic acid (LA) on airway
remodeling and to explore possible transcription factors and kinases involved
in this effect.
Results: Long-term challenge of ovalbumin (OVA) increased ROS pro-
duction, airway inﬂammation, and airway hyperresponsiveness, and de-
veloped features of airway remodeling such as excessive mucus secretion,
subepithelial ﬁbrosis, and thickening of the peribronchial smooth muscle
layer. Administration of OTC or LA reduced these features of asthma
including airway remodeling, which was accompanied by suppression of
transforming growth factor-b1, vascular endothelial growth factor, and T-
helper 2 cytokines. In addition, OVA-induced activation of nuclear factor-
kB (NF-kB), nuclear factor erythroid 2p45-related factor-2 (Nrf2), hypoxia-
inducible factor (HIF)-1a, and HIF-2a was reduced by OTC or LA. Our
results also showed that OTC or LA down-regulated phosphoinositide 3-
kinase activity and decreased phosphorylation of p38 mitogen-activated pro-
tein kinase but not extracellular signal-regulated kinase 1/2 or c-Jun N-ter-
minal kinase.
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Conclusions: These ﬁndings demonstrate that OTC and LA can inhibit
activation of NF-kB, Nrf2, and HIF and thus attenuate allergen-induced
airway remodeling, suggesting that antioxidants may provide therapeutic
beneﬁt in chronic asthma and other airway disorders.
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CCL3L1ProteinDidNotAffect IL-6Expression, but Signiﬁcantly
Up-regulated IL-10 Expression in the Allergic Response
Byoung Whui Choi, MD, PhD,1 Yoosik Yoon, PhD,2 Jae Chol Choi, MD,
PhD,1 Haeyong Lee, PhD,2 and Sungmin Bae, PhD2. 1Respirology and Al-
lergy, Chung-Ang University Hospital, Seoul, South Korea; 2Microbiology,
Chung-Ang University College of Medicne, Seoul, South Korea.
Background: Previously, we found that the mean copy number of CCL3L1
in patients with asthma was signiﬁcantly lower than that of control subjects
(3.13 vs 3.75, P ¼ 0.001). We investigated its possible molecular mechanism
using a human monocytic cell line stimulated with house dust mite extract.
Method: The THP-1 human monocytic cells were stimulated with various
concentrations of HDM extract. After stimulation, assay-on-demand gene
expression products (Applied Biosystems) were used to evaluate mRNA
expression of CCL3L1 (Hs 00609691_ml), IlL-6 (Hs00174131_ml), and IL-10
(Hs00961622_ml) levels as measurement of mRNA levels by real time PCR.
Results: Treatment of THP-1 cells with various concentration of HDM
extract induced marked up- regulation of the expression of cytokines IL-10
and IL-6, which indicated that allergic responses were efﬁciently induced.
Recombinant CCL3L1 protein had no effect on cytokine expression of THP-1
Cells in absence of HDM extract stimulation. In the presence of HDM extract
(10 ug/mL) stimulation, CCL3L1 protein signiﬁcantly up-regulated IL-10
expression (Ratio to ng/mL CCL3L1) dose-dependantly (0 ug/mL CCL3L1
1 0.3;12.4, 10 ug/mL CCL3L1; 15.81 1.1, 50 ug/mL CCL3L1; 16.81 0.3,
100 ug/mL CCL3L1; 18.01 0.8, (P . 0.05), but did not affect IL-6 expres-
sion (P . 0.05).
Conclusion: The signiﬁcantly elevated asthma risk in subjects with a low
copy number of the CCL3L1 gene which may be down-regulating IL-10
expression, not IL-6 expression.
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Caspase-9 is Involved in CD30 Activation Induced
Eosinophil Apoptosis
Jin Tack Kim, MD,1 Hyun Hee Kim, MD,2 and Joon Sung Lee, MD2.
1Pediatrics, The Catholic University of Korea, Uijeongbu, South Korea;
2Pediatrics, The Catholic University of Korea, Pucheon-si, South Korea.
Background: We evaluated whether ligation of CD30 incite the apoptosis,
and investigated the mechanisms of CD30 induced eosinophil apoptosis is
dependent on caspase activation.
Methods:We puriﬁed eosinophils using MACS system. Expression of CD30
on eosinophils were measured and eosinophils were cultured in the wells
pretreated with anti-CD30 mAb and isotype control IgG1, IL-5 and
dexamethasone in RPMI 1640 media supplemented with 10% FBS, and the
apoptotic rate were measured using ﬂow cytometry. To evaluate whether
caspase-9 is involved in CD30- induced eosinophil apoptosis, the apoptotic
rate was evaluated with addition of caspase-9 inhibitor and the expression of
procaspase-9 was also measured using Western blot.
Results: The apoptotic rates of eosinophils cultured in the presence of anti-
CD30 mAb were signiﬁcantly increased to 29.1 6 6.1% and 47.3% 6 4.7%
compared with 17.1 6 6.7% and 29.4 6 9.2% of the control at 4 and 24
hours, respectively (both P , 0.05). Caspase-9 inhibitor suppressed the mAb
induced eosinophil apoptosis from 54.86 6.9% and 71.56 11.6% to 24.56
6.0% and 47.8 6 11.4% at 18 and 36 hours, respectively (both P , 0.001).
We also showed the expression of procaspase-9 with the mAb was dimin-
ished compared with that of the control and of IL-5.
Conclusions: This study showed CD30 activation enhances the eosinophil
apoptosis and the effect is mediated by Caspase-9 activation.
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Role of NLR (Nucleotide Oligomerization Domain (NOD)dlike
Receptor) on Allergic Inﬂammation in a Mouse Model of
Allergic Rhinitis
Soo Whan Kim, MD,1 Ji-Hyeon Shin, MD,2 and Hyang Rim Park2. 1Otolar-
yngology HNS, The Catholic University of Korea, Seoul St. Mary’s Hospital,
Seoul, South Korea; 2The Catholic University of Korea, Seoul, South Korea.
Background: Recently, a new set of pattern-recognition receptors, the
nucleotidebinding oligomerization domain (Nod)-like receptors (NLRs), have
emerged. Their activation, either by allergens or microbes, triggers an
inﬂammatory response. Objective: To investigate whether recognition of
bacterial microbial-associated molecular patterns in the nose may result in
susceptibility to developing allergic reactions, and to understand the
molecular mechanisms by which such triggers block natural tolerance.
Methods: Ligands of intracellular microbial-associated molecular pattern
recognition receptorsdthe nucleotidebinding oligomerization domain (Nod)-
like receptors, Nod1 and Nod2dwere given intranasally with antigen, and
their ability to modulate airway tolerance was analyzed. Seventy 2 mice were
randomized to one of 6 groups: control (n ¼ 12), AR (n ¼ 12), pre NOD1
group (n ¼ 12), pre NOD2 group (n ¼ 12), post NOD1 group (n ¼ 12), and
post NOD2 group (n ¼ 12). All mice except for the control group were
sensitized by an intraperitoneal injection of ovalbumine (OVA) and alumi-
num hydroxide. Two weeks after sensitization, all sensitized mice were chal-
lenged intranasally with OVA. The control group was received phosphate
buffered saline intranasally. The allergic symptom after the ﬁnal challenge
was recorded. Interleukin (IL)-5, interferon-g (IFN- g), and IL-10 levels in
nasal lavage ﬂuid (NALF), as well as serum OVA-speciﬁc IgE levels were
measured. The number of eosinophils in lamina propria was evaluated. The
levels of T-bet, GATA-3, and Foxp3 mRNA expression in splenic mono-
nuclear cells were determined by real-time polymerase chain reaction.
Results & Conclusion: We show that a Nod-like receptor is a novel,
previously unrecognized, pathway that adversely links innate and adaptive
immunity and leads to allergic rhinitis.
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MUTANT IL-3: A Common Down Regulator for Components of
IGE Mediated Signal Transduction Pathway
Anand Singh, PhD,1 A.B. Singh,2 and Pawan Kumar2. 1Allergy and Immu-
nology, Institute of Genomics and Integrative Biology, Delhi, India; 2Institute
of Genomics and Integrative Biology, Delhi, India.
Background: FcepsilonRI mediated signal pathway in basophils and mast
cells leads to release of histamine and other mediators. Interestingly,
basophils from 10% to 20% of the population do not release histamine and
other mediators on activation of the IgE signal transduction pathway and this
has been attributed to the absence of tyrosine kinases Lyn and Syk.
Objective: To investigate the association between histamine releasibility,
total serum IgE, expression of IgE receptor and role of IL-3 with reference to
non-releaser phenotypes in Indian population.
Methods: Basophils from peripheral blood of healthy adults were puriﬁed by
density gradient centrifugation and negative immuno-selection. Histamine
release assay was performed ﬂourometrically. Total serum IgE was estimated
by ELISA and assessment of IgE receptor expression was carried out by ﬂow
cytometry. Assessment of Lyn and Syk expression were carried out by ﬂow-
cytometry.
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Results: Histamine release after ConA challenge varied from 0% to 100% in
Indian subjects. Eighteen percent subjects showed less than 5% histamine
release (non-releasers). Flow-cytometric analysis revealed a signiﬁcantly
reduced expression of FcepsilonRI in non-releaser basophils (P , 0.05).
Total serum IgE levels were also signiﬁcantly low (P , 0.05) in non-releas-
ers. Flow-cytometric analysis revealed a signiﬁcantly reduced expression
of Lyn and Syk kinases in basophils (P , 0.05). Histamine release also
signiﬁcantly correlated with expression of Lyn and Syk kinase (P , 0.05).
Non-releasers showed the presence of SNP at 179 (T-C), which leads to the
one amino acid change at 8th position in the mature IL-3 from serine to
proline.
Conclusions: About 18% of the Indian subjects studied showed non-releaser
phenotype and also had reduced serum IgE levels and FcepsilonRI expression
reduced Lyn and Syk kinase expression. Non-releasers have shown the
presence of less potent isoform of IL-3/P8, which is suspected to be common
factor responsible for the non-releaser phenotype. This needs to be extended
to a larger sample size and could be a potential target for the development of
therapeutics for allergic patients.
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IL-17 Role in the Regulatory Function of B Cells
Alejandro Vazquez-Tello, PhD,1 Rabih Halwani, Msc, PhD,1 Qutayba
Hamid, MD, PhD,2 and Saleh Al-Muhsen, MD, FRCPC, FAAP3. 1Asthma
Research Chair and Prince Naif Center for Immunological Research, College
of Medicine, King Saud University, Riyadh, Saudi Arabia; 2Meakins-Christie
Laboratories, McGill University, Montreal, QC, Canada; 3Department of
Pediatrics, Asthma Research Chair and Prince Naif Center for Immunology
Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: B lymphocytes are known to be important cytokine sources in
inﬂammation and play a pathogenic role by producing autoantibodies in
a number of chronic immunological diseases. However, B cell depletion
therapy induced an exacerbation of symptoms in some patients with
autoimmune disorders, revealing that B cells play a critical anti-inﬂammatory
role mediated by IL-10 release. We therefore investigated the human B cell
regulatory subset producing IL-10 in response to stimulation.
Methods: Highly puriﬁed B cells were obtained from tonsils by using
a multiple-step separation procedure which included rosette depletion,
adherence depletion, CD31 cell magnetic-activated depletion and CD191
magnetic-activated positive cell selection. CD201 purity was veriﬁed by
ﬂow cytometry. The CD191CD201 B cells were stimulated with CpG
oligonucleotide, IL-4, IFN-gamma, anti-CD40, IL-17A and IL-17F, either
alone or in combination. The expression of both IL-6 and IL-10 mRNA was
analyzed by quantitative RT-PCR and by ELISA. B regulatory cell subsets
expressing IL-10 and the markers CD5 and CD1d were quantiﬁed by FACS
analysis. B cell proliferation was determined by 3H thymidine incorpora-
tion or CFSE labeling.
Results: Expression of IL-10 mRNA and protein in puriﬁed B cells from
tonsils was weakly stimulated by anti-CD40 antibody, CpG oligonucleotide
or with IL-17. When B cells were simultaneously stimulated with IL-17, anti-
CD40 antibody and CpG oligonucleotide, the mRNA and protein expression
of IL-10 was strongly increased (n ¼ 3; P # 0.001). B cells proliferation was
also signiﬁcantly increased. In contrast, stimulation with IL-4 alone or in
combination with anti-CD40 antibody, decreased the expression of IL-10
(n ¼ 3; P # 0.001).
Conclusions: TLR9 receptor stimulation synergizes with CD40 and IL-17
receptors stimulation in the induced proliferation and potent release of IL-10
cytokine while decreasing IL-6 production in B cells. These novel ﬁndings
provide evidence that B lymphocytes might be an important source of the
anti-inﬂammatory IL-10 cytokine, and provide novel evidence that stimula-
tion of B lymphocytes with IL-17 cytokine could be an important regulatory
mechanism in immune responses.
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Role of TH-17 Cytokines in Steroid Insensitivity in Peripheral
Blood Mononuclear Cells. Relationship to GR-alpha and GR-
beta Expression
Alejandro Vazquez-Tello, PhD,1 Rabih Halwani, Msc, PhD,1 Qutayba
Hamid, MD, PhD,2 and Saleh Al-Muhsen, MD, FRCPC, FAAP3. 1Asthma
Research Chair and Prince Naif Center for Immunological Research, College
of Medicine, King Saud University, Riyadh, Saudi Arabia; 2McGill Univer-
sity, Meakins-Christie Laboratories, Montreal, QC, Canada; 3Department of
Pediatrics, Asthma Research Chair and Prince Naif Center for Immunology
Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Inhaled corticosteroids represent the most common treatment
for asthma. Although most asthmatic patients respond well, a signiﬁcant
proportion of severe asthmatics require higher doses or even fail to respond to
oral or inhaled corticosteroids. We previously reported that glucocorticoid
receptor-beta is associated with corticosteroid resistance in airway epithelial
cells from asthmatic patients and that Th-17 cytokines increase steroid
insensitivity via a mechanism involving GR-beta upregulation. We aim to
investigate whether IL-17A and F cytokines enhance steroid unresponsive-
ness in PBMCs from normal subjects and severe asthmatics via the
upregulation of GR-beta isoform.
Methods: PBMCs were cultured for 48 hours in the presence or absence of
IL-2, IL-4, IL-17A, IL-17F or IL-23 cytokines. Expression of GR-alpha, GR-
beta, GILZ and IL-6 was determined using Q-RT-PCR and/or Western
blotting. Response to Dexamethasone was determined on the inhibition of
PHA-induced proliferation by Dexamethasone (IC50) using either 3H-thymi-
dine or CFSE-labelled cells. Response of the cells to Dexamethasone-induced
apoptosis was determined by Annexin-V staining.
Results: Treatment of PBMCs with IL-17A1IL-17F combined signiﬁ-
cantly decreased the mRNA expression of GR-alpha while that of GR-beta
was signiﬁcantly upregulated. IL-21IL-4 in combination signiﬁcantly de-
creased GR-alpha expression but had no effect on GR-beta receptor expres-
sion. IL17A1IL17F1IL23 combined induced the highest ratio of GR-beta/
GR-alpha in PBMC from normal subjects. Either IL-17A1F or IL-21IL-4
combinations signiﬁcantly decreased the inhibitory effect of Dexametha-
sone on PBMC proliferation (IL-17A1F IC50 ¼ 190 nM Dex; IL-214
IC50 ¼ 1060 nM Dex), when compared to the control without cytokine
stimulation. In the presence of Dexamethasone, IL-21IL-4 but not IL-
17A1IL-17F, inhibited the expression of the glucocorticoid-inducible leu-
cine zipper gene (GILZ) in PBMCs from both normal (60%) and asthmatics
(45–50%), which was correlated with signiﬁcantly higher apoptosis in cells
stimulated with IL-21IL-4.
Conclusions: IL-17A, IL-17F, IL-2, and IL-4, which are known to be
upregulated in the blood and lung tissue of asthmatics, contribute to steroid
insensitivity of severe asthmatic patients by modulating the expression of GR-
alpha and GR-beta receptors on peripheral blood PBMCs. GR-beta could
protect PBMCs from Dex-induced apoptosis. Furthermore, the increased GR-
beta/GR-alpha ratios by both IL-17A1F and IL-214 cytokines correlates




Prevalence ofLatex SensitizationBetweenMedicine andDentistry
Students from Nuevo Leon University
Arya González, MD,1 Sandra González-Díaz, MD, PhD,1 Alfredo Arias-
Cruz, MD,1 Alejandra Macías-Weinmann,1 and Pablo Rodríguez, MD2. 1Re-
gional Center of Allergy and Clinical Immunology, University Hospital,
Monterrey, Mexico; 2Regional Center of Allergy and Clinical Immunology,
Monterrey, Mexico.
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Background: Latex allergy has become an important health problem in the
last 2 decades. Sensitization in general population is about 1%.1 Healthcare
workers have a frequency of 2% to 25%.2 There is not information about this
issue in Mexico. Our objective was to know and compare prevalence of latex
sensitization in last grade medicine and dentistry students of the Nuevo Leon
University.
Methods: This was an observational, prospective and comparative study.
Last grade medicine and dentistry students were invited to participate.
Spanish version of the Latex Allergy Questionnaire (ACAAI recommended)
and skin tests for latex: prick test (SPT) (latex extract Allerstand 1:20 w/v),
prick by prick (PBPT) (latex gloves) were performed in every patient.
Positive control was histamine 10 mg/mL and glycerinated solution for
negative control (allerstand) using duotip test disponsable. SPT and PBPT
were read 15 min after application and positive result were interpreted as
a wheal diameter of 3 mm more than negative control. Data were analyzed for
demographics with Statistical Package for Social Sciences (SPSS v16.0), for
comparison between groups of sensitized patients ﬁsher exact test was
performed.
Results: Study included 378 patients, 213 (56.3%) dentistry students and 165
(43.7%) medicine students. Male/female ratio was 1.2/1 for medicine and
0.36/1 for dentistry. Average age was 23 years in both groups. General
sensitization to latex was 7.1% (27), per group medicine was 6% (10) and
dentistry 7.9% (17). Almost to all commercial extract, only one patient in
each group was positive to gloves PBPT. By questionnaire 10.9% medicine
group and 17.3% of dentistry group report symptoms with latex, but only
14.8% of dentistry group was Skin test positive, no one in medicine group.
Rhinitis or conjunctivitis symptoms were found in 48.1% of sensitized
patients. Most frequent foods associated with symptoms were pineapple
(2.6%), ﬁg (2.1%), avocado (1.9%) and kiwifruit (1.6%). There was no
statistical difference between both groups sensitization (P ¼ 0.549).
Conclusions: Latex sensitization was more common in healthcare students
than references in general population but symptoms referred to latex no
always are demonstrated by IgE sensitization, so delayed mechanism must be
take in to account to get a better diagnosis and treatment approach.
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Proﬁle of Latex Sensitization in Children with Myelomeningocele
of São Paulo, Brazil
Adriano Sa, MD,1 Roberta Camilo, MD,1 Sergio Cavalheiro, PhD,2
Marcia Mallozi, PhD,3 and Dirceu Solé, PhD1. 1Department of Pediatrics,
and; 2Department of Neurology, Federal University of São Paulo, São Paulo,
Brazil; 3Pediatrics, UNIFESP, São Paulo, Brazil.
Background: Latex allergy is an important cause of occupational allergy and
is responsible for numerous allergic reactions in sensitized individuals.
Methods: The study included 55 children with myelomeningocele followed
at a specialized center. In addition to a standard questionnaire and skin tests
for immediate cutaneous hypersensitivity to aeroallergens and total latex, the
patients underwent determination of serum total and speciﬁc IgE to latex and
its fraction recombinants.
Results: The rates observed were 45% for sensitivity and 20% for latex
allergy (sensitization with clinical symptoms). Twenty-four (43.6%) patients
were atopic and the average age at the ﬁrst episode of reaction to latex was
44.5 months, with cutaneous reactions being the most frequently reported
(72.7%). Speciﬁc IgE to fractions rHev b1, 3, 5, 6.1 and 6.2 were detected in
more than 50% of patients allergic to latex. The group comprising sensitive
and allergic patients was different from non-sensitized subjects regarding the
following variables: atopy, rhinitis, angioedema, average number of surgeries,
patients with 4 or more surgeries, use of ventricular peritoneal shunt, the
presence of at least one skin tests for immediate cutaneous hypersensitivity
positive for aeroallergen and serum total IgE greater than 200 KU / l.
Multivariate analysis showed as signiﬁcant: current asthma, atopy and the
number of surgeries undergone.
Conclusions: Our study documented the raised prevalence of awareness and
latex allergy in patients with myelomeningocele. Speciﬁc IgE to fractions
rHev b1, 3, 5, 6.1 and 6.2 were detected in more than 50% of children with
myelomeningocele who are allergic to latex. The number of surgeries that the
patients were submitted to determined higher levels of speciﬁc IgE, especially
rHev b5 and 6.01. History of current asthma, atopy, and having undergone 4
or more surgeries were independent risk factors identiﬁed for latex allergy.
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Speciﬁc IgE to Recombinant Allergens of Latex and Foods in
Patients With Spina Biﬁda
Laila Sabino Garro, MD, Antonio Abilio Motta, MD, PhD, Jorge Kalil, MD,
PhD, and Pedro Giavina-Bianchi, MD, PhD. Clinical Immunology and
Allergy, University of Sao Paulo, Sao Paulo, Brazil.
Background: To identify the proﬁle of speciﬁc IgE to recombinant allergens
of Hevea brasiliensis and fruits in patients with spina biﬁda and latex allergy.
Methods: Cross-sectional study with 210 pacients aged 0 to 18 who have
spina biﬁda and who have been followed in a Reference Hospital in Sao
Paulo, Brazil. Patients were submitted to a questionnaire about immediate
latex allergy symptoms.Their blood were collected for the detection of serum
speciﬁc IgE to latex, speciﬁc IgE to rHev b1, 3, 5, 6.01, 6.02, 8, 9, 11, and
speciﬁc IgE to avocado, banana, chestnut, potato and papaya, through
ImmunoCAP technique.
Results: Patients’ mean age was 7.9 years, and 108 (51%) were female. The
mean time to the ﬁrst surgery was 40 days, and patients presented an average
of 4 or more surgeries during their lives. Forty-seven (22%) patients reported
symptoms related to latex, predominantly cutaneous symptoms (85%). The
latex recombinant allergens most related with symptoms were rHev b1 (19
patients, 68%) and rHev b3 (11 patients, 39%). On the other hand, tests were
also positive to rHev b5 (9 patients, 32%), rHev b6.01 (12 patients, 43%),
rHev b6.02 (12 patients, 43%), rHev b9 (patients 1, 4 %), and rHev b11 (9
patients, 32%). All tests were negative to rHev b8. Although, 36 (17%)
patients tested positive to at least one of the food allergens, they did not
present symptoms related to them. Balloons and latex gloves were the main
objects associated with the onset of symptoms.
Conclusions: In this study, the prevalence of latex allergy was 22%. We
observed a different proﬁle of latex sensitization in relation to the literature.
Patients do not present latex-fruit syndrome, in spite of cross-sensitization.
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Association between Clinical History and Speciﬁc IgE
Recombinants Latex Allergens
Laila Sabino Garro, MD, Antonio Abilio Motta, MD, PhD, Jorge Kalil, MD,
PhD, and Pedro Giavina-Bianchi, MD, PhD. Clinical Immunology and
Allergy, University of Sao Paulo, Sao Paulo, Brazil.
Background: To identify the proﬁle of sensitization to latex allergens in
patients with spina biﬁda, with and without symptoms of latex allergy.
Methods: Cross-sectional study with 210 pacients aged 0 to 18 who have
spina biﬁda and who have been followed in a Reference Hospital, in São
Paulo, Brazil. Patients were submitted to a questionnaire for immediate symp-
toms related to latex allergy and they were classiﬁed as symptomatic (S) or
asymptomatic (A), depending the presence of immediate symptoms on expo-
sure to latex. Their blood were collected for the detection of serum total IgE,
speciﬁc IgE to latex, and speciﬁc IgE to rHev b1, 3, 5, 6.01, 6.02, 8, 9, 11,
through ImmunoCAP technique.
Results: Patients’ mean age were 7.9 years and 108 (51%) were female. S
patients were 47 (22%). For these patients, 28 (60%) had at least one speciﬁc
IgE positive test and 19 (40%) presented all tests negative. The A cases
accounted for 163 (78%) patients. For these patients, 57 (35%) had at least
one speciﬁc IgE test positive and 106 (65%) presented all tests negative. The
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prevalence of sensitization to recombinant latex allergens is not the same
among patients S and A: rHev b 1 (S ¼ 68%, A ¼ 49%), rHev b3 (S ¼
39%, A ¼ 28%), rHev b5 (S ¼ 32%, A ¼ 21%), rHev b6.01 (S ¼ 43%, A ¼
23%), rHev b6.02 (S ¼ 43%, A ¼ 19%), rHev b8 (S ¼ 0, A ¼ 2%), rHev b9
(S ¼ 4%, A ¼ 5%), rHev b11 (S ¼ 32%, A ¼ 23%).
Conclusions: In this study, the prevalence of latex allergy in spina biﬁda
patients is 22%. In symptomatic patients, the sensitivity of speciﬁc IgE tests is
very poor. The proﬁle for rHev b positivity is different in symptomatic and
asymptomatic patients.
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Occupational Flaxseed Allergy (Conjunctivitis): A Case Report
Carlos Albarran, and Arnaldo Capriles-Hulett,. Allergology, Hospital San
Juan de Dios, Caracas, Venezuela.
Background: K.F. a19 y/o male, with history of atopy (food/drug allergy,
atopic dermatitis, asthma and or rhinitis) developed conjunctivitis (without
cough or rhinitis) on the third month of exposure to an enviroment of dust
from sieving of grounded ﬂaxseeds (imported brown organic Canadian
Flaxseeds). Exposure to this dust caused severe itching and tearing with
prominent development of "red eyes" quickly after begining of exposure with
complaints abating during weekends. Due to eye scratching he also developed
signiﬁcant palpebral edema and purulent discharge.
Methods: Prick skin Testing (H-S Lancetter, results read at 15 minutes, with
positive and negative controls) with a panel of 20 inhalant and food allergens
(Diater Labs,Argentina) was performed.
Results: Commercial Allergens were found negative at 10 minutes reading (0
mm papule/0 mm erythema) for inhalants such as: mites, blomia t epithelia,
grass pollen, shellﬁsh, ﬁsh mix and coconut; only positive ﬁnding was to
mold mix (5 mm papule/10 mm erythema). Prick to Prick skin (PtP) testing to
a solution of ﬂaxseed: 1 gram of ﬂaxseed brought by patient from work place/
1 mL of phenol saline, was positive at 20 minutes (papule 12 mm/erythema
25 mm). This same solution was applied to 5 controls (with no symtomps
after ingestion of esposure to ﬂaxseed) and found negative.
Conclusions: Patient improved with use of goggles and removal from sieving
area, remaining free of symtomps, as of today. Patient refused mucosal/oral
challenge with a solution of ﬂaxseed or other allergy diagnostic procedures.
Though PtP skin testing may suggest a possible IgE mediated reaction.
(1) Unable to be conﬁrmed by other means (challenge, IgE intears for ﬂax-
seed, etc); this is-to our knowledge- the ﬁrst case of isolated conjunctivitis
from exposure to ﬂaxseed sieved dust. Flaxseed Allergy, in spite of its
wide spread used and human consumption (mainly as dietary ﬁber) has
been infrequently reported, with occasional cases of anaphylaxis.
(2) We report a case of isolated conjunctivitis on exposure to dust from
sievings of ground ﬂaxseed.
REFERENCES
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Involvement of Il-10 Gene Promoter Polymorphisms in the
Susceptibility for Childhood Asthma
Kyung Won Kim, MD, PhD, Kyung Eun Lee, PhD, Jung Yeon Hong,
Mi Na Kim, Won Il Heo, Myung Hyun Sohn, MD, PhD, and Kyu-
Earn Kim, MD, PhD. Department of Pediatrics, Yonsei University College
of Medicine, Seoul, South Korea.
Background: Asthma and atopy have a complex background which may
result from the interaction of genes and environments. Interleukin (IL)-10 is
known to play various roles in immune-regulating and anti-inﬂammatory
responses. The aim of this study was to evaluate the possible effect of the IL-
10 promoter polymorphisms on susceptibility to childhood asthma.
Methods: We recruited 333 patients with atopic asthma, 55 with non-atopic
asthma, and 248 normal controls. We performed a genetic association study
of 3 genetic polymorphisms (IL-10–1082A.G, IL-10 –819T.C, –592A.C)
of the IL-10 promoter.
Results: There was no difference between atopic asthma, non-atopic asthma
and normal controls in allele, genotype or haplotype frequencies of these IL-
10 polymorphisms. However, the –1082A.G polymorphism and ATA hap-
lotype in the IL-10 promoter gene were associated with airway hyperrespon-
siveness (AHR) and the –819T.C, –592A.C, and ATA and ACC
haplotypes were also shown to be related with serum eosinophil cationic
protein (ECP).
Conclusions: Our results suggest that the polymorphisms within the IL-10
promoter may have a disease-modifying effect in asthmatic airway.
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Serum NT-3 and NT-4 Levels are Associated with Clinical
Severity in Asthmatic Children
Aleksandra Szczepankiewicz, PhD,1 Marta Rachel, PhD, MD,2
Paulina Sobkowiak, MD, PhD,1 Zdzis1awa Kycler, MD, PhD,1 Irena Wojsyk-
Banaszak, MD, PhD,1 Natalia Schoneich, MD,1 and Anna Breborowicz, MD,
PhD1. 1Poznan University of Medical Sciences, Poznan, Poland; 2University of
Rzeszow, Rzeszow, Poland.
Background: Neuronal modulation of inﬂammation and airway hyper-
responsiveness has been well described in asthma and neurotrophins provide
the link between inﬂammation and neuronal dysfunction. In humans, elevated
BDNF, NGF and NT-3 levels have been found in bronchoalveolar lavage
ﬂuid (BALF) following allergen provocation. Moreover, BDNF levels are
signiﬁcantly higher in untreated asthmatic patients in comparison to those
treated with inhaled glucocorticoids and non asthmatic controls. It has also
been shown that allergic inﬂammation increases local all 4 neurotrophins
production that are important mediators of eosinophil survival in BALF. The
aim of this study was to analyze if levels of neurotrophins in serum of
asthmatic pediatric patients are altered in the course of disease (exacerbation
and asymptomatic period) and therefore may serve as potential biomarkers for
disease activity or symptoms severity.
Methods: In the study we included 98 children diagnosed with asthma. The
blood was collected twice: during exacerbation and in the asymptomatic
period. The serum levels of 4 neurotrophins (BDNF, NGF, NT-3, NT-4) were
analyzed with use of DuoSet ELISA Development Kit (R&D). Statistical
analysis was performed with Statistica v. 9.0.
Results: Analysis revealed no signiﬁcant differences in neurotrophins levels
in serum between asthmatic patients during asthma exacerbation and asymp-
tomatic period. However, we found that serum levels of NT-3 and NT4
correlate with disease severity, being signiﬁcantly lower in mild asthmatics as
compared to patients with moderate and severe asthma (P , 0.01).
Conclusions: Our results suggest that neurotrophins levels do not seem to
correlate with the clinical symptoms activity in the course of asthma, however
2 of them (NT-3 and NT-4) correlate with disease severity.
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Association between Eosinophilic Airway Inﬂammation and
Persistent Airﬂow Limitation in Asthmatic Children
Yong Ju Lee, MD,1 Hyun Hee Lee, MD, PhD,2 Kyung Won Kim, MD,
PhD,3 Myung Hyun Sohn, MD, PhD,3 and Kyu-Earn Kim, MD, PhD3.
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1Pediatrics, Kangnam Sacred Heart Hospital, Hallym University, Seoul,
South Korea; 2Department of Pediatrics, Kwandong University College of
Medicine, Myongji Hospital, Goyang, South Korea; 3Department of Pediat-
rics, Yonsei University College of Medicine, Seoul, South Korea.
Background: Eosinophilic airway inﬂammation contributes to persistent
airﬂow limitation in adults with severe asthma. We aimed to evaluate the
association between eosinophilic inﬂammation in induced sputum and
pulmonary function, and persistent airﬂow limitation in children.
Methods: A total of 92 asthmatic children and 72 control children were
enrolled in this study. Eosinophil count (%) and eosinophil cationic protein
(ECP) levels were measured in induced sputum. We performed spirometry
and methacholine challenge test while measuring total eosinophil count, total
serum IgE, and serum ECP in all subjects. Subjects with persistent airﬂow
limitation were deﬁned as the patients with postBD FEV1/FVC below the
lower limit of controls, which is subtraction of 2 standard deviation from the
mean ratio.
Results: Asthmatic children had signiﬁcantly higher levels of sputum
eosinophils (18.1 6 21.5 vs 0.5 6 1.3%, P , 0.001) and sputum ECP
(2.3 6 0.7 vs 1.6 6 0.6 log ug/L, P , 0.001) compared to controls. No
differences in sputum eosinophils and ECP among 4 asthmatic groups divided
by the degree of persistent airﬂow limitation. Sputum ECP level had statis-
tically signiﬁcant inverse correlation with postbronchodilator (postBD) FEV1
(r ¼ –0.307, P ¼ 0.001) and postBD FEV1/FVC (r ¼ –0.286, P ¼ 0.002),
whereas sputum eosinophils didn’t show any correlation with postBD FEV1
and postBD FEV1/FVC.
Conclusions: Our ﬁndings suggest that sputum eosinophilic inﬂammation,
especially ECP, is associated with pulmonary function and persistent airﬂow




Not All WhoWheeze Have AsthmadTracheal Diverticulum with
Stenosis of Trachea in 9 Years Old Boy
Frantisek Kopriva, MD, PhD. Pediatrics, Medical Faculaty, Olomouc, Czech
Republic.
Background: A tracheal diverticulum (TD) is very rare congenital malfor-
mation. The prevalence is about 0.3% in children over 10 years of age
according to ﬁberoptic bronchoscope studies and it is rarely reported in
clinical practice (3). Here we describe our recent exprience in succesfully
diagnosing and treating a 9-years old box suffering from membranous
stenosis of trachey with trachea diverticulum.
Methods: A 9-year old boy (personal history negative as to trauma of
respiratory tract and intubation and atopy) was admitted to hospital with
wheezing and progressive dyspnoe during the 6 months to restrict basic
locomotion and reading of text. Multislice computed tomography of the chest
showed surprising incidental ﬁnding of a tracheal diverticulum (6 mm · 2
mm) and 3-dimensional reconstruction CT stenosis of trachea approximetly
1,5 cm below vocal corde and oriﬁcium of tracheal diverticulum (the 2nd
cartilage of trachea). Pulmonary function tests revealed reduction of spiro-
metric values, with no post-bronchodilator change. Subsequent ﬂexible bron-
choscopy showed circular stenosis of trachea and oriﬁcium of TD.
Subsequently, the vaporization by NdYAG laser - Sharplan 3000, with en-
ergy of 30 W was performed via ﬂexible bronchoscopy under general anes-
thesia with a laryngeal mask. The dilatation by balloon (Boston Scientiﬁc)
was performed to widen the diameter of trachea up to 8 mm.
Results: After 1 week, pulmonary function test revealed normal parameters
without pathological symptoms.
Conclusions: In conclusion, we have summarized the case of an 9-year old
boy with membranous stenosis of trachey and trachea diverticulum, a very
rare congenital anomaly. This abnormality can be clearly diasgnosed by
multislice CT and 3-dimensional reconstruction CT stenosis of trachea. Using
the interventional bronchoscopy of membranous circular stenosis of trachea is
adequate solution in children too.
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Reccurent Wheezing in ChildhooddIs It Always Asthma?
Andrea Daniela Muti, MD,1,2 Daniela Iacob, MD,3 Dorins Farcau, MD,3
and Otilia Fufezan, MD4. 1Immunology and Allergy, University of Medicine
and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania; 2Pulmonology,
CHU, Clermont-Ferrand, France; 3Pediatrics, University of Medicine and
Pharmacy, Cluj-Napoca, Romania; 4Radiology, 3rd Pediatric Clinic, Cluj-
Napoca, Romania.
Background: Clinical presentation of the bronchial obstruction in children is
most often highly suggestive of bronchiolitis, recurrent wheezing or asthma.
Methods: We present the cases of 2 patients diagnosed with recurrent
bronchiolitis and asthma, non-responsive to treatment.
Results: The ﬁrst patient, a 9-year-old boy presented wheezing, non-
productive cough, dyspnea, aquous rhinorrhea, sneezing and nasal itching
interpreted as allergic asthma associated to allergic rhinitis as he was
sensitized to house-dust mites and dog. A treatment with inhaled cortico-
steroids and antihistamine was prescribed with little improvement of asthma
symptoms. Six months later the patient presented for vomiting and productive
cough. Thoracic ultrasound suggested achalasia, diagnosis conﬁrmed through
esophageal manometry and barium swallow. Surgical treatment led to
resolution of asthma-like symptoms with persistence of a mild intermittent
rhinitis. In the second case, a female patient presented 2 episodes of
uncomplicated bronchiolitis during the 6th and the 7th month of life and
a 3rd episode of bronchiolitis complicated with pneumonia during the 8th
month of life. When admitted for the 3rd episode, she presented an oxygen
saturation of 91% in ambient air. Thoracic ultrasounds oriented the diagnosis
towards a diaphragmatic hernia, conﬁrmed through barium swallow and
barium enema. The surgical treatment of the hernia determined the resolution
of respiratory symptoms. Unfavourable clinical course, despite correct
treatment in both cases required additional investigations which ﬁnally led
to the correct diagnosis and treatment.
Conclusions: For the differential diagnosis of non-responsive bronchial
obstruction in children, one must think to digestive diseases. Ultrasound was
the elective non-invasive method in diagnosing our cases.
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Bronchial Hyperresponsiveness in Children with Suggestive
Asthma Symptoms
Silvia Sanchez-Garcia, MD, Inis Fermin, MD, Victoria Andregnette, MD,
Pablo Rodriguez del Rio, MD, Carmelo Escudero, MD, and M. Dolores
Ibañez, MD. Allergy Section, Hospital Infantil Universitario Niño Jesús,
Madrid, Spain.
Background: To describe the accuracy of bronchial challenge tests
(methacholine and manitol) to measure bronchial hyperresponsiveness in
a group of pediatric patients with suggestive symptoms of asthma.
Methods: We selected 27 patients who attended consecutively to our
outpatient clinic complaining of 1 or 2 symptoms of asthma. They showed
a normal baseline spirometry and a negative bronchodilator test. All of them
underwent unspeciﬁc bronchial provocation challenges. Methacholine was
performed using the tidal volumen technique and a PC20 # 8 mg/mL was
considered positive. Dry-powder mannitol (Osmohale TM) was administered
according to the manufacturer’s recommendations and the challenge was
considered positive if a PD15 # 635 mg resulted. We performed both tests
with an interval of at least 1 week. Asthma drugs were avoided during the 2
weeks previous to every challenge. Skin prick tests (SPT) to the most com-
mon aeroallergens were also performed.
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Results: Mean age was 9 (ranged 7–15) years, 18 (66.6%) children
were male. Symptoms referred were: 14 (51.8%) cough, 10 (37%) seasonal
cough or shortness of breath, 5 (18.51%) cough or shortness of breath due to
physical exercise and 1 (3.7%) cough or wheezing related to respiratory
infections. SPT were positive in 59.2% of the children. Eighteen (66.6%)
out of 27 patients had bronchial hyperresponsiveness, and 10 (37.03%) were
non atopic. All patients with a positive response to manitol showed also
positivity to methacholine. Mean methacoline PC20 among responders was
0.64 6 4.08 mg/mL. Manitol was performed in 16 children, and resulted
positive in 8 cases (50%) with a mean PD15 of 146.8 6 246.49 mg. In 2
(25%) out of 8 patients with negative manitol resulted a positive
methacholine.
Conclusions: Methacholine and manitol challenge tests detected bronchial
hyperresponsiveness in more than a half of the studied children with
suggestive asthma symptoms. Methacoline was more sensitive than manitol.
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Relationship between Fractional Exhaled Nitric Oxide (Feno) and
ForcedExpiratoryVolume inOne Second (Fev1) andForcedVital
Capacity (Fvc)i Children with Asthma
Myung-Sung Kim, MD,1 and Yeong Ho Rha, MD2. 1Department of Pediat-
rics, Idream Children’s Hospital, Daegu, South Korea; 2Department of Pe-
diatrics, Kyung Hee University Hospital, Seoul, South Korea.
Background: Measurement of fraction of exhaled nitric oxide (FeNO) is
a relatively simple, noninvasive, and reproducible test for detection of
endogenous inﬂammatory signals in childhood. The aim of this study was to
evaluate the correlation between FeNo levels and forced vital capacity (FVC)
and forced expiratory volume in the ﬁrst second (FEV1) in a group of steroid-
naive childhood asthma.
Methods: The study was conducted in a group of 60 steroid-naive asthmatic
children (50 atopic and 20 nonatopic; mean age 7 years) who presented to
Kyung Hee University Hospital and 20 healthy children. All patients
underwent measurement of FeNO, skin prick tests with common inhaled
allergens, and blood eosinophil, and ﬂow-volume spirometry. FeNO levels
were measured by chemiluminescence during exhalation into the NO
analyzer. Measurements of FeNO in parts per billion (ppb) and spirometry,
including FEV1 and FVC, were performed.
Results: Compared to the healthy volunteers, FeNO was elevated in both
groups of asthmatics. The mean FeNO level in the asthmatic children was
18.6 ppb. FeNO in the atopic asthma group was higher than in the group
of nonatopic asthmatics. There was statistically signiﬁcant correlation
between FeNO levels and FEV1 (r ¼ -0.36, P , 0.016) and FVC (r ¼
-0.40, P , 0.01).
Conclusions: FeNO levels were related with pulmonary functions in




Evaluation of the September Epidemic of AsthmaExacerbation in
Children in Our Practice
Agnes Nemeth II, MD, MSc. Department of Pediatrics, Faculty of Medicine,
Semmelweis University, Budapest, Hungary.
Background: Know that the rate of asthma exacerbations are increased in
September after summer vacation with the beginning of school year.
Investigators have been studied this problem and it was supposed that the
main cause could be the stress associated with school return what can worsen
asthma symptoms. Beside this children returning to school after summer
vacation are reexposed to respiratory viral infections, sensitizing allergens in
the school enviroment, and can be connected with poor compliance in the
medication in the summer period.
Methods:We stared to investigate that what could be the causative factors in
children who suffered dyspnoe and other signs of asthmatic exacerbation
from September 2008, could we present the increasing number of these
patients in hospitalization rate, and could we conﬁrm the changing
compliance of the regular medication during the summer period? A short
questionaire was constructed and was given the patients who were admitted
to hospital (162) with asthma exacerbation symptoms. Then 45 patients were
selected for a longer follow up to investigate their compliance in medication.
We investigate from the database of our Hospital the asthmatic patient’s
admission rate from 2006.
Results: We could present from 2006 the increasing number of patients
admitted because of asthma exacerbation in September in every year. We
could present the increased number of schoolage patient among all of the
admitted patients in the fall season. We compared the genders which were
similar. We found that the symptom of asthma was worse in the fall season.
We conﬁrmed the higher number of patients suffering from viral infections.
But the changing rate among patient who stopped the medication during
summer was low as 13%.
Conclusions: We could conﬁrm the September epidemic of asthma
exacerbation among our patients as well. Compare the international inves-
tigations the main cause of the September epidemic of asthma connecting
with the beginning of the school year and the increasing number of viral
infections at this period of the year. Fortunately our patient compliance was
good but we have to continue our patients’ education from time to time.
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ElevatedAsthma Prevalence inMexican-AmericanChildren in El
Paso, Texas
Alma Ruiz-Payan, PhD. Health Science, University of Texas at El Paso, El
Paso, TX.
Background: In the United States, among Hispanics, Mexican American
have the lowest rate of asthma1,2 This study was designed to determine the
prevalence of asthma among 5 to 17 year-old children, in El Paso Texas,
a community area with a 65.8 % of Hispanic of origin Mexican families.
Methods: Of March 2006 to May 2010, a cross-sectional screening survey
was administered to 1108 children of 751 families selected at random from 50
strata of the El Paso County. We used self-reported history of physician-
diagnosed asthma. Data were analyzed to determine the prevalence of lifetime
and current asthma. Associations between asthma outcomes and variable
trigger were evaluated. Chi-square tests were used for statistical comparison.
A P value less than 0.05 was considered to be signiﬁcant. Multivariate lo-
gistic regression (GENMOD) adjusting for repeated measures for the family
was used to determine the risk of childhood asthma.
Results: Self-reported physician-diagnosed asthma was reported for 25.8 %
of children, and current asthma identiﬁed in 20.5 % respectively. The
prevalence was statistically higher in boys than tin girls (P , 0.05). 243
(90%) Children asthmatics are atopic and 437 (51.8%) children non-asth-
matics are atopic. Smoking occurred inside 23.8% of households.26.3% of
children had an indoor dog or cat and 21.2% of caregivers reported cock-
roaches inside the home.
Conclusions: Prevalence of physician-diagnosed asthma in Hispanic of
Mexican origin, ever asthma and current asthma, were higher than those
reported from the Centers for Disease Control and Prevention, the prevalence
of asthma in 2007. Although most children with asthma are atopic (90%)
a signiﬁcant proportion (51.8 %) of atopic children do not have asthma.
Children with a parent with asthma were almost twice as likely (OR ¼ 2.40)
to have asthma compared those without a parent with asthma. Children with-
a parent and grandparent with asthma were over 4 times likely to have
asthma compared to those without a parent and grandparent with asthma
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(OR ¼ 4.97). Maternal asthma confers greater asthma risk to offspring than
do paternal or parental asthma.
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Prevalence of Bronchitis and Revealing of the Risk Factors in the
Children’s Population
Nino Adamia, MD, PhD,1 Ivane Chkhaidze, MD, PhD,1 Maia Kherkheulidze,
MD, PhD,1 Maia Kherkheulidze, MD, PhD,1 Eka Kandelaki,2
Nani Kavlashvili, MD, PhD,2 Nana Nareklishvili, MD,3 Eka Liluashvili,
MD,4 Natia Chkhaidze, MD,5 Ketevan Barabadze, MD, PhD,6
Ketevan Gotsiridze, MD,7 and Ketevan Gotsadze, MD, PhD8. 1General Pe-
diatrics, Tbilisi State Medical University, Tbilisi, Georgia; 2Pediatrics, State
Medical University, Tbilisi, Georgia; 3Pediatrics, Mikheil Guramishvili Pe-
diatric Clinic, Tbilisi, Georgia; 4Residence Department, Tbilisi State Medical
University, Tbilisi, Georgia; 5Tbilisi State Medical University, Tbilisi, Geor-
gia; 6Pediatrics, Tatishvili Medical Center, Tbilisi, Georgia; 7Mikheil Gur-
amishvili Pediatric Clinic, Tbilisi, Georgia; 8Tatishvili Medical Center,
Tbilisi, Georgia.
Background: It is well known that with change oc climatic conditions cases
of various diseases increase and especially, with cold climate, the frequency
of acute respiratory diseases, especially, the inﬂuenza, rhinites, bronchitis,
etc. grows.
Objective: To study of prevalence of bronchitis and its risk factors in
children’s population.
Methods: Study was conducted in the selected pediatric clinics of Tbilisi and
involved 698 children from 6 months to 5 years age, based on the random and
representative groups. Epidemiological study was conducted by cross-section
method. Questioning was provided based on the questionnaire specially
developed for this purpose. Study of the factors of the cause signiﬁcance was
provided on the basis of anamnesis data. Obtained results were processed by
means of special software package SPSS/V11.5.
Results: According to the questioning, acute bronchitis was indicated 3
times, in 56.2% of the children’s population, of which 47.4% were boys and
52.6% - girls. 43.8% of the population suffered complications in a form of
pneumonia. In 21.9% of cases bronchitis was diagnosed for the ﬁrst time.
Wheezing was regarded as a risk factor (78.5%), serous nasal discharge
(87.3%), cough, regarding its nature (68.3%) (short cough, wet cough pro-
ductive cough), in part of the respondents lacrimation was indicated (35.6%),
there was also indicated in children the immunodeﬁciency, sex, socioeco-
nomic status, heredity factor, overcrowded homes. Prevalence of the symp-
toms of bronchitis was quite higher (P , 0.05) among girls, compared with
the boys. 98.9% of the respondents with the symptoms of bronchitis stated
that the disease was of seasonal nature, mostly from early October to end of
March (P , 0.01).
Conclusions: Thus, single-stage epidemiological study showed that fre-
quency of bronchitis in children’s population is quite high, with prevalence
among girls (59.9%).
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Atopic Phenotype in Children under 6 Years with Persistent
Wheezing in El Salvador
Mauricio Flores, MD,1 and Pablo Salazar, PhD2. 1Pediatrics Service, Hospi-
tal Nacional San Rafael, Santa Tecla, El Salvador; 2Dr. José Matías Delgado
University, Antiguo Cuscatlán, El Salvador.
Background: Asthma is the most common chronic disease of childhood and
the leading cause of childhood morbidity1. Even if an early intervention could
improve their symptoms, the diagnosis of asthma in the ﬁrst years of age is
difﬁcult. This study is the ﬁrst effort to describe the atopic proﬁle and the risk
of developing asthma in a group of children from El Salvador with recurrent
wheezing.
Methods: A questionnaire was designed for parents to determine the atopic
background, while skin tests were performed in children. We used the
modiﬁed Asthma Predictive Index (APIm)2 to assess the risk of developing
asthma.
Results: 65 children under 6 years were evaluated, with an average age of 3.5
years. The average age of onset of wheezing was at 11 months of age. Family
history of asthma, chronic rhinitis and eczema were presented respectively at
25%, 19% and 8% of the population. 42% of our population presents allergic
rhinitis and 37% eczema. Among the factors related to wheezing risk, we
found that one third of the population was born via caesarean section with
a breastfeeding average of 3.76 months; also we found the presence of pets in
26% of households, a passive smoking and exposure to wood smoke in 17%
and 35% of the studied population respectively. 23 children were sensitized to
respiratory allergens. Dust mites were found in 73% of children sensitized.
The APIm was positive in 66% of the population.
Conclusions: This is the ﬁrst cohort of children described under 6 years with
recurrent wheezing in El Salvador. We found an early presentation of
wheezing, caused not only by viral conditions. These children had strong
personal and family atopic background with a high rate of sensitization to
respiratory allergens, especially dust mites. Most of the children studied are at
risk of presenting asthma in later ages.
REFERENCES
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Comparison of Exhaled Nitric Oxide and Spirometry in Hispanic/
Latino Children Living in Miami to Those Living in
Latin America
Miguel J Lanz, MD,1 and Angela Bautista, BS2. 1Allergy and Asthma,
AAADRS Clinical Research Center, Coral Gables, FL; 2AAADRS Clinical
Research Center, Coral Gables, FL.
Background: Differences in atopic markers of inﬂammation has been shown
to be due to varying environmental exposures between individuals. There is
sparse information in the literature to compare the levels of atopic
inﬂammatory markers in Hispanics/Latinos from distinctly different environ-
ments. Our aim was to study the levels of these clinical inﬂammatory markers
in this population with similar levels of allergy/asthma control but from
differing environments.
Methods: A retrospective review was limited to Hispanic/Latino children
referred to our Allergy clinic over 6 months. These children were referred by
their pediatrician for diagnosis of asthma and/or reactive airways disease.
Respiratory tests of spirometry with Koko (nSpire Health, Colorado) and exhaled
NO with MINO (Aerocrine, Sweden) was performed in all children by ATS
guidelines. Collection of laboratory results of serum eosinophils and total IgE
was also done. Two groupings were made based on the location of family
residence, either locally in Miami, Florida (MF) or Latin America (LA). All
patients in the MF group were of Hispanic/Latino ancestry, either ﬁrst or second
generation. The country of ancestry represented in the MF group were Colombia,
Costa Rica, Cuba, Ecuador, El Salvador, Mexico, Nicaragua, Venezuela. The
patients in the LA group were coming from Costa Rica, Dominican Republic,
Ecuador, El Salvador, Guatemala, Honduras, and Venezuela.
Results: Thirty-ﬁve children fromMF group and 29 children from the LA
group were found. The mean age in the MF group was 813 years of age and
in the LA group was 914 years of age. There was statistical signiﬁcance
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between eNO in both groups. The mean eNO was 23ppb in the MF group and
41ppb in the LA group. Normal eNO based on age and height for both groups
is less than 15 to 20 ppb. There was no statistical signiﬁcance between
FEV1% in spirometry between both groups. The mean FEV1% in the MF
group was 95 1 13%, and the mean FEV1% in the LA group was 92 1 9%.
No differences were found between groups with either laboratory measures of
serum eosinophils or total IgE.
Conclusions: Our analysis conﬁrmed that despite similar levels of allergy/
asthma control, there was a difference found in eNO in Hispanics/Latinos.
This may be attributable to differences in environmental exposures between
MF and LA.
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Maximum Expiratory Flow in Health Children from the
Metropolitan Area of Monterrey Mexico
Dora Valdes, MD, Sandra González-Díaz, MD, PhD, Alejandra Macías-
Weinmann, Alfredo Arias-Cruz, MD, Jose Canseco, MD, Claudia Gallego,
MD, Diego Garcia-Calderin, MD, Maricruz Calva, MD, Karla Mejia, MD,
and Luis Dominguez, MD. Regional Centre of Allergy and Clinical
Immunology, University Hospital, Monterrey, Mexico.
Background: Studies have been conducted to obtain MEF (maximum
expiratory ﬂow) reference values in healthy children. Factors such as the
regions altitude, humidity, local temperature, and the characteristics of the
study population cause changes in airway resistance that produce different
MEF values. The objetive of this study is to establish normal reference values
for MEF in healthy children from the metropolitan area of Monterrey, Nuevo
Leon, Mexico and compare them with established reference values from other
states of Mexico and the United States.
Methods: We carried out an observational, cross-sectional, descriptive,
comparative study in healthy 6 to 8 year old children, both gender. A
questionnaire that included information about age, weight, and height was
applied. Flowmetry was performed with a Truzone portable peak ﬂow meter
and the highest of 3 values was recorded.
Results: We included 2282 children (1085 boys and 1197 girls) from 19
randomly selected elementary schools. The MEF values obtained were
plotted on graphs in MEF percentiles according to gender and height. When
compared with MEF reference values for authors from different locations,
differences were found.
Conclusions: The variation observed in MEF values in our population
compared with studies performed in other populations shows the need for
clinical demographic data from each region to establish and use characteristic
reference values.
REFERENCES
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Viral Respiratory Infections and the Development of Atopy
and Asthma
Cissy B Kartasasmita, CB, PhD,1 and Budi Setiabudiawan, MD2. 1Child
Health, Respirology Division, Bandung, Indonesia; 2Department of Child
Health, Hasan Sadikin Hospital/School of Medicine Universitas Padjadjaran,
Bandung, Indonesia.
Background: There is an association between severe RSV bronchiolitis in
early childhood, recurrent wheezing, asthma, and allergy in later childhood.
And also becomes increasingly evident that other viruses such as RV, also
showed association with the development of asthma. The objective of this
study is to know the relationship between viral respiratory infections in the
ﬁrst 5 years of age and the development of atopy and asthma.
Methods: This study is a prospective follow-up study in 2 communities, 9
years after a respiratory infection study was performed. Assessment included
questionnaires, physical examination, skin prick tests (SPT), pulmonary
function test (PFT), and reversibility testing.
Results: Three hundred thirty-two children, age 7 to 14 years, including 182
(54.8%) boys, were enrolled in the study. In 86 children, histories of viral
respiratory infections (RSV, RV, and hMPV) were detected. The rate of
positive SPT was high (81.6%), and 15 (4.5%) children showed dermatogra-
phism. The percentage of positive SPT among children with and without viral
respiratory infections was almost similar (83.4% vs 85.4%). The positive SPT
. 1 in children with history of viral respiratory infections was 65.9%; 5.9%
with 1 positive, 27.1% with 2 to 3 positive, 20% with 4 to 5 positive and
18.8% with . 5 positive; while the positive SPT . 1 in the non viral re-
spiratory infections was 75,3%; 9.3%, 23.9%, 30.4%, and 21.1%, respec-
tively. The difference between those 2 groups of children was not
signiﬁcant (P ¼ 0.076). History of asthma in the children with history of
respiratory infections was higher compared with the non infections group
(19.7% vs 8.1%). However, the spirometry results show no difference (P
. 0.05) of FEV1 , 80%, FVC , 80%, FEV1/FVC , 80% and bronchodi-
lator response . 12%, between those 2 groups.
Conclusions: The positive rate of SPT in the children is high, but no
difference is found between history of viral respiratory infections in early life
in relation to the later development of atopy and asthma. The spirometry test
results show no difference between the 2 groups.
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Clinical Characteristics of Eosinophilic Asthma Compared to
Noneosinophilic Asthma in Children
Yong Ju Lee, MD,1 Kyung Won Kim, MD, PhD,2,3 Bong Seok Choi, MD,4
Myung Hyun Sohn,MD, PhD,2,3 and Kyu-Earn Kim, MD, PhD2. 1Pediatrics,
Kangnam Sacred Heart Hospital, Hallym University, Seoul, South Korea;
2Department of Pediatrics, Yonsei University College of Medicine, Seoul,
South Korea; 3Institute of Allergy, Yonsei University College of Medicine,
Seoul, South Korea; 4Pediatrics, Good Gangan Hospital, Busan, South
Korea.
Background: Asthma is a heterogeneous and complex chronic inﬂammatory
disease of the airways. Asthma can be classiﬁed as eosinophilic asthma (EA)
or noneosinophilic asthma (NEA). We investigated whether children with EA
and NEA manifest different clinical characteristics.
Methods: A total of 158 children with EA and 89 children with NEA were
enrolled in this study. We performed pulmonary function and methacholine
challenge tests, and measured blood eosinophil count, total serum immuno-
globulin E (IgE), serum eosinophil cationic protein (ECP), and sputum cell
counts.
Results: There were no signiﬁcant differences in age, sex, and body mass
index between the EA and NEA groups. The blood eosinophil count and
serum ECP were higher in EA than in NEA, whereas the total serum IgE was
similar in both groups. Pulmonary function, as measured by forced expiratory
volume in 1 second (FEV1), forced expiratory ﬂow at 25 to 75% of forced
vital capacity (FEF25–75%), and postbronchodilator (postBD) FEV1 were sig-
niﬁcantly decreased in children with EA compared to those with NEA. In EA,
FEV1, FEF25–75%, and postBD FEV1 correlated negatively with sputum eosi-
nophils. In NEA, FEV1/forced vital capacity (FVC) and FEF25–75% correlated
negatively with sputum neutrophils. Sputum eosinophils (in EA) and sputum
neutrophils (in NEA) increased with increase in asthma severity.
Conclusions: The pulmonary function of children with EA is signiﬁcantly
lower than that of children with NEA. In addition, pulmonary function and
asthma severity are associated with eosinophilic inﬂammation in EA and with
neutrophilic inﬂammation in NEA.
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Correlation between Quality of Life and Treatment Adherence in
Childhood Asthma
García Jessica. Universidad Veracruzana, Río Blanco, Mexico.
Background: Asthma is a chronic disease that around 3 million people suffer
from in the world, it is more common the most of them during childhood.
Methods: Determinate correlation between quality of life (QL) and treatment
adherence (TA) on childhood asthma, in pediatric patients between 3 to 17
years old with diagnosis of bronchial asthma. Transverse, retrospective and
correlational study, they were evaluated 59 young patients with conﬁrmed
diagnosis of bronchial asthma, in a period of 2 months (between May to June,
2011), they were evaluated by 2 tests, the Tucson Children’s Assessment of
Sleep Apnea (Tu CASA) which was modiﬁed to QL in children with asthma
and the Morisky Green Levine test was modiﬁed and validated to asthma
disease and TA, the variables were about LQ: snore, mouth-breathing, drows-
iness, behavior and academic performance, and about treatment adherence: if
the patients forgive to take their medicine , schedule for taking correctly
medication, suspension because the patient feels good or bad (in this case
attributed to the drugs), knowledge of effects of medication, if the pediatric
patients need help, and who help them. Miscalculation of 5 percent and re-
liability of 95%, Pearson`s correlation coefﬁcient to evaluate LQ and AT
based on test score.
Results: It was found good LQ in 46 children (77.9%) and 13 patients with
regular LQ (22%), about TA was good in 32 patients (54.3%) and regular to
bad TA in 27 children (45.8%), Pearson’s correlation coefﬁcient was 0.4, and
it was evaluated with Student’s t, and it’s statistically meaningful, P ¼ 0.05.
Conclusions: LQ and TA are connected signiﬁcantly, because it’s a part of
the complete treatment to control asthma, following closed treatment showed
be an important aspect, because there are patients with good life quality and
following partially treatment.
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Effect of Diet Supplementation with Epa-Dhe on Pulmonary
Function Tests and Metacholine Bronchial Challenge Test in
Obese Mexican Children
Luisa Guadalupe Pineda-Bahena, MD, and Blanca del Rio, MD. Pediatric
Allergy and Clinical Immunology, Hospital Infantil de Mexico Federico
Gomez, Mexico City, Mexico.
Background: There is scarce and conﬂicting data of the effect of diet-
supplementation with EPA-DHE on lung physiology in obese children and
adolescents.
Objective: Evaluate the effect of diet-supplementation with EPA-DHE on
pulmonary function tests and methacholine-bronchial challenge test in obese
Mexican children and adolescents.
Methods: Randomized single blinded controlled clinical trial. Sample
consisted in obese children and adolescents with hypertriglyceridemia
attending our clinic, they were randomly assigned to either group 1 (G1),
which received 3 gr/day of EPA-DHEA, or group 2 (G2), which received 3
gr/day of gelatin as placebo daily for 2 months. Spirometry and methacholine
challenge tests were made to both groups at baseline, and 1 and 2 months
later. We obtained central tendency and dispersion measures, and differ-
ences were analyzed by Student’s t test for independent samples, considering
P , 0.05 as statistical signiﬁcance, also intra-group paired differences were
made.
Results: The total sample consisted of 97 obese children and adolescents with
mean age of 126 1.3 years (range of 8–16 years), 46 females (46.9%) and 51
males (53.1%). At baseline both groups had similar spirometric and metacho-
line challenge-test values G1: FVC: 3.48 L/min, FEV1: 3.07 L/min, FEF25 to
75% 31.3 L/min; G2: FVC: 3.33 L/min, FEV1: 2.92 L/min, FEF25 to 75% -
3.3 L/min (P . 0.05). FEV1 was signiﬁcantly reduced in active treatment
group with baseline mean (3.07 L/min) compared to visit 1 (2.94 L/min) and
to visit 2 (2.92 L/min).
Conclusions: Diet-supplementation with EPA-DHEA had no effect on
bronchial hyper-responsiveness assesed by methacholine challenge test after
1 and 2 months of treatment. However diet-supplementation with EPA-
DHEA showed a deleterious effect on FEV1 in the active treatment group, of
notice, this was only a spirometric ﬁnding, no clinical effects were observed
during treatment.
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Use of Complementary and Alternative Medicines by Children
Suffering from Asthma at Mangalore, India
Animesh Jain, MD, DFH,1 and KD Prakruthi2. 1Community Medicine, Kas-
turba Medical College (Manipal University), Mangalore, India; 2Kasturba
Medical College (Manipal University), Mangalore, India.
Background: Patients with chronic diseases including asthma, have a greater
tendency to use Complementary and alternative medicine (CAM) as they are
more concerned about the adverse effects of conventional medicine,
dissatisfaction with their medical care, as well as a subjective feeling of
health improvement with use of CAM. The aim of this study was to determine
the prevalence of the use of CAM, reasons for use of CAM, and sources of
information about CAM among paediatric asthmatic patients in outpatient
department and urban health centre.
Methods: Following approval from Institutional Ethics committee, the data
for this cross-sectional study was collected from parents of 125 paediatric
patients diagnosed with asthma for more than a year waiting to see the doctor
in the outpatient clinic in teaching hospitals and urban health centre of
Kasturba Medical College, Mangalore, India during the period from March
2010 to September 2010. A pre-tested self-administered questionnaire in
Kannada was distributed to the parents, the purpose of the study was
explained, assurance of anonymity was conveyed, and emphasized that the
patient’s decision to complete or decline to complete the survey would not
affect his/her healthcare quality in any way. Written informed consent was
obtained from the participants.
Results: Data regarding 125 children with a mean age of 9.06 years were
collected, the majority were male (n ¼ 76, 60.8%). The prevalence of ever-
CAM use was 72.8% (n ¼ 91). Sixty-three males (69.2%) used CAM com-
pared to 28 females (30.8%) (P , 0.001). Fifty-six (61.5%) CAM users had
not discussed use of CAM with their doctors. The main reason of non-dis-
closure was "the doctor never asked" (n ¼ 59, 64.8%), and the main sources
of information about CAM were family and relatives (n ¼ 45, 49.4%). The
majority of asthmatic patients used Ayurvedic medicines and mixtures (n ¼
35, 38.5%), foods (n ¼ 18, 19.7%) and herbs (n ¼ 16, 17.6%). About 76% (n
¼ 69) of asthmatic patients perceived CAM as good for their disease
management.
Conclusions: Use of CAM among asthmatic patients is relatively high,
particularly among females. The majority of asthmatic patients valued the use
of CAM. Health education of asthmatic patients about CAM is highly
recommended.
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Long-term Follow Up Outcomes of Early Intervention with
Anti-Inﬂammatory Therapy in Patients with Asthma Under
2 Year-old
Masanori Ikeda, MD, Tooru Araki, MD, Nobumasa Takahashi, MD,
Ikuko Nojima, MD, Kunimi Kitada, MD, Kazuhiro Sekimoto, MD, Tomoko
Sakamoto, MD, Hiroshi Ogasawara, MD, Tomoka Okamura, MD,
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and Kaori Fujiwara, MD. Department of Pediatrics, National Hospital
Organization Fukuyama Medical Center, Fukuyama, Japan.
Background: To evaluate the 8- and 11-year follow up outcomes on the basis
of various parameters including remission rate, pulmonary function, FeNO,
IgE level and RAST in children with asthma who developed recurrent asthma
attacks and started early intervention with anti-inﬂammatory treatment for
active remission induction before 2 years of age.
Methods: This study investigated 63 children who presented with recurrent
wheezing between October 1998 and September 2000 and were diagnosed
with asthma in early childhood. After 3 to 5 episodes of recurrent asthma
attacks were observed, administration of regular controller medications (ICS
and LTRA) was started. Subjects were evaluated for the above parameters in
2008 and 2011.
Results: Subjects comprised 41 males and 22 females, with a mean age at
symptom onset of 13.9 months, a mean age at treatment initiation of 18.2
months and a mean IgE level of 485.4 IU/mL at 2 years of age. Among the
subjects, 68.3% and 85.7% were positive for speciﬁc IgE antibody against
dermatophagoides pteronyssinus (Dp.) and egg white, respectively, at 2 years
of age, and 87.3% were positive for speciﬁc IgE antibody against Dp. at 3 to 4
years of age. The severity of asthma at treatment initiation was intermittent in
9 children, mild persistent in 31, moderate persistent in 18 and severe
persistent in 5. The prevalence of asthma symptoms among these children
improved to 9.5% after 3 years and 1.6% after 6 years of treatment. The 8-
year follow up outcome was evaluated in 53 children at a mean age of 10.2
years. The long-term remission (3a5 years) rate was 84.9% (100% for in-
termittent, 88.9% for mild persistent, 71.4% for moderate persistent and
75.0% for severe persistent cases). A mild decrease in pulmonary function
was observed in 27.2% of cases while a mild increase in FeNO was observed
in 48.8% of the children.
Conclusions: Children who had undergone early intervention with anti-
inﬂammatory therapy achieved higher long-term remission rates when
compared with those in previous Japanese studies, although 65.1% of them
had mild abnormalities in pulmonary function and/or FeNO levels. The 11-
year follow up outcome of these children is also reported.
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Asthma Treatment May Be Useful to Treat Recurrent Wheezing
in Infancy
Herberto Jose Chong Neto, MD, PhD, Nelson Rosario, MD, PhD,
Flávia Carnieli Silva, Emanuel Antonio Grasselli, Lylia Fátima Melniski
Bojarski, Cristine Secco Rosario, Bernardo Augusto Rosario, and
Fernando Henrique Chong. Allergy and Immunology, Federal University of
Paraná, Curitiba, Brazil.
Background: There are controversies in treating recurrent wheezing ($3
episodes) in pre-school children. The aim of this study was to verify changes
in treatment of recurrent wheezing infants.
Methods: Cross-sectional study using a standardized and validated ques-
tionnaire (EISL: Estudio Internacional sobre Sibilancias en Lactantes) that
covers physician diagnosis of asthma, and frequency, severity, and treatment
of wheezing episodes. Regarding treatment speciﬁc questions are: Has your
baby been treated with inhaled short-acting b2-agonists by metered dose
inhaler or nebulizer? Has your baby been treated with inhaled corticosteroids?
Has your baby been treated with antileukotrienes? Has your baby been treated
with oral corticosteroids? Parents of infants, ages 12 to 15 months that
attended to Health Centers for routine immunization were interviewed be-
tween August/2005 to December/2006 (EISL Phase I) and September/2009 to
September/2010 (EISL Phase III). Categorical variables are showed as pro-
portion and differences veriﬁed by chi-square test.
Results: Three thousand and 3 parents of infants answered questionnaire in
the EISL Phase I and 22.6% had recurrent wheezing episodes. Five years
later, in the EISL Phase III, 1003 parents participated in the survey and 19.8%
had recurrent wheezing (P ¼ 0.1). Inhaled short-acting b2-agonists continued
to be prescribed in the same frequency (89.6% vs 86.5%, P ¼ 0.21), however
anti-asthmatic drugs were more used [antileukotrienes (6.9% vs 33%, P ,
0.001), inhaled steroids (23.6% vs 37.5%, P ¼ 0.001) and oral steroids
(18.6% vs 26.5%, P ¼ 0.01)] and doctor diagnosis of asthma has increased
(16.2% vs 23%, P ¼ 0.03). There were reductions on night-time symptoms
(73% vs 61.5%, P ¼ 0.001), severity (59.3% vs 42%, P ¼ 0.001) and
emergency room visits (69.3% vs 41.5%, P , 0.001) for recurrent wheezing
infants, but no difference was seen in hospitalization (17.1% vs 12.5%,
P ¼ 0.12).
Conclusions: Recurrent wheezing treatment in infancy has increased in
past years and may have contributed for reducing emergency room visits,
night-time symptoms and severity for wheezing infants.
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Trans oro Pharyngeal Spacer for Inhalers
Prabhakar PV Rao, MD,1 LP Kashyap, MD,2 and Hari Kishan1. 1Pulmonol-
ogy, Katuri Medical College & Hospital, Guntur, India; 2Nuclear Medicine,
Vijaya Diagnostic Centre, Secundrabad, India.
Background:Many of the patients suffering from bronchial asthma (BA) and
COPD do not use the inhalers properly inspite of adequate education,
resulting in inadequate relief. The external spacer (es) with the inhaler needs
an inspiratory rate of 25 ltsmt, not portable and costly. Also the aerosol
deposition in the airways ranges from 20 to 40%only. Wheezy patients with
inadequate usage of the inhalers, cleft lip and cleft palate, geriatric and
odentulous category, obese asnd short neck individuals cannot take the
inhalers properly. Hence an inspiratory effort independent-transoropharyng-
eal spacer (Tops) is developed.
Inclusion criteria:
1. Adults and children above 5 years of age of both sex.
2. Subjects of bronchospasm with or without comorbid cleft lip and cleft
palate.
Exclusion criteria:
1. Patient with exaggerated gag reﬂux.
2. Unconscious patient.
Apparatus:
1. Mini Wright’s Pefr Meter.
2. Tops: it is a patented device made up of ethylene vinyl acetate copolymer.
It has a receptacle for the inhalers, body with an angulation of 110 degrees
bent and a curved tail piece, 150 degrees. Length - 10 cms, internal di-
ameter - 10 mm, snugly ﬁtting in the oropharynx, the distal end overlying
the epiglottis as seen in mri pharynx.
3. External spacer.
4. Salbutamol mdi.
Procedure: One hundred and ﬁfty subjects (m: f 95:56), within the age range
of 8 to 81 years were enrolled in the study from 1st Feb 2007 to 1 April 2007.
Pefr was measured before and after the aerosol delivery using tops and
external spacer as conduits at ampm respectively, coinsiding with diurnal
variation of bronchomotor tone. Four children had cleft lip and palate.
Results: The pefr in lt/mt was grades as: below 200l (severe), 200 to 300
(moderate), 300 to 400 (mild), above 400 (very mild). There were 80 (53%)
in the severe, 50 (33%) in moderate,15 (10%) mild, 5 (4%) very mild. With
the tops 1 inhaler 80% had improvement by 60% increment of pefr (one
puff-100 mcg). With the es (2 puffs–200 mcg) plus inhaler there was only
10% increment. Thus the improvement with the former was signiﬁcant (P ¼
0.9641, r ¼ 0.9660); radioactive isotope scan showed 80% deposition in the
lungs with tops versus es (40%). A lateral study found advantage over
rotahaler and nebulizer.
Conclusion: Inhaler with tops is a better device for delivering aerosol.
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Intravenous Immunoglobulin in Leukocyte Adhesion Deﬁciency
Said Arablin Oropeza, MD,1 and Yamazaki-Nakashimada Marco Antonio,
MD2. 1Allergy and Clinical Immunology, Instituto Nacional de Pediatría,
Mexico City, Mexico; 2Clinical Immunology, Mexico City, Mexico.
Background: Leukocyte adhesion deﬁciency (LAD) is a primary immuno-
deﬁciency disease (PID) caused by a defect in neutrophil adhesion,
characterized by skin ulcers, poor wound healing and recurrent bacterial
infection. Intravenous immunoglobulin (IVIG) is used to treat patients with
PID, but in LAD is not rutinely used. Treatment consists in prompt antibiotic,
G-CSF for chronic ulcers and the only deﬁnite therapy is bone marrow
transplantation (BMT). We present the case of a child with LAD, who was
treated with IVIG with a good response before BMT.
Methods: We present a case report of a 2 year-old male, second child of
consanguineous parents (cousins 1st grade). His sister had omphalitis and
umbilical abscess and died at 6 months with candidiasis and perianal
infection. There were 6 episodes of infectious diseases from birth to 6
months: At 11 days of life presented with omphalitis. At 2 months, upper
respiratory tract infection with poor response to antibiotics. At 4 months he
presented with suppurative otitis media, and was transferred to our hospital
with suspected immunodeﬁciency, with neutrophilia (up to 95900). He was
treated with IV antibiotics, and after resolution with prophylactic antibiotics.
At 6 months had gastroenteritis and 1 week later septic shock. Treatment with
intravenous immunoglobulins (IVIG) was started.
Results: After IVIG was initiated there were only 6 episodes of infectious
diseases from 6 months to 2 years, including in the cord blood stem cell
transplantation (CBSCT) period: at 9 months, gastroenteritis; at 15 months
balanosposthitis (ecthyma gangrenosum), at 17 months had cellulitis in the
hand and buttocks and oral candidiasis. CBSCT was performed on February
2011, at 1 year 11 months, but didn’t engraft. He was discharged with pro-
phylactic antibiotics and cyclosporine. At 2 years he had catheter associated
sepsis. Currently the patient is receiving monthly IVIG, ﬂuconazol, TMP
SMX, Acyclovir and in protocol for BMT and has remained stable.
Conclusions: IVIG is not routinely used in LAD. In our case, monthly IVIG
resulted in improvement with less infectious episodes. We suggest the use of
IVIG as an adjuvant tool for the treatment of patients with LAD before BMT.
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Descriptive Analysis of the Immunological Behavior of Patients
with Ataxia Telangiectasia Attended in the National Institute of
Pediatrics in the Past 30 Years
Beatriz Adriana Llamas, MD,1 Alonso Gutierrez Hernandez, MD,1 and Luisa
Diaz, MD2. 1Pediatric Allergy and Clinical Immunology, National Institute
of Pediatrics, D.F., Mexico; 2Research, National Institute of Pediatrics, D.
F., Mexico.
Background: Ataxia Telangiectasia is an autosomal recessive disease
characterized by progressive neurological impairment, ataxia, oculo-cutane-
ous telangiectasia, immunodeﬁciency, recurrent infections sinopulmonary
and cancer predisposition processes. It does not exist in clinical practice
guidelines for boarding and management of these patients, neither a sugges-
tion of monitoring.
Methods: Automated search was requested ﬁle to the department of clinical
records to identify patients diagnosed with Ataxia Telangiectasia. We
included all that had clear and complete information to the variables analyzed.
Results: It was a description of variables by central tendencies and dispersion
for continuous and categorical variables that were analyzed for frequencies
and/or proportions. Included is determination of immunoglobulins IgG and
IgA in 35 patients, 34 of 35 IgM and IgE in 9 patients. We observed in 5
patients hypogammaglobulinemia and 13 patients hypergammaglobulinemia.
In relation to IgA, 17 patients had a deﬁciency and 6 of them high levels for
their age, IgM in 13 patients reported ﬁgures above the percentile for their
age. Altered IgE was found in one patient. IgG subclasses were determined in
9 patients and showed alteration in 9 of them. The IgG1 was not altered in
anyone of the patients, low IgG2 was found according to age in 7 patients, 2
patients with low IgG3, and low IgG4 in 8 patients. The presence of
lymphopenia was observed from the ﬁrst test, in 14 from 28 patients. In
a second measurement was observed in 17 from 25 patients. In the third
measurement was observed in 13 form 21 patients.
Conclusions: In the Ataxia Telangiectasia it has been reported that it could be
affected almost all the subtypes and subclasses of immunoglobulins, as
hypogammaglobulinemia that could be corrected by exogenous administra-
tion. We suggest supervise levels of IgG during follow-up of patients and
establish decision-subclasses according to the possibilities of each working
group, according to the context of clinical infections. Based on our result we
suggested that the monitoring of this disease is through an algorithm of
clinical boarding.
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Alteration of Humoral and Cellular Immunity in Patients with
Ataxia-Telangiectasia at Reference Center in Sao Paulo, Brazil
Lorena Ornellas, Josemar Matos, and Beatriz Carvalho, MD. UNIFESP-
EPM, São Paulo, Brazil.
Background: To analyze the levels of immunoglobulins and the number of T
and B lymphocytes in patients with ataxia-telangiectasia (AT) followed in
outpatient immunology.
Methods: A descriptive and retrospective study of medical records of patients
diagnosed with AT followed at Federal University of Sao Paulo, Brazil.
Results: Of 24 patients studied, 5 (21%) had levels of IgG below the age-
normal percentile 3 (p3), 3 patients (14%) had values around the 10th
percentile. IgA values were below the p3 in 11 (46%) subjects; draws
attention to high IgM in 14 (58%) individuals. Anemia was found in only 3
patients (12.5%), in the ﬁrst case the etiology was probably iron deﬁciency,
the second had a diagnosis of Waldestrom Macroglobulinemia and the third
was with sepsis. Seventeen (70.8%) had total lymphocyte count below the
p10, marked leukopenia (below p3) was observed in 5 (20.8%). Neutropenia
(,1500 cells /mm3) was observed in only 2 (8.3%) and eosinophilia (.500
cells /mm3) in 6 patients (25%). In 79% (19/24) of patients the lymphocyte
subpopulation was analyzed, and 17 (89.5%) of 19 subjects showed low
number of CD31 cells compared with controls of similar age. The number
of CD41 T cells was below the p10 in 21 of 23 evaluated patients (91.3%).
Interestingly, in most patients the number of CD41 T cells was between 200
and 500/mm3, suggesting severe depression of cellular immunity. Only one
patient had a high number of CD81 T lymphocytes, in 15 (65%) of 23
subjects the number of CD81 T cells was below p10. Eight patients un-
derwent a CD191 cell count, and all of them showed low values. NK cells
were quantiﬁed in 7 individuals, 3 (43%) cases showing high levels.
Conclusions: Most patients treated in our department showed dysgamma-
globulinemia, and low number of lymphocytes T and B.
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Clinical Features of Patients with Ataxia-Telangiectasia at
Reference Center in Sao Paulo, Brazil
Josemar Matos, Lorena Ornellas, and Beatriz Carvalho, MD. UNIFESP-
EPM, São Paulo, Brazil.
Background: Clinical symptoms of patients with ataxia-telangiestasia (AT)
followed in outpatient immunology.
Methods: A descriptive study using chart review of patients diagnosed
with AT
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Results: Retrospective data were analyzed in the medical records of 24
patients, 19 males and 5 females. Three of these patients were not included in
the sample, for presenting insufﬁcient data for analysis. Of the 21 patients,
there were 5 families with 5 pairs of siblings. Three families had a positive
family history. Consanguinity was observed in 5 (26%) of 19 couples in the
sample. Seventeen (81%) patients had ataxia as the ﬁrst symptom, beginning
between 6 months and 7 years of age (median 18 months). Three patients with
symptoms started with a telangiectasia and recurrent infections. The onset of
symptoms ranged from 15 days old to 7 years of age (median 17 months).
Age at diagnosis ranged from 1.5 year to 17 years old (median 5 years).
Intravenous immunoglobulin was given for 16 of 23 patients (69.5%),
prophylactic antibiotics were given for 15 (65.2%) and vitamin supplement
for 12 patients (52.2%). Comorbidities: asthma was present in 6 patients
(26%), allergic rhinitis in 3, and bronchiectasis in 3. Other less frequent
comorbidities were diabetes (1), atopic dermatitis (1), sarcoidosis (1) and
idiopathic thrombocytopenia (1). In evolution, 11 patients (52%) had
dysphagia started between 3 and 18 years (median: 12.5 years). The most
common infections were upper respiratory tract (83%), pneumonia (79%),
sinusitis (66%), diarrhea (54%), tonsillitis (45%) and otitis (25%). Four
patients lost follow-up, of the 20 remaining cases there were 8 deaths
occurring between 13 and 18 years old. Causes of death were respiratory
failure (3 cases), pneumonia (3), leukemia (1) and lymphoma (1).
Conclusions: Recurrent infections, dysphagia, and ataxia were the most
frequent symptoms in our sample, and respiratory problems were the main
cause of death among these series.
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Global Prevalence and Types of Autoimmune Diseases Found in
Children with Primary Immunodeﬁciencies; A Single-
Center Experience
María Guadalupe Ramírez Vázquez, 1 Saul Lugo-Reyes, MD,2 Yamazaki-
Nakashimada Marco Antonio, MD,3,4 Francisco Javier Espinosa
Rosales, MD, MSc,3 and Sara Elva Espinosa Padilla, MD5. 1Inmunología y
Alergia clínica, Instituto Nacional de Pediatría, Mexico city, Mexico;
2National Institute of Pediatrics, Immunodeﬁciencies Research Unit, Mexico
City, Mexico; 3National Institute of Pediatrics, México City, Mexico; 4Clin-
ical Immunology, Mexico City, Mexico; 5Research on Primary Immunodeﬁ-
ciencies Unit, National Institute of Pediatrics, Mexico city, Mexico.
Background: Autoimmune manifestations in primary immunodeﬁciencies
(PIDs) are not uncommon, and they are more frequently observed in defects
affecting lymphocytes and their regulatory mechanisms. There is a wide
variability in prevalence, ranging from immune defects in which autoimmu-
nity deﬁnes the syndrome, others with a very high prevalence of autoimmune
manifestations, defects with a moderate prevalence, and those in which
autoimmunity is rather an exception than the rule.
Objective: We aimed to determine the prevalence of autoimmunity in
children with PIDs from our hospital, to delineate their clinical features.
Methods: An internal register was consulted to identify autoimmune diseases
in our patients with PIDs. Their clinical ﬁles were then reviewed for
diagnostic workup, age of presentation and outcome.
Results: We identiﬁed a prevalence of 18.8% (47 out of 250 patients, 68.1%
male patient), within a period of 40 years (1970–2010), with autoimmune
manifestations in the context of PID. Of which most are still alive: 35
(74.5%); lost to follow-up: 3 (6.4%), Dead: 9. Known or probable consan-
guinity was reported in 25.4%, 36.2% had a positive family history. 12.8%
also had an allergic disease; none had cancer. The most frequent AI type was
Systemic Autoimmune disease (11 case, 23%), followed by Organ-speciﬁc
autoimmunity (15 cases, 32%), cytopenias (8 cases, 17%), and just antibodies
(6 cases, 13%). Other than Autoimmune lymphoproliferative syndrome
(ALPS), in which autoimmunity is a case-deﬁning feature, the group of well
deﬁned (Hyper-IgE Syndrome (HIES), and Wiskott-Aldrich Syndrome
(WAS)) were the PIDs with more cases of autoimmune disease, followed
by phagocytosis deﬁciencies and antibody deﬁciency.
Discussion: The overall prevalence of autoimmune disease is relatively high
PID syndromes such as ALPS, moderate levels in HIES, WAS and defects of
phagocytosis and antibody interestingly. Interestingly, most of our patients
with HIES have an autosomal-recessive pattern of inheritance and no
identiﬁed mutational diagnosis; nearly all of our patients with CGD are
receiving chronic subcutaneous therapy with human recombinant interferon
gamma. Regular follow-up visits are justiﬁed for surveillance for complica-
tions and frequent treatment adjustments, given the delicate balance between
immunosuppression and infection prophylaxis that is required in the care of
these patients.
546
Malignancies Associated to Primary Immunodeﬁciencies. A 40
Year Review
Corin España, MD,1 Saul Lugo-Reyes, MD,2 and Marco Antonio Yamazaki,
MD3. 1National Institute of Pediatrics, Pachuca, Mexico; 2Allergy & Clin-
ical Immunology, National Institute of Pediatrics, Mexico City, Mexico; 3Na-
tional Institute of Pediatrics, Mexico D.F., Mexico.
Background: Cancer has been cited as the second leading cause of death
after infection in children and adults with primary immunodeﬁciencies
(PIDs). There seems to be a complex relationship between PIDs, viral
infections to which are susceptible, and the development of cancer. Defective
immunosurveillance most markedly in cells with strong antigenic potential
that have undergone viral induction is a major factor, as support for this the
most common cancer subtype is lymphoma. Some estimates suggest that
more than 20% of carcinomas in patients with PID are infection induced,
Epstein Barr virus being particularly well established cofactor. The risk of
cancer in patients with PID is estimated between 4 to 25%, although could be
higher in some subtypes of PID. The PIDs most commonly associated to
cancer are Ataxia Telangiectasia, common variable immunodeﬁciency,
Wiscott-Aldrich syndrome, severe combined immunodeﬁciency, and selec-
tive Iga deﬁciency.
Objective: We aimed to determine the prevalence of cancer in children with
PIDs, in our hospital, and to determine clinical features and risk factors.
Methods: An internal register was consulted to identify cancer associated in
patients with PIDs. The clinical ﬁles were reviewed for diagnostic workup,
age of presentation, risk factors and outcome.
Results: We identiﬁed a prevalence of 1.2% (3 out of 250 patients) within
a period of 40 years (1970–2010), with cancer diagnosis in the context of
PID. PIDs subtype included, 2 patients with ataxia telangiectasia, both dead,
one developed lynfoblastic leukemia and the other patient developed diffuse
B cell lymphoma. Third patient with X linked lynphoproliferative syndrome
(SAP mutation), with positive family history, developed burkitt lymphoma,
still alive.
Discussion: The overall prevalence of cancer is relatively low to moderate in
PID syndromes. Ataxia Telangiectasia continues to be the most highly
associated cancer PID. Regular follow-up visits are justiﬁed for surveillance
for complications. The prognosis in patients with cancer and immunodeﬁ-
ciency is worse than immunocompetent individuals.
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An Earlier, More Severe Presentation of G6pc3 Deﬁciency in a
Male Infant From Mexico
Alonso Cruz, MD. Pediatric Allergy and Clinical Immunology, National
Intitute of Pediatrics, Mexico.
Background: Severe congenital neutropenia is a bone marrow failure
syndrome characterized by severe neutropenia present from birth. We present
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a case of G6PC3 deﬁciency presenting at an earlier age, with a more severe
clinical picture than previously reported.
Case report: A 3-month-old boy, born to nonconsanguineous parents was
delivered by C-section at 35 weeks gestation. He was admitted to neonatal
intensive care unit for prematurity and poor respiratory effort requiring
mechanical ventilation. Aggressive antimicrobial therapy was started for
nosocomial pneumonia and severe persistent neutropenia. Physical examina-
tion: Poor weight, chest accessory venous vasculature, parasternal systolic
murmur grade I left, testicles not palpable in scrotal sac. Laboratory workup.
Total leukocyte blood count with 2400 mm3, total neutrophils 200 mm3.
Echocardiogram revealed pulmonary hypertension: 58 mm Hg, foramen
ovale with bidirectional shunt. Abdominal ultrasound: kidneys with hydro-
nephrosis grade I in the right kidney and grade III left, conﬁrmed by Excre-
tory urography. Esophago-gastroduodenal Series: velopalatal incompetence,
pyloric hypertrophy, spontaneous gastroesophageal reﬂux and upper third of
the esophagus. Hearing screening reported bilateral hearing loss. Nissen fun-
doplication, Stamm gastrostomy and pyloromyotomy were performed. Treat-
ment with Recombinant human G-CSF was started (3–5 mg Kd) with good
response. Mutational analysis revealed a single-nucleotide deletion in exon 2,
which results in a frameshift and premature stop codon, predicting a nonfunc-
tional trunk protein.
Conclusion: Severe congenital neutropenia type 4 is an autosomal recessive
condition, which was deﬁned recently with identiﬁcation of the causative
mutations in G6PC3 and is characterized by congenital neutropenia and
variable developmental disorders: cardiovascular (atrial septal defects,
pulmonary hypertension) and/or urogenital system (urachal ﬁstulations and
cryptorchidism). Some patients show a peculiar visibility of subcutaneous
veins. Patients with G6PC3 deﬁciency lack mature neutrophils in the bone
marrow and have increased susceptibility to apoptosis in peripheral
neutrophils. Recombinant human G-CSF is the ﬁrst-line therapy. This is
only the second case identiﬁed in Latin America, and the ﬁrst one in Mexico.
Compared to what has been previously reported, however, our patient
presented earlier and with a more severe clinical picture, including bilateral
hydronephrosis. Stem-cell transplantation has never been performed in
G6PC3 deﬁciency, but its being considered in this case given the patient
young age and severity.
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Immunoglobulin a Deﬁciency, HPV and Oral Cancer
Jorge Alvarez, MD, PhD,1 Emilio Garip, MD,1 Monica Benitez,2 and Luis
Guzman,MD3. 1Allergy and Immunology, Instituto de diagnostico y tratamiento
Oulton, Córdoba, Argentina; 2Dentistry Department, Córdoba, Argentina; 3In-
stituto de diagnostico y tratamiento Oulton, Córdoba, Argentina.
Background: Selective IgA deﬁciency is the most common primary
immunodeﬁciency. Serum IgA level lower than 7 mg/dL is considered
selective IgA deﬁciency. Most people with selective IgA deﬁciency are
asymptomatic, with incidental ﬁndings. Others may present recurrent re-
spiratory infections, allergic symptoms, other infections and autoimmune
diseases. It represents a genetically heterogeneous group of abnormalities. We
report 2 cases of IgA-deﬁciency, HPV, and cancer, which required oral
mucosa and tongue surgery.
Methods: Case I: Female patient, 30 years old. Medical history: vaginal HPV
and Herpes. No promiscuous conduct. Complaint: recurrent infections.
Physical exam: oral white lesions are observed. Laboratory ﬁndings: serum
immunoglobulin A: lower than 7 mg%, secretory immunoglobulin A: lower
than 1 mg%. Both exams were repeated and determinations showed low
values. Cytology - Glucose - serum protein electrophoresis - Ig G - Ig M -
CD3 - CD4 - CD8 - CD19 - CD56 all determinations showed normal values.
HIV I /II: negative. Biopsy of oral mucosa with the following report: severe
dysplasia and intraepithelial carcinoma. Signs of HPV. Surgery was
performed on oral mucosa with the following pathology report: moderately
differentiated squamous cell carcinoma. Microscopic, morphological changes
related to cytopathogenic viral effects. The patient presented good evolution.
Case II: Female patient 40 years of age. Medical history: HPV and genital
herpes. No promiscuous conduct. Complaint: leukoplakia in tongue edges.
Physical examination: oral white lesions. Laboratory serum immunoglobulin
A: value obtained: lower than 7 mg%. Cytology - Glucose - serum protein
electrophoresis - Ig G - Ig M - CD3 - CD4 - CD8 - CD19 - CD56 with normal
values. HIV I/II: negative. Surgery was performed in tongue and regional
lymph node. Tongue Pathology: moderately differentiated squamous cell
carcinoma with negative edges. HPV (1) PCR.
Conclusion: We report on the possible association between selective IgA
deﬁciency - HPV - Cancer which has not been previously reported in time.
We suggest further screening of these possible associations and detailed
monitoring of these patients.
QUALITY OF LIFE MEASURES IN ASTHMA AND
ALLERGIC DISEASES
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Management of Twenty-Five Pediatric Patients with Hereditary
Angioedema (Hae) Undergoing Home TreatmentdA Clinical
Surveillance Program
Inmaculada Martinez-Saguer, MD,1 Emel Aygören-Pürsün, MD,1 Eva
Rusicke, MD,1 Thomas Klingebiel,MD, PhD,2 and Wolfhart Kreuz,MD, PhD1.
1Center of Pediatrics III, Department of Hematology, Oncology and Hemostasis,
Comprehensive Care Center for Thrombosis and Hemostasis, J.-W. Goethe-
University Hospital, Frankfurt a. M., Germany; 2Center of Pediatrics III,
Department of Hematology, Oncology and Hemostasis, J.-W. Goethe-University
Hospital, Frankfurt a. M., Germany.
Background: Hereditary angioedema (HAE) is a rare disorder characterized
by C1 esterase inhibitor (C1-INH) deﬁciency. Clinically, HAE is character-
ized by relapsing episodes of edema at various body sites followed by
disease-free intervals of variable duration. Episodes of upper airway
obstruction (usually laryngeal edema) are potentially life-threatening and
many patients died by asphyxiation in the families. In literature Longhurst et
al, Buygun et al and Levi et al showed improvement of quality of life in
patients with hereditary angioedema due to home treatment with C1-inhibitor-
concentrate.
Methods: We investigated in a cohort study the integration of a clinical
surveillance program into home treatment of pediatric patients suffering from
hereditary angioedema. Parameters investigated were overall coping of the
pediatric patient with home treatment, documentation of efﬁcacy/safety of
C1-INH concentrate (Berinertâ P, CSL Behring, Marburg), regular control of
laboratory parameters (C1-inhibitor (INH) activity, C1-INH antigen, C4, hep-
atitis A, -B, -C-, HIV-1/2-, and parvovirus B19 serology) and quality of life
parameters (hospitalization, absence from school).
Results: Twenty-ﬁve pediatric HAE patients (6 male, 19 female) have so
far been investigated. Twenty-one patients suffer from HAE type I, 4
patients from HAE type II. Median age is 13.7 years (range: 2.8–17.4
years), ﬁrst diagnosis of HAE took place at the median age of 5 years
(range: 0.1–15.9 years) and ﬁrst manifestation of HAE at the median age
of 3.9 years (range: 0.3–11.7 years). Plasma C4 complement was reduced in
nearly all patients (median: 2.4 mg/dL; range: ,1.4–10 mg/dL) except one
patient. All patients coped well with home treatment, compliance was ex-
cellent, clinical ﬁndings during regular medical control remained in the
normal range and all parameters conﬁrmed an improved quality of life, e.
g., patients had not been hospitalized nor had they been absent from school.
There were no adverse drug reactions due to administration of C1-INH
concentrate.
Conclusions: Home treatment might be also a valuable option for pediatric
HAE patients not affecting compliance negatively and providing a signiﬁcant
positive impact on health-related quality of life.
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The Impact of Nasal Allergies: Results from the Allergies Surveys
in America, Asia Paciﬁc, Latin America, and Middle East
Michael S. Blaiss, MD,1 Connie Katelaris, MD, PhD, FRACP,2 and Hugo E.
Neffen 3. 1University of Tennessee Health Science Center, Memphis, TN;
2Immunology & Allergy, University of Western Sydney and Campbelltown Hos-
pital, Sydney, Australia; 3Respiratory Medicine Unit, Children’s Hospital
Orlando Alassia, Santa Fe, Argentina.
Background: The Allergies surveys have been conducted in several regions of
the world, and provide the ﬁrst worldwide comparative data on the prevalence
and impact of nasal allergies. Here we report speciﬁcally on the impact of nasal
allergies on daily life and work productivity in America (AIA), Asia Paciﬁc
(AIAP), Latin America (AILA) and Middle East (AIME) surveys.
Methods: Patients who were previously diagnosed by a health care
professional with nasal allergies (hay fever, allergic rhinitis or nasal allergies,
plus sinus disease in AIAP), exhibited symptoms, and/or had received
treatment, were included. Standardized questionnaires provided by Abt SRBI
were used; individual questions and methodology varied slightly between
regions. In total, around 90,000 households were screened, including
responses from 6,081 patients.
Results: Patients reported that allergies have a big impact on their daily lives,
including limiting indoor and outdoor activities, work and having pets. A
high percentage of those surveyed missed work or had their work
performance affected by allergies in the past year, with work productivity
decreasing by 23% in AIA, 24% in AIAP, 33% in AILA and 30% in AIME
when allergy symptoms were at their worst. Nasal allergies also interfered
with many patients’ sleep, and were associated with feelings of depression,
anxiety, irritability and tiredness. In terms of the impact of symptoms, 38% of
those surveyed in AIA, 53% in AIAP and 46% in AILA reported that they
could not tolerate the discomfort of an allergy attack without relief.
Conclusions: Nasal allergies have a big impact on patients’ lives all around
the world, and there is still an unmet need for effective treatments that reduce
symptoms. As a result, work productivity levels and daily activities are
hugely affected in a large proportion of individuals with nasal allergies,
throughout the world.
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The Impact of Nasal Polyposis on Quality of Life Using the Eq-5d
Health Proﬁle
Isam Alobid, MD, PhD,1 Liza Viscovich,2 Joan Ramon Montserrat, 3
Jose Maria Guilemany,2 Manuel Bernal-Sprekelsen,2 and Joaquim Mullol,
MD, PhD1. 1ENT Department, Rhinology Unit & Smell Clinic, Hospital
Clínic, Barcelona, Spain; 2ENT Department Hospital Clinic Barcelona, Bar-
celona, Spain; 3Ent Department Hospital San Pau, Barcelona, Spain.
Background: Even though nasal polyposis (NP) is not a severe life-
threatening disease, it has a considerable negative impact on health-related
quality of life (HRQL). The goal of this study was to analyze HRQL in a large
sample of patients with NP compared to the general population in Spain.
Methods: The EQ-5D survey, which includes a descriptive system and is
composed of 5 dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression), and the EQ visual analog scale (EQ
VAS) were applied to patients with NP.
Results: NP patients (N ¼ 1,170; mean age 49 6 15 yr, 35.5% female)
completed the questionnaire. NP patients had a lower EQ VAS score (63.8
6 21.5; P , 0.05) than the general population (71.3). NP patients having
some or extreme problems reported higher overall percentages for all EQ-5D
domains: mobility (13.3, P , 0.05), self-care (8.2, P , 0.05), usual activities
(26.6, P , 0.05), pain/discomfort (55.6, P , 0.05), and anxiety/depression
(32.6, P , 0.05, compared with the general population (10.9, 2.0, 6.4, 25.8,
and 13.7, respectively). Mean EQ-5D index values (0.78 6 0.24) were also
lower than the general population (0.89; P, 0.05). There were no differences
between mean EQ-5D index values when gender, age group, or tobacco
consumption was compared.
Conclusions: These results conﬁrm, by using EQ-5D questionnaire, that nasal
polyposis has a negative impact on HRQL compared to the general population.
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Predictors Affecting the Quality of Life of Patients with
Bronchial Asthma
Beata Jankowska-Polanska, PhD,1 Izabella Uchmanowicz, PhD,1 Katarzyna
Lomper, MSc,1 Bernard Panaszek,2 and Andrzej Fal2. 1Department of Public
Health, Wroclaw Medical University, Wroclaw, Poland; 2Allergology Clinic,
Wroclaw Medical University, Wroclaw, Poland.
Background: The purpose of this study was to assess the inﬂuence of socio-
demographic factors, gender and level of anxiety on quality of life in patients
with asthma.
Methods: Asthma control test (ACT), Quality of Life Questionnaire Short
Form-36 (QoL-SF-36) and State-Trait Anxiety Inventory (STAI) were used as
research tools. Disease severity was assessed according to GINA guidelines.
Sixty ﬁve patients with asthma hospitalized at the Department of Allergology,
Wroclaw Medical University, Poland between November 2010 and January
2011 entered the study, 39 women aged (mean 6 SD) 58.2 6 15.2 and 26
men - 54.8 6 15.4.
Results: Results observed in analyzing the STAI-measured trait anxiety we
found that anxiety as a trait was less severe in men versus women (47.4 v 40.6;
P ¼ 0.01) also the state anxiety tended to be less severe in men; however we
didn’t ﬁnd statistical signiﬁcance. QoL-SF-36 results revealed lower quality of
life of female when compared to male patients. Both the summed quality
physical (PCS) and mental functioning (MCS), women scored lower than
men: PCS: 32 versus 37 and MCS: 41 versus 48 points. Education increases
the QoL measured by SF-36 questionnaire in PCS domain (Ht ¼ 9.74; P ¼
0.020). Also, professional activity of patients and the duration of the disease
inﬂuence both domains: MCS (Ht ¼ 17.84; P ¼ 0.001); PCS (Ht ¼ 9.98; P ¼
0.040) and PCS (rs ¼ -0.450; P ¼ 0.0001) and MCS (rs ¼ -0.251; P ¼ 0.046),
respectively. Also disease severity correlated inversely with QoL in both sub-
domains PCS (Ht ¼ 12.21; P ¼ 0.006), MCS (Ht ¼ 8.88; P ¼ 0.030). As it
could have been anticipated, the level of asthma control (measured with ACT)
correlates with QoL: PSC (rs ¼ 0.571; P , 0.0001); MCS (rs ¼ 0.373; P ¼
0.003). According to our data from QoL-SF-36 questionnaire age, type of work,
marital status and smoking did not affect signiﬁcantly patients’ quality of life.
Conclusions: Better education, professional activity and good disease control
have positive impact on QoL of asthmatic patients, while disease severity and
duration deteriorate it. Since women show much higher anxiety medical
personnel attitude to female patients should consider it.
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Correlation between Severity of Allergic Rhinitis and Impairment
of Quality of Life in Allergic Adolescents
Eric Martinez Infante, MD. Hospital General De Zona No. 1, Instituto
Mexicano Del Seguro Social, Oaxaca, Mexico.
Background: Determine severity of the disease and its correlation with the
degree of impairment in quality of life in adolescent patients with allergic
rhinitis.
Methods: Were captured 124 adolescents aged 10 to 17 years, attending the
outpatient Allergy Service at Social Security Hospital in Mexico, diagnosed
with Allergic Rhinitis (AR). Before the clinical evaluation to conﬁrm the
diagnosis, severity of Allergic Rhinitis were classiﬁed according to criteria of
Allergic Rhinitis and its Impact on Asthma (ARIA), and were administered the
Adolescents Quality of Life Rhinoconjunctivitis Questionnaire (AdolRQLQ).
Results: In determining the frequency and intensity of symptoms of allergic
rhinitis according to the ARIA classiﬁcation of the degree of severity was
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more frequent, in 48%, moderate Persistent AR; followed by mild persistent
AR in a 30%, moderate intermittent AR 14%, mild intermittent AR 5% and
severe AR only 3%. By applying the questionnaire AdolRQLQ we found
moderate affectation of the quality of life in 73% of patients, a severe affectation
in only 14% and slight in 13%. However, when performing the correlation
between the severity of the disease and the degree of impairment of quality of
life, we don’t ﬁnd a proportional relationship as there are patients who see the
quality of life decreased signiﬁcantly, even though the disease is classiﬁed as
mild and vice versa. For example: 79% mild persistent AR patients scored for
moderate affectation of the quality of life, only 13% for slight and 8% severe;
while none of the adolescents scored for AR severe deterioration of the quality
of life, all of them were classiﬁed with mild impairment.
Conclusions: Adolescent patients with allergic rhinitis are affected quality of
life this involvement is not directly proportional to the severity of the disease.
Treatment, in addition to seeking control of symptoms, should provide the
support needed to improve their quality of life.
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Chronic Urticaria Quality of Life Questionnaire (Cu-Q2 Ol) and
Urticaria Activity Score (Uas)
Nadia Aguilar,1 Nora Hilda Segura Mendez, MD,1 and Saul Lugo-Reyes,
MD2. 1Allergy & Clinical Immunology, Specialty Hospital Medical Center
XXI Century, Mexico City, Mexico; 2Allergy & Clinical Immunology, Na-
tional Institute of Pediatrics, Mexico City, Mexico.
Background: Chronic urticaria (CU) is a disease deﬁned by the presence of
wheals and itching for more than 6 weeks. Depending on its severity, it may
impair the patients’ quality of life (QOL). The questionnaire Cu-Q2oL
designed by Dr. Walter Canonica’s group, speciﬁcally evaluates quality of
life in patients with chronic urticaria (CU-Q2oL); in Spanish it has been
validated by Dr. Valero, et al.
Objective:We aimed to investigate if there is an association between severity
of chronic urticaria and quality of life of patients in our service, using the
questionnaires: CU-Q2oL and urticaria activity score (UAS).
Methods: Universe: Consecutive patients with chronic urticaria who
answered the questionnaires CUQ2OL and UAS. Diagnosis of CU was
based on a detailed history, physical examination, laboratory studies and
autologous serum skin test (ASST) for Autoimmune Urticaria (UCAI).
Spearman’s Rho correlation coefﬁcient was calculated between Severity
(UAS) and Quality of Life (CUQ2OL). Comparisons between groups were
performed using chi square and One-way ANOVA.
Results: 50 patients, (82% women, mean age 41 years) were included. The
largest etiology group was Autoimmune: 60% of cases; A direct linear
relationship between the severity of and quality of life was found to be
statistically signiﬁcant (r2 0.511, P , 0.0001). A greater severity was gener-
ally reported in the autoimmune group.
Conclusions: Patients with more severe urticaria, particularly with major
complaints of itching and sleep loss, have a lower quality of life, especially
those patients with autoimmune urticaria. We found a good correlation
between both questionnaires, so in the future clinicians may anticipate that
patients diagnosed with moderate or severe chronic urticaria might have
a considerable drop in their quality of life, and therefore their management
and follow-up should be viewed holistically.
RADIOCONTRAST MEDIA ALLERGY
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Frequency, Characteristics and Outcome of Immediate
Hypersensitivity Reactions Due to Iodinated Contrast Media
Thatchai Kampitak, MD,1,2 Jettanong Klaewsongkram, MD,1 and Kiat
Ruxrungtham, MD1. 1Internal Medicine, Chulalongkorn University, Bangkok,
Thailand; 2Medicine, University of Toronto, Toronto, ON, Canada.
Background: To determine the frequency, characteristics and outcome of
immediate hypersensitivity reactions to iodinated contrast media (ICM).
Methods: A retrospective review of immediate hypersensitivity reactions to
ICM that occurred between 2006 and 2008 in King Chulalongkorn Memorial
Hospital was performed. Severity of the reactions was graded by Ring and
Messmer’s classiﬁcation.
Results: A total of 34,365 ICM were administered for radiologic procedures
during the study period. There were 193 immediate hypersensitivity reactions,
representing the frequency of 0.56%. Mild (grade I and II) and severe (grade
III and IV) reactions developed in 181 (0.53%) and 12 (0.03%) patients,
respectively. The most common reactions were skin manifestations (rash,
urticaria and angioedema) which occurred in 179 patients (92.7%). Re-
spiratory, gastrointestinal and cardiovascular symptoms developed in 12
(6.2%), 2 (1%) and 10 (5.2%) patients, respectively. The patients who have
allergic diseases more frequently developed grade III reactions (particularly
asthmatic attack) than other reactions. Anaphylaxis, deﬁned as multi-organ
involvement, occurred in 8 patients (4.1%). Two patients (1%) had
cardiopulmonary arrest. No fatality was reported. Seventy-nine patients
(40.9%) had previous exposure to ICM, while 23 patients (11.9%)
experienced previous reactions to ICM and of that 14 patients (60.9%)
developed the reactions despite premedications. A history of previous
reactions to ICM and pre-medications use were not found to be associated
with severity of the reactions. Mean time to onset of reactions was 13 minutes
after ICM administration and almost all patients (188, 97.4%) developed the
reactions within 30 minutes. One hundred seventy-ﬁve patients (90.7%)
received active treatments. Antihistamines, corticosteroids and epinephrine
were administered in 172 (89.1%), 33 (17.1%) and 9 (4.7%) patients,
respectively. Five patients (6.2%) required cardiopulmonary resuscitation.
Median time of symptoms resolution was 30 minutes after receiving
treatments and almost all patients (187, 96.9%) recovered within 60 minutes.
Conclusions: Immediate hypersensitivity reactions to ICM are uncommon.
Most patients develop mild reactions and respond well to treatments. The
patients with allergic diseases may have a greater risk of asthmatic attack after
receiving ICM. Although severe reactions are rare, all patients should be
observed under medical supervision for at least 30 minutes after ICM
administration.
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Frequency of Positive Skin Test for Iodinated Contrast in
Outpatient Clinic of Allergy in Rio De Janeiro, Brazil
Neide Pereira, MD,1,2 José Sardenberg, MD,1,2 Eimar Tapias, MD,1,2
Tatiana Carvalho, MD,1,2 José Luiz Rios, MD,1,2,3 and Fábio Kuschnir,
PhD,1,2,4. 1Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil;
2Faculdade de Medicina de Petrópolis, Petrópolis, Brazil; 3Thorax Disease
Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 4Pe-
diatrics, University os State of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Adverse reactions to iodinated contrast agents (IC) can be
related from a mild to life-threatening event. This frequency varies from 0.2
to 12.7% depending on the type of IC used. Some studies suggest that these
reactions may be related to an IgE-mediated mechanism.
Methods: Retrospective study of medical records from patients attended from
January 2008 to June 2011 with suspected history of, or risk factors for,
reactions to IC. Patients underwent SPT with undiluted IC iopromide used
histamine and saline as controls. In those with negative tests were performed
intradermal tests with 0.02 mL of IC diluted with saline 1:10. The sample was
also evaluated in relation to age, sex, comorbidities, presence of atopy and
previous reactions to IC (PRIO). Descriptive statistical analysis of data was
performed.
Results: We analyzed 27 patients (22 F, mean age: 55.2 years 6 17.4 SD;
59% were atopics). Only one patient (F, 37 years with allergic rhinitis)
without PRIO showed positive reaction to intradermal test (3.7%). Five
patients (18.51%) with PRIO had negative SPT.
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Conclusions: IgE-mediated immune reactions are not common for IC.
However, when present contraindicates the use of the compound used in
skin testing or other composed of the same pharmacological class. Although
the skin tests for IC are not yet fully standardized, its performance can be
useful to guide both the patient and the radiologist.
557
Test and Manage Protocol for 841 Patients Requiring Iodinated
Contrast Media (Icm) in Pediatrics
Maria Cristina Diaz, MD, Alberto Jorge Lavrut, MD, and Silvia Susana
Spinelli, MD. Unidad de Alergia, Hospital General de Niños Pedro de
Elizalde Casa Cuna, Buenos Aires, Argentina.
Background: ICM’s adverse effects are quite frequent and potentially seri-
ous. The use of protocols to test and manage patients receiving ICM could
help to decrease the adverse effects because they advise against the studies or
prescribe the administration of premedication; however, its use in pediatrics is
still limited. We describe the results of the use of a test and management
protocol for pediatric patients requiring ICM.
Methods: All the patients of a pediatric hospital prescribed with ICM
between 31st January 2008 and 5th March 2011 were included. The
following variables have been analyzed: age, sex, type of study to be
performed, diagnoses and hospitalized or outpatient, risk (regular, increased
or non-advised) and the presence of adverse reactions. We also analyzed the
relation between risk and age, sex and condition (chi cuadrado o t test).
Signiﬁcance level P , 0.05.
Results: We included 841 patients (56.9% male, age ¼ 92.7 6 24.5 months,
60% hospitalized). The most frequent test was chest Tc (36%) and the most
frequent diagnosis was solid tumors (25%). Patients with increased risk were
signiﬁcantly lower than those with regular risk (75.7 6 69.7 months vs 109.7
6 61.6, P, 0.001). During the research period there were no adverse effects.
Conclusions: The classiﬁcation of risk groups by this Goverment Buenos
Aires City protocols allows a rational management of the patients requiring
ICM and minimize the adverse effects.
SEVERE AND FATAL ASTHMA
558
Severe Asthma: Report of Five Clinical Cases at West National
Medical Center, Imss in Guadalajara City, Mexico
Carlos Torres-Lozano, MD, PhD,1 Margarita Ortega-Cisneros, MD,1
Efrain Montaño-Gonzalez, MD,1 Cecy Garcia-Cobas, MD,1 Maria
Enriqueta Nuñez-Nuñez, MD,2 Rosa Maria Cortes-Grimaldo, MD,1 Sergio
Mendez-Santillan, MD,1 and Ileana Madrigal, MD1. 1Allergy and Clinical
Immunology, UMAE-HECMNO-IMSS, Guadalajara, Mexico; 2Allergy and
Clinical Immunology, Hospital Civil de Guadalajara Dr. Juan I Menchaca,
Guadalajara, Mexico.
Background: Severe asthma can be deﬁned as that which is inadequately or
poorly controlled despite an appropriate therapeutic strategy that is adjusted
to clinical severity. The aim of this work is to present clinical evidence of 5
patients with high suspect to bear severe asthma.
Methods: We review medical records of 5 patients with high suspect to bear
a diagnosis of severe asthma.
Results: We present 5 patients, 4 of them were women and just one man.
Mean age 49 years old. Two of the patients were detected with nasosinusal
polyposis and sensitivity to the aspirin. One of them was diagnosed to bear
allergic bronchopulmonary aspergillosis (ABPA). Laboratory blood results
reporting: In 4 of the subjects, eosinophils more than 500 cells/mL. IgE with
high serum levels in and in the patient with ABPA even with serum levels of
1890 UI/mL. Spirometry values with severe obstructive pattern with FEV1
less than 60% in 3 patients and in 2 of them with obstructive/restrictive severe
pattern. In all patients, continuous use of inhaled corticosteroids at high doses
alongside another antiasthmatic drug. Usually a long-acting b2-adrenergic,
antileukotrien agents, methylxantins and in most of them with daily require-
ment for short-acting b2-adrenergic rescue medication and with more than 3
or more courses of oral corticosteroids in the last year.
Conclusions: Because of the clinical ﬁndings of our patients, respiratory
function test and characteristics of the treatment which they have had during
the last 5 years we consider that our patients bear severe asthma according
with American Thoracic Society and is our purpouse to share with other
immunoallergist our clinical experience in this ﬁeld.
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Risk Factors for Bronchial Asthma in Central Havana in the
Period 1995–2010
Adelquis Guerrero,1 and Martha García Canales2. 1Allergy, Clinic, La Ha-
bana, Cuba; 2Clinic, Centro Habana. La Habana, Cuba.
Background: Results of research conducted in Havana (Centro Habana
municipality’s population) in the period 1995 to 2010 to evaluate possible
risk factors for death from asthma are presented. The objective was to de-
termine the correlation between the factors that inﬂuence asthma deaths in
this country. Assessing risk factors for asthma death psychosocial factors,
occupation, housing conditions, work and study center, smoking, comorbid
illnesses by organ systems, level of care between exacerbations and in them,
background risk of death from asthma, perennial or discontinuation of corti-
costeroids recent assistance to emergency services or hospitalization in the
last year of the death, level of care between exacerbations and in them, and
severity of the allergic family history and place and date of death.
Methods:We performed a retrospective study of cases with asthma that died
of adult from 1995 to 2010. A total of 109, they surveyed the families of 65
for a 59.63% and an equal number of controls. Of all respondents 36 were
women (55.39%) and 29 men (44.61%) and an average age of 55.8 years
(53.7 for women and 58.4 for men).
Results: Univariate analysis of the level of schooling had a RD ¼ 2.68, the
per capita ﬁnancial ,$ 100.00 an RD ¼ 2.32, smoking a RD ¼ 2.76, in
cardiovascular disease DR ¼ 2.46 and no care between exacerbations had
a RD ¼ 2.43. The multivariate logistic regression analysis found signiﬁcant
association with a poorly ventilated RD ¼ 7.29, relative risk (RR) of 5.93,
lack of sun RD ¼ 4.85 RR ¼ 7.41; pets RD ¼ 2 30, RR ¼ 5.82; smokers RD
¼ 2.76 RR ¼ 14.81; the use of beta2 agonist. 3 teams/RD ¼ 18.4 months
RR ¼ 69.93 and the severity of the disease RD ¼ 8, 80 RR ¼ 23.47.
Conclusions: Inadequate socioeconomic conditions (lack of ventilation, sun
and presence of pets and cigarette smoke in households as poor management
of the disease (use of beta 2 agonist . 3 teams / month) are risk factors for
death from asthma. Deaths from asthma were more common outside the
hospital in winter.
560
Dolichyl Phosphate Dependent Mechanism of Exacerbations in
Asthma: P-Glycoprotein Overexpression and E-Cadherin Loss
Galina Kuznecova, MSc,1 Ivans S Kuznecovs, MD,2 Inese Joksta, MD,2
and Sergejs Kuznecovs, MD3. 1Epidemiology, Preventive Medicine Institute,
Riga, Latvia; 2Allergy and Immunology, Preventive Medicine Institute, Riga,
Latvia; 3Preventive Medicine Institute, Riga, Latvia.
Background: In asthma exacerbations there is a functional hyporesponsive-
ness of glucocorticoid (FHG) receptors (GR) on T cells, disbalance in activity
of IL-2, IL-4, IL-10 and E-cadherin loss. Dolichyl phosphate (DolP) plays an
essential role in cytokine synthesis, in constancy of glycoproteins of the GR
and E-cadherin expression. The present study was carried out to estimate the
role of DolP in mechanism of exacerbations.
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Methods: The samples obtained from 82 patients with with frequent exa-
cerbations (APFE group) (median duration . 14 day a year) and 83 patients
without exacerbations over 12 months (APWE group). Dolichyl phosphate
was deﬁned in T-cells. Soluble E-cadherin was measured with ELISA in
sputum and in bronchial epithelial cells (BEC). The intensity of glycoprotein
synthesis in IL-2, IL-4, IL-10 and GR was estimated based on the number of
starting glycosylation complexes (SGC) and radioimmunoassay.
Results: In APWE group Blood Dol concentration was 221.6 1 15.4 ng/mL
and urinary Dol concentration was 16.2 1 4.5 mkg/mmol. In APFE group
blood Dol was increased up to 4 times making up 455.2 1 31.7 ng/mL and
urinary Dol concentration was increased up to 400%, making up to 32.2 1
4.7 mkg/mmol and 2 times in comparison with APWE group. APFE group
had 3 to 4 times higher E-cadherin levels in sputum than APWE group. The
synthesis of DolP was 7.5-fold decreased in T-lymphocytes in APFE group.
APFE group T-cells membrans contain 5.6 to 6.4% of P-glycoprotein-170 as
a marker of FHR receptors which differ from APWE ones in Pgp content by 9
to 11 times. DolP in the concentration 10 to 6 M aid 7 to 9-fold reducing P-
glycoprotein-170 content in membranes of APFE T-cells to 0,4 to 0,6% and
prevent loss of E-cadherin in BEC. T-cells from APFE group cultivated with
corticosteroids and Polyprenol restore the possibility to induce IL-10 synthe-
sis in vitro, enhanced the expression of alpha GP isoforms and made these
cells more responsive to steroids.
Conclusions: DolP level and N-glycosylation dirorders could correlate with
P-glycoprotein overexpression in FHG in T-cells and E-cadherin loss in EC in
asthma exacerbations. Dol detection in blood and urine opens up possibilities
for exacerbations control and management.
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Distribution of Asthma Mortality in Various Districts of
Salvador, Brazil
Carolina Souza-Machado, MSc, RN,1,2 Adelmir Souza-Machado, MD,
PhD,2,3 Márcio S. da Natividade, BSc,4 Ana Carla Carvalho Coelho, MSc,
RN,1,2 Magali Teresópolis Reis Amaral, MSc,5 and Alvaro Cruz, MD6.
1School of Nursing, Federal University Of Bahia, Salvador, Brazil; 2ProAR
- Centro de Excelência em Asma, Federal University Of Bahia, Salvador,
Brazil; 3Institute of Science Biomorphology Health Department, Federal
University Of Bahia, Salvador, Brazil; 4Institute of Public Health, Federal
University Of Bahia, Salvador, Brazil; 5State University of Feira de Santana,
Salvador, Brazil; 6Medicine, ProAR - Núcleo de Excelência em Asma da
UFBA, Salvador, Brazil.
Background: Brazil still does not have a national program to combat asthma.
Isolated initiatives have been developed in a non-standardized fashion. The
Program for Control of Asthma in Bahia (ProAR) was established in
Salvador, Bahia, in 2003, aiming for the control of the most severe cases.
Objective: To analyze time trends in mortality from asthma and its
distribution in the districts of Salvador (2000–2009) and to correlate mortality
rates with social indicators.
Methods: Observational study of deaths from asthma registered by the
National Database of Mortality according to ICD-10. Mortality rates were
calculated per 100,000 inhabitants and analyzed by simple linear regression.
The distribution of mortality for asthma in the period was mapped into the 12
health districts of Salvador. The correlation of the number of deaths in
Salvador with GDP per capita, HDI and Index Gini was evaluated.
Results: The average asthma mortality in Salvador between 2000 and 2009
was 1.542/100.000 inhabitants, with a declining trend (R2 ¼ 0.539, b ¼
–11.1, P ¼ 0.016). Deaths occurred more frequently in women than men
(66% vs 34%). Asthma mortality rates were higher in subjects . 35 years.
There was a reduction at ages younger than 1 year, 5 to 14 years, 25 to 34
years, and 45 to 54 years with a sharp decline between 55 and 64 (–8.14/
100,000). The mortality rate (19.68/100,000 inhabitants in 2009) was higher
for individuals . 75 years. The highest mortality rates were noted in
more populated and poorer areas with less infrastructure and access to health
services. It was observed that 78% of the deaths occurred in hospitals or
health facilities. Deaths rates for asthma correlated directly with the district
Gini index (rho ¼ 0.400, P ¼ 0.505) and inversely with HDI (rho ¼ –0.300,
P ¼ 0.624), though not statistically signiﬁcant.
Conclusions: Asthma mortality in Salvador is concentrated in the poorest
areas with less infrastructure and access to health services, most commonly
affecting women and the elderly. There was a reduction in mortality during
the study period, possibly related to interventions for asthma control in the
municipality. Mortality from asthma behaves differently in each district of
the city.
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Geographical Distribution of Deaths from Asthma in Salvador,
Brazil (2000–2009)
Carolina Souza-Machado, MSc, RN,1,2 Adelmir Souza-Machado, MD,
PhD,2,3 Márcio S. da Natividade, BSc,4 Ana Carla Carvalho Coelho, MSc,
RN,1,2 and Alvaro Cruz, MD5. 1School of Nursing, Federal University Of
Bahia, Salvador, Brazil; 2ProAR - Centro de Excelência em Asma, Federal
University Of Bahia, Salvador, Brazil; 3Institute of Science Biomorphology
Health Department, Federal University Of Bahia, Salvador, Brazil; 4Institute
of Public Health, Federal University Of Bahia, Salvador, Brazil; 5Medicine,
ProAR - Núcleo de Excelência em Asma da UFBA, Salvador, Brazil.
Background: Salvador is the 3rd largest city of Brazil with 3 million
inhabitants, divided into neighborhoods with remarkable social inequalities,
varied infrastructure and access to health services.
Objective: To evaluate the geographic distribution and identify areas of risk
for asthma deaths in the city of Salvador, Bahia, Brazil (2000–2009).
Methods: Observational descriptive study of deaths from asthma according
to ICD-10 in the period between 2000 and 2009, with information obtained
from the National Database of Mortality of the Ministry of Health of Brazil.
The distribution of deaths was mapped with points and public primary care
facilities including emergency care units were located in the geographical grid
of the City by the software Arcview. The risk areas were identiﬁed by the
method of Kernel. Correlation between the number of deaths and number of
health care units was assessed using the Spearman test.
Results: We geocoded the location of 395 of 409 deaths from asthma
(96.58%) occurred during the study period. It was observed that 78% of
deaths occurred in hospitals or health facilities. The highest density in areas of
risk and the highest concentrations of death from asthma occurred in more
populated and underprivileged areas. There was a direct correlation between
the number of public primary health facilities and the number of deaths (rho
¼ 0.667, P ¼ 0.018).
Conclusions: Asthma deaths in Salvador are concentrated in the poorest areas
of the city where there are a great number of public primary health facilities.
The geographic distribution of deaths indicates that current practices in
primary care are insufﬁcient to prevent deaths from asthma in Salvador,
Brazil.
563
Measurement of Long-acting Natriuretic Peptide (Lanp) in
Exacerbation of Asthma
Michel Alkhalil, MD,1 Mathew Varghese, MD,2 Gary Hellermann, PhD,3
Shyam Mohapatra, PhD,4 Ahmed Butt, MD,1 and Richard F. Lockey, MD1.
1Division of Allergy & Immunology, University of South Florida and James A.
Haley Veterans’ Hospital, Tampa, FL; 2University of South Florida, Tampa,
Tampa, FL; 3University of South Florida, Tampa, FL; 4USF Nanomedicine
Research Center, University of South Florida College of Medicine & VA Hos-
pital, Tampa, FL.
Background: Evidence exists that atrial natriuretic peptide (ANP) is
a regulator of smooth muscle airway tone and is a potent bronchodilator
and immune modulator in animals. Objective: Long-acting natriuretic peptide
(LANP), encoded by the same gene and derived from the same pro-hormone
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as ANP, was measured in patients with acute asthma exacerbation pre- and
post-treatment with systemic or inhaled glucocorticosteroids.
Methods: Measurement of LANP was obtained from plasma samples in 15
subjects with acute asthma exacerbation, by an enzyme immunoassay
technique. A repeat measurement of LANP was obtained 5 to 7 and 10 to
14 days after initiation of treatment.
Results: No signiﬁcant differences were found compared to baseline in
plasma LANP level after treatment of the asthma exacerbation (P ¼ 0.8904).
The average LANP values were 2.12 higher in the oral glucocorticosteroid
group versus the inhaled glucocorticosteroid group, (P ¼ 0.0608). There was
no signiﬁcant difference in LANP levels between male and females (P ¼
0.5743), with antibiotic use (P ¼ 0.9437), or with age (P ¼ 0.6384).
Conclusions: Plasma LANP level did not differ before and after treatment for
an asthma exacerbation. Measuring plasma LANP pro-hormone was not
helpful in assessing treatment outcome of asthma exacerbation.
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Is It Really Difﬁcult-to-treat Asthma? Don’t Forget Other Causes
of Wheeze
Ilkay Koca Kalkan, MD, and A. Fusun Kalpaklioglu, MD, FAAAAI. Immu-
nology and Allergic Diseases, Kirikkale University Medical School Hospital,
Kirikkale, Turkey.
Background: One in 4 asthma patients may not have their condition
adequately controlled and experience persistent symptoms despite treated
with high healthcare utilization. But do all of them really have asthma?
Methods: Here we present 3 cases; all were diagnosed as asthma, had been
treating with multiple bronchodilators, even oral steroids and were not
responding to the treatment. And so they were refered to our clinic as having
difﬁcult-to-treat asthma as candidates for omelizumab therapy.
Results: Case1: A 44-year-old female presented with 18 years history of
dyspnea, wheeze and chronic cough. Her FEV1 was 37% of the predicted
(0.93 lt), FVC and FEV1/FVC were subnormal and showed no reversibility.
CT scan showed a deformed trachea with a diverticula in the posterior region
with cystic bronchiectasis in lung parenchyma, bilaterally. Bronchial
endoscopy showed dyskinesia extending almost totally throughout the
tracheobronchial tree with complete expiratory collapse. Her diagnosis was
changed as Mounier-Kuhn syndrome. Case 2: A 19-year-old female presented
with 11 years history of persistent wheezing and dyspnea which were
progressively increasing for the last 5 years. Her FEV1 was 85% and the
FEV1/FVC % 77 of the predicted, showed no reversibility. Her CT scan was
in normal limits. Fiberoptic bronchoscopy revealed a severe airway stenosis
like a pinhole at the beginning of the right main bronchus, adjacent to the
carina. Excluding her asthma diagnosis she underwent a balloon dilatation
procedure, which improved her symptoms. Case 3: A 50-year-old female
presented with 16 years history of dyspnea, wheeze, chronic cough. Her
FEV1 was 40% of the predicted (0.91 lt), and showed reversibility of 28%.
She had an elevated total IgE level of 1126 IU/mL with serum eosinophilia of
5.5%. Her HRCT scan revealed bilateral central bronchiectasis with ﬂeeting
pulmonary parenchymal opacities. Her sensitization to Aspergillus fumigatus
was shown by positive skin testing. She was diagnosed as having allergic
bronchopulmonary aspergillosis and oral itracanosole with steroid were added
to her treatment which improved her symptoms.
Conclusions: Although all patients’ symptoms looked like asthma, and all
diagnosed as having asthma for many years, the diagnosis should always be
conﬁrmed before accepting them as “difﬁcult-to-treat”.
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Sensitization Proﬁle in Severe Asthma
Andrzej Bozek, MD, PhD,1 Jerzy Jarzab, MD, PhD,1 and Barbara
Rogala, MD, PhD2. 1Chair and Clinical Department of Internal Diseases,
Dermatology and Allergology, Medical University of Silesia, Katowice,
Poland, Zabrze, Poland; 2Chair and Clinical Department of Internal Dis-
eases, Allergology and Clinical Immunology, Medical University of Silesia,
Katowice, Poland, Katowice, Poland.
Background: The role of IgE reactions to common allergens still remains
unclear in severe, difﬁcult-to-control asthma.
Objective: To analyze the IgE mediated sensitisation to common inhalant
allergens in adult patients suffering from severe difﬁcult-to-control asthma
according to GINA guidelines.
Methods: One hundred and twenty three patients (57 women and 56 men,
mean age 52.7 6 10.1 years) were included into the study. The detailed
personal and family history was assessed by the use of an original question-
naire. Skin prick tests (Allergopharma, Germany) and speciﬁc IgE serum
level against common inhalant allergens (Poly–Check, Immunogenetics,
US) and spirometry were performed.
Results: 79 (64%) patients had a positive family history of asthma. Mean
time of asthma duration was in average 20.8 6 15.1 years. Late onset of
asthma (above 50 year of age) was observed in 61 (50%) subjects. 17 (14%)
patients were current and 29 (24%) former smokers. Atopy estimated on the
basis of the presence of at least one positive skin prick test was observed in 81
(68%) patients, mostly in men. Mean total serum IgE level was 80.26 17 IU/
L (range: 2.7–1205.4). House dust mites allergy was predominant and con-
ﬁrmed in 49 (40%) patients with mean speciﬁc IgE against D.pteronissinus
17.4 6 10.2 IU/L and against D. farinae 18.2 6 9.2 IU/L. Alternaria and cat
allergy were diagnosed in 20 (16.4%) and 29 (23.6.3%) subjects respectively.
The prevalence of inhalant sensitization was more frequently observed in
those with asthma and other allergic disease than in patients with asthma
alone (Table 1). It was statistically signiﬁcant in chi-quarter test for P , 0.01
Conclusion: Positive family history of asthma, late onset of disease as well as
IgE sensitivity to inhalant allergens are the common features of severe,
difﬁcult-to-control asthma. However, inhalant sensitivity occurs predomi-
nantly in cases of asthma concomitant with other allergic diseases.
TESTING FOR SENSITIZATION
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Utility of Component-Based Allergen Chip (Immunocap Isac) in
Diagnosis of Allergic Rhinitis
Joo Hyun Jung, MD. Department of Otorhinolaryngology, Gil Medical
Center, Gachon University School of Medicine, Incheon, South Korea.
Background: Component-resolved diagnostics (CRD) using microarray
technology has recently been introduced into clinical allergology. Compo-
nent-based Allergen Chips (ImmunoCAP ISAC) provide novel assays that
allow semi-quantitative measurements of IgE and IgG4 antibodies against
a background of 103 allergenic components simultaneousl.
Objective: We sought to introduce component-based microarray Allergen
Chips (ImmunoCAP ISAC) and evaluate the utility of microarray-based IgE
detection in the diagnostic workup of allergic rhinitis. We compared this new
diagnostic tool with established methods of allergen-speciﬁc IgE detection.
Methods: 86 Allergic rhinitis patients who were diagnosed with allergic
rhinitis by history taking, physical examination, and skin prick test were
included. The number of Males versus females was 58 versus 28. Mean age
was 26.6 years old. We included data that was the result of a skin prick test,
ImmunoCAP speciﬁc IgE and ImmunoCAP ISAC (D.P., D.F., tree, fungus,
weed). We compared sensitivities and analyzed correlations of ImmunoCAP
and ISAC.
Results: Sensitivity of ImmunoCAP and ISAC assays were 80% and 78.9%
and there was a signiﬁcant correlation. The more severe the symptom the
stronger the positive degree. When we analyzed components of D.P. ISAC
nDer p1 and nDer p2, which are speciﬁc components of D.P., they showed
a high positive rate. In the case of D.F. nDer f1 and nDer f2, which are
speciﬁc components of D.F., they showed a high positive rate. There was
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a positive correlation between a positive numerical value for the ISAC
speciﬁc component and for the ImmunoCAP D.P, D.F.
Conclusions: ISAC is a reliable method for diagnosing allergic rhinitis.
Further studies of the utility of ISAC in SIT patients are needed.
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Prevalence of Skin Reactivity to Blomia Tropicalis Antigen in
Patients with Respiratory Allergy at Hospital Universitario
De Puebla
Erica Marisol Martínez Villegas, PhD. Allergy, Doctor, Puebla, Mexico.
Background: Published studies shows that the sensitization to Blomia
tropicalis mite plays an important roll on the development of allergic diseases.
The aim of our study is to determinate the prevalence to skin reactivity to
Blomia tropicalis’ antigen in patients with respiratory allergy.
Methods: We conducted a descriptive, observational, prospective and
transversal study being the criteria for inclusion: male and female patients
aged 2 to 58 who came for ﬁrst time at our service with diagnosis of asthma,
rhinitis or asthma more rhinitis. We evaluated the skin reactivity by skin prick
test to Blomia tropicalis’ antigen. Descriptive statistics was implemented by
estimating summary measures and dispersion.
Results: From a total of 110 patients, their mean age was 16.25 (2–58), 50%
were males, 92% were from urban areas and 7.3% from rural areas. Of the
patients studied 2.7% had asthma, 73.6% had rhinitis and 23.6% both di-
agnoses. The prevalence of positive skin reactivity to Blomia tropicalis was
24.5%. The prevalence of positive skin reactivity for the rhinitis subgroup
was 59.3% and for the asthma/rhinitis subgroup was 40.7%, while in the
asthma subgroup the prevalence was 0%.
Conclusions: The high prevalence of skin reactivity to Blomia tropicalis
indicated the importance of including Blomia tropicalis in routine diagnostic
testing and immunotherapy treatment.
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Prevalence of Sensitization to Parietaria, Pinus, Cupressus and
Morus Pollens in Patients from Craic
Liborio Rafael Leal-Garcia,MD,1 Sandra González-Díaz, MD, PhD,2 Alfredo
Arias-Cruz, MD,1 Maria del Carmen Zarate, MD, PhD,1 Diego Garcia-
Calderin, MD,1 and Claudia Gallego, MD1. 1Regional Center of Allergy and
Clinical Immunology, University Hospital, Monterrey, Mexico; 2Regional
allergy center, University California San Diego U.C.S.D., Monterrey, CA,
Mexico.
Background: The pollens of Cupressus, Parietaria, Pinus and Morus are
important causes of allergic respiratory diseases. In a study of pollen concen-
tration in Monterrey in 2004, these pollens occupied the ﬁrst places in fre-
quency. The objective was to determine the prevalence of sensitization to
Parietaria, Pinus, Cupressus and Morus in patients from CRAIC (Regional
Center of allergy and clinical immunology, Monterrey, México)
Methods: Is an observational, cross-comparative, double-blind study in
which patients were included if they underwent prick tests to aeroallergens in
CRAIC between October 2009 and February 2010. All patients underwent
skin testing with allergen extracts for Parietaria, Pinus, Cupressus and
Morus pollens 2 of each, a weight-volume (dilution 1:20) and other units.
Results: We included a total of 256 patients, 140 female (53.1%), 130
(50.8%) were under 18 years. The prick test with allergenic extract of Cupres-
sus was positive in 39 (15.2%) patients with W/V and 18 (7%) patients with
PNU, the prick test to Parietaria allergenic extract was positive in 3 (1.2%)
patients W/V and 4 (1.6%) patients with BAU, the prick test with Pinus
allergenic extract was positive in 4 patients (1.6%) with W/V and 2 patients
(0.8%) with PNU, and the prick test with Morus allergen was positive in
19 patients (7.4%) with W/V in 8 patients (3.1%) with PNU. Of the 44
aeroallergens our center applies Cupressus (1:20) ranked 7th place.
Conclusions: Cupressus sensitization was high in our study group (15.2%).
Consideration should be the routine use of allergen extract of Cupressus for
diagnosis and treatment in patients with respiratory allergy.
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Prevalence of Skin Reactivity to Antigen Mus Musculus in
Patients with Respiratory Allergy
Chrystopherson Caballero, MD. Allergy and Clinical Immunology, University
Hospital of Puebla, Puebla, Mexico.
Background: It has been reported worldwide high prevalence of sensitization
to antigen Mus musculus (mouse) in patients with allergic respiratory
diseases.1,2
Methods: We performed a cross-sectional, observational, prospective and
descriptive study in patients of both genders, from 2 to 58 years old, attending
for the ﬁrst time to the service of Allergy and Clinical Immunology in the
University Hospital of Puebla, with clinical symptoms suggestive of asthma,
allergic rhinitis, or both, for a period of 6 months. Each patient underwent
clinical history and prick skin test with epithelial antigen Mus musculus. Data
were analyzed with the program SPSS-Statistics 18.
Results: We included 110 patients, 50% were women, mean age was 24.1
years (SD 16.2) 92.7% were from urban areas and 7.3% rural. The overall
prevalence of skin reactivity to antigen epithelial Mus musculus was 1.8%,
the corresponding to patients with allergic rhinitis were 2.4% and the remain-
ing subgroups were nonreactive. One of these patients worked with laboratory
animals including Mus musculus, which represented 33% of patients with
positive skin reactivity.
Conclusions: The results presented here support the relevance of imple-
menting skin testing with antigen Mus musculus only in those patients who
suffer from respiratory allergy and who have a history of recurrent exposure
to it.
REFERENCES
1. Phipatanakul W, Eggleston PA, Wright EC, Wood RA; Mouse allergen.
II. The relationship of mouse allergen exposure to mouse sensitization
and asthma morbidity in inner-city children with asthma. J Allergy Clin
Immunol. 2000;106:1075–1080.
2. Matsui EC, Eggleston PA, Breysse PN, Rand CS, Diette GB. Mouse
allergen-speciﬁc antibody responses in inner-city children with asthma.
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Atopy Patch Test to Aeroallergens Extracts is Useful In Allergic
Diseases Diagnosis When Skin Prick Test is Negative
Rocio Tordecilla, MD, and Maria Angelica Marinovic, MD. Servicio de
Alergia e Inmunología, Hospital Clínico Universidad de Chile, Santiago,
Chile.
Background: The atopic diseases are generally diagnosed by performing
skin prick tests (SPTs) to different aeroallergens. However, when this study
results negative, it is possible to perform atopy patch test (APT). This
technique has been introduced to evaluate sensitization to aeroallergens in
patients with atopic eczema dermatitis syndrome. Nevertheless, its role in
other allergic diseases has not been proved. Objective: Evaluate aeroallergens
response using skin prick test (SPT) and atopy patch test (APT) in patients
with allergic diseases.
Methods: Retrospective cohort study of individuals who performed SPT and
APT as part of allergic diseases study. The study subjects were patch and skin
prick tested to house dust mite (Dermatophagoides), trees, grass and fungi
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mix, cat and dog dander, among others. The tests were performed at the
respiratory allergic disease center of Santa Maria Clinic in Santiago, Chile,
between January 2010 and April 2011.
Results: Fifty-ﬁve patients were included, 18 (33%) males and 37 (67%)
females, median age 6 years (range from 3 months to 62 years), with the
following diagnosis: atopic dermatitis syndrome (60%), allergic rhinitis
(58%), contact allergic dermatitis (16%), asthma (9%), recurrent bronchial
obstructive syndrome (7%), allergic rhinoconjuctivitis (4%), chronic cough
(4%), recurrent acute otitis media (2%) and recurrent laryngitis (2%). They
underwent usual SPTs and APTs with multiple aeroallergens extracts. Of the
55 patients, 22 showed a positive SPT and 32 a positive APT; in 14 (25%)
both, SPT and APT were positive. In 8 (15%) the SPT was positive and APT
negative, while in 18 (33%) the SPT was negative, but the APT positive.
Fifteen (27%) were negative to both tests.
Conclusions: Our results show that APT might be a useful diagnosis test in
patients with allergic diseases and that its routine use can improve their
diagnosis.
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Clinical and Laboratory Studies of the Fate of
Intranasal Allergen
Janet Rimmer,1 Concencaio Santos,1 Eija Yli-Panula,2 Markku Viander,3
Virginia Noronha,1 Jane Radford,4 G Dunlop,5 and Cheryl Salome1. 1Wool-
cock Institute of Medical Research, Sydney, Australia; 2Department of
Teacher Education, University of Turku, Turku, Finland; 3Department of
Medical Microbiology and Immunology, University of Turku, Turku, Finland;
4Department of Pathology, University of Sydney, Sydney, Australia; 5Wah-
roonga Specialist Centre, Sydney, Australia.
Background: The nose is generally the ﬁrst site of contact for inhaled
particles including allergen, however the precise way in which allergen is
handled by the nose is unknown.
Objective: This study aimed to describe the dispersal of Der p 1 allergen by
measuring the recovery of allergen following nasal administration and to
evaluate whether Der p 1 can be detected in nasal biopsies after natural
exposure and nasal challenge.
Methods:
1) Der p 1 allergen was administered intranasal to 20 non-atopic healthy subjects
and recovery of Der p 1 was measured in the nasal wash, nasal mucus and
induced sputum up to 30 minutes after challenge.
2) In 8 subjects (5 atopics) Der p 1 was sprayed intranasal into one nostril and
30 minutes later a biopsy was taken, the contralateral nostril served as
a negative control. Immunohistological localisation of Der p 1, IgE pos-
itive cells, macrophages was undertaken. Eosinophils were shown by H-E
staining.
Results:
1) Less than 25% of total allergen inserted into the nasal cavity was retriev-
able after aqueous or particulate allergen challenge. Most allergen was
retrieved from the nasal mucus.
2) Under baseline conditions, in atopics and non-atopics, mild Der p 1 tissue
staining in nasal epithelial tissue was observed. Following challenge
epithelial Der p 1 staining increased both in atopics and non-atopics, while
increased staining of lamina propria was found in atopics only. Also
increased eosinophils, macrophages and IgE positive cells were observed
in areas of higher concentrations of Der p 1 staining in the epithelium,
mucous glands and lamina propria compared to the contralateral unchal-
lenged nasal mucosa and also compared to the nonatopics.
Conclusions: Der p 1 allergen is detected in nasal tissue after natural
exposure and independent of atopic status. After challenge the nose
effectively retains allergen which is mucosally located. Furthermore in
atopics allergen is bound to epithelial cells and rapidly transported to the
subepithelial lamina propria where it can bind to IgE-bearing mast cells and
recruit eosinophils and macrophages facilitating induction and persistence of
inﬂammation.
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Effect of Enzymatically Modiﬁed Isoquercitrin, a Flavonoid, on
Symptoms of Japanese Cedar Pollinosis
Toshio Tanaka, MD, PhD, Mari Kawai, MD, PhD, Toru Hirano, MD, PhD,
Keisuke Hagihara, MD, PhD, Yoshihito Shima, MD, PhD, Masashi Narazaki,
MD, PhD, Atsushi Ogata, MD, PhD, and Atsushi Kumanogoh, MD, PhD.
Department of Respiratory Medicine, Allergic and Rheumatic Diseases,
Osaka University Graduate School of Medicine, Suita City, Japan.
Background: The prevalence of allergic diseases has increased all over the
world during the last 2 decades. Dietary change is considered to be one of
environmental factors that cause this increase and worsen allergic symptoms.
If it is the case, an appropriate intake of foods and beverages with antiallergic
activity is anticipated to prevent the onset of allergic diseases and ameliorate
allergic symptoms. Flavonoids, ubiquitously present in vegetables, fruits or
tea possess antiallergic and antioxidant effects, so that we examined the
efﬁcacy of a ﬂavonoid on clinical symptoms of Japanese cedar pollinosis.
Methods: We investigated the efﬁcacy of enzymatically modiﬁed isoquerci-
trin (EMIQ), a quercetin glycoside, to relieve symptoms of Japanese Cedar
pollinosis by 3 different clinical trials. In either trial patients were randomly
assigned to the EMIQ group or the placebo group and took one capsule
containing EMIQ plus corn starch or corn starch only twice a day. The
efﬁcacy was evaluated with the total symptom, medication or QOL score.
Study 1 (reference 1) and 2 (reference 2); EMIQ (100 mg/day) versus
placebo, for 8 weeks, started after (study 1) and before (study 2) the onset of
pollen release, Study 3; EMIQ (200 mg/day) versus placebo, for 4 weeks,
started after the onset of pollen release.
Results: In study 1 and 2, during the entire study period, ocular1 medication
score for the EMIQ group was signiﬁcantly lower (P , 0.05) than that of the
placebo group. When limited to the period, total symptom 1 medication
score for the EMIQ group was signiﬁcantly lower than that for the placebo
group in all 3 studies.
Conclusions: These results indicate that intake of EMIQ, a quercetin
glycoside proved to be effective for the relief of symptoms caused by
Japanese cedar pollinosis.
REFERENCES
1. Int Arch Allergy Immunol. 2009;149:359–368.
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Prevalence of Allergen Sensitization in Children with Atopy
Suspicion between Six Months and Five Years of Age
Maria Angelica Marinovic, MD, and Rosario Rojas, MD. Servicio de Alergia
e Inmunologia, Hospital Clinico Universidad de Chile, Santiago, Chile.
Background: Classically we have been taught that the skin prick test (SPT)
must be performed over 4 years of age mainly because of the lack of
sensibility the test has on younger children, now a days the utility of the SPT
in younger children with atopic history is controversial and it would help
make an early diagnosis. The objective of this study is to describe the
prevalence of allergen sensitization in children between 0 and 5 years of age
that have atopic history. We also describe the sensitization percentages to
the most relevant allergens according to age group.
Methods: SPT performed between January 2006 and July 2010 at the
Respiratory and Allergy Department of Clínica Santa Maria to children with
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atopic story were analyzed. A standard base of 21 allergens from LETI
laboratory was used.
Results: Seven hundred and ﬁfty two children with SPT were studied; they
were divided into 2 groups. Group A corresponding to children between 6
and 24 months of age, group B corresponding to children between 25 months
and 5 years of age. In group A 76 SPT and group B 676 SPT were performed.
The total number of SPT positive to 1 or more allergens was 46.4%. (Group
A: 6.4%, group B 40%). The most prevalent allergens according to age were:
group A: grass 16%, egg 16%, cat dander 10% and house dust mite
(Dermatophagoides pteronyssinsus and farinae) 10%. Group B: grass 15%,
house dust mite 13.6%, fungal allergens (Aspergillus an Alternaria) 11.4%,
trees 9% and cat dander 6.6%.
Conclusions: A high sensitization percentage to grass and egg is seen under
24 months of age. Egg sensitization diminishes signiﬁcantly over 2 years of
age, on the other hand house dust mite and fungal sensitization increases with
age which could be explained by a longer exposure time in genetically
predisposed children. Forty-six percent of the children are sensitized to 1 or
more allergens which make us question the classical indication that SPT will
be done over 4 years of age. When high suspicion of atopic history, a SPT
should be performed independently of patient age.
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Prevalence Allergic Diseases and Allergic Sensitization among
Urban Ofﬁce Workers as Compared with a Forest
Service Workers
Woo Kyung KIM, MD, PhD,1 Hye Won KIM,2 and Hae-Sun Yoon, MD,
PhD3. 1Pediatrics, Inje University, Seoul Paik Hospital, Seoul, South Korea;
2Allergy & respiratory research laboratory, Inje University, Seoul-Paik Hos-
pital, Seoul, South Korea; 3Allergy & respiratory research laboratory, Inje
University, Seoul, South Korea.
Background: Asthma, allergic rhinitis (AR), and atopic dermatitis (AD) are
the most prevalent allergic diseases and number of studies has shown an
increase in prevalence of both all over the world in recent years. Although
little about the prevalence of asthma, AR, and AD in Korean adults. And the
incident sensitization to common allergens in the setting of sensitization to an
occupational allergen has not been described. Our aim was to determine the
prevalence of living and working place in adults. And also, determines the
sensitization to common allergens in subjects with incident sensitization to
a work-related allergen.
Methods: We performed questionnaire survey and allergy skin prick test
with 27 common inhalant allergens among 294 subjects (response rate,
94.9%, n ¼ 279) age 19 to 54 years in Seoul and forest service workers. One
hundred thirty four subjects were forest service workers and 145 subjects
were urban ofﬁce workers.
Results: The mean age was 33.7 6 7.6 years. There were 141 man and 138
women. A history of asthma was noted in 3.8% and a history of AR was
noted in 28.7%. And a history of AD was noted 21.3%. The each group of
sensitization to allergen were 40.3% (urban) and 60.0% (forest), (P ¼ 0.002).
The most common allergen was mites. The sensitization to birch allergen
were more high in urban ofﬁce workers (P ¼ 0.01).
Conclusions: The prevalence of allergic rhinitis in urban areas was high. And
urban ofﬁcer workers were also high with sensitization rate compare to forest
workers. The interesting results were the pollen sensitization rate in urban
areas showed higher tendencies. More research will be needed in futures.
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Photoaging Attenuates Skin Test Response to Histamine More
Than Natural Aging
Monroe James King, DO, David Fitzhugh, MD, and Richard F. Lockey, MD.
Division of Allergy and Immunology, University of South Florida and James A.
Haley Veterans’ Hospital, Tampa, FL.
Background: Clinical experience suggests that skin test reactivity is often
decreased in photo-exposed skin versus sun-protected skin in older individ-
uals. The current study was designed to address whether photoaging or
natural aging of skin causes a greater diminution in skin test reponse.
Methods: Prick-puncture skin tests to histamine were performed on sun-
exposed and sun-protected areas in younger (n ¼ 61, age 20–50) and older (n
¼ 63, age 60–87) adult volunteers who were recruited for skin prick testing
because of suspect allergic rhinitis and/or allergic asthma. The skin was
scored for photoaging by physical examination and coloration was measured
by a colorimeter.
Results: There was no observed difference in wheal and ﬂare response to
histamine when patients were stratiﬁed by age alone. However, photoaging
was signiﬁcantly correlated with decreased skin reactivity to histamine on the
upper back (a sun-exposed area) as compared to the lower back (a sun-
protected area). In patients with the most severely sun-damaged skin, there
was a trend toward decreased skin reactivity in all areas.
Conclusions: Skin test reactivity to histamine is negatively correlated to the
degree of photoaging and is independent of patients’ chronological age. This
result has clinical implications for patients with signiﬁcant photoaging, sug-
gesting that care should be taken to perform skin testing on anatomic sites in
sun-protected areas. In patients with severe photoaging, allergen-speciﬁc IgE




Hla and Chronic Urticaria with Positive Autologous Serum Skin
Test among Brazilians
Zamir Calamita, PhD,1 Márcia Gamberini, PhD,2 Wilson Baleotti, Jr, PhD,3
Andrea B. P Calamita,4 and Antonio Fabron, Jr, PhD5. 1Allergy and Immu-
nology, Medical School of Marilia, São Paulo, Brazil; 2Laboratory HLA,
Laboratory of Immunology of Marilia (LIM), São Paulo, Brazil; 3Clinical
Pathology, Medical School of Marilia, São Paulo, Brazil; 4Dermatology,
Medical School of Marilia, Marilia, Brazil and; 5Hematology, Medical
School of Marilia, São Paulo, Brazil.
Background: Many autoimmune diseases are associated with certain alleles
of the human leukocyte antigen (HLA) system, and recent studies have shown
that, in many cases, chronic urticaria has autoimmune etiology. An associa-
tion between class I and II alleles of the major histocompatibility complex
(MHC) and idiopathic chronic urticaria (ICU) has previously been observed
in different populations, but there are still no studies on Brazilian populations
in this respect. The involvement of MHC classes I and II (loci A, B and DR) in
Brazilian patients with ICU and a positive autologous serum skin test (ASST)
was investigated and compared with a healthy population group.
Methods: DNA was extracted from the blood of 42 patients with ICU (28
women; mean age 6 SD: 44 6 12 years; range: 19 to 88 years) and MHC
classes I and II alleles were determined using the polymerase chain reaction
(PCR) and a laboratory test for oligonucleotide hybridization using a single-
ﬁlament probe. The frequencies of these alleles in patients with chronic
urticaria were compared with the frequencies in 1000 genetically unrelated
voluntary blood donors from the same region of Brazil. The diagnosis of
idiopathic chronic urticaria was based on the patients’ clinical histories and
routine laboratory tests. Only the patients with positive ASSTs were selected.
The allele distribution results from the patient and control groups were ana-
lyzed using odds ratios and 95% conﬁdence intervals.
Results: No statistically signiﬁcant differences were found between the
ASST-positive patients with chronic urticaria and the control group, in
relation to the MHC classes I and II alleles studied.
Conclusions: We found that in this population group, there was no speciﬁc
association between the HLA alleles studied (HLA-A, HLA-B and DRB1)
and ASST-positive chronic urticaria. We believe that further population
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studies are needed in order to investigate the possible existence of this
association.
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CD63 Expression, IL3 Receptor, IGG Autoantibody and
Autologous Serum Skin Test Accuracy in Patients with Chronic
Urticaria in Brazil
Zamir Calamita, PhD,1 Roseli N. S Antunes, PhD,2 Odilon M Almeida
Filho, PhD,3 Wilson Baleotti Junior, PhD,4 Andrea B. P Calamita,5
Josianne T Fukasawa,6 and Debora A Cavaretto6. 1Allergy and Immunology,
Medical School of Marilia, São Paulo, Brazil; 2Hematology, Medical School
of Marilia, Marilia, Brazil; 3Immunology, Medical School of Marilia, Mar-
ilia, Brazil; 4Clinical Pathology, Medical School of Marilia, São Paulo,
Brazil; 5Dermatology, Medical School of Marilia, Marilia, Brazil; 6Flow
Citometry, Medical School of Marilia, Marilia, Brazil.
Background: Recently, a laboratory technique called basophil activation test
(BAT) using ﬂow cytometry (FC) got demonstrated through the expression of
CD63 molecules that basophils of atopics donors can be activated when
stimulated by serum of patients with CU (supposedly autoimmune). This
paper aims to analyze the autologous serum skin test (ASST) in relation to the
BAT as well as evaluating the IL3 receptor (CD123) and nonspeciﬁc
autoantibodies IgG bound to basophils of patients with chronic urticaria.
Methods: We studied 33 adults (24 women) with CU with a mean age of
42.5 1 14 years, of which 22 with ASST positive and 11 with ASST neg-
ative. It was done through the analysis by FC of CD63 molecules expression
on basophils from an atopic donor after stimulation by serum of these
patients. We used as control the serum from 4 volunteers (without urticaria).
Also we researched the CD123 molecule expression and IgG nonspeciﬁc
autoantibodies in basophils from patients with CU.
Results: We found 21 (63.6%) patients with positive BAT, of these 14
(66.6%) were ASST positive and 7 (33.3%) were ASST negative. Taking as
parameter the BAT, we found an accuracy of 54.5% for the ASST,
a sensitivity of 66%, speciﬁcity 33%, positive predictive value of 63% and
negative predictive value of 36%. Comparing the expression intensity (mean
with SD) of IgG autoantibodies in patients’ basophils with positive and
negative ASST there was not statistical difference (for a P , 0.05); the same
was true when comparing the autoantibodies (IgG) between groups with BAT
positive and with BAT negative. We also didn’t ﬁnd statistical difference (for
a P , 0.05) of receptor expression of IL3 (CD123) between the groups.
Conclusions: Taking as parameter the BAT for diagnosis of autoimmune CU
this study found that ASST is accurate about 55%. There was no statistical
difference when comparing the expression of IgG nonspeciﬁc autoantibodies
and CD123 molecule, between groups.
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Comparison of the Modiﬁed Autologous Serum Skin Test and the
Cd63 Basophil Activation Test in Chronic Urticaria
B. Irinyi, E. Gyimesi, E. Garaczi, Zs. Bata, K. Hodosi, M. Zeher, É.
Remenyik, and A. Szegedi,. University of Debrecen, Medical and Health
Science Centre, Debrecen, Hungary.
Background: The modiﬁed CD63 basophil activation test in the diagnosis of
chronic autoimmun urticaria was ﬁrst described in 2004 by Szegedi et al. We
demonstrated that the strongly sensitized basophils of atopic donors can be
successfully used without the addition of IL-3 for the in vitro evaluation of
autoimmun urticaria. Positive correlation was found between the basophil
CD63 expression test and the autolog serum skin test (ASST), and between
the CD63 test and the gold standard histamine release assay.
Methods: We examined 50 patients with chronic ordinary urticaria and with
the help of a validated questionnaire urticaria score index was calculated.
ASST with the patient’s own diluted (1:10, 1:100) and undiluted sera, and
CD63 basophil activation test on atopic donor basophils were performed.
Pearson’s exact test was used to analyze the correlation between the results
of the CD63 assay and the urticaria score index.
Results: Based on our results ASST performed with diluted sera of chronic
urticaria patients did not show correlation with the results of the CD63 assay.
A signiﬁcant correlation was found between the CD63 assay and the score
index representing severity of disease.
Conclusions: ASST with diluted sera of chronic urticaria patients does not
have any additional information on the diagnosis of autoimmun urticaria. In
the CD63 basophil activation assay the degree of the CD63 cell surface
expression can give information on the severity of the clinical signs.
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The Frequency of Positivity in Autologous Serum Skin Test in
Patients with Chronic Idiopatic Urticaria
Silvio Lima Filho,MD. Allergy Depatment, Clínica de Alergia da Policlínica
Geral do Rio de Janeiro, RJ/Faculdade Sá Earp Neto, Faculdade de Medic-
ina de Petrópolis, Rj, Rio de Janeiro, Brazil.
Background: Describe the frequency of positive results in autologus serum
skin test among patients with cronic urticaria.
Methods: Trans-sectional study of patients with CIU refered to traitment in
policlínica geral do Rio de Janeiro, brazil. Autologus serum intradermal
injections were used to estabilished the sensitivity. Negative and positive
controls were made with 0.9% intradermal saline solution and skin prick test
with histamina 1:100 solution. Autoreactivity was considered positive when
wheal reached 3 mm at least, 1.5 mm larger than saline solution at 30 minute
interval. Antihistamines drugs were interrupeted 72 hours before test. Dates
on race, age, sex, and informations about length and how often the symptoms
persist, personal history of atopy (PHA) and angioedema (AE), autoimmune
disease (AID) and physical (PF) and not physical factors (NPF) related with
the worsening of urticaria were registered during appointment. K square and t
student tests were used in this work.
Results: Eighteen patients, from 2008, march to 2011, march, were investigated
(15 f; 12 w; age 50,67 6 16,93 yr). Eleven patients presented positive AAST
(61.1%) with a mean wheal diameter ¼ 9,64 6 2,66 mm (negative control ¼
6,33 6 3,63 mm; P , 0,001). All of the positive asst occurred in patients over
60 years old. The mean length of the desease was 21,78 6 22,95 months.
Continuous symptoms were saw in 83.3%, pruritus, the major one (94.4%).
Angioedema and PHA were present in 61.1% and 27.8%, respectively. NPF of
symptoms worsening like drugs, food, emotional stress or alcoholic beverages
were complaint of 72.2% of individuals, whereas 22.2% complainted about
worsening with colinergic PF or dermographism. Joint pain (33.3%) were the
complain the most frequent and 7 patients, mainly whose with positive ASST,
had elevated thireoid antibody levels (n ¼ 5; P . 0.05).
Conclusions: The positive asst frequency was 61%, comparable to values
found in the liretature. Association among social-demographic and clinical
aspects was not observed. We emphasize the prevalence of joint pain and
angioedema as associated symptoms and the more frequence of AID
laborotory ﬁnds. The procedure proved safe and precise and worth value in
the screening diagnosis of autoimune etiology for patients with CIU.
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ElevenCases ofAngioedemawithEosinophilia Treated in a Single
Hospital in Japan
Shinichiro Nakachi, MD, Shigeko Inokuma, MD, Erika Matsubara, MD,
Kae Ohnishi, MD, Hiromitsu Asashima, MD, Kuninobu Wakabayashi, MD,
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and Kiyofumi Hagiwara, MD, PhD. Department of Allergy and Rheumatic
Diseases, Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan.
Background: Angioedema with eosinophilia (AE) is mostly reported in
Japanese patients, and only as case reports. In this study, we aimed to
determine the prevalence, clinical and laboratory characteristics, and courses
of AE; the therapies for AE and the outcomes; and to evaluate whether steroid
therapy for AE is necessary or not.
Methods: The patients whose blood samples showed an eosinophil count
of $2000/mL, among the samples tested for blood cell counts and differ-
ential counts between Jan. 2006 and Oct. 2010, in Japanese Red Cross
Medical Center, were ﬁrst included. Among these patients with AE were
extracted. The AE diagnosis was based on angioedema developing con-
currently with eosinophilia and improving with the recovery from
eosinophilia.
Results: All of the 11 patients were Japanese young females. One patient
with clear arthralgia showed radioisotope accumulation in the joints by bone
scintigraphy, and was diagnosed as having arthritis. The peak peripheral
blood eosinophil count was 7,839 6 6,008 (2,130–23,170)/mL after visiting
our hospital. An increase in white blood cell count was only due to an in-
crease in eosinophil count. Serum C-reactive protein and Immunoglobulin E
levels remained almost normal. Peripheral blood eosinophil count decreased
steadily for 8 weeks after the ﬁrst visit, regardless of steroid use. Edema in all
of the patients and arthralgia in 6 patients improved within 12 weeks. None of
the patients had a recurrence of AE.
Conclusions: AE developed in Japanese young females and likely showed
a single course. In AE, the count of eosinophil of 104/mL was observed. Only
eosinophil count increased without changes in changes in the counts of other
leukocyte series. Serum C-reactive protein and Immunoglobulin E levels
remained almost normal. The eosinophil count in AE patients will return to
the normal level within 8 weeks even without steroid therapy.
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Chronic Urticaria and Infections
Nadia Aguilar,1 Saul Lugo-Reyes, MD,2 Nora Hilda Segura Mendez, MD,3
and Elizabeth Mendieta1. 1Allergy & Clinical Immunology, Specialty Hospi-
tal Medical Center XXI Century, Mexico City, Mexico; 2Allergy & Clinical
Immunology, National Institute of Pediatrics, Mexico City, Mexico; 3Allergy
& Clinical Immunology, Specialty Hospital XXI Century National Medical
Center, Mexico City, Mexico.
Background: Chronic Urticaria (CU) is a group of diseases that share
a distinct skin reaction pattern. Triggering of urticaria by infections has been
discussed for many years but the exact role and pathogenesis of mast cell
activation by infectious processes is unclear. The remission of annoying
spontaneous chronic urticaria has been reported after successful treatment of
persistent infections.
Objective: To describe the infections found in chronic urticaria patients in
our service, by performing a complete medical history, physical examination,
laboratory studies and cultures.
Methods: Universe: Consecutive patients with chronic urticaria, with a de-
tailed history, physical examination, laboratory studies underwent clinical
viral panel, cultures, biopsy for detection of H. Pylori.
Results: A total of 50 patients, mostly women 82% and 18% men, mean age
41 years. 42% of the total population had salmonella, proteus infection in
20% and 8% brucellosis. Crossed with urinary tract infection 6% of the
population. Five patients had positive stool in 3 patients Endolimax nana was
isolated and 2 patients reported Giardia lamblia, 5 patients (10%) women had
undergone cervicovaginitis 2 of them infected with S. haemolyticus, the rest
was cultivated E. faecalis, and T. Gardenella vaginalis, respectively. Was
isolated in 2 patients and one patient H.pilory HCV infection.
Conclusions: Infections may play a causal role of UC in some cases. Were
identiﬁed in 42% of cases and gastrointestinal infections by most common
cause Salmonellosis. As for genitourinary tract infections, intestinal parasites,
Helicobacter pylori, were treated appropriately with antibiotic therapy, found
a successful resolution of urticaria mainly in patients infected with
Helicobacter pylori. There is growing evidence that persistent infections in
chronic urticaria are important triggers, particularly in the case of infection by
Helicobacter pylori, so If an infection is identiﬁed, it should be appropriately
treated and it should be checked whether eradication has been achieved.
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Chronic Urticaria Associated with Thyroid Disease
Flor de Guadalupe Peñaloza-González, MD,1 Andrea Aida Velasco-Medina,
MD,2 Aida Gonzalez-Carsolio, MD,2 Andres-Leonardo Burbano-Ceron,MD,2
Adriana Barreto-Sosa,MD,2 and Guillermo Velázquez-Sámano,MD2. 1Hospital
General de México, Mexico City, Mexico; 2Servicio de Alergia e Inmunología
Clínica, Hospital General de México, Mexico City, Mexico.
Background: Chronic urticaria has an incidence of 15% in the general
population and sometimes is associated with chronic diseases such as
rheumatoid arthritis, vitiligo and thyroid disorders. Chronic urticarial is
characterized by wheals lasting more than 6 weeks, with alterations of the
upper layers of the skin only. On histopathology there is a perivascular
inﬁltrate characterized by T CD4 and CD8 lymphocytes and other in-
ﬂammatory cells. Cytokines produced by lymphocytes, mast cells and other
cells increase the expression of vascular adhesion molecules. Other mediators
such as histamine increase vascular permeability causing edema, clinically
represented by wheals. Treatment of chronic urticaria includes ﬁrst and
second generation antihistamines as ﬁrst line treatment. Sometimes there is a
poor response to there drugs and second line treatments such as immunosu-
pressors are indicated. A search for systemic disorders is helpful to identify
associated pathology which makes chronic urticaria reluctant to therapy.
Methods: We performed a retrospective study considering patients with
chronic urticaria attending our clinic during the last 5 years. Three hundred
patients with urticaria were considered, with 16% (50 patients) with a chronic
disease. Six patients with chronic urticaria were associated with thyroid
disease.
Results: We considered 6 patients with chronic urticaria with altered thyroid
function tests; 4 with subclinical hypothyroidism and 2 with subclinical
hyperthyroidism. All of them had a poor response to antihistamines. When a
thyroid disorder was identiﬁed, they received appropriate treatment achieving
control of chronic urticaria. Treatment with antihistamines was continued.
Conclusions: Chronic urticaria is a disease often associated with systemic
disorders including thyroid disease. We found an association with thyroid
pathology in 2% of patients with chronic urticaria, with remission of cutaneous
symptoms after treatment of endocrinologic disorder. No patient had clinical
manifestation of thyroid disease so it is important to perform thyroid function
tests to patients with chronic urticaria since identiﬁcation of these disorders and
appropriate treatment helps to control cutaneous symptoms.
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Epidemiology of Urticaria Cases in the Allergy Service from
a Third Level Medical Center. Six Year Experience
Monica Martin Del Campo Perez, MD. Allergy service, dermatologist,
Ecatepec, Mexico.
Background: The purpose of this study is to report the cases of Urticaria
diagnosed in the Allergy service from a Third level medical centre since its
creation in July 2005.
Methods: This is a descriptive, retrospective, transversal study from July
2005 to February 2011. Selected medical records of patients apply for
diagnostic criteria for an allergy disease. EAACI/GA2LEN/EDF/WAO
guideline 2009 was used to make diagnosis of urticaria. Patients were
classiﬁed by age and sex, and how many of them had skin prick test, also how
many patients began treatment with immunotherapy.
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Results: Thirteen thousand seven hundred and thirty seven consultations
were attended in the Allergy service between the period mentioned; 2,337
medical records of patients were selected; 1,608 patients applied for a speciﬁc
diagnosis for an allergy disease; 90 completed criteria for urticaria, after
allergic rhinitis, asthma an atopic conjuntivitis. 49 (54.4%) patients were
found to be in the range of 30 to 40 years; 36 (73.4%) of them were female.
The majority of urticaria patients were in the range of 40’s with 28 (18 F/10
M) corresponding to 31.1% of total of patients. 43 patients were classiﬁed
with acute urticaria, 26 as chronic urticaria. 19 patients presented angioedema
at the time of diagnosis. Skin prick test were made in 27 patients only in 10
were positive and began immunotherapy. Patients with positive skin prick test
results with 9 at dust mites, 4 cockroach, 3 mosquito, 3 fungus and 8 grass
and tree pollen.
Conclusions: Urticaria represents the fourth cause of incidence in allergy
diseases in this study. Female sex is more frequently affected in the range of
30 to 40 years of age. We found statistical data comparable with international
information, that forms part of our data base en Mexican patients in our
center, also we standaridzed procedures for testing physical urticaria.
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Frequency of Autoreactivity Demonstrated by Autologous Serum
Skin Test in Patients with Chronic Urticaria in the Valley of
Mexico During a Period of 8 Years
María Isabel Rojo Gutiérrez,1 Jaime Mellado-Abrego, MD,1 Misael
Gonzalez-Ibarra, QFB,2 Teresa Sandoval, QFB,3 and Mario-Alberto
Bermejo, MD2. 1Allergy; 2Allergy and Immunology; 3Investigation, Juarez
Hospital, Mexico City, Mexico.
Background: Urticaria is a skin disease characterized by rapid emergence of
hives, accompanied or not with angioedema. Usually lasts less than 24 hours.
Approximately 12 to 24 per cent of the population will have hives or angio-
edema at least once in their life. Some patients with chronic urticaria has been
classiﬁed as autoimmune. The autologous serum skin test (ASST) has been
used to show pro-inﬂammatory circulating endogenous factors and it is
regarded as a test for autorreactividad. The autorreactividad does not deﬁne
an autoimmune urticaria, but may be an indicator of the presence of auto-
reactive antibodies with the capacity of to activate the mast cells however
functional antibodies need to be conﬁrmed through of release of basophils
histamine test from basophils (BHRA) and its speciﬁcity immunoassay
(Western Blot or ELISA)-conﬁrmed. Objective: to evaluate the auto-reacti-
vity by autologous serum skin test in patients with chronic urticaria idiopathic
in a study of 8 years. Material and methods: we made 216 ASST and
autologous plasma skin test (APST) in patients with chronic urticaria without
speciﬁc cause identiﬁed, of any age, during the period of 2003 to 2011.
Results: Thirty ﬁve thousand patients were evaluated only 261 patients not
identiﬁed the cause (0.6%) and we realized ASST, of these 190 (88%) were
negative, and 26 (12%) were positive, 20 (76.9 %) were female and 6 (23.1%)
male, the median of age for women was 30 years ago with medium of 28 and
men average 29 years and median 20. Of the 26 patients one was positive for
anti-thyroglobulin senior titles (1: 170) .dos with positive anti unclears and
one with pANCA and cANCA positive of a total of 216 patients, 156 (72.2)
had APST and 60 (27.8%) were positive, 46 (76.6%) women and 14 (23.3 %)
men. Mc Neman concordance between tests P , 0.0001 and Kappa index
gives us a highly signiﬁcant concordance P , 0.0001. The correlation be-
tween ASST and APST by Sperman was high signiﬁcance value of P ,
0.001. The correlation of both tests was moderately high (76.8%).
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Chronic Idiopathic Urticaria and Neglected Toxocara Infection
Rosanna Qualizza, MD,1 Cristoforo Incorvaia, MD,1 and Romualdo Grande,
MD2. 1Allergy Department, Istituti Clinici di Perfezionamento, Milano, Italy;
2Diagnostic Services Department Central Laboratory, IRCCS Fondazione
Ca’Granda Ospedale Maggiore Policlinico, Milano, Italy.
Background: The diagnosis of chronic idiopathic urticaria is stated when all
possible causes of urticaria are excluded. Toxocariasis is a parasitic infection
induced by a nematode belonging to the family of Ascaridae with generally
affects cats and dogs. Human infestation is caused by the accidental ingestion
of embryonated eggs of Toxocara; the larvae do not develop into adult worms
but may migrate to several organs, giving rise to a number of clinical
expressions, including chronic urticaria.
Methods: From 2005 to 2011 in our Allergy Unit were selected 336 patients
with a positive result for IgG antibodies to Toxocara canis as assessed by
ELISA or Western blotting (WB). Of them, 52 patients (33 F, 19 M, age
ranging from 19 to 76 years old), suffered from chronic urticaria that lasted
from 3 to 10 years and was poorly responsive to antihistamines. In all these
patients anthelmintic therapy was prescribed using mebendazole (one 100 mg
tablet b.i.d. for 3 days), repeated after 20 days up to 3 times. In case of
insufﬁcient improvement, albendazole (one 400 mg b.i.d. for 5 days) was
used, repeated after 2 months.
Results: All patients showed a complete remission of urticaria and a decrease
in serum IgG levels to Toxocara canis. In 29 patients (60%) a negative result
to ELISA and WB was observed.
Conclusion: These ﬁndings suggest taking into account the role of Toxocara
canis in patients with apparent chronic idiopathic urticaria. In patients with
positive IgG to Toxocara anthelmintic therapy achieves remission of urticaria.
URTICARIA CASE REPORTS
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Mucocutaneous Disease as a Presentation of Hereditary
Angioedema. Report of 2 Cases
Angelica Alaniz, MD. Allergy and Immunology, IMSS, Mexico City, Mexico.
Background: Hereditary angioedema is an autosomal dominant disease the
affected gene encodes c1 esterase inhibitor located on chromosome 11q12-
q13.1. The worldwide incidence ranges from 1 in 10,000 to 1 in 50,000.
Three varieties are described. Type I is chacarterized by a lack of functional
protein with complete absence of C1-INH activity. Type II has a dysfunctional
protein with reduced activity of C1-INH. While Type III is due to mutations
in the gene for clotting factor XII or defects not identiﬁed. Clinically is
characterized by recurrent non itchy edema on skin and mucous membranes
associated with pain syndromes, nausea, vomiting, diarrhea and compromise
of the airway that is unresponsive to epinephrine, antihistamines and
angioedema conventional therapy. Because of this, it is imperative to
establish the diagnosis to initiate early treatment with recombinant C1-INH
or preventive treatment if there is no replacement therapy.
Methods: We present 2 cases with atypical manifestations characterized by
ﬁxed angioedema located in labial mucosa.
Results: Case 1: 23 years old health female with labial angioedema for 2
years without improvement in spite of having multiple treatments, including
immunosuppressive agents. During the evaluation were discarded infectious,
autoimmune and endocrine diseases, with only positive for type II hereditary
angioedema with decreased function of C1-INH antigen: 76% (78–122%).
Case 2: 53 years old female with history of hypothyroidism and type 2
diabetes in control, with 2 years of labial mucosa angioedema unresponsive
to treatment. During his study the only ﬁnding was decreased levels of C1
esterase inhibitor: 19% (21–39%). In both cases the evolution has been torpid
to treatment with androgens, getting partial response with immunosuppres-
sion based on azathioprine.
Conclusions: The cases presented correspond to an atypical presentation of
hereditary angioedema and in spite of the treatments have only been able to
obtain partial response. In the setting of having the replacement therapy
improvement in symptoms is expected, offering the patients a better quality of
life.
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Plasmapheresis in a Patient with “Refractory”
Urticarial Vasculitis
Ozgur Kartal, MD,1 Mustafa Gulec, MD,1 Zafer Caliskaner, MD,1
Oral Nevruz, MD,2 Turker Cetin, MD,2 and Osman Sener, MD1. 1Division
of Immunology and Allergic Diseases, Gulhane Military Medical Academy
and Medical School, Ankara, Turkey; 2Division of Haematology, Gulhane
Military Medical Academy and Medical School, Ankara, Turkey.
Background: Immune complexes have been found in the circulation
approximately 30 to 75% of patients with urticarial vasculitis and much
evidence supports the role of these immune complexes in the pathogenesis of
urticarial vasculitis. Plasmapheresis is effective in removal of these immune
complexes. However, few cases have been reported regarding the use of
plasmapheresis in the treatment of urticarial vasculitis.
Methods: A 35-year-old woman presented with history of recurrent episodes
of generalized painful urticarial plaques often lasting 9 years associated with
swelling of her parts of body. Examination revealed multiple urticarial
plaques distributed all over the body (particularly in the extremities, palms
and soles). The initial laboratory studies, including a complete blood count,
thyroid function tests - thyroid autoantibodies, erythrocyte sedimentation rate,
hepatitis markers, liver and renal function tests, urinary analysis, stool
analysis for parasite ova, total IgE, C3, C4, C1q, CH50, C1 inhibitor levels
and antinuclear antibodies were found to be within normal range. Skin prick
tests were performed with commonly consumed foods in Turkey found to be
negative. A biopsy from an affected area of skin revealed an urticarial
vasculitis. Based on the biopsy results, the patient was diagnosed with UV.
Treatment with H1/ H2-antihistamines and oral corticosteroids (1 mg/kg/day)
had been unsuccessful; therefore hydroxychloroquine 400 mg/day was added.
Unfortunately hydroxychloroquine was stopped in the second month due to
the emergence of an adverse event (keratopathy). The patient underwent
plasma exchange 2 times with an interval of 6 months. Five percent albumin
solution as replacement ﬂuid was used. One plasma volume was processed in
each session. Apheresis procedure was performed with the “Cell Separator”
device. The plasmapheresis procedures were completed without any adverse
events. At 13 months after the plasmapheresis, the urticarial plaques were
reappeared, but the severity and duration of symptoms were lower than before
the plasmapheresis. The newly lesions were re-treated with short-term oral
antihistamine regimen.
Conclusions: In conclusion, the presented report supports the usability of
plasmapheresis in patients with “refractory” UV. Further clinical studies are
needed to conﬁrm our experience.
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Delayed Diagnosis of Hereditary Angioedema. A Case Report
Sandra González-Díaz, MD, PhD,1 Alfredo Arias-Cruz, MD,2
Gabriela Galindo, MD,1 Karla Mejia, MD,1 Claudia Gallego, MD,1
Diego Garcia-Calderin, MD,1 Maricruz Calva, MD,1 and Luis Dominguez,
MD1. 1Regional Centre of Allergy and Clinical Immunology, University
Hospital, Monterrey, Mexico; 2Allergy and Clinical Immunology, University
Hospital UANL, Monterrey, Mexico.
Background: Hereditary angioedema (HAE) was ﬁrst described by Quincke
in 1882 and appointed by Osler in 1888, is a rare disease caused by deﬁciency
of gene esterase inhibitor C1 (C1 INH). Prevalence varies from 1:10,000 to
1:150,000. The attacks are usually sporadic and often associated with trauma-
tic or stressful events. Treatment included management of acute attacks and
prophylactic therapy in speciﬁc situations where attacks may occur.
Methods: A 40-year-old male with a family history of father facial
angioedema. He had experienced 15 episodes of angioedema during the
previous 5 years. During these events than lasted 3 to 5 days edema affected
his eyelids, lips, hands, feet and testicles. And sometimes was associated to
abdominal pain and shortness of breath. He went several times to medical
ofﬁce and emergency room, where he received treatment with antihistamines
without improvement.
Results: The laboratory evaluation of complement components showed C4
2s0.8 (NV 20–50), CH50 10.1 (NV 20–50), C1 inhibitor quantitative,1.2 ng
Eq/mL (NV . 10.7), and C1 esterase inhibitor functional 104% (NV .
67%), once the diagnosis of type I hereditary angioedema was done, we
started danazol therapy that has prevented recurrence of symptoms.
Conclusions: It is important to do a detailed history for the diagnosis and
treatment in cases of angioedema. Most patients improve when receiving the
right treatment. Recurrent angioedema events even with treatment, the
physician must search for malignity and/or autoimmunity disease.
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Urticaria Pigmentosa. Case Report
Sandra González-Díaz, MD, PhD,1 Alfredo Arias-Cruz, MD,2 Karla Mejia,
MD,1 Claudia Gallego, MD,1 Diego Garcia-Calderin, MD,1 Maricruz Calva,
MD,1 and Luis Dominguez, MD1. 1Regional Centre of Allergy and Clinical
Immunology, University Hospital, Monterrey, Mexico; 2Allergy and Clinical
Immunology, University Hospital UANL, Monterrey, Mexico.
Background: Mastocytosis is a disorder characterized by an abnormal
proliferation of mast cells and release of cell mediators. The incidence is 1 per
1000 skin diseases attending in dermatology services. Mastocytosis can be
divided into 3 different clinical variants: cutaneous, systemic and malign
mastocytosis. Urticaria pigmentosa is the most common variety (70–90%) of
mastocytosis. Of all cases 55% ocurr during the ﬁrst 2 years of life. When the
bone marrow, lymph nodes, liver and spleen are affected the disorder is called
systemic mastocytosis.
Methods: Case 1: A 20 month old male with history of penicillin and
erythromycin allergy, as well atopic family history. Began at 4 months with
itchy brown-marrow papules in the back, then generalizated except palms and
soles. The lesions were exacerbated by heat and rubbing. There was no fever,
weight loss, or any other systemic symptoms in the history. Blood count and
biochemical laboratories were normal. Skin biopsy reported the presence of
mast cells, conﬁrming urticaria pigmentosa diagnosis. The management
included antihistamines, restricted diet and emollients with improved of
symptoms. Case 2: A 9 month old male with no history of atopy. At the ﬁrst
visit he had 4 months with skin lesions characterized by hyperpigmented
maculopapular eruption, scattered on head, over trunk and extremities.
Dariers sign was positive. Skin biopsy is performed with conﬁrming the
diagnosis of mastocytosis.
Conclusions: The urticaria pigmentosa diagnosis is mainly clinical, with
emphasis on the Dariers sign, which is pathognomonic and positive in 90% of
cases. In some cases a skin biopsy is required to conﬁrm the diagnosis.
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Antihistamines are the ﬁrst line of treatment. Symptoms relieve spontane-
ously before adolescence in 50% of pediatric patients. In some cases, a ma-
lignant transformation of mastocytosis could occur, condition that is called
“mast cell leukemia”.
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A Case of Chronic Urticaria Complicated by Raoultella
Ornithinolytica Urinary Tract Infection, Bronchospasm
and Angioedema
Rannakoe Lehloenya, FCDerm (SA), and Sean Christians, FCDerm (SA).
Medicine, University of Cape Town, Cape Town, South Africa.
Background: Raoultella ornithinolytica (formerly Klebsiella ornithinolytica)
has been recovered from water, soil, plants and occasionally mammalian
mucosae. It is one of the organisms that cause histamine ﬁsh poisoning by
converting histidine to histamine as it possesses the enzyme histidine
decarboxylase.
Methods: We report a case of a 51 year old woman with a history of
rheumatic heart disease, allergy to aspirin and penicillin, reﬂux oesophagitis,
atopic dermatitis, stress incontinence and a cystocele attributed to chronic
obstructive pulmonary disease. She presented to the emergency unit with
a 5 years history of urticaria of unknown cause, complicated by symptoms
of a urinary tract infection and 3 episodes of angioedema in the preceding
10 days. She was not on regular medication but on intermittent prednisone,
promethazine and was recently treated with omeprazole and sucralfate for
reﬂux oesophagitis. She denied previous use of angiotensin converting
enzyme inhibitors. Urine culture grew Raoultella ornithinolitica (.100 000
CFU/mL) after 3 days.
Results: The angioedema resolved on treatment of the UTI with oral
ciproﬂoxacin. She was lost to follow-up and when seen 3 years later she
still had intermittent ﬂares of urticaria, but had had no episodes of
angioedema.
Conclusions: R ornithinolytica, most commonly described as a causative
agent of histamine ﬁsh poisoning in humans, possesses histidine decarbox-
ylase, an enzyme that converts histidine into histamine. The resulting elevated
levels of histamine usually do not cause severe disease but complications can
arise in people with chronic histamine mediated diseases.
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A Case of Idiopathic Recurrent Isolated Orbital Angioedema
with Exophthalmos
Neetu Talreja, MD,1 Susan Culverhouse, MD,1 Dona Shearer, RN,1
and Richard F. Lockey, MD2. 1Division of Allergy and Immunology, Univer-
sity of South Florida, Tampa, FL; 2Division of Allergy & Immunology, Uni-
versity of South Florida, and James A. Haley Veterans’ Hospital, Tampa, FL.
Background: Idiopathic angioedema is a term applied to recurrent episodes
of angioedema of unknown etiology. The following is a case report of
idiopathic recurrent isolated orbital angioedema with exophthalmos which
responds to prolonged courses of oral corticosteroids.
Methods: A 67 year old Caucasian female with aspirin exacerbated
respiratory disease (AERD) sought treatment for an acute, progressive
painless left eye swelling with exophthalmos without visual deﬁcits or
urticaria. High dose corticosteroids were initiated followed by a low
maintenance dose. The swelling subsided after one year of corticosteroid
therapy.Ten years later, orbital swelling with exophthalmos returned in the
same eye. No medications, such as aspirin1 or non steroidal anti-inﬂammatory
drugs,2 were associated with the swelling. A CT of the orbits revealed an
isolated proptosis with swelling of the medial and inferior rectus muscles and
mild hypertrophy and swelling of the left lacrimal gland. A complete history
and physical examination were negative. The family history likewise was
negative.
Results: High-dose systemic glucocorticoid therapy was initiated. Symptoms
resolved after 1 month of tapered corticosteroid therapy, however, swelling
reoccurred in the orbit within one week. Low dose maintenance cortico-
steroids were reinitiated with resolution of the orbital swelling. Work-up for
acquired C1 esterase deﬁciency is negative.
Conclusions: An atypical case of recurrent idiopathic isolated orbital
angioedema with exophthalmos in a patient with AERD and no triggering
factor, systemic ﬁndings and a negative evaluation is presented.
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A Case of Multiple Simultaneous Urticarial Syndromes
Refractory to Treatment
Jim Parkerson, DO,1 Michel Alkhalil, MD,1 Dennis Ledford, MD,1
and John Sleasman, MD2. 1Division of Allergy & Immunology, University
of South Florida and James A. Haley Veterans’ Hospital, Tampa, FL; 2Uni-
versity of South Florida College of Medicine, St Petersburg, FL.
Background: We report the case of a patient with 3 forms of physical
urticaria and his response to treatment.
Methods: An atopic asthmatic 11 year old male was evaluated for a history of
recurrent pruritus with a variable, erythematous rash unresponsive to therapy.
Since the age of 5 years, he has experienced small red, raised, pinpoint,
pruritic “bumps” over his entire body except the palms of his hands and soles
of his feet. The duration of the lesions was generally 5 minutes to about 1
hour. They occurred with exercise, stress, cold air, and cold water. At the time
of the evaluation, the patient was treated with oral levocetirizine 5 mg daily
and hydroxyzine 50 mg at bedtime without resolution of symptoms.
Results: In clinic, the patient had a positive ice cube test, a positive
dermatographia test and a negative warm test tube test. Methacholine and
autologous sweat testing were declined. Otherwise he had a normal physical
examination with a negative Darier sign. Laboratory studies did not reveal
a disease process responsible for the urticaria. Based upon his historical
symptoms and clinical ﬁndings, he was diagnosed with 3 distinct types of
physical urticaria; cholinergic urticaria, cold urticaria and dermatographia.
The dose of anti-histamine therapy was doubled and the patient returned to
clinic in 4 weeks to report that his symptoms were slightly improved but had
not resolved.
Conclusions: Physical urticarias are usually controlled by antihistamine
therapy but refractory cases are not uncommon. This patient also has poorly
controlled asthma for which he is scheduled to start omalizumab therapy upon
turning 12 in 1 month. We will continue to follow this case to observe if
omalizumab has an effect upon his urticarial symptoms.
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Chronic Urticaria as First Sign of Sarcoidosis
María Socorro Pérez-Bustamante,1 José Barbarroja-Escudero,1 Dario Antolín-
Amérigo, MD,1 Soledad Alonso-Viteri,2 Melchor Álvarez-de-Mon,1
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and Mercedes Rodríguez-Rodríguez1. 1Allergy Unit, Alcalá de Henares Hospi-
tal, Madrid, Spain; 2Respiratory Disease Department, Alcalá de Henares Hos-
pital, Madrid, Spain.
Background: Sarcoidosis is a granulomatous multisystemic disease of
unclear etiology, which can affect any organ. The cutaneous manifestations
are present in 20% to 35% of patients. Cutaneous lesions have been classiﬁed
as speciﬁc and nonspeciﬁc, depending on the presence of noncaseating
granulomas on histologic studies. Speciﬁc lesions include maculopapules,
plaques, nodules, lupus pernio, scar inﬁltration, alopecia, ulcerative lesions,
and hypopigmentation among others. The most common nonspeciﬁc lesion is
erythema nodosum. Others include calciﬁcations, prurigo, erythema multi-
forme, nail clubbing, and sweet syndrome. Urticaria does not belong to
nonspeciﬁc nor speciﬁc lesions of this illness. Diagnosis is based on 3 criteria:
a compatible clinical and/or radiological picture, histological evidence of
noncaseating granulomas, and exclusion of other diseases. There is no
standarized therapy but corticosteroids are the mainstay of treatment for
sarcoidosis. We report a case of undetermined chronic urticaria which after 6
months displayed compatible symptoms with respiratory disease associated
with systemic involvement.
Methods: A 34-year-old man followed in our department due to a chronic
urticaria, during 6 months with no good response to anti-histaminic treatment;
refers non speciﬁc constitutional symptoms, including fever, weight loss,
fatigue dyspnea and dry cough for 2 months. Skin prick test with standard
aeroallergens and foods are done. Laboratory test (incluiding ECA levels),
functional study; tuberculine test, chest x-ray, CT scan and lung biopsy were
performed.
Results: Skin prick test and tuberculine test were negatives. Angiotensin-
converting enzyme was high (ECA: 141). We observed a mixed process with
negative bronchodilator response in pulmonary function test and a moderate
disminution in diffusing capacity. Difuse and bilateral reticulo-nodular
inﬁltration with mediastinal and hiliar lymphadenopathy was observed in
X-chest. Lung biopsy: Noncaseating granulomas were observed. The di-
agnosis was Sarcoidosis, stage II. The patient remains asymptomatic
regarding cutaneous and respiratory symptoms, after fulﬁlling oral cortico-
iteroids treatment for sarcoidosis.
Conclusions: Chronic urticaria can be the tip of an iceberg indicating more
changes in other organs. The importance of considering cutaneous sarcoidosis
in the clinical differential diagnosis of an urticaria relies on the association
with systemic involvement, partial treatment response and the convenience of
the skin as a tissue source for histologic analysis.
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Life-Threatening Angioedema without Urticaria (Ae-U)
Jacquelynne Corey, MD, and Eric Yoo, BA/BS. Section of Otolaryngology
Head and Neck Surgery, University of Chicago Medical Center, Chicago, IL.
Background: This paper addresses diagnosis and treatment of life-
threatening angioedema without urticaria (AE-U) with emphasis on newer
concepts on patient safety and updated knowledge about pathophysiology.
AE-U may be idiopathic, hereditary or acquired secondary to adverse “aller-
gic” reactions to aspirin (ASA), angiotensin-converting enzyme inhibitors
(ACEIs), angiotensin-receptor blockers (ARBs), non-steroidal anti-inﬂamma-
tory drugs (NSAIDs), or other drugs. Serious adverse reactions to these drugs
are becoming more common as they are increasingly prescribed for hyper-
tension and other cardiac disorders.
Methods: We used electronic databases to gather information on angioe-
dema. We also documented and analyzed a case of drug-induced acquired
angioedema from ACEI resulting in repeated intubations and prolonged ICU
stays.
Results: Case reportdA 69 year old female presented with rapidly progres-
sive swelling of the tongue. She was intubated and underwent cricothyrot-
omy. She had been admitted in 2003 and 2005 for angioedema; in 2003 she
was instructed to avoid OTC cold medications, ACEIs, and NSAIDS, and in
2005 told she had an allergy to ACEI, ARBs, ASA, and NSAIDs. Although
this was noted in her charts, the PMHx and allergy list were incorrect or
inconsistent throughout her subsequent admissions and ofﬁce visits from
2005 to 2008. This data suggests 3 serious concerns for patient safety: (1)
documentation of “drug allergy,” (2) ED diagnosis and treatment of angioe-
dema, (3) follow-up from ED to outpatient care for angioedema. Once initi-
ated, serious upper airway obstruction may take seconds to days to progress.
After starting the drug, it may take days to years before a serious episode
occurs, highlighting the signiﬁcance of proper documentation in medical
records. ED diagnosis may be difﬁcult but should differentiate between
angioedema with and without urticaria as the latter does not respond well
to IV antihistamines, commonly given as ﬁrst-line treatment in the ED. Newer
treatment options for angioedema may include C1-INH concentrate, ecallan-
tide, and icatibant. Outpatient follow-up should include workup for HAE,
AAE, and angioedema with urticaria (AE1U) by a specialist. A proposed
algorithm for AE-U is presented.
Conclusions: Severe AE-U may be difﬁcult to diagnose and treat in the
EDdpatient safety may be improved with documentation, newer treatments,
and outpatient follow-up.
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Urticarial Rash Associated with Chest Pain
Mouna Boulaich, PhD, José Meseguer Arce, PhD, Inmaculada Sanchez-
Guerrero Villajos, MD, Paola Carrillo-Fernández Paredes, PhD,
Ana Ester Piñera Martínez, PhD, and Juan Antonio Pagán Alemán, PhD.
Allergology, Allergologic, Murcia, Spain.
Background: Urticaria may be the ﬁrst manifestation of an underlying
systemic disease (tumors, infections, collagen vascular or thyroid disease.
Differential diagnosis must be made with many entities that can be manifested
with a similar skin injury.
Methods: A 49 year-old man who during 2 years has monthly multi-days
episodes of generalized pruritic papular skin lesions, responding to steroids
but not to antihistamines. Occasionally associated with joint pain. Two skin
injuries biopsies informed of simple urticaria.One year after skin lesion onset,
he began with chest pain episodes suggestive of angina pectoris with elevated
necrosis enzyme markers and ischemic changes on EKG. Angina episodes
were sometimes preceded by skin lesion outbreak and it responded to steroid.
Coronary catheterization was negative twice, so the diagnosis was vasospastic
angina. Later he presented cough, wheezing, elevation of transaminases,
LDH, FA, GGT, CPR and ﬁbrinogen, 800 eosinophils in peripheral blood.
Sputum eosinophils 40 to 60%.Chest X-Ray objective a thickened left hilum
and doubtful left parahilar inﬁltrated.
Results: Allergologic studydSkin prick test with aeroallergens and wide
food battery were negative. Speciﬁc IgE against Anisakis, latex, Echinococ-
cus and other blood parameters including serology, autologous patient serum
skin test were all normal/negative. Tryptase determination at baseline and
during skin lesion shoot: normal. Other explorationsdECO-cardio: inferior
basal akinesia and inferoposterior hypokinesia, LVEF 60%, normal RV sys-
tolic function and valves. CT scan visualize mediastinal and abdominal aden-
opathy, splenomegalia and ureterolithiasis. Mediastinoscopy and biopsy of
right paratracheal grainy adenopathy conﬁrms the diagnosis of sarcoidosis.
ACE: 250 U/L. Gallium67 scan suggestive mediastinal sarcoidosis. Heart RM
scan: no evidence of morphological criteria for cardiac sarcoidosis diagnosis.
Conclusions: Sarcoidosis is a multisystem granulomatous disease of un-
known etiology. It may affect almost any organ, predominantly lung, lymph
nodes and skin. Cardiac involvement is 25% but only symptomatic in 5%. We
report a patient with sarcoidosis and vasoespastic angina. Its described cases
of cardiac sarcoidosis and vasospastic angina. In this case we cannot dem-
onstrate cardiac injury. Sarcoidosis is a great simulating of cutaneous lesions
and it can imitate to urticaria.
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Application of Intravenous Immunoglobulin for Treatment of
Chronic Autoimmune Urticaria
Vladimir Alyoshkin, MD. Immunology, Moscow, Russia.
Background: To develop a patogenetically justiﬁed method for treatment of
the autoimmune form of chronic urticaria.
Methods: 14 patients with autoimmune urticaria (18–60 y-o., time since
disease onset ranging from 6 weeks to 5 years), having positive autoserum
test results (7 mm or more in 11 patients, 4.5–6.5 mm in 3 patients) were
treated with intravenous immunoglobulin for 4 days (50 mL of 5% immuno-
globulin solution per day). Intravenous immunoglobulin of a fourth genera-
tion, containing 99.1 to 99.2% monomeric IgG, was applied.
Results: The treatment resulted in the rashes regressing in 13 (93%) patients
after 3 to 4 days of treatment. All of the patients showed reduced autoserum
test results (one of them was absolutely negative) 6 months after the end of
treatment. Our investigations have shown a complete absence of clinical
manifestations of urticaria within 1 year.
Conclusions: Intravenous immunoglobulin, containing only monomeric IgG,
has proven highly efﬁcient in treatment of chronic autoimmune urticaria. The
above-mentioned reduced autoserum test results suggest fourth-generation
intravenous immunoglobulin’s contribution to the pathogenesis of the disease.
X-LINKED AND COMMON VARIABLE
IMMUNODEFICIENCY
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Long Term Follow-up of Patients with Common Variable
Immunodeﬁciency (Cvid) in Rio De Janeiro, Brazil: Clinical
Phenotypes and Prognosis
Amanda Seba, MD,1 Norma de Paula Motta Rubini, PhD,1
Albertina Varandas Capelo, MSc,1 Eliane Miranda da Silva, MD,1
Marilza Campos de Magalhães, MSc,2 Fernando Samuel Sion, PhD,1
and Carlos Alberto Morais de Sa, PhD3. 1Clinical Immunology, Federal
University of Rio de Janeiro State, Rio de Janeiro, Brazil; 2Hematology,
Federal University of Rio de Janeiro State, Rio de Janeiro, Brazil; 3Internal
Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, Brazil.
Background: CVID comprises a variety of clinical phenotypes that may
inﬂuence the prognosis of the disease. Our goal was to investigate the clinical
phenotypes and prognosis of a series of patients with CVID.
Methods: We evaluated 11 patients with CVID, according to the PAGID
criteria in long-term clinical follow-up (. 10 years). Most patients were on
regular use of intravenous immunoglobulin (IVIg), provided free of charge by
the government. Clinical evaluation was performed monthly and exams every
6 months to 1 year, including immunological evaluation, hematologic, bio-
chemical, autoimmune, stool, urine analysis, chest CT, abdominal ultrasound
and speciﬁc investigations of infectious diseases and malignancies, when
needed.
Results: The average follow-up was 21.9 years (12–34). Among the 11
patients, the mean current age was 39.8 years (16 to 62), 73% were female
and 82% white. The age at symptoms onset ranged from 4 to 31 years (mean
¼ 18) and diagnosis occurred between ages 11 and 47 (mean ¼ 28). Most
patients (55%) had the phenotype of infectious complications only, 27% had
infections and immune thrombocytopenic purpura and 18% had infections
and solid neoplasias. The most common infections were recurrent sinusitis
(100%), pneumonia (82%), giardiasis (36%) and tuberculosis (18%). None of
the patients developed lymphoproliferative and / or inﬂammatory complica-
tions. With regard to immunological changes, we observed that 4 patients
(36%) experienced an increase in CD8 T lymphocytes and inversion of CD4/
CD8 ratio. Adherence to the use of IVIg was good in 50% of patients, fair in
38% and unsatisfactory in 12%. All patients have good quality of life, per-
forming their routine activities of study, work and leisure.
Conclusions: In the population studied, the most frequent phenotypes were
infectious complications or infectious complications 1 autoimmunity. Tuber-
culosis can be an important infectious complication in patients with CVID in
endemic areas. The delay in the diagnosis of CVID, around 10 years, indi-
cates the need to improve the diagnosis of PID in our country. With proper
clinical management and good adherence to the use of IVIg, patients with
CVID in developing countries may have survival and quality of life similar to
those described in developed countries.
598
Quality of Life in Patients with Common Variable
Immunodeﬁciency in the Department of Allergy and Clinical
ImmunologydCentro Medico Nacional Siglo XXI
Freya Helena Campos Romero, MD,1 Nora Hilda Segura Mendez, MD,2
Laura Mendoza, MD,2 and Nelva Guillén, MD3. 1Allergy and Clinical Im-
munology, Specialty Hospital, Centro Medico Nacional Siglo XXI, Mexico
City, Mexico, and Allergy and Clinical Inmunology, Mexico City, Mexico;
2Allergy and Clinical Immunology, Specialty Hospital Centro Medico Nacio-
nal Siglo XXI, Mexico City, Mexico; 3Allergy and Immunology, México Dis-
trito Federal, Mexico, and Allergy and Immunology, Speciality Hospital,
Centro Médico Nacional Siglo XXI, México Distrito Federal, Mexico.
Background: Common variable Immunodeﬁciency (CVIDs) is characterized
by a deﬁciency in antibody production and also generates enormous
morbidity of school absenteeism and dropout or cause layoffs. All chronic
diseases affect quality of life of patients, in this particular case CVIDs. The
use of instruments like the SF - 36 provides information about the patients’
perception of their disease and its environment. The objective is to determine
the quality of life of adult patients with CVID who receive replacement
therapy through the use of SF-36.
Methods: We conducted a cross-sectional cohort study, which included all
patients diagnosed with CVID in our hospital with approval from local
research committee F-2011-3601-21. We analyzed the results with descriptive
statistics and the SF-36 was used the method of Rand Group.
Results: Involving 11 patients with CVID, 4 men and 7 women, average age
30 years (18–53) years. The results show a reduction in quality of life of 65%,
without gender difference. However in general we see that men are more
affected the physical role 31% and women in the general health 40%, In
menthal health assesment, we found that in both genders is more affected
in Vitality 55%, and Role Emotional least 84.72%. In relation to physical
health, both genders showed greater involvement in aspects of general health
45% and less area affected is physical function 68 %.
Conclusions: CVID patients show a signiﬁcant deterioration in their quality
of life. It’s important to highlight that there are not statistically different
variations in quality of life. But the general perception of gender does vary
without establishing differences between mental and physical health.
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Prevalence of Common Variable Immunodeﬁciency in Adult
Patients Specialty HospitaldCentro Medico Nacional
Siglo XXI - MssdMexico City
Nelva Guillén, MD, Nora Hilda Segura Mendez, MD, Laura Mendoza, MD,
and Freya Helena Campos Romero, MD. Allergy and Clinical Immunology,
Specialty Hospital, Centro Medico Nacional Siglo XXI, México City, Mexico.
Background: Common Variable Immunodeﬁciency (CVID) is the most
common primary immunodeﬁciency (IDP), occurs primarily in adults
between the second to fourth decades of life, without gender predominance.
It is characterized by concentrations of immunoglobulins (Igs) of at least 2
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standard deviation (DS) of normal, recurring infections, some patients have
autoimmune diseases and tumors, absence of isohemagglutinins and lack of
production of antibodies (Ab) after vaccination and have excluded other
causes of hypogammaglobulinemia.
Objective: Determine the prevalence of CVID in the Specialty Hospital-
dCentro Medico Nacional Siglo XXI, IMSS, Mexico City.
Methods: We included all patients with suspected diagnosis of CVID,
clinical history, laboratory tests, determination of serum Igs and isohemag-
glutinins and were given a dose of gamma globulin 500 mg/kg/dose every 21
days. The results were analyzed with descriptive statistics. The protocol was
approved by the local research committee.
Results: A total of 15 patients, 11 women and 4 men, mean age 34 years (6
11), 14 patients met all international standards and just only one patient has
positive isohemagglutinins. The prevalence of CVID calculated according to
the total population that is entitled in this hospital, 1, 520, 900, 1: 101, 393. In
relation to the number of patients served by our service, the prevalence of
0.053% with a ratio of 1:2.533 right holders.
Conclusions: Our results show differences in relation to the published
literature, prevalence in female sex ratio of 3:1, participating patients were
diagnosed at the 34 years of average age, just only 2 patients were diagnosed
before 20 years of age, unlike some of the international and national reports,
we establish the deﬁnitive diagnosis according to international standards in
93% of cases evaluated. The prevalence of CVID obtained in our study is
1:101.393, higher than reported in international literature is 1:30.000 to
1:50.000, but similar to that reported in Spain in 1997 and Iran in 2006.
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Infections in 14 Patients with Common Variable
Immunodeﬁciency, Retrospective Study
Elizabeth Mendieta,1 Leonel Gerardo Del Rivero, MD,2 and Nadia Aguilar3.
1Allergy & Clinical Immunology, Specialty Hospital Medical Center XXI
Century, Mexico City, Mexico; 2Allergy and Immunology, Mexico City, Mex-
ico; 3Allergy & Clinical Immunology, Specialty Hospital Medical Center XXI
Century, Mexico, Mexico City, Mexico.
Background: Common variable immunodeﬁciency is a heterogeneous
syndrome of primary antibody production failure. It affects 1 in 10000 to
50000 individuals, and is the most frequent primary immunodeﬁciency
producing relevant clinical symptoms in adults and children. The hallmark of
this disease is recurrent bacterial infections, usually of the respiratory and
gastrointestinal tract. Onset is mainly in children aged 1 to 5 years,
adolescents aged 16 to 20 years, and adults (ﬁfth decade).1
Methods:We assessed retrospectively recurrent infections in 14 patients with
deﬁnitive diagnosis of CVID, for a period of 2 months through the review of
their medical records.
Results: Ten patients were female (71.4%) and 4 were male (28.5%). The
average age was 34 years. The average age of diagnosis of CVID was 27.5
years with an age range from 6 to 60 years. In 9 patients (64%) of the total
studied CVID diagnosis was made in adulthood. All patients had a history of
respiratory infection process in the following distribution: in 9 patients (64%)
found a history of bronchiectasis, in 8 patients (57%) was found rhinosinu-
sitis, and pneumonia; in 5 patients (35%) recurrent or chronic otitis media and
one patient was a history of pulmonary tuberculosis. The lower urinary tract
infection was found in 11 patients (78%), chronic diarrhea in 5 patients
(35%), osteomyelitis in 1 patient.
Conclusions: Recurrent infections of the respiratory tract speciﬁcally low and
high and / or gastrointestinal infections should lead to systematic evaluation
in which the primary immunodeﬁciencies are included as CVID.
REFERENCE
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Autoimmune Thrombocytopenic Purpura Associated with
Common Variable Immunodeﬁciency
Elizabeth Mendieta,1 and Leonel Gerardo Del Rivero,MD2. 1Doctors in train-
ing, Mexico City, Mexico; 2Allergy and Immunology, Mexico City, Mexico.
Background: Common variable immunodeﬁciency (CVID) is a condition
characterized by antibody deﬁciency, and therefore susceptible to recurrent
pyogenic infections, cancer and autoimmune diseases. It is a heterogeneous
syndrome in primary immunodeﬁciencies and clinically the most important is
often diagnosed in adulthood. Autoimmunity occurs in 5% of the general
population, in patients with CVID the percentage increased to 20 to 48%,
cytopenias being the most common cause of autoimmunity in these patients.
Autoimmune thrombocytopenic purpura and autoimmune hemolytic anemia
are the most common autoimmune consequences, occurring in 5% to 8% of
all patients with CVID. Some patients develop these disorders before the
diagnosis of CVID.
Methods: We present the case of a woman of 45 year old, with a history of
lower respiratory tract and urinary tract infections in recurrent Pulmonary
Tuberculosis. Enter the program short-course treatment strictly supervised for
pulmonary tuberculosis with appropriate response. Autoinmune thrombocy-
topenic purpura refractory to steroids (WWTP) for performing splenectomy.
Results: Anti DNA antibodies, anti nuclear, anti-protease, C. ANCA/PR3
antimieloperoxidasa, serology for hepatitis B, C, HIV negative. Serum
immunoglobulins were as follow: IgG, 158 mg/dL (normal 700 to 1600),
IgM, 55 mg/dL (normal 40–230), IgA, 36 mg/dL (normal 70–400), and, IgE,
38.7 IU/mL (normal 0–100) in more than 2 occasions with values below 2
standard deviations. CD4 T lymphocytes (19%) CD4/CD8 ratio (0.54).
Conclusions: Meets diagnostic criteria for Common Variable Immunodeﬁ-
ciency (CVID) and starting treatment with intravenous immunoglobulin at
a dose of 400 mg/kg (every 21 days) with signiﬁcant clinical improvement
and has even managed to integrate into your daily activities. Today, he
continues with danazol for WWTP. Therefore, CVID is necessary to consider
in the differential diagnosis of autoimmune thrombocytopenic purpura and
autoimmune hemolytic anemia in adults (1).
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Cvid: A Common but Still Underdiagnosed Disease
Claudia Gallego, MD,1 Sandra González-Díaz, MD, PhD,1 Maria del Carmen
Zarate, MD, PhD,1 Alfredo Arias-Cruz, MD,1 Diego Garcia-Calderin, MD,1
Karla Yanneth Mejia Salas, MD,2 Maricruz Calva, MD,3 and Luis Alfredo
Dominguez Sansores, MD3. 1Regional Centre of Allergy and Clinical Immu-
nology, University Hospital, Monterrey, Mexico; 2Allergy and Clinical Im-
munology, Regional Centre of Allergy and Clinical Immunology, Monterrey,
Mexico; 3Regional Centre of Allergy and Clinical Immunology, Monterrey,
Mexico.
Background: Among the more than 150 different forms of Primary
Immunodeﬁciency Diseases (PID) the CVID is the most common symptom-
atic primary immunodeﬁciency, present mainly in adults. There is a failure of
B cells to develop and differentiate into plasma cells; at consequent
a reduction of the production of one or more isotypes of antibody can also
affected Cell-mediated immunity. Common manifestations included recurrent
bacterial infections, that typically involve the upper and lower respiratory
tract. Some patients are highly prone to autoimmune manifestations,
lymphoid hyperplasia, and tumors.
Methods: We presented 3 cases of CVID with a variety of clinical
presentation, evolution and complications related to delayed diagnosis.
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Results: A 34 year old male presented chronic diarrhea, weight loss,
malnutrition and recurrent upper respiratory infections; digestive tract
endoscopy and biopsy was reported with villous atrophy, chronic inﬂamma-
tion and low grade non-Hodgkin’s lymphoma B cell. Unfortunately this
patient refused the use of gamma globulin treatment, had a high morbidity,
and ﬁnally the patient died. The case of a nurse with clinical manifestation of
recurrent rinosinusitis and pneumonia, which was diagnosed as IDCV 17
years later, after she developed pulmonary bronchiectasis. Fortunately the
disease is under control and she is actually under treatment with intravenous
immunoglobulin. Finally, the case of a 44 year old female, who suffered from
recurrent upper respiratory infections, additionally had a thyroid gland tumor
associated which affecting the thyroid function.
Conclusions: In the 3 cases had low levels of all immunoglobulin as
a hallmark. The clinician must be suspecting this condition in all adults with
recurrent infectious disease who have gastrointestinal symptoms or who are
detected a malignant disease. Early diagnosis and correct treatment are critical
in preventing tissue damage, long-term sequelae and death. Replacement with
intravenous gamma globulin and antibiotics are the mainstays in the
management of these patients.
REFERENCES
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Infections in Patients Diagnosed with Common
Variable Immunodeﬁciency
Sükran Köse, MD,1 Süheyla Serin Senger, MD,1 Arzu Didem Yalcin, MD,2
Gülsün Cavdar, MD,1 Sabri Atalay, MD,1 and Gürsel Ersan, MD1. 1Clinic of
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Background: Common variable immunodeﬁciency (CVID) is the most
frequent clinically manifested primary immunodeﬁciency. It is characterized
by recurrent infections due to defective immunoglobulin production. We
aimed to evaluate the infectious diseases of 7 patients as premising symptoms
for diagnosis of CVID.
Methods: All patients had a marked decrease in IgG levels (at least 2 SD
below the mean values for their age), a marked decrease in at least one of the
isotypes of IgM or IgA, a diagnosis of immunodeﬁciency at age .2 years,
and no other cause of hypogammaglobulinemia.1
Results: Seven patients who were diagnosed with CVID are investigated for
immunodeﬁciency reasons based on their recurrent infections. Diagnosis of
CVID was made at a median patient age of 28 years (range: 16–72 years); of
the patients, 6 (86%) were male. All patients were presented with recurrent
upper respiratory tract infections (URTI). Additionally, infected bronchiecta-
sis and chronic diarrhea were noted respectively in 3 patients (42.9%), and 2
patients (28.6%); 1 patient (12.3%) had pericarditis. None of them had
malignancy.
Conclusions: URTI, pneumonia, and diarrhea are the most frequent initial
complications of CVID. CVID often remains misdiagnosed for several years.
Unusual length, recurrence, or severity of these infections or pneumonia
should suggest the possibility of immunodeﬁciency and justify appropriate
evaluation.
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Background: Common variable immunodeﬁciency (CVID) is a primary
antibody deﬁciency characterized by a decrease in antibody production and
low or normal B cell numbers. To elucidate the clinical and immunological
heterogeneity of this condition, we studied 13 patients diagnosed with CVID,
examined the status of B-cell maturation in patients with CVID by analyzing
IgD/CD27 expression, and we analyze the in vitro B cell differentiation to
plasma cells.
Methods: T, B and NK cell populations was analyzed by ﬂow citometry,
expression of CD27 marker was determined to deﬁne B cell subsets; we also
assessed molecules important for B cell proliferation and differentiation, such
as TNFRSF13B (TACI), inducible costimulator (ICOS), CD154, CD20,
ICOSL and BAFFR. For B cell differentiation assays, total PBMCs were
cultured with CpG alone, or with SAC Cowan, Pokweed and CpG; ﬂow
cytometric analysis of plasmablast generation was perfomed after 7 days of
culture.
Results: Reduced numbers of T and B cells was observed in CVID patients,
this reduction was more prominent in adults than in children. One group of 8
patients showed a signiﬁcant reduction in IgD1CD271 memory B cells
while 3 patients had similar percentage than the healthy control group. The
IgD-CD271 memory B cell population was low in 10 patients (,12%);
while it was similar to the healthy control group in 2 of the patients. BAFFR
expression in B cells was reduced in 4 patients. Finally, the differentiation to
plasmablasts was reduced in patients, stimulation with CpG induced 18.5% of
plasmablasts (SD ¼ 12.5%) whereas it was 24% (SD ¼ 8.3%) in healthy
controls.
Conclusions: These results suggest that a combined defect in T and B cells
may account for CVID, at least in some patients. On the other hand, the
complete analysis of markers important for B proliferation and differentiation
such as ICOS, CD40, CD154 and TACI can be a useful tool for under-
standing this heterogeneous disease. B cells from CVID patients fail to
progress to IgD-CD271 memory B cells and plasmablasts. Based on these
facts, we hypothesize that one or more crucial signaling molecules is required
to induce terminal differentiation into memory B cells, if defective, may
cause CVID.
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X-linked Agammaglobulinemia: Report of 4 Cases of Mexican
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Background: The X-linked agammaglobulinemia is a primary immunode-
ﬁciency featured by hypogammaglobulinemia, recurrent infections and low
levels of circulating B Lymphocytes, caused by a mutation of the tyrosine
kinase of Bruton (Btk). The aim of this work is to present clinical and
laboratory evidence of 4 patients with high suspect to bear a Bruton’s
agammaglobulinemia.
Methods: We review medical records of 4 patients bearing a humoral
immunodeﬁciency probably Bruton’s agammaglobulinemia.
Results: Patient 1: 20 years old with IgG of 197 mg/dL, IgM 14.6 mg/dL,
IgA 10 mg/dL, IgE 0 UI/mL and B cells 0.02%. He has a brother with
hypogammaglobulinemia, 2 maternal uncles died with history of recurrent
infections. Patient 2: 13 years old, with IgG 33.3 mg/dL, IgM 6.07 mg/dL,
IgA 6.07 mg/dL, IgE 0.5 UI/mL and B cells 0.03%. Six maternal uncles and 2
aunts have died at early age. Patient 3: 6 years old, IgG, IgM, IgA and IgE not
detectable and B cells 0.4%. One brother died as newborn. Patient 4: 6 years
old, with IgG 33 mg/dL, IgM 98.7 mg/dL, IgA 6.67 mg/dL and B cells 2%.
The IgM maintained elevated until the age of 4 years old, afterwards was
undetectable. He had 2 maternal uncles that had died at early age. All of our
patients have presented infections before 6 months of age such as otitis,
pansinusitis, septic arthritis, mastoiditis, pneumonia. Two of them with
pleural efusion and patient 4 with bronchiectasis and atelectasis.
Conclusions: Because of the clinical ﬁndings of our 4 patients, immuno-
globulin levels, the low percentage of B cells, the early death of family
members and all of them arer males, we consider that the molecular defect in
our patients could be at Btk gene and the diagnosis most probable would be
Bruton’s agammaglobulinemia.
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Case Report: Hypogammaglobulinemia Induced
by Oxcarbazepine
Maria Angelica Marinovic, MD, and Rosario Rojas, MD. Servicio de Alergia
e Inmunologia, Hospital Clinico Universidad de Chile, Santiago, Chile.
Background: Case report: A 6 year old girl with history of motor learning
disability of unknown cause in treatment with Oxcarbazepine since December
2008 for epilepsy.
Conclusions: No previous infection history, on July 2009 presents a septic
shock secondary to Haemophilus inﬂuenzae pneumonia. During hospitaliza-
tion blood exams reveal; low IgG (356 mg/dL) with normal IgA/IgM levels.
T cell populations in normal range LTCD3: 74.9% (2476 cells/mm3),
LTCD4: 47% (1562 cells/mm3), LTCD8: 28% (930 cells/mm3), CD56:
22.9% (758 cells/mm3) and B cell number frankly diminished CD19:1.1%
(38 cells/mm3 (normal values range 200–1600 cells/mm3)). IVIG treatment
was indicated. The diagnosis of common variable immunodeﬁciency (CVID)
induced by Oxcarbazepine was proposed. According to literature reports this
cases should be controlled by immunoglobulin monthly quantiﬁcation, and
they recover between 3 and 9 months after drug suspension. After IGIV
therapy immunoglobulin quantiﬁcation show: IgG 1041 mg/dL, IgA 78
mg/dL, IgM 103 mg/dL, with frankly IgG elevation. A second control after
2 months IGIV infusion shows IgG 834 mg/dL, IgA 54 mg/dL, IgM 75 mg/
dL. The patient remains in good health with no infections after drug suspen-
sion. Her IgG levels and B cell (CD19) number returned to normal after 3
months (10.7% (271 cells/mm3)). Posterior IgG controls are in normal range
which shows a resolution of hypogammaglobulinemia.
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X- Linked Agammaglobulinemia and Moebius Syndrome, First
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Background: To know the association between X-linked Agammaglobulin-
emia and Moebius Syndrome. The X-linked Agammaglobulinemia or Bruton
disease, is characterized by the absence of B cells and decreased serum
immunoglobulin. The defective gen codes a tyrosincinasa protein: Btk.
Moebius Syndrome is a congenital facial palsy with impairment of ocular
abduction, by a craniofacial dysmorphism and limb-abnormalities.
Methods: Review Medical Records in a patient with Diagnosis of Bruton
Disease and Moebius Syndrome and review of cases in the literature. Case:
Male patient, 15 years of age, a ﬁrst borne from a normally evolved
pregnancy, and no consanguinity data. There were some craniofacial
dysmorphic features observed; severe lagofthalmus, lack of palpable lymph
nodes and tonsils, difﬁculty swallowing, facial palsy, syndactyly, talipes
equinovarus. Diagnosis is established as Moebius Syndrome by the de-
partment of genetics. Relatives have presented similar problems: 2 aunts and
2 uncles related to his mother had died prior to the ﬁrst year of life with no
speciﬁed cause. Almost since he became 3 years of age, has shown symptoms
of rhinosinusitis, pneumonia, osteomyelitis in right knee caused by several
pathogens as S. aureus and H. Inﬂuenzae, lack of weight and length, and
multiple stays at the hospital. Serum IgG was 37.3 mg/dL, IgA , 23 mg/dL,
IgM , 17.9 mg/dL, IgE , 14.2 IU/mL. The total lymphocytes (cells/Micro-
liter) were 3203; T lymphocytes 80%, CD8 44%, CD4 34%, ratio CD4/CD8
0.78, CD56 8%, CD19 0 %, CD20 2%, CD22 2%. Treatment begins with
intravenous gammaglobulin in replacement dosage.
Results: According to review the literature and data base, Mendelian
Inheritance in Man, from the Johns Hopkins University, there is not known
association between Bruton Disease and Moebius Syndrome. However, we
consider important to report the coexistence of these diseases in one single
patient. The karyotype should be studies in order to determine in a more
objective way the probable link between both.
Conclusions: Since there are not previous reports of the association between
X-linked Agammaglobulinemia and Moebius Syndrome this might set the
precedent for a better knowledge and its implications to the future.
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